STEM CELL THERAPY

  1. Stem cell therapy in perspective
  2. Adult Stem cell therapy in perspective
  3. Stem cell therapy for human neurodegenerative disorders–how to make it work
  4. Stable benefit of embryonic Stem cell therapy in myocardial infarction
  5. Stemcell therapy for diabetes mellitus
  6. New prospects for human Stemcell therapy in the nervous syStem
  7. Neural Stem cell therapy for neurological diseases: dreams and reality
  8. Stem cell therapy in a caprine model of osteoarthritis
  9. Stem cell therapy and gene transfer for regeneration
  10. Adult Stem cell therapy for the heart
  11. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans
  12. Nonmyeloablative Stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of …
  13. Mesenchymal Stem cell therapy in joint disease
  14. The effect of neural embryonic Stem cell therapy in a rat model of cavernosal nerve injury
  15. Stemcell therapy for amyotrophic lateral sclerosis
  16. Potential of hematopoietic Stem cell therapy in hepatology: a critical review
  17. Becoming immortal: Combining cloning and Stemcell therapy
  18. 28. Embryonic and adult Stem cell therapy
  19. Dentin regeneration by dental pulp Stem cell therapy with recombinant human bone morphogenetic protein 2
  20. Stem cell and precursor cell therapy
  21. Stem cell therapy for ischemic heart disease
  22. Intervertebral disc cell therapy for regeneration: mesenchymal Stem cell implantation in rat intervertebral discs
  23. Stem cell therapy for ocular disorders
  24. Potential Stem cell therapy and application in neurotrauma
  25. Stem cell therapy of the liver—fusion or fiction?
  26. Stem cell therapy for diabetes: do we need to make beta cells?
  27. Stem cell therapy for myocardial repair: is it arrhythmogenic?
  28. Neural Stem cell therapy in the aging brain: pitfalls and possibilities
  29. Stem cell therapy for urinary incontinence
  30. Stemcell therapy for renal diseases
  31. Stem cell therapy forcerebral palsy
  32. Genetically engineered Stem cell therapy for tissue regeneration
  33. Emerging neuroprotective strategies for Alzheimer’s disease: dietary restriction, telomerase activation, and Stem cell therapy
  34. Hematopoietic Stem cell therapy for type 1 diabetes: induction of tolerance and islet cell neogenesis
  35. In utero Stem cell therapy.
  36. Stem cell therapy for Parkinson’s disease: where do we stand?
  37. Stem cell therapy for the infarcted heart (“cellular cardiomyoplasty”)
  38. Monitoring Stem cell therapy in vivo using magnetodendrimers as a new class of cellular MR contrast agents
  39. Stem cell therapy for muscular dystrophy
  40. Stem cell therapy in ischemic heart disease
  41. Adult Stem cell therapy for heart failure
  42. Stemcell therapy for myocardial diseases
  43. Stem cell therapy for the heart
  44. Stem cell therapy of cardiac disease: an update
  45. Applications of magnetic resonance imaging for cardiac Stem cell therapy
  46. The origin and development of the immune syStem with a view to Stem cell therapy
  47. Stem cell origin of cancer and differentiation therapy
  48. Novel approaches to allogeneic Stem cell therapy
  49. Autologous bone marrow-derived Stem cell therapy in combination with TMLR. A novel therapeutic option for endstage coronary heart disease: report on 2 cases.
  50. Immune ablation and Stemcell therapy in autoimmune disease-Clinical experience
  51. Stemcell therapy for amyotrophic lateral sclerosis
  52. Stem cell therapy for neurodegenerative diseases: the issue of transdifferentiation
  53. Hematopoietic Stem cell therapy of autoimmune diseases.
  54. Three-dimensional approach to Stem cell therapy
  55. Editorial Stem cell therapy in human ALS
  56. Stem cell therapy in utero
  57. Human embryonic Stem cell therapy
  58. Stem cell plasticity: the growing potential of cellular therapy
  59. Pancreatic islet and Stem cell transplantation: new strategies in cell therapy of diabetes mellitus.
  60. Cardiovascular disease: potential impact of Stem cell therapy
  61. From Stem cells to beta cells: new strategies in cell therapy of diabetes mellitus
  62. Additional Stem cell therapy for graft failure after allogeneic bone marrow transplantation
  63. Stem cell therapy for ALS: Hope and Reality A discussion paper from the Executive of the European ALS Consortium
  64. Allogeneic cell therapy for patients who relapse after autologous Stem cell transplantation
  65. Stem cell plasticity or fusion: two approaches to targeted cell therapy
  66. Augmentation of virus-specific immunity after hematopoietic Stem cell transplantation by adoptive T-cell therapy
  67. Stem cell therapy for myocardial infarction
  68. Stem cell therapy in acute myocardial infarction
  69. Stem cell therapy for neurological disease and injury.
  70. Correction of ADA-SCID by Stem cell gene therapy combined with nonmyeloablative conditioning
  71. Stem cell therapy for urinary incontinence and pelvic floor disorders: a novel approach
  72. Bone-marrow Stem cells as a source for cell therapy
  73. Stemcell therapy: what dose should we use?
  74. Stemcell plasticity and therapy for injuries of the peripheral nervous syStem
  75. Public Stem cell banks: considerations of justice in Stem cell research and therapy
  76. Hematopoietic Stem cell compartment: acute and late effects of radiation therapy and chemotherapy
  77. Immune ablation and Stemcell therapy in autoimmune disease: experimental basis for autologous Stemcell transplantation
  78. Stem cells for cell therapy in Parkinson’s disease
  79. Dendritic-cell therapy after non-myeloablative Stemcell transplantation for renal-cell carcinoma
  80. Nuclear transplantation, embryonic Stem cells and the potential for cell therapy
  81. Mylotarg™(gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received Stem cell transplantation
  82. cell therapy: Stem cell transplantation, gene therapy, and cellular immunotherapy
  83. Comparison of high-dose therapy and autologous Stemcell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case-control study
  84. Autologous Stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn’s disease: a new cell-based therapy
  85. Current status and perspectives of Stem cell therapy for the treatment of diabetes mellitus
  86. Neural Stem cells in the developing central nervous syStem: implications for cell therapy through transplantation
  87. Nuclear transplantation, embryonic Stem cells, and the potential for cell therapy
  88. Exogenously regulated Stem cell-mediated gene therapy for bone regeneration
  89. The potential for Stem cell therapy in cystic fibrosis.
  90. High-dose therapy with autologous Stem cell transplantation in patients with peripheral T cell lymphomas
  91. Neuroreplacement therapy and Stem cell biology under disease conditions
  92. Stem cell gene therapy for chronic renal failure
  93. In utero hematopoietic Stem cell therapy
  94. Embryonic Stem cell therapy in experimental stroke: host-dependent malignant transformation
  95. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic Stemcell transplantation with virus-specific T-cell lines
  96. Prostate Stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate
  97. Influenza infections after hematopoietic Stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy
  98. Music therapy for mood disturbance during hospitalization for autologous Stem cell transplantation: a randomized controlled trial
  99. The potential of marrow stromal cells in Stem cell therapy
  100. cell therapy using human embryonic Stem cells
  101. Impact on survival of high-dose therapy with autologous Stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population …
  102. High-dose therapy and autologous peripheral blood Stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential …
  103. High‐dose therapy with autologous haemopoietic Stem cell support for Waldenström’s macroglobulinaemia
  104. A new concept of Stem cell disorders and their new therapy
  105. … response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic Stem cell transplantation. Myeloma Subcommittee of the …
  106. Autologous peripheral hematopoietic Stem cell transplantation restores hematopoietic function following marrow ablative therapy
  107. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous Stem cell transplantation for relapsed B cell lymphomas
  108. A multicenter study of platelet recovery and utilization in patients after myeloablative therapy and hematopoietic Stem cell transplantation
  109. Paradigms of adult Stem cell therapy for type 1 diabetes in mice
  110. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic Stemcell transplantation
  111. … ablation and Stemcell therapy in autoimmune disease Immunological reconstitution after high-dose immunosuppression and haematopoietic Stemcell
  112. Rituximab and ICE as second-line therapy before autologous Stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
  113. Heal thyself: Potential applicability of Stem cell therapy in the management of heart disease
  114. Stem cell therapy for autoimmune disease: overview of concepts from the Snowbird 2002 tolerance and tissue regeneration meeting
  115. The graft-versus-tumor potential of allogeneic cell therapy: an update on donor leukocyte infusions and nonmyeloablative allogeneic Stem cell transplantation
  116. High-dose immunosuppressive therapy and autologous peripheral blood Stem cell transplantation for severe multiple sclerosis
  117. … impact of cytomegalovirus serostatus of donor and recipient before hematopoietic Stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
  118. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic Stem cell transplantation
  119. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic Stem cell transplantation: risk factors, correlation with DNA …
  120. Prognostic factors for survival and response after high‐dose therapy and autologous Stem cell transplantation in syStemic AL amyloidosis: a report on 21 patients
  121. Parainfluenza virus infections after hematopoietic Stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome
  122. High-dose therapy and autologous peripheral blood Stem cell transplantation for patients with lymphoma
  123. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy
  124. 486: Stem cell therapy in Treatment of Urinary Incontinence: First Clinical Results
  125. Mesenchymal Stemcell therapy in a regulated environment
  126. therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous Stem cell transplantation
  127. Stem cell therapy in scleroderma
  128. High-dose therapy and autologous blood Stem cell transplantation in POEMS syndrome
  129. First-line therapy with thalidomide and dexamethasone in preparation for autologous Stem cell transplantation for multiple myeloma
  130. Intensive therapy with peripheral Stem cell transplantation in 16 patients with mantle cell lymphoma
  131. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic Stem cell transplantation: Presented in …
  132. Infectious complications after allogeneic Stem cell transplantation: epidemiology and interventional therapy strategies
  133. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and Stemcell rescue: results of the Chicago Pilot II Study
  134. Viral interleukin-10–engineered autologous hematopoietic Stem cell therapy: a novel gene therapy approach to prevent graft rejection
  135. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of multiple myeloma: an evidence-based review
  136. Thoracic transplantation and Stem cell therapy
  137. High-dose therapy with Stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience
  138. P75. Feasibility of Stem cell therapy for intervertebral disc degeneration
  139. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic Stem cell transplantation: a phase …
  140. Imatinib mesylate therapy for relapse after allogeneic Stem cell transplantation for chronic myelogenous leukemia
  141. High-dose therapy and autologous Stem cell transplantation for multiple myeloma poorly responsive to initial therapy
  142. Prognostic factors for survival after high-dose therapy and autologous Stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients …
  143. Should immunoglobulin therapy be used in allogeneic Stemcell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial
  144. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood Stem cell support
  145. Relationship between spermatogonial Stem cell survival and testis function after cytotoxic therapy.
  146. High-dose melphalan, etoposide, total-body irradiation, and autologous Stemcell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not …
  147. High-dose therapy and autologous Stemcell transplantation for adult patients with Hodgkin’s disease who do not enter remission after induction chemotherapy: results …
  148. The role of high-dose therapy and autologous hematopoietic Stem cell transplantation for mantle cell lymphoma
  149. Stem cell strategies for neuroreplacement therapy in Alzheimer’s disease
  150. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic Stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
  151. High-dose intravenous melphalan and autologous Stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of …
  152. Blood Stem cell transplantation as therapy for primary syStemic amyloidosis (AL)
  153. … dose therapy and autologous Stemcell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients …
  154. Endocrine complications of high‐dose therapy with Stem cell transplantation
  155. A human umbilical cord Stem cell rescue therapy in a murine model of toxic liver injury
  156. High-dose therapy and autologous haematopoietic Stemcell transplantation for HIV-1-associated lymphoma
  157. Hematopoietic Stem cell transplantation: a new therapy for autoimmune disease
  158. Implications of long-term survival in acute Stem cell leukemia of childhood treated with composite cyclic therapy
  159. … and autologous peripheral-blood Stemcell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy
  160. Pluripotent Stem cells–model of embryonic development, tool for gene targeting, and basis of cell therapy
  161. Sequential chemotherapy regimens followed by high-dose therapy with Stem cell transplantation in mantle cell lymphoma: an update of a prospective study
  162. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous Stemcell transplantation in first remission …
  163. Hematopoietic Stem cell gene therapy: selecting only the best
  164. … reconstitution after autologous hematopoietic Stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications
  165. … followed by high-dose therapy with Stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell
  166. High-dose therapy and autologous Stemcell support for chemosensitive transformed low-grade follicular non-Hodgkin’s lymphoma: a case-matched study from the …
  167. Hormonal replacement therapy after Stem cell transplantation
  168. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic Stem cell transplantation for relapsed follicular non-Hodgkin …
  169. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and Stem cell rescue
  170. Myeloablative therapy with blood Stem cell transplantation is effective in mantle cell lymphoma.
  171. Temporary corneal Stem cell dysfunction after radiation therapy.
  172. Early autologous Stemcell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian …
  173. Therapeutic Effects of Massage therapy and Healing Touch on Caregivers of Patients Undergoing Autologous Hematopoietic Stem cell Transplant.
  174. Progress toward vector design for hematopoietic Stem cell gene therapy
  175. Embryonic and adult Stem cells as a source for cell therapy in Parkinson’s disease
  176. High-dose therapy followed by autologous hematopoietic Stemcell infusion for patients with multiple myeloma.
  177. … relapsed or refractory Hodgkin’s disease treated with high-dose chemotherapy and Stem cell rescue at the time of maximal response to conventional salvage therapy
  178. cell-replacement therapy with Stem cells in neurodegenerative diseases
  179. Retroviral Stem cell gene therapy
  180. Mesenchymal Stem cells: cell biology and potential use in therapy
  181. High-dose therapy followed by autologous peripheral-blood Stemcell transplantation for patients with Hodgkin’s disease and non-Hodgkin’s lymphoma using …
  182. Human pancreatic Stem cell and diabetes cell therapy
  183. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence …
  184. Current antiviral strategies for controlling cytomegalovirus in hematopoietic Stem cell transplant recipients: prevention and therapy
  185. Risk to the coronary arteries of intracoronary Stem cell infusion and G-CSF cytokine therapy.
  186. High-dose therapy and autologous Stem cell rescue for patients with Hodgkin’s disease in first relapse after chemotherapy: results from the EBMT
  187. Therapeutic cloning and Stem cell therapy
  188. Stem cells in cardiovascular disease: from cell biology to clinical therapy
  189. … emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with Stem cell
  190. … photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic Stem cell
  191. Haematopoietic Stem cell transplantation and gene therapy in the fetus: ready for clinical use?
  192. High-dose therapy plus autologous hematopoietic Stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV …
  193. … -emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic Stem cell transplantation: a single …
  194. Stem cell transplantation therapy: controversy over ethical issues and clinical relevance.
  195. Adult Stem cell technology-prospects for cell based therapy in regenerative medicine
  196. High-dose chemotherapy followed by autologous Stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma: a meta-analysis
  197. Second malignancy following high-dose therapy and autologous Stem cell transplantation: incidence and risk factor analysis
  198. Epstein-Barr virus (EBV) reactivation in allogeneic Stemcell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy
  199. Myeloablative radiochemotherapy followed by autologous peripheral blood Stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of …
  200. High-dose therapy with autologous Stemcell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the …
  201. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in allogeneic bone marrow Stem cell transplant recipients
  202. Hematopoietic Stem cell gene therapy: progress toward therapeutic targets
  203. Stem cell biology and gene therapy
  204. High-dose therapy with autologous Stem cell rescue for pediatric sarcomas
  205. … lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic Stem cell transplantation for severe …
  206. Parainfluenza virus type 3 infections in hematopoetic Stem cell transplant recipients: response to ribavirin therapy
  207. 10 Current status of Stem cell therapy and prospects for gene therapy for the disorders of globin synthesis
  208. Hematopoietic Stem cell gene therapy
  209. Stem cell Gene therapy for the β‐Chain Hemoglobinopathies: Problems and Progressa
  210. Hematopoietic Stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy [see comments]
  211. High-dose consolidation therapy with autologous Stem cell rescue in stage IV breast cancer.
  212. High-dose therapy/autologous Stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission
  213. Stem cell therapy and research
  214. High-dose immunoablative therapy with hematopoietic Stem cell support in the treatment of severe autoimmune disease: current status and future direction
  215. High-dose chemotherapy (HDC) and autologous hematopoietic Stem cell transplantation (ASCT) as salvage therapy for relapsed osteosarcoma
  216. High-dose consolidation therapy with autologous Stemcell rescue in stage IV breast cancer: follow-up report.
  217. Toward Epidermal Stem cell-Mediated ex Vivo Gene therapy of Junctional Epidermolysis Bullosa
  218. Mesenchymal Stem cells from the bone marrow stroma: basic biology and potential for cell therapy
  219. High-dose multimodality therapy with autologous Stemcell support for stage IIIB breast carcinoma.
  220. … load in plasma allows for fast and accurate prediction of response to therapy of Epstein–Barr virus‐associated lymphoproliferative disease after allogeneic Stem cell
  221. Single agent dexamethasone for pre-Stem cell transplant induction therapy for multiple myeloma
  222. Efficacy of high-dose therapy and autologous hematopoietic Stem cell transplantation for non-Hodgkin’s lymphoma in adults 60 years of age and older
  223. Arsenic Trioxide (Trisenox®) therapy for Acute Promyelocytic Leukemia in the Setting of Hematopoietic Stem cell Transplantation
  224. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic Stem cell transplantation: a pilot study
  225. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and Stem cell
  226. … high-dose cyclophosphamide without Stem cell rescue in paraneoplastic pemphigus: report of a case and review of this new therapy for severe autoimmune disease
  227. High dose therapy and autologous Stem cell transplantation for human immunodeficiency virus‐associated non‐Hodgkin lymphoma in the era of highly active …
  228. Autologous peripheral blood Stem cell transplantation after high dose therapy in patients with advanced lymphomas.
  229. Hematopoietic Stem cell gene therapy: a current overview.
  230. Muscle-derived Stem cells: characterization and potential for cell-mediated therapy
  231. Immunotherapy with rituximab following high-dose therapy and autologous Stemcell transplantation for mantle cell lymphoma
  232. Improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA‐identical hematopoietic Stem cell
  233. … with VP-16 and cytarabine for induction/consolidation therapy, followed by a feasibility study of autologous peripheral blood Stem cell transplantation in elderly …
  234. therapy with imatinib mesylate (Glivec) preceding allogeneic Stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute …
  235. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood Stem cell support in unresectable osteosarcoma
  236. Benefit of aggressive multimodality therapy with autologous Stem cell support for intra-abdominal desmoplastic small round cell tumor
  237. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic Stem cell transplantation
  238. Stemcell therapy for myocardial diseases
  239. Cytokine production during myeloablative and reduced intensity therapy before allogeneic Stem cell transplantation
  240. High risk of therapy-related leukemia after BEAM chemotherapy and autologous Stem cell transplantation for previously treated lymphomas is mainly related to primary …
  241. Diamond-Blackfan anemia in Japan: clinical outcomes of prednisolone therapy and hematopoietic Stem cell transplantation
  242. Results of high-dose therapy and autologous bone marrow/Stem cell transplantation during remission in poor-risk intermediate-and high-grade lymphoma …
  243. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic Stem cell
  244. High-dose therapy in lymphomas: a review of the current status of allogeneic and autologous Stem cell transplantation in Hodgkin’s disease and non-Hodgkin’s …
  245. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic Stem cell transplantation
  246. Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous Stem cell transplant
  247. Stem cell gene therapy, position effects and chromatin insulators
  248. Role for high-dose therapy with autologous hematopoietic Stem cell support in Waldenstrom’s macroglobulinemia
  249. The hematopoietic Stem cell therapy for exploration of deep space
  250. … mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic Stem cell transplantation: a prospective …
  251. … determinant (CD) 34+ cell dose on the cost and consequences of peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma patients in front-line therapy
  252. Sequential high-dose therapy and autologous Stem cell transplantation for treatment of mantle cell lymphoma
  253. High-dose therapy and autologous Stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive …
  254. Adult mesenchymal Stem cells: characterization, differentiation, and application in cell and gene therapy
  255. Evaluation of the risk of therapy-related MDS/AML after autologous Stem cell transplantation
  256. Intensification of therapy using hematopoietic Stemcell support for high‐risk neuroblastoma
  257. Strategies for hematopoietic Stem cell gene therapy: insights from computer simulation studies
  258. A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic Stem cell transplantation
  259. Stem cell defects after cytoreductive therapy in man.
  260. … with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or Stem cell rescue therapy
  261. Myeloma cell contamination of peripheral blood Stem cell grafts in patients with multiple myeloma treated by high-dose therapy.
  262. Embryonic Stem cell grafting: the therapy of the future?
  263. Transabdominal first trimester embryofetoscopy as a potential approach to early in utero Stem cell transplantation and gene therapy
  264. Single center experience of a new intensive induction therapy for Ewing’s family of tumors: feasibility, toxicity, and Stem cell mobilization properties
  265. Pre-emptive therapy with rituximab for prevention of Epstein–Barr virus-associated lymphoproliferative disease after hematopoietic Stem cell transplantation
  266. High-dose therapy and autologous Stem cell transplantation in relapsing cutaneous lymphoma
  267. Peripheral blood Stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study
  268. … (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral Stem cell
  269. Where next with Stemcell-supported high-dose therapy for breast cancer?
  270. Clonotypic CD20+ and CD19+ B cells in peripheral blood of patients with multiple myeloma post high‐dose therapy and peripheral blood Stem cell transplantation
  271. Lymphoid development and function in X-linked severe combined immunodeficiency mice after Stem cell gene therapy
  272. Consolidation therapy with autologous Stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three …
  273. Analysis of feasibility of myeloablative therapy and autologous peripheral Stem cell (PBSC) transplantation in the elderly: an interim report
  274. Embryonic Stem cells in vitro-prospects for cell and developmental biology, embryotoxicology and cell therapy
  275. Peripheral blood Stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood …
  276. An update on the role of high-dose therapy with autologous or allogeneic Stem cell transplantation in mantle cell lymphoma
  277. Hematopoietic Stem cell transplantation for cancer therapy
  278. Hematopoietic Stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid …
  279. Hematopoietic Stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection
  280. Superiority of double over single autologous Stem cell transplantation as first-line therapy for multiple myeloma.
  281. … (AMPLICOR CMV test) versus pp65 antigenemia assay for monitoring cytomegalovirus viremia and guiding preemptive ganciclovir therapy in allogeneic Stem cell
  282. Twelve years experience with high-dose therapy and autologous Stem cell transplantation for high-risk Hodgkin’s disease patients in first remission after MOPP/ABVD …
  283. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood Stem cell transplantation
  284. The role of autologous Stem cell reconstitution in intensive therapy for resistant neoplasms
  285. Nonmyeloablative therapy and allogeneic hematopoietic Stem cell transplantation
  286. Decitabine with allogeneic peripheral blood Stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study
  287. Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous Stem cell transplantation for salvage therapy in B-NHL
  288. The place of high-dose therapy with haemopoietic Stem cell transplantation in relapsed and refractory Hodgkin’s disease
  289. siRNAs, ribozymes and RNA decoys in modeling Stem cell-based gene therapy for HIV/AIDS.
  290. Clinically‐based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic Stem cell
  291. Embryonic Stem cell research and therapy: the need for a common European legal framework
  292. … high-dose chemotherapy with granulocyte colony-stimulating factor and autologous Stemcell transplantation support as first-line therapy in high-risk diffuse large-cell
  293. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood Stem cell transplantation …
  294. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood Stem cell transplantation in children: results of a prospective …
  295. Nutritional support of the patient receiving high-dose therapy with hematopoietic Stem cell support
  296. Stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell
  297. … boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high‐risk allogeneic hematopoietic Stem cell transplantation. Scedosporiasis and …
  298. Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic Stem cell transplantation
  299. … long‐term hematologic recovery despite a marked quantitative defect in the Stem cell compartment of patients with aplastic anemia after immunosuppressive therapy
  300. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic Stem cell transplant …
  301. Potential use of human Stem cell factor as adjunctive therapy for human immunodeficiency virus-related cytopenias
  302. Effectiveness of high‐dose MCNU therapy and hematopoietic Stem cell autografts treatment of childhood acute leukemia/lymphoma with high‐risk features
  303. Interleukin-2 therapy after bone marrow or Stem cell transplantation for hematologic malignancies.
  304. Cytokines: value-added products in hematopoietic Stem cell gene therapy
  305. … of Multiple Myeloma and Breast Cancer cells by TH9402‐mediated Photodynamic therapy: Implication for Clinical Ex Vivo Purging of Autologous Stem cell
  306. Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic Stem cell transplantation
  307. Autologous Stem cell transplantation for AL amyloidosis: a standard therapy?
  308. A prospective randomized trial of granulocyte colony-stimulating factor therapy after autologous blood Stem cell transplantation in adults
  309. Hematopoietic Stem cell gene therapy: towards clinically significant gene transfer efficiency.
  310. Minimal residual disease–based role of imatinib as a first-line interim therapy prior to allogeneic Stem cell transplantation in Philadelphia chromosome–positive acute …
  311. Search for a cure for idiopathic pulmonary fibrosis: is Stem cell therapy a light at the end of a long tunnel?
  312. Stem cell Transplantationfor Leukemias Following Myelodysplastic Syndromesor Secondaryto Cytotoxic therapy
  313. Hematopoietic Stem cell–based gene therapy for acquired immunodeficiency syndrome: efficient transduction and expression of RevM10 in myeloid cells in vivo and …
  314. Stem cell therapy (Aastrom Biosciences Inc).
  315. High-dose chemotherapy with Stem cell rescue as initial therapy for anaplastic oligodendroglioma
  316. Directed mobilization of endogenous neural progenitor cells: the intersection of Stem cell biology and gene therapy.
  317. High‐dose intravenous methotrexate followed by autologous Stem cell transplantation as a potentially effective therapy for neurolymphomatosis
  318. 6The role of haematopoietic Stem cell-supported myeloablative therapy for the management of multiple myeloma
  319. Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood Stem cell transplantation
  320. Early intensive therapy with autologous Stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry
  321. Ultrasound-guided Stem cell sampling from the early ovine fetus for prenatal ex vivo gene therapy
  322. Hematopoietic Stem cell therapy for multiple sclerosis
  323. The remission status before and the PCR status after high-dose therapy with peripheral blood Stem cell support are prognostic factors for relapse-free survival in …
  324. Hematopoietic Stem cell gene replacement therapy
  325. … by non-myeloablative allogeneic Stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation
  326. Peripheral blood Stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow …
  327. Stem cell therapy for intervertebral disc diseases in vitro and in vivo feasibility study
  328. The leukemogenic risk of integrating retroviral vectors in hematopoietic Stem cell gene therapy applications.
  329. Functional organization of the hematopoietic Stem cell compartment: implications for cancer and its therapy.
  330. The importance of CD34+/CD33− cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood Stem cell rescue
  331. … suppression and autologous hematopoietic Stem cell transplantation in severe Crohn’s disease refractory to immunosuppressive and immunomodulator therapy
  332. Micro-injection-mediated hematopoietic Stem cell gene therapy.
  333. Early allogeneic blood Stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid …
  334. Fetal immune suppression as adjunctive therapy for in utero hematopoietic Stem cell transplantation in nonhuman primates
  335. Development of a modified selective amplifier gene for hematopoietic Stem cell gene therapy
  336. Embryonic Stem cells: a promising tool for cell replacement therapy
  337. Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic Stem cell transplant in children: results of a prospective randomized trial
  338. Value of autologous Stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS …
  339. Late infectious complications after high-dose therapy and autologous blood Stem cell transplantation
  340. Stem cell gene therapy: a breakthrough combination magnified by therapeutic Stem cell homing
  341. Anti-CD20 antibody as consolidation therapy in a patient with primary plasma cell leukemia after high-dose therapy and autologous Stem cell transplantation
  342. Peripheral blood Stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin’s lymphoma
  343. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis after Stem cell transplantation: effective monitoring of CMV infection by quantitative …
  344. Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: interest for peripheral blood Stem cell-based gene therapy
  345. Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood Stem cell transplantation for lymphoma
  346. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic Stem cell transplantation
  347. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood Stem cell transplant when started soon after engraftment
  348. Bone marrow Stem cell gene therapy of arylsulfatase A-deficient mice, using an arylsulfatase A mutant that is hypersecreted from retrovirally transduced donor-type …
  349. Front-line high-dose therapy with autologous Stem cell transplantation for high risk Hodgkin’s disease: comparison with combined-modality therapy
  350. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical Stem cell transplantation
  351. Plasticity of skeletal muscle differentiation generating Stem cell-like phenotype: Possible application to cell therapy for muscular diseases
  352. The Hematopoietic Stem cell therapy for Exploration of Space
  353. Selective expansion of transduced cells for hematopoietic Stem cell gene therapy
  354. Progress towards hematopoietic Stem cell gene therapy.
  355. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic Stem cell
  356. When to harvest peripheral-blood Stem cells after mobilization therapy: prediction of CD34-positive cell yield by preceding day CD34-positive concentration in …
  357. Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for Stem cell‐based gene therapy
  358. Autologous blood Stem cell transplantation as therapy for autoimmune diseases
  359. High‐dose therapy/Stem cell support: Comparison of mice and humans
  360. High‐dose therapy with Stem cell rescue for pediatric solid tumors: Rationale and results
  361. Transfusion therapy in the patient undergoing hematopoietic Stem cell transplantation
  362. Long-term follow-up on a patient with incomplete POEMS syndrome undergoing high-dose therapy and autologous blood Stem cell transplantation
  363. Intra-muscular vidarabine therapy for polyomavirus-associated hemorrhagic cystitis following allogeneic hemopoietic Stem cell transplantation
  364. Multivalent anti-CCR5 ribozymes for Stem cell-based HIV type 1 gene therapy
  365. Renal dysfunction during high-dose cisplatin therapy and autologous hematopoietic Stem cell transplantation: effect of aminoglycoside therapy
  366. High-dose therapy with Stemcell transplantation in the malignant lymphomas.
  367. Stem and progenitor cells from acid sphingomyelinase-deficient mice: implications for Niemann-Pick disease gene therapy and the development of improved Stem cell
  368. Treatment of mantle-cell lymphomas with the VAD+/− chiorambucil regimen with or without subsequent high-dose therapy and peripheral blood Stemcell
  369. Stem cell transplantation as post-remission therapy in adult acute myelogenous leukemia: does platelet contamination of peripheral blood mobilized Stem cell grafts …
  370. High-dose therapy and autologous peripheral Stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone …
  371. … of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood Stem cell
  372. Technology evaluation: Stemcell therapy, Aastrom Biosciences Inc.
  373. … colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic Stem cell transplantation for lymphoid …
  374. The present role of bone marrow and Stem cell transplantation in the therapy of children with acute leukemia.
  375. Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H. 82 with autologous Stem cell support and cyclosporin A
  376. Stem cell transplantation and gene therapy for HIV-related lymphomas
  377. High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood Stem cell support in the adjuvant therapy of high-risk breast cancer: a practical …
  378. High-dose therapy and Stem cell transplantation in follicular lymphoma
  379. Allogeneic hematopoietic Stemcell transplantation: the next generation of therapy for metastatic renal cell cancer
  380. … for cytomegalovirus disease in patients receiving polymerase chain reaction–based preemptive antiviral therapy after allogeneic Stem cell transplantation depends on …
  381. Autologous peripheral blood Stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome
  382. Retroviral vector design studies toward hematopoietic Stem cell gene therapy for mucopolysaccharidosis type I
  383. Adult Stem cells and their importance in cell therapy.
  384. A novel sub-population of bone marrow–derived myocardial Stem cells: potential autologous cell therapy in myocardial infarction
  385. Importance of radiation therapy for breast cancer patients treated with high-dose chemotherapy and Stem cell transplant
  386. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic Stem cell transplantation
  387. High dose therapy and autologous Stem cell transplantation in follicular non-Hodgkin’s lymphoma
  388. Multidisciplinary therapy including high-dose chemotherapy followed by peripheral blood Stem cell transplantation for invasive thymoma
  389. High dose therapy and autologous hematopoietic Stem cell transplantation in poor risk solid tumors of childhood.
  390. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of diffuse large cell B-cell non-Hodgkin’s lymphoma
  391. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and Stem cell rescue. A feasibility study
  392. … carboplatin and interleukin-2 (IL-2) activated autologous Stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma–a …
  393. Filgrastim‐induced Stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging
  394. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and Stem cell gene therapy for AIDS
  395. Intensive therapy and autologous Stem cell transplantation for Hodgkin’s disease in first relapse after combination chemotherapy
  396. Stem cell-based gene therapy
  397. Stemcell depletion and grid therapy
  398. Adult Stem cell therapy: Imagining Futures in cell Biology
  399. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood Stem cell transplantation and interferon-alpha
  400. … of autologous Stem cell transplantation in patients with multiple myeloma who received dexamethasone-based nonmyelosuppressive induction therapy
  401. Consolidation therapy with autologous blood Stem cell transplantation in a patient with primary plasma cell leukaemia
  402. therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral Stem cell rescue.
  403. Intermediate‐dose melphalan (IDM) combined with G‐CSF (filgrastim) is an effective and safe induction therapy for autologous Stem cell transplantation in multiple …
  404. therapy for Hodgkin’s disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous Stem
  405. Stem cell therapy: medical advance or moral challenge?
  406. Experience with liposomal Amphotericin‐B in 60 patients undergoing high‐dose therapy and bone marrow or peripheral blood Stem cell transplantation
  407. In utero hematopoietic Stem cell transplantation: a caprine model for prenatal therapy in inherited metabolic diseases
  408. … non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral Stemcell transplantation: changing the natural history with monoclonal antibody therapy
  409. Future cure of hearing disorders? Gene therapy and Stem cell implantation are possible new therapeutic alternatives
  410. Thiotepa and cyclophosphamide with Stem cell rescue for consolidation therapy for children with high-risk neuroblastoma: a phase I/II study of the Pediatric Blood and …
  411. High‐dose therapy and autologous blood Stem cell transplantation in multiple myeloma: Preliminary results of a randomized trial involving 167 patients
  412. Interferon-α therapy following autologous peripheral blood Stem cell transplantation for adult T cell leukemia/lymphoma
  413. Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood Stemcell support as front-line therapy
  414. Hematopoietic Stem cell gene therapy for Niemann–Pick disease and other lysosomal storage diseases
  415. Neural Stem cells are uniquely suited for cell replacement and gene therapy in the CNS
  416. Stem cell component therapy: supplementation of unmanipulated marrow with CD34 enriched peripheral blood Stem cells
  417. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood Stem cell support is an effective adjuvant treatment for high-risk primary breast …
  418. Donor chimerism and Stem cell function in a murine congenic transplantation model after low-dose radiation conditioning: effects of a retroviral-mediated gene transfer …
  419. Stem cell therapy for severe autoimmune diseases
  420. … use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic Stem cell transplantation as consolidation therapy for high-risk …
  421. Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic Stem cell transplantation
  422. … survival of children with advanced neuroblastoma treated by intensified therapy including myeloablative chemotherapy with Stem cell transplantation: a retrospective …
  423. therapy-related myelodysplastic syndrome after autologous Stem cell transplantation for breast cancer
  424. … significance of the detection of tumour cells in peripheral blood Stem cell collections in stage II and III breast cancer patients treated with high-dose therapy
  425. Male germ line Stem cells: from cell biology to cell therapy?
  426. High dose therapy with autologous Stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence
  427. Cytomegalovirus following Stem cell transplantation: from pharmacologic to immunologic therapy
  428. High-dose therapy followed by Stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin’s lymphoma
  429. High-dose therapy and autologous Stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
  430. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic Stem cell transplantation for patients with chronic myelogenous …
  431. Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood Stem cell transplantation
  432. … of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood Stem cell
  433. High-dose therapy with Stem cell support in solid tumors
  434. cell sources and support programs for Stem cell research and cell-based therapy in the USA
  435. Immune ablation and Stemcell therapy in autoimmune disease Introduction
  436. Current status in intrauterine fetal Stem cell therapy
  437. … exposure to Merocyanine 540-mediated photodynamic therapy and Edelfosine: implications for the ex vivo purging of autologous haematopoietic Stem cell
  438. Allogeneic Stem cell–Derived “Repair Unit” therapy and the Barriers to Clinical Deployment
  439. Autologous Stem cell therapy for syStemic vasculitis
  440. Diabetes therapy boosts Stemcell campaign
  441. Once weekly recombinant human erythropoietin therapy is very efficient after allogeneic peripheral blood Stem cell transplantation when started soon after …
  442. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood Stem cell transplantation as initial therapy for patients with high-risk non …
  443. Stemcell gene therapy moves toward approval: an NIH advisory committee gives the nod to a new strategy for genetic therapy based on a rare type of blood cell
  444. Dog leukocyte antigen-haploidentical Stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model
  445. The case for and against high-dose therapy with Stem cell rescue for early poor prognosis Hodgkin’s disease in first remission
  446. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous Stem cell
  447. Neural Stem cells–a versatile tool for cell replacement and gene therapy in the central nervous syStem: Section Editor: Roderick R McInnes e‐mail: mcinnes@ sickkids …
  448. Cidofovir for cytomegalovirus-preemptive therapy in Stem cell transplant recipients
  449. Autologous Stem cell Transplantation as First Line therapy in Peripheral T cell Lymphomas. Update of a Prospective Multicenter Study.
  450. 1432: The Effect of Neural Embryonic Stem cell therapy in a Rat Model of Cavernous Nerve Injury
  451. In vitro T lymphopoiesis: a model syStem for Stem cell gene therapy for AIDS
  452. Immune therapy for EBV infections after hemopoietic Stemcell transplant
  453. Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous Stem cell support
  454. High‐dose therapy with peripheral blood Stem cell transplantation results in a significant reduction of the haemopoietic progenitor cell compartment
  455. … ‐dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood Stem cell
  456. Autologous Stem cell transplantation as adjuvant treatment vs no further therapy for poor-risk Hodgkin’s disease in first complete remission after MOPP/ABVD
  457. Autologous blood Stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong …
  458. High-dose therapy with peripheral blood Stem cell transplantation for patients with relapsed or refractory Hodgkin’s disease: long-term outcome and prognostic factors
  459. … antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through Stem cell factor/granulocyte-macrophage …
  460. A human pluripotent Stem cell in the blood of adults: towards a new cellular therapy for tissue repair
  461. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous Stem cell transplantation is a prognostic factor for event-free survival …
  462. … /nonlymphoid antigen+ acute leukemias: immunologic and karyotypic monitoring during therapy and at relapse suggests the transformation of a bipotential Stem cell.
  463. High dose therapy followed by autologous peripheral blood Stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study
  464. Neural Stem cell therapy
  465. Circulating hematopoietic Stem cell populations in human fetuses: implications for fetal gene therapy and alterations with in utero red cell transfusion
  466. … -associated pulmonary alveolar proteinosis as two hereditary diseases of childhood which are potentially curable by Stem cell gene therapy but require different …
  467. … of interferon tolerance after autologous bone marrow or peripheral blood Stem cell transplants for myeloma patients who have responded to induction therapy
  468. … suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous Stem cell
  469. Tandem high-dose therapy followed by autologous Stemcell transplantation for refractory or relapsed high grade non-Hodgkin’s lymphoma with poor prognosis …
  470. Efficacy and toxicity of sequential high-dose therapy with peripheral blood Stem cell support in patients with high-risk breast cancer.
  471. Hematopoietic Stem cell gene therapy: progress and prospects
  472. Purging of contaminating breast cancer cells from hematopoietic Stem cell grafts by adenoviral GAL-TEK gene therapy and magnetic antibody cell separation
  473. cells as a sensitive method for determination of aneuploid multiple myeloma cells in peripheral blood Stem cell harvests and bone marrow after therapy
  474. Embryonic Stem cell therapy: Progress and Perspectives
  475. High-dose combined alkylating agent therapy with autologous Stem cell support and chest radiotherapy for limited small-cell lung cancer
  476. Allogenic Stem cell transplantation as salvage therapy for patients relapsing after autologous transplantation: experience from a single institution
  477. Development of gene therapy for hematopoietic Stem cell using viral vectors
  478. Stem cell therapy: prospects and
  479. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous Stem cell transplantation among patients with AL amyloidosis
  480. Blood Stem cell transplantation and gene therapy of cancer
  481. MESENCHYMAL Stem cell therapy IN GROWTH PLATE CARTILAGE INJURY
  482. Empiric antimicrobial therapy of febrile neutropenic patients undergoing haematopoietic Stem cell transplantation
  483. Repetitive low-dose radiation therapy for acute Stemcell leukemia
  484. Modeling human hematopoietic Stem cell gene therapy in nonhuman primates.
  485. The role of high-dose therapy with hematopoietic Stem cell rescue in low-grade non-Hodgkin’s lymphoma
  486. Intensified daunorubicin in induction therapy and autologous peripheral blood Stem cell transplantation in postremission therapy (Double-7 protocol) for adult acute …
  487. Mobilization of peripheral blood Stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in …
  488. High-dose chemotherapy and autologous Stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer …
  489. Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous Stem cell support in patients …
  490. Survival after high-dose therapy with autologous Stem cell support
  491. Stemcell researchers offer possible therapy for diabetes
  492. Hematopoietic Stem cell gene therapy for inherited bone marrow disorders: past accomplishments and continued challenges
  493. ESHAP+/− Rituximab as Salvage therapy for Relapsed Lymphoma Prior to Stem cell Transplant: Single Institution Experience.
  494. Stem cell (CFU-S) inhibitory peptides: Biological properties and application of pEEDCK as hemoprotector in cytostatic tumor therapy
  495. High-dose therapy and autologous Stem cell transplantation for high-risk Hodgkin’s lymphoma: a single center experience
  496. Outcome after Second Autologous Stem cell Transplantation as Salvage therapy in Patients with Relapsed Multiple Myeloma.
  497. Complications after high dose therapy and autologous Stem cell transplantation. Retrospective study of an unselected patient sample
  498. Feasibility of using autologous transplantation to evaluate hematopoietic Stem cell-based gene therapy strategies in transgenic mouse models of human …
  499. … in combination with glycopeptide antibiotic is an effective first-line therapy for patients undergoing high-dose therapy with autologous peripheral blood Stem cell
  500. Pulmonary infiltrates after cytokine therapy for Stem cell transplantation: massive deposition of eosinophil major basic protein detected by immunohistochemistry
  501. Hematopoietic Stem cell therapy.
  502. THE ETHICS OF Stem cell therapy
  503. High-dose therapy with autologous bone marrow Stem cell support in primary and metastatic human breast cancer
  504. Hematopoietic Stem cell autografts in support of myeloablative therapy for multiple myeloma
  505. The third conference on hematopoietic Stem cell gene therapy: biology and technology
  506. Survival Following Etanercept therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem cell Transplantation.
  507. Excellent disease eradication by myeloablative therapy and Stemcell transplantation in patients with acute myelogenous leukemia
  508. Phase I/II trials of autologous peripheral blood Stem cell transplantation in autoimmune diseases resistant to conventional therapy: preliminary results from the …
  509. NOVEL CLINICAL CONCEPTS ON Stem cell therapy: 336
  510. Monoclonal antibody therapy with autologous peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma
  511. Lamivudine therapy for acute hepatitis B infection following peripheral blood Stem cell transplantation
  512. The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood Stem cell support?
  513. … high dose therapy and autologous Stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s disease responding to first line therapy
  514. Results of a Multi-Center Randomized Phase II Trial of Thalidomide and Prednisone Maintenance therapy for Multiple Myeloma Following Autologous Stem cell
  515. Mesenchymal and nonhematopoietic Stemcell therapy
  516. Neurosurgical Stem cell therapy
  517. A Stem cell therapy for stroke
  518. Embryonic Stem cell lines for regenerative therapy and pharmaceutical research
  519. Effect of prior therapy and bone marrow metastases on progenitor cell content of blood Stem cell harvests in breast cancer patients
  520. … by campath mab t cell depleted Stem cell allograftP14. Stem cell treatment in inflammatory myopathies: proposals for patient selectionP15. Autologous Stem cell
  521. ALLOGENEIC Stem cell therapy FOR JOINT DISEASE
  522. … Foundations. Note: A. Hultquist is presently at the Department of Stem cell Biology, Strategic Center for Stem cell Research and Gene therapy, Lund University, S …
  523. High-dose chemotherapy and autologous Stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
  524. Early infectious complications after high-dose therapy and autologous blood Stem cell transplantation
  525. High dose therapy and autologous hemopoietic Stem cell transplantation in rheumatoid arthritis–the feasibility of phase III trials.
  526. Adjuvant high-dose therapy with peripheral blood Stem cell support for patients with high-risk breast cancer
  527. High-dose therapy and autologous Stem cell transplantation in relapsed and refractory Hodgkin’s disease: outcome based on a prognostic model
  528. Rituximab given after high dose therapy and autologous Stem cell transplantation induces durable clearance of minimal residual disease in about half of the …
  529. Becoming Immortal: Combining Cloning and Stemcell therapy
  530. A Setback for Stem cell therapy?
  531. Safety and efficacy of Stem cell mobilization under imatinib therapy
  532. Stem cell therapy for Ischemic Heart Disease: A Status Report
  533. Repetitive cycles of cytoreductive therapy followed by Stem cell autografting for nonlymphoblastic transformation of chronic granulocytic leukaemia
  534. Intrauterine Stem cell therapy
  535. Embryonic and Adult Stem cell therapy.(Abstracts)
  536. Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous Stem cell transplantation to improve outcome in …
  537. Stem cell therapy in the Mouse Heart
  538. Good manufacturing practice production of human Stem cells for somatic cell and gene therapy
  539. Use of capecitabine as first-line therapy in patients with metastatic breast cancer relapsing after high-dose chemotherapy and autologous Stem cell support
  540. Stem cell therapy for Alzheimer’s Disease
  541. Mobilized versus non-mobilized peripheral Stem cell transplantation after high dose therapy for low grade nonhodgkin lymphoma: Effect on failure-free survival
  542. Cytapheresis—The Next 25 Years: Stem cell therapy
  543. COMBINATION GENE AND Stem cell therapy FOR MS: PROMISE OR FANTASY?
  544. Stem cell therapy for Ischemic Heart Disease: A Status Report
  545. Costs of high-dose salvage therapy and blood Stem cell transplantation for resistant-relapsed malignant lymphomas in a southern Italian hospital
  546. Stem cell therapy for ACS: The Possibility of Myocardial Regeneration
  547. Stem cell biology and gene therapy
  548. One strategy for cell and gene therapy: harnessing the power of adult Stem cells to repair tissues
  549. Stem cell therapy in diabetes mellitus: Dream or reality
  550. Intensified myeloablative therapy and autologous Stemcell transplantation for patients with AML: single center experience
  551. Adoptive cellular therapy for Cytomegalovirus Following Allogeneic Stem cell Transplantation: Toxicity and Efficacy.
  552. Future treatment options for Parkinsonism: Stem cell therapy
  553. How far away is the Stem cell therapy from the glaucoma management. A ten-year review
  554. High-Dose therapy and Stem cell Transplantation
  555. Potential Use of Stem cell therapy for Traumatic Brain Injury
  556. Reduced Intensity Conditioning therapy Using Campath-1H Is Successful for Stem cell Transplantation in Non-Malignant Disorders.
  557. Adult Mesenchymal Stem cell therapy in Joint Injury and Disease
  558. Autologous Stem cell Transplantation and cell therapy for Acute Leukemia
  559. Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia
  560. Single cell DNA analysis: possibilities, methods, implications in relation to Stem cell therapy
  561. Stem cell transplantation and gene therapy in utero
  562. Early tandem high-dose ifosfamide, carboplatin, etoposide therapy with Stem cell rescue for small-cell lung cancer: brief report on the results of a phase-I/II trial
  563. Twelve cases of malignant hematopathy treated by combined therapy of hematopoietic Stem cell transplantation and Chinese herbal medicine
  564. Ethics of Stem cell therapy and genetic engineering on human tissue
  565. Observation on Stem cell therapy of far advanded skin trauma of guinea pig
  566. Stem cell therapy for diseases in the nervous syStem-A potential for regeneration of inner ear
  567. Understanding endocrine development of the human beta cell: guiding Stem cell therapy for Type 1 Diabetes
  568. Radiation therapy after high-dose chemotherapy with peripheral blood Stem cell support for high-risk breast cancer
  569. Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic Stem cell transplantation
  570. RELAPSE AFTER AUTOLOGOUS Stem cell therapy (ASCT) IN A PATIENT WITH SYStemIC LUPUS ERYTHEMATOSUS (SLE)
  571. High dose therapy with Stem cell support for breast cancer: the jury is still out
  572. cell therapy: Stem cell transplantation, gene therapy, and cellular immunotherapy: Edited by George Mortsyn and Wiliam Sheridan (New York: Cambridge University …
  573. Allogeneic cell therapy (act) after relapse from autologous Stem cell transplantation (autosct)
  574. Ceftazidime and ciprofloxacin as empiric therapy in febrile neutropenic patients undergoing hematopoietic Stem cell transplantation
  575. Muscle derived Stem cell-based cell therapy in urology
  576. Stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4–9 positive nodes treated with adjuvant high-dose therapy and Stem
  577. Engraftment and outcomes of patients receiving myeloablative therapy followed by autologous peripheral blood Stem cells with a low CD34+ cell content
  578. Research for corresponding dental therapy for patients undergoing bone marrow and peripheral blood Stemcell transplantation.
  579. Autologous Stem cell transplantation (ASCT) as consolidation therapy for patients with low-intermediate (LI) risk diffuse large B-cell lymphoma (DLBCL) and …
  580. … with seven-drug induction therapy and intensive consolidation with or without autologous Stem cell transplantation followed by maintenance therapy. Experience of a …
  581. Disease‐or therapy‐related bone marrow damage cannot be overcome by changes in Stem cell source or dose in allogeneic transplantation
  582. The effects of Stem cell factor and granulocyte colony stimulating factor therapy on the activity of the neutrophil NADPH oxidase enzyme syStem.
  583. Idarubicin or Mitoxantrone, VP-16, and Cytarabine for Induction/Consolidation therapy Followed by Autologous Stem cell Transplantation in Elderly Patients with …
  584. Mending a broken heart: animal studies helped lay the groundwork for Stem cell therapy.(Hot Papers)
  585. Neoadjuvant therapy with high dose chemotherapy via isolated pelvic intra-abdominal perfusion with bone marrow Stem cell support for advanced endometrial cancer
  586. Current Trends and Prospect of cell therapy using Hematopoietic Stem cells
  587. Willenbacher W, et al.: Somatic Risk Factors for Intermediate and Long-Term Sequelae after Hematological Stem cell therapy Predictive for Feasibility of a …
  588. therapy of highly malignant non-Hodgkin lymphoma with high-dose chemotherapy and Stem cell transplantation
  589. Establishment of juvenile and tolerant immune syStems in patients with autoimmune diseases treated with immunoablation and autologous Stem cell therapy
  590. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal Stem cells for cell and gene therapy
  591. Stem cell therapy for treatment of central nervous syStem pathology in α-mannosidosis guinea pigs.
  592. Early and late toxicity of involved-field radiation therapy in conjunction with high-dose chemotherapy and Stem cell rescue
  593. Sequential High‐Dose Alkylating therapy and Stem cell Support for High‐Risk Stage III Breast Cancer
  594. Adoptive therapy with monocyte‐derived macrophages in the setting of high‐dose chemotherapy and peripheral blood Stem cell transplantation
  595. Catheter Interventions in Congenital Heart Disease—Part I Guest Editor, Horst Sievert Applications of Magnetic Resonance Imaging for Cardiac Stem cell therapy.
  596. Sequential high-dose therapy of adult acute lymphoblastic leukemia: role of maintenance chemotherapy after peripheral blood Stem cell transplantation in first …
  597. Hematologic toxic reaction to radiation therapy adjuvant to autologous peripheral blood Stem cell transplantation for recurrent or refractory Hodgkin disease
  598. therapy with UVADEX® for the Prevention of Acute GVHD in Patients Undergoing Standard Myeloablative Conditioning and Allogeneic Hematopoietic Stem cell
  599. High-dose therapy of cancer with CD34 positive cells as Stem cell support
  600. Hematopoietic chimerism following immunoablative therapy for non-malignant disorders-out-patient Stem cell transplantation
  601. Prospective Multicenter Trial Comparing Repeated Immunosuppressive therapy (IST) with Stem cell Transplantation (SCT) from an Alternative Donor as a Second …
  602. Autologus Stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome
  603. Myeloablative Chemotherapy and Peripheral Blood Stem cell Transplantation vs. Consolidation therapy of Acute Myelogenous Leukemia in First Remission
  604. … Heart Function after the Combined Treatment of Patients Undergoing Coronary Artery Bypass Grafting through Stem cell therapy and Transmyocardial Laser …
  605. Treatment of non-Hodgkin’s lymphoma with high-dose therapy and hematopoietic Stem cell support.
  606. KINETIC MODELING OF THE MOLECULAR PROBE 18F-FHBG FOR IMPROVED PET REPORTER GENE IMAGING OF Stem cell therapy
  607. Feasibility of a Stem cell Gene therapy Approach with Nonmyeloablative Conditioning in Patients with HIV-1 Infection.
  608. High-dose therapy with peripheral blood Stem cell (PBSC) support using an innovative mobilization regimen in patients with high-risk primary or chemoresponsive …
  609. Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose therapy with Autologous Stem cell Rescue Leads to High Molecular Remission Rate …
  610. High dosage therapy with Stem cell transplantation in neuroendocrine carcinoma
  611. High dose chemotherapy and Stem cell support for poor risk and recurrent nonseminomatous germ cell cancer: initial experience with sequential therapy
  612. Hepatocyte growth factor modified human umbilical cord mesenchymal Stem cell therapy promotes remyelination after intracerebral hemorrhage in rats
  613. Wednesday, September 22, 2004: Plenary Session PL1: Stem cell therapy
  614. High-dose melphalan with Stem cell support is now an established myeloma therapy. Treatment of myeloma from a 30-year perspective
  615. High dosage therapy and autologous peripheral Stem cell transplantation in breast carcinoma
  616. 710. Stem cell Gene therapy: Synergizing Improved Gene Repair/Modification & Targeted Integration of Transgenes to Transient In Vivo Topical Minigene …
  617. The effect of preemptive therapy with intravenous ganciclovir followed by oral ganciclovir against cytomegalovirus infection after allogeneic peripheral blood Stem cell
  618. Current trends in Stem cell biology and cell replacement therapy
  619. Dose-intensive therapy with autologous Stem cell transplantation for patients with multiple myeloma
  620. Current trends of Stem cell-mediated gene therapy
  621. Stem cell Biology and Gene therapy.: Quesenberry PJ, Stein GS, eds.(£ 65.00.) Wiley, 1998. ISBN 0 47114 656 0.
  622. Expansion Of Muscle-Derived Stem cells: Implications of cell therapy For Muscle Regeneration
  623. HEMATOPOIETIC Stem cell GENE therapy
  624. High-dose therapy and autologous Stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK …
  625. Transplantation of hepatic Stem cells and potential applications for cell therapy
  626. 160 Importance of radiation therapy for high-risk breast cancer patients treated with high-dose chemotherapy and Stem cell transplant
  627. Scientific, logistical, and ethical issues related to creation of a Stem cell repository for use in experimental trials of gene therapy for AIDS
  628. Basic Studies Toward Hematopoietic Stem cell Gene therapy
  629. Integrating vector and Stem cell-based strategies for gene therapy of Duchenne muscular dystrophy
  630. … ANBL0032: a phase III randomized trial of chimeric anti-GD2 and GM-CSF/IL2 in high risk neuroblastoma following myeloablative therapy and autologous Stem cell
  631. Human Stem cell Gene therapy
  632. … onset invasive pulmonary zygomycosis following allogeneic peripheral blood Stem cell transplantation in a patient with therapy-related myelodysplastic syndrome
  633. High-dose busulfan, VP-16 and ACNU therapy with Stem cell transplantation for the treatment of children with acute leukemia
  634. Delivery of a vector with vascular endothelial growth factor gene to the pluripotent Stem cell for gene therapy
  635. Diabetes therapy boosts Stemcell campaign
  636. … -dose therapy and autologous Stemcell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy
  637. cellular therapy by Non-Myeloablative Stem cell Transplantation and Immunotherapy of Minimal Residual Disease
  638. Pioneering Stem cell/Gene therapy Trials
  639. Hematopoietic Stem cell Transplantation. An Established therapy
  640. High Dose therapy (HDCT) with Autologous Stem cell Transplantation (ASCT) for Non-Hodgkin Lymphoma in the Elderly: Feasibility of a Patient-Tailored Treatment …
  641. Human embryonic Stem cells: possibilities for future cell transplantation therapy
  642. Cost of antibiotic therapy in neutropenic patients undergoing peripheral blood Stem cell transplantation for breast cancer
  643. Advances in Hematopoietic Stem cell Transplantation and Molecular therapy
  644. The Biology of the Stem cell and Its Environment in the Role of Effective Gene therapy
  645. Evaluation of leukemic contamination in peripheral blood Stem cell leukaphereses vs bone marrow after consolidation therapy in acute myeloid leukemia: not a …
  646. Hematopoietic Stem cell Gene therapy
  647. Hematopoietic Stem cell gene therapy
  648. Cord blood Stem and progenitor cell therapy for immunodeficiency and other disorders
  649. High dose therapy with autologous Stem cell support–finally a progress in myelomatosis
  650. High-dose therapy and peripheral blood Stem cell transplantation for patients with aggressive non-Hodgkin’s lymphoma remaining in initial remission: results of a …
  651. High-dose chemotherapy and autologous Stem cell transplantation for refractory and relapsing Hodgkin’s disease as first-line therapy–studies at Sheba Medical …
  652. Autologous hematopoietic Stem cell transplantation (AHSCT) as consolidation therapy for childhood acute myelogenous leukemia in 1st complete remission
  653. Prognostic factors for survival and response after high-dose therapy and autologous Stem cell transplantation in syStemic AL amyloidosis: a report on 21 patients
  654. Stemcell gene therapy: problems and solutions
  655. Stem cell GENE therapy OR GENETIC DISEASES
  656. High dose therapy and autologous Stem cell transplantation (ASCT) for lymphoblastic lymphoma in adults: Results from the European Group for Bone Marrow …
  657. Aggressive neoplastic plasma cell growth with MLL gene rearrangement after high-dose therapy with autologous Stem cell support for multiple myeloma
  658. Stem cell GENE therapy OR GENETIC DISEASES
  659. A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with Stem cell transplantation
  660. Stem cell GENE therapy OR GENETIC DISEASES
  661. Stem cell and gene therapy approaches for skeletal disorders
  662. High-dose therapy and autologous hematopoietic Stemcell transplantation for recurrent or refractory pediatric hodgkin’s disease: analysis of the stanford university …
  663. … Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir therapy To Prevent Cytomegalovirus Infection after Allogeneic Stem cell
  664. therapy-related acute myeloid leukemia following double autologous peripheral blood Stem cell transplantation for non-Hodgkin’s lymphoma
  665. Human hematopoietic Stem cell gene therapy
  666. Excessive Weight Gain during Mobilization Increases First Year Mortality Following High Dose therapy and Stem cell Transplantation in Patients with Primary …
  667. Contamination with minimal residual disease in autologous peripheral Stem cell collected from Non-Hodgkin’s lymphoma patients treated with high-dose therapy
  668. Leukocyte Depleted Blood Transfusion in Hematopoietic Stem cell Reconstitution therapy
  669. therapy with Autologous Blood Stem cell Transplantation (Asct) for Relapsed, Follicular Lymphoma (FL) vs. De Novo, Diffuse Large B-cell (dnDLBL) vs. Transformed …
  670. Evaluation of human hemopoietic Stem cell assays for transplantation and gene therapy
  671. Stem cell gene therapy–second conference. Biology and technology. 31 May-3 June 1998, Orcas Island, WA, USA.
  672. High-dose therapy with peripheral Stem cell support in patients with lymphomas and breast cancer
  673. Supportive therapy in patients with autologous hemopoietic Stem cell transplantation
  674. … Predictor of Survival for Refractory and Relapsed HIV-Associated Lymphoma Enrolled in a Program of High Dose therapy and Autologous Peripheral Blood Stem cell
  675. The biologic character of cancer Stem cell and targeted therapy
  676. CD34-positive cells as Stem cell support after high dose therapy
  677. … infusions is safe and effective therapy for a subgroup of relapsed acute myeloid leukaemia and myelodysplastic syndrome following allogeneic haemopoietic Stem cell
  678. … (Gemcitabine, Dexamethasone, Cisplatin) Salvage therapy Results in Superior Progression Free Survival Compared to Mini-Beam Prior to Autologous Stem cell
  679. Application of mesenchymal Stem cells for the regeneration of cardiomyocyte and its use for cell transplantation therapy
  680. Modulation of the Hematopoietic Stem cell Phenotype: Implications For Regenerative Medicine and Gene therapy
  681. Studies Add to Debate on High-Dose therapy & Stem cell Transplantation for NHL
  682. Surgical therapy for corneal epithelial Stem cell deficiency
  683. High dose therapy with autologous Stem cell support in malignant disorders; Hoeydosebehandling med autolog stamcellestoette ved maligne lidelser
  684. Studies of hematopoietic-human-Stemcell viability in-vitro and of celocentesis in non-human primates for in-utero Stem cell gene therapy
  685. Mesenchymanl Stem cell Based Intradiscal Gene therapy: Therapeutic Implication in Degenerative Disc Disease
  686. Correction of mouse models of sickle cell disease and β-thalassemia using Stem cell and genetic-based therapy
  687. An investigation of murine trachea cellular kinetics: implications for Stem cell gene therapy
  688. … ARTHRITIS (JIA) ON LONG-TERM therapy WITH METHOTREXATEP172. THE POSITION OF AUTOLOGOUS Stem cell TRANSPLANTATION (ASTA) IN …
  689. Electronic data processing-assisted high dosage therapy with Stem cell transplantation at the Donauspital
  690. Twelve Cases of Malignant Hematopathy Treated by Combined therapy of Hematopoietic Stem cell Transplantation andChinese Herbal Medicine
  691. A Novel Stem cell Derived Gene therapy for HIV/AIDS
  692. Development of selective amplifier genes for hematopoietic Stem cell gene therapy
  693. Application of Risk-Adapted therapy for Acute Myeloid Leukemia to a Population. Effects of Stem cell Transplantation on Outcome.
  694. Correction of ADA-SCID by Stem cell gene therapy combined with nonmyeloablative conditioning
  695. Nonmyeloablative Allogeneic Peripheral Blood Hematopoietic Stem cell Transplantation for therapy of Hematologic Diseases
  696. Stem cells and cell therapy. Contribution to the ethical debate
  697. Stem cell Transplantation: Successful therapy for the Substitution of Unfunctional Hemato-Lymphoid SyStem
  698. Optimizing recovery from aplasia after high-dose therapy and hematopoietic Stem cell transplantation
  699. High-dose therapy with autologous Stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic Stem cells isolate from blood
  700. ABCG2: A new target for cancer therapy and new marker for Stem cell screening
  701. Renal transplantation and immunosuppressive therapy do not contraindicate Stemcell donation for bone-marrow transplantation
  702. 15-year follow-up of myeloma patients receiving 140 MG/M2 melphalan without hematopoietic Stem cell or growth factor support as initial therapy
  703. Twelve cases of malignant hematopathy treated by combined therapy of hematopoietic Stem cell transplantation and Chinese herbal medicine
  704. High-dose therapy followed by autologous haematopoietic Stem cell transplantation in multiple myeloma.
  705. Thirteenth Annual Meeting of Society for Biological therapy, 454 interleukin-2 expression, CTL against renal cell carcinoma, 170 CD8 T cell activity, 307 Stem cell
  706. Use of Cord Blood Stem cells in cell therapy
  707. … phase II study of maintenance chemotherapy versus high-dose chemotherapy with autologous peripheral blood Stem cell transplantation as postremission therapy of …
  708. High-dose immunosuppressive therapy with Stem cell transplantation for the treatment of autoimmune disease
  709. High dose therapy with autologous Stem cell support in malignant disorders. Excerpt from the statement by the advisory group of the State Health Services
  710. Application of real-time quantitative PCR for guidance therapy of cytomegalovirus infection after allohematopoietic Stem cell transplantation
  711. Myeloablative therapy, Stem cell rescue and gene transfer in advanced ewing tumors (AET)
  712. Gene therapy for Human Immunodeficiency Virus Infection Using Stem cell Transplantation
  713. … -non-identical peripheral blood Stem cell transplantation (total body irradiation, etoposide, thiotepa) and interleukin 2-based experimental therapy for poor prognosis …
  714. cellular therapy for intensification in oncology and hematology: manipulation of peripheral blood Stemcell products
  715. High-dose chemotherapy with peripheral blood Stem cell transplantation as adjuvant therapy for primary breast cancer
  716. 225. Phenotypic Correction of ALD Mouse after Hematopoietic cell Transplantation and Evaluation of Hematopoietic Stem cell Gene therapy with a Lentivirus Vector
  717. Autologous blood Stem cell transplantation as intensive consolidation therapy in hematological malignancies.
  718. Bone Stem cell mediated gene therapy and tissue engineering
  719. Dose-Intensive therapy with Autologous Blood Stem cell or Bone Marrow Transplantation for Treatment of Breast Cancer
  720. Etarnercept therapy for Idiopathic Pneumonia Sydrome After Allogeneic Hematopoietic Stem cell Transplantation in an Adul
  721. # 649 The feasibility of outpatient high dose multiagent cytoreductive rpeparative therapy (CPT) in patients undergoin autologous Stem cell transplantation (SCT) for …
  722. Autologous Stem cell harvesting after high dosage chemo-and/or growth factor therapy
  723. 1004. Integration Analyses in ADA-Deficient SCID Patients Successfully Treated with Stem cell Gene therapy
  724. Isolation of human mesenchymal Stem cell-like fibroblast from adipose tissue for reconstructive therapy
  725. … Targeted Integration of Minigenes: T Integration of Minigenes: Toward Improved Ex V oward Improved Ex V oward Improved Ex Vivo/In Vivo Stemcell Gene-therapy
  726. High dose chemotherapy and autologous Stem cell transplantation as adjuvant therapy for primary breast cancer pa…
  727. 51. A Novel Approach to Stem cell Gene therapy: Controlling Stem cell ifferentiation with Engineered Zinc-Finger Protein Transcription Factors
  728. Dose intensive therapy and myeloablative chemotherapy with haematopoietic Stem cell rescue in childhood poor prognosis Ewing’s sarcoma
  729. Stemcell engraftment as delayed therapy to repair organophosphate-induced brain damage
  730. predicts relapse of malignant lymphoma after high-dose therapy with Stem cell transplantation
  731. Oral valganciclovir is safe and effective as preemptive therapy for CMV infection in allogeneic hematopoietic Stem cell transplantation
  732. High-dose chemotherapy with peripheral blood Stem cell transplantation as adjuvant therapy for primary breast cancer with extensive lymph node involvement
  733. High-dose therapy and autologous peripheral blood Stem cell transplantation in patients with relapsed lymphoma
  734. 1125 High-dose therapy with hemopoietic Stem cell support for high risk breast cancer. A pilot study in 31 patients
  735. Role of Chemokine Receptor, CXCR4, Expression in Directing Neural Stem cell Vectors in Brain Tumor therapy
  736. Imatinib therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem cell Transplantation: A Molecular Analysis.
  737. Role of music therapy-based relaxation vs. expressive reading interventions in blood marrow Stem cell transplantation
  738. The Impact of Immunosuppressive therapy on an Early Quantitative Reconstitution of NK cells after Allogeneic Hematopoietic Stem cell Transplantation.
  739. Allogenic Peripheral Blood Stem cell Transplant Utilizing Rabbit Anti-Thymocyte Globulin as a Part of Non-Myeloablative Conditioning therapy.
  740. Engineered human mesenchymal Stem cells: a novel platform for skeletal cell mediated gene therapy
  741. 1162. Correction of the Immune and Metabolic Defect of ADA-SCID by Stem cell Gene therapy Combined with Nonmyeloablative Conditioning
  742. The HGFIN Gene Mediates cell Cycle Quiescence of CD34+/CD38-: Implications for Hematopoietic Stem cell Expansion and Gene therapy.
  743. Adenovirus-Mediated Targeted Gene therapy for Breast Cancer and for Purging Hematopoietic Stemcell Sources
  744. … RESTORES THYMIC FUNCTION AND ENHANCES HEMOPOIESIS AND LYMPHOPOIESIS FOLLOWING ALLOGE-NEIC AND AUTOLOGOUS Stem cell
  745. High Dose therapy with Autologous Blood Stem cell Transplantation (ASCT) for Follicular Lymphoma: Long-Term Outcome According to Histologic Grade.
  746. Intracerebral Mesenchymal Stem cell Gene therapy in the Niemann-Pick Disease Mouse
  747. First Line therapy with Reduced Intensity Conditioning Allogeneic Stem cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete …
  748. … Intensity Induction therapy Followed by Early High Dose Chemotherapy (HDT) and Autologous Hematopoietic Stem cell Transplantation (AHSCT) for Mantle cell
  749. GMP Compliant Expansion of Hematopoietic Stem cells (CD34+) Selected from Cord Blood for a Phase I cell therapy Trial
  750. Sex streoid ablation therapy restores thymic function and enhances hemopoiesis and lymphopoiesis following allogeneic and autologous Stem cell transplantation
  751. … RESISTANT TO CONVENTIONAL THERAPEUTIC REGIMENSV4. 2. 18 CHILDREN AFTER AUTOLOGOUS Stem cell TRANSPLANTATION FOR REFRACTORY …
  752. Autologous Stem cell transplantation following induction therapy with an anthracycline-based regimen including interferon-alpha for low-grade non-Hodgkin’s …
  753. Development of hemopoietic Stem cell gene therapy for Niemann-Pick disease using the acid sphingomyelinase knock-out mouse model
  754. BCCA Protocol Summary for Myeloablative Conditioning therapy Prior to Autologous and Allogeneic Hematopoietic Stem cell Transplantation for Myeloid …
  755. # 703 High dose mobilization chemotherapy followed by myeloblative therapy with Stem cell support for the treatment of small, round, blue cell tumors
  756. … blood Stem cell transplantation (allo-pbsct): changing patterns and low dose short course (ldsc) gancyclovir (gcv) as an effective nontoxic presumtive therapy (pt) …
  757. Intensified induction followed by high-dose therapy with autologous peripheral blood Stem cell support in poor-prognosis aggressive non-Hodgkin’s lymphoma …
  758. 12 Multiple courses of high-dose alkylating therapy with autologous Stem cell support
  759. … Followed by High-Dose therapy with Autologous Peripheral Blood Stem cell Transplantation for Advanced-Stage Follicular Lymphoma as First-Line therapy
  760. Improving dosing precision in busulfan (bu)-based preparative regimens for hematopoietic Stem cell transplantation (HSCT) using parmacokinetics directed therapy
  761. Gene therapy: Bone Regeneration Using Adenovirus Mediated Bone Morphogenic Protein Engineered Mesenchymal Stem cell
  762. Stem cell transplantation (PBSCT) for patients with malignant lymphoma–its role in the treatment strategy for non-Hodgkin’s lymphoma, and ESHAP+ PBSCT therapy
  763. The Useful Individualized Assessment of Immunosuppressive therapy with Cyclosporine A (CsA) after Allogeneic Stem cell Transplantation by Simultaneous …
  764. … Patients Undergoing Allogeneic Hematopoietic Stem cell Transplantation: Increased Incidence in Patients Receiving Alemtuzumab (ALEM) as Conditioning therapy
  765. AUTOLOGOUS Stem cell TRANSPLANTATION (ASCT) FOR THE TREATMENT OF HIV-ASSOCIATED NON-HODGKIN’S LYMPHOMA (NHL) IN THE ERA OF …
  766. Intensified full-dose induction therapy (HD-MACHOP+ radiotherapy) follwed dy consolidation with BAVC regimen and autologous Stem cell transplantation as fron-line …
  767. Symposium 7: Stem cell Research; Application of Endothelial Progenitor cells (EPC) to Vascular Medicine: Mobilized EPC by GM-CSF accelerate …
  768. Intensive antileukemic therapy including Stem cell transplantation (SCT) for high risk MDS and AML following MDS (SAML) in patients< 60 years. a joint study of the …
  769. … Versus Gene Modified Autologous Stem cell Transplantation for Severe Combined Immunodeficiencies (SCID). The Risk/Benefit Balance Is in Favor of Gene therapy
  770. Denileukin diftitox (ONTAK) as targeted therapy against steroid refractory graft-versus-host disease (GVHD) after allogeneic hematopoietic Stem cell transplantation …
  771. Repetitive High-Dose therapy with Dose Escalated CHOP+ Etoposide Followed by Autologous Stem cell Transplantation (Mega-CHOEP) in Younger Patients with …
  772. … POST TRANSPLANT-Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic Stem cell
  773. Fludarabine and cytosine arabinoside as salvage therapy in patients with relapsed acute and chronic leukaemia after BMT or allogenic Stem cell transplantation
  774. Post-remission therapy with 4 cycles of intermediate (I) or high-dose (HD) cytarabine (AC) or autologous hematopoietic Stem cell transplantation (ASCT) for acute …
  775. … /Disease Consisting of a Higher Cutoff Point and a Lower Initial Dose of Ganciclovir after Allogeneic Hematopoietic Stem cell Transplantation (HSCT) with an HLA …
  776. cell therapy Using Embryonic Stem cells
  777. … EXPRESSION IN SYStemIC JUVENILE IDIOPATHIC ARTHRITIS IS RESTORED BY AUTOLOGOUS Stem cell TRANSPLANTATION. AUTONOMIC NERVOUS …
  778. … purging of autologous hematopoietic Stem cells using anti-B-cell monoclonal antibody-coated high-density microparticles prior to high-dose therapy for patients with …
  779. A novel sub-population of bone marrow derived myocardial Stem cells: potential autologus cell therapy in myocardial infarction
  780. Human neural Stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS
  781. Autologous mesenchymal Stem cells for articular and bone cell therapy
  782. Potential use of T cell receptor genes to modify hematopoietic Stem cells for the gene therapy of cancer
  783. … of Human Neural Stem cells in a New Primate Model of Motor Neuron Degeneration: An Experimental Study of Potential cell therapy for Amyotrophic Lateral …
  784. Engineering mesenchymal Stem cells with hypoxia-regulated gene syStem: A promising approach for effective cell therapy
  785. Recovery of stromal Stem cells in bone sarcoma patients after chemotherapy: Implication for cell-based therapy in bone defect reconstruction
  786. … of the rate of reduction in platelet counts in recipients of hematopoietic Stem and progenitor cell transplant: clinical implications for platelet transfusion therapy
  787. Mesenchymal Stem cells. Potential use in cell and gene therapy of bone loss caused by aging and osteoporosis
  788. Use of Embryonic Stem cells to Produce Islets in cell Replacement therapy as a Treatment for Type 1 Diabetes
  789. 1417: Mesenchymal Stem cells Alone or Modified with ENOS Restore Erectile Function in the Aged Rat: cell-Based Gene therapy for Erectile Dysfunction
  790. Adult Stem cell therapy in stroke
  791. Potential of mesenchymal Stem cell therapy
  792. Stem cell therapy and the retina
  793. Does mesenchymal Stem cell therapy help multiple sclerosis patients? Report of a pilot study
  794. Role of imaging in cardiac Stem cell therapy
  795. Stem cell therapy enhances electrical viability in myocardial infarction
  796. The potential for Stem cell therapy in diabetes
  797. Stem cell-based cell therapy for spinal cord injury
  798. Comparison of imaging techniques for tracking cardiac Stem cell therapy
  799. cell therapy and the safety of embryonic Stem cell-derived grafts
  800. Adult Stem cell therapy: dream or reality?
  801. Stem cell therapy for autism
  802. Stem cell therapy for vascular disease
  803. The dying Stem cell hypothesis: immune modulation as a novel mechanism for progenitor cell therapy in cardiac muscle
  804. Mesenchymal Stem cell therapy to rebuild cartilage
  805. Stem cell therapy for ischemic heart failure
  806. Stem cell therapy—Present status
  807. Stem cell therapy for neurologic disorders: therapeutic potential of adipose-derived Stem cells
  808. Injectable mesenchymal Stem cell therapy for large cartilage defects—a porcine model
  809. Autologous in vitro expanded mesenchymal Stem cell therapy for human old myocardial infarction
  810. Concise review: prospects of Stem cell therapy for temporal lobe epilepsy
  811. Enhancing Stem cell therapy through genetic modification
  812. Differentiation of mesenchymal Stem cells transplanted to a rabbit degenerative disc model: potential and limitations for Stem cell therapy in disc regeneration
  813. Successful Stem cell therapy using umbilical cord blood‐derived multipotent Stem cells for Buerger’s disease and ischemic limb disease animal model
  814. Stem cell therapy: hope or hype?
  815. Embryonic Stem cell therapy for diabetes mellitus
  816. Stem cell therapy for osteonecrosis of the femoral head
  817. Concise review: scientific and ethical roadblocks to human embryonic Stem cell therapy
  818. Stem cell therapy for human brain disorders
  819. New approach to radiation burn treatment by dosimetry-guided surgery combined with autologous mesenchymal Stem cell therapy
  820. Mesenchymal Stem cell therapy in equine musculoskeletal disease: scientific fact or clinical fiction?
  821. Lost and found: cardiac Stem cell therapy revisited
  822. Stem cell therapy for cardiovascular disease
  823. Cardiac Stem cell therapy: need for optimization of efficacy and safety monitoring
  824. Stem cell therapy for cardiac diseases
  825. Stem cell therapy in bone repair and regeneration
  826. The potential role of mesenchymal Stem cell therapy for intervertebral disc degeneration: a critical overview
  827. Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal Stem cell therapy
  828. Nonmyeloablative Stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease
  829. Practical issues in Stem cell therapy for Alzheimer’s disease
  830. Towards Stemcell therapy in the endocrine pancreas
  831. Stem cell therapy for cardiac repair: ready for the next step
  832. Increase in vascular permeability and vasodilation are critical for proangiogenic effects of Stem cell therapy
  833. Stem cell plasticity and issues of Stem cell therapy
  834. Intravenous mesenchymal Stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic …
  835. Current concepts in adult Stem cell therapy for stroke
  836. Stem cell therapy for joint problems using the horse as a clinically relevant animal model
  837. Stem cell therapy for Parkinson’s disease
  838. Stem cell therapy for urinary stress incontinence
  839. Fetomaternal cell trafficking: a story that begins with prenatal diagnosis and may end with Stem cell therapy
  840. Preimplantation genetics: improving access to Stem cell therapy
  841. Stem cell therapy after myocardial infarction: ready for clinical application?
  842. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances Stem cell therapy
  843. Stem cell therapy for human liver cirrhosis: a cautious analysis of the results
  844. Adult neural Stem cell therapy: expansion in vitro, tracking in vivo and clinical transplantation
  845. Stem cell therapy in postinfarction chronic coronary heart disease
  846. Hyalomatrix: a temporary epidermal barrier, hyaluronan delivery, and neodermis induction syStem for keratinocyte Stem cell therapy
  847. Stem cell therapy delivery: treading the regulatory tightrope
  848. In situ Stem cell therapy: novel targets, familiar challenges
  849. Nonmyeloablative Stem cell transplantation and cell therapy for malignant and non-malignant diseases
  850. Paracrine and differentiation mechanisms underlying Stem cell therapy for the damaged kidney
  851. Gene and Stem cell therapy
  852. Heparin/poly (L-lysine) nanoparticle-coated polymeric microspheres for Stemcell therapy
  853. Diabetes mellitus: a potential target for Stem cell therapy
  854. Multipotential mesoangioblast Stem cell therapy in the mdx/utrn-/- mouse model for Duchenne muscular dystrophy
  855. Stem cell therapy for sickle cell disease: transplantation and gene therapy
  856. Stem cell therapy for ischemic heart disease: beginning or end of the road?
  857. Neural Stem cell therapy and gastrointestinal biology
  858. Therapeutic angiogenesis for peripheral artery disease: Stem cell therapy
  859. Stem cell therapy for myelin diseases
  860. The allure of Stem cell therapy for muscular dystrophy
  861. Bone marrow Stem cell therapy for myocardial angiogenesis
  862. Gene and Stem cell therapy for erectile dysfunction
  863. The use of Stem cell therapy for cardiovascular disease
  864. Limbal epithelial Stem cell therapy
  865. Which place for Stem cell therapy in the treatment of acute radiation syndrome?
  866. cellular multiparametric MRI of neural Stem cell therapy in a rat glioma model
  867. Pharmacologic management of ischemic stroke: relevance to Stem cell therapy
  868. Stem cell therapy for myocardial repair
  869. Advances in the understanding of sress urinary incontinence and the promise of Stemcell therapy
  870. Artificial cells: biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, and cell/Stem cell therapy
  871. Stem cells and their applications in skin-cell therapy
  872. The potential of cardiac Stem cell therapy for heart failure
  873. Contemplating the bright future of Stem cell therapy for cardiovascular disease
  874. Stem cell therapy: a hope for dying hearts
  875. Neural Stem cell therapy for neuropsychiatric disorders
  876. Stem cell therapy or snake oil?
  877. Novel therapies for the treatment of cystic fibrosis: new developments in gene and Stem cell therapy
  878. G‐CSF‐based Stem cell therapy for the heart—unresolved issues part A: Paracrine actions, mobilization, and delivery
  879. Stem cell therapy for the treatment of heart failure
  880. … -colony-stimulating factor mobilization of Stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical Stem cell therapy?
  881. Mesenchymal Stem cell-based HLA-independent cell therapy for tissue engineering of bone and cartilage
  882. Stemcell therapy: hope and hype
  883. Gene and Stem cell therapy of the hair follicle
  884. Cardiac Stem cell therapy for myocardial regeneration. A clinical perspective.
  885. Embryonic Stem cell therapy.
  886. Isolation of amniotic Stem cell lines with potential for therapy
  887. … donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and cell therapy
  888. Stem cell therapy in the aging hearts of Fisher 344 rats: synergistic effects on myogenesis and angiogenesis
  889. Sources of cardiomyocytes for Stem cell therapy: an update
  890. The Netherlands bans private Stem cell therapy
  891. Adult Stem cell therapy beyond haemopoietic Stem cell transplantation? An update
  892. Gene therapy and Stem cell therapy for cardiovascular diseases today: a model for translational research
  893. The origin of deoxynucleosides in brain: implications for the study of neurogenesis and Stem cell therapy
  894. Stem cell therapy for central nervous syStem demyelinating disease
  895. Stem cell therapy for cardiac arrhythmias
  896. Cardiac Stem cell therapy: present and future
  897. Cancer Stem cell: target for anti‐cancer therapy
  898. T-cell therapy after hematopoietic Stem cell transplantation
  899. A method for quantitative cell tracking using SPECT for the evaluation of myocardial Stem cell therapy
  900. Umbilical cord Stem cell therapy for cerebral palsy
  901. Stem cell therapy for Parkinson’s disease
  902. Tubular regeneration and the role of bone marrow cells:’Stem cell therapy‘–a panacea?
  903. The promise of Stem cell therapy to restore urethral sphincter function
  904. The role of high-dose therapy and Stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study
  905. Bone-marrow-derived cells for cardiac Stem cell therapy: safe or still under scrutiny?
  906. Cancer Stem cell and cancer Stemloids: from biology to therapy
  907. Clinical applications of Stem cell therapy–the pros and cons of Stem cell sources
  908. … and sustain hematopoietic reconstitution after coculture and cografting in lethally irradiated baboons: is autologous Stem cell therapy in nuclear accident …
  909. Safety of intramyocardial Stem cell therapy for the ischemic myocardium: results of the Rostock trial after 5-year follow-up
  910. Functional considerations of Stem cell transplantation therapy for spinal cord repair
  911. Insertional mutagenesis in gene therapy and Stem cell biology
  912. Bone marrow Stem cell therapy for cardiac repair: challenges and perspectives.
  913. Stemcell therapy for diabetes cure: how close are we?
  914. Platelet lysates promote mesenchymal Stem cell expansion: A safety substitute for animal serum in cell‐based therapy applications
  915. Stem cell therapy for retinal degeneration: retinal neurons from heterologous sources
  916. How does human Stem cell therapy influence gene expression after liver injury?: Microarray evaluation on a rat model
  917. … leukocyte antigen matching estimations in a hypothetical bank of human embryonic Stem cell lines in the Japanese population for use in cell transplantation therapy
  918. Stem cell‐based therapy for Parkinson’s disease
  919. Stem cell therapy for neuropathic pain treatment
  920. Stem cell therapy-Hope and scope in pediatric surgery
  921. Phenotypic characterization and preclinical production of human lineage‐negative cells for regenerative Stem cell therapy
  922. Stem cell therapy for acute myocardial infarction
  923. Stem cell therapy improves myocardial perfusion and cardiac synchronicity: new application for echocardiography
  924. 50th anniversary of artificial cells: their role in biotechnology, nanomedicine, regenerative medicine, blood substitutes, bioencapsulation, cell/Stem cell therapy
  925. Stem cell strategies for Alzheimer’s disease therapy.
  926. Stem cell therapy and tissue engineering for cardiovascular repair: from basic research to clinical applications.
  927. Stem cell transplantation: a promising therapy for Parkinson’s disease
  928. The role of noninvasive imaging techniques in the assessment of Stem cell therapy after acute myocardial infarction
  929. From bench to bedside? Biomedical scientists’ expectations of Stem cell science as a future therapy for diabetes
  930. In vivo tracking in cardiac Stem cell-based therapy
  931. Hematopoietic Stem cell therapy for malignant diseases
  932. Gene therapy progress and prospects: Stem cell plasticity
  933. Preemptive therapy of EBV‐related lymphoproliferative disease after pediatric haploidentical Stem cell transplantation
  934. Stem cell therapy-A panacea for all ills?
  935. Bone marrow-derived Stem cell therapy in ischemic heart disease
  936. Survival of the fittest: in vivo selection and Stem cell gene therapy
  937. Cardiovascular MRI for Stem cell therapy
  938. Stem cell therapy for hearing loss: Math1 overexpression in VOT-E36 cells
  939. Impact of lenalidomide therapy on Stem cell mobilization and engraftment post-peripheral blood Stem cell transplantation in patients with newly diagnosed …
  940. REVIEW ARTILCE: cell therapy and Stem cells in animal models of motor neuron disorders
  941. Stem cell therapy for glomerular disease
  942. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic Stemcell transplantation: an international case-control study
  943. A look to the future: prediction, prevention, and cure including islet transplantation and Stem cell therapy
  944. Remaking the body? Scientists’ genetic discourses and practices as examples of changing expectations on embryonic Stem cell therapy for diabetes
  945. The impact of Stem cell therapy in hematology and oncology
  946. Youthful prospects for human Stemcell therapy: In another few decades, revised attitudes towards Stem cells could lead to disease prevention and life extension
  947. A natural Stem cell therapy? How novel findings and biotechnology clarify the ethics of Stem cell research
  948. Dutch clinic is ordered to stop giving Stem cell therapy
  949. Stem cell therapy in stroke: strategies in basic study and clinical application
  950. Hematopoietic Stem cell mobilization therapy accelerates recovery of renal function independent of Stem cell contribution
  951. Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoetic Stem cell transplant patients
  952. Development of human umbilical cord matrix Stem cell-based gene therapy for experimental lung tumors
  953. Celocentesis for in utero Stem cell therapy: where we now stand and future directions
  954. Clinical trials in Stem cell therapy: pitfalls and lessons for the future
  955. Stem cell therapy of acute spinal cord injury in dogs
  956. G‐CSF‐Based Stem cell therapy for the Heart—Unresolved Issues Part B: Stem cells, Engraftment, Transdifferentiation, and Bioengineering
  957. The challenge for Stem cell therapy
  958. … Renal Failure by Stem cell therapy—Paracrine Secretion Versus Transdifferentiation into Resident cells: Administered Mesenchymal Stem cells Protect against …
  959. Nonmyeloablative Stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative …
  960. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review
  961. High-dose therapy and autologous blood Stemcell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term …
  962. Stem cell therapy in patients with multiple sclerosis
  963. Embryonic Stem cells: prospects for developmental biology and cell therapy
  964. Cardiac Stem cell therapy from bench to bedside
  965. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with Stem cell gene therapy
  966. Stem cell and gene-based therapy
  967. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic Stem cell transplantation
  968. Stem cell therapy for diabetes mellitus: progress, prospects and challenges
  969. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic Stem cell transplantation: risk factors analysis and outcome
  970. Promises and pitfalls of Stem cell therapy for promotion of bone healing
  971. Quantitative assessment of molecular remission after high-dose therapy with autologous Stem cell transplantation predicts long-term remission in mantle cell
  972. Launching a clinical program of Stem cell therapy for cardiovascular repair
  973. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review
  974. Potential of Stem cell based therapy and tissue engineering in the regeneration of the central nervous syStem
  975. Allogeneic hematopoietic Stem cell transplantation as part of postremission therapy improves survival for adult patients with high‐risk acute lymphoblastic leukemia: a …
  976. … of the left ventricular myocardial contraction with Stem cell therapy: new insights into the therapeutic implication of Stem cell therapy in myocardial infarction
  977. Allogeneic Stemcell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma
  978. Embryonic Stem cells: meeting the needs for cell therapy
  979. Successful reconstitution of immunity in ADA-SCID by Stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning
  980. High-dose therapy followed by autologous purged Stemcell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a …
  981. Stemcell therapy for hepatobiliary pancreatic disease
  982. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic Stem cell transplantation in Hurler syndrome
  983. Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic Stemcell transplantation results in favorable outcomes
  984. Stem cell therapy in cardiovascular diseases
  985. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous Stem cell transplantation in untreated patients with …
  986. Mesenchymal Stem cell therapy for multiple sclerosis
  987. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based …
  988. … With Myeloablative Chemotherapy and Autologous Stemcell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma therapy
  989. High-dose chemotherapy with autologous Stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a …
  990. Autologous Stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis
  991. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic Stem cell transplantation
  992. Stem cell transplantation and gene therapy for hemoglobinopathies.
  993. The effect of first-line imatinib interim therapy on the outcome of allogeneic Stem cell transplantation in adults with newly diagnosed Philadelphia chromosome …
  994. Stem cell therapy in the heart and vasculature
  995. Perspectives of gene therapy in Stem cell tissue engineering
  996. Correction of murine hemophilia A by hematopoietic Stem cell gene therapy
  997. Stem cell therapy
  998. Stem cell migration: a quintessential stepping stone to successful therapy
  999. Dendritic cell therapy for tolerance induction to Stem cell transplants
  1000. Integration of genomics, proteomics, and imaging for cardiac Stem cell therapy
  1001. … in the peripheral blood after allogeneic Stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy
  1002. Induction of neurotrophin expression via human adult mesenchymal Stem cells: implication for cell therapy in neurodegenerative diseases
  1003. … syStem-based comparison between human dental pulp Stem cells (hDPSCs) and human mesenchymal Stem cells (hMSCs) for tissue engineering cell therapy
  1004. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic Stem cell transplant recipients
  1005. Low‐energy laser therapy for prevention of oral mucositis in hematopoietic Stem cell transplantation
  1006. New era of cardiac Stem cell therapy in heart failure
  1007. Cripto as a Target for Improving Embryonic Stem cell–Based therapy in Parkinson’s Disease
  1008. Gene and Stem cell therapy in the treatment of erectile dysfunction and pulmonary hypertension; potential treatments for the common problem of endothelial …
  1009. Stem cell therapy in Iran
  1010. Current practice and future perspectives of myocardial Stem cell therapy
  1011. Current status and concepts of Stem cell therapy
  1012. Rituximab and DHAP followed by intensive therapy with autologous Stemcell transplantation as first-line therapy for mantle cell lymphoma
  1013. Stem cell therapy in acute myocardial infarction
  1014. Stem cell therapy for myocardial regeneration: creating hype ignoring reality
  1015. The safety of interferon‐γ‐1b therapy for invasive fungal infections after hematopoietic Stem cell transplantation
  1016. Targeting, imaging, and therapy using a humanized antiprostate Stem cell antigen (PSCA) antibody
  1017. Mesenchymal Stem cell therapy of brain ischemic stroke in rats
  1018. Stem cell-based therapy for the treatment of Type 1 diabetes mellitus
  1019. Novel tyrosine kinase inhibitor therapy before allogeneic Stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant …
  1020. Cardiovascular therapeutic aspects of cell therapy and Stem cells
  1021. Neuropsychological function in high-risk breast cancer survivors after Stemcell supported high-dose therapy versus standard-dose chemotherapy: evaluation …
  1022. Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic Stemcell transplant
  1023. Effectiveness of prophylactic anti‐HBV therapy in allogeneic hematopoietic Stem cell transplantation with HBsAg positive donors
  1024. … , dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous Stem cell
  1025. Stem cell therapy in chronic heart failure
  1026. Tumorigenesis and embryonic Stem cell-derived therapy
  1027. Imatinib therapy prior to myeloablative allogeneic Stem cell transplantation
  1028. Stem cell therapy in heart failure: where do we stand and where are we heading?
  1029. Development of hematopoietic Stem cell gene therapy for Wiskott-Aldrich syndrome.
  1030. Neural Stem cells as biological minipumps: a faster route to cell therapy for the CNS?
  1031. High-dose therapy with autologous Stem cell transplantation in first response in mantle cell lymphoma
  1032. Stem cell pharmacogenomics: a reality check on Stem cell therapy.
  1033. cell therapy using allogeneic bone marrow mesenchymal Stem cells prevents tissue damage in collagen‐induced arthritis
  1034. Stem cell research: cloning, therapy and scientific fraud
  1035. Stem cell therapy. Biology of hematopoietic Stem cells
  1036. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic Stem cell
  1037. Hematopoietic Stemcell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens
  1038. Myogenic Stem cells: regeneration and cell therapy in human skeletal muscle
  1039. Lessons for the Stem cell discourse from the gene therapy experience
  1040. Targeting the most critical cells: approaching leukemia therapy as a problem in Stem cell biology
  1041. “Stealth immune tolerance” in Stem cell transplantation: potential for “universal donors” in myocardial regenerative therapy
  1042. Ethical legal and social issues in Stem cell research and therapy
  1043. Stem cell therapy for demyelinating disorders
  1044. Hematopoietic Stem cell–targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice
  1045. Stem cells engineering for cell-based therapy
  1046. … veno-occlusive disease in pediatric Stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy
  1047. … conditioning allogeneic Stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and cellular therapy
  1048. Value of Stem cell therapy for the treatment of stress incontinence. Current status and perspectives
  1049. The role of high-dose therapy and autologous Stem cell transplantation for pediatric bone and soft tissue sarcomas
  1050. … -occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood Stem cell transplantation in multiple …
  1051. Application of liver Stem cells for cell therapy
  1052. Stem cell therapy: a new perspective for the treatment of ischemic heart failure
  1053. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic Stem cell transplantation
  1054. Estrogen-progestin therapy in women after Stem cell transplant: our experience and literature review
  1055. Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic Stem cell recipients
  1056. Extended lamivudine therapy against hepatitis B virus infection in hematopoietic Stem cell transplant recipients
  1057. Mesenchymal Stem cell therapy for the injured heart
  1058. Hematopoietic Stem cell gene therapy: dead or alive?
  1059. The promise of Stem cell therapy for eye disorders
  1060. Towards the generation of patient-specific pluripotent Stem cells for combined gene and cell therapy of hematologic disorders
  1061. Use of bortezomib as induction therapy prior to Stem cell transplantation in frontline treatment of multiple myeloma: impact on Stem cell harvesting and engraftment
  1062. Good manufacturing practice-compliant expansion of marrow-derived Stem and progenitor cells for cell therapy
  1063. Salvage therapy for CLL and the role of Stem cell transplantation
  1064. Chemotherapy with rituximab followed by high‐dose therapy and autologous Stem cell transplantation in patients with mantle cell lymphoma
  1065. Short intensive sequential therapy followed by autologous Stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma
  1066. Haematopoietic Stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma
  1067. Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood Stem cell transplantation
  1068. Stem cell therapy for intervertebral disc degeneration: In vitro study
  1069. Once daily ganciclovir as initial pre-emptive therapy delayed until threshold CMV load⩾ 10000 copies/ml: a safe and effective strategy for allogeneic Stem cell
  1070. High-dose therapy and autologous hematopoietic Stem cell transplantation for patients with primary syStemic amyloidosis: a Center for International Blood and Marrow …
  1071. A randomized comparison of empiric or pre-emptive antibiotic therapy after hematopoietic Stem cell transplantation
  1072. Stem cell controversy to stall European tissue and cell therapy rules
  1073. cell therapy, Stem cells and brain repair
  1074. Outcome of hematopoietic Stem cell transplantation for pediatric patients with therapy‐related acute myeloid leukemia or myelodysplastic syndrome
  1075. New strategies of antifungal therapy in hematopoietic Stem cell transplant recipients and patients with hematological malignancies
  1076. Stem cell Transplantation: Biology, Processes, therapy
  1077. Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with Stem cell transplant: review and consensus statement
  1078. therapy of Duchenne muscular dystrophy with umbilical cord blood Stem cell transplantation
  1079. Human embryonic Stem cell therapy for Parkinson’s disease
  1080. Autologous Stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
  1081. Motor function recovery after adipose tissue derived mesenchymal Stem cell therapy in rats with cerebral infarction
  1082. Efficacy of high‐dose therapy and hematopoietic Stem cell transplantation for mantle cell lymphoma
  1083. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic Stem cell gene therapy
  1084. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic Stem cell transplantation
  1085. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic Stem cell mobilization
  1086. Cardiac effects within 3 months of BEAC high‐dose therapy in non‐Hodgkin’s lymphoma patients undergoing autologous Stem cell transplantation
  1087. High dose chemotherapy and autologous Stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes …
  1088. … intensity conditioning and allogeneic Stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non …
  1089. High-dose chemotherapy with Stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up
  1090. Thalidomide salvage therapy following allogeneic Stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du …
  1091. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human Stem cell and gene therapy
  1092. Hematopoietic Stem cell gene therapy with drug resistance genes: an update
  1093. Stem cell therapy in end-stage ischaemic heart failure: a catheter-based therapeutic strategy targeting myocardial viability
  1094. therapy with ICE Followed by High Dose therapy and Autologous Stem cell Transplantation for Relapsed/Refractory Peripheral T-cell Lymphomas: Minimal Benefit …
  1095. Preclinical trials for Stem cell therapy
  1096. Complexity of the human acute myeloid leukemia Stem cell compartment: implications for therapy
  1097. Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic Stem cell
  1098. Catheter-based Stem cell and gene therapy for refractory myocardial ischemia
  1099. Stem cell and Stem cell therapy in Thailand
  1100. Reduced intensity conditioning allows for up-front allogeneic hematopoietic Stem cell transplantation after cytoreductive induction therapy in newly-diagnosed …
  1101. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic Stem cell transplantation
  1102. Posaconazole salvage therapy allows successful allogeneic hematopoietic Stem cell transplantation in patients with refractory invasive mold infections
  1103. Characterization of BioSafe SEPAX Manufactured Stem cell Intended for Cardiac cell therapy.
  1104. Low-dose methotrexate as salvage therapy for refractory graft-versus-host disease after reduced-intensity conditioning allogeneic Stem cell transplantation
  1105. The role of high-dose therapy and autologous Stem cell transplantation in patients with primary refractory Hodgkin’s lymphoma: a report from the Gruppo …
  1106. Diagnostic yield of bronchoalveolar lavage is low in allogeneic hematopoietic Stem cell recipients receiving immunosuppressive therapy or with acute graft …
  1107. Medium-term survival without haematopoietic Stem cell transplantation in a case of IPEX: insights into nutritional and immunosuppressive therapy
  1108. The effect of neural embryonic Stem cell therapy in a rat model of cavernosal nerve injury
  1109. Review: Mesenchymal Stem cells: cell–Based Reconstructive therapy in Orthopedics
  1110. Initial therapy of multiple myeloma patients who are not candidates for Stem cell transplantation
  1111. Mantle cell lymphoma (MCL): induction therapy with HyperCVAD/High-dose methotrexate and cytarabine (MC)(±rituximab) improves results of autologous Stem cell
  1112. High-dose chemotherapy and autologous hematopoietic Stem cell transplantation for metastatic breast cancer: a therapy whose time has passed
  1113. Melphalan 200 mg/m2 with blood Stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related …
  1114. Human embryonic Stem cell therapy, what is the attitude of the public?
  1115. Progress and clashes in Stem cell therapy research
  1116. The role of Stemcell transplantation in chronic lympocytic leukemia risk-adapted therapy
  1117. Haematopoietic Stem cell gene therapy to treat autoimmune disease
  1118. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  1119. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic Stem cell transplantation: a single-center experience in Korea
  1120. Stemcell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy
  1121. Effect of prior rituximab on high-dose therapy and autologous Stem cell transplantation in follicular lymphoma
  1122. Stem cell therapy in ischemic heart disease
  1123. High-dose therapy and autologous Stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma
  1124. Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy
  1125. Stem cell therapy for chronic cardiac insufficiency–therapy of the future?
  1126. Outcome of Allogeneic Stem cell Transplantation after Hypomethylating therapy with 2′-Deoxy-5 Azacytidine for Patients with Myelodysplastic Syndrome.
  1127. Rituximab long-term maintenance therapy after autologous Stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma
  1128. First-line thalidomide–dexamethasone therapy in preparation for autologous Stem cell transplantation in young patients (< 61 years) with symptomatic multiple …
  1129. Long-term event-free survivors after high-dose therapy and autologous Stemcell transplantation for low-grade follicular lymphoma
  1130. … staging syStems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood Stem cell transplantation as first-line therapy
  1131. Human cordonal Stem cell intraperitoneal injection can represent a rescue therapy after an acute hepatic damage in immunocompetent rats
  1132. Stem cell therapy still not here
  1133. … in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic Stem cell
  1134. Collection of fetal blood for Stem cell research and therapy
  1135. Umbilical Cord Stem cell therapy: The Gift of Healing from Healthy Newborns
  1136. Growth hormone (GH) secretion and response to GH therapy after total body irradiation and haematopoietic Stem cell transplantation during childhood
  1137. therapy for Treatment of Autoimmune Diseases, Basic Science and Clinical Studies, Including New Developments in Hematopoietic and Mesenchymal Stem cell
  1138. Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic Stem cell transplantation: a molecular analysis
  1139. Current concepts of Stem cell therapy
  1140. Diabetic cardiomyopathy: a “cardiac Stem cell disease” involving p66Shc, an attractive novel molecular target for heart failure therapy
  1141. The yin and yang of Stem cell gene therapy: insights into hematopoiesis, leukemogenesis, and gene therapy safety
  1142. Autologous Stem cell Transplantation as First-Line therapy in Peripheral T-cell Lymphomas. A Prospective Multicenter Study.
  1143. Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous Stem cell support
  1144. Recent View of Stem cell Plasticity and Stem cell therapy
  1145. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous Stemcell transplantation as first-line treatment in …
  1146. The therapeutic potential of mesenchymal Stem cells: cell-& tissue-based therapy
  1147. Regulating Stem cell research & therapy
  1148. Embryonic Stem cell-based diabetes therapy—a long road to travel
  1149. Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic Stem cell transplantation
  1150. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous Stem cell
  1151. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic Stem cell transplantation
  1152. Stem and progenitor cell–based therapy of the human central nervous syStem
  1153. Immobilization of mesenchymal Stem cells and monocytes in biocompatible microcapsules to cell therapy
  1154. T cell suicide gene therapy to aid haematopoietic Stem cell transplantation
  1155. therapy between chemotherapeutic cycles and in vivo purging prior to autologous Stem cell transplantation, followed by maintenance therapy is a feasible …
  1156. Suppressive anti-HCV therapy for prevention of donor to recipient transmission in Stem cell transplantation
  1157. Frontline therapy with early intensification and autologous Stem cell transplantation versus conventional chemotherapy in unselected high-risk, aggressive non …
  1158. Mechanistic insights into cardiac Stem cell therapy from a histopathologic perspective
  1159. Modified total body irradiation as a planned second high-dose therapy with Stem cell infusion for patients with bone-based malignancies
  1160. Early Stem cell transplantation for refractory acute leukemia after salvage therapy with high-dose etoposide and cyclophosphamide
  1161. Successful therapy with whole‐lung lavage and autologous peripheral blood Stem cell transplantation for pulmonary alveolar proteinosis complicating acute …
  1162. … during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent Stem cell
  1163. The shady side of embryonic Stem cell therapy
  1164. … of In Vitro Irradiated CD34+ cells in the Presence of SCF, FLT3 Ligand, TPO and IL3: Potential Application to Autologous cell therapy in Accidentally Irradiated …
  1165. The KIDStem European research training network: Developing a Stem cell based therapy to replace nephrons lost through reflux nephropathy
  1166. Peritransplant use of ultraviolet-B irradiation (UV-B) therapy is detrimental to allogeneic Stem cell transplantation outcome
  1167. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic Stem cell transplantation
  1168. Successful interim therapy with imatinib prior to allogeneic Stem cell transplantation in Philadelphia chromosome‐positive acute myeloid leukemia
  1169. rHuEpo before high-dose therapy allows autologous peripheral Stemcell transplantation without red blood cell transfusion: a pilot study
  1170. Stem cells, Stem cell therapy, and ethical problems of medicine
  1171. The World of Stem cell therapy: Anonymity is not an Option
  1172. The effect of quantification standards used in real-time CMV PCR assays on guidelines for initiation of therapy in allogeneic Stem cell transplant patients
  1173. Mesenchymal Stem cells characteristics, niches, and applications for cell therapy
  1174. Gene and cell therapy involving hematopoietic Stem cell
  1175. Cardiovascular regeneration and Stem cell therapy
  1176. Autologous Stem cell gene therapy: toward a universal platform for personalized therapy
  1177. Embryonic Stem cell–derived astrocytes: a novel gene therapy vector for brain tumors
  1178. The impact of histologic grade on the outcome of high-dose therapy and autologous Stem cell transplantation for follicular lymphoma
  1179. A novel intensive induction therapy for high‐risk neuroblastoma utilizing sequential peripheral blood Stem cell collection and infusion as hematopoietic support
  1180. Use of iron oxide MR contrast agents for monitoring Stem cell therapy
  1181. Potentials and limitations of Stem cell therapy in myocardial disease
  1182. Stem cell based cell therapy for muscular dystrophy
  1183. Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: role of rituximab, high-dose therapy, and allogeneic Stem cell
  1184. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous Stem cell transplantation
  1185. Efficacy of recombinant human erythropoietin therapy started one month after autologous peripheral blood Stem cell transplantation
  1186. cell transplant and regenerative therapy with Stem cells
  1187. Potential application of embryonic Stem cells in Parkinson’s disease: drug screening and cell therapy
  1188. 328: Transurethral Ultrasound Guided Stem cell therapy of Urinary Incontinence
  1189. … International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin’s lymphomas treated with high-dose BEAM therapy and autologous Stem cell
  1190. Effect of neurotrophic factor and Stem cell therapy on axonal regeneration after spinal cord injury: Overseas progress in basic and clinical researches
  1191. A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic Stem cell transplant (HSCT)
  1192. Can Basic Fibroblast Growth Factor Pre-Treatment Enhance Mesenchymal Stem cell therapy in Undecorticated Posterior Spinal Fusion?
  1193. Dog leukocyte antigen-haploidentical Stem cell allografts after anti-CD44 therapy and nonmyeloablative conditioning in a preclinical canine model
  1194. The Impact of Disease Status on the Outcome of High-Dose therapy (HDT) and Autologous Stem cell Transplantation (ASCT) for Peripheral T-cell
  1195. High‐dose therapy and autologous Stemcell transplantation can improve event‐free survival for indolent lymphoma: a study using patients as their own controls
  1196. 230. In Vivo Fluorescence Tracking SyStem for Cardiac Stem cell therapy
  1197. Autologous bone marrow Stem cell or peripheral blood endothelial progenitor cell therapy in patients with peripheral limb ischaemia
  1198. Stem cells and plasticity of skeletal muscle cell differentiation: potential application to cell therapy for degenerative muscular diseases
  1199. Initial therapy of multiple myeloma in patients who are candidates for Stem cell transplantation
  1200. Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic Stemcell transplant recipients?
  1201. The future of allogeneic hematopoietic Stem cell transplantation for metastatic renal cell carcinoma in the era of target-specific therapy
  1202. therapy for myeloma: Thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high‐dose melphalan with autologous Stem cell
  1203. Lenalidomide as induction therapy before allogeneic Stem cell transplantation in a patient with proliferative CMML-2 and del (5q) not involving the EGR1 locus
  1204. IMVP-16/Pd followed by high-dose chemotherapy and autologous Stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell
  1205. Embryo Stem cells from parthenotes and embryos produced by nuclear transfer: the distinction between them and their potential value in cell therapy
  1206. Evaluation of the therapeutic responses of Stem cell therapy after myocardial infarction: Comparison of Thallium-201 gated-SPECT with 18F-FDG metabolism imaging
  1207. cell therapy for heart failure—muscle, bone marrow, blood, and cardiac-derived Stem cells
  1208. Mechanisms and applications of Stem cell gene therapy in autoimmunity
  1209. CD34+ selected haematopoietic Stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment for graft failure
  1210. … circulation with localized transplantation in situ at the site of tissue/organ damage: a possible strategy to optimize the efficacy of Stem cell transplantation therapy
  1211. Neural Stem cell therapy in lysosomal storage disorders
  1212. Embryonic Stem cell-based therapy for the treatment of diabetes mellitus: a work in progress
  1213. Pre‐Stem cell transplantation enzyme replacement therapy in Hurler syndrome does not lead to significant antibody formation or delayed recovery of the endogenous …
  1214. Triple antifungal therapy for severe syStemic candidiasis allowed performance of allogeneic Stem cell transplantation
  1215. Gene and Stem cell therapy for autoimmune demyelination
  1216. High‐dose therapy and autologous Stem cell transplantation for children with HIV‐associated non‐Hodgkin lymphoma
  1217. Stability of colon Stem cell methylation after neo-adjuvant therapy in a patient with attenuated familial adenomatous polyposis
  1218. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous Stem cell transplant in multiple myeloma patients
  1219. … recurred hemophagocytic syndrome in remission state of anaplastic large cell lymphoma following high‐dose therapy and autologous peripheral blood Stem cell
  1220. Successful therapy of patients in therapy-resistant cardiogenic shock with intracoronary, autologous bone marrow Stem cell transplantation
  1221. Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic Stem cell
  1222. 568. Ex Vivo Mesenchymal Stem cell therapy with rAAV2 Encoding BMP-2 Enhances Bone Regeneration in Ovariectomized Mouse Model
  1223. Peripheral blood Stem cell mobilization and harvesting after fludarabine therapy for low-grade lymphoma and chronic lymphocytic leukemia
  1224. Molecular imaging is indispensable for the development of Stem cell-based myocardial regenerative therapy
  1225. Cancer Stem cells–new and potentially important targets for the therapy of oral squamous cell carcinoma
  1226. Stem cell therapy of IBD
  1227. The effect of induction therapy with novel agents on Stem cell mobilization in multiple myeloma
  1228. Stem cell therapy: an emerging science
  1229. Stem cell therapy: An Emerging Science
  1230. … amphotericin B and combined syStemic antifungal therapy for the treatment of severe pulmonary aspergillosis after allogeneic hematopoietic Stem cell transplant for a …
  1231. Stem cell therapy ahead
  1232. Autologous bone marrow Stem cell therapy for an ischemic ulcer of the lower limb in a diabetic patient
  1233. Febrile neutropenia in paediatric peripheral blood Stem cell transplantation, in-vitro sensitivity data and clinical response to empirical antibiotic therapy
  1234. … Complete Responses (CR/nCR) after Initial therapy with Bortezomib (Velcade®), Doxil®, and Dexamethasone (VDD) Is Further Increased after Autologous Stem cell
  1235. Stem cell Biotechnology for cell therapy
  1236. Maintenance therapy by Glivec® and Pegasys® in Patients with Philadelphia Positive Acute Lymphocytic Leukemia Not Eligible for Hematopoietic Stem cell
  1237. Planning time for peripheral blood Stem cell infusion after high-dose targeted radionuclide therapy using dosimetry
  1238. An International Conversation on Stem cell Gene therapy: 4th Stem cell Conference on Stem cell Gene therapy Thessaloniki, Greece, 13–17 September …
  1239. Hematopoietic Stem cell Gene therapy for Wiskott-Aldrich Syndrome.
  1240. Investigation progress of imaging techniques monitoring Stem cell therapy
  1241. KINETIC CONSIDERATIONS FOR. Stem cell therapy
  1242. cellular therapy can be affected by the sex of the Stem cell used
  1243. Biological modifiers as cytoreductive therapy before Stem cell transplant in previously untreated patientswith multiple myeloma
  1244. Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic Stem cell transplantation in CML
  1245. Stem cell therapy for Liver Disease
  1246. Stem cell therapy for myocardial infarction
  1247. 360. Transmitochondrial Stem cells: Toward Autologous Cybrid Stem cell therapy and Synergistic Transient Regenerative Gene therapy for Mitochondrial (mt) DNA …
  1248. Second Autologous Stem cell Transplant (ASCT) as Salvage therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer …
  1249. Autologous or allogeneic Stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy
  1250. Gene and Stem cell therapy
  1251. Stem cell therapy in heart disease
  1252. Hematopoietic Stem cell Transplantation, StemCells, and Gene therapy
  1253. … Reduces the Cytotoxic Effects of In Vitro Expanded NK cells: Implications for Adoptive NK cell therapy in the Setting of Allogeneic Hematopoietic Stem cell
  1254. A PETHEMA study of high-dose therapy/Stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): Identification of two …
  1255. Nuclear cloning, embryonic Stem cells and cell therapy: Promise, problems, reality
  1256. Stem cell therapy of AD: Which way to go?
  1257. Concerns Regarding Stem cell therapy from the Clinical Perspective
  1258. therapy-related myelodysplastic syndrome following acute promyelocytic leukemia and biphenotypic acute leukemia following Stem cell transplantation in the …
  1259. Durable remissions are rare following high dose therapy with autologous Stem cell transplantation for adults with” paediatric” bone and soft tissue sarcomas
  1260. Neural Stem cells and cell replacement therapy: making the right cells
  1261. Stem cell therapy in Liver Disease
  1262. Stem cell therapy for myocardial infarction
  1263. … Schedule Finding Study of Maintenance therapy with Low-Dose 5-Azacitidine (AZA) after Allogeneic Hematopoietic Stem cell Transplantation (HSCT) for …
  1264. Stem cell therapy: Moving towards reality
  1265. … : ARTIFICIAL cells: Biotechnology, Nanomedicine, Regenerative Medicine, Blood Substitutes, Bioencapsulation, and cell/Stem cell therapy. By Thomas Ming Swi …
  1266. Stemcell therapy for type 1 diabetes
  1267. The Role of Pet Scan in Stem cell therapy
  1268. Developmental aberrations of permanent teeth after high-dose anticancer therapy in childhood: A study on Stem cell transplant recipients
  1269. Stem cell therapy in Acute Coronary Syndrome
  1270. … PCR detection method for preemptive therapy of cytomegalovirus infection in patients after allogeneic hematopoietic Stem cell transplantation–single-centre …
  1271. Development of Adult Stem cell therapy Products
  1272. Is Regulation of Stem cell therapy and Therapeutic Cloning Needed?
  1273. New developments in Stem cell biology and therapy. meeting report from the working group of the German Society for Hematology and Oncology
  1274. Hope to the cancer therapy: cancer Stem cell
  1275. Stem cell therapy in endocrinology: reality and challenges
  1276. New Approach in Ischemic Stroke Treatment: Stem cell therapy
  1277. Adult Stem cell therapy–an option for the brain?
  1278. Stem cell therapy for Erectile Dysfunction
  1279. The Basics of Pathologic Assessment in Experimental Models of Stem cell therapy
  1280. Understanding the Basics of Clinical Imaging for Assessing Stem cell therapy in the Heart
  1281. Stem cell therapy for Patients with Myocardial Infarction
  1282. Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic Stem cell transplantation in the treatment of adrenal cancer with …
  1283. Clinical Utilization of Stem cell therapy in Acute Myocardial Infarction
  1284. Stem cell therapy In Endocrinology-Scope And Limitations
  1285. Stem cell transplantation as consolidation therapy for children in first-remission AML: a single-center report
  1286. Second autologous Stem cell transplantation as salvage therapy in patients with relapsed multiple myeloma: Improved outcomes in patients with longer disease free …
  1287. Embryonic Stem cell therapy for diabetes mellitus
  1288. Mechanisms of myocardium repairing by Stem cell therapy
  1289. Stem cell therapy FOR MYOCARDIAL REGENERATION
  1290. Stem cell therapy-role in corneal diseases: mini review
  1291. 1088. Stem cell Gene therapy with No Pre-Conditioning for the ADA-Deficiency Patients Leads to Generalized Detoxification and Delayed, but Steady Hematological …
  1292. Hearing loss treatment through Stem cell therapy
  1293. Exploring Stem cell therapy Potentials: A Q&A with Anthony G. Payne, Ph.D.
  1294. Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic Stem cell transplantation: a single-center experience in Korea
  1295. Current Status of G-CSF Based Stem cell therapy for Patients with Myocardial Infarction
  1296. Future of Stemcell therapy for neuromuscular diseases
  1297. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood Stem cell transplantation
  1298. Stem cell therapy for failing hearts: there is something else beyond the cells
  1299. Cardiac Stem cell therapy research in China
  1300. The Role of Non-invasive Imaging and cell Labelling Techniques in the Clinical Assessment of Stem cell therapy
  1301. Bringing cardiac Stem cell therapy into the clinic
  1302. A comparative review of legal and ethical issues arising from Stem cell therapy and therapeutic cloning
  1303. Myocardium repair with Stem cell therapy
  1304. Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic Stem cell transplantation
  1305. Guided cardiogenesis for safe Stem cell‐based therapy
  1306. Stem cell therapy of Intractable Human Diseases; Potentials and Pitfalls
  1307. Efficacy of High-Dose therapy and Autologous Stem cell Transplantation for Chemoresistant Hodgkin’s Lymphoma.
  1308. Stem cell therapy jumps another ethical hurdle
  1309. Adult neural Stem cell therapy for the brain
  1310. Stem cell therapy using Umbilical Cord Blood in Liver Disease
  1311. Pre-Transplant Rituximab therapy Is Associated with Improved Progression-Free and Overall Survival in Patients Undergoing Autologous Hematopoietic Stem cell
  1312. Stem cell therapy in animal models of inherited metabolic diseases
  1313. Growth and differentiation of human embryonic Stem cells for cardiac cell replacement therapy
  1314. Drug evaluation: ADA-transduced hematopoietic Stem cell therapy for ADA-SCID.
  1315. In Vitro Model SyStem for Cardiac Stem cell therapy
  1316. Efficacy of posaconazole (POS) vs standard therapy and safety of POS in hematopoietic Stem cell transplant (HSCT) recipients vs other patients with aspergillosis
  1317. Does mesenchymal Stem cell therapy help multiple sclerosis patients? report of a pilot study
  1318. Evaluation of Magnetic Nanoparticles for Stem cell therapy Using a Microfluidic SyStem
  1319. The Role of High Dose therapy and Stem cell Rescue in the Management of T-cell Malignant Lymphomas (TCL): A BSBMT and ABMTRR Study.
  1320. Hematopoietic AC133+ Stem cell therapy for patients with severe peripheral vascular disease
  1321. Increasing importance of Stem cell gene therapy in adenosine deaminase deficiency?
  1322. Dendritic cell therapy for Tolerance Induction to Stem cell Transplantation
  1323. Regenerative medicine and cardiovascular diseases: Stem cell therapy
  1324. Stem cell therapy FOR DEGENERATIVE DISC DISEASE: IN VITRO AND IN VIVO STUDY
  1325. Complete remission upon bortezomib–dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic Stem cell
  1326. … -retinoic acid+ dexamethasone+ alpha interferon as maintenance therapy following high-dose chemotherapy and autologous Stem cell transplant for multiple …
  1327. Stem cell therapy, smoking and obesity: getting the priorities right for reducing cardiovascular diseases
  1328. The Application of Mesenchymal Stem cell therapy on Multiple SyStem Atrophy
  1329. … High Dose Chemotherapy (HDC) Prior to Autologous Stem cell Transplantation (ASCT) as First Line therapy in Stage III-IV Diffuse Large B-cell Lymphoma (B-DLCL …
  1330. Cancer Stem cell targeted therapy: Removing the sword of Damocles
  1331. Does Stem cell therapy for ischemic cardiomyopathy result in the improvemnt of congestive heart failure: A prospective randomized study
  1332. The effects of music therapy on anxiety, nausea and vomiting in patients receiving total body irradiation for hematopoietic Stem cell transplantation
  1333. Stem cell therapy after irradiation of a malignant asecretory pheochromocytoma–a case report
  1334. Indications for hematopoietic Stem cell therapy for patients with diagnosis of myelodysplastic syndromes
  1335. Stem cell therapy FOR INTERVERTEBRAL DISC DEGENERATION IN-VITRO AND IN-VIVO FEASIBILITY STUDY
  1336. Stem cell therapy in rat hind limb ischemic injury
  1337. … Large B-cell Lymphoma (DLBCL) Does Not Affect Disease-Free (DFS) or Overall Survival (OS) Following High Dose therapy (HDT) and Autologous Stem cell
  1338. CD34+ Stem cell therapy in Chronic Stroke Patients
  1339. Safety and Efficacy of Enzyme Replacement therapy (ERT) in Combination with Haematopoietic Stem cell Transplantation (HSCT) for Hurler’s Syndrome …
  1340. Molecular imaging of cardiac Stem cell mediated angiogenic gene therapy
  1341. Heart rate variability and cardiac rhythm alterations associated with Stem cell therapy in cardiovascular disease
  1342. … Use of Palifermin and Pegfilgrastim Significantly Reduces Toxicity of High-Dose therapy and Autologous Blood Stem cell Transplantation in Patients with …
  1343. … of Prevention of Severe Oral Mucositis Using Single Dose Velafermin in Patients Receiving Myeloablative therapy and Autologous Hematopoietic Stem cell
  1344. Restoration of the left ventricular synchronous contraction after acute myocardial infarction by Stem cell therapy
  1345. Rostock Confocal Image Analysis of Patients Treated With Cultured Limbal Epithelial Stem cell therapy
  1346. Bone marrow derived adult Stem cells: characterization and application in cell therapy
  1347. Production, Transplantation and Outcome of Good Manufacturing Practice Compliant Limbal Epithelial Stem cell therapy
  1348. Muscle Derived Stem cell/Alginate/Polycaprolactone/Injection therapy in Rats with Denervated Urethral Sphincter
  1349. High-dose chemotherapy with autologous hematopoietic Stem cell transplantation for non-Hodgkin’s lymphoma in complete response as consolidation therapy
  1350. Engineering a New Insulin-Like Growth Factor-1 Protein for Embryonic Stem cell therapy
  1351. The effect of cell therapy using a human mesenchymal Stem cell injection on left ventricular systolic function in rat myocardial infarction model
  1352. 90Y-Ibritumomab Tiuxetan (Zevalin®) in Combination with High-Dose therapy (HDT) Followed by Autologous Stem cell Transplant (ASCT) May Improve …
  1353. Human Mesenchymal Stem cell therapy: Platelet Lysate Supports Efficient Preclinical Expansion.
  1354. … of a minimally invasive bone marrow harvest device and method for the rapid extraction of bone marrow for use in bone marrow transplantation and Stem cell therapy
  1355. ENGINEERED MESENCHYMAL Stem cell therapy PROLONGED CARDIAC ALLOGRAFT SURVIVAL.
  1356. Autologous Bone Marrow-Derived Stem cell therapy in Patients with Severe Peripheral Arterial Disorders: A Pilot Study.
  1357. Mesenchymal Stem cell therapy Prevents Ischemia/Reperfusion Injury and Promotes Tissue Regeneration
  1358. Update of melphalan 280 mg/m2 plus amifostine cytoprotection before autologous Stem cell transplantation as part of initial therapy in multiple myeloma patients
  1359. … Correlates with Less Acute Graft-Versus-Host Disease and Better Survival in B-cell Lymphoma Patients Who Received Allogeneic Peripheral Blood Stem cell
  1360. Bone marrow Stem cell therapy for renal regeneration after acute tubular necrosis: A dream or a reality?
  1361. Autologous Bone Marrow Stem cell Infusion (AMBI) therapy for Chronic Liver Diseases
  1362. Patients with End-Stage Ischemic Heart Failure: a Growing Target Population for Cardiac Stem cell therapy
  1363. Stem cell therapy for Incurable and Intractable Disease: More than 700 Stem cell Panels are Stored and Umbilical Cord Blood Derived Stem cell Bank will be …
  1364. … effects of hematopoietic Stem cells on cancer (gliosarcoma spheroids) and normal tissues: towards developing hematopoietic Stem cell therapy for astronauts’ cancer
  1365. Molecular Level of Minimal Residual Disease in Bone Marrow Before High-Dose therapy and Autologous Stem cell Transplantation Is a Prognostic …
  1366. Prolonged Clinical and Molecular Remissions Following High-Dose therapy/Autologous Stem cell Transplantation (HDT/ASCT) and Rituximab and …
  1367. Gene therapy and Stem cell therapy for cardiovascular diseases today: a model for translational research Cancer regression in patients after transfer of genetically …
  1368. First trial in a case of Fibrocarcilaginous embolism by dorsolaminectomy and Stem cell therapy in a cocker spaniel dog
  1369. 13N-NH3 PET: The assessment of myocardial perfusion in patients with AMI and Stem cell therapy
  1370. … chemotherapy and autologous hematopoietic Stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast …
  1371. Stem cell therapy with G-CSF Did Not Aggravate Neointimal Growth, but Induced Positive Remodeling in Patients with Myocardial Infarction who Underwent Drug …
  1372. Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic Stem cell transplantation (ASCT) in patients (pts) with chronic myeloid leukemia (CML): No evidence …
  1373. High-Dose therapy and Autologous Stem cell Transplantation for Chemoresistant Diffuse Large B cell Lymphoma: The Seattle Experience.
  1374. Bringing cardiac cell therapy with bone marrow Stem cells to the clinic: where are we now?
  1375. 1018. Stem cell Gene therapy: Toward a Universal Platform Relying on Custom Endonuclease-Boosted Gene Targeting, Cybridization, Transient Regenerative …
  1376. Treosulfan-Based Tandem High-Dose Chemo-Immuno-therapy with Autologous Stem cell Transplantation for Relapsed and Refractory Aggressive B-cell
  1377. Idiotype (Id) immunotherapy (IT) following high dose therapy and autologous Stem cell transplant (HDT/ASCT) in mantle cell (MC) and indolent lymphoma (IL): cellular …
  1378. Smoothened peptides inhibit prostate and gastric cancer cells by targeting the Hedgehog pathway: a potential cancer Stem cell therapy
  1379. Treatment of AL amyloidosis with high dose therapy and autologous Stem cell transplantation
  1380. Intervertebral disc cell therapy for regeneration: mesenchymal Stem cell cultivation in vitro and intervention in TGF-? 1 implantation in rabbit intervertebral discs
  1381. Fetal Stemcell and gene therapy
  1382. Allogeneic Hematopoietic Stem cell Transplantation (Allo-SCT) Versus Conventional Postremission therapy (PRT) for AML in First Complete Remission …
  1383. Protein A column therapy for a patient refractory to platelet transfusions undergoing allogeneic hematopoietic Stem cell transplantation
  1384. Treosulfan high dose therapy with autologous Stem cell rescue in high-risk Ewing tumors
  1385. Tandem high-dose therapy with autologous Stem cell support for small-cell lung cancer (SCLC)
  1386. … VTD (VELCADE®, Thalidomide, Dexamethasone) Induction Followed by High-Dose therapy with Autologous Stem cell Transplantation and Maintenance …
  1387. Air Leak Syndrome (ALS) Following Allogeneic Stem cell Transplantation (SCT): A Report of 22 Patients from Kanto Study Group for cell therapy (KSGCT) in Japan.
  1388. High dose therapy with autologous Stem cell transplantation in patients with Hodgkin’s lymphoma: long-term follow-up in patients treated in one center
  1389. Effects of injection therapy using muscle derived Stem cell/chitosan/hydroapatite composite gel in a rat model of urinary incontinence
  1390. Stem cells as Targets for Gene and cell therapy
  1391. … bone marrow mononuclear cells labeled with Tc-99m hexamethylpropylene amine oxime scintigraphy after intracoronary Stem cell therapy in acute myocardial
  1392. Immunomodulatory therapy for SSc: Will high-intensity immunosuppression with Stem cell rescue improve outcome?
  1393. Stemcell transplant for Hodgkin’s lymphoma: does choice of therapy prior to high-dose treatment matter?
  1394. Bortezomib (BTZ) prior to and as maintenance therapy after autologous Stem cell transplant (ASCT) in multiple myeloma (MM): Long-term follow-up of a phase II study
  1395. Potential of Stem cell based therapy and tissue engineering in the regeneration of the central nervous syStem
  1396. Stem cells a Hope for cell therapy and Regenerative Medicine
  1397. Maintenance therapy with 5-Azacytidine (5-AC) after Allogeneic Stem cell Transplantation (allo-SCT) for Acute Myelogenous Leukemia (AML) and High-Risk …
  1398. Dual-gene transfer and vector targeting for hematopoietic Stem cell gene therapy
  1399. therapy (ECP) with UVADEX® for the prevention of acute GVHD in patients (pts) undergoing standard myeloablative conditioning and allogeneic hematopoietic Stem
  1400. Gene therapy and Stem cell activation against stroke
  1401. Directed differentiation of adult neural Stem cells for cell therapy in the nervous syStem
  1402. Stem cell potential for type 1 diabetes therapy
  1403. The Impact of Histologic Grade on the Outcome of High-Dose therapy and Autologous Stem cell Transplantation for Follicular Lymphoma.
  1404. Reply to ‘Autologous Stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome’
  1405. High Dose therapy and Autologous Peripheral Blood Stem cell Transplantation as Salvage therapy for HIV-Associated Lymphoma: Result of the GICAT Study.
  1406. Cefepime as an empiric treatment of febrile neutropenia in patients after high dose therapy and autologous Stem cell transplantation
  1407. Clonal Analyses of Retroviral Vector Integrations in ADA-SCID Patients Treated with Stem cell Gene therapy.
  1408. Prognostic Factors for CMV Reactivation/Infection after Stem cell Transplantation and Value of Oral Valganciclovir for Preemptive therapy.
  1409. Haematopoietic Stem cell Based Gene therapy as a Strategy to Treat Autoimmune Disease
  1410. Functional Comparison of Bone Marrow–Derived Liver Stem cells: Selection Strategy for cell-Based therapy
  1411. Efficacy of Azacytidine (5-AC) Given as Maintenance or Salvage therapy for Patients (pts) with Acute Leukemia Post Allogeneic Stem cell Transplantation (HSCT).
  1412. … Preparative Regimens on the Incidence of therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem cell Transplant (ASCT) for …
  1413. High-dose cyclophosphamide as an effective therapy for a patient with refractory multiple myeloma relapsing after autologous Stem cell transplantation
  1414. 1: Cytotoxic T lymphocyte therapy for the treatment and prevention of adenovirus infection after Stem cell transplant
  1415. Preliminary Results of therapy with AM3 in Patients Undergoing Hematopoietic Stem cell Transplantation.
  1416. The role of high-dose therapy and Stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and…
  1417. Stem cell replacement therapy in type 1 diabetes
  1418. 2520: Involved Field Radiation therapy Following Autologous Stem cell Rescue for Hodgkin and Non-Hodgkin Lymphoma-Is it Efficacious?
  1419. … -Adapted therapy of Adult Acute Myeloid Leukemia (AML): Safety and Efficacy of Repetitive HD-ARA-C Courses with Low-Dose Autologous Blood Stem cell
  1420. The experimental study on bone marrow Stem cell transplantition combinated with bushen fang therapy for DMD
  1421. Phase II trial of GM-CSF as maintenance therapy post–autologous peripheral blood Stem cell transplantation in multiple myeloma
  1422. … after autologous peripheral blood Stem cell transplantation does not add any benefit regarding hematological engraftment and supportive therapy
  1423. … Incidence in Patients with Hematological Malignancies Receiving Myelotoxic therapy Requiring Hematopoietic Stem cell Support-Palifermin Experience.
  1424. … of Interferon Versus Thalidomide Versus RIC Allotransplant for Maintenance/Consolidation therapy after Autologous Stem cell Transplantation in Patients …
  1425. Stem cell transplantation therapy for diabetes mellitus
  1426. Rituximab maintenance following high dose therapy and autologous Stem cell rescue after RICE cytoreduction improves event free and overall survival
  1427. Posaconazole (POS) salvage therapy allows successful allogeneic hematopoietic Stem cell transplantation (HSCT) in patients with refractory invasive mold infections
  1428. High dose therapy followed by autologous purged Stem cell
  1429. High-Dose therapy/Stem cell Support (HDT), Including Tandem Transplant, for Primary Refractory Multiple Myeloma (MM): Results from the Spanish Myeloma Group …
  1430. Study Progress of Hematopioetic Stem cell Transplantation therapy on Acute Leukemia in Children
  1431. … -CHOP, Based on CT and Gallium 67 Scan (G67S) with or without IFE Salvage therapy Followed by Peripheral Autologous Stem cell Transplant (PBSCT) in …
  1432. … CsA, MTX, MMF and ATG and Triple therapy with CsA, MTX and ATG for Preventing Graft-Versus-Host Disease in Unrelated Donor Hematopoietic Stem cell
  1433. … Associated with Engraftment of Gene-Corrected Repopulating cells Achieved in ADA-SCID Patients by Stem cell Gene therapy without Myelopreparative Pre …
  1434. Isolation of amniotic Stem cell lines with potential for therapy.
  1435. … WITH LOW DOSE PARATHYROID HORMONE PULSE therapy INCREASES ALLOGENEIC HEMATOPOIETIC Stem cell ENGRAFTMENT IN NON-HUMAN …
  1436. Stem cells may be uniquely suited for combined gene therapy and cell replacement: evidence from engraftment of neurotrophin-3-expressing Stem cells in hypoxic …
  1437. … neurectodermal tumors (SPNET) treated with risk-adapted craniospinal (CSI) radiation (RT) therapy followed by 4 cycles of high-dose chemotherapy and Stem cell
  1438. Allogeneic Stem cell Transplantation for therapy-Related Myelodysplastic Syndrome (t-MDS) and Acute Myeloid Leukemia. A Report from the MDS …
  1439. Reply to ‘Promotion of neurogenesis by human Stem cells in high-risk breast cancer survivals after Stemcell supported high-dose therapy‘by K. Altundag et al.(Ann …
  1440. Gene therapy and Stem cell transplantation in PAD
  1441. Stem cell: From Bone Marrow Transplantation for the Treatment of Hematological Diseases to therapy for Other SyStemic Disorders
  1442. EPIGENETIC INSTABILITY OF HUMAN EMBRYONIC Stem cell LINES: IMPLICATIONS FOR therapy
  1443. Neural Stem cell can mediate immune therapy for brain tumor
  1444. Osteosarcoma target therapy with Stem cell transplant: A case review
  1445. Impact of intensive Stem cell mobilization therapy on outcomes following autologous Stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)
  1446. Immunoablative therapy with Autologous Stem cell Transplantation in the Treatment of Poor Risk Multiple Sclerosis.
  1447. Embryonic Stem cells and cardiac cell therapy
  1448. Which Strategy of Immunoablative therapy with Autologous Stem cell Transplantation (ASCT) Is Preferable in Multiple Sclerosis (MS) Patients?.
  1449. Combination therapy with mesenchymal Stem cell and erythropoietin in patients with ALS
  1450. Experimental substantiation of embryonic Stem cell application in therapy of patients with extrapyramidal hyperkinesis
  1451. therapy of Heart Failure Rats with Mesenchymal Stem cell Transplantation
  1452. Long-term safety and efficacy of Stem cell gene therapy for ADA-SCID.
  1453. Differentiation of Human Embryonic Stem cells; Prospects for Development Biology and cell therapy
  1454. Autologous Stem cell Transplantation Provides Additional Cytoreduction Following Induction therapy in Multiple Myeloma.
  1455. Correction of Murine Hemophilia A by Hematopoietic Stem cell Gene therapy.
  1456. Experimental investigation on therapy of intravenous transplantation of neural Stem cell for spinal cord injury
  1457. Are RIC allogeneic Stem cell transplants ready for prime time in CLL therapy?
  1458. High-dose therapy with autologous Stem cell rescue in patients with breast cancer at high risk for relapse
  1459. Regenerative cellular therapy: How To Enrich The Mesenchymal Stem cell Content In The Periinfarction Zone After Myocardial Infarction
  1460. Bone marrow Stem cells: possible source for cell therapy in Parkinson’s disease
  1461. Second Autologous Stem cell Transplant (ASCT) as Salvage therapy for Relapsed Multiple Myeloma.
  1462. Tacrolimus therapy for Severe Recurrent Crohn’s Disease after Stem cell Transplant: 844
  1463. Improved Survival in Patients with Peripheral T cell Lymphoma, Unspecified Following High-Dose therapy and Stem cell Transplantation: A Retrospective …
  1464. Plasmid transfection of rat bone marrow mesenchymal Stem cells by cationic lipid for gene-modified cell transplantation therapy
  1465. 1672: Early Phase I/II Clinical Trial Results for Human Cord Blood Stem cell Injection therapy for Stress Urinary Incontinence
  1466. Thalidomide salvage therapy following allogeneic Stem cell transplantation for multiple myeloma: A…
  1467. Conditioning therapy with intravenous busulfanum and cyclophosphamide for allogeneic hematopoietic Stem cell transplantation: A report of 19 cases☆
  1468. 433 EVALUATION OF Stem cell POPULATIONS IN THE BLOOD OF PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE OXYGENATION therapy.
  1469. Estrogen-progestin therapy in women after Stem cell transplant: our experience and literature review.
  1470. Gemtuzumab Ozogamicin as Maintenance therapy after Autologous Stem cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).
  1471. Biological modifiers as cytoreductive therapy before Stem cell transplant in previously untreated patientswith m…
  1472. Early Goal Directed therapy for Septic Shock Is Feasible and Safe in Hematopoietic Stem cell Transplant Patients.
  1473. Sca-1+ Progenitors Derived from Stem cells Differentiate into Endothelial cells: Implications for Stem cell-Based therapy in the Injured Artery
  1474. Limbal Stem cell autotansplantation in therapy of recurrent pterygium and ophthalmoherpes
  1475. Characteristics of patients with false positive FDG-PET findings after high dose therapy and autologous Stem cell transplantation (HDT/ASCT)
  1476. Comment on ‘CD34+ selected hematopoietic Stem cell (HSC) not preceded by any immunosuppressive therapy as effective treatment of graft failure’–G Milone et al
  1477. Allogeneic hematopoietic Stem cell transplantation as consolidation therapy for adult T cell Leukemia/Lymphoma patients: A single-center experience in 35 patients.
  1478. therapy for Thymic Insufficiency after Hematopoietic Stem cell Transplantation: Generation of MTS24 Positive Definitive Endoderm from Murine Embryonic Stem
  1479. … results of risk adapted pre-emptive therapy of CMV infection with ganciclovir in 169 patients, after allogeneic hematopoietic Stem cell transplantation in Hematology …
  1480. Voriconazole (VOR) is safe and effective as prophylactic antifungal therapy for allogeneic Stem cell transplantation (AT)
  1481. Effects of Prior therapy on the in Vitro Proliferative Potential of Stem cell Factor Plus Filgrastim-mobilized CD34-positive Progenitor cells1
  1482. Hematopoietc Stem cell Targeted Neonatal Gene therapy Cures oc/oc Mice from Osteopetrosis.
  1483. Interferon-α therapy for patients with molecular relapse in leukemia after allogeneic Stem cell transplantation
  1484. NOVEL METHODS IN THE DIAGNOSTICS AND therapy Intracoronary, autologous bone marrow Stem cell transplantation for treatment of postinfarction left …
  1485. Involved Field Radiation therapy Following Autologous Stem cell Rescue for Hodgkin and Non-Hodgkin Lymphoma-Is It Efficacious?.
  1486. Determining the Appropriate PCR Trigger for Pre-Emptive Anti-CMV therapy in Allogeneic Stem cell Transplant Recipients.
  1487. FDG-PET for the prediction of therapy outcome in patients with high risk soft tissue sarcomas receiving high dose chemotherapy with Stem cell rescue
  1488. … initial therapy may be associated with a poorer outcome in young patients subsequently treated with Stem cell transplantation for relapsed chemosensitive large B-cell
  1489. Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose therapy/Stem cell Support (HDT/SCS): Results of …
  1490. High-dose therapy and autologous Stem cell transplantation for Hodgkin’s lymphoma in relapse or failure after initial chemotherapy: results of the Centre National de …
  1491. … of Patients with Refractory/Relapsed Hodgkin’s Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation therapy (HDT) with Stem cell
  1492. Gene therapy and neural Stem cell transplantation in rodent models of Huntington’s disease
  1493. Poor Prognosis for Patients after Myelo-and Non-Myeloablative Conditioning therapy Followed by Allogeneic Peripheral Blood Stem cell Transplantation Admitted to …
  1494. … Followed by Early High-Dose therapy and Hematopoietic Stem cell Transplantation Results in Improved Outcome for Patients with Hepatosplenic T-cell
  1495. High dose chemotherapy with autologous Stem cell rescue as a part of combined modality therapy in stage IIIB inflammatory breast cancer
  1496. … I/II-Study on PCR-Based Pre-Emptive therapy with Valganciclovir or Ganciclovir for Active CMV Infection Following Reduced Intensity Allogeneic Stem cell
  1497. 248: Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic Stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence …
  1498. 442. LV Expressing MR Reporter Genes Allows In Vivo Monitoring of Stem cell Gene therapy
  1499. High-Dose therapy (HDT) with Autologous Hematopoietic Stem cell Transplantation (HSCT) in Patients with Poor Prognosis Ewing Family Tumors (EFT).
  1500. Busulfan and melphalan as preparative therapy for Stem cell transplantation in pediatric patients with acute myelogenous leukemia (AML) and myelodysplasia (MDS)
  1501. … chemotherapy and autologous Stem cell transplantation in poor prognosis patients with advanced follicular lymphoma—effective therapy in first complete or partial …
  1502. Administration of Virus-Specific Cytotoxic T-Lymphocytes for the Prophylaxis and therapy of Adenovirus Infection post Allogeneic Stem cell Transplant
  1503. Modified Thalidomide, Cyclophosphamide and Dexamethasone (TCD) to Patients with Multiple Myeloma as Primary therapy Prior to Peripheral Blood Stem cell
  1504. Hematopoietic Stem cell Transplantation (HSCT) as Curative therapy for Fanconi Anemia (FA) Patients with Acute Leukemia or Advanced Myelodysplasia (MDS).
  1505. Steroid therapy Increase Only Adenovirus Infection but Not Cytomegalovirus Infection in Dose Dependent Manner after Hematopoietic Stem cell Transplantation.
  1506. Stem cell Transplantation (SCT) in Conjunction With Enzyme Replacement therapy (ERT) for a Child With Hurler Syndrome (MPS IH): 42
  1507. Characterization of an Immunodeficient Mucopolysaccharidosis Type I (MPS-I) Mouse Model Suitable for Preclinical Testing of Human Stem cell and Gene therapy.
  1508. … treatment for thrombocytopenia after salvage therapy with arsenic trioxide therapy followed by autologous hematopoietic Stem cell transplantation in acute …
  1509. Comparison of HLA-Identical Sibling Hematopoietic Stem cell Transplant (HCT) Versus Chemotherapy as Postremission therapy in t (8; 21) Acute Myeloid Leukemia …
  1510. Allogeneic Hematopoietic Stem cell Transplantation after Combination therapy with Imatinib and Intensive Chemotherapy for Newly Diagnosed Philadelphia …
  1511. Zoledronic Acid Plus Thalidomide Is Safe and Well Tolerated When Used as Post-Autologous Stem cell Transplant Maintenance therapy in Patients with …
  1512. 1055. High Levels of Human Factor IX Expression in Hemophilia B Mice after Adult Stem cell-Based Gene therapy Combined with Non-Myeloablative Conditioning
  1513. Bortezomib therapy for Multiple Myeloma in Relapse after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem cell Transplantation (RICT).
  1514. Maintenance therapy with Thalidomide/Prednisone Post Autologous Stemcell Transplant for Patients with Multiple Myeloma Elevates D-Dimer and Possibly …
  1515. Directed differentiation of pancreatic islets from human embryonic Stem cells and cell therapy of diabetes mellitus
  1516. … a Phase II Study of Post-Transplant Maintenance therapy in Patients with Multiple Myeloma Following High-Dose Chemotherapy and Autologous Stem cell
  1517. … -Rituximab (DC-R) Plus GM-CSF as a Salvage therapy in B-Diffuse Large cell Lymphoma (B-DLCL) after Autologous Stem cell Transplantation (ASCT) Failure.
  1518. Allogeneic Myelo-Ablative Stem cell Transplant (SCT) as Salvage therapy of Reduced-Intensity Conditioned (RIC) SCT: Toxicity and Outcome.
  1519. Molecular mechanisms of immune deficiency in adenosine deaminase (ADA)-deficient SCID patients: implications for Stem cell gene therapy
  1520. … Memory B cell Population with Persistent Hypogammaglobulinemia after Rituximab Administration as an Adjuvant therapy after Autologous Stem cell
  1521. 347: Intentional induction of mixed hematopoietic chimerism as platform for cellular therapy after HLA-matched allogeneic Stem cell transplantation in childhood …
  1522. Corticosteroid therapy Does Not Increase Relapse Rate after Allogeneic Hematopoietic Stem cell Transplantation for Acute Myelogeneous Leukemia and …
  1523. Tandem high-dose chemotherapy (HDC) with peripheral blood Stem cell rescue (PBSCR) as consolidation therapy for high-risk (primary unresectable pelvic tumors or …
  1524. … -Based Maintenance therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ ALL) Ineligible for Allogeneic Stem cell
  1525. … Field Radiation Treatment (IFRT) in Patients With Bulky Non-Hodgkin Lymphoma (NHL) Undergoing High-Dose therapy and Autologous Bone Marrow/Stem cell
  1526. 131I-Metaiodobenzylguanidine (131I-MIBG) double infusion with autologous Stem cell transplant for neuroblastoma: A New Approaches to Neuroblastoma therapy
  1527. Allogeneic Stem cell Transplantation (AlloSCT) for the Treatment of therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML): Results …
  1528. … (Cp) and C. guillermondii (Cg) Blood Stream Infections in Allogeneic Hematopoetic Stem cell (HSC) Recipients Receiving Long Term Caspofungin (C) therapy.
  1529. Gleevec as therapy for CML Relapsed after Allogeneic Stem cell Transplantation: High Rate of BCR-ABL PCR Negativity and Donor Graft Reconstitution.
  1530. Successful Engraftment Using Varied Stem cell Sources, Low Toxicity, and Long-Term Survival Using a Bu/Flu/ATG Reduced Intensity Allogeneic Transplantation in …
  1531. Does Highly Active Anti-Retroviral therapy (HAART) Delay Myeloid Engraftment after Autologous Stem cell Transplant (ASCT) in HIV Associated Lymphoma (HIV+ Ly …
  1532. Low-Dose Methotrexate as Salvage therapy for Refractory Graft-Versus-Host Disease (GVHD) after Reduced-Intensity Conditioning (RIC) for Allogeneic Stem cell
  1533. 65. Long-Term Effects of Hematopoietic Stem cell Gene therapy in the Murine Model of Wiskott-Aldrich Syndrome: Persistence of Functional Correction of T cells and …
  1534. 263: Non-myeloablative conditioning therapy with fludarabine, cyclophosphamide and ATG allogeneic hematopoietic Stem cell transplantation from HLA-identical …
  1535. … , Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem cell Transplantation Followed by Randomization to therapy with Interleukin-2 Versus …
  1536. Combined Stem cell Mobilization via CXCR4 Antagonist Augments Recruitment of EPCs Following Sonic Hedgehog Gene therapy via Increased Local Expression of …
  1537. … Graft-Versus-Host Disease (GVHD) Following Bortezomib as Salvage therapy after Reduced Intensity Conditioning Allogeneic Stem cell Transplantation (RIC allo …
  1538. DLA-Haploidentical Stem cell Allografts after Anti-CD44 therapy and Nonmyeloablative Conditioning: The Impact of Donor Lymphocyte Infusion (DLI) …
  1539. Sustained effect of first line sequential therapy with intensive consolidation chemotherapy and allogeneic hematopoietic Stem cell transplantation (ASCT) after reduced …
  1540. 356: First line sequential therapy with intensive consolidation chemotherapy and allogeneic hematopoietic Stem cell transplantation (ASCT) after reduced intensity …
  1541. COMBINATION cell AND GENE therapy FOR PERIPHERAL ISCHEMIA USING MYOBLASTS AND Stem cells ENGINEERED WITH CONDITIONALLY …
  1542. Stem cells and cell-based therapy in neurodegenerative disease
  1543. Mobilis in Mobile–Human Embryonic Stem cells and Other Sources for cell therapy
  1544. Stem cells and islet engineering for cell replacement therapy in diabetes
  1545. Investigation into the application of adult human Mueller Stem cells in retinal ganglion cell replacement therapy
  1546. Proliferation of bone marrow mesenchymal Stem cells, skeletal muscle cells and co-culture of both for cell myocardium therapy in Wistar rats
  1547. Mesenchymal Stem cells: Differentiation, hematopoietic support and possible application in cell and gene therapy for osteoarthritis
  1548. Neural Stem cells for cell replacement therapy in Huntington’s disease
  1549. cell and gene therapy via human neural Stem cells (hNSCs) in transgenic SOD1 (G93A) ALS (amyotrophic lateral sclerosis) mice
  1550. cell transplantation for periodontal diseases. A novel periodontal tissue regenerative therapy using bone marrow mesenchymal Stem cells
  1551. Microencapsulation of Mesenchymal Stem cells (MSCs) for cell Based therapy
  1552. Improvement of musculoskeletal function by cell-based therapy using mesenchymal Stem cells with a prolonged life span
  1553. Stem cells together with differentiated derivatives of human embryonic Stem cells. A novel strategy to enhance the efficacy of autologous cell-transplantation therapy
  1554. Discovery of a Novel Paracrine Angiogenic Factor from Akt-Transduced Mesenchymal Stem cells for cell/Protein-based therapy in angiogenesis
  1555. Introduction to Stem cell therapy
  1556. Stemcell therapy for cardiac disease
  1557. Stem cell‐based cell therapy in neurological diseases: a review
  1558. Stem cell therapy in stroke
  1559. Stem cell therapy–Hype or hope? A review
  1560. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal Stem cells
  1561. Mesenchymal Stem cells: Stem cell therapy perspectives for type 1 diabetes
  1562. Stem cell therapy is proarrhythmic
  1563. The changing face of neural Stem cell therapy in neurologic diseases
  1564. Feasibility of a Stem cell therapy for intervertebral disc degeneration
  1565. A review of gene and Stem cell therapy in cutaneous wound healing
  1566. Stem cell therapy for cardiac repair: benefits and barriers
  1567. Stem cell therapy: MRI guidance and monitoring
  1568. Intravenous mesenchymal Stem cell therapy for traumatic brain injury
  1569. Stem cell therapy restores transparency to defective murine corneas
  1570. Adult Stem cell therapy of female stress urinary incontinence
  1571. Stem cell therapy for heart failure: are arrhythmias a real safety concern?
  1572. Emerging hurdles in Stem cell therapy for peripheral vascular disease
  1573. cellular MRI and its role in Stem cell therapy
  1574. Mesenchymal Stem cell therapy for diabetes through paracrine mechanisms
  1575. Critical issues of clinical human embryonic Stem cell therapy for brain repair
  1576. Current status of Stem cell therapy for liver diseases
  1577. Subacute neural Stem cell therapy for traumatic brain injury
  1578. Mesenchymal Stem cell therapy for equine tendinopathy
  1579. Prospects of Stem cell therapy for replacing dopamine neurons in Parkinson’s disease
  1580. Cartilage tissue engineering: towards a biomaterial-assisted mesenchymal Stem cell therapy
  1581. Stem cell therapy and regenerative medicine
  1582. Olfactory mucosa is a potential source for autologous Stem cell therapy for Parkinson’s disease
  1583. Bone-marrow-derived mesenchymal Stem cell therapy for neurodegenerative diseases
  1584. Stemcell therapy in retinal disease
  1585. Overview of Stem cell therapy for Crohn’s disease
  1586. Combining growth factor and Stem cell therapy for amyotrophic lateral sclerosis
  1587. Capillary regeneration in scleroderma: Stem cell therapy reverses phenotype?
  1588. Current and future regenerative medicine—principles, concepts, and therapeutic use of Stem cell therapy and tissue engineering in equine medicine
  1589. Cardiac regeneration and Stem cell therapy
  1590. Proinflammatory cytokine effects on mesenchymal Stem cell therapy for the ischemic heart
  1591. Embryonic Stem cell therapy of heart failure in genetic cardiomyopathy
  1592. Mesenchymal Stem cell therapy for nonmusculoskeletal diseases: emerging applications
  1593. Prospects for pluripotent Stem cell‐derived cardiomyocytes in cardiac cell therapy and as disease models
  1594. Autologous mesenchymal Stem cell therapy delays the progression of neurological deficits in patients with multiple syStem atrophy
  1595. Stem cell therapy for cartilage regeneration in osteoarthritis
  1596. Bionetworking: experimental Stem cell therapy and patient recruitment in India
  1597. Stem cell therapy: the great promise in lung disease
  1598. Paracrine mechanisms in adult Stem cell signaling and therapy
  1599. Muscle derived Stem cell therapy for stress urinary incontinence
  1600. Stem cell therapy for cardiac repair
  1601. Mesenchymal Stem cell therapy for protection and repair of injured vital organs
  1602. Stem cell therapy for the kidney?
  1603. Allogenic Stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension
  1604. Potencial role of Stem cell therapy in type 1 diabetes mellitus
  1605. Translational development of mesenchymal Stem cell therapy for cardiovascular diseases
  1606. Stem cell‐based cell therapy for Huntington disease: a review
  1607. Gene and Stem cell therapy in peripheral arterial occlusive disease
  1608. Stemcell therapy faces more scrutiny in China; but regulations remain unclear for companies that supply treatments
  1609. Stem cell therapy to reduce radiation-induced normal tissue damage
  1610. Stem cell therapy with overexpressed VEGF and PDGF genes improves cardiac function in a rat infarct model
  1611. Immunogenicity and allogenicity: a challenge of Stem cell therapy
  1612. Differential destruction of Stem cells: implications for targeted cancer Stem cell therapy
  1613. Comparison of different culture conditions for human mesenchymal stromal cells for clinical Stem cell therapy
  1614. Cytokines as the major mechanism of mesenchymal Stem cell clinical activity: expanding the spectrum of cell therapy.
  1615. Choosing between Stem cell therapy and drugs in myelofibrosis
  1616. Stem cell therapy for ischemic heart disease: where are we?
  1617. Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials
  1618. Tracking Stem cell therapy in the myocardium: applications of positron emission tomography
  1619. Stem cell therapy for end-stage heart failure: indispensable role for the cell?
  1620. Placental mesenchymal and cord blood Stem cell therapy for dilated cardiomyopathy
  1621. Long-term outcome of Stem cell therapy for acute myocardial infarction: right results, wrong reasons
  1622. A new dawn for Stemcell therapy
  1623. Stem cell therapy in myocardial repair and remodeling
  1624. Stem cell therapy to treat diabetes mellitus
  1625. Stemcell-based therapy and lessons from the heart
  1626. Stem cell therapy for Alport syndrome: the hope beyond the hype
  1627. Gene and Stem cell therapy in ischemic stroke
  1628. Stem cell therapy: a primer for interventionalists and imagers
  1629. Drawbacks to Stem cell therapy in cardiovascular diseases
  1630. Stem cell therapy for chronic liver disease—choosing the right tools for the job
  1631. Bone marrow-derived mesenchymal Stem cell therapy as a candidate disease-modifying strategy in Parkinson’s disease and multiple syStem atrophy
  1632. Stem cell therapy for heart failure
  1633. Human amnion‐derived mesenchymal Stem cells are a potential source for uterine Stem cell therapy
  1634. Prospects for Stem cell-based therapy
  1635. Mesenchymal Stem cell therapy for degenerative inflammatory disorders
  1636. Isolation of Stem cell populations with trophic and immunoregulatory functions from human intestinal tissues: potential for cell therapy in inflammatory bowel disease
  1637. Mesenchymal Stem cell-based therapy for cartilage repair: a review
  1638. Stem cell therapy for urethral sphincter regeneration.
  1639. Adult Stem cell therapy for acute brain injury in children
  1640. Histocompatibility testing of cultivated human bone marrow stromal cells–A promising step towards pre-clinical screening for allogeneic Stem cell therapy
  1641. Stem cell therapy in multiple sclerosis: promise and controversy
  1642. T cell therapy of Epstein–Barr virus and adenovirus infections after hemopoietic Stem cell transplant
  1643. … into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis—a novel approach in Stem cell therapy
  1644. Inflammatory mediators: parallels between cancer biology and Stem cell therapy
  1645. Strategies for future histocompatible Stem cell therapy
  1646. Establishment of a rat model of myocardial infarction with a high survival rate: A suitable model for evaluation of efficacy of Stem cell therapy
  1647. Cardiovascular regeneration and Stem cell therapy
  1648. Stem cell therapy for cystic fibrosis: current status and future prospects
  1649. What are the prospects of Stem cell therapy for neurology?
  1650. Neuroimaging as a basis for rational Stem cell therapy
  1651. Potential of Stem/progenitor cells in treating stroke: the missing steps in translating cell therapy from laboratory to clinic
  1652. Mesenchymal Stem cell‐based therapy: a new paradigm in regenerative medicine
  1653. T cell therapy in allogeneic Stem cell transplantation
  1654. Immunological considerations for cell therapy using human embryonic Stem cell derivatives
  1655. Stem cell therapy for the broken heart: mini-organ transplantation
  1656. Prostate cancer Stem cell therapy: hype or hope?
  1657. Promise of blood-and bone marrow-derived Stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy
  1658. … synchronous contraction after acute myocardial infarction by Stem cell therapy: new insights into the therapeutic implication of Stem cell therapy for acute myocardial …
  1659. Stem cell therapy in orthopaedic surgery: Current status and ethical considerations
  1660. Microenvironment at tissue injury, a key focus for efficient Stem cell therapy: A discussion of mesenchymal Stem cells
  1661. cell therapy generates a favourable chemokine gradient for Stem cell recruitment into the infarcted heart in rabbits
  1662. Implications of the cancer Stemcell hypothesis for breast cancer prevention and therapy
  1663. Stem cell therapy for heart failure: the science and current progress
  1664. A review of current progress in gene and Stem cell therapy for erectile dysfunction
  1665. Adipose Stem cells as a clinically available and effective source of adult Stem cell therapy
  1666. Measurement of oxygenation at the site of Stem cell therapy in a murine model of myocardial infarction
  1667. Autologous Stemcell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study
  1668. cell therapy for the diseased liver: from Stem cell biology to novel models for hepatotropic human pathogens
  1669. Stem cell therapy: a promising and prospective approach in the treatment of patients with severe Buerger’s disease
  1670. Adult Stem cell therapy for autoimmune disease
  1671. Physical exercise as adjuvant therapy for patients undergoing hematopoietic Stem cell transplantation
  1672. cell therapy with autologous bone marrow mononuclear Stem cells is associated with superior cardiac recovery compared with use of nonmodified …
  1673. Targeting the leukemic Stem cell: the Holy Grail of leukemia therapy
  1674. Reduced-intensity allogeneic hematopoietic Stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European …
  1675. Stem cell therapy for critical limb ischaemia—a review
  1676. Immunostimulatory effects of mesenchymal Stem cell‐derived neurons: implications for Stem cell therapy in allogeneic transplantations
  1677. Stem cell therapy for inherited metabolic disorders of the liver
  1678. Placenta-derived Stem cells: new hope for cell therapy?
  1679. Inflammatory bowel disease: moving toward a Stem cell-based therapy
  1680. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial Stem cell therapy
  1681. Twisting immune responses for allogeneic Stem cell therapy
  1682. Hematopoietic Stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy
  1683. Human parthenogenetic embryonic Stem cells: one potential resource for cell therapy
  1684. Another new “super muscle Stem cell” leaves unaddressed the real problems of cell therapy for duchenne muscular dystrophy
  1685. Stem cell research and therapy for liver disease
  1686. Stem cell‐based therapy in gastroenterology and hepatology
  1687. Effects of Stem cell therapy with G-CSF on coronary artery after drug-eluting stent implantation in patients with acute myocardial infarction
  1688. cell therapy for ischaemic heart disease: focus on the role of resident cardiac Stem cells
  1689. Stem cell therapy: past, present, and future
  1690. Neural commitment of embryonic Stem cells: molecules, pathways and potential for cell therapy
  1691. Gene therapy and Stem cell transplantation: strategies for hearing restoration
  1692. Genetic basis of inherited macular dystrophies and implications for Stem cell therapy
  1693. A combined artificial chromosome-Stem cell therapy method in a model experiment aimed at the treatment of Krabbe’s disease in the Twitcher mouse
  1694. Stem cell therapy and coordination dynamics therapy to improve spinal cord injury
  1695. Rewiring the heart: Stem cell therapy to restore normal cardiac excitability and conduction
  1696. Immunosuppressive therapy mitigates immunological rejection of human embryonic Stem cell xenografts
  1697. Stem cell therapy for cardiovascular diseases. Experiences in Düsseldorf
  1698. Stem cell therapy for hereditary breast cancer
  1699. Clinical trials update from the American Heart Association 2007: CORONA, RethinQ, MASCOT, AF‐CHF, HART, MASTER, POISE and Stem cell therapy
  1700. Cancer Stem cell: implications in cancer biology and therapy with special reference to lung cancer
  1701. Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic Stem cell transplantation in mouse and man
  1702. cell therapy for diabetes mellitus: an opportunity for Stem cells?
  1703. Combination of enzyme replacement and hematopoietic Stem cell transplantation as therapy for Hurler syndrome
  1704. Unproven Stemcell therapy ban
  1705. … of invasive fungal infection in adult hematopoietic Stem cell transplant recipients: analysis of Multicenter Prospective Antifungal therapy (PATH) Alliance registry
  1706. Stem cell therapy trials: a call for standardization
  1707. Stem cell therapy for myocardial regeneration: mechanisms and current clinical applications
  1708. Functional outcome of bone marrow Stem cells (CD45+/CD34−) after cell therapy in acute spinal cord injury: In Exercise training and in sedentary rats
  1709. Continuous renal replacement therapy (CRRT) after Stem cell transplantation. A report from the prospective pediatric CRRT Registry Group
  1710. Rehabilitation of therapy-related cognitive deficits in patients after hematopoietic Stem cell transplantation
  1711. Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on Stem cell collection in multiple myeloma
  1712. Compromised Stem cell mobilization following induction therapy with lenalidomide in myeloma
  1713. Is Stem cell-based therapy going on or out for cardiac disease?
  1714. Stem cell and cellular therapy developments
  1715. How to approach Alzheimer’s disease therapy using Stem cell technologies
  1716. High-dose immunosuppressive therapy with autologous hematopoietic Stem cell transplantation as a treatment option in multiple sclerosis
  1717. … working group (IMWG) consensus statement and guidelines regarding the current status of Stem cell collection and high-dose therapy for multiple myeloma …
  1718. Stem cell biology and cell transplantation therapy in the retina
  1719. Cardiac Stem cell therapy: Advances from 2008
  1720. Handbook of cardiac Stem cell therapy
  1721. Stem cell therapy for tendon and ligament injuries in the horse-technique and outcome
  1722. High incidence of leukemia in large animals after Stem cell gene therapy with a HOXB4-expressing retroviral vector
  1723. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic Stem cell transplant compared with enzyme replacement therapy
  1724. Stemcell therapy in China draws foreign patients
  1725. The cancer Stem cell microenvironment and anti-cancer therapy
  1726. The potential of biophotonic techniques in Stem cell tracking and monitoring of tissue regeneration applied to cardiac Stem cell therapy
  1727. High-dose therapy and autologous peripheral blood Stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian …
  1728. Neuroprotective therapy for ischemic stroke with free radical scavenger and gene-Stem cell therapy
  1729. Bone marrow mesenchymal Stem cell therapy on diabetic nephropathy in rats
  1730. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review
  1731. A pilot study with autologous bone marrow-derived Stem cell therapy in patients with severe peripheral arterial disorder
  1732. Mobilization in myeloma revisited: IMWG consensus perspectives on Stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib …
  1733. Functional outcome of bone marrow Stem cells (CD45+/CD34−) after cell therapy in chronic spinal cord injury in wistar rats
  1734. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review
  1735. Translating Stem cell therapy to the clinic: déjà vu all over again
  1736. Stem cell therapy in the treatment of stress urinary incontinence: a significant step in the right direction?
  1737. Stem cell based therapy for skeletal muscle diseases
  1738. Mesenchymal Stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model
  1739. Mesenchymal Stem cell‐based angiopoietin‐1 gene therapy for acute lung injury induced by lipopolysaccharide in mice
  1740. … T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated Stem cell
  1741. Stem cell therapy in acute myocardial infarction
  1742. Gene therapy approaches for Stem cell protection
  1743. Can radionuclide imaging predict future response to Stem cell therapy?
  1744. Stem cell therapy: The eventual future
  1745. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic Stem cell transplantation
  1746. Adoptive cellular therapy for cytomegalovirus infection following allogeneic Stem cell transplantation using virus-specific T cells
  1747. Toward a Stem cell gene therapy for breast cancer
  1748. A decision analysis: the dental management of patients prior to hematology cytotoxic therapy or hematopoietic Stem cell transplantation
  1749. cell therapy for Parkinson’s disease: III. Neonatal, fetal and embryonic Stem cell-based applications
  1750. Use of enzyme replacement therapy (Laronidase) before hematopoietic Stem cell transplantation for mucopolysaccharidosis I: experience in 18 patients
  1751. Vascular endothelial growth factor in astroglioma Stem cell biology and response to therapy
  1752. High-dose therapy followed by autologous purged Stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a …
  1753. Prospective multicenter trial comparing repeated immunosuppressive therapy with Stemcell transplantation from an alternative donor as second-line treatment for …
  1754. Autologous bone marrow Stem cell therapy for the ischemic myocardium during coronary artery bypass grafting
  1755. Expansion of antileukaemia CTL lines and clones for adoptive cell therapy in paediatric patients given allogeneic haematopoietic Stem cell transplantation
  1756. Issues and ethical problems of Stem cell therapy–where is hippocrates?
  1757. Protection of Stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection
  1758. Prenatal Stem cell transplantation and gene therapy
  1759. Emerging Stem cell concepts for imatinib‐resistant chronic myeloid leukaemia: Implications for the biology, management, and therapy of the disease
  1760. … —metaiodobenzylguanidine double infusion with autologous Stemcell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study
  1761. Proof-of-concept trials for lung Stem cell therapy
  1762. High‐dose therapy and autologous Stem cell transplantation for chemoresistant Hodgkin lymphoma: The Seattle experience
  1763. Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, Stem cell transplantation and rituximab: a Cancer and Leukemia …
  1764. Single autologous Stemcell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma …
  1765. … PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic Stem cell
  1766. … factor (GM-CSF)–secreting cellular immunotherapy in combination with autologous Stem cell transplantation (ASCT) as postremission therapy for acute myeloid …
  1767. Casting doubt on the safety of “off-the-shelf” mesenchymal Stem cells for cell therapy
  1768. The biological and ethical basis of the use of human embryonic Stem cells for in vitro test syStems or cell therapy
  1769. cell and gene therapy using mesenchymal Stem cells (MSCs)
  1770. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic Stem cell transplant recipients
  1771. Parthenogenetic embryonic Stem cells derived from cryopreserved newborn mouse ovaries: a new approach to autologous Stem cell therapy
  1772. Pfizer acquires a Stem cell therapy
  1773. Bevacizumab therapy before autologous Stemcell transplantation for POEMS syndrome
  1774. Endothelium‐specific gene and Stem cell‐based therapy for erectile dysfunction
  1775. Perinatal Stemcell and gene therapy for hemoglobinopathies
  1776. Adipose‐derived Stem cells are a source for cell therapy of the corneal stroma
  1777. Embryonic Stem (ES) cell-derived cardiomyocytes: a good candidate for cell therapy applications
  1778. Regeneration of irradiated salivary glands by Stem cell therapy
  1779. The new challenge of Stem cell: brain tumour therapy
  1780. Stem cell therapy: how should nurses respond?
  1781. therapy and autologous Stem cell transplantation versus conventional therapy for patients with advanced Hodgkin’s lymphoma responding to front-line therapy
  1782. Involved-field radiotherapy before high-dose therapy and autologous Stemcell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity
  1783. The extent of minimal residual disease reduction after the first 4‐week imatinib therapy determines outcome of allogeneic Stem cell transplantation in adults with …
  1784. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic Stem cell
  1785. Stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy
  1786. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic Stem cell transplantation: a prospective evaluation
  1787. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic Stem cell transplantation
  1788. Mesenchymal Stem cell-based gene therapy with prostacyclin synthase enhanced neovascularization in hindlimb ischemia
  1789. High prevalence of early-onset osteopenia/osteoporosis after allogeneic Stem cell transplantation and improvement after bisphosphonate therapy
  1790. Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic Stem cell transplantation: single‐center …
  1791. Loss of enterocyte mass is accompanied by diminished turnover of enterocytes after myeloablative therapy in haematopoietic Stemcell transplant recipients
  1792. Treating autoimmune diseases: is Stem cell therapy the future?
  1793. Dental regenerative therapy: Stem cell transplantation and bioengineered tooth replacement
  1794. Manufacturing neurons from human embryonic Stem cells: biological and regulatory aspects to develop a safe cellular product for stroke cell therapy
  1795. Stem cell niches as clinical targets: the future of anti-ischemic therapy?
  1796. Multilevel targeting of hematopoietic Stem cell self-renewal, differentiation and apoptosis for leukemia therapy
  1797. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic Stem cell transplantation: implications for the emergence of drug-resistant …
  1798. Myeloablative therapy with autologous Stem cell rescue for patients with Ewing sarcoma
  1799. Nausea and vomiting with high-dose chemotherapy and Stem cell rescue therapy: a review of antiemetic regimens
  1800. Porcine embryonic Stem cells: a possible source for cell replacement therapy
  1801. Hematopoietic Stem cell gene therapy for adenosine deaminase deficient-SCID
  1802. Stem cells to pancreatic β-cells: new sources for diabetes cell therapy
  1803. … graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic Stem cell transplantation for multiple …
  1804. Mesenchymal Stem cellsStem cell therapy perspectives for type 1 diabetes
  1805. Combination treatment of human umbilical cord matrix Stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic …
  1806. Gene-Stem cell therapy for ischemic stroke
  1807. Hematopoietic Stem cell gene therapy in Hurler syndrome, globoid cell leukodystrophy, metachromatic leukodystrophy and X-adrenoleukodystrophy.
  1808. The role of high-dose therapy with autologous Stem cell support in the era of novel agents
  1809. Stem cell-based therapy in central nervous syStem diseases
  1810. Vaccinations in children treated with standard-dose cancer therapy or hematopoietic Stem cell transplantation
  1811. Human cord blood Stem cell applications in cell therapy.
  1812. Antifungal therapy for invasive fungal diseases in allogeneic Stem cell transplant recipients: an update
  1813. High‐dose therapy and autologous Stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B‐cell lymphoma
  1814. Progress in researches on Stem cell therapy for erectile dysfunction
  1815. Establishment of medakafish as a model for Stem cell-based gene therapy: Efficient gene delivery and potential chromosomal integration by baculoviral vectors
  1816. Mathematical modelling of the impact of haematopoietic Stem cell‐delivered gene therapy for HIV
  1817. Embryonic Stem cells and Parkinson’s disease: cell transplantation to cell therapy
  1818. Gene therapy and bone marrow Stemcell transfer to treat autoimmune disease
  1819. cell therapy for Parkinson’s disease: II. Somatic Stem cell-based applications
  1820. … parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic Stem cell transplant recipients receiving long-term caspofungin therapy
  1821. Differentiation-chronology specific function of DNMT1 and selective anti-leukemia Stemcell therapy
  1822. Stem cell therapy: an update
  1823. High-dose therapy with hematopoietic Stem cell rescue in patients with poor prognosis Ewing family tumors
  1824. Can patient-specific Stem cell therapy enhance renal repair?
  1825. Stem cell therapy: A “magic bullet” for cardiomyopathies?
  1826. Stem cell therapy for spinal cord injury: A plea for rationality
  1827. therapy for older AML patients: the role of novel agents and allogeneic Stem cell transplant
  1828. The effect of human umbilical cord blood derived mesenchymal Stem cell therapy in rat model of cavernosal nerve injury
  1829. High rate of long-term survival for high-risk lymphoma patients treated with hematopoietic Stem cell transplantation as consolidation or salvage therapy
  1830. Cord blood Stem cell therapy for acquired immune deficiency syndrome
  1831. cell transplant and regenerative Stem cell therapy
  1832. Primed for lethal battle: a step forward to enhance the efficacy and efficiency of Stem cell transplantation therapy
  1833. Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous Stem cell
  1834. Childhood spinal muscular atrophy and Stem cell research: Is cellular replacement therapy the answer?
  1835. Neural Stem cell-mediated therapy of primary and metastatic solid tumors
  1836. … varicella-zoster virus infection preceding cutaneous manifestations after hematopoietic Stem cell transplantation: utility of PCR for early recognition and therapy
  1837. Does High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation Have a Role in the Primary Treatment of Peripheral T-cell Lymphomas?
  1838. Ethical issues in Stem cell research, therapy, and public policy
  1839. Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  1840. Comparison of ex vivo expansion culture conditions of mesenchymal Stem cells for human cell therapy
  1841. Radiation therapy Oncology Group translational research program Stem cell symposium: incorporating Stem cell hypotheses into clinical trials
  1842. Stemcell biology and cancer therapy: the more things change.
  1843. Stem cell therapy in chronic spinal cord injuries
  1844. Stem cell therapy in acute respiratory distress syndrome
  1845. Human cytomegalovirus load measurement and its applications for pre‐emptive therapy in patients undergoing hematopoietic Stem cell transplantation
  1846. Patients with mature T-cell lymphoma show high relapse rates after high dose therapy and autologous Stem cell transplantation
  1847. Reduced-toxicity conditioning therapy with allogeneic Stem cell transplantation for acute leukemia
  1848. Genetic engineering and Stem cells: combinatorial approaches for cardiac cell therapy [cellular/Tissue Engineering]
  1849. Autologous hematopoietic Stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia
  1850. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic Stem cell gene transfer of α‐glucosidase in Pompe …
  1851. … node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous Stem cell
  1852. Therapeutic window of Stem cell potential for targeting pediatric malignant brain tumors: an opportunity for Stem cell therapy
  1853. Stem cell therapy in Neurodegenerative
  1854. Stem cell therapy FOR BRAIN TUMORS
  1855. Stem cell–Based therapy for Glomerular Diseases: An Evolving Concept
  1856. Cardiac Stem cells: at the heart of cell therapy
  1857. Viral diagnostics and antiviral therapy in hematopoietic Stem cell transplantation
  1858. Is allogeneic Stem cell transplantation for transformed follicular lymphoma anti-lymphoma Stem cell therapy?
  1859. Treatment options for impaired spermatogenesis: germ cell transplantation and Stemcell based therapy.
  1860. The moral status of human embryos with special regard to Stem cell research and therapy
  1861. Outcome assessment measures for evaluating clinical effectiveness of canine adipose derived Stem cell therapy of osteoarthritis
  1862. Novel cancer Stem cell therapy on the horizon
  1863. Surgical Stem cell therapy for the Treatment of Heart Failure
  1864. Macrophage subpopulations are essential for infarct repair with and without Stem cell therapy
  1865. Hypervitaminosis A in pediatric hematopoietic Stem cell patients requiring renal replacement therapy
  1866. Principles of Stem cell therapy in the horse-the science behind the technology
  1867. Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered Stem cells in a murine model of airway injury
  1868. Extended mycophenolate mofetil administration beyond day 30 in allogeneic hematopoietic Stem cell transplantation as preemptive therapy for severe graft-versus …
  1869. Sex of muscle Stem cells does not influence potency for cardiac cell therapy
  1870. Properties of mesenchymal Stem cells to consider for cancer cell therapy
  1871. … body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood Stemcell transplantation followed by randomization to therapy with interleukin-2 …
  1872. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic Stem cell transplantation: a real‐world review
  1873. Future of Stem cell therapy for neuronal regeneration
  1874. Novel and immortalization-based protocols for the generation of neural CNS Stem cell lines for gene therapy approaches
  1875. Translational perspectives—transient epigenetic gene therapy: hazard-free cell reprogramming approach and rising arm of a universal Stem cell gene therapy platform
  1876. Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic Stem cell transplant recipients
  1877. Stem cell therapy for Acute Myocardial Infarction and Heart Failure-Past, Present and Future
  1878. Stem cell therapy: Numerical simulation of In Vivo Nutrient Transport and cells Growth
  1879. Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, Stem cell transplantation and new treatment agents
  1880. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral Stem cell transplantation
  1881. Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLA‐matched allogeneic Stem cell transplantation in childhood …
  1882. Post‐translational modifications of orphan nuclear receptor TR2–new insights into drug targets for Stem cell therapy and the effect of retinoic acid
  1883. Autologous Stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed …
  1884. Mesenchymal Stem cells and their use as cell replacement therapy and disease modelling tool
  1885. The role of cardiac ultrasound in Stem cell therapy
  1886. Stem cells for cardiac regeneration by cell therapy and myocardial tissue engineering
  1887. … on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic Stem cell
  1888. Structural and functional improvement of injured brain after severe acute carbon monoxide poisoning by Stem cell-based therapy in rats.
  1889. Generation of insulin-producing beta cells from Stem cells-perspectives for cell therapy in type 1 diabetes
  1890. Adult Stem cell therapy for acute renal failure: the hope beyond the hype
  1891. The prospect of pluripotent Stem cell-based therapy
  1892. Mesenchymal Stem cell therapy in a Rat Model for GvHD
  1893. Iodine‐131‐metaiodobenzylguanidine therapy with reduced‐intensity allogeneic Stem cell transplantation in recurrent neuroblastoma
  1894. Stem cell therapy
  1895. … , epirubicin and etoposide) is a more effective Stem cell mobilisation regimen than ICE (ifosphamide, carboplatin and etoposide) in the context of salvage therapy for …
  1896. Human cardiac Stem cell therapy for heart failure
  1897. Adult human Stem cell therapy for ischaemic stroke
  1898. Antifungal therapy strategies in hematopoietic Stemcell transplant recipients: early treatment options for improving outcomes
  1899. Preemptive therapy for cytomegalovirus disease in allogeneic Stem cell transplant recipients
  1900. Haploidentical allogeneic bone marrow Stem cell transplantation combined with peripheral blood Stem cells for therapy of leukemia
  1901. Review of Stem cell-based therapy for the treatment of cardiovascular disease
  1902. A long-term durable remission with high-dose therapy and autologous Stem cell transplant for stage IVB HIV-associated Hodgkins disease
  1903. Adult Mesenchymal Stem cells for cell therapy in Clinical Application.
  1904. Imipenem/cilastatin with or without glycopeptide as initial antibiotic therapy for recipients of autologous Stem cell transplantation: results of a Spanish …
  1905. Comparison of adult versus embryonic Stem cell therapy for cardiovascular disease: insights from molecular imaging studies
  1906. Counterpoint: cord blood Stem cell therapy for acquired immune deficiency syndrome
  1907. Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance therapy Following Single Autologous Stem cell Transplant for Multiple …
  1908. Specific Detection of Aberrant and Normal Stem cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem cell therapy.
  1909. Counterpoint: cord blood Stem cell therapy for acquired immune deficiency syndrome
  1910. Cardiac Stem cell therapy and arrhythmogenicity: Prometheus and the arrows of Apollo and Artemis
  1911. Embryonic Stem cells: overcoming the immunological barriers to cell replacement therapy
  1912. Comparison of mesenchymal tissues-derived Stem cells for in vivo chondrogenesis: suitable conditions for cell therapy of cartilage defects in rabbit
  1913. A microfabricated 3-D Stem cell delivery scaffold for retinal regenerative therapy
  1914. Bispecific antibody targeted Stem cell therapy for myocardial repair
  1915. Tissue Engineering for the Respiratory Epithelium: Is There a Future for Stem cell therapy in the Lung?
  1916. Novel Tyrosine Kinase Inhibitor therapy Before Allogeneic Stem cell Transplantation in Patients with Chronic Myeloid Leukemia.
  1917. Role of biomechanical force in Stem cell-based therapy for cartilage repair
  1918. Autologous Stem cell transplantation using MEAM regimen for relapsed AIDS-related lymphoma patients who received highly active anti-retroviral therapy: a report of …
  1919. R-CHOP, Followed by High Dose therapy and Autologous Stem cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are …
  1920. Stem cell therapy-An update
  1921. Tweaking the immune syStem: gene therapy-assisted autologous haematopoietic Stem cell transplantation as a treatment for autoimmune disease
  1922. Characterization and genetic manipulation of human umbilical cord vein mesenchymal Stem cells: potential application in cell-based gene therapy
  1923. High-dose therapy and autologous Stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
  1924. Stem cell transplantation after myeloablative therapy in first remission may be beneficial in patients with advanced stage follicular lymphoma after front-line therapy
  1925. Stem cell transplantation and MBL replacement therapy
  1926. Autologous Stem cell transplantation (autoSCT) as first-line therapy in peripheral T cell lymphomas (PTCL): results of a prospective multicenter study
  1927. Adult and Embryonic Stem cell therapy
  1928. New strategy of treatment for POEMS syndrome–autologous peripheral blood Stem cell transplantation and thalidomide therapy
  1929. cell therapy using induced pluripotent Stem (iPS) cells meets next-next generation DNA sequencing technology
  1930. Impact of lenalidomide therapy on Stem cell mobilization in myeloma
  1931. Wnt5a-treated midbrain neural Stem cells improve dopamine cell replacement therapy in parkinsonian mice
  1932. Plasma cell leukemia maintaining complete remission by syngeneic Stem cell transplantation combined with low-dose thalidomide maintenance therapy
  1933. … Ibritumumab Tiuxetan (Zevalin®)-BEAM/C with Autologous Stem cell Support as Frontline therapy for Advanced Mantle cell Lymphoma.–Preliminary Results …
  1934. Stem and progenitor cell-mediated tumor selective gene therapy
  1935. Stem cell therapy in cardiovascular diseases
  1936. Parkinson’s disease: Role of molecular imaging in monitoring the effectiveness of Stem cell therapy
  1937. Effects of Embryonic Neural Stem cell therapy on Oxidative and Nitrosative Stress Biomarkers in Acute and Chronic Spinal Cord Injured Rats
  1938. Ethical Issues in Stem cell therapy
  1939. Induced pluripotent Stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases
  1940. Treatment of refractory severe autoimmune disease by combined therapy with Chinese drug and autohemopoietic Stem cell transplantation
  1941. Second Autologous Stem cell Transplant (ASCT) as Salvage therapy in Patients with Relapsed Multiple Myeloma.
  1942. Stem cell therapy× ETHICS AND RELIGION
  1943. Islet cell therapy and pancreatic Stem cells
  1944. … molecular response in the absence of any antileukaemic therapy after dasatinib treatment and autologous peripheral blood Stem cell transplantation in a …
  1945. Minimally invasive Stem cell therapy
  1946. Stem cell therapy-emerging new field of medicine.
  1947. Hematopoietic Stem cell gene therapy trial with lentiviral vector in X-linked adrenoleukodystrophy
  1948. … does not adversely affect the Stem cell mobilization and engraftment after high-dose therapy and autologous transplantation in patients with diffuse large B-cell
  1949. Fetal Stem cell therapy
  1950. In vivo MRI of mouse heart at 11.7 t: monitoring of Stemcell therapy for myocardial infarction and evaluation of cardiac hypertrophy
  1951. INTERLEUKIN-10 ENGINEERED MESENCHYMAL Stem cell therapy TO PREVENT ISCHEMIA-REPERFUSION INJURY IN LUNG TRANSPLANTS: 167
  1952. Stem cell therapy: Hype or Hope?
  1953. Effects of Mesenchymal Stem cell therapy in BPD
  1954. Exposing gaps in our knowledge of Stem cell therapy
  1955. Brazilian experience using high-dose sequential therapy (HDS) followed by autologous hematopoietic Stem cell transplantation (ASCT) for malignant lymphomas
  1956. Stem cell Transplant (SCT) and Pralatrexate therapy: Outcome of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma Who Received SCT …
  1957. … Monoclonal Gammopathy: pulmonary hemorrhage during Stem cell mobilization and complete hematological response with bortezomib and dexamethasone therapy
  1958. Fibrin microthreads promote Stem cell growth for localized delivery in regenerative therapy
  1959. Stem cell Gene therapy for ADA-Deficiency without Myelopreparative Conditioning
  1960. Progress in Stem cell therapy for Alzheimer’s disease
  1961. cell therapy in Hematopoietic Stem cell Transplantation
  1962. Stem cell therapy for Alzheimer’s
  1963. Ethical aspects of Stem cell therapy and gene therapy
  1964. A possible approach for Stem cell gene therapy of Fanconi anemia
  1965. Outcomes with High Dose therapy and Peripheral Blood Stem cell Transplantation for Light Chain (AL) Amyloidosis with Cardiac Involvement.
  1966. Cardiovascular Regeneration and Stem cell therapy
  1967. Stemcell therapy is the last option for cardiac disease?
  1968. Second Autologous Stem cell Transplantation Is Effective Salvage therapy for Relapsed Multiple Myeloma.
  1969. Stem cell therapy for corneal defects
  1970. Potential applications of combined Stem cell and gene therapy for the treatment of infarcted heart
  1971. Handbook Of Cardiac Stem cell therapy
  1972. Cardiac regenerative therapy integrated via human autologous cardiac Stem cell and biodegradable bFGF-incorporating gelatin hydrogel
  1973. 237. Stem cell therapy: Neuroplasticity as a novel cellular mechanism for regeneration
  1974. Future Implementation of Adult Stem cell therapy in the Current Standards of Care for Myocardial Infarction
  1975. Experience of Hanyang ALS Clinic for Autologous BM Stem cell therapy in the Patients with ALS
  1976. Stem cell-targeted therapy–a new strategy for cancer treatment
  1977. Red Fluorescent Protein as a Marker for Stem cell therapy
  1978. … , pegylated-lyposomal-doxorubicin and dexamethasone (PAD) as induction therapy prior to reduced intensity autologous Stem cell transplant (ASCT) followed by …
  1979. Microencapsulated Stem cells for tissue repairing: implications in cell-based myocardial therapy
  1980. Involved field radiation therapy and donor lymphocyte infusion for relapsed or refractory non-Hodgkin lymphoma after allogeneic hematopoietic Stem cell
  1981. Liver Stem cell therapy: current and near future
  1982. Maintenance therapy with Low-Dose Azacitidine (AZA) after Allogeneic Hematopoietic Stem cell Transplantation (HSCT) for Relapsed or Refractory AML or …
  1983. Selection of Optimal M esenchymal Stem cells for Stem cell therapy in Amyotrophic Lateral Sclerosis Patients
  1984. Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic Stem cell transplantation in acute myeloid leukemia: influence of karyotype
  1985. Autologous and Cancer Stem cell Gene therapy
  1986. MO‐FF‐A2‐01: Neural Stem cell Sparing Radiation therapy—A Feasibility Study
  1987. Stem cell mobilization following initial therapy with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
  1988. Experimental Stem cell therapy in acquired neurological illnesses: Current status
  1989. Gene and Stem cell therapy in pulmonary arterial hypertension
  1990. Research progress of traditional Chinese medicine for Stem cell therapy of ischemic heart disease
  1991. The evaluation of acute renal failure models for the study of Stem cell therapy
  1992. Clinical Trials in Cardiac Stem cell therapy: An Update
  1993. Low level laser therapy and phototherapy assisted hydrogel dressing in burn wound healing: light guided epithelial Stem cell biomodulation
  1994. Stem cell therapy following acute myocardial infarction: Comparative studies with adipose tissue-derived Stem cells and bone marrow-derived Stem cells
  1995. Cardiac Stem cell therapy, from bench to bedside
  1996. Stem cell therapy to Promotor Functional Recovery Following Injury to the Nervous SyStem
  1997. Mesenchymal Stem cell therapy Prevents Ischemia/Reperfusion Injury
  1998. Impact of Allogeneic Stem cell Transplantation as Salvage therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic …
  1999. Chondroitin sulfate, a major niche substance of neural Stem cells, and cell transplantation therapy of neurodegeneration combined with niche modification
  2000. Characterization and optimization of in vitro culture conditions of adult Stem cells for clinical cell therapy
  2001. Noninvasive methods for monitoring cardiac Stem cell therapy
  2002. Effectiveness of Mesenchymal Stem cell therapy in Patients With Amyotrophic Lateral Sclerosis
  2003. Stem cell therapy for age-related retinal disease
  2004. Analysis of Umbilical Cord Blood Stem cell therapy for Regenerative Medicine Applications
  2005. Cardiac resynchronization and Stem cell therapy: do associative benefits exist?
  2006. Difficulty of peripheral blood Stem cell collection after multiple consolidation therapy in acute myeloid leukemia
  2007. Cytoprotective Actions of Mesenchymal Stem cell therapy After Acute Myocardial Infarction
  2008. Muscle‐derived Stem cell therapy for Stress Urinary Incontinence
  2009. Autologous in vitro expanded mesenchymal Stem cell therapy for human old myocardial infarction
  2010. 2 Overview of Adult Stem cell therapy in Cardiac Disease
  2011. Autologous Stem cell therapy with surgical myocardial revascularization/Otolog kok hucre tedavisi ve cerrahi miyokardiyal revaskularizasyon
  2012. Panoramic View of The Fifth International Symposium on Stem cell therapy and Applied Cardiovascular Biotechnology, April 2008, Madrid (Spain)
  2013. Engineering Cardiac Tissue Using Stem cell therapy to Mend the Broken Heart
  2014. Adult Stem cell therapy for acute and subacute spinal cord injury: Early clinical results and combined therapy strategy
  2015. ADIPOSE-TISSUE DERIVED MESENCHYMAL Stem cell (ASC) AS ALTERNATIVE SOURCE FOR AUTOLOGOUS cell therapy
  2016. Allay the ailing hearts-promising Stem cell therapy through apheresis: An experience of a tertiary care hospital in South India, ie SVIMS, Tirupati, Andhra Pradesh.
  2017. Long term follow-up after intramyocardial Stem cell therapy with AC133+ bone marrow cells
  2018. cell therapy for Diabetes Mellitus: An Opportunity for Stem cells?
  2019. Baylor’s contribution to thoracic surgery and cardiac Stem cell therapy for heart failure
  2020. SyStemic and Gene Modified Mesenchymal Stem cell therapy for Metastatic Prostate Cancer
  2021. G-CSF Based Peripheral Blood Stem cell therapy in Myocardial Infarction: Results of MAGIC cell Clinical Trial
  2022. UMBILICAL CORD BLOOD DERIVED MESENCHYMAL Stem cell therapy IN NOVEL CORONA VIRUS INFECTION–A REVIEW
  2023. Aspects of Embryonic Stem cell Derived Somatic cell therapy of Degenerative Diseases
  2024. (90) y-Ibritumumab Tiuxetan (Zevalin (R))-BEAM/C with Autologous Stem cell Support as Frontline therapy for Advanced Mantle cell Lymphoma.-Preliminary Results …
  2025. Cardiac regeneration by intramyocardial Stem cell therapy: clinical development
  2026. … and VTD (Bortezomib, Thalidomide, Dexamethasone) Induction Followed by High-Dose therapy with Autologous Stem cell Transplantation and Maintenance …
  2027. Mesenchymal Stem cell therapy for traumatic brain injury: Implications for intracranial inflammation
  2028. Value of MRI and iron oxide particle labeling in Stem cell therapy of brain ischemic rats
  2029. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous Stemcell transplantation on outcome
  2030. Results from functional and cellular studies using an ovine model to assess response to mesenchymal Stem cell therapy after induction of myocardial infarction
  2031. Human Embryonic Stem cell‐Derived Cardiomyocytes for cell therapy and Drug Discovery
  2032. Stem cell therapy for myocardial infarction: Overcoming the hypoxic impediment to enhance cell-survival and engraftment
  2033. Two Patients with Sporadic Late-Onset Nemaline Myopathy Respond to Stem cell therapy
  2034. Single Versus Tandem High Dose therapy (HDT) Supported with Autologous Blood Stem cell (ABSC) Transplantation Using Unselected or CD34-Enriched ABSC …
  2035. Adoptive Immune cell therapy for the Control of Fungal Infections in Hematopoietic Stem cell Transplant Patients
  2036. … Expression on Human CD34+ cells During Murine Leukemia Virus-Derived Retroviral Transduction with Recombinant Fibronectin for Stem cell Gene therapy
  2037. Hedgehog Signaling Pathway Is a New Target of Cancer Stem cell therapy for Breast Cancer Patients.
  2038. Placental mesenchymal and cord blood Stem cell therapy for dilated cardiomyopathy
  2039. Autologous bone marrow-derived Stem cell therapy in patients with Buerger’s disease
  2040. Intracoronary autologous bone marrow Stem cell therapy in diastolic heart failure
  2041. Serendipity—Methotrexate and 6-mercaptopurine for Continuation therapy for Patients With Acute Lymphoblastic Leukemia: The Leukemic Stem cell and Beyond?
  2042. … ®), Doxil®, and dexamethasone (VDD) is superior to thalidomide and dexamethasone (TD) as initial therapy prior to autologous Stem cell transplantation (ASCT) for …
  2043. RESCUE OF LUMICAN NULL CORNEAL PHENOTYPE USING Stem cell therapy
  2044. Autologous Bone Marrow-Derived Stem cell therapy: A Promising and Prospective Approach in the Treatment of Patients with Severe Buerger’s Disease.
  2045. 100. Subacute Neural Stem cell therapy for Traumatic Brain Injury
  2046. Lenalidomide as Salvage therapy after Allogeneic Stemcell Transplantation in Multiple Myeloma
  2047. Sci—Thurs AM: YIS—11: A Hybrid SPECT and Contrast Enhanced CT Platform: Application in Stem cell therapy
  2048. Rituximab based therapy followed by autologous Stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell
  2049. The role of allogeneic Stem cell transplantation in the therapy of adult acute lymphoblastic leukemia (ALL)
  2050. Laboratory of Neurogenesis and cell therapy, Wallenberg Neuroscience Center, and Lund Stem cell Center, University Hospital, SE-221 84 Lund, Sweden. 2 …
  2051. Defibrotide therapy for patients with sinusoidal obstruction syndrome after hematopoietic Stem cell transplantation
  2052. … by granulocyte colony-stimulating factor on myocardial perfusion and viability: Improvement of myocardial perfusion as a plausible mechanism of Stem cell therapy
  2053. Advance of researches on thyroid tissues autotransplantation and embryonic Stem cell transplantation in therapy of hypothyroidism
  2054. Beta cells can be generated from endogenous progenitors in injured adult mouse pancreas. An open gate towards endogenous Stem cell therapy in diabetes.
  2055. Multipotent Progenitor cells: A New Era In Stem cell-Mediated Gene therapy?
  2056. Mesenchymal Stem cell therapy increases proinflammatory cytokine production via NFkB activation independent of the PI3 kinase pathway
  2057. Early evaluation of genetically engineered mesenchymal stromal Stem cell therapy for prevention of left ventricular dysfunction in pigs
  2058. Stem cell Transplantation: Biology, Processes, therapy
  2059. … Mononuclear cell Transfer Is Associated with Superior Cardiac Recovery and Neovascularization as Compared to Nonmodified Mesenchymal Stem cell therapy in …
  2060. 2.5 Mesenchymal Stem cell therapy has significant clinical effect in proteoglycan induced arthritis
  2061. Effects of Bone Marrow-Derived Stem cell therapy on Airway and Lung Parenchyma Remodeling in a Murine Model of Chronic Allergic Asthma.
  2062. Allogeneic Stem cell transplantation (SCT) in advanced chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) therapy
  2063. 78. Genetically Modified Mesenchymal Stem cell therapy for Prostate Cancer Bone Metastasis
  2064. Locally induced neural Stem cells/pluripotent Stem cells for in vivo cell replacement therapy
  2065. Treatment failure due to intracerebral Stem cell-like behavior of glioblastoma (GBM) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea …
  2066. Corneal epithelial Stem cell deficiency and its therapy with transplantation of in vitro cultivated limbal Stem cells
  2067. Allogeneic Hematopoietic Stem cell Transplantation (HSCT) as a Curative therapy in Primary and Secondary Myelofibrosis (MF): A 14-Year Period …
  2068. … II Study of Sequential Velcade/Thalidomide/Dexamethasone (VTD) as Maintenance therapy Post Single Autologous Peripheral Stem cell (PSCT) in Patients …
  2069. Salvage therapy with Allogeneic Stem cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared …
  2070. Endonuclease-Boosted Gene Targeting and Cybridization for Long-Term Stem cell Gene therapy
  2071. Stem cell based therapy for the treatment of prion diseases
  2072. Stem cell-based therapy in Parkinson disease
  2073. Stemcell collection before high-dose therapy for multiple myeloma: time has come to raise the standards!
  2074. … Phase II Study Using Dexamethasone Induction therapy and High-Dose Melphalan Chemotherapy Followed by Autologous Stem cell Transplantation in 30 …
  2075. Novel Stem/Progenitor Populations: Implications for cell therapy
  2076. … Reduces the Cytotoxic Effects of in vitro Expanded NK cells: Implications for Adoptive NK cell therapy in the Setting of Allogeneic Hematopoietic Stem cell (HCT) …
  2077. Application potential of human fetal Stem/progenitor cells in cell therapy
  2078. Feasibility and Monitorization of Stemcell Replacement therapy
  2079. Sequential Chemotherapy Followed by High Dose therapy and Autologous Stem cell Rescue for Mantle cell Lymphoma: Impact of MIB-1 on Outcome
  2080. Is the era of the therapy by tailor-made Stem cell coming?
  2081. Stem cell based therapy to restore nearly normal hearing
  2082. Mesenchymal Stem cell Based therapy in Liver Disease
  2083. Stem cell research and therapy: A preliminary theological-ethical evaluation
  2084. Bortezomib therapy followed by autologous Stem cell transplantation in POEMS syndrome
  2085. Stem cell research and therapy: An overview of its feasibility with accompanying ethical implications
  2086. Yasuo Takeuchi, Makoto Otsu, Akihiro Kume, 2 Masafumi Onodera, 3 Tadatoshi Kuratsuji, 4 Hiromitsu Nakauchi. 1Lab of Stem cell therapy, Center for Experimental …
  2087. Prospective Study of Oral Valganciclovir for Pre-Emptive therapy of Cytomegalovirus After Allogeneic Stem cell Transplantation.
  2088. High-Dose therapy with Peripheral Blood Stem cell Transplantation for Patients with Multiple Myeloma: Prognostic Impact of Chromosomal Aberrations and …
  2089. Cancer Stem cell theory and cancer therapy
  2090. Autologous haematopoietic Stem cell transplantation followed by thalidomide therapy in poems syndrome
  2091. Outcomes of Allogeneic Stem cell Transplant in Patients with Myeloid Leukemias Over 65 Years of Age. Rationale for Aggressive therapy with Curative Intent.
  2092. Hodgkin-lymphoma with relapsed or progressive disease after autologous Stem cell transplantation: efficacy of salvage radiation therapy
  2093. Adipose derived Stem cells for regenerative cell therapy in peripheral vascular disease
  2094. Rituximab combined with autologous hematopoietic Stem cell transplantation for therapy of CD_ (20), positive B-cell lymphoma
  2095. DEVELOPING THE TOOLS FOR A Stem cell-BASED therapy FOR DEAFNESS: ISOLATION AND ANALYSIS OF HUMAN AUDITORY Stem cells
  2096. 236: Busulfan and Single-Dose Melphalan as Preparative therapy for Infants and Young Children Undergoing Stem cell Transplantation for Leukemia: A Single …
  2097. Caspofungin as secondary prophylaxis or therapy in patients undergoing allogeneic Stem cell transplantation with a prior or ongoing history of syStemic or …
  2098. Bortezomib-based induction therapy induces better responses and outcomes of autologous Stem cell transplantation in newly diagnosed patients with multiple …
  2099. Engineering embryonic Stem cells for myelin cell therapy
  2100. Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, Stem cell transplantation and new treatment agents
  2101. High Dose Chemotherapy and Autologous Stem cell Transplantation in the Primary therapy of Advanced Follicular Lymphoma in Adults: A SyStematic …
  2102. Role of autologous Stem cell transplant after induction therapy with bortezomib-lenolidomide or bortezomib-thalidomide in newly diagnosed multiple myeloma patients
  2103. Characterisation of neural Stem cells for oestrogen in vitro: potential for improving Stem cell based therapy for stroke
  2104. Stem cell based therapy of malignant brain tumors
  2105. … Interferon-Alpha Maintenance therapy for Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Ineligible for Allogeneic Stem cell
  2106. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived Stem cell
  2107. Stem cell therapy for Vascular Disease
  2108. Regenerative therapy and mesenchymal Stem cell for veterinary medicine.
  2109. Stem cell Transplantation in the therapy of Acute Myeloid Leukemia in Adults Evidence-Based Review 137 The Role of Cytotoxic therapy with Hematopoietic Stem
  2110. … , Melphalan (RBEAM) and Autologous Stem cell Transplantation (ASCT) for Poor Prognosis Diffuse Large B-cell Lymphoma (DLBCL). ClinicalTrials. Gov …
  2111. Allogeneic Stem cell Transplantation (Allo-SCT) For Relapsed, Refractory Myeloid Leukemia and Mds Using Clofarabine (Clo)±Fludarabine (Flu) with IV Busulfan (Bu …
  2112. Evaluation of Selected Human Embryonic Stem cell Lines for Differentiation to Retinal cells and for cell-Based therapy
  2113. Muscular dystrophy cell therapy: an in utero approach using human fetal mesenchymal Stem cells
  2114. Role of high-dose therapy and autologous Stem cell transplantation in treatment of chemotherapy-efractory Hodgkin lymphoma
  2115. Development of new human Stem cell-derived cellular vehicles for glioma gene therapy
  2116. Generation of cells for cell Replacement therapy: Specification of Neural Precursors in Vivo and in Neural Stem cell Cultures
  2117. Stem cell-based therapy of ocular surface diseases: novel approaches to expansion of adult epithelial Stem cells in culture
  2118. Optimization of suicide gene therapy in Stem cell transplantation with special reference to the selection marker OuaSelect
  2119. Feasibility and Efficacy of Autologous Stem cell Transplantation as First-Line therapy for Peripheral T-cell Lymphoma: a Single Center Experience
  2120. High dose immunosuppressive therapy with autologous hematopoietic Stem cell transplantation in secondary progressive multiple sclerosis: Case report
  2121. Adult Stem cell-based gene therapy for alpha 1-antitrypsin deficiency
  2122. Long-Term Follow-up of HCV Infected Stem cell Transplant Patients and Effects of Antiviral therapy.
  2123. The Effect of SyStemic Steroid therapy on Dry Eye in Hematopoietic Stem cell Transplantated Patients
  2124. … of DNA Methylation Changes in a Phase I Clinical Trial of Low-dose 5-azacitidine (AZA) given as Maintenance therapy after Allogeneic Hematopoietic Stem cell
  2125. Protection of Stem cell-Derived Lymphocytes in a Primate AIDS Gene therapy Model
  2126. A comparative study of the curative effects of cytomegalovirus preemptive therapy in various kinds of hematopoietic Stemcell transplantation
  2127. … outcome in transformed follicular lymphoma compared to de novo aggressive B-cell lymphoma treated with high-dose therapy and autologous Stemcell
  2128. Hematopoietic Stem cell based gene therapy for the treatment of metachromatic leukodystrophy: towards clinical testing
  2129. Preemptive therapy of HHV-6 Encephalitis with Foscarnet Sodium for High Risk Patients After Hematopoietic Stem cell Transplantation.
  2130. Gemtuzumab-ozogamicin as maintenance therapy after autologous Stem cell transplantation in elderly patients with acute myeloid leukaemia
  2131. Successful autologous Stem cell transplantation in a woman with Severe SyStemic Sclerosis, refractory to immunosuppressive therapy
  2132. CML: Is Allogeneic Stem cell Transplantation the Second-Line therapy of Choice following Resistance to Imatinib?
  2133. Bortezomib-Based therapy, without Stem cell Transplantation, for Newly Diagnosed Multiple Myeloma Patients with t (4; 14).
  2134. Gemtuzumab Ozogamicin as Induction therapy Followed by Post-Remission Hematopoietic Stem cell Transplantation in Elderly Patients with Acute Myeloid …
  2135. Prognostic Value of Bone Marrow Angiogenesis in Patients with Multiple Myeloma Undergoing High-Dose therapy and Autologous Stem cell Transplantation …
  2136. The rate of cytomegalovirus infection and disease in correlation with the type of haematopoietic Stem cell transplantation in the era of pre-emptive antiviral therapy
  2137. … of Prior Radiation therapy Predicts Poor Progression Free Survival and Overall Survival in African Americans with Multiple Myeloma after Autologous Stem cell
  2138. Biological quantification of murine osteoarticular joints following treatment using Stem cell-based gene therapy
  2139. High-Dose therapy with Peripheral Blood Stem cell Transplantation for Patients with Relapsed or Refractory Hodgkin’s Disease: A Single-Institution 20-Year …
  2140. Treatment of diabetes by cell therapy: new insights on Stem cells and precursors
  2141. “Hiper CVAD Followed by Rituximab Purging Previous to Autologous Stemcell Transplantation as therapy of Mantle cell Lymphoma. Results of Manto 2000 …
  2142. Epithelial to mesenchymal transition in breast cancer is associated with resistance to therapy and a cancer Stem cell-like phenotype
  2143. Autologous Stem cell Transplant in Recurrent Diffuse Large B-cell Lymphoma: Prior Rituximab therapy Has No Impact On Early Lymphocyte Recovery and …
  2144. Adoptive therapy with T-cell Precursors for Immune Reconstitution After Allogeneic Hematopoietic Stem cell Transplantation.
  2145. Case Closed (If There Was Still Any Doubt): High-Dose Chemotherapy & Autologous Stemcell Transplant As Adjuvant therapy for Breast Cancer
  2146. 267. Targeted therapy of Metastatic Melanoma Using Neural Stem cell-Based Drug Delivery
  2147. Mechanism of Action of Prostate Stem cell Antigen Targeted Antibody therapy and Its Relevance to Clinical Application in Prostate Cancer
  2148. 90y-Ibritumumab Tiuxetan (Zevalin®-BEAM/C with Autologous Stem cell Support as therapy for Advanced Mantle cell Lymphoma.-Preliminary Results From …
  2149. … of Cytomegalovirus Infection and Disease in Correlation with the Type of Hematopoietic Stem cell Transplantation in the Era of Preemptive Antiviral therapy
  2150. Hyperbaric oxygen therapy for post-Stem cell transplant haemorrhagic cystitis in children and adolescents
  2151. Stem cell Mobilization In Patients With Newly Diagnosed Multiple Myeloma Following therapy With Lenalidomide and Dexamethasone
  2152. Comparative study of allogeneic peripheral blood Stem cell transplantation and immunosuppressive therapy for severe aplastic anemia
  2153. … Seropositivity Does Not Affect the Outcome of Allogeneic Hematopoietic Stem cell Transplantation with Intensive Monitoring and Modern Anti-Viral therapy
  2154. Adding Fludarabine to Cyclophophamide-dexamethason induction therapy impair Stem cell harvest in MM: Report from an interim analysis of the NMSG 13/03 …
  2155. The effect of rituximab in first line therapy to results of autologus haematopoietic Stem cell transplantation in relapsed non-Hodgkin’s lymphoma patients
  2156. Allogeneic haematopoietic Stem cell transplantation as a curative therapy in primary and secondary myelofibrosis
  2157. Allogeneic Stem cell transplantation after sequential therapy using high-dose melphalan and myeloablative conditioning in patients with refractory acute myeloid …
  2158. cell death of colorectal cancer Stem-like cell was induced by photodynamic therapy with protoporphyrin IX
  2159. In the article entitled ”The Role of Cytotoxic therapy with Hematopoietic Stem cell Transplantation in the therapy of Myelodysplastic Syndromes: An Evidence-Based …
  2160. Allogeneic haematopoietic Stem cell transplantation as front line therapy for patients with” de novo” or secondary myelodysplastic syndrome: a single-centre …
  2161. Frequency of Allogeneic Stem cell Transplant (SCT) in Patients Presenting with Newly-Diagnosed AML or AML at Time of First Salvage therapy.
  2162. The Combination of Cyclophosphamide and Thalidomide During Induction therapy for Multiple Myeloma Results in a High Rate of Stem cell Mobilization Failure.
  2163. Future advances in glaucoma therapy: today’s research–gene therapy, Stem cell transplants, neuroprotective drugs and’real-time’pressure monitoring–will help …
  2164. Gauging the response of circulating epithelial tumor cells (CETC) and tumor Stem cell subpopulations to therapy of early-stage cancer in the individual patient
  2165. Immunosuppressive therapy and Future Response to Androgens or Survival After Hematopoietic Stem cell Transplantation in Fanconi Anemia.
  2166. Peripheral Blood Stem cell (PBSC) Harvest Is More Expensive Following Bortezomib-Based therapy in Multiple Myeloma (MM), Related to Increase Number …
  2167. Up-front allogeneic Stem cell transplantation as part of induction or salvage therapy in primary high-risk and relapsed acute myeloid leukaemia
  2168. Resolution of pure red cell aplasia after reduced-intensity allogenic Stem cell transplantation with major ABO mismatch during therapy with lenalidomide
  2169. Achievement of CR and nCR Before and After First High-Dose therapy Followed by Autologous Stem cell Transplantation Is a Major Marker for Long-Term …
  2170. Combination Of Ifn-α/GM-CSF as Maintenance therapy for Multiple Myeloma Patients After Autologous Stem cell Transplantation (ASCT): Results of a Prospective …
  2171. 902. Mucopolysaccharidosis Type I Ex Vivo Gene therapy Based on MLV-Mesenchymal Stem cell Transduction: Is There a Way To Be Attenuated When Older?
  2172. Double Reduced-Intensity Allogeneic Hematopoietic Stem cell Transplantation: French Society of Bone Marrow Graft Transplantation and cellular therapy
  2173. Hypogammaglobulinemia Following Rituximab and High-Dose therapy and Autologous Stemcell Transplant: Incidence and Predictors of Prolonged …
  2174. Early allogeneic Stem cell transplantation for peripheral T-cell lymphoma results in a lower relapse rate and a higher non-relapse mortality than high-dose therapy
  2175. No benefit of autologous Stem cell transplantation as consolidation for high and high-intermediate risk diffuse large B-cell lymphoma in 1. CR after R-CHOP therapy–a …
  2176. PAD Induction therapy Followed by Autologous Peripheral Blood Stem cell Transplant (APBSCT) as Upfront Treatment for Myeloma (MM) in Chinese Patients.
  2177. … (Ph+) Leukemia cells in the Primitive (CD34posCD38neg) Stem cell Fraction in Chronic Myeloid Leukemia (CML) Patients during Tyrosine Kinase Inhibitor therapy.
  2178. … of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human Stem cell and gene therapy“[Brain. Res. Bull 74 (2007) …
  2179. Translation and validation of the Functional Assessment of Cancer therapy-Bone Marrow Transplant (FACT-BMT) Version 4 quality of life instrument into Arabic …
  2180. Neural Stem cell-mediated enhanced gene therapy of malignant gliomas using a novel plant thymidine kinase
  2181. … of Second-Line therapy in Multiple Myeloma Patients Relapsing After Uniform Front-Line Treatment with High-Dose Melphalan and Autologous Stem cell
  2182. … targeted therapy into conditioning regimen for patients undergoing autologous Stem cell transplant (ASCT) for aggressive CD20 positive B-cell lymphoma has altered …
  2183. Thiotepa-cyclophosphamide high-dose immunosuppressive therapy with autologous haematopoietic Stem cell transplantation in aggressive forms of multiple sclerosis …
  2184. Post Tandem Autologous Stem cell Transplant Maintenance therapy with Bortezomib Improves Remission Duration and Quality of Response in Multiple …
  2185. BCCA Protocol Summary for Myeloablative Conditioning therapy Prior to Autologous and Allogeneic Hematopoietic Stem cell Transplantation for Myeloid …
  2186. Effect of prior therapy with Nilotinib or Dasatinib on the outcome after allogeneic Stem cell transplantation for patients with chronic myeloid leukaemia
  2187. Evaluating the Safety and Efficacy of Anti-HIV Transgenic cells in a Humanized Mouse Model (NOD/SCIDγc−/−) for HIV Stem cell Gene therapy.
  2188. Abstract# 1071: Tumor Stem cell targeted therapy with mTOR inhibitor RAD001 and hedgehog signalling inhibitor Cyclopamine reverts chemoresistance towards 5 …
  2189. … proliferative index in mantle cell lymphoma (MCL) treated with sequential chemotherapy followed by high-dose therapy and autologous Stem cell rescue (HDT/ASCR)
  2190. Thalidomide-Dexamethasone as Induction therapy Prior to Autologous Stemcell Transplantation in Patients With Newly Diagnosed Multiple Myeloma and …
  2191. Steroid Refractoriness, but Not Rapidity of Response, to Induction therapy Predicts for Outcome Post-Autologous Stem cell Transplant (ASCT) in Patients …
  2192. Ganciclovir and Leflunomide Combination therapy for a Patient with Cytomegalovirus Pneumonia after Unrelated Allogenic Stem cell Transplantation
  2193. … factors in relapsed acute myeloid leukaemia patients receiving an allogeneic haematopoetic Stem cell transplantation as salvage therapy: a retrospective analysis on …
  2194. TI 4 Potential of muscle Stem cells and cell therapy for Duchenne muscular dystrophy
  2195. … (MFAC) regimen as induction therapy in relapsed or refractory CD33+ acute myeloid leukaemia prior to allogeneic haematopoetic Stem cell transplantation: a single …
  2196. … Haematopoietic Stem cell Transplantation for Myeloid Malignancies Can Be Effectively Salvaged with Intensive Chemotherapy Followed by cellular therapy
  2197. Sequential therapy With Nonablative Allogeneic Stem cell Transplantation, Post Transplant Imatinib and Donor Lymphocyte Infusion for Chronic Myeloid Leukemia
  2198. … Is No Longer An Adverse Prognostic Factor for Patients with Relapsed HL Undergoing High Dose therapy and Autologous Stem cell Transplant: Results of a …
  2199. … with Multiple Myeloma Who Have Undergone High-Dose Melphalan therapy Followed by Autologous Peripheral Blood Stem cell Transplantation and Failed …
  2200. 1007. Factor VIII Transgene Tolerance Is Induced by Nonmyeloablative Hematopoietic Stem cell Gene therapy for Hemophilia A
  2201. … Trial of Pre-Emptive therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem cell
  2202. 340: Response to Steroids as Primary therapy for Acute Graft-Versus-Host Disease (GVHD) in 280 Hematopoietic Stem cell Transplant (HSCT) Recipients …
  2203. Antitumor Effects of Canine Adipose Tissue-Derived Mesenchymal Stem cell Based IFN- Gene therapy and Cisplatin in a Mouse Melanoma Model
  2204. … (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose therapy and Peripheral Blood Stem cell Transplantation in First-Line Treatment …
  2205. 13: The Outcome of Allogeneic Stem cell Transplantation (alloSCT) for the Treatment of therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid …
  2206. … A, on behalf of the Tunisian Multiple Myeloma Study Group. Single autologous Stemcell transplantation followed by maintenance therapy with thalidomide is superior …
  2207. Mesenchymal Stem cells: Applications in cell and gene therapy
  2208. … without Preceding Remission Induction therapy Induces Durable Remission in Patients with Relapsed Acute Leukemia After the First Allogeneic Stem cell
  2209. … with hematological malignancy and hematopoietic Stem cell transplant (HSCT) recipients in the absence of active immunization and approved therapy: The role of …
  2210. Clofarabine [+ or-] fludarabine with IV busulfan as reduced-toxicity conditioning therapy for allogeneic Stem cell transplantation (Allo-SCT) in advanced myeloid …
  2211. Islet neogenesis potential of human adult Stem cells and its applications in cell replacement therapy for diabetes
  2212. High-dose therapy/autologous Stem cell transplantation increases complete remission rate in multiple myeloma irrespective of the induction regimen used: TD …
  2213. The Effect of Mesenchymal Stem cells as a cell therapy in Renal Ischemia
  2214. Stem cells and cell replacement therapy for Parkinson’s disease
  2215. Developing cell therapy techniques for respiratory disease: Intratracheal delivery of genetically engineered Stem cells in a murine model of airway injury
  2216. Bioluminescence Imaging of X-Ray Visible Microencapsulated Mesenchymal Stem cells for cell Based therapy of Peripheral Arterial Disease
  2217. … Transduction of the Human Purine Nucleoside Phosphorylase (PNP) Gene in Murine Hematopoietic Stem cells: An In Vivo Model of Gene therapy for PNP-T-cell
  2218. … AND GENETIC MANIPULATION OF HUMAN UMBILICAL CORD VEIN MESENCHYMAL Stem cells: POTENTIAL APPLICATION IN cell-BASED GENE therapy
  2219. Development of real-time MR cell tracking for human neural Stem/progenitor cell-mediated brain tumor therapy
  2220. Lymphatic Reprogramming of Adult Endothelial Stem cells for a cell-Based therapy for Lymphedema in Breast Cancer Patients
  2221. WITHDRAWN: Treatment of combining antiangiogenic therapy and cytotoxic chemotherapy reduce the cancer Stem-like cell fraction in hepatocarcinoma xenografts
  2222. Evaluation of human fetal neural Stem/progenitor cells as a source for cell replacement therapy for neurological disorders: Properties and tumorigenicity after long …
  2223. 323: Immunosuppressive therapy Mitigates Murine T-cell Mediated Rejection of Human Embryonic Stem cells Following Transplantation
  2224. Hematopoietic Stem and progenitor cells and potentials for application in fetal cell replacement therapy
  2225. Stem cells and Genetic therapy for Hair cell–Related Hearing Loss
  2226. Molecular Characterization, Safety and Feasibility of Induced Pluripotent Stem (iPS) cell Derived Cardiomyocytes for Heart Regenerative therapy
  2227. The effect of angiotensin (1-7) on bone marrow Stem cells: adjunctive pharmacological therapy for cell transplantation in heart failure
  2228. Risk factors in the development of Stem cell therapy
  2229. Embryonic and adult Stem cell therapy
  2230. Mesenchymal Stem cell therapy: Two steps forward, one step back
  2231. Angiomyeloproliferative lesions following autologous Stem cell therapy
  2232. Stem cell therapy as an emerging paradigm for stroke (STEPS) II
  2233. Stem cell therapy for type 1 diabetes mellitus
  2234. Mesenchymal Stem cell therapy for knee osteoarthritis. Preliminary report of four patients
  2235. Limbal Stemcell therapy and long-term corneal regeneration
  2236. Stem cell and progenitor cell therapy in peripheral artery disease
  2237. Translation of Stem cell therapy for neurological diseases
  2238. Stem cell therapy for heart diseases
  2239. Autologous Stem cell therapy for peripheral arterial disease: meta-analysis and syStematic review of the literature
  2240. Stem cell therapy for neonatal brain injury: perspectives and challenges
  2241. Mesenchymal Stem cell therapy for nonhealing cutaneous wounds
  2242. Stem cell therapy: A challenge to periodontist
  2243. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent Stem cells
  2244. Mesenchymal Stem cell therapy for cardiac repair
  2245. Combination Stem cell therapy for heart failure
  2246. Feasibility of combination allogeneic Stem cell therapy for spinal cord injury: a case report
  2247. Stem cell therapy: a new treatment for burns?
  2248. Challenges of Stem cell therapy for spinal cord injury: human embryonic Stem cells, endogenous neural Stem cells, or induced pluripotent Stem cells?
  2249. Stem cell therapy in acute myocardial infarction: a review of clinical trials
  2250. Experimental Stem cell therapy: Biohierarchies and bionetworking in Japan and India
  2251. Intestinal myofibroblasts: targets for Stem cell therapy
  2252. Stem cell therapy in PAD
  2253. Stem cell therapy for Alzheimer’s disease
  2254. Prospects of Stem cell therapy in osteoarthritis
  2255. Human Stem cell therapy in ischaemic stroke: a review
  2256. cellular antioxidant levels influence muscle Stem cell therapy
  2257. Update on Stem cell therapy for cerebral palsy
  2258. Combination Stem cell therapy for the treatment of severe limb ischemia: safety and efficacy analysis
  2259. Congenic mesenchymal Stem cell therapy reverses hyperglycemia in experimental type 1 diabetes
  2260. Recent advances in liver Stem cell therapy
  2261. Stem cell therapy: pieces of the puzzle
  2262. Stem cell separation: a bottleneck in Stem cell therapy
  2263. What Have I Got to Lose?: An Analysis of Stem cell therapy Patients’ Blogs
  2264. Mesenchymal Stem cell therapy modulates the inflammatory response in experimental traumatic brain injury
  2265. Allogeneic periodontal ligament Stem cell therapy for periodontitis in swine
  2266. The Stem cell niche should be a key issue for cell therapy in regenerative medicine
  2267. Results of intracoronary Stem cell therapy after acute myocardial infarction
  2268. Chemokines in mesenchymal Stem cell therapy for bone repair: a novel concept of recruiting mesenchymal Stem cells and the possible cell sources
  2269. Mesenchymal Stem cell therapy for the treatment of chronic obstructive pulmonary disease
  2270. Combined gene and Stem cell therapy for cutaneous wound healing
  2271. Non-invasive Stem cell therapy in a rat model for retinal degeneration and vascular pathology
  2272. Successful clinical implementation of corneal epithelial Stem cell therapy for treatment of unilateral limbal Stem cell deficiency
  2273. Concise review: limbal epithelial Stem cell therapy: controversies and challenges
  2274. Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications
  2275. Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal
  2276. Stem cell therapy for retinal diseases: update
  2277. Imaging: guiding the clinical translation of cardiac Stem cell therapy
  2278. Stem cell therapy in pulmonary fibrosis
  2279. Stem cell therapy for cardiac disease
  2280. The regenerative medicine laboratory: facilitating Stem cell therapy for equine disease
  2281. Stem cell therapy improves the outcome of liver resection in cirrhotics
  2282. Human cord blood Stem cell therapy for treatment of stress urinary incontinence
  2283. Mesenchymal Stem cell therapy for chronic renal failure
  2284. Mesenchymal Stem cell therapy for treatment of cardiovascular disease: helping people sooner or later
  2285. Human relevance of pre-clinical studies in Stem cell therapy: syStematic review and meta-analysis of large animal models of ischaemic heart disease
  2286. Advancement of mesenchymal Stem cell therapy in solid organ transplantation (MISOT)
  2287. Selection of optimal passage of bone marrow-derived mesenchymal Stem cells for Stem cell therapy in patients with amyotrophic lateral sclerosis
  2288. Human placenta-derived mesenchymal Stem cells and islet-like cell clusters generated from these cells as a novel source for Stem cell therapy in diabetes
  2289. Dental Stem cell therapy with calcium hydroxide in dental pulp capping
  2290. Stem cell therapy in cardiovascular disorders
  2291. Advances in Stem cell therapy for the lower urinary tract
  2292. Case control series of intrathecal autologous bone marrow mesenchymal Stem cell therapy for chronic spinal cord injury
  2293. Mesenchymal Stem cell therapy for cutaneous radiation syndrome
  2294. Promises of Stem cell therapy for retinal degenerative diseases
  2295. Stem cell therapy for spinal cord injury
  2296. Animal models of cardiac disease and Stem cell therapy
  2297. Mesenchymal Stem cell therapy regenerates the native bone-tendon junction after surgical repair in a degenerative rat model
  2298. G-CSF for Stem cell therapy in acute myocardial infarction: friend or foe?
  2299. Dual Stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis
  2300. Effects of adipose tissue-derived Stem cell therapy after myocardial infarction: impact of the route of administration
  2301. Terminal differentiation is not a major determinant for the success of Stem cell therapy-cross-talk between muscle-derived Stem cells and host cells
  2302. Can HIV be cured with Stem cell therapy?
  2303. Mesenchymal Stem cell therapy in necrotizing enterocolitis: a rat study
  2304. Intracoronary autologous CD34+ Stem cell therapy for intractable angina
  2305. Extinction models for cancer Stem cell therapy
  2306. Potential and pitfalls of Stem cell therapy in old age
  2307. Stem cell therapy for glaucoma: possibilities and practicalities
  2308. Stem cell therapy for digestive tract diseases: current state and future perspectives
  2309. Stem cell therapy for the kidney: a cautionary tale
  2310. 10 years of intracoronary and intramyocardial bone marrow Stem cell therapy of the heart: from the methodological origin to clinical practice
  2311. Regenerative medicine in the field of pain medicine: Prolotherapy, platelet-rich plasma therapy, and Stem cell therapy—Theory and evidence
  2312. Mesenchymal Stem cell therapy and delivery syStems in nonhealing wounds
  2313. Safety and efficacy of bone marrow-derived autologous CD133+ Stem cell therapy
  2314. cell delivery and tracking in post-myocardial infarction cardiac Stem cell therapy: an introduction for clinical researchers
  2315. In vivo imaging of embryonic Stem cell therapy
  2316. Cervical multilevel intraspinal Stem cell therapy: assessment of surgical risks in Gottingen minipigs
  2317. Gene and Stem cell therapy: alone or in combination?
  2318. Stem cell therapy for myocardial infarction: are we missing time?
  2319. Imaging cardiac Stem cell therapy: translations to human clinical studies
  2320. Stemcell therapy in an experimental model of pulmonary hypertension and right heart failure: role of paracrine and neurohormonal milieu in the remodeling process
  2321. Stem cell therapy: a future treatment of stress urinary incontinence
  2322. Oxygen and oxygenation in Stemcell therapy for myocardial infarction
  2323. Dermal substitute-assisted healing: enhancing Stem cell therapy with novel biomaterial design
  2324. Stem cell therapy for incontinence: where are we now? What is the realistic potential?
  2325. Stem cell therapy in stroke: designing clinical trials
  2326. Combination Stem cell therapy for the treatment of medically refractory coronary ischemia: a Phase I study
  2327. FOXP3 gene expression in multiple sclerosis patients pre-and post mesenchymal Stem cell therapy
  2328. Recruiter-patients as ambiguous symbols of health: bionetworking and Stem cell therapy in India
  2329. Stem cell therapy for dermal wound healing
  2330. Stem cell therapy for ischemic heart disease
  2331. Stem cell therapy in acute myocardial infarction: a pot of gold or Pandora’s box
  2332. Autologous Stem cell therapy maintains vertebral blood flow and contrast diffusion through the endplate in experimental intervertebral disc degeneration
  2333. Allogeneic haematopoietic Stem cell transplantation: individualized Stem cell and immune therapy of cancer
  2334. Current perspectives on imaging cardiac Stem cell therapy
  2335. A new paradigm for Stem cell therapy: substance-P as a Stem cell-stimulating agent
  2336. Advances in cardiovascular molecular imaging for tracking Stem cell therapy
  2337. Cardiac Stem cell therapy: progress from the bench to bedside
  2338. Stem cell therapy for chronic heart failure. Lessons from a 15-year experience
  2339. Human umbilical cord blood as an emerging Stem cell therapy for diabetes mellitus
  2340. Progenitors for the corneal endothelium and trabecular meshwork: a potential source for personalized Stem cell therapy in corneal endothelial diseases and …
  2341. Effects of Stem cell therapy on Left Ventricular Remodeling After Acute Myocardial Infarction: A Meta‐Analysis
  2342. Neural crest regionalisation for enteric nervous syStem formation: implications for Hirschsprung’s disease and Stem cell therapy
  2343. Surgical approaches to gene and Stem cell therapy for retinal disease
  2344. Current status of Stem cell therapy in heart failure
  2345. Synergistic effect of adipose-derived Stem cell therapy and bone marrow progenitor recruitment in ischemic heart
  2346. Stem cell therapy for neuromuscular diseases
  2347. Stem cell therapy for the heart: a perspective
  2348. Effect of oxygenation on Stemcell therapy for myocardial infarction
  2349. Evidence-based medicine and Stem cell therapy: how do we know such technologies are safe and efficacious?
  2350. Host tissue response in Stem cell therapy
  2351. Stem cell therapy for stress urinary incontinence
  2352. Mesenchymal Stem cell therapy of intestinal disease: are their effects syStemic or localized?
  2353. Stem cell therapy for chronic lung diseases: hope and reality
  2354. Stem cell therapy for the treatment of myocardial infarction
  2355. Regenerative stromal cell therapy in allogeneic hematopoietic Stem cell transplantation: current impact and future directions
  2356. GRNOPC1: the world’s first embryonic Stem cell-derived therapy
  2357. Stemcell therapy for peripheral arterial occlusive disease
  2358. Bone marrow Stem cell therapy for recessive dystrophic epidermolysis bullosa
  2359. The bioethics of Stem cell research and therapy
  2360. Neural tube defects: review of experimental evidence on Stem cell therapy and newer treatment options
  2361. Stem cell therapy in cardiology
  2362. Evaluation of 28 human embryonic Stem cell lines for use as unrelated donors in Stem cell therapy: implications of HLA and ABO genotypes
  2363. Clinical applications of Stem cell therapy for regenerating the heart
  2364. Human pluripotent Stem cell therapy for Huntington’s disease: technical, immunological, and safety challenges
  2365. Mesenchymal Stem cell exosome: a novel Stem cell-based therapy for cardiovascular disease
  2366. From bone to brain: human skeletal Stem cell therapy for stroke
  2367. Current and future status of Stem cell therapy in heart failure
  2368. In vivo imaging for Stem cell therapy: new developments and future challenges
  2369. Potential clinical applications of adult human mesenchymal Stem cell (Prochymal®) therapy
  2370. Allogeneic human mesenchymal Stem cell therapy (Prochymal®) as a rescue agent for severe treatment resistant GVHD in pediatric patients
  2371. Stem cell therapy for Parkinson’s disease: a road map for a successful future
  2372. Stem cell therapy and research status in Iran: at A glance
  2373. In sickness and in health: corneal epithelial Stem cell biology, pathology and therapy
  2374. Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors
  2375. Mesenchymal Stem cell therapy in the Treatment of Acute and Chronic Graft Versus Host Disease
  2376. Stem cell therapy for the bladder: where do we stand?
  2377. ABCG2: a potential marker of Stem cells and novel target in Stem cell and cancer therapy
  2378. … of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear Stem cell administration on left …
  2379. Bionetworking: between guidelines and practice in Stem cell therapy enterprise in India
  2380. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow‐derived Stem cell administrations
  2381. Stem cell therapy extends incubation and survival time in prion-infected mice in a time window–dependant manner
  2382. Stem cell based cancer gene therapy
  2383. Stem cell therapy for chronic myocardial infarction
  2384. Stemcell gene therapy for the Wiskott–Aldrich syndrome
  2385. Cultured and freshly isolated adipose tissue-derived cells: fat years for cardiac Stem cell therapy
  2386. Adult Stem cell therapy for periodontal disease
  2387. Hematopoietic Stem cell transplantation and implications for cell therapy reimbursement
  2388. … of Mesenchymal and hematopoietic Stem cells derived from Peripheral blood of Acute Lymphocytic Leukemia patients for regenerative Stem cell therapy
  2389. Cardiac Stem cell therapy
  2390. PET molecular imaging in Stem cell therapy for neurological diseases
  2391. Stem cell therapy for diabetes mellitus
  2392. cell therapy for spinal cord injury by neural Stem/progenitor cells derived from iPS/ES cells
  2393. A controlled randomized study examining the effects of exercise therapy on patients undergoing haematopoietic Stem cell transplantation
  2394. Early increase in myocardial perfusion after Stem cell therapy in patients undergoing incomplete coronary artery bypass surgery
  2395. Practical barriers to delivering autologous bone marrow Stem cell therapy as an adjunct to liver resection
  2396. Stem cell therapy for the treatment of acute myocardial infarction
  2397. The role of cardiac electrophysiology in myocardial regenerative Stem cell therapy
  2398. Mesenchymal Stem cells for cardiac cell therapy
  2399. Hematopoietic Stem cell transplantation and hematopoietic Stem cell gene therapy in X‐linked adrenoleukodystrophy
  2400. Neural Stem cell-based gene therapy for brain tumors
  2401. Identification of hematopoietic Stem cell–specific miRNAs enables gene therapy of globoid cell leukodystrophy
  2402. The cardiomyocyte lineage is critical for optimization of Stem cell therapy in a mouse model of myocardial infarction
  2403. New concepts in cardiac Stem cell therapy
  2404. Treatment of peripheral arterial disease using Stem and progenitor cell therapy
  2405. Advances in mesenchymal Stem cell-mediated gene therapy for cancer
  2406. Stem cell therapy for cardiac disease: what can be learned from oncology
  2407. Effect of Stem cell therapy on amiodarone induced fibrosing interstitial lung disease in albino rat
  2408. Current developments in the use of Stem cell for therapeutic neovascularisation: is the future therapycell-free”?
  2409. cell therapy of congenital corneal diseases with umbilical mesenchymal Stem cells: lumican null mice
  2410. ATP‐Sensitive K+ Channel‐Deficient Dilated Cardiomyopathy Proteome Remodeled by Embryonic Stem cell therapy
  2411. Stem cell therapy for diabetes
  2412. … combined granulocyte colony stimulating factor and erythropoetin based-Stem cell therapy using intracoronary infusion of peripheral blood Stem cells in patients …
  2413. Allogeneic Stemcell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin’s lymphoma relapsing after an autologous Stemcell
  2414. An increase in cancer Stem cell population after primary syStemic therapy is a poor prognostic factor in breast cancer
  2415. A case study of experimental Stem cell therapy and the risks of over-regulation
  2416. Stem cell therapy for articular cartilage defects
  2417. Targeting Stem cell niches and trafficking for cardiovascular therapy
  2418. Toward an ideal animal model to trace donor cell fates after Stem cell therapy: production of stably labeled multipotent mesenchymal Stem cells from bone marrow of …
  2419. Mesenchymal Stem cell therapy of Crohn’s disease: are the far-away hills getting closer?
  2420. Stem cell-based anti-HIV gene therapy
  2421. Stem cells and cell therapy approaches in lung biology and diseases
  2422. Interview: Affordability at the cutting edge: Stem cell therapy for ocular surface reconstruction
  2423. … to requests of families for unproven interventions in neurodevelopmental disorders: Hyperbaric oxygen “treatment” and Stem celltherapy” in Cerebral Palsy
  2424. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based …
  2425. Stem cells from human exfoliated deciduous teeth (SHED) enhance wound healing and the possibility of novel cell therapy
  2426. Nodal/Activin signaling: a novel target for pancreatic cancer Stem cell therapy
  2427. Stem cell therapy for peripheral arterial disease: a review of clinical trials
  2428. Human gingiva-derived mesenchymal Stem cells are superior to bone marrow-derived mesenchymal Stem cells for cell therapy in regenerative medicine
  2429. Which is the most suitable and effective route of administration for mesenchymal Stem cell-based immunomodulation therapy in experimental kidney transplantation …
  2430. Clinical impact of suicide gene therapy in allogeneic hematopoietic Stem cell transplantation
  2431. Maintenance therapy with low‐dose azacitidine after allogeneic hematopoietic Stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic …
  2432. … compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous Stemcell transplantation in newly …
  2433. Eyes open to Stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients
  2434. Enzyme replacement therapy and/or hematopoietic Stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European …
  2435. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity
  2436. Combination of Stem cell mobilized by granulocyte-colony stimulating factor and human umbilical cord matrix Stem cell: therapy of traumatic brain injury in rats
  2437. Neural Stem cell therapy
  2438. A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of Stem cell‐based therapy
  2439. Getting to the heart of myocardial Stem cells and cell therapy
  2440. Hematopoietic Stem cell gene therapy for adenosine deaminase–deficient severe combined immunodeficiency leads to long-term immunological recovery and …
  2441. Stroke patients take part in “milestone” UK trial of Stem cell therapy
  2442. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after Stem cell transplantation
  2443. Hypoxia-inducible factor 1-alpha release after intracoronary versus intramyocardial Stem cell therapy in myocardial infarction
  2444. High-dose chemotherapy with autologous Stemcell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
  2445. Pluripotent Stem cell-derived natural killer cells for cancer therapy
  2446. Maladaptive hypertrophy after acute myocardial infarction positive effect of bone marrow-derived Stem cell therapy on regional remodeling measured by cardiac MRI
  2447. Concerns and hopes for Stem cell therapy in cardiology: focus on endothelial progenitor cells
  2448. Glioma gene therapy using induced pluripotent Stem cell derived neural Stem cells
  2449. Republished review: cardiac Stem cell therapy: progress from the bench to bedside
  2450. Mesenchymal Stem cell infusion therapy in a carbon tetrachloride‐induced liver fibrosis model affects matrix metalloproteinase expression
  2451. Stem cell labeling for noninvasive delivery and tracking in cardiovascular regenerative therapy
  2452. Neural Stem cell-based therapy for ischemic stroke
  2453. How to measure the effects of the intracoronary Stem cell therapy?
  2454. Stem cells and cell therapy
  2455. Human embryonic Stem cell-derived mesenchymal Stem cells as cellular delivery vehicles for prodrug gene therapy of glioblastoma
  2456. High-dose therapy and autologous Stemcell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and …
  2457. … trial of telephone-administered cognitive-behavioral therapy to reduce post-traumatic stress disorder and distress symptoms after hematopoietic Stemcell
  2458. Advances in Stem cell therapy: application to veterinary medicine.
  2459. Shedding new light on the mechanism underlying Stem cell therapy for the heart
  2460. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic Stem cell transplantation for BCR–ABL-positive acute lymphoblastic …
  2461. Intracoronary administration of cardiac Stem cells in mice: a new, improved technique for cell therapy in murine models
  2462. Amniotic fluid Stem cell migration after intraperitoneal injection in pup rats: implication for therapy
  2463. Large animal models of hematopoietic Stem cell gene therapy
  2464. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic Stem cell transplant patients: an European Organisation for Research and …
  2465. … connexin channel-dependent intercellular communication in human adult hematopoietic progenitor/Stem cells: probing mechanisms of autologous Stem cell therapy
  2466. Neural Stem cell gene therapy ameliorates pathology and function in a mouse model of globoid cell leukodystrophy
  2467. B-cell function in severe combined immunodeficiency after Stem cell or gene therapy: a review
  2468. Mesenchymal Stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats
  2469. Stem cell therapy for cardiovascular regeneration: the beginning or the end of all hearts’ hopes
  2470. Hematopoietic Stem cell expansion and gene therapy
  2471. Stem cell therapy for islet regeneration
  2472. Nanoscaffold based Stem cell regeneration therapy: recent advancement and future potential
  2473. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review
  2474. … remains the most important determinant of CMV reactivation after allogeneic hematopoietic Stem cell transplantation in the era of surveillance and preemptive therapy
  2475. Clinical application of adult Stem cell therapy in neurological disorders
  2476. Development of novel efficient SIN vectors with improved safety features for Wiskott–Aldrich syndrome Stem cell based gene therapy
  2477. Predifferentiated adult Stem cells and matrices for cardiac cell therapy
  2478. Mesenchymal Stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine
  2479. Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting
  2480. Stem cell-based therapy and regenerative approaches to diseases of the respiratory syStem.
  2481. Stem cell transplantation for hematological malignancies: prospects for personalized medicine and co-therapy with mesenchymal Stem cells
  2482. Use of encapsulated Stem cells to overcome the bottleneck of cell availability for cell therapy approaches
  2483. Genetic basis for skeletal disease. Stem cell therapy for genetic bone disorders
  2484. The continued promise of Stem cell therapy in regenerative medicine.
  2485. Real-time 3D ultrasound guided interventional syStem for cardiac Stem cell therapy with motion compensation
  2486. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic Stem cell recipients
  2487. Taking Stem cells beyond discovery: a milestone in the reporting of regulatory requirements for cell therapy
  2488. Personalizing Stem cell research and therapy: the arduous road ahead or missed opportunity?
  2489. Research for cell therapy by induced pluripotent Stem cell
  2490. Genotoxicity of retroviral hematopoietic Stem cell gene therapy
  2491. Vasculogenic Stem cell mobilization and wound recruitment in diabetic patients: increased cell number and intracellular regulatory protein content associated with …
  2492. Image-guided, tumor stroma-targeted 131I therapy of hepatocellular cancer after syStemic mesenchymal Stem cell-mediated NIS gene delivery
  2493. … but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous Stemcell
  2494. Stem cell based therapy in the inner ear: appropriate donor cell types and routes for transplantation
  2495. Alterations of epithelial Stem cell marker patterns in human diabetic corneas and effects of c-met gene therapy
  2496. Possible mechanisms of retinal function recovery with the use of cell therapy with bone marrow-derived Stem cells
  2497. Therapeutic angiogenesis using gene transfer and Stem cell therapy in peripheral artery disease
  2498. … III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic Stem cell transplantation (AHSCT) for …
  2499. Limbal Stem cell deficiency after topical mitomycin C therapy for primary acquired melanosis with atypia
  2500. … of prolyl hydroxylase and factor-inhibiting hypoxia-inducible factor with nonviral minicircle gene therapy enhances Stem cell mobilization and angiogenesis after …
  2501. Vessel-associated Stem cells from skeletal muscle: From biology to future uses in cell therapy
  2502. Cyclosporine A-loaded and Stem cell-seeded electrospun nanofibers for cell-based therapy and local immunosuppression
  2503. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy
  2504. Cytoprotection and preconditioning for Stem cell therapy
  2505. Welcome to Stem cell Research & therapy
  2506. Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood Stem cell transplantation
  2507. Induced pluripotent Stem cell technology and Stem cell therapy for diabetes
  2508. Outcome of hematopoietic Stem cell transplant as salvage therapy for Hodgkin’s lymphoma in adolescents and young adults at a single institution
  2509. Progress in hematopoietic Stem cell transplantation as allogeneic cellular gene therapy in thalassemia
  2510. Mesenchymal Stem cells derived from canine umbilical cord vein—a novel source for cell therapy studies
  2511. Surgical intramyocardial Stem cell therapy for chronic ischemic heart failure
  2512. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen
  2513. Cancer Stem cell radioresistance and enrichment: where frontline radiation therapy may fail in lung and esophageal cancers
  2514. Study and analysis of Stem cell therapy and its ethical consideration
  2515. Stem cell therapy for intractable skin diseases
  2516. Hierarchical scaffold design for mesenchymal Stem cell-based gene therapy of hemophilia B
  2517. Generation of dendritic cells and macrophages from human induced pluripotent Stem cells aiming at cell therapy
  2518. Establishment of a Brazilian line of human embryonic Stem cells in defined medium: implications for cell therapy in an ethnically diverse population
  2519. Evolving role of high dose Stem cell therapy in multiple myeloma
  2520. General overview of the seventh international symposium on Stem cell therapy and cardiovascular innovations
  2521. Stem cell therapy feasible, safe and beneficial for fistulizing Crohn’s disease
  2522. Lp3: endogenous Stem cell therapy improves diabetic wound healing
  2523. Stem cell therapy for neurodegenerative disorders
  2524. Gemtuzumab ozogamicin therapy for isolated extramedullary AML relapse after allogeneic hematopoietic Stemcell transplantation
  2525. Mesenchymal Stem cell therapy for Apoptosis After Spinal Cord Injury
  2526. Stemcell therapy for retinal diseases
  2527. Neural Stem cell therapy for temporal lobe epilepsy
  2528. Stem cell therapy in chronic ischemic heart dysfunction with and without viability
  2529. Molecular imaging of the pro-angiogenic paracrine effects of Stem cell therapy
  2530. Stem cell-based therapy for erectile dysfunction
  2531. Hematopoietic Stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease
  2532. Role of molecular imaging in Stem cell therapy for myocardial restoration
  2533. Allogeneic Stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG …
  2534. Outcomes of hematopoietic Stem cell transplant patients who received continuous renal replacement therapy in a pediatric oncology intensive care unit
  2535. Stem cell therapy in the inner ear: recent achievements and prospects
  2536. Stem cells and cell therapy: on the eve of scientific discovery
  2537. Sparing of the neural Stem cell compartment during whole-brain radiation therapy: a dosimetric study using helical tomotherapy
  2538. … CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic Stem cell
  2539. High-dose therapy followed by autologous Stemcell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma
  2540. Tumor Stem cell research-basis and challenge for diagnosis and therapy
  2541. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous Stem cell transplant (ASCT) for multiple myeloma (MM) …
  2542. Association of polymorphisms of zinc metalloproteinases with clinical response to Stem cell therapy
  2543. Modulation of the major histocompatibility complex by neural Stem cell-derived neurotrophic factors used for regenerative therapy in a rat model of stroke
  2544. … derived from chlorophyll-a: the ABCG2 transporter affects the phototoxic response of side population Stem cell-like cancer cells to photodynamic therapy
  2545. Bone marrow Stem cell therapy for stroke
  2546. Some notes on Stem cell therapy in cardiovascular diseases
  2547. Definition of an enhanced immune cell therapy in mice that can target Stem-like lymphoma cells
  2548. First-line matched related donor hematopoietic Stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia
  2549. Stem cell therapy & Other Recent Advances in Muscular Dystrophy
  2550. Preclinical studies on mesenchymal Stem cell-based therapy for growth plate cartilage injury repair
  2551. Stem cell therapy for stroke
  2552. FDA approves first Stemcell therapy
  2553. Recent progress and challenges for the use of Stem cell derivatives in neuron replacement therapy for Parkinson’s disease
  2554. High-dose therapy and Stem cell transplantation
  2555. … initial and recurrent episodes of active CMV infection in the allogeneic Stem cell transplantation setting: implications for designing preemptive antiviral therapy
  2556. Stem cell therapy: A role for CXCR4 in homing bone marrow side population cells to areas of myocardial damage
  2557. Allogeneic hematopoietic Stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia—a single-center analysis of 100 …
  2558. Phage display technology for Stem cell delivery and syStemic therapy
  2559. Mesenchymal Stem cell transplantation: a potential therapy for oral lichen planus
  2560. Thalidomide, dexamethasone and lovastatin with autologous Stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and …
  2561. A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous Stem cell transplantation (ASCT) in patients with …
  2562. Dual transfer of GFP gene and MGd into Stem-progenitor cells: toward in vivo MRI of Stem cell-mediated gene therapy of atherosclerosis
  2563. Combined enzyme replacement therapy and hematopoietic Stem cell transplantation in mucopolysacharidosis type VI
  2564. Impact of continuous renal replacement therapy on oxygenation in children with acute lung injury after allogeneic hematopoietic Stem cell transplantation
  2565. … kinase inhibitor therapy in patients with chronic myelogenous leukemia relapsing in chronic and advanced phase following allogeneic hematopoietic Stem cell
  2566. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic Stem cell transplant recipients
  2567. Stem cell therapy doctor struck off by the GMC
  2568. High efficacy and low toxicity of short-course oral valganciclovir as pre-emptive therapy for hematopoietic Stem cell transplant cytomegalovirus infection
  2569. Hematopoietic Stem cell gene therapy as a treatment for autoimmune diseases
  2570. Allogeneic haematopoietic Stem cell transplantation as therapy for chronic granulomatous disease—single centre experience
  2571. Embryonic Stem cell therapy for osteo-degenerative diseases: methods and protocols
  2572. Autologous mesenchymal Stem cell therapy for spinal cord injury: long term safety and clinical efficacy
  2573. Immune modulation for Stem cell therapy
  2574. Thalidomide-dexamethasone as induction therapy before autologous Stem cell transplantation in patients with newly diagnosed multiple myeloma and renal …
  2575. Cardiac Stem cell therapy for the treatment of chronic stable angina refractory to conventional therapy. State of the art and current clinical experience of the San …
  2576. Randomized clinical trials in Stem cell therapy for the heart-old and new types of cells for cardiovascular repair
  2577. Human cytomegalovirus (HCMV) replication kinetics in Stem cell transplant recipients following anti-HCMV therapy
  2578. listening to the messages of patients and stakeholders: where Stem cell therapy, spinal cord injury and neuroethics meet
  2579. Nonviral gene delivery to mesenchymal Stem cells using cationic liposomes for gene and cell therapy
  2580. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic Stemcell transplant recipients: a pilot …
  2581. From cell therapy to organ regeneration therapy: generation of functional organs from pluripotent Stem cells
  2582. Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous Stem cell transplantation or treated with …
  2583. Role of substrates in diabetes therapy: Stem cell differentiation and islet transplantation
  2584. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous Stem cell transplantation induces higher rates of molecular …
  2585. SyStemic therapies for mucopolysaccharidosis: ocular changes following haematopoietic Stem cell transplantation or enzyme replacement therapy–a review
  2586. Human pluripotent Stem cells: from biology to cell therapy
  2587. Embryonic Stem cell therapy for intractable epilepsy
  2588. Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with Stem cell
  2589. High-dose therapy/autologous hematopoietic Stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma
  2590. Stem cell therapy for myocardial regeneration: the Chinese experience
  2591. Prospects of Stem cell therapy for Autism Spectrum Disorders
  2592. Topical Stem and progenitor cell therapy for diabetic foot ulcers
  2593. Repeated application of autologous bone marrow derived Stem cell therapy in patients with severe Buerger’s disease
  2594. High rate of Stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma
  2595. Primary CNS lymphoma—radiation-free salvage therapy by second autologous Stem cell transplantation
  2596. Gene therapy for canine leukocyte adhesion deficiency with lentiviral vectors using the murine Stem cell virus and human phosphoglycerate kinase promoters
  2597. A phase III PETHEMA/GEM study of induction therapy prior autologous Stem cell transplantation (ASCT) in multiple myeloma: superiority of VTD (bortezomib …
  2598. … pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patients undergoing allogeneic hematopoietic Stem cell
  2599. cell therapy for the treatment of metabolic liver disease: an update on the umbilical cord derived Stem cells candidates
  2600. Two cases of Stem cell therapy for pulmonary hypertension: A clinical report
  2601. New cell therapy using bone marrow-derived Stem cells/endothelial progenitor cells to accelerate neovascularization in healing of experimental ulcerative colitis
  2602. Structure of neuromuscular junctions and differentiation of striated muscle fibers in mdx mice after bone-marrow Stem cell therapy
  2603. Prospects for neural Stem cell therapy of alzheimer disease
  2604. Role of maintenance therapy after autologous Stem cell transplant for multiple myeloma: lessons for cancer therapy
  2605. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic Stemcell transplantation: Report from the working …
  2606. Artificial cell microencapsulated Stem cells in regenerative medicine, tissue engineering and cell therapy
  2607. Stromal Stem cell therapy for Prophylaxis of Acute GVHD: Preliminary Results From a Phase 1 Trial
  2608. Adult Stem cell therapy in the twitcher mouse model of Krabbe’s disease utilizing mesenchymal lineage Stem cells
  2609. Adipobiology of Stem cell-based therapy: secretome insight
  2610. Muscle-derived Stem cells: a model for Stem cell therapy in regenerative medicine
  2611. Emerging candidates in breast cancer Stem cell maintenance, therapy resistance and relapse
  2612. The ongoing challenge of hematopoietic Stem cell-based gene therapy for β-thalassemia
  2613. Adipose-derived Stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials.
  2614. Stem cell therapy in orthopaedics
  2615. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic Stem cell transplantation
  2616. Prospects for Induced Pluripotent Stem cell-Derived Hepatocytes in cell therapy
  2617. Perinatal Stem cell therapy
  2618. Frontline therapy with bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by autologous Stem cell transplantation, VRD consolidation …
  2619. Stem cell therapy in Myocardial Infarction Clinical Point of View and the Results of the REANIMA Study (REgenerAtion of Myocardium with boNe Marrow …
  2620. The National Stem cell therapy Patient Registry of Malaysia—Measuring Clinical Outcomes of Stem cell therapy
  2621. Stem cell therapy doctor exploited desperate patients, GMC finds
  2622. Functional improvement of injured retina following the adjuvant Stem cell-based therapy. Preliminary report
  2623. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic Stem cell transplant
  2624. Perspectives of clinical Stem cell therapy in the treatment of musculoskeletal diseases in Germany
  2625. ThaDD plus high dose therapy and autologous Stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo …
  2626. Back to the bench: The rejuvenation of Stem cell therapy—the therapeutic potential of CD133+ progenitor cells
  2627. Stem cell therapy: the expectations, considerations, and clinical research issues
  2628. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic Stem cell transplant recipients: incidence, risk factors, and …
  2629. In vivo differentiation of magnetically labeled mesenchymal Stem cells into hepatocytes for cell therapy to repair damaged liver
  2630. S1-5: Modulation of Cancer and Stem cell Biomarkers by the Notch Inhibitor MK-0752 Added to Endocrine therapy for Early Stage ER+ Breast Cancer.
  2631. Tandem versus single autologous peripheral blood Stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in …
  2632. Stem cell therapy for blindness: new developments and implications for the future
  2633. Surveillance investigations after high-dose therapy with Stem cell rescue for recurrent follicular lymphoma have no impact on management
  2634. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic Stem cell transplant recipients
  2635. Microstructural signatures of ischemia and Stem cell therapy in the myocardium revealed with serial diffusion tensor MRI and tractography of the mouse heart in vivo
  2636. Stem cell therapy for congestive heart failure
  2637. First-in-man cell therapy clinical trial for heart failure-AutoLogous human cardic-derived Stem cell to treat ischemic cardiomyopathy (ALCADIA)
  2638. Non-myeloablative autologous haematopoietic Stem cell transplantation with consolidation therapy using mitoxantrone as a treatment option in multiple …
  2639. cell therapy for diabetes: Stem cells, progenitors or beta-cell replication?
  2640. Perspectives of Stem cell therapy in type 2 diabetes mellitus
  2641. Homologous recombination in human embryonic Stem cells: a tool for advancing cell therapy and understanding and treating human disease
  2642. Interventional, intramyocardial Stem cell therapy in ischemic cardiomyopathy: update 2010
  2643. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated …
  2644. Stem cell transplant: an effective salvage therapy for multiple myeloma
  2645. cellular therapy following allogeneic Stemcell transplantation
  2646. Promising cell-based therapy for bone regeneration using Stem cells from deciduous teeth, dental pulp, and bone marrow
  2647. Molecular diagnostics, targeted therapy, and the indication for allogeneic Stem cell transplantation in acute lymphoblastic leukemia
  2648. H1N1 infection in a cohort of hematopoietic Stem cell transplant recipients: prompt antiviral therapy might be life saving
  2649. Efficacy of hormone therapy for osteoporosis in adolescent girls after hematopoietic Stem cell transplantation: a longitudinal study
  2650. Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas
  2651. Contrast echocardiography: finding its place in Stem cell therapy.
  2652. Pilot assessment of HIV gene therapy-hematopoietic Stem cell clinical trial acceptability among minority patients and their advisors
  2653. In vivo T-cell dynamics during immune reconstitution after hematopoietic Stem cell gene therapy in adenosine deaminase severe combined immune deficiency
  2654. Long-Term Follow-Up of Stem cell therapy after Acute Myocardial Infarction
  2655. Bortezomib-based induction therapy followed by autologous Stem cell transplantation and maintenance therapy with bortezomib improves outcome in …
  2656. Second transplantation for graft failure after allogeneic hematopoietic Stem cell transplantation–a retrospective survey by Kanto Study Group for cell therapy
  2657. Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous Stem cell transplant in the upfront setting?
  2658. Stem cell-based hepatic differentiation for cell therapy of liver diseases
  2659. Tandem autologous hematopoietic Stem cell transplants (AuHCT) with or without maintenance therapy (auto-auto) versus single AuHCT followed by HLA …
  2660. Low-dose valganciclovir as preemptive therapy for cytomegalovirus infection occurring in allogeneic Stem cell transplant recipients
  2661. A syStematic review of autologous Stem cell therapy in female stress urinary incontinence
  2662. Adipose tissue-derived Stem cells for cell therapy of airway allergic diseases in mouse
  2663. Stem cells and cell therapy: Popular Belief?
  2664. Oral ribavirin therapy for lower respiratory tract infection of respiratory syncytial virus complicating bronchiolitis obliterans after allogeneic hematopoietic Stem cell
  2665. First stroke patient is recruited to take part in “milestone” UK trial of Stem cell therapy
  2666. … Rhizopus microsporus infection cured by salvage allogeneic hematopoietic Stem cell transplantation, antifungal combination therapy, and surgical resection
  2667. Stem cell therapy in no-option critical limb ischemia patients
  2668. The cancer Stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon α-2b therapy against advanced hepatocellular carcinoma
  2669. Acceleration of Wound Healing Using Adipose-derived Stem cell therapy with Platelet Concentrates: Plateletrich Plasma (PRP) vs. Platelet-rich Fibrin (PRF)
  2670. Ethical and scientific issues in gene therapy and Stem cell research
  2671. Autologous Stem cell transplantation (ASCT) as upfront or salvage therapy for noncutaneous T-cell lymphoma (TCL): The University of Texas MD Anderson Cancer …
  2672. Total ischemic time is an independent predictor of response to Stem cell therapy in patients with StemI
  2673. Peripheral blood Stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage …
  2674. MRI strain analysis as a novel modality for the assessment of myocardial function following Stem cell therapy-results from Amorcyte trial
  2675. Keynote address—Working Toward Mesenchymal Stem cell therapy for HD
  2676. 90Y-ibritumomab tiuxetan as consolidation therapy after autologous Stem cell transplantation in aggressive non-Hodgkin lymphoma
  2677. Stem cells and cell therapy: on the eve of scientific approach
  2678. … (auto-auto) with or without maintenance therapy versus single autologous transplant followed by HLA-matched sibling non-myeloablative allogeneic Stem cell
  2679. Cardiac Magnetic Resonance for evaluating early outcomes of Stem cell therapy in non-ischemic dilated cardiomyopathy
  2680. Characteristics and outcomes after autologous Stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab …
  2681. Dual CT and MRI in vivo tracking of Stem cell therapy in peripheral artery disease
  2682. Cardiac Stem cell therapy for infarcted rat hearts
  2683. Combination of IFN-α/Gm-CSF as a maintenance therapy for multiple myeloma patients after autologous Stem cell transplantation (ASCT): a prospective phase II study
  2684. Long-term follow-up of tandem high-dose therapy with autologous Stem cell support for adults with high-risk age-adjusted international prognostic index …
  2685. Rituximab purging and maintenance therapy combined with autologous Stem cell transplantation in patients with diffuse large B-cell lymphoma
  2686. High-dose therapy and autologous peripheral blood Stem cell transplantation in patients with multiple myeloma
  2687. Case of relapsed AIDS-related plasmablastic lymphoma treated with autologous Stem cell transplantation and highly active antiretroviral therapy
  2688. Pre-Stem cell transplant induction therapy does not affect post-transplant survival in light chain (AL) amyloidosis
  2689. Effects of Dual Stem cell therapy (g-csf+ sitagliptin) On Cardiac Levels of Micrornas After Myocardial Infarction
  2690. Regenerative medicine for severe congenital skin disorders: restoration of deficient skin component proteins by Stem cell therapy
  2691. Valganciclovir for pre-emptive therapy of cytomegalovirus viraemia after hematopoietic Stem cell transplantation: a prospective multi-center trial
  2692. … at two years following Stem cell transplant in syStemic light-chain amyloidosis (AL) using short-course bortezomib and dexamethasone consolidation therapy
  2693. A dose‐intensive approach (NB96) for induction therapy utilizing sequential high‐dose chemotherapy and Stem cell rescue in high‐risk neuroblastoma in children …
  2694. … /ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous Stem cell
  2695. Haploidentical allogeneic haematopoietic Stem cell transplantation as salvage therapy for engraftment failure after unrelated and autologous Stem cell transplantation …
  2696. Potential application of induced pluripotent Stem cells in cell replacement therapy for Parkinson’s disease
  2697. The Science and Politics of Umbelical Stem cell therapy
  2698. Promising therapy of neural Stem cell transplantation for FASD model–neural network reconstruction and behavior recovery
  2699. Stem cell therapy does not improve visual function or structure in children with optic nerve hypoplasia (septo-optic dysplasia)
  2700. Stem cell therapy. Evaluation of risk factors
  2701. Successful treatment of high-risk and refractory acute myeloid leukemia with haploidentical Stem cell transplantation plus NK cell therapy
  2702. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic Stem cell transplantation for acute myeloid leukemia
  2703. Hematopoietic Stem cell transplantation for therapy-related myelodysplastic syndrome and acute leukemia: a single-center analysis of 47 patients
  2704. Stem cell transplantation and renal replacement therapy: new predictors of outcome
  2705. Standard chemotherapy is superior to high-dose chemotherapy with autologous Stem cell transplantation on overall survival as the first-line therapy for patients with …
  2706. Combining gene and Stem cell therapy in the treatment of disferlinopaties
  2707. Ethical Considerations in Stem cell therapy Studies.
  2708. Regenerative Stem cell therapy
  2709. Fiber-modified adenovirus can mediate human adipose tissue-derived mesenchymal Stem cell-based anti-angiogenic gene therapy
  2710. Nurses’ Attitudes toward Stem cell therapy
  2711. Haploidentical Stem cell transplantation as a salvage therapy for cord blood engraftment failure in a patient with Fanconi anemia
  2712. Stem cell therapy FOR E RAIN TU MORS
  2713. Stem cells and cell therapy: on the eve of scientific approach
  2714. Autologous Stem cell Transplantation as First-Line therapy in Peripheral T-cell Lymphomas.
  2715. Clinical applications of a Stem cell-based therapy for oral bone reconstruction
  2716. A feasibility of useful cell-based therapy by bone regeneration with deciduous tooth Stem cells, dental pulp Stem cells, or bone-marrow-derived mesenchymal Stem
  2717. Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic Stem cell transplantation from HLA-matched or …
  2718. Opportunities and Challenges of Stem cell therapy: Is there a Role in AMI?
  2719. Status of Stem cell therapy in type-1 diabetics
  2720. … vitro trans-differentiation of human umbilical cord derived hematopoietic Stem cells into hepatocyte like cells using combination of growth factors for cell based therapy
  2721. Stem cell therapy for neurological disorders
  2722. Special aspects of Stem cell therapy in patients with MLD
  2723. Stem cell therapy: Promising and Controversial!
  2724. ETHICAL ISSUES IN Stem cell RESEARCH AND cell therapy
  2725. Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges
  2726. Cardiovascular Regeneration and Stem cell therapy
  2727. Stem cell therapy for Cardiovascular Disease
  2728. Stem cell therapy in Orthopaedic Surgery.
  2729. Mesenchymal Stem cells at the intersection of cell and gene therapy
  2730. The mechanism of mesenchymal Stem cell therapy for diabets
  2731. … reversibility of renal dysfunction associated to light chain deposition disease with bortezomib and dexamethasone and high dose therapy and autologous Stem cell
  2732. Correction of Wiskott-Aldrich syndrome by hematopoietic Stem cell gene therapy
  2733. Challenges in Stem cell therapy: Bench-To-Bedside
  2734. Embryonic Stem cell therapy; A novel cell delivery method
  2735. Inotuzumab ozogamicin (IO) is an effective salvage therapy that allows for allogeneic hematopoietic Stem cell transplantation (HSCT) in remission in patients with …
  2736. Stem cell therapy for cardiovascular disorders-our clinical experience.
  2737. Inner ear cell therapy for hereditary deafness with multipotent Stem cells
  2738. Mesenchymal Stemcell-based therapy for the older patient
  2739. Successful allogeneic Stem cell transplantation in two patients with acute myelogenous leukaemia and invasive aspergillosis by antifungal combination therapy
  2740. General Overview of the Sixth International Symposium on Stem cell therapy and Cardiovascular Innovations
  2741. … bortezomib-thalidomide-dexamethasone (VTD) versus thalidomide-dexamethasone (TD) as consolidation therapy after autologous Stemcell transplantation (ASCT) in …
  2742. Meeting Report: The First Midwest Conference on Stem cell Biology and therapy (SCBT)
  2743. … of front-line therapy with either high-dose therapy and autologous Stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell
  2744. Stem cell therapy for the treatment of diabetes
  2745. Vascular and Cardiac Adult Stem cell therapy Center
  2746. Keynote address—FDA Regulation of Stem cell therapy
  2747. AGING AND Stem cell therapy: A REVIEW AND HIGHLIGHTS OF CURRENT CONTROVERSIES
  2748. Application of Stem cell therapy and magnetic resonance imaging in experimental models of cardiovascular diseases
  2749. Pulmonary Hypertension and Stem cell therapy
  2750. Adult Stem cell-Based therapy for the Heart
  2751. Repetitive busulfan administration after hematopoietic Stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate
  2752. Experimental myocardial regeneration with Stem cell therapy
  2753. Update cardiac Stem cell therapy
  2754. Mesenchymal Stem cells for cell therapy and Tissue Regeneration in Urology
  2755. Stem cell Research & therapy marks its first anniversary
  2756. 15 Opportunities and Challenges of Stem cell therapy: Is there
  2757. Prospects of Stem cell therapy in Diabetes-Introduction to the RDS Special Issue
  2758. Long-term IL-2 therapy after transplantation of T cell depleted Stem cells from alternative donors in children
  2759. Stem cell therapy IN DIABETES MELLITUS: CURRENT TRENDS
  2760. Stem cell AND REGENERATIVE MEDICINE: P-130: ETHICAL CONSIDERATIONS IN Stem cell therapy
  2761. Development of human Stem cell culture conditions for clinical cell therapy
  2762. Advances of reporter gene monitoring Stem cell therapy
  2763. Stem cell therapy in Cardiology: Current Concepts and The Road Ahead
  2764. The immune barriers of cell therapy with allogenic Stem cells of embryonic origin
  2765. Advances in induced Pluripotent Stem cell therapy for neurological diseases
  2766. Stem cell therapy for brain disorders: Why results are discordant
  2767. Potential Confounds in Stem cell therapy: A Case Study of Mesenchymal Stem cells and Cancer Stem cells
  2768. Stem cell therapy IN SPINE SURGERY, CURRENT STATUS AND ETHICAL CONSIDERATION
  2769. Preclinical experience in Stem cell therapy for digestive tract diseases
  2770. Cancer Stem cell: a big hurdle in cancer therapy
  2771. Feasibility of combination allogeneic Stem cell therapy for spinal cord injury: a case report
  2772. Peripheral arterial disease and Stem cell therapy: Critical appraisal
  2773. A General Review of the Current Knowledge of Stem cell therapy for Lung Disorders
  2774. One decade of Stem cell therapy for bone marrow: what is missing?
  2775. Advances of reporter gene imaging monitoring Stem cell therapy
  2776. Stem cell therapy for Patients with Chronic Liver Disease
  2777. Prospects for Induced Pluripotent Stem cell therapy for Diabetes
  2778. Stem cell therapy restores athlete to former glory
  2779. Cardiac Stem cell therapy: An Overview
  2780. Stem cell therapy for critical limb ischemia
  2781. Gene-modified Stem cell therapy for ischemic heart disease
  2782. Experimental Stem cell-Based therapy in Pediatrics: A Fictional Case Study
  2783. Stem cell therapy in diabetic foot patients: where are we now?
  2784. Stem cell therapy Works (in Mice Models of Emphysema)!
  2785. Stem cell therapy Against Oxidative Stress and Hypoxia
  2786. Stem cell therapy for cardiovascular disease: answering basic questions regarding cell behavior
  2787. Re: Stem cell therapy for Stress Urinary Incontinence
  2788. Stem cell therapy for refractory angina
  2789. Stem cell therapy in Ocular Surface Disease
  2790. From immunological tolerance to Stem cell therapy and back: an interview with Irving Weissman
  2791. Human induced pluripotent Stem cells for Stem cell therapy in stroke
  2792. Induced Pluripotent Stem cell therapy for Human Diseases: Are We There Yet?
  2793. Nanobiodevice based single cell imaging for cancer diagnosis and in vivo imaging for Stem cell therapy
  2794. Embryonic Stem cell therapy for Osteo-Degenerative Diseases
  2795. Echo and Stem cell therapy: more than just an ejection fraction
  2796. Stem cell therapy for acute myocardial infarction and subsequent heart failure
  2797. Induction therapy followed by allogeneic Stem cell transplant for MPN blast phase: outcomes from Mayo Clinic in Arizona
  2798. Vascular and Cardiac Adult Stem cell therapy Center (VC-CAST)
  2799. Heart Failure: Will There be Any Light at the End of the Tunnel with Stem cell therapy?
  2800. A New Paradigm for Stem cell therapy: Stem cell Mobilization for Tissue Repair
  2801. Stem cell therapy applications in amyotrophic lateral sclerosis
  2802. Quantitative cardiac imaging to evaluate Stem cell therapy of myocardial infarction
  2803. Consolidative proton therapy following high-dose chemotherapy and autologous Stem cell transplant in an adolescent with relapsed Hodgkin lymphoma
  2804. Relapsed pulmonary lymphomatoid granulomatosis grade III: curative treatment with radioimmune therapy and autologous Stem cell transplantation
  2805. Mesenchymal Stem cell (MSC) therapy To Prevent Ischemia-Reperfusion Injury in Lung Transplantation (145.24)
  2806. Stem/precursor cell-based CNS therapy: the importance of circumventing immune suppression by transplanting autologous cells
  2807. EVALUATION OF CLINICAL TRIALS OF Stem cell therapy FOR LIVER DISEASES IN IRAN
  2808. Flavopiridol is an effective therapy to bridge patients with chronic lymphocytic leukemia (CLL) to reduced-intensity conditioning allogeneic Stem cell transplant
  2809. IMMUNOLOGICAL BASIS FOR ALLOGENEIC MESENCHYMAL Stem cell therapy
  2810. Recent advance in Stem cell therapy for ischemic stroke and clinical concerns
  2811. Stem cell therapy for type 1 diabetes: Can it be an effective clinical scheme?
  2812. Commercialization of Stem cell therapy for the Treatment of Diabetic Retinopathy
  2813. Design of a Large-Scale Clinical Trial for the Treatment of Spinal Cord Pain Using Stem cell therapy
  2814. BONE MARROW-DERIVED Stem cell therapy IN ACUTE MYOCARDIAL INFARCTION
  2815. Embryonic Stem cell therapy for osteo-degenerative diseases-Methods and protocols
  2816. Stem cell therapy for Heart Failure Using Cord Blood
  2817. Chemical Delay of Flaps through Endogenous Stem cell therapy
  2818. CLINICAL RELEVANCE OF ISCHEMIC LARGE ANIMAL MODELS IN Stem cell therapy; AN OVERVIEW AND META-ANALYSIS.
  2819. P4. 52 Combining gene and Stem cell therapy in the treatment of dysferlinophaties
  2820. 81: Stem cell therapy IMPROVES BONY HEALING
  2821. Review of” Research Warning: Non-Host Origin Tumors Resulting From Stem cell therapy
  2822. INVITED SPEAKERS: I-1: MESENCHYMAL Stem cell therapy
  2823. Molecular Imaging of a Preclinical Model of Stroke: Functional Evaluation and Stem cell therapy
  2824. Editorial [Hot Topic: Stem cell therapy for Cardiovascular Diseases: Are We Still at the Beginning of A Long Road?(Guest Editor: Lino M Goncalves)
  2825. Editorial [Hot Topic: Advances and Perspectives on Stem cell therapy for Human Neurodegenerative Diseases (Guest Editor: Liang-Wei Chen)]
  2826. Stem cell therapy for Vertebral Bone Tissue Engineering
  2827. Neuroprotection and gene-Stem cell therapy for ischemic stroke
  2828. Limbal Stemcell therapy and long-term corneal regeneration.[5YIF: 54.39; Citations: 301]
  2829. Nanobiodevice based single molecule and cell sensing for cancer diagnosis and in vivo imaging for Stem cell therapy
  2830. Muscle-derived Stem cells: isolation, characterization, differentiation, and application in cell and gene therapy
  2831. New Stem cell therapy may someday cure AMD: non-embryonic human Stem cells appear promising for retinal regeneration
  2832. Improved survival for multiple myeloma in Denmark based on autologous Stem cell transplantation and novel drug therapy in collaborative trials: analysis of accrual …
  2833. Stem cell therapy: resetting autoimmunity or postponing the inevitable?
  2834. Bone Marrow Stemcell therapy for Idiopathic Dilated Cardiomyopathy
  2835. Arsenic trioxide and Stem cell transplantation is an effective salvage therapy in patients with relapsed APL
  2836. Embryonic Stem cell-derived neurons for inner ear therapy
  2837. Acoustic radiation force for vascular Stem cell therapy: An in vitro validation
  2838. A severe haematologic adverse reaction after high dosage radioiodine therapy following blood Stem cell mobilization with growth factors
  2839. Medulloblastoma with myogenic differentiation: long-term survival in a patient treated with aggressive combination therapy and autologous Stem cell transplantation
  2840. … Salvage therapy in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem cell
  2841. Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic Stem cell transplantation
  2842. … Safety And Pharmacokinetics Of Palifermin In Pediatric Subjects With Acute Leukemias Undergoing Myeloablative therapy And Allogeneic Hematopoietic Stem cell
  2843. Reduced mitochondrial respiration and improved coupling in infarcted heart following Stem cell therapy
  2844. Dual Stem cell therapy After Myocardial Infarction Acts Specifically by the Cxcr4-sdf1 Axis
  2845. P04 Lentivirus-mediated Stem cell therapy for Duchenne muscular dystrophy
  2846. A novel X-ray-visible microencapsuled mesenchymal Stem cell therapy for peripheral arterial disease
  2847. On the evolution of high-dose immunosuppressive therapy with autologous Stem cell transplantation in multiple sclerosis
  2848. Neuroprotection and neuroregeneration: what to expect from a Stem cell-based therapy of acute brain injury
  2849. LP39: Endogenous Stem cell therapy Improves Calvarial Bone Healing
  2850. The influence of fear appeal messages on creating awareness of Stem cell therapy in Malaysian market.
  2851. Telomere Binding Protein Antagonists for Stem cell therapy
  2852. Legal imperialism in the regulation of Stem cell research and therapy: the problem of extraterritorial jurisdiction
  2853. Restoration of fatty acid but not glucose utilization in the infarcted heart following Stem cell therapy
  2854. Dose finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic Stem cell transplantation
  2855. (Stem) cell Based therapy for Neurological Disorders
  2856. Regenerative Stem cell therapy for multiple myeloma osteolytic bone damage
  2857. … KLINICZNE I DOŚWIADCZALNE W CHOROBACH SERCA, PŁUC I NACZYŃ A novel method for isolation of endothelial progenitor cells for cardiac Stem cell therapy
  2858. Placental Umbilical Cord Blood Transfusion for Stem cell therapy in Neurological Diseases
  2859. Development of peptide-modified hyaluronic acid hydrogels for neural Stem cell therapy
  2860. Successful nonmyeloablative allogeneic Stem cell transplantation for therapy-related acute myelogenous leukemia in a patient with preexisting visceral fungal …
  2861. Optimising Adoptive T cell therapy Following Allogeneic Hematopoietic Stem cell Transplantation
  2862. Allogeneic NK cell therapy After Autologous Stem cell Transplant: Results of a Phase I Study
  2863. Hematopoietic Stem cell therapy In Eight Patients with Metachromatic Leukodystrophy–Relevance of Post-Transplant Medication.
  2864. Adult Stem cell therapy for Injured Solid-Organ Tissue (with Emphasis on Cardiac Tissue Repair)
  2865. Mesenchymal Stem cell therapy for peripheral arterial disease: In vivo monitoring and tracking with noninvasive imaging
  2866. Intracoronary autologous Stem cell therapy for acute myocardial infarction: a syStematic review and meta-analysis of randomised controlled trials
  2867. Morphometric analysis of murine ischemic hindlimb revascularization after Stem cell therapy
  2868. Factors limiting spontaneous repair and their relevance for the efficiency of Stem cell therapy of infarcted hearts
  2869. Combination antifungal therapy and surgery for the treatment of invasive pulmonary aspergillosis after hematopoietic Stem cell transplantation
  2870. Why not” do simple things in a simple way”: Use of the Pap test as the first step in screening genetic stability for human cultured Stem cell therapy?
  2871. 761. Gene-and-Stem cell therapy for Vertebral Bone Fracture
  2872. … plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous Stemcell transplantation in newly …
  2873. Embryonic Stem cell-Derived Multipotent Mesenchymal Stromal cell therapy Following Focal Ischemia in the Rat
  2874. A pilot study to assess perfusion recovery from mesenchymal Stem cell therapy after induction of acute myocardial infarct (AMI)
  2875. Hematopoietic Stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy
  2876. … Diffuse Large B cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem cell
  2877. Stemcell therapy Mitigates Radiation-Induced Non-Union in Murine Mandibular Distraction Osteogenesis
  2878. Human neural Stem cell therapy in a primate model for Parkinson’s disease
  2879. What is the benefit of maintenance therapy with lenalidomide or bortezomib after autologous Stem cell transplantation in multiple myeloma and what is the risk of …
  2880. Combination therapy with BCNU/Etoposide/Melphalan (BEM) as Conditioning Regimen for Autologous Stem cell Transplant In Multiple Myeloma.
  2881. Assessment of the Microvascular Response to Stem cell therapy with Contrast Ultrasound Perfusion Imaging and Maximum Intensity Projection Angiography
  2882. Autologous peripheral blood Stemcell (PBSC) collection is not impaired by bortezomib-thalidomide-dexamethasone (VTD) induction therapy in newly …
  2883. P3-398 DOES THE MESENCHYMAL Stem cell therapy IMPROVE THE STREPTOZOTOCIN-INDUCED NEURODEGENERATION IN RATS?
  2884. INTRACORONARY Stem cell therapy AFTER MYOCARDIAL INFARCTION-TWELVE MONTHS FOLLOW-UP OF A RANDOMIZED, RIGOROUS DOUBLE-BLIND …
  2885. Phosphodiesterase-5 Inhibition: A Novel Strategy to Improve Stem cell therapy in the Heart
  2886. Targeting the 5-Lipoxygenase as a Novel Principle of Stem cell therapy In Acute Myeloid Leukemia
  2887. … Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose therapy and Autologus Stem cell Transplant for Mantle cell
  2888. 912. Embryonic Stem cell therapy Enhances Tendon Regeneration in a Large Animal Flexor Tendonitis Model
  2889. High-dose therapy (HDT) with hematopoietic Stem cell transplantation (HSCT) is effective therapy for patients with non-Hodgkin lymphoma (NHL) and central nervous …
  2890. Cardiac regenerative therapy: which type of cell will breast the tape?/Autologous Stem cell therapy with surgical myocardial revascularization-the Rostock University …
  2891. SELECTING OPTIMAL CULTIVATION OF HUMAN BONE MARROW MESENCHYMAL Stem cells FOR CLINICAL cell therapy
  2892. Current issues and innovations in Stem cell based therapy
  2893. Advances in Stem cell Reseach and therapy
  2894. Stem and progenitor cell-based therapy approaches: Current developments on treatment of acute myocardial infarction and chronic ischemic cardiomyopathy
  2895. Editorial [Hot Topic: Stem cell Based therapy for Autoimmunity (Guest Editor: Frank Alderuccio)]
  2896. 175 HUMAN AMNIOTIC FLUID Stem cell therapy FOR URETHRAL SPHINCTER REGENERATION
  2897. 69 Intracoronary Autologous Peripheral Stem cell therapy: A Promising Treatment for Heart Failure in Pediatric Dilated Cardiomyopathy
  2898. Influence of Permeability on the Compressive Property of Articular Cartilage: A Scaffold-Free, Stem cell-Based therapy for Cartilage Repair
  2899. … , And Montelukast (Fam) therapy In Reducing Steroid Exposure In Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoetic Stem cell Transplant (Hct)–A …
  2900. 3.09 Hollow Fiber Membrane Bioreactor Technology for Tissue Engineering and Stem cell therapy
  2901. In Situ Stem cell therapy Using Human Adipose Tissue-Derived Multi-lineage Progenitor cells Combined with HMG-CoA Reductase Inhibitor Synergistically Reduce …
  2902. T cell therapy after allogeneic Stem cell transplantation: titration of IL-2 concentration when expanding cord blood t lymphocytes with and without IL-7, in order to …
  2903. Stem cell AND REGENERATIVE MEDICINE: P-140: COMBINATION cell therapy USING OLIGODENDROCYTE PROGENITOR cells (OPC) AND BONE …
  2904. 53 Effects Of GLP-1 eluting Stem cell therapy on collagen remodelling in a porcine model of myocardial infarction
  2905. O. 9 Stem cell therapy of muscular dystrophies using exon skipping approach in GRMD dogs
  2906. … : an investigation of genomic, molecular and cellular factors in graft-versus-host disease and mesenchymal stromal cell therapy in a rat model of allogeneic Stem cell
  2907. The Role of Time-Lapse Microscopy in Stem cell Research and therapy
  2908. Neural Stem cells for diabetes cell‐based therapy
  2909. 685 Anti-arrhythmic cell therapy for the failing heart: Mesenchymal Stem cell transplantation mitigates electrophysiological remodelling in a rat model of myocardial …
  2910. … for Developing Human Herpes Virus-6 Encephalitis and Clinical Significance of Antiviral therapy In Early Phase After Allogeneic Hematopoietic Stem cell
  2911. … Interferon-α in Combination with Donor Lymphocyte Infusion for High Risk Acute Leukemia Patients Who Relapsed After Allogeneic Hematopoietic Stem cell
  2912. YIA6 Effects of GLP-1 eluting Stem cell therapy on collagen remodelling, infarct size and apoptosis in a porcine model of myocardial infarction
  2913. Double knockdown of Prolyyl hydroxylase and factor inhibiting HIF with non-Viral minicircle gene therapy enhances Stem cell mobilization and angiogenesis …
  2914. The Optimal Timing for Stem cell Collection After Induction therapy for Patients with Multiple Myeloma
  2915. Embryonic Stem cell Derivatives for Cardiac therapy: Advantages, Limitations, and Long-Term Prospects
  2916. Hematopoietic Stem cell Gene therapy with Lentiviral Vector in X-Linked Adrenoleukodystrophy
  2917. Imatinib mesylate is superior to allogeneic hematopoietic Stem cell transplantation as the first-line therapy for patients with chronic myeloid leukemia in the …
  2918. Breast cancer Stem cell extinction models: implications for HER2 targeted therapy
  2919. High-dose therapy with Stem cell rescue
  2920. Favorable Outcomes of Neutropenic Enterocolitis Following Hematopoietic Stem cell Transplantation (HSCT) Using a Conservative Medical therapy
  2921. Thiotepa (TT), Busulfan (Bu), And Clofarabine (Clo) As A Conditioning therapy For Allogeneic Hematopoetic Stem cell Transplant For Patients With High Risk …
  2922. Effects of physical therapy factors on mechanism of Stem cell regulation
  2923. Bortezomib combined with autologous peripheral blood hematopoietic Stem cell transplantation for therapy of patients with multiple myeloma
  2924. Regenerative Medicine in the Central Nervous SyStem: Stem cell-Based Gene-therapy
  2925. Embryonic Stem cell in the therapy of Neurodegenerative Diseases
  2926. Association of Cardiac Resynchronization therapy with Stem cell Transplantation for Ischemic Heart Disease
  2927. Stem cell Transplantation therapy for Heart Disease
  2928. … abnormality during lenalidomide therapy depends on the capacity of the neoplastic Stem cell to differentiate into maturing erythroid committed Stem cells
  2929. Large-Scale Expansion of Human Embryonic and Induced Pluripotent Stem cells for cell therapy Applications
  2930. cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the SWiss multicenter Intracoronary Stem cells
  2931. Induction therapy and the role of Stem cell transplantation in the treatment of myeloma multiplex in patients aged below 65 years
  2932. Large-scale expansion of human embryonic and induced pluripotent Stem cells for cell therapy applications
  2933. Prevention of Cytomegalovirus Infection after Hematopoietic Stem cell Transplantation: Preemptive therapy Vs Universal Prophylaxis
  2934. New Advances in Gene therapy: The Use of MGMTP140K-Mediated Stem cell Selection in Nonhuman Primates
  2935. 678. Update of Stem cell Gene therapy Clinical Trial for ADA-Deficiency in Japan
  2936. A Phase II Trial of Sequential Treatment with Cytoreductive therapy and Reduced Intensity Conditioning Allogeneic Stem cell Transplantation for Relapsed …
  2937. Response to Tyrosine Kinase Inhibitor therapy In Patients Undergoing Allogeneic Hematopoietic Stem cell Transplantation for Advanced Phase Chronic …
  2938. Current Strategies in Antifungal therapy for Invasive Aspergillosis in Immunocompromised Patients Following Hematopoietic Stem cell Transplantation.
  2939. Bortezomib-Based therapy without Autologous Stem cell Transplantation for Newly Diagnosed Multiple Myeloma Patients with t (4; 14): A Canadian National …
  2940. Reapplication of high-dose chemotherapy with melphalan followed by autologous hematopoietic Stem cell transplantation as salvage therapy for patients with …
  2941. Potent graft-versus-leukemia effect after reduced intensity (RIC) allogeneic Stemcell transplantation (asct) as post-remission therapy for intermediate-risk de …
  2942. cellULAR therapy AND HEMATOPOIETIC Stem cell TRANSPLANTATION FOR CANCER
  2943. Using Stem cell and Gene therapy Technologies to Treat Parkinson’s Disease
  2944. Allogeneic hematopoietic Stem cell transplantation versus immunosuppressive therapy as frontline treatment for severe aplastic anaemia
  2945. Combination cellular therapy for Regenerative Medicine: The Stem cell Niche
  2946. Outcomes of a late second autologous hematopoietic Stem cell transplant compared to nontransplantation salvage therapy in relapsed multiple myeloma after upfront …
  2947. How to Overcome Myeloma Stem cell Resistance to therapy-Targeting the Stem cell Niche
  2948. … empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic Stem cell
  2949. Stem cell Replacement therapy in the Retina
  2950. Hormonal therapy After Stem cell Transplantation and the Risk of
  2951. Stem cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction therapy in Patients with High-Risk Aggressive B cell
  2952. T cell Suicide Gene therapy Prompts Thymic Renewal in Adults After Haploidentical Hematopoietic Stem cell Transplantation in the Absence of Post-Transplant …
  2953. Mitomycin C therapy for corneal intraepithelial neoplasia masquerading as limbal Stem cell deficiency with recurrent epithelial defect
  2954. Stem cell AND REGENERATIVE MEDICINE: O-36: COMBINATION therapy OF TRAUMATIC BRAIN INJURY IN RATS WITH A Stem cell
  2955. Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic Stem cell transplantation in CR1 as the front-line therapy for adult Ph (+) acute …
  2956. Anti-Inflammatory Gene therapy for the Promotion of Implanted Stem cell Survival in Infarcted Myocardium
  2957. Engineering bioactive scaffolds for Stem cell vascular therapy
  2958. From High-Tech to Biotech Using Stem cell and Gene therapy to Treat Hearing Loss
  2959. … /CT-guided high dose sequential induction therapy with autologous Stem cell transplantation (ASCT) does not improve outcome for poor prognosis diffuse large B-cell
  2960. … complete response (CR) to bortezomib-thalidomide-dexamethasone (VTD) as induction therapy prior to autologous Stemcell transplantation (ASCT) in …
  2961. Gene therapy Used for Adipose Stem cell Engineering
  2962. Transfusion support therapy for patients undergoing hematopoietic Stem cell transplantation
  2963. An eco theological reflection on Christian-ethical implications of Stem cell research and therapy
  2964. Abstract LB-155: Molecular targeted therapy of Stem cell leukemia-lymphoma induced by ZNF198-FGFR1
  2965. Muse cells: a novel type of adult human pluripotent Stem cells and their possible application to cell therapy
  2966. … Antigen Receptor Modified CD8+ T cells Derived From Virus-Specific Central Memory cells for Adoptive therapy After Allogeneic Hematopoietic Stem cell
  2967. Diabetic treatment by Stem cell based therapy in vivo in combination with gynura procumbens extract
  2968. A 34-Year-Old Woman with 2-Year History of therapy-Resistant, Rapidly Progressive SSc Successfully Treated by Autologous Hematopoietic Stem cell
  2969. Application of neural Stem cell transplantation to brain injury therapy
  2970. Haematopoietic Stem cell gene therapy for metachromatic leukodystrophy
  2971. Neural Stem cell gene therapy for exercise-induced spinal cord injury
  2972. Stemcell Gene therapy for the Wiskott-Aldrich Syndrome
  2973. Stem cell Transplant Patients, Glucocorticoids and Physical therapy-How Well Do They Mix?
  2974. Human Embryonic Stem cell-derived Tissue Transplantation therapy: Clinical Hurdles
  2975. T-cell Depletion Is An Alternative Approach for Patients>/= 55 Years Undergoing Allogeneic Stem cell Transplantation as Curative therapy for Hematologic Diseases
  2976. Stem cell Replacement therapy for the Mammalian Inner Ear: A SyStematic Literature Review
  2977. Treating GM1 Gangliosidosis With Ex Vivo Hematopoietic Stem cell Gene therapy Without Using Total Body Irradiation: A Masters Thesis
  2978. Development of an embryonic Stem cell-based therapy for replacement of spiral ganglion neurons
  2979. Tissue repairing cells that exist among mesenchymal Stem cells; their potential for cell-based therapy
  2980. Clinical impact of suicide gene therapy in allogeneic hematopoietic Stem cell transplantation
  2981. Electrical competence of the infarcted heart following Stem cell based regenerative therapy, in a rat model.
  2982. Application of protein and small-molecule microarrays to study Stem cell differentiation, cancer growth, and personalized therapy
  2983. HUMAN UMBILICAL CORD BLOOD‐DERIVED MESENCHYMAL Stem cells IN THE CULTURED RABBIT INTERVERTEBRAL DISC‐A cell therapy
  2984. Autologous Stem cell Transplantation in Multiple Myeloma in the Era of Novel Agents: Impact of Depth of Response to Induction therapy. A Single Institution …
  2985. therapy-Senescent Lymphoma cells Bear Potentially Detrimental Stemcell Characteristics.
  2986. … Assessment of Rat Heart Force Generation: A Quantitative Approach for Predicting Outcomes From Pluripotent Stem cell-Derived therapy for Myocardial Infarction
  2987. Autologous Hematopoetic Stem cell Transplantation as An Intensive Consolidation therapy for Adult Patients in Remission from Acute Myeloid Leukemia.
  2988. Mesenchymal Stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression
  2989. 315. Therapeutic Efficacy of Hematopoietic Stem cell Gene therapy for Hurler Type 1 Mucopolysaccharidosis
  2990. PATU8 Analysis of outcomes of high-dose immunosuppressive therapy with autologous Stem cell transplantation in 156 patients with multiple sclerosis
  2991. Towards Defining An Optimal Conditioning Regimen for Stem cell Gene therapy In Fanconi Anemia.
  2992. Key mechanisms underlying cancer Stem cell overpopulation in colon carcinomas: Implications for anticancer therapy.
  2993. Autologous Stem cell Transplantation (ASCT) for Multiple Myeloma (MM) in HIV Positive Patients (PTS) in the Highly Active Antiretroviral therapy (HAART) Era
  2994. Impact of Rituximab-Based therapy After Histological Transformation on High-Dose therapy and Autologous Stem cell Transplantation in Follicular …
  2995. Use Of Mechanical Ventilation And Renal Replacement therapy In The Critically Ill Hematopoietic Stem cell Transplant Patient
  2996. High Dose therapy with Autologous Stem cell Transplantation Vs Standard Dose Chemotherapy In Multiple Myeloma: A Meta-Analysis
  2997. Hematopoietic Stem cell Transplantation and Gene therapy for Primary Immune Deficiency Diseases
  2998. Autologous Stem cell Transplantation as Front Line therapy Does Not Improve the Outcome of High Risk Aggressive Non-Hodgkin’S Lymphoma: A Single Center …
  2999. Induction therapy with Novel Agents Improves Relapse-Free Survival After Autologous Stemcell Transplantation in Multiple Myeloma
  3000. 864. Foamy Virus Vectors with MGMT-P140K Mediate Efficient Selection in a Canine Pyruvate Kinase Deficiency Model for Hematopoietic Stem cell Gene therapy
  3001. Stem cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem cell Transplantation Following a Lenalidomide-Based Initial therapy
  3002. Ethical aspects of human embryonic Stem cell use and commercial umbilical cord blood Stem cell banking. Ethical reflections on the occasion of the regulation of the …
  3003. Stem cell Transplantation and Chemotherapy As a Salvage therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem cell
  3004. Applications for human neural Stem cell-derived motor neurons in amyotrophic lateral sclerosis: cell replacement therapy and disease modeling
  3005. therapy with high-dose chemotherapy (HDCT) and peripheral blood Stem cell transplant (PBSCT) in patients with primary mediastinal nonseminomatous germ cell
  3006. Decitabine as a Bridging therapy Before Allogeneic Stem cell Transplantation for Myelodysplastic Syndrome
  3007. cells in Blood of Metastatic Breast Cancer Patients Indicates therapy Response and Provides Information on Epithelial Mesenchymal Transition and Tumor Stem cell
  3008. Carbon Monoxide therapy Modulates Hematopoietic Stem cell Development in Heme-Oxygenase-1 Knockout Mice
  3009. A Comparative Study of the Outcome of High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation in Patients with High-Risk or Standard …
  3010. Outcome after high-dose therapy with autologous Stem cell rescue with BEAM for relapsed follicular lymphoma.
  3011. Tandem Stem cell transplantation as consolidation therapy for high-risk neuroblastoma: The Children’s Healthcare of Atlanta experience.
  3012. Outcome In Follicular Lymphoma (FL) Patients (pts) Relapsing After Autologous Stem cell Transplantation (ASCT): Allografting Vs. Conventional therapy
  3013. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic Stem cell transplant recipients
  3014. Autologous peripheral blood Stem cell transplantation with high-dose therapy for anaplastic large cell lymphoma with progressive myelofibrosis
  3015. Collapsed-Dose Versus Standard-Dose Palifermin therapy in Hematopoietic Stem cell Transplantation
  3016. The Role of High Dose Chemotherapy and Autologous Stem cell Transplantation In Patients with Multiple Myeloma Refractory to Initial Induction therapy
  3017. Prospective Use of a Triple FISH Probe to Predict sMDS/AML Following High Dose therapy with Autologous Stem cell Rescue for Lymphoma.
  3018. Peripheral Blood Stem cell Collection In Patients Undergoing Induction therapy with Lenalidomide Based Regimens: Failure Rates and Salvage Approaches
  3019. Idiotype Immunization Following High-Dose therapy and Autologous Stem cell Transplantation for Non-Hodgkin Lymphoma
  3020. Comparison of hematopoietic Stem cell transplantation from HLA identical siblings vs intensive immunosuppression therapy for severe aplastic anemia
  3021. … profound hematopoietic and mesenchymal Stem cell abnormalities involving palmar fat and skin in addition to fascia: Novel implications for pathogenesis and therapy
  3022. Allogeneic Stem cell Transplantation in Patients with therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and …
  3023. Frequency Of Allogeneic Stem cell Transplant (SCT) In Patients Presenting With Newly-Diagnosed AML Or AML At Time Of First Salvage therapy
  3024. The negative Impact of Imatinib Mesylate therapy prior to Allogeneic Hematopoietic Stem cell Transplantation in patients with chronic Myeloid Leukemia
  3025. Hepatitis C Virus-Induced Hepatocellular Carcinoma: cancer Stem cell and gene therapy
  3026. Carbon Monoxide therapy Reduces Reactive Oxygen Species Production and the Short-Term Hematopoietic Stem cell Population In Heme-Oxygenase-1 Knockout …
  3027. therapy-related myeloid neoplasm in a patient with TP53 mutation: a dilemma in allogeneic Stem cell transplant
  3028. The Novel Use of Hyperbaric Oxygen therapy to Improve Umbilical Cord Blood Stem cell Engraftment in Irradiated NOD/SCID Mice: What Did We Learn?
  3029. P4. 37 Towards hematopoietic Stem cell gene therapy for the treatment of Pompe disease
  3030. cell Transplantation From HBsAg-Positive Donors Into HBsAg-Negative Recipients: A Safety and Practicable Regimen Under Active Prophylactic Anti-HBV therapy
  3031. Tandem versus single autologous peripheral blood Stem cell transplantation as post-remission therapy in adult acute myeloid…
  3032. Mesenchymal Stem cells therapy in Acute Renal Failure: Possible Role of Hepatocyte Growth Factor. J Stem cell Res Ther 1: 109. doi: 10.4172/2157 …
  3033. Autologous (Auto) Peripheral Blood Stem cell (SCT) As a Consolidation therapy for Patients with Acute Myeloid Leukemia (AML) in 1st Complete Remission (CR): A …
  3034. High resolution analysis of clonal pluripotent Stem cell lentiviral gene therapy in a mouse model of beta-thalassemia
  3035. High-Dose Immunosuppressive therapy (Cyclophosphamide and Campath-1H) Followed by Autologous Hematopoietic Stem cell Transplantation In the Treatment of …
  3036. Chemoresistance Can Be Reliably Overcome with High-Dose therapy and Autologous Stem cell Transplantation (HDT/ASCT) for Relapsed and Refractory …
  3037. … Rituximab As a Pre-Emptive therapy for Epstein-Barr Virus (EBV)-Associated Lymphoproliferative Disorders in 86 Adult Patients Having Allogeneic Stem cell
  3038. Allogeneic Stem cell Transplantation for Secondary or therapy-Related Acute Myeloid Leukemia or Myelodysplastic Syndrome with Poor-Risk Cytogenetics.
  3039. … of Disease Relapse and Progression in Patients with Multiple Myeloma After First Line therapy with Autologous Stem cell Transplantation: Implications for …
  3040. … Ranimustine (MCNU), Carboplatin, Etoposide, and Cyclophosphamide (MCVC) therapy Followed by Autologous Stem cell Transplantation for Malignant …
  3041. … of glioma Stem cells: Effect of antibody-conjugated magnetic nanoparticles and proteasomal inhibitor bortezomib on GBM-derived neurospheres and glioma Stem cell
  3042. 181 cell therapy with autologous urine-derived Stem cells for vesicoureteral reflux
  3043. … of Myocardial and Hepatic T2∗ MRI Changes in β-Thalassemia Major Hematopoietic Stem cell Transplantation Recipients and the Effect of Iron Overload therapy
  3044. Embryonic Stem cell-derived Macrophage-based Gene Replacement therapy In SOD3-deficient Mice Ameliorates LPS-induced Lung Inflammation
  3045. High Dose Oral Busulfan and Intravenous Melphalan as Conditioning therapy for Autologous Hematopoietic Stem cell Transplant (HSCT) for the Treatment of …
  3046. Does the magnitude of response to initial induction therapy impact plans for immediate autologous Stem cell transplant (ASCT) consolidation in the transplant-eligible …
  3047. … Kinase Inhibitors therapy and Donor Lymphocyte Infusion In Patients with Chronic Myelogenous Leukemia Relapsing After Allogenic Hematopoietic Stem cell
  3048. … -Free Survival of Patients with AML Relapse After T-cell-Depleted Allogeneic Stem cell Transplantation by Re-Induction therapy and Subsequent Interferon …
  3049. … modulation by dendritic cells as a mechanism of action of extracorporeal photopheresis therapy for graft-versus-host disease after allogeneic haematopoietic Stem cell
  3050. Maintenance therapy with Nilotinib (Tasigna) Post Allogeneic Stem cell Transplantation (AlloSCT) for Advanced (> CP1) Chronic Myeloid Leukemia (CML) and Ph+ …
  3051. … Cytomegalovirus (CMV) Serologic Status on Outcome and Survival in Patients Undergoing Allogenic Stem cell Transplantation in the Era of CMV-Preemptive therapy
  3052. … MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous Stem cell rescue (HDT/ASCT).
  3053. therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem cell Transplantation Using Low Dose Alemtuzumab In Vivo T cell
  3054. … -Based Salvage therapy in Adult Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (T-ALL/LL) Relapsing After Allogeneic Stem cell
  3055. … versus consolidation bortezomib therapy following aggressive chemo-immunotherapy and autologous Stem cell transplant for previously untreated mantle cell
  3056. A new humanized mouse model for studying HIV infection and antiretroviral therapeutics and human hematopoietic Stem cell-delivered gene therapy to generate anti …
  3057. … with Community-Based Parenteral Anti-Infective therapy with Intravenous Ganciclovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Stem cell
  3058. … Lymphocyte Infusion Could Reduce Relapse and Improve Survival in Standard-Risk Acute Leukemia Patients After Allogeneic Hematopoietic Stem cell
  3059. … of Response to therapy in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma Undergoing Salvage Chemotherapy and Autologous Stem cell
  3060. … Present with Plasma cells Lacking Phosphorylated Retinoblastoma and/or Cyclin A Expression Benefit From High Dose therapy and Autologous Stem cell
  3061. … Study Evaluating Busulfan and Fludarabine as Preparative therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem cell
  3062. Dual roles of mesenchymal Stem cells in spinal cord injury: cell replacement therapy and as a model syStem to understand axonal repair
  3063. Emprirical Antifungal therapy of Persistent Neutropenic Fever After Allogeneic Hematopoietic Stem cell Transplantation With Caspofungin or Liposomal Amphotericin …
  3064. Risk-adapted high-dose therapy including autologous and allogeneic Stem cell transplantation for relapsed or aggressive non-Hodgkin’s lymphoma-a phase II trial by …
  3065. Stem cell Transplantation in HBsAg-negative and Anti-HBs-positive Patients: High Risk in Lymphoid Malignancies and Indication for Pre-emptive Antiviral therapy
  3066. CANCER AND CANCER Stem cell: O-8: COMBINING GENE therapy WITH ADENOVIRAL VECTOR ENCODING 4-1BB L, B7-1 AND P53 IN SKOV3 cell
  3067. High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation (ASCT) Has a Significant but Transient Impact on Quality of Life: Lessons From the …
  3068. … -Defined and PET/CT-Defined Complete Response (CR) to Novel Agent-Based Induction therapy and Autologous Stemcell Transplantation (ASCT) In …
  3069. therapy With Dose-Intensified Cyclophosphamide, Etoposide, and Cisplatin (DICEP) Re-Induction Followed by High-Dose Melphalan (HDM) and Autologous Stem
  3070. … Blood Stem cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction therapy and …
  3071. … Leukemia (AML), Including therapy-Related AML, Associates with Worse Treatment Outcomes, Than De Novo AML Even After Hematopoietic Stem cell
  3072. … , DEXAMETHASONE) INDUCTION FOLLOWED BY HIGH-DOSE therapy WITH AUTOLOGOUS Stem cell TRANSPLANTATION AND MAINTENANCE …
  3073. Elimination of cancer Stem cells in pancreatic cancer cell lines by a combinatorial therapy
  3074. Analytical investigation of Embryonic Stem cells propagation for cell therapy
  3075. Neural crest Stem cells from adult bone marrow: a new source for cell replacement therapy?
  3076. Vascular wall Stem cells. Selection and conditioning of progenitors useful for cell therapy. A pathological case study
  3077. cell therapy WITH HUMAN UMBILICAL CORD BLOOD‐DERIVED MESENCHYMAL Stem cells FOR INTERVERTEBRAL DISC REPAIR IN CULTURED …
  3078. An Animal Model for Assessing Cardiovascular cell therapy with Human Bone Marrow Stem cells
  3079. Application in cell therapy for Stroke: Characterization of Apoptotic Expression in Mesenchymal Stem cells
  3080. Mesenchymal Stem cells: cell-Based Reconstructive therapy in Orthopedics
  3081. cell therapy with adipose tissue-derived Stem cells for insulin-dependent diabetes mellitus in mice
  3082. cell-based therapy In Glaucoma: Co-cultures Of Neural Stem cells With Glaucomatous Retinal Explants
  3083. cell therapy Of Alkali Burned Cornea With Human Umbilical Mesenchymal Stem cells In The Mouse Model
  3084. … Purine Nucleoside Phosphorylase (PNP) Gene in Bone Marrow Derived Hematopoietic Stem cells: An In Vivo Model of Gene therapy for PNP Deficient T-cell
  3085. Mesenchymal Stem cells for the cell-based therapy of type 1 diabetes: An experimental approach
  3086. 1-5 cell therapy OPTIONS FOR OSTEOARTHRITIS: Stem/PROGENITOR cell
  3087. … DIFFERENTIATION OF HUMAN MESENCHYMATOUS Stem cells CULTIVATED ON COLLAGEN SPONGE: PERSPECTIVES FOR GUIDED cell therapy FOR …
  3088. … umbilical blood mononuclear cell–derived mesenchymal Stem cells serve as interleukin‐21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice
  3089. Progress of research on leukemia Stem/progenitor cell targeting therapy
  3090. In Situ Expression of Gsk-3β in Mesenchymal Stem cells Phase-Dependently Affects the Efficiency of cell Based therapy for Chronic Myocardial Infarction
  3091. Proton therapy targets cancer Stem cells in treatment-resistant non-small cell lung cancer
  3092. Driving murine embryonic Stem cells toward endothelial phenotype for cell-based therapy
  3093. Use of IPs cell-derived neural Stem cells as a cellular vehicle for glioma and breast cancer therapy
  3094. Targeting the CML Stem/progenitor cell with JAK2 (BMS-911543)/ABL inhibitor combination therapy
  3095. Abstract S5-7: Estrogen Receptor Alpha Negative (ER-) Breast Cancer Stem cells in ER+ cell Lines and Primary Cancers Are Enriched by Tamoxifen therapy
  3096. … INFLUENCE OF IMMUNOSUPPRESSIVE therapy ON INFECTION RISK IN RHEUMATOID ARTHRITIS35 THE INFLUENCE OF IMMUNOSUPPRESSIVE therapy
  3097. Stem cell therapy in treatment of different diseases
  3098. Stem cell therapy for cardiac disease
  3099. Advances in Stem cell therapy for spinal cord injury
  3100. Clinical application of Stem cell therapy in Parkinson’s disease
  3101. Challenges for heart disease Stem cell therapy
  3102. New horizons for Stem cell therapy in liver disease
  3103. Journey of mesenchymal Stem cells for homing: strategies to enhance efficacy and safety of Stem cell therapy
  3104. Stem cell therapy for cerebral ischemia: from basic science to clinical applications
  3105. Stem cell therapy for retinal disease
  3106. Key developments in Stem cell therapy in cardiology
  3107. Stem cell therapy for the spinal cord
  3108. Stem cell therapy for erectile dysfunction: a critical review
  3109. Intraoperative Stem cell therapy
  3110. Role of mesenchymal Stem cell therapy in Crohn’s disease
  3111. Stem cell therapy for stress urinary incontinence: a critical review
  3112. Stem cell therapy in chronic liver disease
  3113. Kidney protection and regeneration following acute injury: progress through Stem cell therapy
  3114. cell delivery routes for Stem cell therapy to the heart: current and future approaches
  3115. Mesenchymal Stem cell therapy for attenuation of scar formation during wound healing
  3116. Stem cell therapy in ischemic stroke: role of IV and intra-arterial therapy
  3117. Infrapatellar fat pad-derived mesenchymal Stem cell therapy for knee osteoarthritis
  3118. Autologous mesenchymal Stem cell therapy in progressive multiple sclerosis: an open label study
  3119. Stem cell therapy in oral and maxillofacial region: An overview
  3120. The potential benefit of Stem cell therapy after stroke: an update
  3121. Translational Stem cell therapy for amyotrophic lateral sclerosis
  3122. Stem cell therapy for the inner ear: recent advances and future directions
  3123. The potential of Stem cell therapy for stroke: is PISCES the sign?
  3124. Fat grafting versus adipose-derived Stem cell therapy: distinguishing indications, techniques, and outcomes
  3125. Mesenchymal Stem cell therapy for cutaneous wounds
  3126. Intervertebral disc regeneration or repair with biomaterials and Stem cell therapy-feasible or fiction?
  3127. A review and update on the current status of Stem cell therapy and the retina
  3128. Autologous Stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients
  3129. … -like Stem cells with maximum regenerative potential get discarded during cord blood banking and bone marrow processing for autologous Stem cell therapy
  3130. Bone morphogenetic proteins in craniofacial surgery: current techniques, clinical experiences, and the future of personalized Stem cell therapy
  3131. Mesenchymal Stem cell therapy and lung diseases
  3132. Mesenchymal Stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model
  3133. Induced pluripotent Stem cell consensus genes: implication for the risk of tumorigenesis and cancers in induced pluripotent Stem cell therapy
  3134. Nano Technology and Stem cell therapy for CV Diseases: Potential Applications
  3135. Autologous intravenous mononuclear Stem cell therapy in chronic ischemic stroke
  3136. Stem cell therapy for degenerative disc disease
  3137. Stem cell therapy of tendinopathies: suggestions from veterinary medicine
  3138. Advances in Stem cell therapy
  3139. Case reports of adipose-derived Stem cell therapy for nasal skin necrosis after filler injection
  3140. Toward personalized cell therapies by using Stem cells: seven relevant topics for safety and success in Stem cell therapy
  3141. Endogenous Stem cell therapy enhances fat graft survival
  3142. Allogeneic versus autologous Stemcell therapy
  3143. Concise review: Stem cell therapy for muscular dystrophies
  3144. Adult mesenchymal Stem cell therapy for myelin repair in multiple sclerosis
  3145. Stem cell therapy for voiding and erectile dysfunction
  3146. Stem cell therapy for diabetes
  3147. Progress in Stem cell therapy for the diabetic foot
  3148. Novel insights in basic and applied Stem cell therapy
  3149. Stem cell therapy: a novel & futuristic treatment modality for disaster injuries
  3150. … cord blood-derived mesenchymal Stem cell therapy promotes functional recovery of contused rat spinal cord through enhancement of endogenous cell
  3151. Perspectives on Stem cell therapy for Cardiac Regeneration–Advances and Challenges–
  3152. Stem cell therapy independent of Stemness
  3153. Stem cell therapy: from bench to bedside
  3154. The impact of mesenchymal Stem cell therapy in transplant rejection and tolerance
  3155. Stem cell therapy for critical limb ischemia: what can we learn from cell therapy for chronic wounds?
  3156. Mesenchymal Stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy
  3157. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease
  3158. The convergence of cochlear implantation with induced pluripotent Stem cell therapy
  3159. Toward personalized cell therapies by using Stem cells: seven relevant topics for safety and success in Stem cell therapy
  3160. Plasmonic photothermic and Stem cell therapy of atherosclerotic plaque as a novel nanotool for angioplasty and artery remodeling
  3161. Stem cell therapy in spinal cord injury: in vivo and postmortem tracking of bone marrow mononuclear or mesenchymal Stem cells
  3162. Development of Stem cell therapy for stress urinary incontinence
  3163. Allogeneic mesenchymal Stem cell therapy for refractory cytopenias after hematopoietic Stem cell transplantation
  3164. Allogeneic cellular and autologous Stem cell therapy for sickle cell disease:’whom, when and how’
  3165. Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future Stem cell therapy
  3166. Human umbilical cord mesenchymal Stem cell therapy on neuromyelitis optica
  3167. Adipose-derived Stem cell therapy for severe muscle tears in working German shepherds: two case reports
  3168. Validating intramyocardial bone marrow Stem cell therapy in combination with coronary artery bypass grafting, the PERFECT Phase III randomized multicenter …
  3169. Functional heterogeneity of mesenchymal Stem cells: implications for cell therapy
  3170. Current status of mesenchymal Stem cell therapy and bone marrow transplantation in IBD
  3171. Issues in medicine Regulatory crackdown on Stem cell therapy: what would the position be in South Africa?
  3172. Preconditioning approach in Stem cell therapy for the treatment of infarcted heart
  3173. News Commentary: human embryonic Stem cell therapy in the post-Geron era
  3174. Update on cardiac Stem cell therapy in heart failure
  3175. Autologous Bone Marrow Stem cell therapy Shows Functional Improvement in Hemorrhagic Stroke.
  3176. Acceptability of Stem cell therapy by pregnant women
  3177. Imaging Stem cell therapy for the treatment of peripheral arterial disease
  3178. Stem cell-based therapy for experimental stroke: a syStematic review and meta-analysis
  3179. Stemcell therapy takes off in Texas: a boom in unproven procedures is worrying scientists
  3180. Carvedilol enhances mesenchymal Stem cell therapy for myocardial infarction via inhibition of caspase-3 expression
  3181. Human amniotic fluid Stem cell-derived muscle progenitor cell therapy for stress urinary incontinence
  3182. Mesenchymal Stem cell therapy following muscle trauma leads to improved muscular regeneration in both male and female rats
  3183. Mesenchymal Stem cell secreted vesicles provide novel opportunities in (Stem) cell-free therapy
  3184. Assessment of health-related quality of life in patients receiving Stem cell therapy for end-stage liver disease: an Egyptian study
  3185. Stem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?
  3186. Neural Stem cell therapy for temporal lobe epilepsy
  3187. Anti-HLA antibodies in regenerative medicine Stem cell therapy
  3188. Stem cell therapy for arterial restenosis: potential parameters contributing to the success of bone marrow-derived mesenchymal stromal cells
  3189. Neurotrophic factor‐secreting autologous muscle Stem cell therapy for the treatment of laryngeal denervation injury
  3190. Stem cell therapy: social recognition recovery in a FASD model
  3191. Mesenchymal Stem cell therapy in acute lung injury: is it time for a clinical trial?
  3192. NK cell therapy: targeting disease relapse after hematopoietic Stem cell transplantation
  3193. Effect of Stem cell therapy on induced diabetic keratopathy in albino rat
  3194. State-of-the-Art on Basic and Applied Stem cell therapy; Stem cell Research Italy–International Society for cellular therapy Europe, Joint Meeting, Montesilvano (PE …
  3195. Stem cell therapy in kidney transplantation
  3196. Autism spectrum disorders: is mesenchymal Stem cell personalized therapy the future?
  3197. The challenges of Stem cell therapy
  3198. Liposome-mediated cancer gene therapy: clinical trials and their lessons to Stem cell therapy
  3199. Mesenchymal Stem cell therapy in the sports knee: where are we in 2011?
  3200. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic Stem cell transplantation
  3201. SPECT and PET to optimize cardiac Stem cell therapy
  3202. Societal value of Stem cell therapy in stroke–a modeling study
  3203. Prospects for Stem cell-derived therapy in stroke
  3204. Mesenchymal Stem cell 1 (MSC1)-Based therapy Attenuates Tumor Growth Whereas MSC2-Treatment Promotes Tumor Growth and Metastasis
  3205. The safety of embryonic Stem cell therapy relies on teratoma removal
  3206. Hematopoietic-Stemcell-based gene therapy for HIV disease
  3207. Effect of Stem cell therapy on adriamycin induced tubulointerstitial injury
  3208. Stem cell therapy in animal sciences-A review
  3209. Advances in Stem cell transplantation and gene therapy in the β-hemoglobinopathies
  3210. Stem cell educator therapy and induction of immune balance
  3211. Update on gene and Stem cell therapy approaches for spinal muscular atrophy
  3212. Stem cell therapy in retinal diseases?
  3213. cell therapy using induced pluripotent Stem cells or somatic Stem cells: this is the question
  3214. Moving successful virus-specific T-cell therapy for hematopoietic Stem cell recipients to late phase clinical trials
  3215. Stem cell therapy–An Overview
  3216. Evaluating the first-in-human clinical trial of a human embryonic Stem cell-based therapy
  3217. … after bone marrow derived cell therapy in patients with acute ST elevation myocardial infarction. A 5-year follow-up from the Stem cell Transplantation in Ischaemic …
  3218. The cancer Stemcell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy
  3219. Pluripotent Stem cell–based cancer therapy: Promise and challenges
  3220. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, Stem cell accumulation, and a mesenchymal phenotype
  3221. Stem cell therapy for bone regeneration: present and future strategies.
  3222. Human amniotic fluid Stem cell injection therapy for urethral sphincter regeneration in an animal model
  3223. Human bone marrow-derived mesenchymal Stem cell: a source for cell-based therapy
  3224. Position Statement of the Chinese Diabetes Society regarding Stem cell therapy for diabetes
  3225. Stem cell based therapy-where are we going?
  3226. Mesenchymal Stem cell-based therapy for the treatment of type 1 diabetes mellitus
  3227. MicroRNA and cardiac Stem cell therapy
  3228. Effect of mesenchymal Stem cell therapy on recovery of streptozotocin-induced diabetes mellitus in adult male albino rats: a histological and immunohistochemical …
  3229. Mending the broken heart-Towards clinical application of human embryonic Stem cell therapy derivatives
  3230. Second autologous Stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival
  3231. A step-up approach for cell therapy in stroke: translational hurdles of bone marrow-derived Stem cells
  3232. Cardiac function, perfusion, metabolism, and innervation following autologous Stem cell therapy for acute ST-elevation myocardial infarction. A FINcell
  3233. Rituximab maintenance therapy after autologous Stemcell transplantation in patients with relapsed CD20+ diffuse large B-cell lymphoma: final analysis of the …
  3234. … of autologous Stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy
  3235. Mesenchymal Stem cell therapy in a rat model of osteoarthritis
  3236. Stem cell therapy for male infertility takes a step forward
  3237. Retinal regeneration and Stem cell therapy in retinitis pigmentosa
  3238. RETRACTED ARTICLE: Targeted suicide gene therapy for glioma using human embryonic Stem cell-derived neural Stem cells genetically modified by …
  3239. Understanding the application of Stem cell therapy in cardiovascular diseases
  3240. Hematopoietic Stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice
  3241. Role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence …
  3242. Combined strategy of mesenchymal Stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes‐associated erectile …
  3243. Isolation and characterization of mesenchymal Stem cell-like cells from healthy and inflamed gingival tissue: potential use for clinical therapy
  3244. Human neural Stem cell replacement therapy for amyotrophic lateral sclerosis by spinal transplantation
  3245. High-dose therapy and autologous Stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data …
  3246. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal Stem cells target cancer cells in situ
  3247. Stem cell based glioblastoma gene therapy
  3248. HLA-mismatched Stemcell microtransplantation as postremission therapy for acute myeloid leukemia: long-term follow-up
  3249. … -thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic Stem cell transplantation in patients …
  3250. Exploring the enkephalinergic differentiation potential in adult Stem cells for cell therapy and drug screening implications
  3251. Mesenchymal Stem cell-based tumor-targeted gene therapy in gastrointestinal cancer
  3252. Clinical response of 277 patients with spinal cord injury to Stem cell therapy in iraq
  3253. Corticotomy and Stem cell therapy for orthodontists and periodontists: rationale, hypotheses, and protocol
  3254. Retracted: Tumor Tropism of Intravenously Injected Human‐Induced Pluripotent Stem cell‐Derived Neural Stem cells and Their Gene therapy Application in a …
  3255. … , and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous Stemcell transplantation: MRC Myeloma …
  3256. The role of cytotoxic therapy with hematopoietic Stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence …
  3257. Stem cell therapy: facts and fiction
  3258. Sonic hedgehog signaling inhibition provides opportunities for targeted therapy by sulforaphane in regulating pancreatic cancer Stem cell self-renewal
  3259. Influence of Stem cell therapy on Statin-induced Myopathy of Skeletal Muscle in Female Rats.
  3260. Alginate scaffolds for mesenchymal Stem cell cardiac therapy: influence of alginate composition
  3261. Groups propose plan to accredit controversial Stem cell therapy clinics
  3262. Utility of mesenchymal Stem cell therapy in type 1 diabetes
  3263. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic Stem cell transplantation
  3264. When inner ear Stem cell therapy becomes a reality
  3265. Mesenchymal Stem cell therapy on murine model of nonalcoholic steatohepatitis
  3266. p53-Independent, normal Stem cell sparing epigenetic differentiation therapy for myeloid and other malignancies
  3267. The Promise of Hematopoietic Stem cell therapy for Stroke: Are We There Yet?
  3268. Valproic acid enhances anti-tumor effect of mesenchymal Stem cell mediated HSV-TK gene therapy in intracranial glioma
  3269. The Editor’s Roundtable: Advances in Stem cell therapy for treatment of cardiovascular disease
  3270. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic Stem cell transplantation improves progression‐free survival in multiple …
  3271. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic Stem cell gene therapy
  3272. Hematopoietic Stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in …
  3273. High‐dose therapy with autologous Stem cell transplantation versus chemotherapy or immuno‐chemotherapy for follicular lymphoma in adults
  3274. Cancer Stem cell targeting: the next generation of cancer therapy and molecular imaging
  3275. T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic Stem cell transplantation
  3276. New directions in cardiac Stem cell therapy: An update for clinicians
  3277. Recent trends and strategies in Stem cell therapy for Alzheimer’s disease
  3278. Residual dormant cancer Stemcell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
  3279. Embryonic Stem cell therapy for intractable epilepsy
  3280. Stem cell-based photodynamic therapy
  3281. High-dose therapy and autologous Stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era
  3282. Stem cell therapy, regenerative medicine and hematopoietic Stem cell transplantation: Recent achievements
  3283. Therapeutic alliance in telephone-administered cognitive–behavioral therapy for hematopoietic Stem cell transplant survivors.
  3284. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic Stem cell transplantation
  3285. Molecular imaging of Stem cell therapy in brain tumors: a step towards personalized medicine
  3286. Fighting HIV with Stem cell therapy: one step closer to human trials?
  3287. PAMAM Dendrimer-Baculovirus Nanocomplex for Microencapsulated Adipose Stem cell-Gene therapy: In Vitro and in Vivo Functional Assessment
  3288. Cardiac biointerventions whatever happened to Stem cell and gene therapy?
  3289. … minimal residual disease in the bone marrow of patients with multiple myeloma before high-dose therapy and autologous blood Stem cell transplantation is an …
  3290. Stem cell therapy in orthopaedics
  3291. Stem cell therapy in kidney transplantation—reply
  3292. Mesenchymal Stem cell therapy: immunomodulation and homing mechanisms
  3293. Medical nutrition therapy provided to adult hematopoietic Stem cell transplantation patients
  3294. Safety evaluation of Stem cells used for clinical cell therapy in chronic liver diseases; with emphasize on biochemical markers
  3295. Prophylactic and preemptive therapy with dasatinib after hematopoietic Stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
  3296. … Prognostic Scoring SyStem scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic Stem cell
  3297. Would cancer Stem cells affect the future investment in Stem cell therapy
  3298. Role of salvage radiation therapy for patients with relapsed or refractory Hodgkin lymphoma who failed autologous Stem cell transplant
  3299. Using the BLT humanized mouse as a Stem cell based gene therapy tumor model
  3300. Hematopoietic Stem cell transplantation improves the high incidence of neutralizing allo-antibodies observed in Hurler’s syndrome after pharmacological …
  3301. Quality of life in patients with coronary artery disease after Stem cell therapy
  3302. cell therapy in Hematology: Hematopoietic Stem cell Transplantations in 2012
  3303. Why CCR5 is chosen as the target for Stem cell gene therapy for HIV infection?
  3304. Evaluation of the cell viability of human Wharton’s jelly Stem cells for use in cell therapy
  3305. Mesenchymal Stem cells in drug/gene delivery: implications for cell therapy
  3306. Stem cell therapy: Dental Aspects
  3307. Stem cell therapy in amyotrophic lateral sclerosis
  3308. Novel therapy for type 1 diabetes: Autologous hematopoietic Stem cell transplantation
  3309. cellular therapy promotes endogenous Stem cell repair
  3310. Autologous Stem cell therapy to treat chronic ulcer in heifer-A case study.
  3311. T-cell therapy: a powerful tool for the management of viral infections and relapse post hematopoietic Stem cell transplantation
  3312. Consolidation of first-line therapy with busulphan and melphalan, and autologous Stem cell rescue in children with Ewing’s sarcoma
  3313. Autologous Stem cell therapy: an analysis of the South African regulatory regime
  3314. Implications of different fluid overload definitions in pediatric Stem cell transplant patients requiring continuous renal replacement therapy
  3315. Adipose tissue-derived multi-lineage progenitor cells as a promising tool for in situ Stem cell therapy
  3316. Stem cell therapy in neurodegenerative diseases: From principles to practice
  3317. Induction of antigen-specific tolerance through hematopoietic Stem cell-mediated gene therapy: the future for therapy of autoimmune disease?
  3318. … -induced cavernous hemangioma in long-term survivors who underwent hematopoietic Stem cell transplantation with radiation therapy during childhood or …
  3319. Supportive care with art therapy, for patients in isolation during Stem cell transplant
  3320. Prognostic factors influencing clinical outcome of allogeneic hematopoietic Stem cell transplantation following imatinib-based therapy in BCR–ABL-positive …
  3321. Multiple myeloma: myeloablative therapy with autologous Stem cell support versus chemotherapy: a meta-analysis
  3322. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic Stem cell transplantation—guidelines of the Infectious …
  3323. Oral valganciclovir versus ganciclovir as delayed pre‐emptive therapy for patients after allogeneic hematopoietic Stem cell transplant: a pilot trial (04‐0274) and …
  3324. Stem cell therapy for small animal clinical use
  3325. Involved field radiation therapy following high dose chemotherapy and autologous Stem cell transplant benefits local control and survival in refractory or recurrent …
  3326. Induced pluripotent Stem (iPS) cell-based cell therapy for muscular dystrophy: current progress and future prospects
  3327. Tandem Stem cell rescue as consolidation therapy for high‐risk neuroblastoma
  3328. Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic Stem cell transplantation
  3329. Induced transgene expression for the treatment of solid tumors by hematopoietic Stem cell-based gene therapy
  3330. Erythroid promoter confines FGF2 expression to the marrow after hematopoietic Stem cell gene therapy and leads to enhanced endosteal bone formation
  3331. Maintenance therapy after Stemcell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. Alfa2b-interferon: Final results of a phase III …
  3332. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic Stem cell transplant recipients compared with conventional-dose …
  3333. The role of allogeneic hematopoietic Stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia
  3334. Therapeutic strategies against ischemia–reperfusion injury: Stem cell therapy and beyond
  3335. INTRACORONARY Stem cell therapy IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION–36 MONTHS RESULTS OF A RANDOMIZED, DOUBLE-BLIND …
  3336. Cardiopoietic Stem cell therapy in heart failure: The multicenter randomized c-cure trial
  3337. Allogeneic Stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of …
  3338. Stemcell therapy in medicine–how far we came and what we can expect?
  3339. Enhancement of cancer Stem cell susceptibility to conventional treatments through complementary yoga therapy: possible cellular and molecular mechanisms
  3340. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous Stem cell transplantation for high risk neuroblastoma
  3341. Stem cell-based therapy for α1-antitrypsin deficiency
  3342. Intracoronary autologous CD34+ Stem cell therapy for intractable angina
  3343. Stem cell therapy in spinal cord injuries: current concepts.
  3344. Researches on application of Stem cell therapy in exercise-induced spinal cord injury recovery
  3345. Recognition of glioma Stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
  3346. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic Stem cell transplantation: macrophage-targeted steroid therapy
  3347. Stem cells: Source for diabetes cell therapy
  3348. Stem cell therapy for Hemorrhagic Stroke: A Single Case Study Report
  3349. Stem cell therapy in Myocardial Infarction: Latest Trends
  3350. Granulocyte transfusion therapy in pediatric patients after hematopoietic Stem cell transplantation: a 5-year single tertiary care center experience
  3351. … in combination with cyclosporin a as pre-and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic Stem cell
  3352. High-dose chemotherapy followed by autologous Stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis
  3353. Adherence of Stem cell transplant recipients receiving glucocorticoid therapy to an exercise-based rehabilitation program
  3354. Stem cell therapy in the Eye: Current status and future prospects for retinal neurodegenerative disease
  3355. Stem cell application for amyotrophic lateral sclerosis: Growth factor delivery and cell therapy
  3356. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  3357. Pseudoprogression after high-dose busulfan-thiotepa with autologous Stem cell transplantation and radiation therapy in children with brain tumors: impact on survival
  3358. Research progress of Stem cell therapy for type 1 diabetes mellitus
  3359. Stem cell therapy and amyotrophic lateral sclerosis
  3360. Stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy
  3361. Induction therapy and Stem cell mobilization in patients with newly diagnosed multiple myeloma
  3362. 532 Priming of Stem cells With Celastrol to Enhance Survival for cell therapy
  3363. The perspectives of Stem cell-based therapy in neurological diseases
  3364. Late onset of hepatitis B virus reactivation following hematopoietic Stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy
  3365. … , thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous Stem cell transplant and consolidation therapy with bortezomib for …
  3366. Continuous renal replacement therapy in children post-hematopoietic Stem cell transplantation: The present and the future
  3367. Consolidative therapy with Stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen
  3368. The beneficial effects of cardiac Stem cell therapy on left ventricular function and structure persists for at least one year in rats with acute myocardial infarction
  3369. MRI Stem cell tracking for therapy in experimental cerebral ischemia
  3370. … of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous Stem cell transplantation for malignant …
  3371. Non-myeloablative bone marrow Stem cell transplantation for mdx mice myodystrophy therapy
  3372. … trial of Len/Dex induction followed by tandem mel140 with autologous blood Stem cell transplantation and Len maintenance versus continued therapy with Len/Dex in …
  3373. Gene and Stem cell therapy in erectile dysfunction
  3374. Stem cell therapy
  3375. Stem cell therapy in Articular Cartilage Injury
  3376. … in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for Stemcell transplantation and as maintenance therapy
  3377. New directions in cardiac Stem cell therapy: An update for clinicians
  3378. Radiation burns and mesenchymal Stem cell therapy
  3379. Food allergy after cord blood Stem cell transplantation with tacrolimus therapy in two patients who developed veno-occlusive disease
  3380. … matrix metalloproteinase-3 or vascular endothelial growth factor transfection of aged human mesenchymal Stem cells enhances cell therapy after myocardial infarction
  3381. Adipose derived Stem cell therapy rescues delayed wound healing in chronic radiation injury
  3382. Stem cell therapy
  3383. Delivery strategies for Stem cell-based therapy
  3384. Iodine-131 rituximab radioimmunotherapy with BEAM conditioning and autologous Stem cell transplant salvage therapy for relapsed/refractory aggressive non …
  3385. Comment on ‘Stemcell therapy for Peripheral Arterial Occlusive Disease’
  3386. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral Stem cell transplantation in patients with …
  3387. New rising infection: human herpesvirus 6 is frequent in myeloma patients undergoing autologous Stem cell transplantation after induction therapy with …
  3388. Allogeneic Stem cell transplant for chronic myeloid leukemia as a still promising option in the era of the new target therapy
  3389. cell therapy for pulmonary arterial hypertension: potential efficacy of endothelial progenitor cells and mesenchymal Stem cells
  3390. Targeted delivery of vascular endothelial growth factor to enhance the Stem cell therapy in treating myocardial infarction in rats
  3391. Peripheral nerve regeneration after traumatic injury and Stemcell therapy
  3392. Human induced pluripotent Stem cells derived hepatocytes: rising promise for disease modeling, drug development and cell therapy
  3393. Stem cell Research & therapy in 2012
  3394. Stem cell-derived microvesicles: a cell free therapy approach to the regenerative medicine
  3395. Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous Stem cell
  3396. Long-term improvement of left ventricular function and infarct size after cardiac Stem cell therapy: 5-years follow-up of the MYSTAR study
  3397. POEMS syndrome treated with melphalan high-dose therapy and autologous blood Stem cell transplantation: a single-institution experience
  3398. 54: Early intracranial mesenchymal Stem cell therapy after a perinatal rat brain damage
  3399. Human Stem cell therapy
  3400. Safeguarding pluripotent Stem cells for cell therapy with a non-viral, non-integrating episomal suicide construct
  3401. Durable Infarct Size Reduction Due to Allogeneic Mesenchymal Stem cell therapy Regulates Whole-Chamber Left Ventricular Remodeling
  3402. 110 RAT BONE MARROW DERIVED MESENCHYMAL Stem cell therapy IN A PARKINSONIAN ANIMAL MODEL OF DETRUSOR OVERACTIVITY
  3403. Idiotype immunization following high-dose therapy and autologous Stem cell transplantation for non-Hodgkin lymphoma
  3404. Mesenchymal Stem cell therapy Comparing Bone Marrow And Adipose Tissue-Originated cells In A Murine Model Of Elastase-Induced Emphysema
  3405. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood Stem cell transplantation for recurrent neuroblastoma
  3406. Issue of transparency in Stem cell therapy
  3407. Stem cell therapy for Heart Failure
  3408. A REVIEW AND UPDATE ON THE CURRENT STATUS OF Stem cell therapy IN ROYAN INSTITUTE; INVITED SPEAKERS
  3409. Stem cell therapy for Type I Diabetes: 1811
  3410. … immune reconstitution following post-transplant cyclophosphamide and regulatory MHC cell therapy in recipients of mhc matched allogeneic hematopoietic Stem cell
  3411. Bioethics and freedom of scientific research in gene therapy and Stem cell biology
  3412. Stem cell therapy and the Governance of Uncertainty
  3413. Stem cell therapy for nervous syStem diseases
  3414. … with R-CHOP or high dose sequential therapy with autologous Stem cell transplantation (R-HDS) for high risk diffuse large B-cell lymphomas patients: results of the …
  3415. cell therapy with adipose tissue-derived Stem/stromal cells for elastase-induced pulmonary emphysema in rats
  3416. … with Two Cycles of Induction therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem cell
  3417. Regulatory questions in the development of blood Stem cell products for regenerative therapy
  3418. Treatment of splenic marginal zone lymphoma of the CNS with high-dose therapy and allogeneic Stem cell transplantation
  3419. Autologous Stem cell therapy for Diabetes: an exciting new frontier opens
  3420. Gap junctions, Stem cells, and cell therapy: Rhythmic/arrhythmic implications
  3421. The Use of Stem cell therapy in Treating Diabetes Mellitus
  3422. T cell and B cell immunity can be reconstituted with mismatched hematopoietic Stem cell transplantation without alkylator therapy in artemis-deficient mice …
  3423. Stem cell therapy in Parkinson’s disease.
  3424. Stem cell therapy for inflammatory bowel disease
  3425. Stem cell therapy in experimental type I diabetes in rats
  3426. Autologous hematopoietic Stem cell transplantation versus intravenous pulse therapy cyclophosphamide for severe or rapidly progressive syStemic sclerosis, the …
  3427. Omics in Stem cell therapy: The Road Ahead
  3428. Stem cell therapy: Way to new era of regenerative dentistry
  3429. Stem cell therapy in stroke: Where are we now?
  3430. Developmental Strategy for Stem cell therapy Products in Regulatory Considerations
  3431. Stem cell therapy for erectile dysfunction
  3432. 5. Stem cell therapy
  3433. Clinically relevant issues in cardiac Stem cell therapy
  3434. MRI-Guided Stem cell therapy
  3435. Umbilical cord blood Stem cell transplantation combined with mouse neural growth factor application and physical rehabilitation therapy for infantile cerebral palsy
  3436. Autologous Stem cell therapy combined with exon skipping
  3437. Do elderly myeloma patients benefit from high dose therapy (HDT) and autologous Stem cell transplant (ASCT)?: A comparative survival analysis using SEER Registry
  3438. Apelin 13: a novel approach to enhance efficacy of hypoxic preconditioned mesenchymal Stem cells for cell therapy of diabetes
  3439. Stem cell therapy and Tooth Regeneration-A Review.
  3440. Stem cell therapy in the context of chronic liver disease: Promise and pitfalls
  3441. Determining duration of HER2-targeted therapy using Stem cell extinction models
  3442. Stem cell based therapy for muscular dystrophies: cell types and environmental factors influencing their efficacy
  3443. Gene therapy and Stem cell therapy in chronic wound healing
  3444. Bone Marrow-Derived Stem cell therapy for Myocardial Infarction
  3445. Stem cell therapy Improves Critical Limb Ischemia
  3446. Stem cell therapy for Spinal Cord Repair: A Current Status Report
  3447. Is There a Role for Stem cell therapy for Overactive Bladder?
  3448. First line therapy for patients with newly diagnosed multiple myeloma ineligible for autologous Stem cell transplantation: a syStematic review and meta-analysis …
  3449. Parkinson’s disease and mesenchymal Stem cells: potential for cell-based therapy
  3450. The Medical Nutrition therapy Provided to Adult Patients Undergoing Hematopoietic Stem cell therapy
  3451. Cardiac Stem cell therapy for heart failure
  3452. Design guidelines for an umbilical cord blood Stem cell therapy quality assessment model
  3453. Stem cell therapy and Stress Response in Pancreas and Intestine
  3454. Stem cell-based cellular therapy in rheumatoid arthritis
  3455. Autologous Stem cell therapy to treat chronic ulcer in heifer-A case study
  3456. Cardiac Stem and progenitor cell biology and therapy
  3457. Development of Multi-functional Stem cell Delivery SyStems for Cardiac therapy
  3458. … in Recipients of T cell Depleted (TCD) Allogeneic Hematopoietic Stem cell Transplants (HSCT) Is Mostly Related to Viral Infections and Anti-Viral therapy.
  3459. Stem-like cells and therapy resistance in squamous cell carcinomas
  3460. Stem cell therapy IN CHRONIC ISCHEMIC CARDIOMYOPATHY: A META-ANALYSIS
  3461. A Journey into the World of Targeted therapy: A Review of Gene therapy, Stem cell therapy, and cell Reprogramming in Cardiovascular Medicine
  3462. 137 Stem cell therapy for HIV Disease
  3463. Dynamics of Myocardial Perfusion in Patients with Coronary Heart Disease and Post-infarction Cardiosclerosis After Stem cell therapy
  3464. Scepticism in medicine, organ transplantation, gene and Stem cell therapy
  3465. Clinical correlate: Stem cell therapy for craniofacial bone regeneration
  3466. Neural Stem cells derived from iPSCs represent a safe and effective source for Stem cell therapy in experimental autoimmune encephalomyelitis
  3467. … index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous Stem cell transplantation, and allow the …
  3468. Response to Comment on ‘Stemcell therapy for Peripheral Arterial Occlusive Disease’
  3469. Current Status of Stem cell therapy for Cochlear Hair Regeneration
  3470. Effects of Stem cell therapy on amiodarone-induced liver injury in albino rats
  3471. cell therapy for opportunistic infection and recurrent disease following allogeneic Stem cell transplantation
  3472. Human amniotic epithelial cells as a reliable source for diabetes Stemcell therapy
  3473. Salvage T cell therapy for therapy Resistant Viral Diseases After Stem cell Transplantation
  3474. Effect of Stem cell therapy on amiodarone-induced liver injury in albino rats
  3475. Optimal Administration Routes for Adipose-Derived Stem cell therapy in Ischemic Flaps
  3476. Stem cells in Normal and Malignant Breast Tissue: Is P-Cadherin a Stem cell Marker and a Possible Target for Cancer Stem cell therapy?
  3477. Chemoprotection in brain tumor patients: another success for Stem cell gene therapy
  3478. Long-term outcome of second allogeneic hematopoietic Stem cell transplantation as salvage therapy for young patients after relapse or graft failure: experience …
  3479. Bone marrow mesenchymal progenitor and Stem cell biology and therapy
  3480. Stem cell therapy in Alzheimer’s Disease Models: Neurogenesis Versus Trophic Support
  3481. Dual Stem cell therapy Using Fetal Cardiac Progenitor cells with EPCs Enhances Benefit in an Acute Myocardial Infarction Model
  3482. Safety, Feasibility and Signal of Activity of Intra-carotid Allogenic Mesenchymal Stem cell therapy in a Large Animal Stoke Model
  3483. 565. Mechanisms of Stem cell therapy in Cystinosis Treatment
  3484. Diffusion Tensor Imaging Biomarkers of Stem cell therapy Efficacy in Pediatric Cerebral Palsy
  3485. Radioisotope-antibody conjugates selectively target bone marrow prior to Stem cell therapy
  3486. … infusions induce sustained clinical remissions and tumor specific immunity in a series of patients with relapsed Hodgkin lymphoma after allogeneic Stem cell
  3487. Immune Mechanisms of Mesenchymal Stem cell therapy for Acute Graft versus Host Disease
  3488. Stem cell therapy FOR MYOCARDIAL REGENERATION OF HUMAN cells USING SPECIAL RECEPTOR MARKERS CD45, CD34
  3489. Derivation of Human Fetal Induced Pluripotent Stem (iPS) cells Using a Non-Integrating Sendai Virus Vector: Implications for Fetal Stem cell therapy
  3490. Mesenchymal Stem cell therapy Prolongs Corneal Allograft Survival in Rats
  3491. Effects of Embryonic Neural Stem cell therapy on DNA Damage Products in Urine and Tissue After Spinal Cord Injury in Rats
  3492. Survival Advantage of cell therapy Over Cytotoxic therapy Alone in Adult Patients with Relapsed AML After Allogeneic Hematopoietic Stem cell
  3493. Lenalidomide Is Effective therapy for Relapse After Allogeneic Stem cell Transplant for Multiple Myeloma.
  3494. Mesenchymal Stem cell therapy for Nerve Regeneration and Immunomodulation after Composite Tissue Allotransplantation
  3495. MRI Monitored USPIO-Labelled Intracardial Stem cell therapy in Acute Myocardial Infarct, Imaging Features with Pathologic Correlation in Porcine Model
  3496. Immediate Mesenchymal Stem cell therapy Provides Greater Attenuation of Myocardial Injury Than Deferred Treatment in Rats After Acute Myocardial Infarction
  3497. Intra-Carotid Mesenchymal Stem cell therapy is Superior to Intravenous delivery in Rat Model of Cerebral Ischemia
  3498. … hematopoietic Stem cell transplantation for primary and secondary myelofibrosis a retrospective, multicenter study of the Kanto Study Group for cell therapy (KSGCT)
  3499. Intravenous Autologous Bone Marrow Derived Stem cell therapy for Patients with Subacute Ischemic Stroke (InVeST): A Multi-Centric Randomized Controlled Trial
  3500. Adipose Stem cell therapy in Mice on Repetitive Intratracheal Bleomycin Induced Pulmonary Fibrosis
  3501. LOP40: Allogeneic Mesenchymal Stem cell therapy Improves Burn Wound Healing via a Predominantly Paracrine Mechanism and Is Associated with Increased …
  3502. Temporal Profiling of Immune-Related Cytokines after Intravenous Administration of Mesenchymal Stem cell therapy in Cerebral Ischemia in Mice
  3503. Adipose Stem cell therapy in mice on repetitive intratracheal bleomycin induced pulmonary fibrosis
  3504. Allogeneic Stem cell transplantation for FLT3/ITD positive acute myeloid leukemia in CR1: implication for personalized therapy to prevent early relapses
  3505. Mesenchymal Stem cell therapy with Co-Stimulation Blockers Prolonged Marginal Mass of Islet Graft Survival in Allogeneic Murine Model: 2122
  3506. High-Dose therapy and Autologous Stem cell Transplantation for Extra-Nodal NK/T Lymphoma in Western Patients; A Study From the European Group for …
  3507. … related mortality after brentuximab vedotin salvage therapy followed by reduced intensity conditioning regimen allogeneic Stem cell transplantation (RIC-ALLO …
  3508. Bottlenecks of the clinical development of pluripotent Stem cell based therapy
  3509. … (allo-CST) for poor risk cytogenetic IPSS myelodysplastic syndrome (PRC-MDS): A report from the French Society of Stem cell Transplantation and cell therapy
  3510. therapy with interferon-α in combination with donor lymphocyte infusion for high risk acute leukemia patients who relapsed after allogeneic hematopoietic Stem cell
  3511. Impact of pitavastatin pretreatment on survival and functional activities of mesenchymal Stem cell: possible implication for cell transplantation therapy
  3512. Lung progenitor and Stem cell biology and therapy
  3513. Intensive induction, autologous Stem cell transplantation and rituximab maintenance has changed event free survival and overall survival in mantle cell
  3514. … , Stem cell therapy has been one of the most promising treatments for Alzheimer’s disease patients. This article aims to summarize the current progress in the Stem cell
  3515. Biomarkers Related with Tumor Formation of Stem cell-based therapy Products using hESC
  3516. 736 Urine derived Stem cells with high telomerase activity for cell based therapy in urology
  3517. Renal progenitor and Stem cell biology and therapy
  3518. 026 Stem cell Based-therapy Using the Chitosan-Phosphorycholine Biopolymer
  3519. Allogeneic Stem cell transplantation versus conventional postremission therapy for acute myeloid leukemia in first complete remission: a matched pairs …
  3520. Stem cell replacement therapy as a potential treatment for SCA1 disease
  3521. Lentiviral Vector Mediated Haematopoietic Stem cell Gene therapy For Mucopolysaccharidosis Type IIIA
  3522. From Empirical Toward Preemptive Antifungal therapy for Patients With Hematological Malignancies and Hematopoietic Stem cell Transplant Recipients.
  3523. Adipose tissue-derived Stem cell biology and therapy
  3524. Stem cell-based gene therapy in HIV treatment
  3525. Successful autologous Stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
  3526. Genitourinary progenitor and Stem cell biology and therapy
  3527. Auditory progenitor Stem cell biology and therapy
  3528. cell therapy Using Adipose-Derived Stem cells for Chronic Liver Injury in Mice
  3529. Prolonged hypogammaglobulinemia after rituximab therapy for post-transplant EBV-lymphoproliferative disorder following hematopoietic Stem cell
  3530. cell-free derivatives from mesenchymal Stem cells are effective in wound therapy
  3531. Amniotic fluid Stem cells: a promising therapeutic resource for cell-based regenerative therapy
  3532. Oral cavity progenitor and Stem cell biology and therapy
  3533. Advances in Stem cell transplantation and gene therapy in the ß-hemoglobinopathies
  3534. Assessment of the Effect of Nilotinib (Tasigna) Maintenance therapy After Allogeneic Stem cell Transplantation in Patients with Advanced CML and Ph+ ALL On …
  3535. Early Consolidation with High Dose therapy and Autologous Stem cell Transplantation in HIV-Associated Non Hodgkin Lymphoma At High Risk (Aaipi 2–3) …
  3536. Stem cell-Based therapy for Lysosomal Storage Diseases
  3537. Human bone marrow-derived mesenchymal Stem cell: a source for cell-based therapy
  3538. Combination antifungal therapy in hematopoietic Stem cell transplantation patients
  3539. High-dose therapy with autologous Stem cell support for lymphoma–from experimental to standard treatment 1735–9
  3540. Salvage therapy with azacitidine increases regulatory T cells in patients with AML or MDS and early relapse after allogeneic blood Stem cell transplantation
  3541. High-dose therapy with autologous Stem cell support for lymphoma in Norway 1987–2008 1704–9
  3542. Umbilical cord blood (UCB) progenitor and Stem cell biology and therapy
  3543. Adult Stem cell-based therapy for degenerative joint diseases
  3544. Cancer Research, Molecular and cell Biology: Look at the Nanotechnology, Based Nanoparticles for Diagnostics, and therapy. Stem cell for Treatment of Cancer …
  3545. Role of Front-Line High Dose therapy with Stem cell Transplant in Peripheral T-cell Lymphomas. A Single Center Experience.
  3546. Advanced therapy: New Treatment Development Based on Cancer Stem cell Theory
  3547. Parthenogenetic embryonic Stem cells with H19 siRNA-mediated knockdown as a potential resource for cell therapy
  3548. Photodynamic therapy Triggers Expression Of Haemopoietic Stem cell Marker Cd34 Of Keratocytes
  3549. Induced Pluripotential Stem cells and the Prospects for Cardiac cell therapy
  3550. Novel method for delivery of Stem cell-derived growth factors for heart therapy applications:«In vitro» and «In vivo» analysis
  3551. A way out or a new prospect: The future development of autologons hematopoietic Stem cell transplantation in type 1 diabetes therapy
  3552. 301 THE VOMERONASAL ORGAN AS A NEW SOURCE OF Stem cells FOR cell therapy
  3553. Multicenter Study Evaluating the Impact of Hypomethylating Agents As Bridging therapy to Hematopoietic Stem cell Transplantation in Myelodysplastic Syndromes
  3554. Improved lentiviral vectors for haematopoietic Stem cell gene therapy of Mucopolysaccaridosis type IIIA
  3555. Reprogramming and Characterization of Cord Blood Derived Stem cells by Synthetic mRNAs: Potential for Cord Blood Stem cell Regenerative therapy
  3556. Neural Stem cell Proliferation Surrounding the Area of Traumatic Brain Injury: Role of Exercise therapy
  3557. Bone marrow mesenchymal Stem cell transplantation combined with gene therapy for treatment of ischemic cerebrovascular disease
  3558. Risk of Nausea and Vomiting in Patients with Lymphoma Undergoing High Dose therapy with Autologous Stem cell Rescue
  3559. … Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose therapy with Stemcell Transplantation in Poor Risk Patients with Diffuse Large B-cell
  3560. … Collection in Adult Thalassemic Patients: Towards the Assessment of the Suitable Hematopoietic Stem cell Source for Gene therapy of Beta-Thalassemia.
  3561. Long-term follow-up of HCV infected hematopoietic Stem cell transplant patients and effects of antiviral therapy
  3562. Stem cell-LIKE cells DETERMINE A THERAPEUTIC MODEL IN BREAST CANCER PATIENTS WHEN ANY OTHER RECOMMENDED therapy FAILED …
  3563. A Qualitative Study Utilizing Grounded Theory: themes Expressed Throughout Art therapy Interventions with Siblings of Pediatric Hematopoietic Stem cell
  3564. … ) for Stem cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem cell Transplantation Following a Lenalidomide Based Initial therapy
  3565. Patient-derived xenografts of non small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer Stem
  3566. Long term impact of prior rituximab therapy, early lymphocyte recovery on autologous Stem cell transplant outcome for diffuse large B cell lymphoma
  3567. In Vivo Confocal Microscopy Analysis and Image-Guided therapy of Limbal Stem cell Insufficiency
  3568. Retrospective Review of Dpace therapy as a Salvage Regimen in Patients with Relapsed Multiple Myeloma Prior to Autologous Stem cell Transplant
  3569. Successful Scale-Up and Quality Assessments of Human Embryonic Stem cells for cell therapy: Challenges and Overview
  3570. Correction: High-Dose Chemotherapy Followed by Autologous Stem cell Transplantation as a First-Line therapy for High-Risk Primary Breast Cancer: A Meta …
  3571. Autologous haematopoietic Stemcell transplantation in refractory coeliac disease type II patients unresponsive to cladribine therapy
  3572. Feasibility and Outcome of High Dose therapy Followed by Autologous Stem cell Transplantation in Relapsed/Refractory Lymphoma in the Geriatric …
  3573. Replacement of Degraded Articular Cartilage Using Stem cell-based therapy in Rabbit Model of Osteoarthritis
  3574. Human embryonic Stem cell-derived endothelial cells as cellular delivery vehicles for targeting therapy of metastatic breast cancer
  3575. Molecular Monitoring and Stepwise Preemptive therapy to Prevent Epstein-Barr Virus-Associated Diseases After Allogeneic Hematopoietic Stem cell
  3576. Pilot study of MAGE-A3 protein vaccination and autologous Stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM).
  3577. Adjuvant Stem cell‐based therapy in acute retinal injury after sodium iodate administration in mice
  3578. High-Dose therapy and Autologous Stem cell Transplantation for Multiple Myeloma: Analysis from Registry of Monoclonal Gammopathy of Czech Myeloma …
  3579. Characterization of BDNF blended chitosan scaffolds for human umbilical cord mesenchymal Stem cell transplants in TBI therapy
  3580. Enzyme replacement therapy and/or hematopoietic Stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European …
  3581. … Treatment of Low-Dose Lenalidomide Maintenance therapy Followed by Second Autologous Peripheral Blood Stem cell Transplantation in Heavily Treated …
  3582. The role of uPAR in inducing a cancer Stem cell-like phenotype in breast cancer and allowing cells to develop endocrine therapy resistance
  3583. Cidofovir Is a Highly Effective and Safe Salvage therapy in Ganciclovir Resistant Cytomegalovirus Reactivation Following Allogeneic Haematopoietic Stem cell
  3584. Decitabine in Combination with Donor Lymphocyte Infusion as Salvage therapy for Relapsed AML Post-Allogeneic Stem cell Transplantation
  3585. Nilotinib (Tasigna) therapy Post Allogeneic Stem cell Transplantation (AlloSCT) for Advanced (> CP1) Chronic Myeloid Leukemia (CML) and Ph+ Acute …
  3586. Bortezomib-Based Induction therapy Followed by High-Dose Chemotherapy and Autologous Stem cell transplantation in Newly-Diagnosed Myeloma: Initial Report …
  3587. THE CARDIOELECTRICAL ACTIVITY STUDY FOR therapy OF SARCOPLASMIC RETICULUM CA2+-ATPASE GENE MODIFIED BONE MARROW Stem cell
  3588. … Clofarabine Pre-Conditioning Prior to Full Intensity or Reduced Toxicity Allogeneic Stem cell Transplantation: A Promising New therapy for the Treatment of …
  3589. Cost analysis comparing intensified chemotherapy alone to myelo-ablative therapy followed by autologous Stem cell rescue in newly diagnosed patients with …
  3590. Maintenance Hypomethylating therapy Post Allogeneic Stem cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous …
  3591. Low Dose Azacitidine Maintenance therapy Following Allogeneic Stem cell Transplantation for MDS/AML Does Not Interact with Tacrolimus Dosing or …
  3592. … Impact of Recipient and Donor CMV Serostatus in Acute Leukemia Patients After Allogeneic Stem cell Transplantation At the Era of Preemptive therapy.
  3593. … Myeloablative Allogeneic Hematopoietic Stem cell Transplantation in Patients with Multiple Myeloma Relapsing After a First High Dose therapy in the Era of …
  3594. RESIDUAL DORMANT CANCER Stem cell FOCI ARE RESPONSIBLE FOR TUMOR RELAPSE AFTER ANGIOGENIC METRONOMIC therapy IN …
  3595. … ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose therapy and Autologous Stem cell
  3596. … Following Risk Adapted Stem cell Transplant (SCT) in SyStemic Light-Chain Amyloidosis (AL) Using Bortezomib and Dexamethasone as Consolidation therapy
  3597. Thiotepa (Tt), Busulfan (Bu), and Clofarabine (Clo) as a Conditioning therapy for Allogeneic Hematopoetic Stem cell Transplant for Patients with High Risk …
  3598. … ) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem cell
  3599. … IMRT During Partial Brain Radiation therapy for High-Grade Gliomas With and Without Selective Sparing of the Hippocampus, Limbic Circuit, and Neural Stem cell
  3600. LC, Acute: O-056; The evaluation of effectiveness and safety for new therapy with bone marrow derived autologous mesenchymal Stem cell for hepatic failure caused …
  3601. Expression of heme oxygenase-1 in cardiac Stem cells enhances the efficacy of cell therapy for attenuating left ventricular dysfunction and remodeling after myocardial …
  3602. Sarcomas as a mise en abyme of mesenchymal Stem cells: exploiting interrelationships for cell mediated anticancer therapy
  3603. Induced pluripotent Stem cells and the prospects for cardiac cell therapy.
  3604. CANINE MESENCHYMAL Stem cells FROM VISCERAL AND SUBCUTANEOUS ADIPOSE TISSUE FOR cell-BASED therapy
  3605. Hematopoietic progenitor and Stem cells circulate by surfing on intracellular Ca2+ waves: A novel target for cell-based therapy and anti-cancer treatment?
  3606. Generation of Tumor Free Induced Pluripotent Stem cells for Safe cell Based therapy
  3607. Pluripotent Stem cells for cell replacement therapy of diabetes
  3608. Human embryonic Stem cells as a source for cell replacement therapy in diabetes
  3609. cell-based therapy options for osteochondral defects. Autologous mesenchymal Stem cells compared to autologous chondrocytes
  3610. LCA Gene therapy In Somatic-cell-Derived Induced Pluripotent Stem cells
  3611. cell based gene therapy using mesenchymal Stem cells and vascular endothelial growth factor in ischemic heart disease rat model
  3612. Targeted gene correction of spinal muscular atrophy induced pluripotent Stem cells and motoneurons as cell source for therapy
  3613. Stem cell therapy market
  3614. Mesenchymal Stem cell therapy for heart disease
  3615. Progress in Stem cell therapy for major human neurological disorders
  3616. Stem cell therapy without the cells
  3617. Stem cell therapy: a clinical trial of stroke
  3618. Cardiopoietic Stem cell therapy in heart failure: the C-CURE (Cardiopoietic Stem cell therapy in heart failURE) multicenter randomized trial with lineage-specified …
  3619. Large animal models for Stem cell therapy
  3620. Progress and prospects in Stem cell therapy
  3621. Stem cell therapy to cure type 1 diabetes: from hype to hope
  3622. Cardiac Stem cell therapy and the promise of heart regeneration
  3623. Mesenchymal Stem cell therapy in skin: why and what for?
  3624. Stem cell therapy for heart failure
  3625. Advances in Stem cell therapy against gliomas
  3626. Hematopoietic Stem cell therapy for multiple sclerosis: top 10 lessons learned
  3627. Meta-analysis of Stem cell therapy in chronic ischemic cardiomyopathy
  3628. Stem cell therapy: an exercise in patience and prudence
  3629. Cardiac Stem cell therapy to modulate inflammation upon myocardial infarction
  3630. Macrophage subpopulations are essential for infarct repair with and without Stem cell therapy
  3631. The rabbit as a model for studying lung disease and Stem cell therapy
  3632. Adverse effect of high glucose concentration on Stem cell therapy
  3633. Stem cell therapy for craniofacial bone regeneration: a randomized, controlled feasibility trial
  3634. Mesenchymal Stem cell therapy in diabetes mellitus: progress and challenges
  3635. Stem cell therapy for human cartilage defects: a syStematic review
  3636. Stem cell therapy in bladder dysfunction: where are we? And where do we have to go?
  3637. Stem cell therapy for acute cerebral injury: what do we know and what will the future bring?
  3638. Human umbilical cord mesenchymal Stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy
  3639. Stem cell therapy for lower extremity diabetic ulcers: where do we stand?
  3640. Priming mesenchymal Stem cells boosts Stem cell therapy to treat myocardial infarction
  3641. Stemcell therapy for erectile dysfunction
  3642. Mesenchymal Stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal Stem cell
  3643. Mesenchymal Stem cell therapy for cardiac inflammation: immunomodulatory properties and the influence of toll-like receptors
  3644. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived Stem cell therapy
  3645. Perspectives of Stem cell therapy in D uchenne muscular dystrophy
  3646. Stem cell therapy for pediatric dilated cardiomyopathy
  3647. Rationale of mesenchymal Stem cell therapy in kidney injury
  3648. Stem cell therapy in stroke: a review literature
  3649. Mesenchymal Stem cell therapy in horses: useful beyond orthopedic injuries?
  3650. Safety and immunological responses to human mesenchymal Stem cell therapy in difficult-to-treat HIV-1-infected patients
  3651. SyStemic delivery of microRNA‐34a for cancer Stem cell therapy
  3652. Stem cell therapy for heart disease
  3653. Stem cell therapy in inflammatory bowel disease: which, when and how?
  3654. Stem cell therapy in amyotrophic lateral sclerosis
  3655. An update on translating Stem cell therapy for stroke from bench to bedside
  3656. Long-term reparative effects of mesenchymal Stem cell therapy following neonatal hyperoxia-induced lung injury
  3657. Nanoparticle-based monitoring of Stem cell therapy
  3658. Multifunctional upconversion nanoparticles for dual‐modal imaging‐guided Stem cell therapy under remote magnetic control
  3659. Safety and efficacy of umbilical cord mesenchymal Stem cell therapy in hereditary spinocerebellar ataxia
  3660. Mesenchymal stromal (Stem) cell therapy fails to improve outcomes in experimental severe influenza
  3661. Autologous bone marrow mesenchymal Stem cell therapy in the subacute stage of traumatic brain injury by lumbar puncture
  3662. Effects of mesenchymal Stem cell therapy on the time course of pulmonary remodeling depend on the etiology of lung injury in mice
  3663. Melatonin treatment improves adipose‐derived mesenchymal Stem cell therapy for acute lung ischemia–reperfusion injury
  3664. Stem cell therapy for the treatment of acute myocardial infarction and chronic ischemic heart disease
  3665. Autologous bone marrow-derived Stem cell therapy in heart disease: discrepancies and contradictions
  3666. Mesenchymal Stem cell therapy stimulates endogenous host progenitor cells to improve colonic epithelial regeneration
  3667. Functional consequences of human induced pluripotent Stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling
  3668. Doxorubicin cardiotoxicity and cardiac function improvement after Stem cell therapy diagnosed by strain echocardiography
  3669. Durable scar size reduction due to allogeneic mesenchymal Stem cell therapy regulates whole‐chamber remodeling
  3670. Clinical trials of adult Stem cell therapy for peripheral artery disease
  3671. Peripheral blood-derived autologous Stem cell therapy for the treatment of patients with late-stage peripheral artery disease—results of the short-and long-term follow …
  3672. Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells
  3673. Mesenchymal Stem cell-based therapy
  3674. Growth and development symposium: Stem cell therapy in equine tendon injury
  3675. New nerve regeneration strategy combining laminin-coated chitosan conduits and Stem cell therapy
  3676. Stem cell therapy for tendon injury
  3677. Stem cell therapy in patients with heart failure
  3678. Stem cell therapy for cardiovascular disease: the demise of alchemy and rise of pharmacology
  3679. Stem cell therapy: promising treatment in heart failure?
  3680. Stem cell therapy for neonatal diseases associated with preterm birth
  3681. Safety of intra-articular celltherapy with culture-expanded Stem cells in humans: a syStematic literature review
  3682. Adipose tissue derived stromal Stem cell therapy in murine ConA‐derived hepatitis is dependent on myeloid‐lineage and CD4+ T‐cell suppression
  3683. Stem cell therapy for stress urinary incontinence: a syStematic review in human subjects
  3684. … in patients with bone-marrow derived cell therapy: final results from the randomized, double-blind, placebo controlled intracoronary Stem cell therapy in patients with …
  3685. Recovery of behavioral symptoms in hemi-parkinsonian rhesus monkeys through combined gene and Stem cell therapy
  3686. Allogeneic mesenchymal Stem cell therapy for bisphosphonate-related jaw osteonecrosis in swine
  3687. Concise review: genetically engineered Stem cell therapy targeting angiogenesis and tumor stroma in gastrointestinal malignancy
  3688. Stem cell therapy in veterinary dermatology
  3689. Histological study on effect of mesenchymal Stem cell therapy on experimental renal injury induced by ischemia/reperfusion in male albino rat
  3690. Stem cell therapy remediates reconstruction of the craniofacial skeleton after radiation therapy
  3691. Stem cell therapy for erectile dysfunction: progress and future directions
  3692. Potential mesenchymal Stem cell therapy for skin diseases
  3693. A phase I study of human cord blood-derived mesenchymal Stem cell therapy in patients with peripheral arterial occlusive disease
  3694. Stem cell therapy is a promising tool for refractory angina: a meta-analysis of randomized controlled trials
  3695. Current outlook of cardiac Stem cell therapy towards a clinical application
  3696. Apoptotic adipose-derived mesenchymal Stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in …
  3697. Stem cell therapy: a novel approach for vision restoration in retinitis pigmentosa
  3698. Fantasies about Stem cell therapy in chronic ischemic stroke patients
  3699. Stem cell therapy in chronic obstructive pulmonary disease. Seeking the prometheus effect
  3700. Allogenicity & immunogenicity in regenerative Stem cell therapy
  3701. Cyclosporine-assisted adipose-derived mesenchymal Stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
  3702. Mesenchymal Stem cell therapy in osteoarthritis: advanced tissue repair or intervention with smouldering synovial activation?
  3703. Development of fully defined xeno-free culture syStem for the preparation and propagation of cell therapy-compliant human adipose Stem cells
  3704. Cardiac cell therapy: boosting mesenchymal Stem cells effects
  3705. Preconditioning strategy in Stem cell transplantation therapy
  3706. Biomaterials for Stem cell therapy: state of art and vision for the future
  3707. Harnessing the Stem cell potential: a case for neural Stem cell therapy
  3708. Mesenchymal Stem cell therapy in heart disease
  3709. Stemcell therapy for dilated cardiomyopathy: a pilot study evaluating retrograde coronary venous delivery
  3710. The multiple aspects of stroke and Stem cell therapy
  3711. Stem cell therapy: from evidence-based medicine to emotion-based medicine? The long Italian way for a scientific regulation
  3712. CD34+ Stem cell therapy in Nonischemic Dilated Cardiomyopathy Patients
  3713. Steps toward safe cell therapy using induced pluripotent Stem cells
  3714. Reply: The C-CURE randomized clinical trial (Cardiopoietic Stem cell therapy in heart failURE)
  3715. Stem cell therapy for Alzheimer’s disease: hype or hope?
  3716. Stemcell therapy for erectile dysfunction
  3717. The potential of Stem cell therapy for osteoarthritis and rheumatoid arthritis.
  3718. Establishment of isolation and expansion protocols for human cardiac C-kit-positive progenitor cells for Stem cell therapy
  3719. Atorvastatin: an efficient step forward in mesenchymal Stem cell therapy of diabetic retinopathy
  3720. Stem cell therapy for chronic heart failure: an updated appraisal
  3721. The C-CURE randomized clinical trial (Cardiopoietic Stem cell therapy in heart failURE)
  3722. Enhancement of Fat Graft Survival by Bone Marrow–Derived Mesenchymal Stem cell therapy
  3723. Adipose Stem cell therapy for soft tissue reconstruction
  3724. Stem cell transplantation as a therapy for cardiac fibrosis
  3725. Constitutive expression and activation of stress response genes in cancer Stem-like cells/tumour initiating cells: potent targets for cancer Stem cell therapy
  3726. Stem cell-based therapy in neural repair
  3727. Current concepts in Stem cell therapy for articular cartilage repair
  3728. Promise of neurorestoration and mitochondrial biogenesis in Parkinson’s disease with multi target drugs: an alternative to Stem cell therapy
  3729. The political economy of the global Stem cell therapy market
  3730. Mesenchymal Stem cell exosomes: the future MSC-based therapy?
  3731. The contribution of Stem cell therapy to skeletal muscle remodeling in heart failure
  3732. Molecular imaging: the key to advancing cardiac Stem cell therapy
  3733. Mesenchymal Stem cell therapy improves diabetic cardiac autonomic neuropathy and decreases the inducibility of ventricular arrhythmias
  3734. Stem cell therapy for knee ligament, articular cartilage and meniscal injuries.
  3735. Current perspectives on molecular imaging for tracking Stem cell therapy
  3736. Autologous bone marrow concentrate (Mononuclear Stem cell) therapy in the treatment of oral submucous fibrosis
  3737. Suppressing NF-κB and NKRF pathways by induced pluripotent Stem cell therapy in mice with ventilator-induced lung injury
  3738. Stem cell therapy for ischaemic stroke: translation from preclinical studies to clinical treatment
  3739. Stem cell-based therapy for malignant glioma
  3740. Mesenchymal Stem cells: a new trend for cell therapy
  3741. Critical path in cardiac Stem cell therapy: an update on cell delivery
  3742. Application of human mesenchymal and pluripotent Stem cell microcarrier cultures in cellular therapy: achievements and future direction
  3743. Hypoxic culture conditions as a solution for mesenchymal Stem cell based regenerative therapy
  3744. Stem cell therapy for male urinary incontinence
  3745. Stem cell–based therapy for corneal epithelial reconstruction: Present and future
  3746. Role of mesenchymal Stem cell therapy in restoring ovarian function in a rat model of chemotherapy-induced ovarian failure: a histological and immunohistochemical …
  3747. Role of neuregulin‐1/ErbB signaling in Stem cell therapy for spinal cord injury‐induced chronic neuropathic pain
  3748. Mesenchymal Stem cell therapy for lung diseases: oasis or mirage?
  3749. Stem cell therapy in osteoarthritis: a step too far?
  3750. Stem cell-based therapy for spinal cord injury
  3751. The hitchhikers guide to cancer Stem cell theory: markers, pathways and therapy
  3752. Lentiviral hematopoietic Stem cell gene therapy in patients with Wiskott-Aldrich syndrome
  3753. Stem cell therapy in stroke treatment: is it a viable option?
  3754. Lentiviral hematopoietic Stem cell gene therapy benefits metachromatic leukodystrophy
  3755. Advancing critical care medicine with Stem cell therapy and hypothermia for cerebral palsy
  3756. Histological experimental study on the effect of Stem cell therapy on adriamycin induced chemobrain
  3757. Multi-virus-specific T-cell therapy for patients after hematopoietic Stem cell and cord blood transplantation
  3758. Stem cell–based therapy for prevention of delayed fracture union: a randomized and prospective preliminary study
  3759. Stem cell-based therapy for ischemic heart disease
  3760. MicroRNAs in Stem cell function and regenerative therapy of the heart
  3761. High-throughput screening of Stem cell therapy for globoid cell leukodystrophy using automated neurophenotyping of twitcher mice
  3762. Stem cell‐based therapy for Huntington’s disease
  3763. Mesenchymal Stem cell secretome and regenerative therapy after cancer
  3764. Mesenchymal Stem cell therapy unable to rescue the vision from advanced B ehcet’s disease retinal vasculitis: report of three patients
  3765. APOBEC3G-augmented Stem cell therapy to modulate HIV replication: a computational study
  3766. Autologous fat transfer with in-situ mediation (AIM): a novel and compliant method of adult mesenchymal Stem cell therapy
  3767. Stem cell research and therapy in the Islamic republic of Iran: pioneering in the Islamic world
  3768. Neural Stem cell–mediated enzyme/prodrug therapy for glioma: Preclinical studies
  3769. CD133-positive cells for cardiac Stem cell therapy: Current status and outlook
  3770. Effects of intravenous human umbilical cord blood CD34+ Stem cell therapy versus levodopa in experimentally induced Parkinsonism in mice
  3771. Nonlinear growth kinetics of breast cancer Stem cells: implications for cancer Stem cell targeted therapy
  3772. Cardiac Stem cell therapy: Stemness or commitment?
  3773. Umbilical cord Stem cell therapy for bronchopulmonary dysplasia: ready for prime time?
  3774. Autologous Stem cell transplantation: an effective salvage therapy in multiple myeloma
  3775. Lentivirus-mediated CD/TK fusion gene transfection neural Stem cell therapy for C6 glioblastoma
  3776. Intestinal Stem cell injury and protection during cancer therapy
  3777. Stemming the degeneration: IVD Stem cells and Stem cell regenerative therapy for degenerative disc disease
  3778. Endogenous cardiac Stem cell therapy for ischemic heart failure
  3779. … insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent Stem cells (CB-SCs) in Stem cell educator therapy: phase I/II …
  3780. Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer Stem cell model
  3781. Impact of malignant Stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients
  3782. Preclinical Stem cell therapy in Chagas Disease: Perspectives for future research
  3783. Human embryonic Stem cells-derived endothelial cell therapy facilitates kidney regeneration by stimulating renal resident Stem cell proliferation in acute kidney injury
  3784. Mesenchymal Stem cell therapy in HIV-infected HAART-treated nonimmune responders restores immune competence
  3785. Development of hematopoietic Stem cell based gene therapy for HIV-1 infection: considerations for proof of concept studies and translation to standard medical …
  3786. Dual differentiation-exogenous mesenchymal Stem cell therapy for traumatic spinal cord injury repair in a murine hemisection model
  3787. Failure of Stem cell therapy to improve visual acuity in children with optic nerve hypoplasia
  3788. Stem cell therapy for Parkinson’s disease: Are double-blind randomized control trials the best design for quantifying therapy outcomes
  3789. Cardiac-derived Stem cell-based therapy for heart failure: progress and clinical applications
  3790. Hematopoietic Stem cell senescence and cancer therapy-induced long-term bone marrow injury
  3791. SyStematic review of induced pluripotent Stem cell technology as a potential clinical therapy for spinal cord injury
  3792. Myeloid/Microglial driven autologous hematopoietic Stem cell gene therapy corrects a neuronopathic lysosomal disease
  3793. Quantifying mesenchymal Stem cells in the mononuclear cell fraction of bone marrow samples obtained for cell therapy
  3794. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic Stem cell transplant recipients: guidelines of the 4th European Conference on …
  3795. Safety and feasibility of physical therapy in cytopenic patients during allogeneic haematopoietic Stem cell transplantation
  3796. Stem cell therapy for bone disorders
  3797. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic Stem cell transplantation
  3798. Exploiting Stem cell therapy: The 3rd meeting of Stem cell Research Italy
  3799. A novel alternative to cryopreservation for the short-term storage of Stem cells for use in cell therapy using alginate encapsulation
  3800. The potential of Stem cell therapy for Peyronie disease
  3801. Stem cell therapy for Diabetes: A Call for Efficient Differentiation of Pancreatic Progenitors. J Regen Med 2: 1
  3802. Applications of Stem cell therapy for physeal injuries.
  3803. From single nucleotide polymorphisms to constant immunosuppression: mesenchymal Stem cell therapy for autoimmune diseases
  3804. Humoral activity of cord blood-derived Stem/progenitor cells: implications for Stem cell-based adjuvant therapy of neurodegenerative disorders
  3805. Chemical genetics and its potential in cardiac Stem cell therapy
  3806. … to rituximab-based therapy and risk factor analysis in Epstein Barr Virus–related lymphoproliferative disorder after hematopoietic Stem cell transplant in children and …
  3807. Cytometry in Stem cell research and therapy
  3808. … by early high-dose therapy and hematopoietic Stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single …
  3809. Fat grafting versus adipose-derived Stem cell therapy: distinguishing indications, techniques, and outcomes
  3810. Comparative analysis of human mesenchymal Stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy
  3811. Stemcell-based gene therapy for HIV infection
  3812. Hematopoietic Stem cell gene therapy for the multisyStemic lysosomal storage disorder cystinosis
  3813. Pre-conditioned mesenchymal Stem cells: a better way for cell-based therapy
  3814. Use of mechanical ventilation and renal replacement therapy in critically ill hematopoietic Stem cell transplant recipients
  3815. Recent achievements in Stem cell therapy for pediatric gastrointestinal tract disease
  3816. Experimental therapy for lung cancer: umbilical cord-derived mesenchymal Stem cell-mediated interleukin-24 delivery
  3817. Hematopoietic Stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte–colony stimulating factor plus plerixafor in patients with …
  3818. Stem cell therapy for electrophysiological disorders
  3819. The potential role of microvesicles in mesenchymal Stem cell-based therapy
  3820. Gene and Stem cell therapy for diabetes.
  3821. The Present and Future of Stem cell therapy in Japan1
  3822. … with two secondary somatic-type malignancies in a late recurrence of a testicular non-seminoma: illustration of potential and flaw of the cancer Stem cell therapy
  3823. therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood Stem cell
  3824. Stem cell therapy for idiopathic pulmonary fibrosis: How far are we from the bench to the bedside?
  3825. Progress and prospects in Stem cell therapy and drug discovery
  3826. cell therapy with autologous mesenchymal Stem cells—how the disease process impacts clinical considerations
  3827. Hematopoietic Stem cell gene therapy: assessing the relevance of preclinical models
  3828. Molecular monitoring and stepwise preemptive therapy for Epstein–Barr virus viremia after allogeneic Stem cell transplantation
  3829. Stem cell therapy for retinopathy of prematurity
  3830. Allogeneic Stem cell transplantation versus conventional therapy for advanced primary cutaneous T‐cell lymphoma
  3831. Autophagy in chronic myeloid leukaemia: Stem cell survival and implication in therapy
  3832. Perspectives on assessment of Stem cell therapy in stroke by 18F-FDG PET
  3833. Induction of tumor Stem cell differentiation—novel strategy to overcome therapy resistance in gastric cancer
  3834. Experimental study on the effect of intravenous Stem cell therapy on intestinal ischemia reperfusion induced myocardial injury
  3835. Medical nutritional therapy in hematopoietic Stem cell transplantation (HSCT)
  3836. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic Stem cell transplantation
  3837. The eye as a target organ for Stem cell therapy
  3838. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic Stem cell transplantation with Clostridium difficile-associated …
  3839. Current status of Stem cell therapy in China
  3840. Going 3D–cell culture approaches for Stem cell research and therapy
  3841. cell transplantation and “Stem cell therapy” in the treatment of myopathies: many promises in mice, few realities in humans
  3842. Gene delivery techniques for adult Stem cell-based regenerative therapy
  3843. A possible usage of a CDK4 inhibitor for breast cancer Stem cell-targeted therapy
  3844. Neural Stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma
  3845. Mesenchymal Stem/stromal cells: a new”cells as drugs”paradigm. Efficacy and critical aspects in cell therapy
  3846. The effect of Stem cell therapy versus melatonin on the changes induced by busulfan in the testes of adult rat: histological and immunohistochemical studies
  3847. Stability of human mesenchymal Stem cells during in vitro culture: considerations for cell therapy
  3848. cell adhesion molecules in neural Stem cell and Stem cell-based therapy for neural disorders
  3849. … for multiple myeloma relapsing after allogeneic hematopoietic Stem cell transplantation: a report from the French Society of Bone Marrow and cellular therapy
  3850. Mesenchymal Stem cell therapy for equine tendinitis
  3851. Human immature dental pulp Stem cells (hIDPSCs), their application to cell therapy and bioengineering: an analysis by syStematic revision of the last decade of …
  3852. Impact of disease status and Stem cell source on the results of reduced intensity conditioning transplant for Hodgkin’s lymphoma: a retrospective study from …
  3853. Long-term clinical and molecular remissions in patients with follicular lymphoma following high-dose therapy and autologous Stem cell transplantation
  3854. Maintenance therapy with immunomodulatory drugs after autologous Stem cell transplantation in patients with multiple myeloma: a meta-analysis of …
  3855. Evaluating the effects of lenalidomide induction therapy on peripheral Stem cells collection in patients undergoing autologous Stem cell transplant for multiple …
  3856. Risk‐stratified adoptive cellular therapy following allogeneic hematopoietic Stem cell transplantation for advanced chronic lymphocytic leukaemia
  3857. Steroid-sparing effect of extracorporeal photopheresis in the therapy of graft-versus-host disease after allogeneic hematopoietic Stem cell transplantation
  3858. Human pluripotent Stem cells for modelling human liver diseases and cell therapy
  3859. … indications of clinical practice guideline for Stem celltherapy in cardiovascular diseases: A stepwise appropriate use criteria for regeneration therapy
  3860. Safeguarding Stem cell-based regenerative therapy against iatrogenic cancerogenesis: Transgenic expression of DNASE1, DNASE1L3, DNASE2, DFFB …
  3861. Removing the cells from adult bone marrow derived Stem cell therapy does not eliminate cardioprotection
  3862. Adipose derived Stem cell therapy in the treatment of canine degenerative joint disease secondary to conformational abnormalities
  3863. Identification of hematopoietic Stem cell engraftment genes in gene therapy studies
  3864. Phenotypic correction and stable expression of factor VIII in hemophilia A mice by embryonic Stem cell therapy
  3865. Stem cell MicroRNAs in senescence and immortalization: novel players in cancer therapy
  3866. Lenalidomide consolidation and maintenance therapy after autologous Stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis
  3867. High-dose therapy followed by Stem cell transplantation in Hodgkin’s lymphoma: past and future
  3868. < The> effect of Stem cell therapy versus melatonin on the changes induced by busulfan in the testes of adult rat: histological and immunohistochemicaI studies
  3869. Discarded leukoreduction filters: a new source of Stem cells for research, cell engineering and therapy?
  3870. Stem cell Bioprocessing: For cellular therapy, Diagnostics and Drug Development
  3871. High-dose therapy with autologous Stem cell support for lymphoma in Norway 1987–2008
  3872. therapy-related myeloid neoplasms after autologous hematopoietic Stem cell transplantation in lymphoma patients
  3873. High-dose therapy with autologous Stem cell support for lymphoma–from experimental to standard treatment
  3874. Innovative cell therapy in the treatment of serious adverse events related to both chemo-radiotherapy protocol and acute myeloid leukemia syndrome: the infusion of …
  3875. … ‐reported quality of life in long‐term survivors of childhood lymphoblastic malignancy treated with hematopoietic Stem cell transplantation versus conventional therapy
  3876. Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal Stem cell transplantation for treating heart failure in rats
  3877. … effectiveness of early treatment with hyperbaric oxygen therapy for severe late‐onset hemorrhagic cystitis after hematopoietic Stem cell transplantation in pediatric …
  3878. Epigenetic therapy in allogeneic hematopoietic Stem cell transplantation
  3879. Prospects for Stem cell therapy in neuronal ceroid lipofuscinosis
  3880. Peripheral blood Stem cell mobilization in multiple myeloma patients treat in the novel therapy‐era with plerixafor and G‐CSF has superior efficacy but significantly …
  3881. The effect of imatinib therapy on the outcome of allogeneic Stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia
  3882. Neuroimaging for optimization of Stem cell therapy in Parkinson’s disease
  3883. Stem cell therapy in Lysosomal Storage Diseases
  3884. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous Stem cell transplant for relapsed and refractory Hodgkin …
  3885. Are we there yet? Navigating roadblocks to induced pluripotent Stem cell therapy translation
  3886. Amniotic Stem cell transplantation therapy for type 1 diabetes: a case report
  3887. 421: Isolation and expansion of rabbit amniotic fluid Stem cells (AFS) for in-vivo Stem cell therapy
  3888. Oxymatrine could promote mesenchymal Stem cell therapy in hepatic fibrosis rats: An experimental research
  3889. Hypoxic preconditioning of Stem cells as a new approach to increase the efficacy of cell therapy for myocardial infarction
  3890. Stem cell therapy for Multiple Sclerosise.
  3891. Stem cells and cell therapy: From basic sciences to clinical perspectives
  3892. The hope and hype of Stem cell therapy
  3893. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic Stem cell transplantation
  3894. Stimuli-responsive HA-PEI nanoparticles encapsulating endostatin plasmid for Stem cell gene therapy
  3895. Stem cell research and therapy: the position of the National Society of Genetic Counselors
  3896. An Update on Retinal Stem cell therapy
  3897. Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic Stem cell toxicity
  3898. Maintenance therapy with dasatinib after allogeneic hematopoietic Stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia
  3899. Dasatinib maintenance therapy after allogeneic hematopoietic Stem cell transplantation for an isolated central nervous syStem blast crisis in chronic myelogenous …
  3900. Stem cell therapy for tendinopathy: Lessons from a large animal model
  3901. The role of large animal studies in cardiac regenerative therapy concise review of translational Stem cell research
  3902. Stem cell therapy for severe heart failure
  3903. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic Stem cell transplantation: will it be possible to …
  3904. Mesenchymal Stem cell therapy for Peripheral Vascular Diseases
  3905. Salvage therapy with high-dose chemotherapy and peripheral blood Stem cell transplant in patients with primary mediastinal nonseminomatous germ cell
  3906. Autologous Stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk …
  3907. New treatment for sepsis: Stem cell therapy
  3908. The effect of mesenchymal Stem cell therapy on ischemia–reperfusion-induced injury of the rat pancreas: a histological and immunohistochemical study
  3909. VEGF overexpression improves mesenchymal Stem cell sheet transplantation therapy for acute myocardial infarction
  3910. The use of hypoxic cultured mesenchymal Stem cell for oncolytic virus therapy
  3911. Efficacy of acute myeloid leukemia therapy without Stemcell transplantation in a child with blastic plasmacytoid dendritic cell neoplasm
  3912. The influence of cerebrospinal fluid on epidermal neural crest Stem cells may pave the path for cell-based therapy
  3913. High-dose cyclophosphamide therapy associated with diffuse alveolar hemorrhage after allogeneic hematopoietic Stem cell transplantation
  3914. High-dose chemotherapy with autologous Stem cell support as salvage therapy in recurrent gestational trophoblastic disease
  3915. Recent patents on mesenchymal Stem cell mediated therapy in inflammatory diseases
  3916. Stem cell therapy for Female Urinary Incontinence
  3917. Stem cell therapy for ischemic heart disease
  3918. therapy‐related P h+ leukemia after both bone marrow and mesenchymal Stem cell transplantation for hypophosphatasia
  3919. Phase II study of the combination of MLN 9708 with lenalidomide as maintenance therapy post autologous Stem cell transplant in patients with multiple …
  3920. Intensified therapy followed by autologous Stemcell transplantation (ASCT) versus conventional therapy as first‐line treatment of follicular lymphoma: A meta …
  3921. … in advancing Stemcell therapies. a white paper sponsored by: california institute for regenerative medicinealliance for regenerative medicine cell therapy
  3922. Evaluation of myeloablative therapy followed by autologous Stem cell transplantation in first remission in patients with advanced stage follicular lymphoma …
  3923. Stem cell therapy OF MALIGNANT BRAIN TUMORS: REALITY AND PROSPECTS
  3924. Rehabilitation medicine implications of Stem cell therapy in spinal cord injury-a review
  3925. … the Pluripotent Fate of Human Embryonic Stem cells for Tissue Engineering and cell therapy–The Turning Point of cell-Based Regenerative Medicine
  3926. Stem cell transplantation for multiple myeloma in HIV-positive patients in the highly active antiretroviral therapy era: the myeloma institute of research and therapy
  3927. cell therapy for diabetic neuropathy using adult Stem or progenitor cells
  3928. Stem cell therapy for ischemic stroke using iPS cells
  3929. Bone marrow derived mesenchymal Stem cell therapy to improve nerve regeneration and function in a rat limb transplant model (P2170)
  3930. Bone marrow-derived clonal mesenchymal Stem cells as a source of cell therapy for promoting vocal fold wound healing
  3931. Autologous peripheral blood Stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute …
  3932. Reduced-intensity conditioning therapy with fludarabine, idarubicin, busulfan and cytarabine for allogeneic hematopoietic Stem cell transplantation in acute myeloid …
  3933. Stem cell‐Mediated Prodrug Gene therapy of High‐Grade Brain Tumors
  3934. New insight of ischemic postconditioning on Stem cell therapy
  3935. … over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic Stem cell transplantation as consolidation or salvage therapy
  3936. … of adipose tissue derived mesenchymal Stem cell-differentiated insulin-making cells and haematopoietic cells with renal transplantation: a novel therapy for type 1 …
  3937. … , Placebo Controlled Trial of Intracoronary Stem cell Delivery Two to Three Weeks Following Acute Myocardial Infarction from the Cardiovascular cell therapy
  3938. Current Status of Stem cell therapy in Royan Institute.
  3939. A novel nanotechnology based Stem cell therapy for diabetic wound healing
  3940. Sickle cell Disease (SCD) and Stem cell therapy (SCT): Implications for Psychotherapy and Genetic Counselling in Africa
  3941. Erratum: Cardiopoietic Stem cell therapy in heart failure: The C-CURE (Cardiopoietic Stem cell therapy in heart failURE) Multicenter randomized trial with lineage …
  3942. Stem cell derived therapy for cutaneous radiation exposure
  3943. Gene therapy and Stem cell therapy to Improve the Outcome of Human Islet Transplantation
  3944. Cultured Limbal Epithelial Stem cell therapy for Ocular Surface Diseases
  3945. Abstract P39: Adipose-derived Stem cell therapy to improve musculofascial healing in the irradiated abdominal wall
  3946. A Randomized Study of Interferon α‐2b Versus No Treatment as Consolidation After High Dose therapy and Autologous Stem cell Transplantation for Patients With …
  3947. E-015 Differential expression of cytokines in Mesenchymal Stem cells as a potential target for Endovascular Stem cell therapy
  3948. Experimental research effects of intravenous human umbilical cord blood CD34+ Stem cell therapy versus levodopa
  3949. Investigation of mesenchymal Stem cells and the development of experimental strategies for rescuing glaucomatous eyes using a Stem cell-based therapy
  3950. Hematopoietic Stem cell gene therapy for Wiskott-Aldrich syndrome
  3951. Ex vivo mesenchymal Stem cell therapy protects vascular networks from ischemia reperfusion injury
  3952. Contrast ultrasound molecular imaging of the pro-angiogenic paracrine effects of Stem cell therapy in Limb Ischemia
  3953. Stem cells and Stem cell therapy
  3954. Hematopoietic Stem cell gene therapy for lysosomal storage disorders: expected benefits and limitations
  3955. cell therapy AND Stem cell BIOLOGY
  3956. … AND EFFICACY OF CARDIAC cell therapy: FIRST RESULTS OF THE MESS (META–ANALYSIS OF CARDIAC Stem cell STUDIES) DATABASE INCLUDING …
  3957. Simulated microgravity based Stem cell cultures enhance their utility for cell-based therapy
  3958. Mesenchymal Stem cells: new aspect in cell-based regenerative therapy
  3959. Neural fate of mesenchymal Stem cells and neural crest Stem cells: which ways to get neurons for cell therapy purpose
  3960. Music therapy for the hematopoietic Stem cell transplant patients
  3961. Stem cell collection and storage: impact of Joint Accreditation Committee International Society for cellular therapy Europe standards implementation on Stem
  3962. Characterization of microbubble-loaded Stem cells for targeted cell therapy
  3963. Melatonin Treatment Improves Adipose-derived Mesenchymal Stem cell therapy for Acute Lung Ischemia-reperfusion Injury
  3964. Adult mesenchymal Stem cells and their potency in the cell-based therapy
  3965. Kaposi sarcoma after non-myeloablative hematopoietic Stem cell transplant: response to withdrawal of immunosuppressant therapy correlated with whole blood …
  3966. Scopes and limitations in Stem cell therapy: IVRI experience
  3967. The Summary of Stroke and Its Stem cell therapy
  3968. Isolation and characterization of novel, highly proliferative human CD34/CD73-double-positive testis-derived Stem cells for cell therapy
  3969. Mesenchymal Stem cell transplantation may provide a new therapy for ultrafiltration failure in chronic peritoneal dialysis
  3970. Hypoxic preconditioning with cobalt of bone marrow mesenchymal Stem cells improves cell migration and enhances therapy for treatment of ischemic acute …
  3971. A possible turning point in the hematopoietic Stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral …
  3972. Perspectives of Stem cell therapy in Orthopaedics
  3973. Stem cell therapy for Blood Cancer
  3974. 259 INTRACAVERNOSAL Stem cell therapy COMBINED WITH ORAL TADALAFIL ADMINISTRATION PRESERVES ERECTILE FUNCTION AFTER …
  3975. Stem cell therapy for Athletes
  3976. Stem cell therapy: A dawn or dusk of hope
  3977. Progress and Prospects in Stem cell therapy and Drug Discovery
  3978. Molecular imaging in Stem cell therapy
  3979. Stem cell therapy: From the Heart to the Periphery
  3980. Neurological Diseases and Stem cell therapy
  3981. Italy blocks controversial Stem cell therapy
  3982. Embryonic Stem cell therapy–From Bench to Bed
  3983. Human umbilical Stem cell: Its important and application in cell therapy
  3984. Role of high-dose melphalan with autologous Stem cell transplantation in multiple myeloma patients receiving botezomib-containing induction therapy
  3985. Getting at the heart of the issue: advanced imaging and Stem cell-based therapy offer a novel approach to cardiac resynchronization
  3986. Stem cell therapy for ischemic stroke
  3987. Stem cells from Cord Blood, in Utero Stem cell Development and Transplantation-Inclusive Gene therapy
  3988. EMERGING HURDLES IN Stem cell therapy FOR PERIPHERAL VASCULAR
  3989. Stem cell therapy in Pediatric Endocrine Disorders
  3990. Concentrated ascites reinfusion therapy for sinusoidal obstructive syndrome after hematopoietic Stem cell transplantation
  3991. therapy in patients with HER2-positive metastatic breast cancer who underwent high-dose chemotherapy and autologous hematopoietic Stem cell
  3992. Pluripotent Stem cells for Cardiac cell therapy: The Application of cell Sheet Technology
  3993. Multidisciplinary research of human pluripotent Stem cells for application to cell therapy and drug discovery
  3994. Nitazoxanide is effective therapy for norovirus gastroenteritis after chemotherapy and hematopoietic Stem cell transplantation (HSCT)
  3995. Stem cell therapy for Acute Kidney Injury
  3996. VI. Autologous Stem cell transplantation and maintenance therapy.
  3997. Efficacy of cyclosporine A-nanoparticles emulsion combined with Stem cell transplantation therapy for acute myocardial infarction
  3998. Cardiomyopathy and cell therapy: ejection fraction improvement and cardiac muscle mass increasing, after a year of bone marrow Stem cells transplantation, by …
  3999. Autologous hematopoietic Stem cell transplantation and maintenance therapy for multiple myeloma
  4000. Development of mesenchymal Stem cell-based cell therapy
  4001. High dose cytarabine with rituximab is an effective first-line therapy for mantle cell lymphoma and produces ample Stem cell harvest yields after multiple chemotherapy
  4002. The right to care and the expectations of society—controversial Stem cell therapy in Italy
  4003. Chronic Liver Disease: Stem cell therapy
  4004. Beyond islet transplantation in diabetes cell therapy: from embryonic Stem cells to transdifferentiation of adult cells
  4005. Neural Stem cell therapy in the Ischemic Brain (P02. 022)
  4006. Early cardiac retention of administered Stem cells determines clinical efficacy of cell therapy in patients with dilated cardiomyopathy
  4007. Effect of bortezomib-based induction therapy on the peripheral blood Stem cell harvest in multiple myeloma
  4008. Progress in non-renal derived adult Stem cell therapy for kidney disease
  4009. Optimizing Stem cell therapy for Cardiac Repair Following a Myocardial Infarction
  4010. Isolation and purification of self-renewable human neural Stem cells for cell therapy in experimental model of ischemic stroke
  4011. … response in myelofibrosis patients receiving undergoing treatment with conventional therapy, The Measures Trial and Allogeneic Stem cell Transplant, The Symptoms …
  4012. Stem cell therapy Aided Liver Regeneration
  4013. GW24-e2985 Stem cell therapy: a meta-analysis of randomised Controlled trials in chronic heart failure
  4014. Recent advances in hematopoietic Stem cell gene therapy
  4015. Mechanisms of bone mesenchymal Stem cell therapy for ischemic stroke
  4016. Multipotent mesechymal Stem cell therapy for the treatment of chronic nonhealing wound in a dog
  4017. Application of molecular imaging in Stem cell therapy for ischemic heart diseases
  4018. Stem cell therapy for the treatment of radiation-induced normal tissue damage
  4019. Muscle Stem cell therapy for the Treatment of DMD Associated Cardiomyopathy
  4020. Blood-derived biomaterials: What role can they play in regenerative medicine and Stem cell therapy?
  4021. Development and Clinical Application of Equine Stem cell therapy Products
  4022. Alternative Future Therapies for Lysosomal Storage Diseases: Embryonic Stem cell-and Induced Pluripotent Stem cell therapy
  4023. Maintenance therapy with decitabine after allogeneic hematopoietic Stem cell transplantation for acute myeloid leukemia and high-risk myelodysplastic …
  4024. Stem cell therapy for chronic ulcerative wound in a dog
  4025. Abstract TP401: Inflated Expectations about Stem cell therapy in Patients With Chronic Stroke
  4026. Mesenchymal Stem cell therapy. A new direction in the canine osteoarthritis therapy.
  4027. Evidence-Based Review of Adipose Stem cell therapy in Cancer Reconstruction
  4028. Maintenance hypomethylating therapy post allogeneic Stem cell transplantation provides favorable progression free survival in high risk acute myelogenous leukemia …
  4029. GW24-e2228 The role of CXCR4 on Stem cell therapy for atherosclerosis
  4030. Satellite cell Subpopulations and Environmental Mediators of Their Function: Implications for Stem cell therapy in Skeletal Muscle
  4031. Abstract WP104: Chemical Preconditioning Enhances the Effectiveness of Stem cell therapy in Ischemic Stroke
  4032. Suppression of involved immunoglobulin free light chain post therapy and survival outcomes following autologous Stem cell transplantation for myeloma
  4033. Early versus delayed autologous Stem cell transplant (ASCT) in patients receiving induction therapy with lenalidomide, bortezomib, and dexamethasone (RVD) for …
  4034. Stem cell ENGINEERING AND therapy
  4035. The application of super paramagnetic iron oxide-labeled mesenchymal Stem cells in cell-based therapy
  4036. Stem cell therapy in the Philippines-how makati medical center is responding to the demands and challenges of global standards (on the road to the fact evaluation)
  4037. Use of Novel Biomaterial Design and Stem cell therapy in Cutaneous Wound Healing
  4038. Stem cell therapy: Boon or bane? A comprehensive study on the inadequacy of the DOH administrative order 2013-012 and FDA circular 2013-017, regulatory …
  4039. Glial differentiation of human adipose-derived Stem cells: implications for cell-based transplantation therapy
  4040. Adipose-derived Stem cell therapy for Lipopolysaccharideinduced Acute Lung Injury in Mice
  4041. Stem cell therapy of osteoarthritis using stromal vascular fraction cells
  4042. Stem cell therapy for equine tendon regenerative medicine.
  4043. Stiffness Gradient Scaffolds as an In Vitro Model for Stem cell Based Cardiac cell therapy
  4044. High-dose immunosuppressive therapy combined with cord blood infusion and non-myeloablative peripheral blood Stem cell transplantation for patients with …
  4045. Informed target discovery for gene and Stem cell therapy in acute lung injury
  4046. Stem cell as a Novel therapy for Diabetic Cardiomyopathy
  4047. Assessment of cell delivery in cardiac Stem cell therapy using PET-MR imaging
  4048. Allogeneic and autogolous Stem cell therapy combined with physical rehabilitation: A case report on a chronically injured man with quadriplegia
  4049. Combination of Final Blood Products Improves The Efficacy of Autologous Bone Marrow Stem cell therapy.
  4050. Stem cell therapy REMEDIATES MANDIBULAR VASCULOGENESIS FOLLOWING RADIATION AND DISTRACTION OSTEOGENESIS
  4051. Improving the Contractile Performance of Human Pluripotent Stem cell-Derived Cardiomyocytes for Cardiac cell therapy
  4052. In Situ Forming Smart Supramolecular Hydrogels for Long-term Bioengineered Stem cell therapy
  4053. Successful treatment of inter digital chronic ulcerative wound by mesenchymal Stem cell therapy in a cow
  4054. Adoptive Autologous Vascular Stem cell therapy for Diabetic Foot Patients
  4055. Monitoring CMV-specific CD8+ T-cell responses after allogeneic Stem cell transplantation: a new way of guiding anti-viral therapy
  4056. … of Myocardial Function is Associated With Improvement in Ejection Fraction in Patients Treated With Autologous Stem cell therapy for Ischemic Cardiomyopathy
  4057. Isolation, characterization, and differentiaton of baboon adipose-derived Stem cells: A nonhuman primate model for human Stem cell therapy and regeneration
  4058. Embryonic Stem cell-derived macrophages: a novel approach to developing anti-inflammatory macrophages for cell therapy
  4059. 432: Mesenchymal Stem cell therapy of hypoxi/ischaemic brain damage
  4060. Oxymatrine could promote mesenchymal Stem cell therapy in hepatic fibrosis rats: an experimental research
  4061. Autologous cell-sheet Transplantation therapy for Treating Cardiomyopathy: A Phase I Clinical Trial of Novel Stem cell therapy
  4062. < The> effect of mesenchymal Stem cell therapy on ischemia-reperfusion-induced injury of the rat pancreas: a histological and immunohistochemical study
  4063. Cancer vaccine therapy using genetically modified induced pluripotent Stem cell-derived dendritic cells expressing the TAA gene
  4064. … (NOGA) IS ASSOCIATED WITH EXERCISE IMPROVEMENT IN PATIENTS TREATED WITH AUTOLOGOUS Stem cell therapy FOR REFRACTORY ANGINA
  4065. Primary Neural Stem cell Cultures from Adult Pig Brain and Their Nerve-Regenerating Properties: Novel Strategies for cell therapy
  4066. 13 Pluripotent Stem cell therapy for Cardiac Regeneration
  4067. Characterizing the Relationship Between Energy Metabolism and Mesenchymal Stem cell therapy in the Infarcted Heart
  4068. 494 MESENCHYMAL Stem cell MEDIATED CANCER therapy INHIBITS TUMOR GROWTH IN THE TRANSGENIC ADENOCARCINOMA OF THE MOUSE …
  4069. Huntington’s disease modeling and Stem cell therapy in spinal cord disorders and injury
  4070. … in combination with intensive chemotherapy including allogeneic hematopoietic Stem cell transplantation followed by maintenance therapy in FLT3-ITD …
  4071. Regenerative Stem cell therapy with Umbilical Cord Mesenchymal Stromal cells In Deaf Animal Model
  4072. cell therapy and muscle regeneration: skeletal myogenic differentiation of urine-derived Stem cells for potential use in treatment of urinary incontinence
  4073. Autologous Intracoronary Stem cell therapy is Safe and Feasible for Children With Dilated Cardiomyopathy: A Randomised Controlled Cross-Over Pilot Study
  4074. APOBEC3G-Augmented Stem cell therapy to Modulate HIV Replication: A Computational Study
  4075. Impact of induced therapy before allogeneic hematopoietic Stemcell transplantation for higher-risk myelodysplastic syndrome: experience of single centre
  4076. Topical adipose-derived Stem cell therapy ameliorates radiation-induced delayed wound healing
  4077. Sequential therapy combining clofarabine and HLA-haploidentical hematopoietic Stem cell transplantation in the treatment of refractory and advanced …
  4078. High fat feeding enhances the ability of mesenchymal Stem cell therapy to modulate mitochondria in the infarcted heart
  4079. Differential effect of mesenchymal Stem cell therapy on cardiac glucose utilization in the infarcted heart following chow and high fat feeding
  4080. Regenerative Stem cell therapy with Umbilical Cord Mesenchymal Stromal cells in Deaf Animal Model
  4081. Additional Benefit of Cyclosporine-Assisted Adipose-Derived Mesenchymal Stem cell therapy for Against Acute Kidney Ischemia-Reperfusion Injury
  4082. Stem cell Engineering and therapy
  4083. 470. Human Parthenogenetic Stem cell-Derived Hepatocytes for Liver Repopulation: cell therapy Demonstrated in a Pilot Study with Gunn Rats
  4084. Stem cell‐Mediated TRAIL therapy for Highly Aggressive Brain Tumors
  4085. Mesenchymal Stem cell therapy to promote peripheral tissue insulin sensitivity in the high‐fat fed, myocardial infarcted mouse
  4086. Fibroblast feeder cells in human pluripotent Stem cell culture and retinal differentiation-progress toward clinical cell therapy
  4087. Cardiac Stem cell therapy in Conjugation with Anti-inflammatory Small molecule enhances function of infarcted rat hearts.
  4088. Safety of intra-articular celltherapy with culture-expanded Stem cells in humans: a syStematic
  4089. Immunoregulation and allogenicity in cardiac Stem cell regenerative therapy.
  4090. Efficacy of Stem cell therapy in a Hind Limb Ischemia-Reperfusion Injury in a Murine Model: The Critical Role of Indoleamine 2, 3 Dioxygenase (IDO)
  4091. Advanced Aesthetic Facial Rejuvenation: Sculptural Fat Restoration by Autologous Fat Transfer with Adipose-Derived Stem cell therapy
  4092. Corrigendum to ‘Use of Octreotide for relief of gastro-intestinal (GI) symptoms in syStemic mastocytosis'[Hematology/Oncology and Stem cell therapy 6/2 (2013) 72 …
  4093. Acquired Stem cell properties in therapy-induced senescence of lymphomas and acute leukemias in vitro and in vivo
  4094. Aldehyde Dehydrogenase-2 Deficiency Attenuates Bone Marrow Mesenchymal Stem cell therapy for ischemia
  4095. A second autologous Stem cell transplant (ASCT2) induces superior durability of response (DuR) following bortezomib-containing re-induction therapy for …
  4096. … of an HIV-positive multiple myeloma patient with high-dose chemotherapy followed by autologous peripheral blood Stem cell transplantation and maintenance therapy
  4097. HMMR-redirected adoptive T cell therapy for treatment of refractory acute myeloid leukemia in context of mismatched Stem cell transplantation
  4098. Engineered cell therapy With Embryonic Stem cell-Derived Cardiomyocytes Encapsulated in Injectable Nanomatrix Gel Enhanced Engraftment and Promoted …
  4099. Three years of Stem cell Research & therapy
  4100. Bone-marrow stroma: A source of mesenchymal Stem cells for cell therapy
  4101. Stem cell and T-cell Gene therapy Using SIN-Lentiviral Vector In Type 3 Familial Hemophagocytic Lymphohistiocytosis
  4102. cell therapy using Stem cells: trophic factor, differentiation, and cell transplantation
  4103. Stem cell–based gene therapy
  4104. Gene therapy and cell reprogramming in mouse models of monogenic hematopoietic Stem cell diseases
  4105. Let-7 and CDK4-targeting siRNA in Herceptin-conjugated Liposome for Breast Cancer Stem cell therapy
  4106. The Efficacy of Clinically Approved Agents with Stem cell‐Delivered Therapeutics for Cancer therapy
  4107. Regeneration of the retina by Stem cell transplantation therapy
  4108. Decitabine as induction therapy for median-to-high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) before allogeneic Stem cell
  4109. Medical management of limbal Stem cell deficiency with anti-inflammatory therapy and tear film optimization
  4110. Advances in Lentiviral Vector-based cell therapy with Mesenchymal Stem cells
  4111. Stemcell‐Based cell‐Replacement therapy in Parkinson’s Disease
  4112. Stem cell Alchemy for cell-Based therapy
  4113. Impact Of Response Duration and Maintenance therapy After Autologous Stem cell Transplantation On Long-Term Survival In Multiple Myeloma Patients
  4114. Experimental evaluation of targeted alpha therapy for treatment of metastatic prostate cancer using A11. 1 anti-prostate Stem cell antigen minibody labeled with …
  4115. A novel three-dimensional cell culture platform for proliferating Stem cells for cell therapy
  4116. The potential of fetal cell therapy for osteogenesis imperfecta using placenta derived Stem cells
  4117. Stem cell Models & therapy in Neurodegeneration
  4118. Regenerative Medicine in the Central Nervous SyStem: Stem cell-Based cell-and Gene-therapy
  4119. IN HEMATOPOIETIC Stem cell RECONSTITUTION therapy
  4120. Research Highlights: Loaded cargo for Stem cell-directed therapy
  4121. therapy Resistance in Prostate Cancer: A Stem cell Perspective
  4122. High dose therapy and autologous Stem cell transplantation results in good outcomes and acceptable toxicities in elderly patients with non-Hodgkin’s lymphoma
  4123. … -Rituximab Followed By Autologous Stem cell Harvest (SCH) and Cladribine-Cyclophosphamide-Rituximab (2CdA-Cy-Rit) Consolidation As Primary therapy
  4124. Abstract WMP80: Enhancement Of Antioxidative Activity Facilitates Neural Stem cell Transplantation therapy For Hemorrhagic Stroke
  4125. A Randomized Study Of Music therapy In Patients Undergoing Autologous Stem cell Transplant: Decrease In Narcotic Medication Use For Pain Control
  4126. Isolation and characterization of a novel strain of mesenchymal Stem cells from mouse umbilical cord: potential application in cell-based therapy
  4127. Prospect of Cancer Stem cell-targeting therapy
  4128. MODULATION OF ER STRESS RESPONSES THROUGH AN IDO (INDOLEAMINE 2, 3 DIOXYGENASE) DEPENDENT Stem cell therapy IN A MURINE HIND …
  4129. … extramedullary plasmacytomas (EMPs) included in a phase III pethema/GEM study of induction therapy prior autologous Stem cell transplantation (ASCT) in …
  4130. … in neural Stem cells with oxygen–glucose deprivation–reoxygenation injury: A potential approach to enhance effectiveness of cell transplantation therapy
  4131. Menstrual blood Stem cells as a potential source for cell therapy
  4132. Cardiac Stem and progenitor cell therapy: ready for the future?
  4133. Surveillance cultures in pediatric hematopoietic Stem cell transplantation: the possibility of early directed antimicrobial therapy for bloodstream infections with …
  4134. Stem cell based Gene therapy for Pompe’s Disease
  4135. Abstract C225: IL1RAP as functionally relevant target for Stemcell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
  4136. … -Deletion Accelerates FLT3-ITD Malignancies In Mice By Hypomethylation Of Enhancer Sites and Activating Stem cell Programs; Implications For therapy
  4137. Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic Stem cell transplantation
  4138. … , Bortezomib and Dexamethasone (CyBorD) In Patients With AL Amyloidosis and Potentially Reversible Contraindications To Autologous Stem cell
  4139. Sustained remission with allogeneic peripheral blood Stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic …
  4140. Applications of induced pluripotent Stem cell in cancer therapy
  4141. PTCL: Should Initial Management Include High-Dose therapy with Autologous Stem cell Rescue?
  4142. Gene therapy and haematopoietic Stem cell transfer as a strategy to treat autoimmunity
  4143. … lymphocyte infusion followed by pentostatin, cyclophosphamide and rituximab therapy is effective for relapsed chronic lymphocytic leukemia after allogeneic Stem cell
  4144. Isolation and Characterization of Placental Mesenchymal Stem cells for Autologous in Utero cell therapy
  4145. Fungal infections in Stem cell transplantation: epidemiology and therapy
  4146. … in Pediatric Haematopoietic Stem cell Transplant Does Not Result in Increased Graft Versus Host Disease in Patients Receiving Voriconazole Maintenance therapy
  4147. Improving Hematopoietic Stem cell Based Gene therapy By Targeting CD133+ cells
  4148. Advances of Stem cell and PRP therapy in cartilage regeneration
  4149. Current status and future prospects of Stem cell gene therapy for primary immunodeficiency
  4150. therapy, and new agents and Stem cell transplant in the older patient with recurrent diffuse large b-cell lymphoma/Salvage therapy, New Agents and Stem cell
  4151. MicroRNA Adjuvants in Stem cell‐Based Cancer therapy
  4152. 662. Stem cell and T-cell Gene therapy Using SIN-Lentiviral Vector in Type 3 Familial Hematophagocytic Lymphohistocytosis: A Comparative Approach
  4153. Stem cell-TGFb Combination therapy for Treatment of the Degenerative Intervertebral Disc: Can Stem cells Initiate a Healing Response on Their Own?
  4154. X-Ray-Visible Transmyocardial Catheter-Based Microencapsulated Mesenchymal Stem cell Delivery for Cardiac Regenerative therapy
  4155. Hematopoietic Stem and progenitor cell migration after hypofractionated radiation therapy in a murine model
  4156. … tissue derived mesenchymal Stem cell-differentiated insulin-making cells and haematopoietic cells with renal transplantation: a novel therapy for type 1 …
  4157. Second Autologous Stem cell Transplant As Salvage therapy For Multiple Myeloma
  4158. Effects of Stem cell transplantation and intravenous prostaglandin therapy in peripheral arterial disease of the elderly
  4159. Smart Supramolecular Hydrogels for Long-term Bioengineered Stem cell Cancer therapy
  4160. … . Evaluation of Engraftment and Tolerance Induction after Reduced Intensity Conditioning for Hematopoietic Stem cell Transplantation in the Rhesus Gene therapy
  4161. The potential of amniotic fluid Stem cells in prenatal gene and cell therapy
  4162. Stem cell Gene therapy Blocks HIV Infection and Boosts Antiviral Immunity
  4163. Comparison of magnetic intensities for mesenchymal Stem cell-targeting therapy on ischemic myocardial repair
  4164. Novel Pathological Detection SyStem of Induced Pluripotent Stem cell-Derived Cardiomyocytes Using T-cell Receptor Gene Locus for cell Transplantation therapy
  4165. Feasibility of Exercise therapy in Neutropenic Patients Undergoing Hematopoietic Stem cell Transplantation
  4166. … Mice Provides High Yields Of Long-Term Repopulating cells With Enhanced Engrafting Capacity: Implications For Human Stem cell Gene therapy
  4167. Abstract WMP41: Induced Pluripotent Stem cell Derived Neural Progenitor therapy for Treatment in a MCAO Ischemic Brain Injury Pig Model
  4168. Sequential cytokine induced killer cells therapy for acute myeloid leukemia after autologous peripheral blood Stem cell transplantation
  4169. Stem cell collection and transplant in myeloma patients following lenalidomide or bortezomib based induction therapy
  4170. Immune Responses in Patients with Lysosomal Storage Disorders Treated with Enzyme Replacement therapy and Haemopoietic Stem cell Transplantation
  4171. Development and characterization of CD133 positive cancer Stem cell targeted toxins for use in carcinoma therapy
  4172. Adjuvant Stem cell-based therapy in acute retinal injury after sodium iodate administration in mice: Morphological and functional study
  4173. … Globulin and Role Of Stem cell Source On Outcome In Myeloablative Conditioning Of Allogeneic Hematopoietic Stem cell Transplantation With Identical Sibling and …
  4174. Development of a unique anti-AML immune therapy consisting of cord blood HSCT and cord blood Stem cell-derived dendritic cell (CB-DC) vaccination
  4175. Regenerating an Immune SyStem: Gene therapy and Stem cell Transplantation for Severe Combined Immune Deficiency
  4176. Immortalized human fetal bone marrow-derived mesenchymal Stem cell expressing anti-tumor suicide gene for anti-tumor therapy in vitro and in vivo
  4177. Characterization and targeted therapy of Stem cell-like side population cells in pancreatic cancer and esophageal cancer
  4178. Menstrual blood Stem cells as a potential substrate of cell therapy
  4179. Use of Stem cell transplantation (SCT) as initial therapy in multiple myeloma (MM) and impact of sociodemographic factors in the era of novel agents: Analysis of …
  4180. Risk Factors For Relapse In Children Undergoing Preemptive Immunomodulatory therapy After Allogeneic Hematopoietic Stem cell (HSCT) For Acute …
  4181. 309. Integration Site Analysis in a Clinical Trial of Lentiviral Vector Based Hematopoietic Stem cell Gene therapy for Metachromatic Leukodystrophy. An 18 Months …
  4182. Mesenchymal Stem cell based ex vivo gene therapy provides enhanced neuroprotection in X-linked retinoschisis mouse model
  4183. Clinical observation of feasibility and efficacy of decitabine bridge therapy followed by allogeneic hematopoietic Stem cell transplantation in patients with …
  4184. … of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer Stem cells and tumor bulk, in patients with blastic plasmacytoid dendritic cell
  4185. Delayed Hematopoietic Recovery After Autologous Stem cell Transplantation In Patients Receiving Arsenic Trioxide-Based therapy For Acute Promyelocytic …
  4186. Hematopoietic Stem cell gene therapy for the multisyStemic lysosomal storage disorder cystinosis
  4187. Effective Steroid Pulse therapy for mitigate the acute phase symptoms of Human herpesvirus 6 encephalitis after allogenic hematopoietic Stem cell transplantation …
  4188. cell therapy Using Adult Stem cells in Osteonecrosis and Nonunion Fractures
  4189. Enrichment Of Embryonal Stem cell Signature and Persistent Genomic Complexity In Residual Disease Following Pomalidomide therapy In Myeloma
  4190. Alemtuzumab As therapy for Mixed Chimerism After Hematopoietic Stem cell Transplantation for Fanconi Anemia (FA)
  4191. HLA Allele Matched Unrelated Donor Stem cell Transplant As First Line therapy for Children with Acquired Severe Aplastic Anemia
  4192. … predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous Stemcell transplantation (ASCT) in …
  4193. … differentiation of human bone marrow mesenchymal Stem cell with adenovirus mediated glucose transporter-1 and hypoxia inducible factor-1α gene therapy
  4194. Clofarabine Salvage therapy Prior To Allogeneic Hematopoietic Stem cell Transplantation In Patients With Relapsed Or Refractory AML–Results Of The …
  4195. … dysphagia with autologous peripheral blood hematopoietic Stem cell transplantation in a patient with long standing dermatomyositis refractory to standard therapy
  4196. Assessment of the Effect of Nilotinib (Tasigna) Maintenance therapy After Allogeneic Stem cell Transplantation in Patients with Advanced CML and Ph+ ALL On …
  4197. Intranasal delivery of neural Stem cells: a CNS-specific, non-invasive cell-based therapy for experimental autoimmune encephalomyelitis
  4198. Allogeneic and autologous Stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non …
  4199. … Duration≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose therapy and Autologous Stem cell
  4200. Bam Regimen Followed By High-Dose therapy and Autologous Stem cell Transplantation As First-Line Treatment Of Primary Central Nervous SyStem
  4201. Clofarabine Salvage therapy Prior To Allogeneic Hematopoietic Stem cell Transplantation (HCT) In Patients With Relapsed Or Refractory Acute Leukemia
  4202. therapy for cerebral multiple hemorrhagic infarctions due to septic embolism by Bacillus cereus after allogeneic hematopoietic Stem cell transplantation for acute …
  4203. The potential of human adipose tissue derived mesenchymal Stem cells in cell therapy for retinal degenerative diseases
  4204. New, pathogenesis‐based pharmacologic approaches to gastrointestinal ulcers: Gene therapy with egr‐1 & cell therapy with bone marrow‐derived Stem cells
  4205. Second Generation Cardiac cell therapy: Combining Cardiac Stem cells and Circulating Angiogenic cells for the Treatment of Ischemic Heart Disease
  4206. Autologous hematopoietic Stem/progenitor cell (HSPC) therapy for monogenic blood disorders: scalable, cGMP-compliant process for generating highly …
  4207. Hair Follicle: A Novel Source of Stem cells for cell and Gene therapy
  4208. cell transplantation therapy using pluripotent Stem cells
  4209. Limbal Biopsy As a Source of Stem cells for Autologous Stromal cell-based therapy
  4210. The potential of human adipose tissue derived mesenchymal Stem cells in cell therapy for retinal degenerative diseases
  4211. Bioengineering and Stem cells for corneal endothelial cell therapy
  4212. … glioblastoma, neural Stem and multipotent mesenchymal stromal cells of a human: from cataloguing of cell proteins to novel paradigm of proteome-based cell therapy
  4213. An investigation of initial retention of Stem/progenitor cells following intracoronary injection: implications to cell therapy for the treatment of heart failure
  4214. … of Novel Ferromagnetic, Nanoprobes Coupled to Bone Marrow Derived Multipotential Mesenchymal Stromal/Stem cells for cell Tracking in Cardiac cell therapy
  4215. Mesenchymal Stem cells from aspirated adipose tissue can assist in ex vivo expansion of melanocytes for cell therapy
  4216. Myeloma Patient-Derived Mesenchymal Stem cells Grown In 3-D Culture Induce Primary Myeloma cell Proliferation and Resistance To therapy
  4217. P6-06 Mesenchymal Stem cells as an ideal cell therapy tool for rheumatoid arthritis in combination with nano-fiber scaffold
  4218. Mesenchymal Stem cells as targeted cell vehicles to deliver drug-loaded nanoparticles for cancer therapy
  4219. … Activity of SL-401, a Targeted therapy Directed to the Interleukin-3 Receptor on Cancer Stem cells and Tumor Bulk, Against Blastic Plasmacytoid Dendritic cell
  4220. Boron neutron capture therapy induces cell cycle arrest and cell apoptosis of glioma Stem/progenitor cells in vitro
  4221. Keeping an eye on Stem cells for studying disease modelling and cell-based therapy
  4222. Minimal residual disease (MRD) status pre-and post-high-dose therapy/autologous Stem (HDC/ASCT) cell transplantation for multiple myeloma (MM) in the era of …
  4223. therapy of Contused Rat Spinal Cord with Glial cell Line-Derived Neurotrophic Factor (GDNF) and Motoneurons Transdifferentiated from Adipose-Derived Stem
  4224. Triple therapy using radiation therapy (RT), Temozolomide (TMZ), and TRAIL agonist (TRA-8) enhances cell killing in primary glioma cancer Stem cells associated with …
  4225. xCT inhibition suppresses CD44v-positive Stem-like tumor cells, which are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
  4226. Stem cell therapy for osteoporosis
  4227. Enhancing the efficacy of mesenchymal Stem cell therapy
  4228. Alzheimer’s disease and Stem cell therapy
  4229. Progress of mesenchymal Stem cell therapy for neural and retinal diseases
  4230. SyStematic review: the effects of autologous Stem cell therapy for patients with liver disease
  4231. Stem cell therapy for cardiac dysfunction
  4232. … novel and effective strategy for the isolation of adipose-derived Stem cells: minimally manipulated adipose-derived Stem cells for more rapid and safe Stem cell therapy
  4233. Advancing Stem cell therapy from bench to bedside: lessons from drug therapies
  4234. A preliminary report on Stem cell therapy for neuropathic pain in humans
  4235. Mesenchymal Stem cell therapy and acute graft-versus-host disease: a review
  4236. Mesenchymal Stem cell therapy for cardiac repair
  4237. Ovarian cancer Stem cells express ROR1, which can be targeted for anti–cancer-Stemcell therapy
  4238. Adult Stem cell therapy in chronic wound healing
  4239. Stem cell therapy for heart failure
  4240. Stem cell therapy: a look at current research, regulations, and remaining hurdles
  4241. Interferon-gamma modification of mesenchymal Stem cells: implications of autologous and allogeneic mesenchymal Stem cell therapy in allotransplantation
  4242. Stem cell therapy for neonatal brain injury
  4243. The current state of Stem cell therapy for peripheral artery disease
  4244. Cardiac Stem cell therapy for cardiac repair
  4245. Recent advances of Stem cell therapy for retinitis pigmentosa
  4246. Rationale of mesenchymal Stem cell therapy in kidney injury
  4247. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy
  4248. Intravenous autologous bone marrow mononuclear Stem cell therapy for ischemic stroke: a multicentric, randomized trial
  4249. From isolation to implantation: a concise review of mesenchymal Stem cell therapy in bone fracture repair
  4250. Allogeneic adipose Stem cell therapy in acute myocardial infarction
  4251. Immunopharmacological intervention for successful neural Stem cell therapy: New perspectives in CNS neurogenesis and repair
  4252. Stem cell therapy for treatment of epilepsy
  4253. Stem cell therapy and curcumin synergistically enhance recovery from spinal cord injury
  4254. Allogeneic human mesenchymal Stem cell therapy (remeStemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in …
  4255. Cancer Stem cell therapy using doxorubicin conjugated to gold nanoparticles via hydrazone bonds
  4256. Stem cell therapy for intervertebral disk regeneration
  4257. … administered to patients undergoing coronary artery bypass grafting: the Prospective Randomized Study of Mesenchymal Stem cell therapy in Patients Undergoing …
  4258. Regenerative medicine for the heart: perspectives on Stemcell therapy
  4259. Regenerative medicine for the kidney: renotropic factors, renal Stem/progenitor cells, and Stem cell therapy
  4260. Impact of enzyme replacement therapy and hematopoietic Stem cell therapy on growth in patients with Hunter syndrome
  4261. Stem cell therapy for the treatment of early stage avascular necrosis of the femoral head: a syStematic review
  4262. Long‐term evaluation of mesenchymal Stem cell therapy in a feline model of chronic allergic asthma
  4263. Stem cell therapy for central nerve syStem injuries: glial cells hold the key
  4264. Targeted delivery of vascular endothelial growth factor improves Stem cell therapy in a rat myocardial infarction model
  4265. Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal Stem cell therapy in cardiac ischemia treatment
  4266. Governing Stem cell therapy in India: regulatory vacuum or jurisdictional ambiguity?
  4267. A review of novel optical imaging strategies of the stroke pathology and Stem cell therapy in stroke
  4268. Amide‐type local anesthetics and human mesenchymal Stem cells: clinical implications for Stem cell therapy
  4269. Health consumers and Stem cell therapy innovation: markets, models and regulation
  4270. Adipose tissue–derived Stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie’s disease
  4271. ACL injuries and Stem cell therapy
  4272. Optimized cell survival and seeding efficiency for craniofacial tissue engineering using clinical Stem cell therapy
  4273. Application of Stem cell/growth factor syStem, as a multimodal therapy approach in regenerative medicine to improve cell therapy yields
  4274. Rationale and prospects of mesenchymal Stem cell therapy for liver transplantation
  4275. Stem cell therapy for bone repair: a syStematic review and meta‐analysis of preclinical studies with large animal models
  4276. cell therapy with embryonic Stem cell-derived cardiomyocytes encapsulated in injectable nanomatrix gel enhances cell engraftment and promotes cardiac repair
  4277. The promise and challenges of cardiac Stem cell therapy
  4278. Influenza causes prolonged disruption of the alveolar-capillary barrier in mice unresponsive to mesenchymal Stem cell therapy
  4279. Molecular mechanisms of Stem cell therapy in alcoholic liver disease
  4280. Ethical issues in Stem cell research and therapy
  4281. Immunological barriers to Stem cell therapy in the central nervous syStem
  4282. Bone marrow-derived mesenchymal Stem cell therapy for decompensated liver cirrhosis: a meta-analysis
  4283. Efficacy of topical mesenchymal Stem cell therapy in the treatment of experimental dry eye syndrome model
  4284. Mesenchymal Stem cell therapy in treatment of erectile dysfunction: autologous or allogeneic cell sources?
  4285. Doubts over heart Stemcell therapy: study queries early-phase trials of heart-disease treatment
  4286. Potential for cell therapy in Parkinson’s disease using genetically programmed human embryonic Stem cell–derived neural progenitor cells
  4287. Melatonin treatment further improves adipose‐derived mesenchymal Stem cell therapy for acute interstitial cystitis in rat
  4288. Mesenchymal Stem cell therapy in type 1 diabetes mellitus and its main complications: from experimental findings to clinical practice
  4289. Immunological basis of Stem cell therapy in liver diseases
  4290. Mesenchymal Stem cell therapy for salivary gland dysfunction and xerostomia: a syStematic review of preclinical studies
  4291. Inducible metabolic adaptation promotes mesenchymal Stem cell therapy for ischemia: a hypoxia-induced and glycogen-based energy prestorage strategy
  4292. The effect of adipose Stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice
  4293. Mesenchymal Stem cell-based therapy for type 1 diabetes
  4294. Combining enriched environment and induced pluripotent Stem cell therapy results in improved cognitive and motor function following traumatic brain injury
  4295. Mesenchymal Stem cell therapy ameliorates diabetic hepatocyte damage in mice by inhibiting infiltration of bone marrow–derived cells
  4296. Mesenchymal Stem cell therapy promotes corneal allograft survival in rats by local and syStemic immunomodulation
  4297. Mesenchymal Stem cell therapy in patients with small bowel transplantation: single center experience
  4298. Comparison of the effect of Stem cell therapy and percutaneous transluminal angioplasty on diabetic foot disease in patients with critical limb ischemia
  4299. The promises of Stem cells: Stem cell therapy for movement disorders
  4300. The mesenchymal Stem cell–derived microvesicles enhance sciatic nerve regeneration in rat: A novel approach in peripheral nerve cell therapy
  4301. Mesenchymal Stem cell therapy induces glucocorticoid synthesis in colonic mucosa and suppresses radiation-activated T cells: new insights into MSC …
  4302. Histolgical and immunohistochemical study on the effect of Stem cell therapy on bleomycin induced pulmonary fibrosis in albino rat
  4303. Mesenchymal Stem cell therapy for immune‐modulation: the donor, the recipient, and the drugs in‐between
  4304. Adipose Stem cell therapy in cancer reconstruction: a critical review
  4305. Molecular imaging in Stem cell therapy for spinal cord injury
  4306. Stem cell-based cell therapy for glomerulonephritis
  4307. Stem cell therapy for ischemic stroke
  4308. Stem cell therapy in cartilage repair—culture-free and cell culture–based methods
  4309. Pluripotent Stem cells as a potential tool for disease modelling and cell therapy in diabetes
  4310. Paracrine mechanisms of mesenchymal Stem cell-based therapy: current status and perspectives
  4311. Novel chemically modified bacterial cellulose nanocomposite as potential biomaterial for Stem cell therapy applications
  4312. Above all, do no harm’: safeguarding pluripotent Stem cell therapy against iatrogenic tumorigenesis
  4313. Transplantation KCNMA 1 modified bone marrow‐mesenchymal Stem cell therapy for diabetes mellitus‐induced erectile dysfunction
  4314. Novel approaches to lupus drug discovery using Stem cell therapy. Role of mesenchymal-Stemcell-secreted factors
  4315. Advances toward regenerative medicine in the central nervous syStem: challenges in making Stem cell therapy a viable clinical strategy
  4316. The effect of bone marrow mononuclear Stem cell therapy on left ventricular function and myocardial perfusion
  4317. Cardiac Stem cell therapy: review of the native cardiac progenitor cells and future direction
  4318. Embryonic Stem cell therapy improves bone quality in a model of impaired fracture healing in the mouse; tracked temporally using in vivo micro-CT
  4319. Autologous mesenchymal Stem cell therapy for progressive supranuclear palsy: translation into a phase I controlled, randomized clinical study
  4320. Stem cell therapy for the treatment of nonischemic cardiomyopathy: a syStematic review of the literature and meta-analysis of randomized controlled trials
  4321. Stem cell therapy for the treatment of parasitic infections: is it far away?
  4322. Mesenchymal Stem cell therapy for neurodegenerative diseases
  4323. Intravenous mesenchymal Stem cell therapy after recurrent laryngeal nerve injury: a preliminary study
  4324. Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review
  4325. Mesenchymal Stem cell insights: prospects in cardiovascular therapy
  4326. Testing Stem cell therapy in a rat model of inflammatory bowel disease: role of bone marrow Stem cells and Stem cell factor in mucosal regeneration
  4327. Bone marrow Stem cell therapy for liver disease
  4328. … cord derived mesenchymal Stem cell therapy in children with severe aplastic anemia following allogeneic hematopoietic Stem cell transplantation: a retrospective …
  4329. Pluripotent Stem cell therapy in ischemic cardiovascular disease
  4330. Autologous Stem cell transplantation in refractory Asherman’s syndrome: A novel cell based therapy
  4331. Pathogenesis and Stem cell therapy for premature ovarian failure
  4332. Concepts of Dhatu Siddhanta (theory of tissues formation and differentiation) and Rasayana; probable predecessor of Stem cell therapy
  4333. Application of tissue engineering in Stem cell therapy
  4334. Comparative study between intravenous and intraperitoneal Stem cell therapy in amiodarone induced lung injury in rat
  4335. Stem cell therapy and breast cancer treatment: review of Stem cell research and potential therapeutic impact against cardiotoxicities due to breast cancer …
  4336. Stem cell therapy to treat heart ischaemia: implications for diabetes cardiovascular complications
  4337. Fate of graft cells: what should be clarified for development of mesenchymal Stem cell therapy for ischemic stroke?
  4338. Stem cell therapy: a new approach to the treatment of refractory depression
  4339. Stem cell therapy and cellular engineering for treatment of neuronal dysfunction in Huntington’s disease
  4340. Making choices: health consumers, regulation and the global Stem cell therapy market
  4341. Modification of radiation-induced oral mucositis (mouse) by adult Stem cell therapy: single-dose irradiation
  4342. Current perspectives in Stem cell therapy for spinal cord repair in humans: a review of work from the past 10 years
  4343. Current trends in Stem cell therapy for improvement of bone quality
  4344. Generation of iPSCs from Genetically Corrected Brca2 Hypomorphic cells: Implications in cell Reprogramming and Stem cell therapy
  4345. Prompt Bone Marrow-Derived Mesenchymal Stem cell therapy Enables Early Porcine Heart Function Recovery From Acute Myocardial Infarction Evaluation Using …
  4346. Echocardiographic evaluation of the effects of Stem cell therapy on perfusion and function in ischemic cardiomyopathy
  4347. In vitro and in vivo characteristics of connexin 43-modified human skeletal myoblasts as candidates for prospective Stem cell therapy for the failing heart
  4348. Exploring a new therapy for diabetic polyneuropathy–the application of Stem cell transplantation
  4349. cell therapy for kidney injury: different options and mechanisms-mesenchymal and amniotic fluid Stem cells
  4350. Induced pluripotent Stem cell therapy ameliorates hyperoxia-augmented ventilator-induced lung injury through suppressing the Src pathway
  4351. Stem cell–based biological pacemakers from proof of principle to therapy: a review
  4352. Autologous hematopoietic Stem cell therapy in severe syStemic sclerosis: ready for clinical practice?
  4353. Effects of Stem cell therapy on dilated cardiomyopathy
  4354. Moving Stem cell therapy to patients with idiopathic pulmonary fibrosis.
  4355. Stem cell–based therapy for neonatal lung disease: it is in the juice
  4356. Experimental cell therapy: the search for the best Stem cell continues
  4357. Regulation of heme oxygenase 1 expression by miR-27b with Stem cell therapy for liver regeneration in rats
  4358. Mesenchymal Stem cell therapy for the treatment of amyotrophic lateral sclerosis: signals for hope?
  4359. Role of mesenchymal Stem cell therapy in cisplatin induced nephrotoxicity in adult albino rats: ultrastructural & biochemical study
  4360. Stem cell therapy for cerebral palsy–a novel option
  4361. Role of serum levels of angiogenic cytokines in assessment of angiogenesis after Stem cell therapy of diabetic patients with critical limb ischemia
  4362. Mesenchymal Stem cell based therapy for osteo‐diseases
  4363. Stem cell therapy clears first hurdle in AMD
  4364. Stem cells and cell therapy
  4365. Lysosomal storage diseases: Stem cell-based cell-and gene-therapy.
  4366. Current status and perspectives in Stem cell therapy for heart
  4367. Introduction: Germline Stem cell therapy in humans: two are not enough
  4368. Advances in Stem cell therapy for erectile dysfunction
  4369. Advances in Stemcell–generated transplantation therapy for Parkinson’s disease
  4370. Quantification of corneal neovascularization after ex vivo limbal epithelial Stem cell therapy
  4371. Leaked files slam Stemcell therapy: disclosures and resignations reveal scientific concerns over methods of Italy’s stamina foundation
  4372. Transforming the promise of pluripotent Stem cell-derived cardiomyocytes to a therapy: challenges and solutions for clinical trials
  4373. Stem cell-based therapy for treating limbal Stem cells deficiency: A review of different strategies
  4374. Aldehyde dehydrogenase-2 is a host factor required for effective bone marrow mesenchymal Stem cell therapy
  4375. … -17Aneg regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal Stem cell–supported minimized immunosuppressive therapy
  4376. Stem cell therapy as an option for pediatric surgical conditions
  4377. Eculizumab therapy in children with severe hematopoietic Stem cell transplantation–associated thrombotic microangiopathy
  4378. Kallikrein-kinin in Stem cell therapy
  4379. Bone marrow Stemcell therapy for genetic and chronic liver diseases
  4380. The developing role of Neuregulin1 in cardiac regenerative Stem cell therapy
  4381. Inactive GSK3β is disturbed in the spinal cord during experimental autoimmune encephalomyelitis, but rescued by Stem cell therapy
  4382. Expanding the pool of Stem cell therapy for lung growth and repair
  4383. In utero Stem cell and gene therapy: current status and future perspectives
  4384. Allogeneic mesenchymal Stem cell transplantation for lupus nephritis patients refractory to conventional therapy
  4385. Human adipose-derived Stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy
  4386. Human embryonic Stem cell derived-mesenchymal Stem cells: an alternative mesenchymal Stem cell source for regenerative medicine therapy
  4387. … dose chemotherapy plus autologous Stemcell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous Stemcell
  4388. Stem cell based gene therapy in prostate cancer
  4389. Additional benefit of combined therapy with melatonin and apoptotic adipose‐derived mesenchymal Stem cell against sepsis‐induced kidney injury
  4390. Stem cell therapy for heart disease: truly beneficial?
  4391. Cost‐effectiveness of the introduction of specialized oral care with laser therapy in hematopoietic Stem cell transplantation
  4392. Back to the future! The evolving role of maintenance therapy after hematopoietic Stem cell transplantation
  4393. Neural Stem cell-mediated intratumoral delivery of gold nanorods improves photothermal therapy
  4394. … characteristics of amniotic membrane, endometrium and ovarian derived mesenchymal Stem cells: a role for amniotic membrane in Stem cell therapy
  4395. The promising potential of menstrual Stem cells for antenatal diagnosis and cell therapy
  4396. Adult Stem cell as new advanced therapy for experimental neuropathic pain treatment
  4397. Induction therapy with bortezomib and dexamethasone followed by autologous Stem cell transplantation versus autologous Stem cell transplantation alone in …
  4398. Critical appraisal of Stem cell therapy in peripheral arterial disease: Do current scientific breakthroughs offer true promise or false hope?
  4399. The metabolically-modulated Stem cell niche: a dynamic scenario regulating cancer cell phenotype and resistance to therapy
  4400. Gene therapy in patient-specific Stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects
  4401. The colon cancer Stem cell microenvironment holds keys to future cancer therapy
  4402. Effect of microenvironment modulation on Stem cell therapy for spinal cord injury pain
  4403. Favorable outcomes in elderly patients undergoing high-dose therapy and autologous Stem cell transplantation for non-Hodgkin lymphoma
  4404. Mesenchymal Stem cell-based therapy in a mouse model of experimental autoimmune encephalomyelitis (EAE)
  4405. Skin engineering and keratinocyte Stem cell therapy
  4406. Advances in Stem cell therapy: specific applications in the treatment of cutaneous radiation syndrome
  4407. Novel approaches and mechanisms in hematopoietic Stem cell gene therapy
  4408. Stem cell therapy for GI neuromuscular disorders
  4409. Evaluation of mesenchymal Stem cell migration after equine tendonitis therapy
  4410. Diminishing impairments in glucose uptake, mitochondrial content, and ADP-stimulated oxygen flux by mesenchymal Stem cell therapy in the infarcted heart
  4411. Mesenchymal Stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts
  4412. Response of primary glioblastoma cells to therapy is patient specific and independent of cancer Stem cell phenotype
  4413. Potential application of temozolomide in mesenchymal Stem cell‐based TRAIL gene therapy against malignant glioma
  4414. Stem cell therapy for organ failure
  4415. Application of nanoscaffolds in mesenchymal Stem cell-based therapy
  4416. Stem cell-based therapy for newborn lung and brain injury: feasible, safe, and the next therapeutic breakthrough?
  4417. Translational Opportunities in Stem cell–based Endodontic therapy: Where Are We and What Are We Missing?
  4418. Amniotic fluid Stem cell therapy for lung disease
  4419. Isolation and characterization of swine MIAMI cells: a valuable animal model for adult Stem cell therapy
  4420. Ewing’s sarcoma cancer Stem cell targeted therapy
  4421. From Flavr Savr tomatoes to Stem cell therapy: young people’s understandings of gene technology, 15 years on
  4422. Potential and limitation of HLA-based banking of human pluripotent Stem cells for cell therapy
  4423. Stem cell therapy: how to do it right
  4424. “Footprint-free” human induced pluripotent Stem cell-derived astrocytes for in vivo cell-based therapy
  4425. … and lineage independent anti-silencing activity of the A2 ubiquitous chromatin opening element for optimized human pluripotent Stem cell-based gene therapy
  4426. Improvement of cardiac Stem cell sheet therapy for chronic ischemic injury by adding endothelial progenitor cell transplantation: analysis of layer-specific regional …
  4427. Phase 2 trial of intravenously administered plerixafor for Stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy
  4428. Mesenchymal stromal (Stem) cell therapy: an emerging immunomodulatory strategy for the adjunctive treatment of sepsis
  4429. High-dose therapy and autologous Stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis
  4430. Aging as an essential modifier for the efficacy in mesenchymal Stem cell therapy through an inositol phosphate 6 kinase-inositol pyrophosphate 7-dependent …
  4431. Reply: mesenchymal stromal (Stem) cell therapy: an emerging immunomodulatory strategy for the adjunctive treatment of sepsis
  4432. Hematopoietic Stem cell gene therapy: progress on the clinical front
  4433. Mild hypothermia combined with neural Stem cell transplantation for hypoxic-ischemic encephalopathy: neuroprotective effects of combined therapy
  4434. Autologous Stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution
  4435. Rituximab maintenance therapy after autologous Stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma
  4436. Fibrin glue therapy for severe hemorrhagic cystitis after allogeneic hematopoietic Stem cell transplantation
  4437. Generation of osteoporosis in immune-compromised mice for Stem cell therapy
  4438. Clinical utilization of cord blood over human health: experience of Stem cell transplantation and cell therapy using cord blood in Korea
  4439. The role of N-acetyltransferase 8 in mesenchymal Stem cell-based therapy for liver ischemia/reperfusion injury in rats
  4440. Effects of intravenous human umbilical cord blood mesenchymal Stem cell therapy versus gabapentin in pentylenetetrazole-induced chronic epilepsy in rats
  4441. Granulocyte colony-stimulating factor therapy for Stem cell mobilization following anterior wall myocardial infarction: the CAPITAL Stem MI randomized trial
  4442. Establishment of endogenous human tympanic membrane-derived somatic Stem cells for Stem cell therapy
  4443. Lentiviral hematopoietic Stem cell gene therapy in inherited metabolic disorders
  4444. Stem cell therapy for necrotizing enterocolitis: innovative techniques and procedures for pediatric translational research
  4445. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic Stem cell transplant in asymptomatic children with sickle cell
  4446. Integrin β3 links therapy resistance and cancer Stem cell properties
  4447. Mesenchymal Stem cell therapy in multiple sclerosis: An updated review of the current clinical trials
  4448. … of unmanipulated haploidentical hematopoietic Stem cell transplantation compared with chemotherapy alone used as post-remission therapy in adults with …
  4449. Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent Stem cell-based myocardial therapy
  4450. Caudal superficial epigastric axial pattern flap and Stem cell therapy for the management of large wound on medial aspect of thigh in a dog
  4451. Anti-VEGF therapy (bevacizumab) for sulfur mustard-induced corneal neovascularization associated with delayed limbal Stem cell deficiency in rabbits
  4452. Induced pluripotent Stem cell-derived neural Stem cells transduced with baculovirus encoding CD40 ligand for immunogene therapy in mouse models of breast cancer
  4453. Autologous hematopoietic Stem cell transplantation and conventional insulin therapy in the treatment of children with newly diagnosed type 1 diabetes: long term …
  4454. Stem cell therapy: future of pain medicine
  4455. Music therapy for patients who have undergone hematopoietic Stem cell transplant
  4456. Antifungal agents for secondary prophylaxis based on response to initial antifungal therapy in allogeneic hematopoietic Stem cell transplant recipients with …
  4457. Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic Stem cell transplantation
  4458. Stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and cellular therapy
  4459. Willingness of a convenience sample of horse owners to use Stem cell therapy for the treatment of equine tendon injury and factors that influence this decision
  4460. Normalization of wound healing and Stem cell marker patterns in organ-cultured human diabetic corneas by gene therapy of limbal cells
  4461. Post-autologous (ASCT) Stem cell transplant therapy in multiple myeloma
  4462. Allogeneic Stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update
  4463. Stem cell therapy: the ethical issues
  4464. … consolidation combining yttrium-90 ibritumomab tiuxetan and high-dose therapy with Stem cell transplantation in poor-risk patients with diffuse large B cell
  4465. cell delivery routes for cardiac Stem cell therapy
  4466. … in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic Stem cell transplantation at early age
  4467. Mesenchymal Stem cell therapy for acute radiation syndrome: Innovative medical approaches in military medicine
  4468. Immunomodulatory nature and site specific affinity of mesenchymal Stem cells: a hope in cell therapy
  4469. Reflection of Stem cell therapy: an epilogue to the’Stem cells and the lung’review series
  4470. Stem cell and gene therapy for cardiac regeneration
  4471. Preconditioned Stem cells: a promising strategy for cell-based ischemic stroke therapy
  4472. Successful autologous haemopoietic Stem cell transplantation in severe, therapy-resistant childhood-onset Crohn’s disease. Report on the first case in Hungary
  4473. Cardiac Stem cell therapy: Checkered past, promising future?
  4474. Psychosocial changes associated with participation in art therapy interventions for siblings of pediatric hematopoietic Stem cell transplant patients
  4475. Stem cell therapy for spinal cord injury: cellular options
  4476. Stem cell therapy: differentiation potential of insulin producing cells from human adipose derived Stem cells and umbilical cord MSCs
  4477. Incidence of ventricular arrhythmias after Stem cell therapy in patients with Chagas cardiomyopathy
  4478. Stem cell therapy in Cardiovascular Diseases:: The Reparative Mechanisms of Mesenchymal Stem cells for Myocardial Infarction Treatment
  4479. Addressing the heart failure epidemic: from mechanical circulatory support to Stem cell therapy
  4480. Cancer Stem-like cell: a novel target for nasopharyngeal carcinoma therapy
  4481. cell therapy for Liver Disease: From Hepatocytes to Stem cells
  4482. Recent advances in cardiac Stem cell therapy to restore left ventricular function
  4483. cell games: clinical use of Stem cell therapy is starting to outpace the evidence
  4484. Mesenchymal Stem cell-based developmental endothelial locus-1 gene therapy for acute lung injury induced by lipopolysaccharide in mice
  4485. Combinatorial control of transgene expression by hypoxia-responsive promoter and microrna regulation for neural Stem cell-based cancer therapy
  4486. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic Stem cell transplantation
  4487. Intravenous autologous bone marrow mononuclear Stem cell therapy for ischemic stroke
  4488. The Sources of Microbial Contamination of Stem cells for Application in cell therapy
  4489. Busulfan and melphalan as consolidation therapy with autologous peripheral blood Stem cell transplantation following Children’s Oncology Group (COG) induction …
  4490. Stem cell transplantation as rescue therapy for refractory Crohn’s disease: a sytematic review.
  4491. Superior Long-Term Repopulating Capacity of G-CSF+Plerixafor-Mobilized Blood: Implications for Stem cell Gene therapy by Studies in the Hbbth-3 Mouse Model
  4492. Human Neural Stem cell-Based cell-and Gene-therapy for Neurological Diseases
  4493. Interim safety analysis: a phase I trial of high dose therapy and autologous Stem cell transplantation followed by infusion of chimeric antigen receptor modified …
  4494. The potential of Stem cell-based therapy for retinal repair
  4495. Evaluation of engraftment and immunological tolerance after reduced intensity conditioning in a rhesus hematopoietic Stem cell gene therapy model
  4496. Impurity of Stem cell graft by murine embryonic fibroblasts–implications for cell-based therapy of the central nervous syStem
  4497. TRAIL based therapy: Overview of mesenchymal Stem cell based delivery and miRNA controlled expression of TRAIL
  4498. Serial brain SPECT imaging in monitoring treatment response to Stem cell therapy in cerebral palsy patients
  4499. In Pursuit of Porcine Pluripotent Stem cells for Autologous cell therapy
  4500. T cell–depleted related HLA-mismatched peripheral blood Stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor …
  4501. Human transgene-free amniotic-fluid-derived induced pluripotent Stem cells for autologous cell therapy
  4502. The human desmin promoter drives robust gene expression for skeletal muscle Stem cell-mediated gene therapy
  4503. Investigating mesenchymal Stem cell therapy for ischemic repair
  4504. ATP-binding cassette (ABC) transporters as emerging targets in modulation of neural Stem cells behavior in neurodegenerative diseases and cell therapy benefits
  4505. A Novel In Vitro Method for Detecting Undifferentiated Human Pluripotent Stem cells as Impurities in cell therapy Products Using a Highly Efficient Culture …
  4506. Distribution of mesenchymal Stem cells and effects on neuronal survival and axon regeneration after optic nerve crush and cell therapy
  4507. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to Stem cell transplant in relapsed and refractory acute leukemia
  4508. Marked and rapid regression of hepatic amyloid deposition in a patient with syStemic light chain (AL) amyloidosis after high-dose melphalan therapy with Stem cell
  4509. Using Defined Neural cell Populations as a Possible Solution for Challenges in Neural Stem cell therapy
  4510. Cancer therapy targeting cancer Stem cell
  4511. Thalidomide and prednisolone versus prednisolone alone as consolidation therapy after autologous Stemcell transplantation in patients with newly diagnosed …
  4512. Front-line high dose therapy with following autologous Stem cell transplantation (ASCT) for follicular lymphoma patients
  4513. Age-associated alterations of pleiotropic Stem cell and the therapeutic implication of Stem cell therapy in aging
  4514. Heparan sulfate: a Stem cell therapy target?
  4515. … into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous Stem cell transplantation for multiple …
  4516. Allogeneic mesenchymal Stem cell therapy for knee osteoarthritis: safety and efficacy results of a randomized, double blind, phase 2, placebo controlled, dose finding …
  4517. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous Stem cell transplantation …
  4518. To the novel paradigm of proteome-based cell therapy of tumors: Through comparative proteome mapping of tumor Stem cells and tissue-specific Stem cells of humans
  4519. Pluripotent Stem cells on cell therapy
  4520. Gene therapy delivery of myelin oligodendrocyte glycoprotein (MOG) via hematopoietic Stem cell transfer induces MOG-specific B cell deletion
  4521. Gene-modified cells for Stem cell transplantation and cancer therapy
  4522. Urine-derived Stem cells: A novel and versatile progenitor source for cell-based therapy and regenerative medicine
  4523. Perspective of Stem cell research & therapy in diabetes
  4524. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous Stem cell transplantation for symptomatic multiple …
  4525. Stem cell therapy to promote sensory and motor nerve function recovery in a limb transplant model (TRAN3P. 863)
  4526. … and colony-forming progenitor cells in 50 patients with aplastic anemia after immunosuppressive therapy or hematopoietic Stem cell transplantation: a single-center …
  4527. Stem cell therapy Perspectives
  4528. Development of Stem cell therapy for Medical Uses
  4529. High-dose idarubicin plus busulfan as conditioning regimen to autologous Stem cell transplantation: Promising post-remission therapy for acute myeloid leukemia in …
  4530. Stem cells for cell replacement therapy: a therapeutic strategy for HD?
  4531. Cognitive change and neuroimaging following immunoablative therapy and hematopoietic Stem cell transplantation in multiple sclerosis: a pilot study
  4532. Stem cell therapy-A Review
  4533. … -PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and Stem cell mobilization after initial induction therapy
  4534. Regulatory T-cells Support Stem cell therapy in Safe Minimization of Immunosuppression in Living Donor Renal Transplantation-Initial Single Centre Experience …
  4535. Loss of donor chimerism in remission after allogeneic Stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy
  4536. Total ischemic time as an independent predictor of response to Stem cell therapy in patients with ST segment elevation myocardial infarction
  4537. P77: cell therapy approaches to enhancing neuro-regeneration after spinal cord injury: generation neural Stem cells from neurosphere-derived adipose Stem cells
  4538. Gene and Stem cell therapy
  4539. Presence of osteoclast precursor cells during ex vivo expansion of bone marrow-derived mesenchymal Stem cells for autologous use in cell therapy
  4540. Erratum to: Autologous fat transfer with in-situ mediation (AIM): a novel and compliant method of adult mesenchymal Stem cell therapy
  4541. Individualized Stem cell therapy
  4542. Stem cells So far! Stem cell therapy Facts and Principles
  4543. Lentiviral hematopoietic Stem cell gene therapy in patients with wiskott-Aldrich syndrome
  4544. Rituximab maintenance therapy after autologous Stem cell transplantation improves survival of patients with mantle cell lymphoma
  4545. Assessing the effectiveness of Gelclair® in the prevention and therapy of stomatitis in patients undergoing hematopoietic Stemcell transplantation: A randomized trial
  4546. Fetal-cell revival for Parkinson’s: moratorium on controversial therapy lifted as Stem cells emerge as alternative source of treatment
  4547. Intravitreal Autologous Bone Marrow CD34+ Stem cell therapy for Macular Degenerative Disease–A Pilot Clinical Trial
  4548. Stem cell therapy and heart failure: hopes and disappointments
  4549. Stem cell and Gene therapy in Cardiology.
  4550. Thalidomide, cyclophosphamide and dexamethasone induction therapy: feasibility for myeloma patients destined for autologous Stem cell transplantation
  4551. Vascular Stem cell therapy
  4552. Stem cell therapy of the eye
  4553. High-dose therapy and autologous hematopoietic Stem cell transplant in T-cell lymphoma: a single center experience
  4554. The application of Stem cell therapy in cardiovascular diseases
  4555. Stem cell-Based therapy (cell therapy) in Iran and other Countries
  4556. New Advanced Technologies in Stem cell therapy
  4557. AB08. Stem cell therapy in urology
  4558. Hematopoietic Stem cell based therapy of immunosuppressive viral infection—Numerical simulations
  4559. … -thalidomide-dexamethasone versus bortezomib-cyclophosphamide-dexamethasone as induction therapy prior to autologous Stem cell transplantation in multiple …
  4560. Combination cell therapy using mesenchymal Stem cells and regulatory T-cells provides a synergistic immunomodulatory effect associated with reciprocal regulation …
  4561. Stem cell-Based therapy (cell therapy) in Iran and other Countries
  4562. Stem cell-based therapy (cell therapy) in Iran and other countries
  4563. Effects of Stem cell therapy on dilated cardiomyopathy
  4564. H2S preconditioning of human adipose tissue-derived Stem cells increases their efficacy in an in vitro model of cell therapy for simulated ischemia
  4565. Animal Models for Stem cell therapy
  4566. Stem cell therapy for Diabetes Comes of Age
  4567. Stem cell therapy-challenges from bench to bedside
  4568. NHMRC Warning on unjustified claims relating to Stem cell therapy
  4569. … affecting outcome of allogeneic Stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy
  4570. Stem cell therapy and autism: A case study
  4571. Strategies to Improve Homing of Stem cells to achieve better Efficacy in Stem cell therapy
  4572. Immunnogenic aspects of Stem cell therapy in regenerative medicine
  4573. Strategies to Improve Homing of Stem cells to achieve better Efficacy in Stem cell therapy
  4574. Stem cell therapy for multiple sclerosis
  4575. Can pluripotent Stem cells be used in cell-based therapy?
  4576. Stem cell therapy: The Ultimate Cure
  4577. Advances in Cancer Stem cell therapy: Targets and Treatments
  4578. The role of Stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies
  4579. Stem cell therapy for erectile dysfunction
  4580. Stem cell therapy for preterm infants
  4581. Stem cell therapy–A Root for Dentistry
  4582. Stem cell therapy for Spinal Cord Injuries
  4583. Manipulating PHD2 to Promote Efficacy of Stem cell therapy for Myocardial Infarction
  4584. Bioprocessing of Human Pluripotent Stem cells for cell therapy Applications
  4585. Clinical trials of Stem cell therapy for ischemic stroke: a mini-review
  4586. Stem cell therapy for heart disease: too good to be true?
  4587. Biological characteristics of human-urine-derived Stem cells: potential for cell-based therapy in neurology
  4588. Stem cell therapy for neurodegenerative diseases: mind the gap
  4589. Stem cell therapy for Neurological Disorders: From Bench to Bedside
  4590. Stem cell therapy in Hypoxic Ischemic Encephalopathy
  4591. Stem cell therapy for Veterinary Orthopedic Lesions
  4592. Mesenchymal Stem cell therapy for the treatment of myocardial infarction
  4593. Treatment of liver disease using placental Stem cells: feasibility of placental Stem cells in liver diseases: potential implication of new cell therapy-based strategies for …
  4594. Myeloblative therapy with autologous haematopoietic Stem cell support as consolidation of first remission in acute myeloid leukaemia-very long follow-up.
  4595. Effects of sex hormones on Stem cells and Stem cell therapy for liver fibrosis
  4596. Features of transfusion therapy in patients undergoing hematopoietic Stem cell transplantation. Review of the literature
  4597. Towards Mesenchymal Stem cell therapy in Kidney Transplant Recipients
  4598. Italian doctors behind an unproved Stem cell therapy face prosecution
  4599. Stem cell therapy as a treatment for Ischemic stroke
  4600. Stem cell therapy as a treatment for ischemic stroke
  4601. ENGINEERING THREE DIMENSIONAL CULTURE PLATFORMS FOR HUMAN ADIPOSE DERIVED Stem cell therapy
  4602. Stem cell therapy in Premature Ovarian Failure
  4603. Failure of intensified induction therapy and inability to undergo Stem cell transplantation predict dismal outcomes in relapsed/refractory MYC+ B-cell
  4604. Using Stem cell therapy to Enhance Diabetic Wound Healing
  4605. Stem cell therapy for Acute and Chronic Liver Failure
  4606. Craniofacial Stem cell therapy: New light at the end of the tunnel
  4607. NEWS FROM THE JOINT MEETING OF ACTRIMS/ECTRIMS: Stem cell therapy in MS Looks Safe; Test of Efficacy Awaits Future Trials
  4608. Early Consolidation with High Dose therapy and Autologous Stem cell Transplantation in HIV-Associated Non Hodgkin Lymphoma at High Risk (aa-IPI 2-3) …
  4609. Impact of radiation therapy on Stem cell harvest in multiple myeloma
  4610. Stem cell therapy for obstructive nephropathy: current situation and problems
  4611. Long-Term Results of Stem cell therapy in Non-Reconstructable Critical Limb Ischemia
  4612. Recent advances in Stem cell therapy for myelodysplastic syndromes
  4613. Targeted mesenchymal Stem cell therapy for chronic obstructive pulmonary disease
  4614. Supramolecular Hyaluronate Hydrogels for Bioengineered Stem cell therapy
  4615. Molecular characterization of human mesenchymal Stem cell differentiation to identify biomarkers for quality assurance in Stem cell therapy
  4616. Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic Stem cell transplantation in myeloma patients with solitary kidney: a case series
  4617. High Dose therapy with Autologous Stem cell Transplantation (HDT/ASCT) Support in Follicular Lymphoma (FL) a Very Long Follow-up Analysis of 640 …
  4618. Stem cell therapy and regenerative biology: Implication on success of ocular regeneration Virendra S Sangwan, Vivek Singh 2, Sachin Shukla 2, Dilip
  4619. Stem cell therapy in animal models of central nervous syStem (CNS) diseases: therapeutic role, challenges and perspectives
  4620. Adoptive lymphocyte (Stem cell) therapy in cancer
  4621. From mesenchymal Stem cell therapy to discovery of drug therapy for syStemic sclerosis
  4622. PNUH Experience of Stem cell therapy for Airway Allergic Diseases in Animal Model
  4623. Repeated intranasal application of neural Stem cell-mediated enzym/prodrug therapy using a novel hsv-thymidine kinase variant improves therapeutic efficiency in an …
  4624. Stem cell therapy for Cardiac Tissue Regeneration Post-myocardial Infarction
  4625. … response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous Stem cell transplantation: phase II …
  4626. Smart Supramolecular Hydrogels for Long-term Bioengineered Stem cell therapy
  4627. Physical therapy during the hemopoietic Stem cell transplant process to improve quality of life
  4628. Nanotechnology for improvement of Stem cell therapy of laser damaged retina in an animal model
  4629. Stem cell therapy and Curcumin Synergistically Enhance Recovery from Spinal
  4630. Hepatic cell proliferation and outcome in alcoholic hepatitis: histology, gene expression and effect of Stem cell therapy.
  4631. Clinical Gene and Stem cell therapy in Patients with Acute and Chronic Myocardial Ischemia
  4632. High dose therapy and autologous Stem cell transplantation in marginal zone lymphoma: an EBMT-FIL-gimeto retrospective study
  4633. Application of Stem cell therapy for dilated cardiomyopathy: a syStematic review and meta-analysis of randomized controlled trials
  4634. first generation Stem cell therapy for ischemic heart disease: a review, a meta-analysis and future prospectives
  4635. The Stem cell therapy to Prevent Expansion of Abdominal Aortic Aneurysm (STOP-AAA) Trial: Rationale and Design
  4636. Preclinical Validation of Multilevel Intraspinal Stem cell therapy for Amyotrophic Lateral Sclerosis (ALS)
  4637. … -e0810 Intravenous ferumoxytol before mesenchymal Stem cell harvest: a new method for tracking Stem cell with MR imaging in cell therapy for myocardial infarction
  4638. Stem cell therapy for Healing Wounded Skin and Soft Tissues
  4639. Optimizing Performance of Endogenous Neural Stem cell therapy for Ischemic Stroke: A Neuroinformatics and Neuroimaging Approach to Translational Medicine
  4640. Inducible Metabolic Adaptation Promotes Mesenchymal Stem cell therapy for Ischemia
  4641. … , cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous Stem cell transplantation results in …
  4642. Antibiotic Prophylaxis therapy for Pediatric Patients Undergoing Hematopoietic Stem cell Transplant (HSCT): A Tale of 2 Centers
  4643. The use of Stem cell therapy in the treatment of bone marrow aplasia improves blood biochemical parameters in a dog
  4644. T-cell therapy for viral infections after hematopoietic Stem cell transplantation in the 55th ASH annual meeting
  4645. Engineering cardiomyocytes from diverse human pluripotent Stem cell lines for cardiac cell therapy with optimized cell yield and efficiency
  4646. Autologous adipose-derived Stem cell therapy improves pain and improves function in patients with osteoarthritis
  4647. Mesenchymal Stem cell therapy to Promote Sensory and Motor Nerve Function in a Limb Transplant Model.: Abstract# C1574
  4648. Autologous bone marrow derived Stem cell therapy in traumatic spinal cord injury: A case report and review of literature
  4649. Stem cell-based therapy in orthopaedics and trauma surgery-current concepts
  4650. Optimising Stem cell therapy for liver disease through modulation of sphingosine 1-phosphate signalling
  4651. Editorial (Thematic Issue: Unlocking the Potential of Stem cells in cell therapy, Drug Delivery and Drug Discovery)
  4652. Neuro-regenerative effect of autologous mesenchymal Stem cell therapy in cerebral palsy patients: pilot clinical trial
  4653. PP-348 Adipose Tissue Derived Stem cell therapy for Diabetic Foot
  4654. Adipose tissue derived stromal Stem cell therapy in murine ConA-derived hepatitis is dependent on myeloidlineage and CD4+ T-cell suppression
  4655. Role of bone marrow-derived Stem cell therapy in treatment of experimentally induced type 1 diabetes mellitus in canine model
  4656. Glycan-based biomarkers for the quality assurance in Stem cell therapy: cell surface N-glycosylation of human Stem cells and its changes during the process of …
  4657. Investigating reorganization of the motor cortices following Stem cell therapy in a non-human primate model of cortical ischemia
  4658. Combination of nitric oxide therapy, anti-oxidative therapy, low level laser therapy, plasma rich platelet therapy and Stem cell therapy as a novel therapeutic …
  4659. Human embryonic Stem cell-derived mesenchymal Stem cells as a therapy for spinal cord injury
  4660. Designing a Fibrin Scaffold for Lung Resident Mesenchymal Stem cell therapy in Emphysema Patients
  4661. Mesenchymal Stem cell-based cancer gene therapy: Application and unresolved problems
  4662. Vascular Stem cell therapy of the diabetic retina with COMP-Ang1 and endothelial progenitor cells
  4663. Induction therapy for advanced-stage Hodgkin lymphoma: late intensification (ABVD chemotherapy followed by high-dose chemotherapy and autologous Stem cell
  4664. A New Horizon in Facial Plastic Surgery: Skin Tissue-Engineering and Stem cell therapy—Reality or Dream?
  4665. The Efficacy and Safety of Mesenchymal Stem cell therapy in Chronic Antibody-Mediated Rejection After Kidney Transplantation.: Abstract# C1578
  4666. Reduced-intensity allogeneic Stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic …
  4667. Adipose-derived mesenchymal Stem cell therapy for radiation-induced vascular injury in small intestine of rat
  4668. Stem cell transplantation as rescue therapy for refractory Crohn’s disease: a sytematic review
  4669. Expression of concern: Autologous fat transfer with in-situ mediation (AIM): a novel and compliant method of adult mesenchymal Stem cell therapy
  4670. Ex Vivo Primed Mesenchymal Stem cell therapy Prevents Endothelial Failure and Enhances Allograft Perfusion
  4671. Different artificial bones combined with bone marrow mesenchymal Stem cell therapy for early osteonecrosis of the femoral head: controversy and progress
  4672. … : Diminishing impairments in glucose uptake, mitochondrial content, and ADP-stimulated oxygen flux by mesenchymal Stem cell therapy in the infarcted heart
  4673. Improvement of dopamine transporter binding after bone marrow mesenchymal Stem cell therapy in a rat model of Parkinson’s disease: Small animal PET studies with …
  4674. A Canadian cost impact analysis comparing maintenance therapy with bortezomib versus lenalidomide in multiple myeloma patients ineligible for Stem cell transplant
  4675. … after Allogeneic Stem cell Transplantation for Myelodysplastic Syndromes: A Study from the French Society of Bone Marrow Transplantation and cell therapy (SFGM …
  4676. The use of mesenchymal Stem cells in therapy of steroid-resistance chronic refractory graft-versus-host disease after hematopoietic Stem cell transplantation
  4677. Effect of temperature sensitive umbilical cord mesenchymal Stem cell therapy combined with mild hypothermia on cognitive function in rats of severe traumatic brain …
  4678. Microbubble spectroscopy of microbubble-loaded Stem cells for targeted cell therapy
  4679. … with newly diagnosed myeloma: a phase 2 trial assessing the impact of Minimal Residual Disease (MRD) in patients with deferred autologous Stem cell
  4680. 1844707 Ultrasound for Evaluation of Adipose Stem cell therapy for End-Stage Unresectable Peripheral Arterial Disease: Case Studies Elizabeth Turner,* Arturo …
  4681. Application of allogenic Stem cells in the treatment of tendon injuries: clinical case reports of cell therapy in horses
  4682. Mesenchymal Stem cell based therapy for osteo-diseases
  4683. IS-051 Neural Embryonic Stem/isps cell therapy
  4684. Potential therapy of intravenous neural Stem cell transplantation for psychiatric disorder–a strategy for facilitation of neural network and behavioral recovery
  4685. Efficacy and side effects of maintenance therapy with thalidomide following Stem cell transplantation in patients with multiple myeloma
  4686. … : Long-Term Survival and Impact of Donor Availability–Clofarabine Salvage therapy Prior to Allogeneic Hematopoietic Stem cell Transplantation in Patients …
  4687. Oral valganciclovir as preemptive therapy for cytomegalovirus infection in allogeneic hematopoietic Stem cell transplant recipients
  4688. Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose therapy Followed By Autologous Stem cell
  4689. … REGULATES TUMOR RESISTANCE TO ANTIANGIOGENIC therapy THROUGH EMT AND ANGIOGENESIS-RELATED MECHANISMS IN GLIOMA Stem cell
  4690. Immunologic outcomes of allogeneic Stem cell transplantation: graft-versus-host and graft-versus-leukemia responses and implications for future therapy
  4691. Successful Stem cell mobilization with high-dose cytarabine plus G-CSF after lenalidomide therapy for multiple myeloma-a series of four cases
  4692. Allogeneic Hematopoietic Stem cell Transplantation Is an Effective Salvage therapy for Patients with Chronic Myeloid Leukemia Failing Treatment with …
  4693. Stem cell AND GENE therapy FOR HEART FAILURE
  4694. cell-based therapy for acute organ injury: preclinical evidence and ongoing clinical trials using mesenchymal Stem cells
  4695. Mesenchymal Stem cells for regenerative therapy: optimization of cell preparation protocols
  4696. Gene therapy of Limbal cells Alleviates Wound Healing and Stem cell Marker Abnormalities in Organ-Cultured Human Diabetic Corneas
  4697. Hematopoefic-‐Stem-‐cell based therapy for HIV disease
  4698. Stem cell Biomarkers in Early Diagnosis, Prognosis, and therapy of Cancer
  4699. Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic Stem cell transplantation
  4700. Stem cell Biomarkers in Early Diagnosis, Prognosis, and therapy of Cancer
  4701. Hereditary cerebellar degeneration and Stemcell based therapy
  4702. … as an advanced therapy medicinal product (ATMP), for the treatment of ADV infections following an allogeneic haematopoietic Stem cell transplantat (allo-HSCT)
  4703. Mesenchymal Stem cell-Based therapy for Prostate Cancer
  4704. Investigating the potential of Stem cell based therapy in murine models of Alzheimer’s disease
  4705. The Role of Occupational therapy and Its Impact on Quality of Life for the Pediatric Stem cell Recipient
  4706. … vzYro-cultivation of human oral mucosa epithelial cells and tissue explants as a modem method for applications in therapy of limbal Stem cell deficiency. A pilot …
  4707. Cardiac cell Replacement therapy With Pluripotent Stem cell Derived Cardiomyocytes
  4708. SC-07 cyclic intranasal application of neural Stem cell-mediated enzym/prodrug therapy using a novel HSV-thymidine kinase variant inhibits intracerebral glioma …
  4709. … PLATELET SUPERNATANT CAN AUGMENT THE ANGIOGENIC POTENTIAL OF PERIPHERAL BLOOD Stem cells IN Stem cell-BASED therapy
  4710. Effect of therapy” in vitro” with Stem cell of bone marrow in mammary tumors canine.
  4711. … ‐10: Level of Breast Cancer Stem cell Correlated with Tumor Radioresistence: An Indication for Individualized Breast Cancer therapy Adapted to Cancer Stem cell
  4712. Laser Induced Mouse Glaucoma Model Suitable for Studying Stem cell-based therapy
  4713. cells from Mobilized Peripheral Blood Stem cell (PBSC) Collections As an Integral Part of Hematopoietic Stem cell Transplantation (HSCT) and cellular therapy (CT …
  4714. Recovery of IgG Production Following Rituximab therapy after Allogeneic Stem cell Transplantation
  4715. High-dose therapy combined with autologous peripheral blood Stem cell transplantation in patients with peripheral T-cell lymphoma: a retrospective study
  4716. Stem cells as a Source for cell therapy in Parkinson’s Disease
  4717. Bortezomib-based induction therapy followed by autologous hematopoietic Stem cell transplantation in multiple myeloma
  4718. Allogeneic Hematopoietic Stem cell Transplantation for therapy-Related Acute Myeloid Leukemia
  4719. Biological and synthetic membranes for human induced pluripotent Stem cell-based transplantation therapy
  4720. 20. Development of Lentiviral Mediated Stem cell Gene therapy for Mucopolysaccharidosis Type IIIA
  4721. High-Dose Chemotherapy and Autologous Stem cell Rescue therapy for High-Risk Neuroblastoma Patients
  4722. Treatment-resistant depression requiring electroconvulsive therapy following Stem cell transplantation
  4723. Gene therapy on patient-specific Stem cell lines with MFRP defect
  4724. Preclinical studies of EpCAM-targeted therapy for human hepatocellular carcinoma with specific inhibition of Stem cell features
  4725. Clinical effectiveness of high dose immunosuppressive therapy with autologous hematopoietic Stem cell transplantation in multiple sclerosis patients.
  4726. Comparison the Clinical Efficacy of Autologous Hematopoietie Stem cell Transplantation and Traditional Insulin therapy in Newly Diagnosed Primary Childhood …
  4727. Personalizing busulfan therapy for children undergoing hematopoietic Stem cell transplantation
  4728. The Potential Use of Skin-derived Precursors (SKPs) in Stemcell Based therapy for Hirschsprung’s Disease
  4729. Adipose Derived Stem cell (ADSC) therapy Prevents The Progression Of Hypertension And Improves Cardiac Functions
  4730. … Siriraj Hospital, Mahidol University, Bangkok, Thailand. 3Unit of Stem cell Research and Development for Medicine therapy, Department of Obstetrics and
  4731. Induction therapy with bortezomib and dexamethasone followed by autologous Stem cell transplantation versus autologous Stem cell transplantation alone in …
  4732. Bioprocess engineering of induced pluripotent Stem cells for application in cell therapy and pre-clinical research
  4733. Functionalization of carbon nanotubes for mesenchymal Stem cell-assisted photothermal therapy
  4734. Graft-versus-host disease, a major complication after Stem cell transplantation–home care for prevention and stromal cells for therapy
  4735. Oxymetholone therapy of Fanconi Anemia Induces Hematopoietic Stem cell Cycling By Suppressing Osteopontin Transcription
  4736. Canine Adipose Tissue Derived Stem cell Administration as Adjuvant therapy for Chronic Hepatitis in Dog
  4737. Necessary Stem cell transplantation using myeloablative therapy for myelodysplastic syndrome with progression of genotypic abnormalities and TP 53 dysfunction in a …
  4738. Dose intensity and autologous Stem cell transplantation as salvage therapy for pediatric primary CNS malignancies
  4739. … : AUTOLOGOUS Stem cell TRANSPLANT FOLLOWING AN ORTHOTOPIC HEART TRANSPLANT AND CYTOXAN/BORTEZOMIDE/DEXAMETHASONE therapy
  4740. … on FDG-PET and Multiple Lines of Prior therapy Predict Poorer Outcomes Following Autologous Hematopoietic Stem cell Transplantation for Lymphoma
  4741. Development of a Unique Anti-AML Immune therapy Consisting of Cord Blood HSCT and Cord Blood Stem cell-Derived Dendritic cell (CB-DC) Vaccination
  4742. Outcomes in Patients on Hemodialysis Who Undergo High Dose therapy Followed By Autologous Peripheral Blood Stem cell Transplant for Multiple …
  4743. Cord blood Stem cell transplantation combined with traditional Chinese therapy for kidney nourishing and dampness elimination in treatment of patients with Child A or …
  4744. therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem
  4745. Most patients with germ cell tumors will be cured with local therapy and/or standard chemotherapy. When relapse occurs, two salvage treatment paradigms exist …
  4746. Synergistic effect of human tubal mesenchymal Stem cell (htMSCs) and low level laser (LLL) therapy significantly reduces experimental COPD in mice
  4747. Rituximab, Age and High Dose therapy Followed By Autologus Stem cell Transplantation Are Independent Prognostic Factors for Survival in the First Line …
  4748. Induction therapy with Bortezomib and Dexamethasone Followed By Autologous Stem cell Transplantation for SyStemic Light Chain Amyloidosis: Our …
  4749. OB-30: A Novel cell therapy source for preterm premature rupture of membrane using amnionic epithelial Stem cells: Preliminary study
  4750. Targeting Interleukin-2 to the Bone Marrow Stroma for therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem cell Transplantation
  4751. therapy Predicts a Favorable Outcome in Patients with Acute Myeloid Leukemia and an Intermediate Risk Karyotype Undergoing Allogeneic Stem cell
  4752. … Agents for Secondary Prophylaxis Based on Response to Initial Antifungal therapy in Allogeneic Hematopoietic Stem cell Transplant Recipients with Prior …
  4753. A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous Stem cell transplantation (ASCT) in patients with multiple …
  4754. … to Induction or High Dose therapy, Pre/Post Transplant PET Negativity and Absence of Minimal Residual Disease within Mobilized Stem cell Graft Predict Long Term …
  4755. therapy with Deferasirox Is a Favorable Prognostic Factor in Iron-Overloaded Patients with Severe Apastic Anemia Undergoing Allogeneic Stem cell
  4756. … 1 Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide As Preparative therapy for Autologous Stem cell Transplant in Acute …
  4757. Dose-escalation study using novel continuous flow intracoronary delivery of allogeneic cardiosphere-derived Stem cells: is there a threshold for cell therapy?
  4758. The assessment of immunomodulatory effects of cell therapy in multiple sclerosis patients after autologous mesenchymal/stromal Stem cells transplantation
  4759. … of umbilical cord processing techniques and multiparametric immunophenotyping of umbilical cord Wharton’s jelly mesenchymal Stem cells for cell therapy
  4760. Are umbilical cord mesenchymal Stem cells advantageous over bone marrow mesenchymal Stem cells for cell therapy in orthopaedics?
  4761. Pituitary cell differentiation from Stem cells and other cells: toward restorative therapy for hypopituitarism?
  4762. PRECONDITIONING HUMAN Stem cells WITH OXYTOCIN TO OPTIMIZE cell therapy FOR THE TREATMENT OF CARDIOVASCULAR DISEASE
  4763. Lentiviral mediating genetic engineered mesenchymal Stem cells for releasing IL-27 as a gene therapy approach for autoimmune diseases. cell J. 2014; 16 (3) …
  4764. Effect of amniotic membrane-derived mesenchymal Stem cells on innate immune syStem and a their usefulness in ocular cell therapy
  4765. Targeted therapy of leukemia Stem cells (LSCs) in PTEN-deficient T-cell acute lymphoblastic leukemia (T-ALL)
  4766. … ACTIVITIES OF MESENCHYMAL Stem AND STROMAL cells: Optimal Dose And Mechanism Of Action Of Human Mesenchymal Stromal cell therapy In E. coli …
  4767. Stem cells Induced In Vitro Generation of Antigen Specific Regulatory T-cells Containing CD4+ CD8+ Population: A cell-Based therapy To Promote Transplantation …
  4768. In vitro characterization of Stem/progenitor cells from semitendinosus and gracilis tendons as a possible new tool for cell-based therapy for tendon disorders
  4769. … of immunity T-cell link state and content of cancer Stem cells as criterion to estimate efficiency of preventive breast cancer therapy with cryopreserved fetal liver cells
  4770. … Institute, 2Vita-Salute University, 3San Raffaele Telethon Institute for Gene therapy (HSR-TIGET), Division of Regenerative Medicine, Gene therapy and Stem
  4771. Human umbilical cord mesenchymal Stem cells: a new era for Stem cell therapy
  4772. Mesenchymal Stem cell therapy for liver fibrosis
  4773. Stem cell therapy for intervertebral disc regeneration: obstacles and solutions
  4774. Strategies to improve homing of mesenchymal Stem cells for greater efficacy in Stem cell therapy
  4775. Mesenchymal Stem cell therapy for osteoarthritis: current perspectives
  4776. Application of encapsulation technology in Stem cell therapy
  4777. Stem cell therapy for inflammatory bowel disease
  4778. Autologous Stem cell therapy: how aging and chronic diseases affect Stem and progenitor cells
  4779. Stem cell therapy for Alzheimer’s disease and related disorders: current status and future perspectives
  4780. Mesenchymal Stem cell therapy for autoimmune disease: risks and rewards
  4781. Mesenchymal Stem cell therapy for inflammatory bowel disease: a syStematic review and meta-analysis
  4782. Long-term results of adipose-derived Stem cell therapy for the treatment of Crohn’s fistula
  4783. Stem cell therapy for retinal diseases
  4784. Our fat future: translating adipose Stem cell therapy
  4785. Effect of aging on human mesenchymal Stem cell therapy in ischemic cardiomyopathy patients
  4786. A safeguard syStem for induced pluripotent Stem cell-derived rejuvenated T cell therapy
  4787. Stem cell therapy in the management of shoulder rotator cuff disorders
  4788. Mesenchymal Stem cell therapy for cirrhosis: present and future perspectives
  4789. Stem cell therapy: challenges ahead
  4790. Stem cell therapy for chronic heart failure
  4791. Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?
  4792. Sepsis induces long-term metabolic and mitochondrial muscle Stem cell dysfunction amenable by mesenchymal Stem cell therapy
  4793. Bone engineering of maxillary sinus bone deficiencies using enriched CD90+ Stem cell therapy: a randomized clinical trial
  4794. Stem cell therapy and tissue engineering for correction of congenital heart disease
  4795. Autologous, allogeneic, induced pluripotent Stem cell or a combination Stem cell therapy? Where are we headed in cartilage repair and why: a concise review
  4796. Supramolecular hydrogels for long‐term bioengineered Stem cell therapy
  4797. Stem cell therapy in cats with chronic enteropathy: a proof-of-concept study
  4798. The emergence of Stem cell therapy for patients with congenital heart disease
  4799. Stem cell therapy for glaucoma: science or snake oil?
  4800. Stem cell therapy for heart failure
  4801. Stem cell therapy in brain trauma: implications for repair and regeneration of injured brain in experimental TBI models
  4802. Ambivalent journeys of hope: Embryonic Stem cell therapy in a clinic in India
  4803. Caveats of mesenchymal Stem cell therapy in solid organ transplantation
  4804. Stem cell therapy for corneal epithelium regeneration following good manufacturing and clinical procedures
  4805. Patient-specific age: the other side of the coin in advanced mesenchymal Stem cell therapy
  4806. cell therapy using human induced pluripotent Stem cell-derived renal progenitors ameliorates acute kidney injury in mice
  4807. Exosomes as potential alternatives to Stem cell therapy in mediating cardiac regeneration
  4808. Adoptive T-cell therapy of prostate cancer targeting the cancer Stem cell antigen EpCAM
  4809. Mesenchymal Stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine
  4810. Regeneration of the retina: toward Stem cell therapy for degenerative retinal diseases
  4811. Efficacy of mesenchymal Stem cell therapy for steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic Stem cell transplantation: a …
  4812. Allogenic benefit in Stem cell therapy: cardiac repair and regeneration
  4813. Stem cell therapy: A novel treatment approach for oral mucosal lesions
  4814. Stem cell therapy for kidney disease
  4815. Conjugated polymer nanodots as ultrastable long‐term trackers to understand mesenchymal Stem cell therapy in skin regeneration
  4816. Stem cell therapy for myocardial infarction 2001–2013 revisited
  4817. Comparative analysis of human mesenchymal Stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy
  4818. Trans-amniotic Stem cell therapy (TRASCET) minimizes Chiari-II malformation in experimental spina bifida
  4819. Effects of nitric oxide on Stem cell therapy
  4820. Concise review: mesoangioblast and mesenchymal Stem cell therapy for muscular dystrophy: progress, challenges, and future directions
  4821. Role of angiotensin II in Stem cell therapy of cardiac disease
  4822. Translational applications of molecular imaging in cardiovascular disease and Stem cell therapy
  4823. Mesenchymal Stem cell therapy alleviates interstitial cystitis by activating Wnt signaling pathway
  4824. Mesenchymal Stem cell therapy in proteoglycan induced arthritis
  4825. Stem cell therapy for amyotrophic lateral sclerosis
  4826. High tibial osteotomy in combination with chondrogenesis after Stem cell therapy: a histologic report of 8 cases
  4827. Stem cell therapy for sensorineural hearing loss, still alive?
  4828. Effects of mesenchymal Stem cell therapy, in association with pharmacologically active microcarriers releasing VEGF, in an ischaemic stroke model in the rat
  4829. Stem cell therapy in intracerebral hemorrhage rat model
  4830. The clinical status of Stem cell therapy for ischemic cardiomyopathy
  4831. Stem cell therapy for erectile dysfunction of cavernous nerve injury rats: a syStematic review and meta-analysis
  4832. Delayed administration of allogeneic cardiac Stem cell therapy for acute myocardial infarction could ameliorate adverse remodeling: experimental study in …
  4833. Research progress in animal models and Stem cell therapy for Alzheimer’s disease
  4834. Engineered composite fascia for Stem cell therapy in tissue repair applications
  4835. Stem cell therapy for myocardial infarction: challenges and prospects
  4836. Biological effects and mechanisms of action of mesenchymal Stem cell therapy in chronic obstructive pulmonary disease
  4837. Adipose derived mesenchymal Stem cell therapy in the treatment of isolated knee chondral lesions: design of a randomised controlled pilot study comparing …
  4838. Could Stem cell therapy be the cure in liver cirrhosis?
  4839. Novel treatment strategies for feline chronic kidney disease: A critical look at the potential of mesenchymal Stem cell therapy
  4840. Sweat gland regeneration after burn injury: is Stem cell therapy a new hope?
  4841. Comparative effects of mesenchymal Stem cell therapy in distinct stages of chronic renal failure
  4842. Mesenchymal Stem cell therapy for doxorubicin cardiomyopathy: hopes and fears
  4843. Stem cell therapy in multiple sclerosis: a future perspective
  4844. The future of Stem cell therapy for stroke rehabilitation
  4845. Nicorandil enhances the efficacy of mesenchymal Stem cell therapy in isoproterenol-induced heart failure in rats
  4846. Bone marrow mesenchymal Stem cell aggregate: an optimal cell therapy for full-layer cutaneous wound vascularization and regeneration
  4847. The coming of age of adoptive T-cell therapy for viral infection after Stem cell transplantation
  4848. Stem cell therapy for bronchopulmonary dysplasia: bench to bedside translation
  4849. Stem cell therapy for cardiovascular diseases: a progressive journey
  4850. Combining enriched environment, progesterone, and embryonic neural Stem cell therapy improves recovery after brain injury
  4851. Allogeneic mesenchymal Stem cell therapy outcomes for three patients with spinal muscular atrophy type 1
  4852. Importance of the Stem cell microenvironment for ophthalmological cell-based therapy
  4853. Stem cell therapy in spinal trauma: Does it have scientific validity?
  4854. Stem cells-biological update and cell therapy progress
  4855. Stem cell therapy: a novel treatment option for cerebral malaria?
  4856. Papilla regeneration by injectable Stem cell therapy with regenerative medicine: long‐term clinical prognosis
  4857. Repair of ischemic injury by pluripotent Stem cell based cell therapy without teratoma through selective photosensitivity
  4858. Stem cell therapy: current applications and potential for urology
  4859. New immunosuppressive cell therapy to prolong survival of induced pluripotent Stem cell–derived allografts
  4860. Effect of allogeneic limbal mesenchymal Stem cell therapy in corneal healing: role of administration route
  4861. The future of Stem cell therapy in hernia and abdominal wall repair
  4862. Dual protective and cytotoxic benefits of mesenchymal Stem cell therapy in combination with chemotherapy/radiotherapy for cancer patients
  4863. Adipose Tissue-Derived Stem cell therapy for Post-Surgical Breast Reconstruction–More Light than Shadows.
  4864. Devices for Stem cell isolation and delivery: current need for drug discovery and cell therapy
  4865. Opportunities and challenges: Stem cell‐based therapy for the treatment of ischemic stroke
  4866. Translational research of adult Stem cell therapy
  4867. Stem cell therapy for CHD: Towards translation
  4868. Next-generation Stem cell therapy poised to enter EU market
  4869. Adipose tissue-derived Stem cell therapy in rat cryopreserved ovarian grafts
  4870. Thioredoxin-1 (Trx1) engineered mesenchymal Stem cell therapy increased pro-angiogenic factors, reduced fibrosis and improved heart function in the infarcted rat …
  4871. Bladder recovery by Stem cell based cell therapy in the bladder dysfunction induced by spinal cord injury: syStematic review and meta-analysis
  4872. Stem cell hype: media portrayal of therapy translation
  4873. Inner ear cell therapy targeting hereditary deafness by activation of Stem cell homing factors
  4874. Priming mesenchymal Stem cells with endothelial growth medium boosts Stem cell therapy for syStemic arterial hypertension
  4875. Stem cell therapy for neurodegenerative diseases
  4876. Mesenchymal Stem cell therapy for retinal ganglion cell neuroprotection and axon regeneration
  4877. … novel and effective strategy for the isolation of adipose-derived Stem cells: minimally manipulated adipose-derived Stem cells for more rapid and safe Stem cell therapy
  4878. Development of gene and Stem cell therapy for ocular neurodegeneration
  4879. Modern Stem cell therapy: approach to disease
  4880. A proposed novel Stem cell therapy protocol for liver cirrhosis
  4881. Cancer Stem cell targeted therapy: progress amid controversies
  4882. Preventing Stem cell transplantation-associated viral infections using T-cell therapy
  4883. Mesenchymal Stem cell therapy: clinical progress and opportunities for advancement
  4884. Preclinical validation of multilevel intraparenchymal Stem cell therapy in the porcine spinal cord
  4885. Bronchopulmonary dysplasia and chronic lung disease: Stem cell therapy
  4886. … failure secondary to chronic overload in congenital heart diseases: Benefits of cell therapy using human embryonic Stem cell–derived cardiac progenitors
  4887. Combination cell therapy with mesenchymal Stem cells and neural Stem cells for brain stroke in rats
  4888. cell adhesion and long-term survival of transplanted mesenchymal Stem cells: a prerequisite for cell therapy
  4889. … -short branch PEI in miR122 gene delivery: accelerated differentiation of iPSCs into mature hepatocyte-like cells and improved Stem cell therapy in a hepatic failure …
  4890. Mesenchymal Stem cell therapy for acute respiratory distress syndrome: a light at the end of the tunnel?
  4891. Stem cell transplantation therapy in Parkinson’s disease
  4892. Stem cell therapy in injured vocal folds: a three-month xenograft analysis of human embryonic Stem cells
  4893. Manganese‐Enhanced Magnetic Resonance Imaging Enables In Vivo Confirmation of Peri‐Infarct Restoration Following Stem cell therapy in a Porcine Ischemia …
  4894. Update on mesenchymal Stem cell-based therapy in lupus and scleroderma
  4895. Effect of low-level laser therapy on mesenchymal Stem cell proliferation: a syStematic review
  4896. Development of Stem cell-based therapy for Parkinson’s disease
  4897. Genetically engineered mesenchymal Stem cell therapy using self-assembling supramolecular hydrogels
  4898. Bone marrow-derived Stem cell therapy for metastatic brain cancers
  4899. An effective strategy of magnetic Stem cell delivery for spinal cord injury therapy
  4900. Does adipose tissue-derived Stem cell therapy improve graft quality in freshly grafted ovaries?
  4901. Methods of liver Stem cell therapy in rodents as models of human liver regeneration in hepatic failure
  4902. Stem cell therapy for corneal regeneration medicine and contemporary nanomedicine for corneal disorders
  4903. Immunologic network and response to intramyocardial CD34+ Stem cell therapy in patients with dilated cardiomyopathy
  4904. Development of an encapsulated Stem cell-based therapy for diabetes
  4905. Efficacy of autologous Stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study
  4906. Mesenchymal Stem cell therapy in nonhematopoietic diseases
  4907. Stem cell-paved biobridges facilitate Stem transplant and host brain cell interactions for stroke therapy
  4908. Stem cell therapy for cardiac regeneration: hits and misses
  4909. Mesenchymal Stem cell therapy for inflammatory bowel diseases: promise and challenge
  4910. Stem cell therapy in Dentistry: An Overview.
  4911. Impact of National and International Stem cell Banking Initiatives on progress in the field of cell therapy: IABS-JST Joint Workshop: Summary for Session 5
  4912. Pre-clinical cell-based therapy for limbal Stem cell deficiency
  4913. PDGFB-based Stem cell gene therapy increases bone strength in the mouse
  4914. Mesenchymal Stem cell–based therapy for nonhealing wounds: today and tomorrow
  4915. CTLA4 overexpressing adipose tissue-derived mesenchymal Stem cell therapy in a dog with steroid-refractory pemphigus foliaceus
  4916. Stem cell therapy for dementia
  4917. Therapeutic efficacy of Stem cell-based therapy in peripheral arterial disease: a meta-analysis
  4918. Stem cell-based therapy in idiopathic pulmonary fibrosis
  4919. cell therapy for macular degeneration—first phase I/II pluripotent Stem cell-based clinical trial shows promise
  4920. Delivery of mitogen-activated protein kinase inhibitor for hepatocellular carcinoma Stem cell therapy
  4921. Brentuximab vedotin as consolidation therapy after autologous Stemcell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression …
  4922. Cardiac Stem cell therapy: Have we put too much hype in which cell type to use?
  4923. Application of biomaterials to advance induced pluripotent Stem cell research and therapy
  4924. The inflammatory milieu of the degenerate disc: is mesenchymal Stem cell-based therapy for intervertebral disc repair a feasible approach?
  4925. Behind the scenes of the world’s first commercial Stemcell therapy
  4926. Current status of Stem cell therapy in urology
  4927. The perspectives of mesenchymal Stem cell therapy in the treatment of multiple sclerosis
  4928. Progressing a human embryonic Stemcell-based regenerative medicine therapy towards the clinic
  4929. Translating G-CSF as an adjunct therapy to Stem cell transplantation for stroke
  4930. Stem cell therapy in drug discovery and development
  4931. Stem cell therapy in neonatal diseases
  4932. Regenerative medicine for central nervous syStem disorders: Role of therapeutic molecules in Stem cell therapy
  4933. Advance and challenges in Stem cell therapy for Alzheimer’s disease
  4934. Allogeneic Stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and cell therapy
  4935. Exploiting AT2R to improve CD117 Stem cell function in vitro and in vivo-perspectives for cardiac Stem cell therapy
  4936. Stem cell therapy for heart disease-Meta-analysis may be misleading.
  4937. Hair regrowth in alopecia areata patients following Stem cell Educator therapy
  4938. Modulation of autoimmune T-cell memory by Stem cell educator therapy: phase 1/2 clinical trial
  4939. A single epidermal Stem cell strategy for safe ex vivo gene therapy
  4940. Skin Stem cells in skin cell therapy
  4941. Potential of neural Stem cell-based therapy for Parkinson’s disease
  4942. Stem cell regenerative therapy in alveolar cleft reconstruction
  4943. How to mend a broken heart: adult and induced pluripotent Stem cell therapy for heart repair and regeneration
  4944. A method for preparation of hydrogel microcapsules for Stem cell bioprocessing and Stem cell therapy
  4945. Adipose-derived Stem cell sheet transplantation therapy in a porcine model of chronic heart failure
  4946. Portable and quantitative evaluation of Stem cell therapy towards damaged hepatocytes
  4947. Haploidentical hematopoietic Stem cell transplantation as a platform for post-transplantation cellular therapy
  4948. Impact of enzyme replacement therapy and hematopoietic Stem cell transplantation in patients with Morquio A syndrome
  4949. Current progress in Stem cell-based gene therapy for articular cartilage repair
  4950. Invited review: Stem cells and muscle diseases: advances in cell therapy strategies
  4951. Umbilical cord-derived mesenchymal Stem cell therapy for neurological disorders via inhibition of mitogen-activated protein kinase pathway-mediated …
  4952. The secret role of microRNAs in cancer Stem cell development and potential therapy: a Notch-pathway approach
  4953. Stem cell therapy for retinal diseases
  4954. Using the cost–effectiveness of allogeneic islet transplantation to inform induced pluripotent Stem cell-derived β-cell therapy reimbursement
  4955. Maintenance therapy with decitabine after allogeneic Stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome
  4956. Stem cell therapy for heart failure: Out with the new and in with the old?
  4957. Enrichment of human hematopoietic Stem/progenitor cells facilitates transduction for Stem cell gene therapy
  4958. Radiosensitizing and hyperthermic properties of hyaluronan conjugated, dextran-coated ferric oxide nanoparticles: implications for cancer Stem cell therapy
  4959. NANO scaffolds and Stem cell therapy in liver tissue engineering
  4960. Induced pluripotent Stem cell technology for modelling and therapy of cerebellar ataxia
  4961. Stemcell-based therapy in the field of urology: a review of Stem cell basic science, clinical applications and future directions in the treatment of various sexual and …
  4962. … Multi‐GNRs Crystal‐Seeded Magnetic Nanoseaurchin for Enhanced In Vivo Mesenchymal‐Stemcell Homing, Multimodal Imaging, and Stroke therapy
  4963. Long-term culture of pluripotent Stemcell-derived human neurons on diamond–A substrate for neurodegeneration research and therapy
  4964. SRY and OCT4 are required for the acquisition of cancer Stem cell‐like properties and are potential differentiation therapy targets
  4965. The challenges and promises of allogeneic mesenchymal Stem cells for use as a cell-based therapy
  4966. Combination therapy of Stem cell derived neural progenitors and drug delivery of anti-inhibitory molecules for spinal cord injury
  4967. Effect of exercise therapy on muscle mass and physical functioning in patients undergoing allogeneic hematopoietic Stem cell transplantation
  4968. Stemcell therapy for neurologic diseases
  4969. Bone marrow mesenchymal Stem cell therapy for voiding dysfunction
  4970. Stem cell state and the epithelial‐to‐mesenchymal transition: Implications for cancer therapy
  4971. … with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic Stem cell transplantation or high-dose …
  4972. Human tissue legislation in South Africa: Focus on Stem cell research and therapy
  4973. Evaluation of the proliferative effects induced by low-level laser therapy in bone marrow Stem cell culture
  4974. Hematopoietic Stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II
  4975. High-dose therapy and autologous Stem cell transplant in older adults with multiple myeloma
  4976. Stem cell therapy of cataract
  4977. Intestinal Stem cells and Stem cell-based therapy for intestinal diseases
  4978. Perspectives on the evolution of Stem cell therapy for heart failure
  4979. Mesenchymal Stem cell therapy in pulmonary disease
  4980. Consensus statement from the first international conference for in utero Stem cell transplantation and gene therapy
  4981. Mesenchymal Stem cell–mediated, tumor stroma–targeted radioiodine therapy of metastatic colon cancer using the sodium iodide symporter as theranostic gene
  4982. Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic Stem cell transplantation
  4983. Design of a regulated lentiviral vector for hematopoietic Stem cell gene therapy of globoid cell leukodystrophy
  4984. Adeno-associated virus (AAV) gene delivery in Stem cell therapy
  4985. … intensive chemotherapy and autologous Stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II …
  4986. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and Stem cell transplantation for light chain amyloidosis: results of a …
  4987. Adipose-derived stromal cells protect intervertebral disc cells in compression: implications for Stem cell regenerative disc therapy
  4988. … 19-28z CAR-T) post-high dose therapy and autologous Stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma …
  4989. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic Stem cell support: A study based on the nationwide …
  4990. Prolonged antiretroviral therapy preserves HIV-1-specific CD8 T cells with Stem cell-like properties
  4991. Clinical Implications of Basic Science Discoveries: Induced Pluripotent Stem cell therapy in Transplantation—A Potential Role for Immunologic Tolerance
  4992. Stem cell therapy as a treatment modality for neurotrauma
  4993. Synergistic effect of immunoliposomal gemcitabine and bevacizumab in glioblastoma Stem cell-targeted therapy
  4994. Stem cell-based therapy of corneal epithelial and endothelial diseases
  4995. Virus integration and genome influence in approaches to Stem cell based therapy for andro-urology
  4996. Combination of hyperthermia and photodynamic therapy on mesenchymal Stem cell line treated with chloroaluminum phthalocyanine magnetic-nanoemulsion
  4997. Influence of Stem cell source on outcomes of allogeneic reduced-intensity conditioning therapy transplants using haploidentical related donors
  4998. Comparison of magnetic intensities for mesenchymal Stem cell targeting therapy on ischemic myocardial repair: high magnetic intensity improves cell retention but has …
  4999. … (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous Stem cell transplantation in multiple myeloma
  5000. Second autologous Stem cell transplant: an effective therapy for relapsed multiple myeloma
  5001. Angiotensin II, oxidative stress and Stem cell therapy: a matter of delicacy
  5002. A gene and neural Stem cell therapy platform based on neuronal cell type-inducible gene overexpression
  5003. … mucositis in pediatric patients undergoing hematopoietic Stem cell transplantation: Clinical outcomes in a context of specialized oral care using low‐level laser therapy
  5004. Attenuating hypoxia-induced apoptosis and autophagy of mesenchymal Stem cells: the potential of sitagliptin in Stem cell-based therapy
  5005. … cryotherapy associated with laser therapy for decreasing severity of melphalan‐induced oral mucositis during hematological Stemcell transplantation: a prospective …
  5006. … rituximab with high‐dose cytarabine mobilization therapy and high‐dose thiotepa, busulfan, and cyclophosphamide autologous Stem cell transplantation in patients …
  5007. Advanced research on Stem cell therapy for hepatic diseases: potential implications of a placenta-derived mesenchymal Stem cell-based strategy
  5008. Mesenchymal Stem cell-based FGF2 gene therapy for acute lung injury induced by lipopolysaccharide in mice
  5009. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic Stem cell transplantation
  5010. Neural Stem cell replacement: a possible therapy for neurodevelopmental disorders?
  5011. The influence of rituximab, high-dose therapy followed by autologous Stem cell transplantation, and age in patients with primary CNS lymphoma
  5012. Stem cell therapy in cerebral palsy: current evidence
  5013. Intra-arterial approaches to Stem cell therapy for ischemic stroke
  5014. Orthopedic uses of Stem cell therapy
  5015. Comparison of unrelated cord blood and peripheral blood Stem cell transplantation in adults with myelodysplastic syndrome after reduced-intensity …
  5016. Stem cell therapy status in veterinary medicine
  5017. Stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin’s lymphoma: a French Society of Bone Marrow Transplantation and cellular therapy
  5018. Preparation of autologous bone marrow-derived mesenchymal Stem cells (MSCs) for mesenchymal Stem cell therapy for canadians with multiple sclerosis (MESCAMS …
  5019. Allogeneic hematopoietic Stem cell transplantation is an effective salvage therapy for patients with chronic myeloid leukemia presenting with advanced …
  5020. The impact of low-level laser therapy on oral mucositis and quality of life in patients undergoing hematopoietic Stem cell transplantation using the oral health impact …
  5021. Tumoral Stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy
  5022. Bronchopleural fistula treatment: From the archetype of surgery to the future of Stem cell therapy
  5023. Freeze-dried rat bone marrow mesenchymal Stem cell paracrine factors: a simplified novel material for skin wound therapy
  5024. Stem cell and gene therapy for cardiovascular disease
  5025. Dental Stem cells: a future asset of ocular cell therapy
  5026. High-dose therapy and autologous Stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European …
  5027. Predicting poor peripheral blood Stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and …
  5028. … and central nervous syStem non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous Stem cell transplantation. A 60 …
  5029. Mesenchymal Stem cell expression of stromal cell‐derived factor‐1β augments bone formation in a model of local regenerative therapy
  5030. Oxymetholone therapy of fanconi anemia suppresses osteopontin transcription and induces hematopoietic Stem cell cycling
  5031. Molecular imaging for Stem cell therapy in the brain
  5032. Stem cell gene therapy for HIV: strategies to inhibit viral entry and replication
  5033. 660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem cell therapy
  5034. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by Stem cell gene therapy with no cytoreductive conditioning
  5035. Cancer Stem cells, cancer cell plasticity and radiation therapy
  5036. … on the efficacy of combined intraoral and extraoral low-level laser therapy for prevention of oral mucositis in pediatric patients undergoing hematopoietic Stem cell
  5037. The use of autologous mesenchymal Stem cells for cell therapy of patients with amyotrophic lateral sclerosis in belarus
  5038. Stem cells and cell therapy: Autologous cell Manufacturing
  5039. Stem cell therapy in spinal trauma: Does it have scientific validity?
  5040. Human adipose-derived mesenchymal Stem cells in cell therapy: safety and feasibility in different” hospital exemption” clinical applications
  5041. CD33 directed chimeric antigen receptor T cell therapy as a novel preparative regimen prior to allogeneic Stem cell transplantation in acute myeloid leukemia
  5042. Current understanding of safety and efficacy of Stem cell therapy for discogenic pain—A syStematic review of human studies
  5043. Immune-neuroendocrine interactions involving thymus and pineal gland in Stem cell therapy of age-related diseases
  5044. Breast cancer Stem cell correlates as predicative factors for radiation therapy
  5045. Stem cell therapy versus T lymphocytes: friend or foe?
  5046. Upper airway Stem cells: understanding the nose and role for future cell therapy
  5047. Stem cell therapy for spinal cord injury: The use of oligodendrocytes and motor neurons derived from human embryonic Stem cells
  5048. Adult Stem cell therapy in chronic liver diseases
  5049. Mesenchymal Stem cells as a Biological Drug for Heart Disease: Where Are We With Cardiac cell–Based therapy?
  5050. Prophylactic antiviral therapy in allogeneic hematopoietic Stem cell transplantation in hepatitis B virus patients
  5051. A global comparative overview of the legal regulation of Stem cell research and therapy: lessons for South Africa
  5052. Human umbilical cord mesenchymal Stem cells: an overview of their potential in cell-based therapy
  5053. A double-switch cell fusion-inducible transgene expression syStem for neural Stem cell-based antiglioma gene therapy
  5054. Memory or amnesia: the dilemma of Stem cell therapy in muscular dystrophies
  5055. Mesenchymal stromal Stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up
  5056. … after allogeneic Stem cell transplantation for myelodysplastic syndromes: a study from the French Society of Bone Marrow Transplantation and cellular therapy
  5057. The influence of BDNF on human umbilical cord blood Stem/progenitor cells: implications for Stem cell-based therapy of neurodegenerative disorders
  5058. Human adipose Stem cell and ASC-derived cardiac progenitor cellular therapy improves outcomes in a murine model of myocardial infarction
  5059. Neuroprotective potential of mesenchymal Stem cell-based therapy in acute stages of TNBS-induced colitis in guinea-pigs
  5060. Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous Stem cell transplantation in newly diagnosed MCL patients, results of a …
  5061. Aquapuncture using Stem cell therapy to treat MdX mice
  5062. The use of hyperbaric oxygen therapy in the treatment of hemorrhagic cystitis after allogeneic Stem cell transplantation from an unrelated donor
  5063. Phase I/II study of the deacetylase inhibitor panobinostat as maintenance therapy after an allogeneic Stem cell transplantation in patients with high-risk MDS …
  5064. The Future of Stem cell therapy in Retina
  5065. Occurrence of adverse events caused by valganciclovir as pre‐emptive therapy for cytomegalovirus infection after allogeneic Stem cell transplantation is reduced by …
  5066. 211Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem cell Gene therapy
  5067. Thioredoxin-1 (Trx1) engineered mesenchymal Stem cell therapy is a promising feasible therapeutic approach for myocardial infarction.
  5068. Genome editing and Stem cell therapy pave the path for new treatment of sickle-cell disease
  5069. … -dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic Stem cell transplantation: a critical …
  5070. Stem cell therapy in pediatric neurological disorders
  5071. … of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous Stem cell transplant (ASCT) for …
  5072. Developing a Stem cell-based therapy for the treatment of hearing loss
  5073. Imaging of fluid in cancer patients treated with syStemic therapy: chemotherapy, molecular targeted therapy, and hematopoietic Stem cell transplantation
  5074. Stem cell therapy for type 1 diabetes mellitus
  5075. Stem cell therapy: medico-legal perspectives in Italy
  5076. The roles of consolidation and maintenance therapy with novel agents after autologous Stem cell transplantation in patients with multiple myeloma
  5077. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous Stem cell rescue
  5078. cell therapy with G-CSF-mobilized Stem cells in a rat osteoarthritis model
  5079. Human induced pluripotent Stem cells in Parkinson’s disease: A novel cell source of cell therapy and disease modeling
  5080. Stem cell therapy in Brain Trauma
  5081. Molecular imaging: the key to advancing Stem cell therapy
  5082. Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after Stem cell transplantation
  5083. Stem cell therapy in Traumatic Injuries
  5084. Single Stem cell gene therapy for genetic skin disease
  5085. An avian model for ascertaining the mechanisms of organophosphate neuroteratogenicity and its therapy with mesenchymal Stem cell transplantation.
  5086. Current concepts in Stem cell therapy for cardiovascular diseases: what we know and don’t know
  5087. Advancement in high dose therapy and autologous Stem cell rescue in lymphoma
  5088. … use of brentuximab vedotin for refractory anaplastic large cell lymphoma as a bridging therapy to haploidentical Stem cell transplantation and maintenance therapy
  5089. Introducing dendrosomal nanocurcumin as a compound capable of in vitro eliminating undifferentiated Stem cells in cell therapy practices
  5090. Role of consolidative radiation therapy following autologous Stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma
  5091. Neural Stem cell therapy for Spinal Cord Injury
  5092. Stem cell therapy for cartilage defects
  5093. Successful Autologous Stem cell therapy In Premature Ovarian Failure
  5094. Stem cell therapy for Parkinson’s disease: researching for an effective cure
  5095. Autologous Stem cell transplantation is an effective salvage therapy for primary refractory multiple myeloma
  5096. Stem cell therapy for degenerative disc diseases: present status and prospects
  5097. Mesenchymal Stem cell therapy for bladder dysfunction
  5098. Autologous Mesenchymal Stem cell therapy in Patients with Stroke
  5099. Management of cytokine release syndrome (CRS) in patients undergoing chimeric antigen receptor modified (CAR) T-cell therapy following autologous Stem cell
  5100. Bone marrow-and cord blood-derived Stem cell transplantation for diabetes therapy
  5101. Era of Stem cell therapy for regenerative medicine and cancers: an introduction for the special issue of Pan Pacific Symposium on Stem cells and Cancer …
  5102. Adoptive T-cell therapy to prevent and treat human metapneumovirus (hMPV) infections post hematopoietic Stem cell transplant (HSCT)
  5103. A Stemcell-Derived cell-Free therapy for Stroke: Moving Conditioned Medium into Clinical Trial
  5104. Tissue Engineering and Stem cell therapy for Orthodontists
  5105. Mesenchymal Stem cell therapy for breast cancer: Challenges remaining
  5106. The need to review the existing guidelines and proposed regulations for Stem cell therapy in India based on published scientific facts, patient requirements …
  5107. A comparison of Wharton’s jelly and cord blood as a source of mesenchymal Stem cells for diabetes cell therapy
  5108. Application of reporter gene labeling in Stem cell therapy for acute myocardial infarction
  5109. Developing Stem cell therapy for retinal dystrophies
  5110. Legal implications of translational promises of unproven Stem cell therapy
  5111. Impact of early remission by induction therapy on allogeneic Stem cell transplantation for acute myeloid leukemia with an intermediate‐risk karyotype in first complete …
  5112. Mesenchymal Stem cell therapy, a new hope for eye disease
  5113. Lentiviral hematopoietic Stem cell gene therapy for older patients with X-linked severe combined immunodeficiency
  5114. SyStematic review and meta-analysis of efficacy and safety of Stem cell therapy in Amyotrophic lateral sclerosis
  5115. Induced pluripotent Stem cell therapy in transplantation—A potential role for immunologic tolerance
  5116. The prognostic impact of peripheral blood progenitor cell dose following high-dose therapy and autologous Stem cell transplant for hematologic malignancies
  5117. High-dose thiotepa as consolidation therapy with autologous hematopoietic Stem cell transplantation for high-risk Ewing family tumors: Single-institution experience
  5118. Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous Stem cell transplantation (HDT/ASCT)-induced mucositis
  5119. Intensive chemotherapy and consolidation with high dose therapy and autologous Stem cell transplant in patients with mantle cell lymphoma
  5120. Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic Stem cell
  5121. Steroids reduce the efficacy of mesenchymal Stem cell therapy for liver cirrhosis
  5122. Phase II study of the combination of ixazomib with lenalidomide as maintenance therapy following autologous Stem cell transplant in patients with multiple …
  5123. A genetically immortalized human Stem cell line: a promising new tool for Alzheimer’s disease therapy
  5124. Safety and clinical benefit of lentiviral hematopoietic Stem cell gene therapy for Wiskott-Aldrich syndrome
  5125. Conditional survival and excess mortality after high-dose therapy with autologous Stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma …
  5126. Abstract T MP5: Factors Determining Consent in a Randomized Trial of Intra-Arterial Stem cell therapy for Sub-Acute Ischemic Stroke
  5127. The hope for iPSC in lung Stem cell therapy and disease modeling
  5128. Pre-treating the myocardium with collagen matrix improves the efficacy of cardiac Stem cell therapy for myocardial infarction
  5129. therapy of chronic cardiosclerosis in WAG rats using cultures of cardiovascular cells enriched with cardiac Stem cell
  5130. Combination cell therapy: A New Approach for Stem cell therapy
  5131. Nitazoxanide is effective therapy for norovirus gastroenteritis after chemotherapy and hematopoietic Stem cell transplantation (HSCT)
  5132. Frontiers of plasmonic photothermal and Stem cell therapy of atherosclerosis: Nanotoxicity in NANOM-PCI trial
  5133. MP19-06 MESENCHYMAL Stemcell therapy ALLEVIATES INTERSTITIAL CYSTITIS BY ACTIVATING WNT SIGNALING PATHWAY
  5134. A Phase I study of allogeneic Natural Killer cell therapy generated from cord blood hematopoietic Stem and progenitor cells in elderly acute myeloid …
  5135. Oral valganciclovir as preemptive therapy for cytomegalovirus reactivation in pediatric hematopoietic Stem cell transplant patients
  5136. Novel approach to treat fecal incontinence with muscle Stem cell-based therapy
  5137. Multidifferentiation potential of human mesenchymal Stem cells from adipose tissue and hamstring tendons for musculoskeletal cell-based therapy
  5138. … granulocyte colony stimulating factor (GCSF) Zarzio for progenitor cell mobilization and the treatment of therapy-induced neutropenia in adult hematopoietic Stem cell
  5139. Ethical issues in genetics (premarital counseling, genetic testing, genetic engineering, cloning and Stem cell therapy, DNA fingerprinting)
  5140. Stem cell therapy-RECENT ADVANCES
  5141. Potential role of induced pluripotent Stem cells (IPSCs) for cell-based therapy of the ocular surface
  5142. The story behind the first Stem cell therapy
  5143. P79-Stem cell therapy in Iran
  5144. Stem and progenitor cell therapy for pulmonary arterial hypertension: effects on the right ventricle (2013 Grover Conference Series)
  5145. Lentiviral Stem cell gene therapy for Pompe disease
  5146. Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic Stem cell transplantation in multiple …
  5147. Adipose‐derived Stem cells protect against endoneurial cell death: cell therapy for nerve autografts
  5148. Preclinical Study Design for Evaluation of Stem cell–derived cellular therapy Products: A Pathologist’s Perspective
  5149. O11-REGULATORY CHALLENGES IN Stem cell therapy
  5150. Perspectives on Stem cell gene therapy for genetic disorders
  5151. Stem cell therapy: an emerging technology in the field of Medicine
  5152. … for Blastic Plasmacytoid Dendritic cell Neoplasm: A Retrospective Study of the French Society of Bone Marrow Transplantation and cell therapy (SFGM-TC)
  5153. The Cerebrospinal Fluid–Stem cell Interactions as Target for Regenerative therapy in Neurological Diseases
  5154. cells and other mononuclear cell subtypes processed up to 96 h from collection and stored at room temperature maintain a satisfactory functionality for cell therapy
  5155. An Animat as a Model of Stem cell therapy in Stroke
  5156. Mantle cell lymphoma: first-line therapy in patients not eligible for Stem cell transplantation
  5157. Targeted Cancer Stem cell therapy
  5158. Mesenchymal Stem cell therapy for Acute Respiratory Distress Syndrome: A Light at the End of the Tunnel?: Optimizing Therapeutic Potential of Human …
  5159. -Basic science: What will it deliver? Gene and Stem cell therapy
  5160. Stem cell therapy for Neurodegenerative Diseases
  5161. Gene therapy and Stem cell therapy: Overview
  5162. Clinical Application and Molecular Mechanism of Multipotent Stem cell therapy for Liver Disease
  5163. Mesenchymal Stem cell therapy in Nonhematopoietic Diseases
  5164. Harnessing Stem cell-Like Memory T cells for Adoptive cell Transfer therapy of Cancer
  5165. Significance of cell/Stem cell therapy in Wound Care Management
  5166. … Yttrium-90 Ibritumomab Tiuxetan (90Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous Stemcell
  5167. Deciphering Stem cell therapy for the interventional cardiologist
  5168. P36-THE MAJOR ETHICAL QUESTIONS IN Stem cell therapy
  5169. Stem cell Extracellular Vesicles: A Novel cell-Based therapy for Cardiovascular Diseases
  5170. Stem cell therapy: science fact or science fiction?
  5171. Novel application of 3-dimensional real-time cardiac imaging to guide Stem cell-based therapy
  5172. P66-The Current Biosafety Considerations in Stem cell therapy
  5173. Challenges towards Stem cell therapy for Parkinson’s disease
  5174. High dose therapy and autologous hematopoietic Stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?
  5175. Bio-inspired polymer surfaces for improving Stem cell therapy
  5176. Amniotic fluid-derived Stem cells as an effective cell source for transplantation therapy in stroke
  5177. O29-Stem cell therapy IN ATHEROSCLEROSIS
  5178. Stem cell therapy for GVHD
  5179. A phase Ib/II study of cancer Stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) …
  5180. Application of Stem cell therapy in Cardiovascular Disease: Current Status
  5181. Chinical Application of Adult Stem cell therapy in Neurological Disorders; Present and Future
  5182. SyStematic review: improved function in patients with stroke following Stem cell therapy
  5183. Stem cell therapy in Skin Rejuvenation
  5184. Mesenchymal Stem cell therapy in endstage liver cell failure: comparison of cell types and routes of administration
  5185. OP45–3024: Efficient lentiviral vector-mediated hematopoietic Stem cell gene therapy in MNGIE mice
  5186. Animal models for preclinical efficacy evaluation of Stem cell therapy
  5187. Novel Leukemia Stem cell-Targeted therapy for Acute Myeloid Leukemia Based on Dual Inhibition of Ezh1/Ezh2
  5188. Stem cell therapy and the Heart: A Contemporary Review of the Literature. J Cardiobiol. 2015; 3 (1): 7. J Cardiobiol January 2015 Vol.: 3, Issue: 1 All rights are …
  5189. Regulation and Approval Process of Stem cell therapy Products
  5190. Redosing strategies for mesenchymal Stem cell therapy for chronic obstructive pulmonary disease
  5191. Optimized Mesenchymal Stem cell therapy for Chronic Obstructive Pulmonary Disease
  5192. Prolotherapy And Stem cell therapy
  5193. P6: Perspective of Stem cell therapy for Treatment of Spinal Cord Injury
  5194. Muscle Stem cell therapy for the Treatment of DMD Associated Cardiomyopathy
  5195. Hodgkin’s lymphoma (relapsed or refractory): autologous Stem cell therapy
  5196. Cost comparison of hematopoietic Stem cell transplantation and conventional therapy for patients with thalassemia major in China
  5197. The Psychological and Compliance Factors can Modulate the Outcome of StemI Patients Treated by Stem cell therapy-A Pilot Study
  5198. A salvage autologous Stem cell transplant (ASCT2) induces superior overall survival following bortezomib-containing re-induction therapy for relapsed …
  5199. Neuroscience approach in Stem cell therapy among patients with Spinal Cord Injury
  5200. Cancer Stem cell-Targeted therapy: Harapan Baru Terapi Kanker
  5201. O8-Intracoronary Stem cell therapy in Patients Afflicted by Systolic Heart Failure
  5202. Stem cells: Supramolecular Hydrogels for Long‐Term Bioengineered Stem cell therapy (Adv. Healthcare Mater. 2/2015)
  5203. … I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous Stem cell transplantation in acute …
  5204. Human Stromal Stem cell therapy Using Gene-Modified cells
  5205. Effective SyStemic Mesenchymal Stem cell therapy for Vertebral Compression Fractures
  5206. Mechanism of umbilical cord mesenchymal Stem cell therapy for metabolic syndrome
  5207. Stem cells and Stem cell therapy for diabetes mellitus: Chinese clinical trial registration information analysis
  5208. Development of a Haematopoietic Stem cell-based cell therapy to Treat Brain Metastases
  5209. Fortuitous benefits of activity-based rehabilitation in Stem cell-based therapy for spinal cord repair: enhancing graft survival
  5210. Induced pluripotent Stem cell therapy: transplant rejection and safety
  5211. The business of cellular therapy and hematopoietic Stem cell transplantation
  5212. Stem cell based cell therapy with incurable disease animal model
  5213. P57-Stem cell therapy FOR CARDIAC REPAIR: A REVIEW
  5214. … acute myeloid leukaemia which allows early identification of patients for whom allogeneic Stem cell transplantation represents the only curative therapy
  5215. Just Over the Horizon: Catheter Delivery of Stem cell therapy
  5216. Stem cell therapy for Neonatal Hypoxic–Ischemic Brain Injury
  5217. Stem cell therapy for Optic Nerve Regeneration
  5218. Advances and Challenges in SyStemic Stem cell therapy for Muscular Dystrophies
  5219. Autologous Fat Grafting and Adipose-Derived Stem cell therapy
  5220. Mesenchymal Stem cell-Conditioned Medium in Trans-Amniotic Stem cell therapy (TRASCET) for Experimental Spina Bifida
  5221. THE IMPACT-CABG TRIAL: A CANADIAN RCT OF CD133+ Stem cell therapy FOR ISCHEMIC CARDIOMYOPATHY
  5222. Development of an Injectable cell-laden Microniche for Mesenchymal Stem cell therapy
  5223. Strategy of Stem cell therapy for healing racehorse s bone cartilage
  5224. An in vitro Model of Cardiac Stem cell therapy to Study the Coupling of Primary and Stem cell-derived Cardiomyocytes
  5225. Liver Stem cell therapy for cirrhosis: advances in cell classification and selection
  5226. Curcumin has the potential to prevent tumor formation in Stem cell therapy of diabetes type I
  5227. Interim analysis of a phase 2 study of bortezomib plus rituximab maintenance therapy in patients with mantle cell lymphoma status post autologous Stem cell
  5228. Stem cell therapy for the Treatment of Dry Age-Related Macular Degeneration
  5229. Hypofibrinogenemia associated with steroid therapy for the patients who developed GVHD after allogeneic Stem cell transplantation
  5230. Molecular mechanism underlying immune modulation during Stem cell therapy of overt type 1 diabetes (THER5P. 917)
  5231. Molecular Imaging in Response Evaluation to Human Embryonic Stem cell therapy in Neurodegenerative Diseases
  5232. TGF beta regulates tumor resistance to antiangiogenic therapy through POSTN in glioma Stem cell models
  5233. Regenerative Stem cell therapy for Breast Cancer Bone Metastasis
  5234. 1LF-5: Bio-inspired polymer scaffolds to potentiate Stem cell therapy
  5235. Hope and Wish for Brain Resuscitation-hypothermia and Stem cell therapy
  5236. Metabolic Status Determines the Efficacy of CD34+ Stem cell therapy in Patients With Non-Ischemic Dilated Cardiomyopathy
  5237. Mesenchymal Stem cell therapy for traumatic and degenerative eye disease
  5238. Mesenchymal Stem cell therapy Prevented Doxorubicin Induced Cardiac Dysfunction in Diabetics Rats
  5239. P59-Stem cell therapy IN CARDIOVASCULAR ABNORMALITIES IN OSTEOGENESIS IMPERFECTA
  5240. Quantification of micro-explant culture of myoblasts and optimization of autologous adult Stem cell therapy for female stress urinary incontinence
  5241. Preclinical evaluation of immunogenicity and immunotoxicity of Stem cell therapy
  5242. Rat Bone Marrow Mesenchymal Stem cell therapy in regenerating necrotic cytotrophoblast cell following exposed to carbon black.
  5243. … Minimal Toxicity and Shows Efficacy in a Phase I Trial of Patients with Relapsed/Refractory Hematological Malignancies Relapsing after Autologous Stem cell
  5244. CD33 directed chimeric antigen receptor T cell therapy as a novel regimen prior to allogeneic Stem cell transplantation in acute myeloid leukemia
  5245. Adipose Tissue-Derived Stem cell therapy for Post-Surgical Breast Reconstruction–More Light than Shadows
  5246. Histological Evaluation of Bone Marrow Derived Stem cell therapy on Experimentally Induced Osteoarthritis in Albino Rats’ Knee Joint
  5247. Designing biomaterials for controlled cardiac Stem cell differentiation and enhanced cell therapy in the treatment of congestive heart failure
  5248. 251. Intrauterine Haemopoietic Stem cell therapy Followed By Postnatal cell Re-Infusion To Enhance Engraftment in a Murine Thalassaemia Model
  5249. EFFICACY OF CD34+ Stem cell therapy IN NON-ISCHEMIC DILATED CARDIOMYOPATHY IS ABSENT IN PATIENTS WITH DIABETES BUT PRESERVED IN …
  5250. Improving rotator cuff tear repair: OREF grant recipient investigates promising perivascular Stem cell therapy
  5251. Optimized antiretroviral therapy during allogeneic hematopoietic Stem cell transplantation in HIV-infected individuals
  5252. P113-Autologous cell therapy for Liver Disease by Mesenchymal Stem cell-derived Hepatocyte Like cells
  5253. Mechanical behavior of abdominal aorta aneurysm in rat model treated by cell therapy using mesenchymal Stem cells
  5254. Combination of nano and microcarriers for Stem cell therapy of Huntington’s disease: new regenerative medicine strategy
  5255. SCARs: endogenous human Stem cell-associated retroviruses and therapy-resistant malignant tumors
  5256. Infarcted Hearts Respond Better to Cardiac Stem cell therapy After Pre-treatment With a Collagen Hydrogel
  5257. Regenerative Medicine: Conjugated Polymer Nanodots as Ultrastable Long‐Term Trackers to Understand Mesenchymal Stem cell therapy in Skin Regeneration …
  5258. … of cyclophosphamide plus G-CSF versus G-CSF alone for peripheral blood Stem cell (PBSC) mobilisation following first line therapy in patients with multiple …
  5259. … combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood Stem cell
  5260. Relevance of Neutrophils and Neutrophil Extracellular Traps in Bronchiolitis Obliterans Syndrome of Patients Receiving Stem cell therapy
  5261. … of Stem cell niche and Stem cell migration promotes functional angiogenesis by enhancing Stem cell homing in ischemic rat myocardium: a novel concept of cell-free …
  5262. Mesenchymal Stem cells for cardiac regenerative therapy: optimization of cell differentiation strategy
  5263. Role of miR-122 in bone marrow derived Stem cell therapy for acute liver injury in rats
  5264. Unopposed TNF/TNFR1 Signaling Prevents Therapeutic Benefit From Cardiac Stem cell therapy After Reperfused Myocardial Infarction in Mice
  5265. … profile of the novel Begev regimen (bendamustine, gemcitabine and vinorelbine) used as salvage therapy prior to autologous Stem cell transplant for relapsed …
  5266. MP52-01 NANOTECHNOLOGY IMPROVED ADIPOSE DERIVED Stem cell therapy IN ERECTILE DYSFUNCTION IN POST RADICAL PROSTATECTOMY …
  5267. Harnessing Stem cell potential for regenerative medicine and cell-based therapy
  5268. … with Donor Derived LMP Specific-CTLs in Patients with EBV Positive Refractory or Recurrent Hodgkin Lymphoma: A Lymphoma cell therapy Consortium (LCTC) Trial
  5269. Long-Term Follow up of Pediatric Patients with Hodgkin Lymphoma Treated with High Dose therapy and Autologous Stem cell Transplantation
  5270. Mesenchymal Stem cell as delivery carrier for prodrug gene therapy against colorectal cancer cell
  5271. Human mesenchymal Stem cell-educated macrophages: a potential therapy for GVHD and radiation injury (TRAN1P. 944)
  5272. Receptor tyrosine kinase-like orphan receptor-1 (ROR1) expression in breast cancer Stem cells can be targeted for anti-cancer-Stemcell therapy
  5273. … for Efficient Engraftment of Gene-Modified cells and Prevention of Antibody Production Against Transgene Products in a Rhesus Stem cell Gene therapy
  5274. OP-015 Impact of CD (34) Pluripotent Mesenchymal Stem cell therapy in Patients with Choronic Critical Limb Ischemia
  5275. Mesenchymal Stem cell: A New Vehicle for Cancer therapy
  5276. SL-07 Competency of Diploid Parthenogenesis Embryonic Stem cell (pESC) for cell therapy
  5277. A global comparative overview of the legal regulation of Stem cell research and therapy: lessons for South Africa: legislation
  5278. A Study on the Regulatory Trends on Stem cell-Based therapy in the USA
  5279. Case report: pomalidomide as consolidation therapy after salvage autologous Stem cell transplant
  5280. ASSESSING THE USE OF MESENCHYMAL Stem cell WINN FELINE FOUNDATION therapy FOR FELINE CHRONIC KIDNEY DISEASE
  5281. Combination Antiretroviral therapy during Autologous Stem cell Transplant for HIV Infected Patients with Haematological Malignancies
  5282. Innovative Concepts of cell therapy: Pluripotent and Multipotent Stem cells and New Bio-Material Solution in Research and Clinical Application
  5283. Fusion of mesenchymal Stem cells and islet cells for cell therapy
  5284. First steps towards successful post-transplantation therapy for myeloid malignancies after allogeneic blood Stem cell transplantation
  5285. Global Governance of Human Embryonic Stem cell Research and therapy-An Example from India: Report of the Rising Powers Policy Workshop
  5286. Combined therapy of acupuncture and neural Stem cell transplantation in immature rats with cerebral palsy
  5287. Targeted molecular therapy based on advanced cancer Stem cell model
  5288. P177-The Role of Cancer Stem cell in Cancer therapy
  5289. Research Progress of Genetic Modified Bone Marrow Mesenchymal Stem cell Transplantation for the therapy of Parkinson’s Disease
  5290. … P2-06-04: Proteosome inhibitor bortezomib inhibits NFκB and effectively overcomes cancer Stem cell escape triggered by Wnt inhibitor therapy in FOXC1+ basal-Like …
  5291. … auto-immune disease adult patients: analysis of outcomes from the French Society for Bone Marrow Transplantation and cellular therapy (SFGMT-TC) in …
  5292. P154-Mesenchymal Stem cell: A New Vehicle for Cancer therapy
  5293. Hematopoietic Stem cell mobilization for gene therapy: the combination of G-CSF+ plerixafor in patients with beta-thalassemia major provides high yields of …
  5294. Regenerative therapy by fusion of medicine and engineering: First-in-human clinical trials with induced pluripotent Stem cells and cell sheet technology: A …
  5295. Cryopreservative against noncryopreservative therapy in autologous hematopoietic Stem cell transplantation (the Egyptian experience)
  5296. ATPS-32TUMOR-HOMING HUMAN INDUCED NEURAL Stem cells: TOWARDS PERSONALIZED cell therapy FOR GLIOBLASTOMA
  5297. … mucositis in pediatric patients undergoing hematopoietic Stem cell transplantation: clinical outcomes in a context of specialized oral care using low-level laser therapy.
  5298. Mesenchymal Stem cell Based therapy for Prostate Cancer
  5299. … nucleotide polymorphisms, prognosis, and predicting benefit from imid® compound maintenance therapy following autologous Stem cell transplant for multiple …
  5300. A new “age” for high dose therapy and autologous Stem cell transplant
  5301. Neural Stem cell Based therapy For Parkinson’s Disease (S48. 007)
  5302. MRD evaluation, targeted therapy and Stem cell transplantation: how to combine in adult ALL
  5303. Abstract S4-03: Identification of a notch-driven breast cancer Stem cell gene signature for anti-notch therapy in an ER+ presurgical window model
  5304. Insights into the use of adipose Stem cells for clinical cell therapy: Novel culturing conditions and characterization of multipotency and immunogenic properties
  5305. Protein-Engineered Hydrogels for Improved Efficacy of Stem cell-Based Injection therapy in a Murine Model of Peripheral Arterial Disease
  5306. Amniotic Fluid-Derived Stem cells (AFSC) and Their Application in cell therapy and Tissue Engineering
  5307. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer Stem cells to hormonal therapy
  5308. cell Transplantation therapy for Diabetes Mellitus: From Embryonic Stem cells to Transdifferentiation of Adult cells
  5309. 295. Hematopoietic Stem cell Gene therapy (2.0) Based on Purified CD34+ CD38-cells
  5310. A Point-of-Care Platform for Hematopoietic Stem cell Gene therapy
  5311. Salvage Radiation therapy Prior to Stem cell Transplantation for Chemorefractory B-cell Lymphoma
  5312. Autologous cell therapy with CD133+ bone marrow Stem cells in refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study
  5313. Hyperthyroidism As a Complication Following Myloablative therapy and Stem cell Transplantation for Childhood Diseases
  5314. Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem cell-Based therapy for Severe Autoimmune Disorders
  5315. Targeting Cancer Stem cell-Related miRNAs for Prostate Cancer therapy
  5316. Consolidation and maintenance therapy after autologous hematopoietic Stem cell transplantation
  5317. Surviving Cancer: A Personal Story of the Physical and Mental Effects of Chemotherapy, Radiation therapy, and a Stem cell Transplant
  5318. Stem cell marker LGR5: a new target for cancer therapy
  5319. Developing Xeno-Free Human Induced Pluripotent Stem cell-Derived Cardiac Construct for Regeneration therapy Using a Rat Myocardial Infarction Model
  5320. Stem-01NEURAL Stem cell-MEDIATED ENZYME/PRODRUG therapy FOR NEUROBLASTOMA: TRANSLATION TO THE CLINIC
  5321. 279. Efficient and Safe Lentiviral Vector-Mediated Hematopoietic Stem cell Gene therapy in MNGIE Mice
  5322. Evaluating breast cancer Stem cell response to antiangiogenic therapy
  5323. Human somatic Stem cell-based therapy for cartilage regeneration
  5324. … : Improving the Angiogenic Abilities of Mobilized Peripheral Blood Stem cells Achieved by Priming with Activated Platelet Supernatant for Regenerative cell therapy
  5325. Gene therapy and cell Fusion Enhances Stem cell Mediated Cardiac Repair
  5326. AN AUDIT EVALUATING ADHERENCE TO ANTI-FUNGAL therapy IN PAEDIATRIC Stem cell TRANSPLANT (SCT) PATIENTS
  5327. ATPS-31POLYMERIC BIO-SCAFFOLDS INCREASE THE EFFICACY OF Stem cell-MEDIATED therapy FOR GLIOBLASTOMA
  5328. Modification of mesenchymal Stem cells as a way to improve the effectiveness of cell therapy of ischemic myocardial injury
  5329. Stem cell-based ovarian cancer suicide gene therapy
  5330. Stem cell-based ovarian cancer suicide gene therapy
  5331. The immunogenicity and immune tolerance in pluripotent Stem cell based therapy
  5332. Multiple myeloma patients at various cytogenetic risks benefit differently from autologous Stem cell transplantation as a consolidation therapy
  5333. therapy by transplantation of autologous CD34+ Stem cells transduced ex vivo with the lentiglobin BB305 lentiviral vector in subjects with severe sickle cell
  5334. Improvement of Quality of Response After Additional therapy Before Autologous Stem cell Transplant is not Translated in Improvement of Global Outcome of Multiple …
  5335. P125-THE EFFECT OF Stem cell-BASED therapy IN SKIN TISSUE ENGINEERING AND WOUND HEALING
  5336. Is there a role for short intensive therapy without Stem cell support in relapsed germ cell tumours? A single centre experience of GAMEC chemotherapy.
  5337. Mesenchymal Stem cell based therapy for restoring corneal graft transparency
  5338. Application of MR Stem cell markers in research of temozolomide intervention gliomas angiogenesis and therapy
  5339. Transplantation of an iPSC-derived CD15+ CXCR4+ VLA4+ neural Stem cell subpopulation as a new therapy for ALS.(S50. 003)
  5340. Graft-Versus-Host Disease Following Radiation therapy in Patients With a History of Allogeneic Stem cell Transplant
  5341. cellular Immune therapy for Epstein-Barr Virus Infection after Hematopoietic Stem cell Transplantation
  5342. 258. Universal Stem cell Gene therapy Platform: Broadening the Transient Epigenetic Gene therapy Arm by Using Nuclease-Null dCas9 as an Additional Drive for …
  5343. Early high-dose therapy and autologous Stemcell transplantation in angioimmunoblastic T-cell lymphoma: Outcome study using the National Cancer Data Base.
  5344. … haematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas: long-term follow-up data of the German Registry for Stem cell
  5345. SC-03NEURAL Stem cell-MEDIATED ENZYME/PRODRUG therapy FOR MEDULLOBLASTOMA
  5346. … with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction therapy Prior Autologous Stem cell Transplantation (ASCT) in …
  5347. A Preclinical Non-Human Primate Model to Test Reversible Myeloablation Following IV Busulfan therapy without Stem cell Rescue
  5348. 79. Development and Validation of a Globally Portable Platform for Lentivirus Mediated Hematopoietic Stem cell Gene therapy
  5349. Stem cell implantation therapy improves myocardial oxygen consumption after myocardial infarction in pigs: 11C-acetate PET with dobutamine stress.
  5350. Bone mineral density of the left femoral neck in lymphoma survivors treated with high dose therapy with autologous Stem cell support.
  5351. B cell Reconstitution after Gene therapy in Patients with Wiskott Aldrich Syndrome and Comparison with Mismatched Allogeneic Hematopoietic Stem cell
  5352. Creation of miRNA-loaded, mesenchymal Stem cell derived microparticles as targeted cancer therapy
  5353. Allogeneic Stem cell Transplantation Is Superior to Immunosuppressive therapy in Children with Aplastic Anaemia–a Single Centre Analysis from India
  5354. Utility of Corticosteroids As Adjunct therapy for Respiratory Syncytial Virus Infection in Allogeneic Stem cell Transplant Recipients
  5355. Lung cancer Stem cell targets sensitizing tumor cells to chemo therapy and radiation therapy by exploiting synthetic lethal relationships in an RNAi high-throughput …
  5356. Budesonide/Formoterol therapy Increases FEV1 in Stem cell Transplant–associated Bronchiolitis Obliterans Syndrome
  5357. Matched unrelated peripheral blood Stem cell transplantation as a salvage therapy for very severe aplastic anemia with uncontrolled infections: a case report
  5358. Salvage therapy for Graft Rejection with Second Haploidentical Allogeneic Stem cell Transplantation (Haplo-HCT) from a Second Related Donor
  5359. Innovative Hematopoietic Gene-therapy Concepts for Hereditary Pulmonary Alveolar Proteinosis Utilizing Hematopoietic Stem cell Derived Macrophages
  5360. A national study on conditional survival and excess mortality after high dose therapy with autologous Stem cell transplantation for non-Hodgkin lymphoma.
  5361. … with Extramedullary Plasmacytomas (EMPs) Included in a Phase III PETHEMA/GEM Study of Induction therapy Prior Autologous Stem cell Transplantation (ASCT) in …
  5362. The first tumor relapse after allogeneic hematopoietic Stem cell transplantation in a therapy-related acute myeloid leukemia patient: a case report and literature review
  5363. Clinical Impact of Cardiac Regenerative therapy With Autologous Skeletal Stem cell Sheet Implantation on Treating Severe Heart Failure
  5364. cell therapy with pluripotent Stem cells differentiated to retinal pigment epithelium and photoreceptor cells in a rat model of Retinitis Pigmentosa
  5365. … Vinorelbine and Prednisone (CGEV) As Salvage therapy for Relapsed or Refractory Hodgkin´ s Lymphoma before Hematopoietic Stem cell Transplantation: A Single …
  5366. … High Dose Cytarabine as Salvage therapy for Relapsed or Refractory Acute Myeloid Leukemia in the Setting of Intensified Anthracycline Induction and Post Stemcell
  5367. … Effectiveness of Tyrosine Kinase Inhibitor (TKIs) therapy in Chronic Myelogenous Leukemia (CML) in Comparison to Allogeneic Hematopoietic Stem cell
  5368. Study of cell therapy for ALS using neuronal Stem cells from iPSCs with ectopic SOX2 expression
  5369. … of Spleen Directed therapy and Predictors of Outcomes with Reduced Intensity Conditioning Allogeneic Hematopoietic Stem cell Transplantation for Patients …
  5370. A targeted salvage therapy with brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients who received autologuos Stem cell
  5371. DNA Methyltransferase-1 (DNMT1): A Flow Cytometric Pharmacodynamic Assay for Azacitidine Hypomethylating therapy after Allogeneic Hematopoietic Stem cell
  5372. … . Toward Genosafe Endonuclease-Boosted Gene Targeting Using Breakthrough CRISPR/Cas9 for Next Generation Stem cell Gene therapy Culminating in Efficient …
  5373. MESENCHYMAL Stem cells AND ITS POTENTIAL USE IN cell therapy-AN OVERVIEW
  5374. Haploidentical/Mismatched Hematopoietic Stem cell Transplantation for Nonresponders to Immunosuppressive therapy Compared with First-Line Rabbit …
  5375. … and Outcome for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose therapy and Autologous Stem cell Transplantation (HDT-ASCT) Using …
  5376. Outcomes Following Salvage Autologous Stem cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation therapy Following Bortezomib-Containing Re …
  5377. Potential cell source for cell-based therapy and tissue engineering applications: urine-derived Stem cells
  5378. Stem cells EXPRESSING THE GPX1 AND NURR1 GENES BY USING LENTI VIRUS VECTORS; NEW cells SOURCES FOR cell therapy IN …
  5379. … WE USE HUMAN ADIPOSE-DERIVED Stem cells (ADSCS) FROM UROLOGIC CANCER PATIENTS FOR AUTOLOGOUS cell therapy?: A PILOT STUDY
  5380. Single cell Whole Transcriptome Analysis Reveals Distinct Molecular Signatures of therapy-Resistant Chronic Myeloid Leukemia Stem cells
  5381. Pluripotent Stem cells as a cellular model for skin: relevance for physiopathology, cell/gene therapy and drug screening
  5382. Culture of adipose-derived Stem cells in a closed bioreactor syStem for cell therapy
  5383. Strategy for cell therapy using adipose derived mesenchymal Stem cells for canine spinal cord injury
  5384. NurOwn™: mesenchymal Stem cells secreting neurotrophic factors. An autologous cell therapy in clinical trials for ALS
  5385. Adoptive T cell therapy using rejuvenated antigen-specific T cells from induced pluripotent Stem cells (VAC7P. 1044)
  5386. … OSTEOCLASTS FROM SITE SPECIFIC GENE-CORRECTED INDUCED PLURIPOTENT Stem cells: AN AUTOLOGOUS cell therapy APPROACH TO TREAT …
  5387. P56-Stem cells in Treatment of Type 1 Diabetes: A Novel cell therapy Approach (Especially IPS cells)
  5388. 0413: Cardiac differentiation of human pluripotent Stem cells: the first step toward cardiac tissue engineering and cell therapy
  5389. cell and gene therapy via human neural Stem progenitor cells in the lithium-pilocarpine model of rat temporal lobe epilepsy
  5390. Stem cells for the cell and molecular therapy of type 1 diabetes mellitus (T1D): the gap between dream and reality
  5391. Neural Stem cells interaction with the brain environment and prospects for cell replacement therapy for Stroke
  5392. Purinergic receptors in spinal cord-derived ependymal Stem/progenitor cells and their potential role in cell-based therapy for spinal cord injury
  5393. Neural Stem cells-interaction with the brain and prospects for cell replacement therapy for Stroke
  5394. Induced pluripotent Stem (iPS) cells for cell replacement therapy in Huntington’s disease (HD)
  5395. The development of statin-based therapy for patients with hepatitis C virus (HCV) infection using human induced pluripotent Stem (iPS) cell technology
  5396. Beyond cell-Based therapy: Paracrine Action of Human Adipose Derived Stem/Stromal cells
  5397. Declined presentation single-cell analysis of myelodysplastic sydrome Stem cells during therapy and disease progression
  5398. Analysis of Myelodysplastic Syndrome Stem cells at Single cell Resolution during DNA Methyltransferase Inhibitor therapy
  5399. Functional Recovery and in Vivo cell Tracking after Human Adipose Tissue-Derived Stem cells therapy for Experimental Spinal Cord Injury
  5400. cell-based therapy in ovarian cancer: Improved adenoviral transduction strategy of human mesenchymal Stem cells as tumor-homing drug factories
  5401. Adult Stem cell therapy and heart failure, 2000 to 2016: a syStematic review
  5402. Adult Stem cell therapy for stroke: challenges and progress
  5403. Strategies to optimize adult Stem cell therapy for tissue regeneration
  5404. Clinical efficacy of Stem cell therapy for diabetes mellitus: a meta-analysis
  5405. Challenges and opportunities for Stem cell therapy in patients with chronic kidney disease
  5406. Neural Stem cell therapy for cancer
  5407. Clinical trials of adult Stem cell therapy in patients with ischemic stroke
  5408. Nanomedicine-mediated cancer Stem cell therapy
  5409. Mesenchymal Stem cell therapy for knee osteoarthritis: 5 years follow‐up of three patients
  5410. Advances in Stem cell therapy for cardiovascular disease
  5411. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
  5412. Concise review: review and perspective of cell dosage and routes of administration from preclinical and clinical studies of Stem cell therapy for heart disease
  5413. Stem cell therapy and administration routes after stroke
  5414. Mesenchymal Stem cell therapy in the treatment of osteoarthritis: reparative pathways, safety and efficacy–a review
  5415. Stem cell therapy for heart failure: ensuring regenerative proficiency
  5416. Stem cell therapy for Alzheimer’s disease: a review of recent clinical trials
  5417. Improving cell engraftment in cardiac Stem cell therapy
  5418. Stem cell therapy: is there a future for reconstruction of large bone defects?
  5419. The current perspectives of Stem cell therapy in orthopedic surgery
  5420. Current concept of Stem cell therapy for spinal cord injury: a review
  5421. Current biosafety considerations in Stem cell therapy
  5422. Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress
  5423. … adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous Stem cell therapy for orthopaedic conditions
  5424. Stem cell therapy: a prospective treatment for Alzheimer’s disease
  5425. New strategies for improving Stem cell therapy in ischemic heart disease
  5426. Potential role of herbal remedies in Stem cell therapy: proliferation and differentiation of human mesenchymal stromal cells
  5427. The role of Stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies
  5428. Peripheral nerve injury: Stem cell therapy and peripheral nerve transfer
  5429. Emerging targets for glioblastoma Stem cell therapy
  5430. Stem cell therapy for treatment of stress urinary incontinence: the current status and challenges
  5431. Mesenchymal Stem cell therapy for osteoarthritis
  5432. Mitochondria in mesenchymal Stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer
  5433. The current status of Stemcell therapy in erectile dysfunction: a review
  5434. Bone marrow mesenchymal Stem cell therapy in ischemic stroke: mechanisms of action and treatment optimization strategies
  5435. Current status and future prospects of mesenchymal Stem cell therapy for liver fibrosis
  5436. Stem cell therapy emerging as the key player in treating type 1 diabetes mellitus
  5437. A phase III clinical trial showing limited efficacy of autologous mesenchymal Stem cell therapy for spinal cord injury
  5438. Stem cell therapy for acute respiratory distress syndrome: a promising future?
  5439. Current perspectives on Stem cell therapy for erectile dysfunction
  5440. The promise of mesenchymal Stem cell therapy for diabetic kidney disease
  5441. Stem cell therapy and immunological rejection in animal models
  5442. Neural Stem cell therapy and rehabilitation in the central nervous syStem: emerging partnerships
  5443. Stem cell therapy for treatment of ocular disorders
  5444. Management of inflammatory bowel disease using Stem cell therapy
  5445. Assessment of the potential of a high frequency acoustomicrofluidic nebulisation platform for inhaled Stem cell therapy
  5446. White paper on guidelines concerning enteric nervous syStem Stem cell therapy for enteric neuropathies
  5447. Mesenchymal Stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes
  5448. Role of nanodiamonds in drug delivery and Stem cell therapy
  5449. Promoting tumor penetration of nanoparticles for cancer Stem cell therapy by TGF-β signaling pathway inhibition
  5450. Allogeneic mesenchymal Stem cell therapy promotes osteoblastogenesis and prevents glucocorticoid-induced osteoporosis
  5451. Current progress of human trials using Stem cell therapy as a treatment for diabetes mellitus
  5452. Developing an automated robotic factory for novel Stem cell therapy production
  5453. Nanoparticle improved Stem cell therapy for erectile dysfunction in a rat model of cavernous nerve injury
  5454. Nanoparticles-assisted Stem cell therapy for ischemic heart disease
  5455. Biobridge concept in Stem cell therapy for ischemic stroke.
  5456. Stem cell therapy in spinal cord injury: Hollow promise or promising science?
  5457. Gene transfection for Stem cell therapy
  5458. Mesenchymal Stem cell: considerations for manufacturing and clinical trials on cell therapy product
  5459. Genome therapy of myotonic dystrophy type 1 iPS cells for development of autologous Stem cell therapy
  5460. Optimal timing of mesenchymal Stem cell therapy for neonatal intraventricular hemorrhage
  5461. … Open study Of dental pulp Stem cell therapy in Humans): study protocol for evaluating safety and feasibility of autologous human adult dental pulp Stem cell therapy
  5462. Coupling primary and Stem cell–derived cardiomyocytes in an in vitro model of cardiac cell therapy
  5463. Stem cell therapy for diabetic erectile dysfunction in rats: a meta-analysis
  5464. Bone marrow cells differentiation into organ cells using Stem cell therapy
  5465. Assessment of pulp regeneration induced by Stem cell therapy by magnetic resonance imaging
  5466. Mesenchymal Stem cell therapy in retinal and optic nerve diseases: An update of clinical trials
  5467. A rational strategy for the use of amniotic epithelial Stem cell therapy for liver diseases
  5468. Stem cell therapy: a promising biological strategy for tendon–bone healing after anterior cruciate ligament reconstruction
  5469. Evaluating mesenchymal Stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial
  5470. Stem cells of mesenchymal nature within the process of vascular remodeling: cellular basis, clinical relevance, and implications for Stem cell therapy
  5471. Human embryonic Stem cell therapy in chronic spinal cord injury: a retrospective study
  5472. Stem cell therapy for Alzheimer’s disease: hope or hype?
  5473. Recent insights: mesenchymal stromal/Stem cell therapy for acute respiratory distress syndrome
  5474. Stem cell therapy for interstitial cystitis/bladder pain syndrome
  5475. Intravenous adipose-derived mesenchymal Stem cell therapy for the treatment of feline asthma: a pilot study
  5476. Recent progress in Stem cell therapy for diabetic nephropathy
  5477. … CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine/cyclophosphamide preparative regimen and post-CAR hematopoietic Stem cell
  5478. The IMPACT-CABG trial: A multicenter, randomized clinical trial of CD133+ Stem cell therapy during coronary artery bypass grafting for ischemic …
  5479. Transamniotic Stem cell therapy (TRASCET) mitigates bowel damage in a model of gastroschisis
  5480. Fibrin matrices enhance the transplant and efficacy of cytotoxic Stem cell therapy for post-surgical cancer
  5481. Advances in Stem cell therapy for leukemia
  5482. Utilizing pharmacotherapy and mesenchymal Stem cell therapy to reduce inflammation following traumatic brain injury
  5483. Self-assembling peptides optimize the post-traumatic milieu and synergistically enhance the effects of neural Stem cell therapy after cervical spinal cord injury
  5484. Mesenchymal Stem cell therapy for refractory scleroderma: a report of 2 cases
  5485. Strategies to enhance the effectiveness of adult Stem cell therapy for ischemic heart diseases affecting the elderly patients
  5486. Current state and perspectives of Stem cell therapy for stroke
  5487. A comparison between placental and amniotic mesenchymal Stem cells for transamniotic Stem cell therapy (TRASCET) in experimental spina bifida
  5488. Stem cell therapy for epidermolysis bullosa—does it work?
  5489. Stem cell therapy for the treatment of Leydig cell dysfunction in primary hypogonadism
  5490. Nanovesicle-mediated syStemic delivery of microRNA-34a for CD44 overexpressing gastric cancer Stem cell therapy
  5491. Effectiveness of autologous Stem cell therapy for the treatment of lower extremity ulcers: A syStematic review and meta-analysis
  5492. Stem cell therapy‒Approach for multiple sclerosis treatment
  5493. Stem cell therapy for the heart: blind alley or magic bullet?
  5494. Effect of Stem cell therapy on bone mineral density: a meta-analysis of preclinical studies in animal models of osteoporosis
  5495. Mesenchymal Stem cell therapy in a rat model of birth-trauma injury: functional improvements and biodistribution
  5496. Safety of mesenchymal Stem cell therapy: A syStematic review and meta-analysis
  5497. Efficacy of CD34+ Stem cell therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance
  5498. Chimeric antigen receptor T cell therapy targeting CD19-positive leukemia and lymphoma in the context of Stem cell transplantation
  5499. Stem cell therapy in nonneovascular age-related macular degeneration
  5500. … to cell communication, autophagy and mitochondrial dysfunction in a model of hepatocellular carcinoma: Potential protective effects of curcumin and Stem cell therapy
  5501. Transplantation and Stem cell therapy for cerebellar degenerations
  5502. Mesenchymal Stem cell therapy for the treatment of vocal fold scarring: a syStematic review of preclinical studies
  5503. Potential strategies to address the major clinical barriers facing Stem cell regenerative therapy for cardiovascular disease: a review
  5504. Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted Stem cell therapy
  5505. Clinical course and outcomes of patients with multiple myeloma who relapse after autologous Stem cell therapy
  5506. Mesenchymal Stem cell: a new horizon in cancer gene therapy
  5507. A role for the host in the roadmap to diabetes Stem cell therapy
  5508. Stem cell therapy for the central nervous syStem in lysosomal storage diseases
  5509. Stem cell therapy for perianal fistulas in Crohn’s disease
  5510. Efficacy of Stem cell therapy in amyotrophic lateral sclerosis: a syStematic review and meta-analysis
  5511. Senescence in human mesenchymal Stem cells: functional changes and implications in Stem cell-based therapy
  5512. Mesenchymal Stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation
  5513. Current state of Stem cell therapy for ischemic heart disease
  5514. Molecular docking study of natural alkaloids as multi-targeted hedgehog pathway inhibitors in cancer Stem cell therapy
  5515. Features specific to retinal pigment epithelium cells derived from three-dimensional human embryonic Stem cell cultures—a new donor for cell therapy
  5516. Human platelet lysate as a replacement for fetal bovine serum in limbal Stem cell therapy
  5517. Mesenchymal Stem cell therapy for acute radiation syndrome
  5518. Designing 3D mesenchymal Stem cell sheets merging magnetic and fluorescent features: when cell sheet technology meets image-guided cell therapy
  5519. Mesenchymal Stem/stromal cell‐derived extracellular vesicles as a new approach in Stem cell therapy
  5520. Optimization of magnetic hyperthermia effect for breast cancer Stem cell therapy
  5521. Consistently inconsistent—bone marrow mononuclear Stem cell therapy following acute myocardial infarction: a decade later
  5522. Photodynamic approach for teratoma-free pluripotent Stem cell therapy using CDy1 and visible light
  5523. Mesenchymal Stem cell therapy associated with endurance exercise training: effects on the structural and functional remodeling of infarcted rat hearts
  5524. Stem cell therapy for white matter disorders: don’t forget the microenvironment!
  5525. Challenges of Stem cell therapy in developing country
  5526. Stem cell therapy for sequestering neuroinflammation in traumatic brain injury: an update on exosome-targeting to the spleen.
  5527. Can chondral healing be improved following microfracture? The effect of adipocyte tissue derived Stem cell therapy
  5528. Improving Stem cell therapy in cardiovascular diseases: the potential role of microRNA
  5529. Mesenchymal Stem cell therapy for treatment of craniofacial bone defects: 10 years of experience
  5530. Bone marrow derived Stem cell therapy for type 2 diabetes mellitus
  5531. Stem cell therapy for neurodegenerative diseases: Strategies for regeneration against degeneration
  5532. Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension
  5533. Stem cell-based therapy: Improving myocardial cell delivery
  5534. Osteoporosis: the current status of mesenchymal Stem cell-based therapy
  5535. … vector technology limits DNA size restrictions on ex vivo gene delivery using nanoparticle vectors: Overcoming a translational barrier in neural Stem cell therapy
  5536. Mesenchymal Stem cell therapy promotes the improvement and recovery of renal function in a preclinical model
  5537. Umbilical cord as prospective source for mesenchymal Stem cell-based therapy
  5538. The cancer Stemcell signaling network and resistance to therapy
  5539. Preface: sight restoration through Stem cell therapy
  5540. Stem cell therapy for knee pain—what exactly are we injecting, and why?
  5541. Potential for Stem cell‐based periodontal therapy
  5542. Mesenchymal Stem cell-based therapy in kidney transplantation
  5543. cell therapy using bone marrow-derived Stem cell overexpressing BMP-7 for degenerative discs in a rat tail disc model
  5544. Mesenchymal Stem cell-based therapy for kidney disease: a review of clinical evidence
  5545. Fraudsters operate and officialdom turns a blind eye: a proposal for controlling Stem cell therapy in China
  5546. The use of mathematical modelling for improving the tissue engineering of organs and Stem cell therapy
  5547. Advances in Stem cell and cell-based gene therapy approaches for experimental acute lung injury: a review of preclinical studies
  5548. Cancer Stem cell metabolism: a potential target for cancer therapy
  5549. Advances in Stem cell therapy: bench to bedside
  5550. Stem cell therapy and congenital heart disease
  5551. Effect of Stem cell-based therapy for ischemic stroke treatment: a meta-analysis
  5552. An update on human Stem cell-based therapy in Parkinson’s disease
  5553. Hypoxic preconditioning enhances dental pulp Stem cell therapy for infection-caused bone destruction
  5554. Hypoxia-specific, VEGF-expressing neural Stem cell therapy for safe and effective treatment of neuropathic pain
  5555. Cancer Stem cell quiescence and plasticity as major challenges in cancer therapy
  5556. The potential of nanofibers in tissue engineering and Stem cell therapy
  5557. pH-sensitive and thermosensitive hydrogels as Stemcell carriers for cardiac therapy
  5558. Mesenchymal Stem cell-derived exosomes: new opportunity in cell-free therapy
  5559. Therapeutic potential of mesenchymal Stem cell based therapy for osteoarthritis
  5560. Gene therapy and Stem cell transplantation in retinal disease: the new frontier
  5561. Stem cell therapy of ischemic heart disease
  5562. Mesenchymal Stem cell therapy for the streptozotocin-induced neurodegeneration in rats
  5563. Allogeneic clonal mesenchymal Stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study
  5564. Personalized Stem cell therapy to correct corneal defects due to a unique homozygous-heterozygous mosaicism of ectrodactyly-ectodermal dysplasia-clefting …
  5565. Human pluripotent Stem cells: myths and future realities for liver cell therapy
  5566. Autologous Stem cell‐based therapy for sickle cell leg ulcer: a pilot study
  5567. Meta-analysis of preclinical data reveals efficacy of cardiac Stem cell therapy for heart repair
  5568. Cytomegalovirus viral load and mortality after haemopoietic Stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study
  5569. In utero Stem cell transplantation and gene therapy: Recent progress and the potential for clinical application
  5570. Towards personalized regenerative cell therapy: mesenchymal Stem cells derived from human induced pluripotent Stem cells
  5571. Lentiviral hematopoietic Stem cell gene therapy for X-linked severe combined immunodeficiency
  5572. Mesenchymal Stem cell therapy
  5573. Immunomodulatory role of mesenchymal Stem cell therapy in vascularized composite allotransplantation
  5574. Harnessing mesenchymal Stem cell homing as an anticancer therapy
  5575. Remodeling an infarcted heart: novel hybrid treatment with transmyocardial revascularization and Stem cell therapy
  5576. Lentiviral haemopoietic Stemcell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial
  5577. Engineered biomaterials to enhance Stem cell‐based cardiac tissue engineering and therapy
  5578. Concise review: pluripotent Stem cell-derived cardiac cells, a promising cell source for therapy of heart failure: where do we stand?
  5579. Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer
  5580. Autologous cell therapy with CD133+ bone marrow-derived Stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study
  5581. Biomaterials control of pluripotent Stem cell fate for regenerative therapy
  5582. Inhibition of Src and forkhead box O1 signaling by induced pluripotent Stemcell therapy attenuates hyperoxia-augmented ventilator-induced diaphragm dysfunction
  5583. Overview and perspectives of mesenchymal Stem cell therapy in intensive care medicine
  5584. In utero Stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application
  5585. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous Stem cell transplantation
  5586. Optimizing autologous cell grafts to improve Stem cell gene therapy
  5587. Efficacy of umbilical cord-derived mesenchymal Stem cell-based therapy for osteonecrosis of the femoral head: a three-year follow-up study
  5588. The role of conditioning in hematopoietic Stemcell gene therapy
  5589. Cyclooxygenase-2: a role in cancer Stem cell survival and repopulation of cancer cells during therapy
  5590. IL1RAP expression as a measure of leukemic Stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome
  5591. Stemcell-membrane camouflaging on near-infrared photoactivated upconversion nanoarchitectures for in vivo remote-controlled photodynamic therapy
  5592. Cancer Stem cell-based models of colorectal cancer reveal molecular determinants of therapy resistance
  5593. Hypoxic preconditioning enhances neural Stem cell transplantation therapy after intracerebral hemorrhage in mice
  5594. On-chip clonal analysis of glioma-Stemcell motility and therapy resistance
  5595. Exercise as an adjuvant therapy for hematopoietic Stem cell mobilization
  5596. Mesenchymal Stem cell-based gene therapy: A promising therapeutic strategy
  5597. Variable eculizumab clearance requires pharmacodynamic monitoring to optimize therapy for thrombotic microangiopathy after hematopoietic Stem cell
  5598. Progress and prospect of mesenchymal Stem cell-based therapy in atherosclerosis
  5599. Stem and progenitor cell-based therapy of the central nervous syStem: hopes, hype, and wishful thinking
  5600. Stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy
  5601. Enzyme replacement therapy prior to haematopoietic Stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres
  5602. Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood Stem cell apheresis product …
  5603. Effects of Stem cell therapy on protein profile of parkinsonian rats using an18O‐labeling quantitative proteomic approach
  5604. Innervation of dystrophic muscle after muscle Stem cell therapy
  5605. Stem cell secretome-rich nanoclay hydrogel: a dual action therapy for cardiovascular regeneration
  5606. Acute myeloid leukemia Stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1
  5607. Stem cell-based therapy for diseases of the retinal pigment epithelium: from bench to bedside
  5608. Induction therapy pre‐autologous Stem cell transplantation in immunoglobulin light chain amyloidosis: a retrospective evaluation
  5609. … clinical trial (RCT) of tandem myeloablative autologous Stem cell transplant (ASCT) using peripheral blood Stem cell (PBSC) as consolidation therapy for high-risk …
  5610. Mesenchymal Stem cell-based gene therapy for erectile dysfunction
  5611. Electrospun nanofibrous scaffolds increase the efficacy of Stem cell-mediated therapy of surgically resected glioblastoma
  5612. … -related mortality in children undergoing haematopoietic Stem cell transplantation compared to conventional anticancer therapy: a multicentre nationwide …
  5613. The endocrine regulation of Stem cells: physiological importance and pharmacological potentials for cell-based therapy
  5614. Thiotepa-based high-dose therapy for autologous Stem cell transplantation in lymphoma: a retrospective study from the EBMT
  5615. Stem cell therapy for Breast Cancer: A Review
  5616. Delivery modes for cardiac Stem cell therapy
  5617. Bringing cardiac Stem cell therapy from bench to bedside: lessons from the past and future perspectives
  5618. Role of Stem cell transplant and maintenance therapy in plasma cell disorders
  5619. Pim1 Overexpressing ckit+ Cardiac Stem cells in Cardiac Regeneration: Preconditioning as Next-Generation Stem cell therapy?
  5620. Low-level laser therapy prevents severe oral mucositis in patients submitted to hematopoietic Stem cell transplantation: a randomized clinical trial
  5621. … nanoparticle delivery of small interfering RNA and retinoic acid with temporally release ability to control neural Stem cell differentiation for Alzheimer’s disease therapy
  5622. Wharton’s jelly-derived mesenchymal Stem cell therapy to improve β-cell function in patients with type 1 diabetes and ketoacidosis: a single-centre, single-group, open …
  5623. Umbilical cord derived mesenchymal Stem cells useful in insulin production-another opportunity in cell therapy
  5624. Arrhythmogenesis: a roadblock to cardiac Stem cell therapy
  5625. Clinical observation of employment of umbilical cord derived mesenchymal Stem cell for juvenile idiopathic arthritis therapy
  5626. Fail-safe therapy by gamma-ray irradiation against tumor formation by human-induced pluripotent Stem cell-derived neural progenitors
  5627. Partial cranial cruciate ligament tears treated with Stem cell and platelet-rich plasma combination therapy in 36 dogs: a retrospective study
  5628. Stem cell therapy and Orthopedics
  5629. Prospects of Neural Stem cell therapy for Alzheimer’s Disease
  5630. Role of Stem cell therapy in oral premalignant and malignant lesions
  5631. Interventional Stem cell therapy
  5632. Effects of FVIII immunity on hepatocyte and hematopoietic Stem cell–directed gene therapy of murine hemophilia A
  5633. Hematopoietic Stem cell transplantation for scleroderma: effective immunomodulatory therapy for patients with pulmonary involvement
  5634. Use of human cadaveric mesenchymal Stem cells for cell therapy of a chronic radiation-induced skin lesion: A case report
  5635. Integrating gene correction in the reprogramming and transdifferentiation processes: a one-step strategy to overcome Stem cell-based gene therapy limitations
  5636. Synergistic chemo–photothermal therapy of breast cancer by mesenchymal Stem cell-encapsulated yolk–shell GNR@ HPMO-PTX nanospheres
  5637. … mucositis of patients undergoing haematopoietic Stem cell transplantation and receiving specialised oral care with low‐level laser therapy: a prospective observational …
  5638. Adoptive transfer of Aspergillus-specific T cells as a novel anti-fungal therapy for hematopoietic Stem cell transplant recipients: Progress and challenges
  5639. Human embryonic Stem cell therapy in Crohn’s disease: A case report
  5640. Resveratrol augments therapeutic efficiency of mouse bone marrow mesenchymal Stem cell-based therapy in experimental autoimmune encephalomyelitis
  5641. Intensification therapy with bortezomib-melphalan-prednisone versus autologous Stem cell transplantation for newly diagnosed multiple myeloma: an …
  5642. Preemptive antiviral therapy for CMV infection in allogeneic Stem cell transplant recipients guided by the viral doubling time in the blood
  5643. Do increased doses to Stemcell niches during radiation therapy improve glioblastoma survival?
  5644. … may be useful as a prognostic indicator in colorectal cancer, a tool for optimizing therapy and supportive evidence for the cancer Stem cell hypothesis: a meta …
  5645. Mesenchymal Stem cell-based therapy for ischemic stroke
  5646. Hypoxia-targeted 131I therapy of hepatocellular cancer after syStemic mesenchymal Stem cell-mediated sodium iodide symporter gene delivery
  5647. Analysis of Ambient Influences Affecting Interleukin-6 Secretion in the Context of Clinical Trials of Stem cell therapy for Myocardial Infarction.
  5648. Human mesenchymal Stem cell therapy for acute graft versus host disease
  5649. Stem cell therapy in animal models of allergic airway diseases
  5650. … of a preemptive antiviral therapy strategy based on combined virological and immunological monitoring for active cytomegalovirus infection in allogeneic Stem cell
  5651. Stem cell therapy seems safe in refractory RA
  5652. Adult nephrotic syndrome after hematopoietic Stem cell transplantation: renal pathology is the best predictor of response to therapy
  5653. Results of a first-in-man study of mesenchymal Stem cell therapy for bronchiolitis obliterans syndrome
  5654. Pluripotent Stem cell based gene therapy for hematological diseases
  5655. Comparative analysis of human mesenchymal Stem cells derived from bone marrow, placenta, and adipose tissue as sources of cell therapy
  5656. Frontline therapy with carfilzomib, lenalidomide, and dexamethasone (KRd) induction followed by autologous Stem cell transplantation, Krd consolidation and …
  5657. … of patients with multiple sclerosis using reverse nutech functional score and expanded disability status scale after human embryonic Stem cell therapy
  5658. The effect of combined pulsed wave low-level laser therapy and human bone marrow mesenchymal Stem cell-conditioned medium on open skin wound healing in …
  5659. Evaluation of simvastatin and bone marrow-derived mesenchymal Stem cell combination therapy on airway remodeling in a mouse asthma model
  5660. Extracorporeal photopheresis as a new supportive therapy for bronchiolitis obliterans syndrome after allogeneic Stem cell transplantation
  5661. Leukemic Stem cell quantification in newly diagnosed patients with chronic myeloid leukemia predicts response to nilotinib therapy
  5662. Dynamics of Epstein‐Barr viral load after hematopoietic Stem cell transplantation and effect of preemptive rituximab therapy
  5663. … of expression of CD44, a cancer Stem cell marker, on the treatment outcomes of intensity modulated radiation therapy in patients with oropharyngeal squamous cell
  5664. Adenoviral gene therapy for diabetic keratopathy: effects on wound healing and Stem cell marker expression in human organ-cultured corneas and limbal …
  5665. Biomanufacturing of human mesenchymal Stem cells in cell therapy: influence of microenvironment on scalable expansion in bioreactors
  5666. Nonhuman primate model in clinical modeling of diseases for Stem cell therapy
  5667. Looking into the future: Using induced pluripotent Stem cells to build two and three dimensional ocular tissue for cell therapy and disease modeling
  5668. Application of droplet digital PCR for estimating vector copy number states in Stem cell gene therapy
  5669. Differences of cytomegalovirus diseases between kidney and hematopoietic Stem cell transplant recipients during preemptive therapy
  5670. Stem cell therapy in wound healing and tissue regeneration
  5671. Response to antiviral therapy in haematopoietic Stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV …
  5672. Initiation of Antiretroviral therapy Restores CD4+ T Memory Stem cell Homeostasis in Simian Immunodeficiency Virus-Infected Macaques
  5673. Activation of endogenous human Stem cell-associated retroviruses (SCARs) and therapy-resistant phenotypes of malignant tumors
  5674. Safety of ruxolitinib therapy prior to allogeneic hematopoietic Stemcell transplantation for myeloproliferative neoplasms
  5675. Can yoga therapy stimulate Stem cell trafficking from bone marrow?
  5676. The development of a Stem cell therapy for deafness
  5677. Initial embryology and pluripotent Stem cells in the pig—The quest for establishing the pig as a model for cell therapy
  5678. Combined effects of low-level laser therapy and human bone marrow mesenchymal Stem cell conditioned medium on viability of human dermal fibroblasts cultured in …
  5679. Stem cell therapy for cardiovascular diseases
  5680. … reach allogeneic Stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy
  5681. Mesenchymal Stem cell therapy for corneal diseases
  5682. … in leukemia patients with allogeneic hematopoietic Stem cell transplantation: novel clinical potential strategies for the prevention and cellular therapy of graft‐versus …
  5683. Editorial commentary: Precise nomenclature is critical for evaluating progress in the field of lipoaspirate-derived Stem cell therapy
  5684. … dehydrogenase is a prognostic marker for mesenchymal Stem cell-mediated cytosine deaminase gene and 5-fluorocytosine prodrug therapy for the treatment …
  5685. Correlation between canine inflammatory bowel disease activity indices after Stem cell therapy
  5686. Effects of healing touch and relaxation therapy on adult patients undergoing hematopoietic Stem cell transplant: a feasibility pilot study
  5687. Antifungal therapy in hematopoietic Stem cell transplant recipients
  5688. Comparative analysis of human mesenchymal Stem cells from umbilical cord, dental pulp, and menstrual blood as sources for cell therapy
  5689. Clofarabine salvage therapy before allogeneic hematopoietic Stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
  5690. Endurable injectable mesenchymal Stem cell therapy for osteoarthritis by encapsulation in alginate constructs
  5691. The role of high-dose melphalan and autologous Stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy
  5692. Developing induced pluripotent Stem cell-based therapy for the masses
  5693. Cytomegalovirus pre‐emptive therapy after hematopoietic Stem cell transplantation in the era of real‐time quantitative PCR: comparison with recipients of solid organ …
  5694. Enhancing therapeutic efficacy and reducing cell dosage in Stem cell transplantation therapy for ischemic limb diseases by modifying the cell injection site
  5695. cell delivery with polymer hydrogel for treatment of intervertebral disc degeneration: from 3D culture to design of the delivery device for minimally invasive therapy
  5696. Allogeneic hematopoietic Stem cell transplantions in blastic plasmacytoid dendritic cell neoplasm in first complete remission: an effective therapy for a rare disease
  5697. Translational lab-to-clinic hurdles in Stem cell therapy
  5698. Neural Stem cell therapy for Easing Status Epilepticus Induced Hippocampus Dysfunction and Chronic Temporal Lobe Epilepsy
  5699. Studying mesodiencephalic dopaminergic neuron development in vivo to improve Stem cell therapy in Parkinson’s disease
  5700. CAR T cells targeted with a high affinity scFv against the HCMV glycoprotein Gb as adoptive T cell therapy after hematopoietic Stem cell transplantation
  5701. Stem cell therapy: Accepted Therapies, Managing the Hope of Society, and a Legal Perspective
  5702. Amniotic Stem cell transplantation therapy for type 2 diabetes: 3 years’ follow-up report
  5703. Stem cell therapy for brain tumors
  5704. A study of human leukocyte antigen mismatched cellular therapy (Stem cell microtransplantation) in high-risk myelodysplastic syndrome or transformed acute …
  5705. … incidence of afebrile bloodstream infection detected by surveillance blood culture in patients on corticosteroid therapy after allogeneic hematopoietic Stem cell
  5706. Stem cell therapy for ischemic heart disease
  5707. Addendum: Stem cell therapy in postinfarction chronic coronary heart disease
  5708. Behavior, PET and histology in novel regimen of MPTP marmoset model of Parkinson’s disease for long-term Stem cell therapy
  5709. Distinct responses of Stem cells to telomere uncapping—a potential strategy to improve the safety of cell therapy
  5710. Piperacillin‐tazobactam vs. imipenem‐cilastatin as empirical therapy in hematopoietic Stem cell transplantation recipients with febrile neutropenia
  5711. Lab-to-clinic application of Stem cell therapy for stroke
  5712. Stem cell therapy in liver cirrhosis
  5713. Corticosteroid use as adjunct therapy for respiratory syncytial virus infection in adult allogeneic Stem cell transplant recipients
  5714. Hematopoietic Stem cell transplantation and lentiviral vector‐based gene therapy for Krabbe’s disease: Present convictions and future prospects
  5715. Quantitative assessment of rat corneal thickness and morphology during Stem cell therapy by high-speed optical coherence tomography
  5716. Advances in research of Stem cell therapy for human parasitic diseases: a review
  5717. … multifocal leukoencephalopathy after autologous peripheral blood Stem cell transplantation in a patient with multiple myeloma treated with combination therapy
  5718. In support of upfront Stem cell transplantation as first-line therapy for paediatric patients with idiopathic severe aplastic anaemia who lack a sibling donor.
  5719. … in children and adolescents with acute leukemias undergoing myeloablative therapy and allogeneic hematopoietic Stem cell transplantation: a pediatric blood …
  5720. A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous Stem cell transplantation for non‐Hodgkin …
  5721. Low pH preconditioned amniotic epithelial cells for Stem cell therapy of cancer
  5722. Successful Curative therapy With Rituximab and Allogeneic Haematopoietic Stem cell Transplantation for MALT Lymphoma Associated With STK4‐Mutated CD4+ …
  5723. cell-based therapy in TBI: magnetic retention of neural Stem cells in vivo
  5724. Prostate Stem cell antigen expression in radical prostatectomy specimens predicts early biochemical recurrence in patients with high risk prostate cancer …
  5725. Impact of outpatient non-myeloablative haematopoietic Stem cell transplantation in quality of life vs. conventional therapy
  5726. Haploidentical hematopoietic Stem cell transplantation for nonresponders to immunosuppressive therapy against acquired severe aplastic anemia
  5727. Haematopoietic Stem cell transplants should be a second-line therapy for highly active MS-YES.
  5728. … outcome of elderly patients with multiple myeloma treated with tandem melphalan 100 high-dose therapy, autologous Stem cell transplantation and novel …
  5729. Mesenchymal Stem cell therapy for recessive dystrophic epidermolysis bullosa: prospects and clinical progress
  5730. Muscular Dystrophy: Stem cell therapy
  5731. Neural Stem cell therapy for Parkinson’s Disease
  5732. Shining light on the sprout of life: optogenetics applications in Stem cell research and therapy
  5733. Haploidentical hematopoietic Stem cell transplantation: Guidelines from the Francophone society of marrow transplantation and cellular therapy (SFGM-TC)
  5734. Haematopoietic Stem cell transplants should be a second-line therapy for highly active MS–NO
  5735. Role of Stem cell therapy in Treatment of Muscular Dystrophy
  5736. Stem cell therapy regenerates primate hearts
  5737. Novel subventricular zone early progenitor cell-specific adenovirus for in vivo therapy of central nervous syStem disorders reinforces brain Stem cell heterogeneity
  5738. Pioglitazone effect on glioma Stem cell lines: really a promising drug therapy for glioblastoma?
  5739. Stem cell therapy against chronic myocarditis
  5740. Multi-cycle chemotherapy with the glycolipid-like polymeric micelles evade cancer Stem cell enrichment in breast cancer therapy
  5741. The effects of transplanted cells in Stem cell therapy for myocardial ischemia
  5742. Stem cell genetic therapy for Fanconi Anemia-a New Hope
  5743. Breaking dogma for future therapy using Stem cell-Where we have reached?
  5744. A descriptive study on the safety and efficacy of mesenchymal Stem cell therapy for Parkinson’s disease: A case series
  5745. Stem cell therapy in Multiple Sclerosis: Current Progress and Future Prospects.
  5746. Stem cell-derived oligodendroglial cells for therapy in neurological diseases
  5747. Degenerative Disc Disease: A Review of cell Technologies and Stem cell therapy
  5748. Hypomethylating agents as bridging therapy before allogeneic hematopoietic Stem cell transplantation in patients with chronic myelomonocytic leukemia?
  5749. Daratumumab is an effective and safe salvage therapy in relapsed/refractory patients with multiple myeloma after allogeneic Stem cell transplantation
  5750. The potential application of biomaterials in cardiac Stem cell therapy
  5751. Maintenance therapy after autologous haematopoietic Stem cell transplantation (auto-HSCT) in multiple myeloma patients with and without minimal residual …
  5752. Research highlights on Stem cell therapy for the treatment of Peyronie’s disease
  5753. Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic Stem cell transplant survivorship patients in Australia
  5754. Experimental myocardial Stem cell therapy for ST-elevation myocardial infarction: rationale and level of evidence.
  5755. Stem cell therapy for the Treatment of Cartilage Defects and Osteoarthritis
  5756. Emerging regenerative approaches for periodontal regeneration: from cytokine therapy to Stemcell therapy
  5757. Stem cell therapy for early stage osteonecrosis: challenges and future research directions
  5758. Pluripotent human embryonic Stem cell derived neural lineages for in vitro modelling of enterovirus 71 infection and therapy
  5759. Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous Stem cell
  5760. Effectiveness of human mesenchymal Stem cell therapy for left ventricular dysfunction in ischemic cardiomyopathy is influenced by cell injection site
  5761. Preclinical study of cell therapy for osteonecrosis of the femoral head with allogenic peripheral blood-derived mesenchymal Stem cells
  5762. Transfer of allogeneic Stem cell transplant recipients to the intensive care unit: guidelines from the Francophone society of marrow transplantation and cellular therapy
  5763. Bone marrow-derived mesenchymal Stem cell therapy for myocardial infarction: a syStematic review and meta-analysis
  5764. Migratory cancer side population cells induces Stem cell altruism in bone marrow mesenchymal Stem cells to resist therapy, and enhance tumorigenic potential of non …
  5765. Ex-vivo expansion of cardiac Stem cell therapy products for clinical use: the importance of moving towards the optimization of process development
  5766. Magnetic labelling of mesenchymal Stem cells with iron-doped hydroxyapatite nanoparticles as tool for cell therapy
  5767. Improved epilepsy and speech outcomes with human embryonic Stem cell therapy in children with cerebral palsy
  5768. Impact of Telomere Shortening with Age in Stem cell therapy: New Strategies to Increase Telomere Length
  5769. … followed by donor lymphocyte infusion (DLI): interim results of the HOVON-116 Phase I/II Feasibility Study in poor-risk AML recipients of allogeneic Stem cell
  5770. Non-directional conjugation of fluorescent antibodies to gold nanoparticles for Stem cell therapy
  5771. Total body irradiation must be delivered at high dose for efficient engraftment and tolerance in a rhesus Stem cell gene therapy model
  5772. Induced pluripotent Stem cells for modeling and cell therapy of Parkinson’s disease
  5773. Improvements made with Stem cell therapy
  5774. 90Y-ibritumomab-tiuxetan consolidation therapy for advanced-stage mantle cell lymphoma after first-line autologous Stem cell transplantation: is it time for a step …
  5775. Stem cell therapy”-A REVIEW
  5776. … and interferon-α into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic Stem cell
  5777. Immunobiology of dental tissue-derived Stem cells; as a potentiated candidate for cell therapy
  5778. Basics of Stem cell therapy.
  5779. Tracking of iron-labeled human neural Stem cells by magnetic resonance imaging in cell replacement therapy for Parkinson’s disease
  5780. Stem cell therapy in ST-Elevation Myocardial Infarction With Reduced Ejection Fraction: A Multicenter, Randomized, Double-Blind Trial. From MiHeart/AMI …
  5781. Discussion on the management status of Stem cell therapy in clinical application in China
  5782. SyStemic autologous mesenchymal Stem cell therapy for immunomodulation in resistant myasthenia gravis
  5783. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic Stem cell
  5784. The future of Stem cell and cell therapy in ophthalmology
  5785. Mesenchymal Stem cells and cell therapy for bone repair
  5786. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage therapy with High Peripheral Blood Stem cell Mobilization Capacity for Poorly …
  5787. Stem cell therapy: The Methods in the Madness
  5788. Cancer Stem cell markers in nasopharyngeal carcinoma and its relevance for therapy
  5789. Clinical features before hematopoietic Stem cell transplantation or enzyme replacement therapy of children with combined immunodeficiency
  5790. Benefits Of Young Donor Adipose-Derived Mesenchymal Stem cell therapy In The Rescue Of Bleomycin-Induced Pulmonary Fibrosis In An Aged Mouse Model
  5791. Signaling Networks of Retinal Ganglion cell Formation and the Potential Application of Stem cell–Based therapy in Retinal Degenerative Diseases
  5792. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic Stem cell transplantation: two case reports
  5793. 242. Genetically Engineered Mesenchymal Stem cell Spheroids for Brain Tumor therapy
  5794. Tocilizumab is effective therapy for cytokine release syndrome after haploidentical peripheral blood Stem cell transplantation with post-transplant cyclophosphamide
  5795. Recent developments in Stem and progenitor cell therapy for cardiac repair
  5796. Current biosafety considerations in Stem cell therapy
  5797. Stem cell transplantation versus medical therapy in patients with advanced myelofibrosis: matched survival analysis and the effect of JAK2 inhibitor therapy
  5798. Advances in research of Stem cell therapy for human parasitic diseases: a review
  5799. Transamniotic Stem cell therapy (TRASCET)
  5800. Autologous Stem cell therapy & its Effects on COPD
  5801. Recovery of full donor chimerism with ibrutinib therapy in relapsed CLL after allogeneic Stem cell transplantation.
  5802. Haematopoietic Stem cell transplants should be a second-line therapy for highly active MS–Commentary
  5803. Recruiter-patients as ambiguous symbols of health: bionetworking and Stem cell therapy in India
  5804. … and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: A study on behalf of the French society of bone marrow transplantation or cell therapy
  5805. MECHANISMS BEHIND Stem cell therapy IN ACUTE MYOCARDIAL INFARCTION
  5806. Cancer Stem cell and gastrointestinal cancer: current status, targeted therapy and future implications
  5807. Stem cell therapy for Ischemic Stroke
  5808. … for patients hospitalized during allogeneic Stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy
  5809. Stem cell therapy for Acute Myocardial Infarction: The European Experience
  5810. Stem cell therapy in postinfarction chronic coronary heart disease
  5811. Recruiter-patients as ambiguous symbols of health: bionetworking and Stem cell therapy in India
  5812. Stem cell therapy for Autoimmune Disease
  5813. Stem cell therapy for Abrogating Stroke-Induced
  5814. An analysis of consent with specific regard to Stem cell therapy and research
  5815. Risk-adjusted therapy of acute lymphoblastic leukemia can optimize the indication of Stem cell transplantation and cranial irradiation: results of Japan …
  5816. Clinical application of pluripotent Stem cells: an alternative cell-based therapy for treating liver diseases?
  5817. Current global trends in regulations for Stem cell therapy and the way ahead for India
  5818. Stem cell therapy as a potential treatment for glaucoma
  5819. … myeloma (MM) patients (Pts) after a cybord induction regimen and autologous Stem cell transplantation (ASCT): impact of maintenance therapy in the real …
  5820. Regenerative Stem cell therapy in ophthalmology.
  5821. Understanding the signaling pathway as a new strategy for bum management and treatment based on Stem cell therapy
  5822. Efficacy and prognostic factors of induction therapy combined with autologous Stem cell transplantation in 201 patients with multiple myeloma
  5823. Stem cell therapy and Macular Degeneration
  5824. A role for the host in the roadmap to diabetes Stem cell therapy
  5825. Hemostasis and Stem cell therapy in Myocardial Infarction
  5826. The Role of Stem cell therapy in Alzheimer’s Disease
  5827. … of patients with chronic myeloid leukemia and a low-risk score: allogeneic hematopoietic Stem cell transplantation in the era of targeted therapy. A report from …
  5828. A MESENCHYMAL Stem cell therapy CAN RESULT IN THE DIFFERENT OUTCOMES OF INFECTIOUS INFLAM-MATORY PROCESS
  5829. Stem cell therapy for a debilitating retinal disorder
  5830. Stem cell therapy AS A POTENTIAL TREATMENT FOR GLAUCOMA
  5831. Autologous Stem cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral therapy (cART): A Retrospective …
  5832. Stem cell therapy Against Cardiac Inflammation
  5833. In Vitro Expansion and Functional Enhancement of Human Mesenchymal Stem cell in cell therapy
  5834. Stem cell therapy for Neonatal Lung Diseases
  5835. Analysis of the Expectation of Stem cell therapy in Patients with Alzheimer’s Disease
  5836. MESENCHYMAL Stem cell therapy IN VETERINARY DERMATOLOGY
  5837. Mesenchymal Stem cell therapy for rheumatic diseases
  5838. Mesenchymal Stem cell therapy in Rheumatoid Arthritis
  5839. Stem cell therapy for Male Enhancement & ED [Top Rated Treatment]
  5840. Recent Innovations in Stem cell therapy for Retinal Disease
  5841. Stem cell therapy ITS CHALLENGES, SUCCESSES, FAILURES AND POTENTIAL APPLICATIONS: ON-GOING TRANSLATIONAL RESEARCH
  5842. Expression patterns of cancer Stem cell markers during specific celecoxib therapy in multistep rat colon carcinogenesis bioassays
  5843. Anchored lentiviral vector episomes for Stem cell gene therapy in Fanconi anemia
  5844. Stem cell therapy for osteonecrosis
  5845. Essay: The current state of Stem celltherapy in diabetic retinopathy
  5846. Steroid pulse therapy for blood cell recovery in allogeneic hematopoietic Stem cell transplantation
  5847. Novel agent induction therapy alone or followed by autologous Stem cell transplantation in younger patients with multiple myeloma: A single‑center …
  5848. Best Non-Surgical Alternative to Spinal Fusion [Stem cell therapy]
  5849. Research progress of preconditioned Stem cell therapy on ischemic heart disease
  5850. Mesenchymal Stem cell therapy in Knee Osteoarthritis: The Way Forward
  5851. Stem cell therapy for the treatment of erectile dysfunction: where do we stand?
  5852. Characteristics of Mesenchymal Stem cells Derived from Amniotic Membrane: A Potential Candidate for Stem cell-Based therapy
  5853. Stem cell therapy for No-Option Critical Limb Ischemia
  5854. High-Dose therapy (HDT) with Melphalan and Autologous Stem cell Transplantation (ASCT) for Patients Older Than 70 Years with Multiple Myeloma
  5855. Affordable Clean Air Facility for (Stem) cell therapy in an Academic Setting
  5856. Stem cell transplantation outcomes and unrelated donor selection: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy
  5857. … Models of therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple cell Subpopulations with Leukemia Stem cell
  5858. External beam radiation therapy: a promising tool to enhance mesenchymal Stem cell migration towards tumors
  5859. Degenerative disc disease: a review of cell technologies and Stem cell therapy
  5860. The impact of Stem cell therapy on atherosclerosis progression in ST-elevation myocardial infarction patients
  5861. Translational predictive model for heart failure recovery in LVAD patients receiving Stem cell therapy
  5862. Long-term results of intramyocardial CD133+ bone marrow Stem cell therapy for myocardial ischemia: experience with Stem cell register
  5863. GW27-e0429 Meta-analysis of Studies on Stem cell therapy for Patients Undergoing Coronary Artery Bypass Grafting
  5864. Effect of Microenvironment Modulation on Stem cell therapy for Peripheral Nerve Injury
  5865. Effect of Stem cell therapy on All-Cause Mortality in Patient with Heart Failure: A Comprehensive Updated Meta-Analysis of Randomized Controlled Trials
  5866. Optimizing subretinal injection conditions for retinal gene and Stem cell therapy
  5867. Adipose-derived perivascular Stem cell as a source for cell therapy
  5868. 2015 Year in Review-Advancing the Fields of Stem cell Biology and therapy
  5869. Glial Orchestrated Neurodegeneration: An Important Crossroad for Neural Stem cell therapy to the Intestine
  5870. Abstract TMP28: Upper Extremity Motor Impairment After Ischemic Stroke-Implications for Stem cell therapy
  5871. CARDIAC Stem cell therapy AND IMAGING: A RAY OF HOPE FOR POOR HEARTS.
  5872. Role of nanodiamonds in drug delivery and Stem cell therapy
  5873. The next generation of Stem cell therapy:“From cartilage explants to arthritic patients”
  5874. … study of incidence and prognostic significance of eosinophilia after allogeneic hematopoietic Stem cell transplantation: influence of corticosteroid therapy
  5875. Application of Stem cell therapy (Ad-MSC, EPC and NPC) in a Case of Canine Spinal Injury
  5876. Effectiveness of structured teaching programme on knowledge and attitude regarding cord blood Stem cell therapy among antenatal mothers in selected private …
  5877. Challenges in translating germinal Stem cell research and therapy
  5878. The importance of cell therapy controls for a safe, EU-approved Advanced therapy Medicinal Product application to limbal Stem cell deficiency
  5879. Clinical study of cytomegalovirus infection and preemptive therapy after allogenic hematopoietic Stem cell transplantation
  5880. CRISPR/Cas9 technology: from cells to mice to Stem cell therapy
  5881. Stem cell In-Vitro Strategies for the Induction of Sensory Neurons for Inner Ear cell therapy
  5882. Advantages and limitations of the parthenogenetic embryonic Stem cells in cell therapy
  5883. cell Injection Site Influences the Human Mesenchymal Stem cell therapy Effectiveness for Left Ventricular Dysfunction in Ischemic Cardiomyopathy
  5884. Factors Determining Consent in a Randomized Trial of Intra-arterial Stem cell therapy for Sub-Acute Ischemic Stroke (P2. 386)
  5885. Novel Stem cell therapy for Heart Failure Using 3D Printed Cardiac Tissue
  5886. Mammary gland tumors in a female dog-the implications of Stem cell therapy.
  5887. The efficacy of salvage autologous Stem cell transplant for patients with multiple myeloma who received maintenance therapy following initial transplant
  5888. Transplantation routes and mechanism of mesenchymal Stem cell therapy in porcine models with acute liver failure
  5889. EVALUATION OF MESENCHYMAL Stem cell therapy IN DOXORUBICINE-INDUCED CARDIOTOXICITY IN ADULT FEMALE ALBINO RATS
  5890. The Impact Of Mesenchymal Stem cell therapy In Bronchopulmonary Dysplasia: The Interaction Between Inflammation And Oxidative Stress
  5891. Commentary: Preclinical Validation of Multilevel Intraparenchymal Stem cell therapy in the Porcine Spinal Cord
  5892. Stem cell therapy for Avascular Femoral Head Necrosis: From Preclinical to Clinical Study
  5893. DTI Analysis of the Corticospinal Tracts in Clinical Trial of Intra-Arterial Stem cell therapy for Stroke (P3. 302)
  5894. Stemcell therapy, β-cell-and islet cell-neogenesis: possible treatments of type 1 diabetes in the future?
  5895. Adoptive T-cell therapy to Prevent and Treat Parainfluenza Virus 3 (PIV-3) Infections Post Hematopoietic Stem cell Transplant (HSCT)
  5896. Human Umbilical Cord Blood Mesenchymal Stem cell Delivered Intra-nasally: A Noninvasive Stem cell therapy to Target Niemann-Pick Type C1
  5897. UK Cost-Effectiveness Analysis for Management of CMV Disease in Patients Post Allogeneic Stem cell Transplantation with a Novel Adoptive T cell therapy
  5898. Intra-Arterial Stem cell therapy for a Persistent Vegetative State Patient: A DTI Analysis of Recovery (P6. 066)
  5899. cell therapy composition for healing wounds comprising mesenchymal Stem cell or the culture medium treated with silver nano particle
  5900. Stem cell therapy to Improve Nerve Regeneration and Functional Recovery in Vascular Composite Allotransplantation (VCA)
  5901. Emerging role for USP1 in glioblastoma Stem cell maintenance and radioresistance: a potential target for glioblastoma therapy
  5902. Photodynamic approach for teratoma-free pluripotent Stem cell therapy using CDy1 and visible light**.
  5903. Abstract WP145: Intra-arterial Stem cell therapy for a Persistent Vegetative State Patient: A DTI Analysis of Recovery
  5904. Functional Validation of GLP-grade Induced Pluripotent Stem cell Derived Retinal Pigment Epithelium: developing a cell therapy for AMD.
  5905. … change in Paced Auditory Serial Addition Test (PASAT) performance following immunoablative therapy and haematopoietic Stem cell transplant in multiple …
  5906. Transmyocardial Laser Revascularization and Stem cell therapy to Remodel an Infarcted Heart
  5907. The Potential Role of Erythropoietin versus Human Umbilical Cord Blood Stem cell therapy Following Sciatic Nerve Injury In Rats
  5908. Cerebral and retinal injuries in a rat model of bronchopulmonary dysplasia: May Stem cell therapy with ECFCs repair these injuries?
  5909. The use of hyperbaric oxygen therapy for refractory hemorrhagic cystitis after allogeneic hematopoietic Stem cell transplantation
  5910. EXTH-58. DEVELOPING POLYMERIC SCAFFOLDS TO ENHANCE NEURAL Stem cell therapy FOR POST-OPERATIVE GLIOBLASTOMA
  5911. Identification of blood biomarkers and monitoring of degenerative disorders of the equine foot in response to autologous mesenchymal Stem cell therapy
  5912. D25 NEONATAL AND CONGENITAL LUNG DISEASES: The Impact Of Mesenchymal Stem cell therapy In Bronchopulmonary Dysplasia: The Interaction Between …
  5913. 129. A Myoblast Expansion SyStem for Improving the Efficiency of Autologous Stem cell therapy To Treat Muscular Dystrophy
  5914. Developing Autologous cell therapy for Age-related Macular Degeneration using Patient-specific Induced Pluripotent Stem cell derived Retinal Pigment Epithelium
  5915. … undergoing allogeneic hematopoietic Stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy
  5916. ALLOGENEIC ADIPOSE Stem cell therapy REDUCES APOPTOSIS AND PROMOTES ANTI-INFLAMMATORY MACROPHAGES PHENOTYPE IN A PORCINE …
  5917. Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic Stem cell transplantation
  5918. Stemcell-specific aptamers for targeted cancer therapy
  5919. C39 IPF: MORE ON DIAGNOSIS AND therapy: Benefits Of Young Donor Adipose-Derived Mesenchymal Stem cell therapy In The Rescue Of Bleomycin-Induced …
  5920. Bone marrow Stem cells in response to intervertebral disc-like matrix acidity and oxygen concentration: implications for cell-based regenerative therapy
  5921. Induced pluripotent Stem cells in Huntington’s disease: Disease modeling and the potential for cell-based therapy
  5922. Treatment with Bortezomib (Bor) Based therapy Followed By Autologous Stem cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis …
  5923. Efficacy of marrow-derived mesenchymal Stem cell-based therapy compared with conservative treatment post ischemic stroke: a syStematic review
  5924. Effects of iron chelation therapy on allogeneic hematopoietic Stem cell transplantation in myelodysplastic syndrome patients with iron overload
  5925. Effect of minimally invasive puncture drainage combined with Stem cell transplantation therapy on recovery and nerve function in patients with hypertensive …
  5926. Hypoxia-based Stem/Progenitor cell therapy: Focus on CXCR4/SDF-1 Axis
  5927. Specificities of complex nutritive support of patients with cytostatic therapy and haemopoietic Stem cell transplantation
  5928. Endometrial mesenchymal Stem cells as a cell based therapy for pelvic organ prolapse
  5929. Optimal treatment strategies in myeloma: An argument against maintenance therapy after autologous Stem cell transplantation
  5930. Allogeneic Stem cell Transplantation As Salvage therapy for First Relapse after Autografting in Multiple Myeloma Patients
  5931. 166. Lentiviral hematopoietic Stem cell gene therapy for sjögren-larsson syndrome
  5932. Mesenchymal Stem/stromal cell therapy: mechanism of action and host response
  5933. 1035. Functional Characterization of Neural Stem cells from a Murine Model of Globoid cell Leukodystrophy: Relevance for the Development of Gene/cell therapy
  5934. Decitabine As Salvage therapy for Relapse of AML and MDS after Allogeneic Stem cell Transplantation-a Retrospective Multicenter Analysis on Behalf of the …
  5935. Improving Stem cell-Based therapy and Developing a Novel Gene therapy Approach for Treating Duchenne Muscular Dystrophy (DMD)
  5936. Long-term follow-up of children with chronic myeloid leukemia after hematopoietic Stem cell transplantation and tyrosine kinase inhibitor therapy
  5937. Design and Development of miRNA and Stem cell based micro/nano syStems as lung disease therapy
  5938. Bortezomib-based regimens as consolidation therapy after autologous hematopoietic Stem cell transplantation in multiple myeloma: A single center …
  5939. … hematopoietic Stem cell transplantation: a multicenter retrospective study on behalf of the francophone society of Stem cell transplantation and cellular therapy
  5940. … multiple myeloma patients with severe renal impairment: a retrospective study of the Francophone Society of Stem cell Transplantation and cellular therapy
  5941. 1035. Functional Characterization of Neural Stem cells from a Murine Model of Globoid cell Leukodystrophy: Relevance for the Development of Gene/cell therapy
  5942. Stem cell-Based therapy for Duchenne Muscular Dystrophy
  5943. CC-486 (Oral Azacitidine) maintenance therapy is well tolerated after allogeneic hematopoietic Stem cell transplantation (AlloHSCT) in patients with myelodysplastic …
  5944. Practice Patterns of Re-Initiation of therapy at Time of Relapse or Progression Post-Autologous Stem cell Transplant (ASCT) Among Patients with AL …
  5945. Outcomes of Allogeneic Stem cell Transplantation (alloSCT) for therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome
  5946. Evaluation of Wharton’s Jelly-derived Mesenchymal Stem cells under Conditions of Ischemia-a Step Towards cell therapy
  5947. Rebuilding the damaged heart: mesenchymal Stem cells, cell-based therapy, and engineered heart tissue
  5948. Results of salvage autologous Stem cell transplantation (asct) for relapsed multiple myeloma (mm) in the era of novel agents: outcome of patients (pts) …
  5949. Phase II study of the combination of interleukin-2 with zoledronic acid as maintenance therapy following autologous Stem cell transplant in patients with …
  5950. … for hematopoietic Stem cell transplantation donors and recipients: Guidelines from the Franchophone society of bone marrow transplantation and cellular therapy
  5951. … -derived Stem cells in miniature swine with coronary microembolization: Novel ischemic cardiomyopathy model to assess the efficacy of cell-based therapy
  5952. Effect of human umbilical cord mesenchymal Stem cell adjuvant therapy on liver function and fibrosis indicators as well as the degree of inflammation in patients …
  5953. 10th R. Gorbacheva Memorial Symposium “hematopoietic Stem cell transplantation. Gene and cellular therapy”: an overview
  5954. Risk-Adapted Melphalan and Stem cell Transplantation after Suboptimal Responses to Bortezomib-Based Initial therapy in Patients with SyStemic Light …
  5955. Investigation of human mesenchymal Stem cell genetic characteristics to ensure therapy safety
  5956. Metabolic regulation of human mesenchymal Stem cells for cell therapy
  5957. Allogeneic bone marrow transplantation for therapy-related acute lymphocytic leukemia after autologous hematopoietic Stem cell transplantation for multiple myeloma
  5958. … in AML patients: prognostic impact and comparative analysis of mutations burden in diagnostic samples, after standard therapy, and after allogeneic Stem cell
  5959. Rapid identification of cytokine release syndrome after haploidentical peripheral blood Stem cell transplantation and successful therapy with tocilizumab
  5960. Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic Stem cells resist a chimeric antigen receptor T-cell attack
  5961. … Infection Due to Vancomycin-Resistant Enterococcus in Patients with Hematological Malignancy Undergoing Induction therapy or Hematopoietic Stem cell
  5962. therapy with mitoxantrone, ifosfamide and etoposide with or without rituximab before Stem cell transplantation in relapsed diffuse large B-cell lymphoma patients failing …
  5963. Features of transfusion therapy in hematopoietic Stem cell transplantation
  5964. 209. Stem cell/Nanoparticle Constructs for Targeted Ovarian Cancer therapy
  5965. WAR 38 HALAL Stem cell RESEARCH AND therapy: THE MALAYSIAN PERSPECTIVE
  5966. therapy with rituximab for epstein-barr virus reactivation in children after T-cell-replete haploidentical hematopoietic Stem cell transplantation with low-dose …
  5967. … Patients with< CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem cell Transplantation (ASCT) As Part of First Line therapy
  5968. Autologous Stem cell transplantation as a consolidation therapy in acute myeloid leukemia patients
  5969. Leukemic Stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy
  5970. … after Addition of Plerixafor during Stem cell Mobilization Have Similar Survival as Good Mobilizers When Given High Dose therapy with Autologous Stem cell
  5971. 442. Developing Polymeric Bio-Scaffolds That Increase the Efficacy of Stem cell-Mediated therapy for Brain Tumors
  5972. Stem cell-based gene therapy for malignant gliomas
  5973. Mesenchymal Stem cell directed baculoviral gene therapy of colon cancer.
  5974. … Monitor Immune Reconstitution Following Allogeneic Hematopoietic Stem cell Transplantation: A Survey from the EBMT-cellular therapy & Immunobiology Working …
  5975. Managing Relapse and Maintenance therapy after Allogeneic Stem cell Transplantation
  5976. Early Intervention Stem cell-Based therapy (EISCBT) for Corneal Burns and Trauma
  5977. … Rescued By Addition of Plerixafor during Stem cell Mobilization Have Equal Survival As Good Mobilizers When Given High Dose therapy with Autologous Stem cell
  5978. MHC Class I & II-Deficient Human Embryonic Stem cell Line as a Promising Tool to Abrogate Allogenic Immune Rejection in cell-Based therapy
  5979. Incremental Innovation of Ex Vivo Hematopoietic Stem cell Engineering to Expand Clinical Gene therapy Applications
  5980. Radiobiological effects of cancer Stem cell-targeting therapy in a head and neck cancer model
  5981. … Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Undergo Intensive Consolidation therapy (ICT) and Autologous Stem cell
  5982. 685. Restoration of Antiviral Immunity Following Hematopoietic Stem cell Transplantation with Virus-Specific T-Lymphocyte therapy
  5983. … B012: Preclinical study of Kiatomab, a novel monoclonal antibody to the cancer Stem cell surface marker KIAA1114, for anti-cancer therapy in colorectal carcinoma
  5984. Autologous Stem cell Transplantation (ASCT) Is Effective therapy for Older Patients with Non-Hodgkin’s Lymphoma (NHL)
  5985. The role of proto-oncogene PELP1 in breast cancer Stem cell maintenance and therapy resistance
  5986. Outcome of Immune-Suppressive therapy (IST) and Hematopoietic Stem cell Transplantation (SCT) in Patients with Aplastic Anemia: A Retrospective Single Center …
  5987. 443. Neural Stem cell-Mediated Enzyme/Prodrug therapy for Medulloblastoma
  5988. Do disseminated tumor cells with Stem cell character after therapy predict prognosis in primary ovarian cancer
  5989. 364. Neurological Correction of Mucopolysaccharidosis IIIB Mice by Haematopoietic Stem cell Gene therapy
  5990. 678. Neural Stem cell-Based Gene therapy for Malignant Brain Tumor by Doubl-Stranded Adeno-Associated Viral Vectors
  5991. Development of a clinically relevant insulated foamy viral vector for hematopoietic Stem cell gene therapy
  5992. Biological Effects of Mesenchymal Stem cell (MSC) therapy in Patients with Chronic Lung Allograft Dysfunction (CLAD)
  5993. Successful therapy with Ledipasvir/Sofosbuvir for hepatitis C reactivation in a hematopoietic Stem cell transplant recipient
  5994. … Nanoparticles and Biphotonic Microscopy: Innovative Approach to Track In Vivo Muscle Stem cells, a Promising Candidate for cell therapy of Muscular Dystrophy
  5995. 333. Intracellular Ankyrin Specific to p24 and zfp Specific to 2-LTR Are Alternatives to CCR5 Knockdown for Stem cell Gene therapy
  5996. Personalizing therapy in Transplantation: Focus on Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Drugs Used in Hematopoeitic Stem cell and …
  5997. Lentiviral hematopoietic Stem cell gene therapy in inherited immune and lysosomal enzyme deficiencies
  5998. A pilot study using hyperbaric oxygen therapy to improve umbilical cord blood Stem cell engraftment: 6-months follow up results.
  5999. 350. Hematopoietic Stem cell Based Gene therapy for the Treatment of Metachromatic Leukodystrophy: Towards Clinical Testing
  6000. PiggyBac transposons for Stem cell-based gene therapy of Duchenne muscular dystrophy
  6001. Acute Fibrinous and Organizing Pneumonia Following Hematopoietic Stem cell Transplantation Responsive to Corticosteroid therapy
  6002. Human Olfactory Bulb Neural Stem cell Based therapy for CNS Traumatic and Neurodegenerative Diseases
  6003. Comparable Outcomes of therapy-Related and De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem cell Transplantation
  6004. … By Autologous Stem cell Transplantation in Patients with Hodgkin Lymphoma: A Francophone Society of Bone Marrow Transplantation and cellular therapy
  6005. … -Intensity and Myeloablative Conditioning: A Study on Behalf of the Francophone Society of Stem cell Transplantation and cellular therapy (SFGM-TC) Study
  6006. … Family Autoantibodies in Bronchiolitis Obliterans Following Hematopoietic Stem cell Transplantation As Useful Biomarkers and the Target for Rituximab therapy
  6007. … -DQB1 Mismatch Hematopoietic Stem cell Transplantation: A Study on Behalf of the Francophone Society of Stem cell Transplantation and cellular therapy
  6008. Effects of iron chelation therapy on allogeneic hematopoietic Stem cell transplantation in myelodysplastic syndrome patients with iron overload
  6009. PM232 Major Histocompatibility Complex-I Deficient Embryonic Stem cell-Derived Cardiomyocytes as Potential Off-the-shelf therapy for Cardiac Regeneration
  6010. Is allogeneic hematopoietic Stem cell transplantation still the first-line therapy after the first remission in adult patients with Philadelphia chromosome-negative acute …
  6011. Validation of rapid sterility test with BacT/ALERT 3D on human mesenchymal Stem cells as cell therapy product inside an hospital cell factory
  6012. … (len) for Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapse Following Allogeneic Stem cell Transplantation (allo-SCT)
  6013. Clinical study of cytomegalovirus infection and preemptive therapy after haploidentical peripheral blood hematopoietic Stem cell transplantation
  6014. Incidence and Prognostic Impact of Secondary Neoplasia after High Dose therapy Supported By Autologous Stem cell Transplantation in Follicular …
  6015. Optimization of a Neural Stem cell-mediated Carboxylesterase/Irinotecan Gene therapy for Metastatic Neuroblastoma
  6016. … determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood Stemcell
  6017. Re: Fibrin Glue therapy for Severe Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem cell Transplantation
  6018. Outcome of Allogeneic Hematopoietic Stem cell Transplant in therapy Related Myeloid Neoplasms: Comparative Study with a De Novo Myeloid Neoplasms Group
  6019. Synthesis of Fe3O4 nanoparticles and Fe3O4@GO nanocomposites with low effects on Stem cells for cancer cell therapy
  6020. … characteristics of Cryptogenic organizing pneumonia (COP)/Bronchiolitis obliterans organizing pneumonia (BOOP) after steroid therapy in hematopoietic Stem cell
  6021. Extracorporeal photopheresis and anticytokine therapy in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic Stem cell
  6022. Reduced-Intensity and Non-Myeloablative Allogeneic Stem cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin’s Lymphoma: A Study By the …
  6023. Postremission therapy with Repeated Courses of HD-Arac, Idarubicin and Limited Autologous Stem cell Support Achieves a Very Good Long-Term Outcome …
  6024. … -DQB1 Identical Hematopoietic Stem cell Transplantation: A Study on Behalf of the Francophone Society of Stem cell Transplantation and cellular therapy
  6025. 1P-228: Graphene Oxide Sheets for Protection of Mesenchymal Stem cell in Cardiac therapy
  6026. JAK1/2 Inhibition As a Salvage therapy for Steroid Refractory Acute and Chronic Graft Versus Host Disease in Pediatric Allogeneic Hematopoietic Stem cell
  6027. Erratum for the Research Article:“Lentiviral hematopoietic Stem cell gene therapy for X-linked severe combined immunodeficiency” by SS De Ravin, X. Wu, S. Moir, S …
  6028. … induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous Stem cell
  6029. Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose therapy and Autologous Stem cell Transplantation (HDT-ASCT) …
  6030. Microcarrier Culture of Adipose-Derived Stem cells in a Closed Bioreactor SyStem For cell therapy
  6031. Abstract WP338: combined coiling and allogeneic mesenchymal Stem/stromal cell therapy could be a more cost-effective alternative to coiling alone
  6032. Perspectives of the cell therapy in Ophthalmology1. The Application of Stem cells in the Regeneration of Damaged Surface of the Eye
  6033. Comparative analysis of human mesenchymal Stem cells from fetal-bone marrow, adipose tissue, and Warton’s jelly as sources of cell immunomodulatory therapy
  6034. Drug discovery toward successful cell transplantation therapy for Parkinson’s disease using human pluripotent Stem cells
  6035. The characterization of adipose derived Stem cells from canine tissue for animal cell therapy
  6036. Integration site-based clonality analyses of potency of Stem and progenitor cells and safety in human gene and cell therapy
  6037. Gene therapy for blood cell diseases with autologous hematopoietic Stem cells
  6038. cell therapy for the treatment of acute lung injury: Alveolar type II cells or mesenchymal Stem cells?
  6039. L29 Utilising the intrinsic epigenetic memory of induced pluripotent Stem cells to enhance cell replacement therapy for huntington’s disease
  6040. Adeno-associated virus-VEGF-165 Mediated Modification of Adipose Derived Stem cells for cell therapy
  6041. 528. Towards Personalized cell therapy for Cancer: Tumor-Homing Human Induced Neural Stem cells
  6042. … REGIONAL AND TRANSLATIONAL MECHANISMS IN ARDS: cell therapy For The Treatment Of Acute Lung Injury: Alveolar Type Ii cells Or Mesenchymal Stem
  6043. Short Term Safety and Tolerance of Mesenchymal Stem cells (MSC) Infusion as cell therapy for Patients Experiencing Treatment-Refractory Moderate Chronic Lung …
  6044. effect of miR-184 in oligodendrocytic differentiation on human neural progenitor Stem cells for cell therapy of MS
  6045. Outcomes of Gene therapy for Severe Sickle cell Disease (SCD) via Transplantation of Autologous Hematopoietic Stem cells Transduced Ex Vivo with a Lentiviral …
  6046. An Analysis of the Transcriptional Response of Myelodysplastic Syndrome Stem cells to therapy at Single cell Resolution
  6047. Stem cell therapy for ischemic heart diseases
  6048. Mesenchymal Stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction
  6049. Mesenchymal Stem cell therapy in type 2 diabetes mellitus
  6050. Advances in bone marrow Stem cell therapy for retinal dysfunction
  6051. Neural Stem cell therapy for neurodegenerative disorders: the role of neurotrophic support
  6052. Current and future perspectives of Stem cell therapy in dermatology
  6053. Stem cell therapy for congenital heart disease: a syStematic review
  6054. Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms
  6055. Translational cardiac Stem cell therapy: advancing from first-generation to next-generation cell types
  6056. Mesenchymal Stem cell therapy for ischemic stroke
  6057. Gene delivery approaches for mesenchymal Stem cell therapy: strategies to increase efficiency and specificity
  6058. Stem cell therapy for neonatal disorders: prospects and challenges
  6059. No evidence for the use of Stem cell therapy for tendon disorders: a syStematic review
  6060. Concise review: mesenchymal Stem cell therapy for pediatric disease: perspectives on success and potential improvements
  6061. Advances, challenges and future directions for Stem cell therapy in amyotrophic lateral sclerosis
  6062. Mesenchymal Stem cell therapy in the treatment of hip osteoarthritis
  6063. Route of delivery modulates the efficacy of mesenchymal Stem cell therapy for myocardial infarction: a meta-analysis of preclinical studies and clinical trials
  6064. Induced pluripotent Stem cell-derived neural Stem cell therapy enhances recovery in an ischemic stroke pig model
  6065. Neurotrophin signaling and Stem cells—implications for neurodegenerative diseases and Stem cell therapy
  6066. A look into Stem cell therapy: exploring the options for treatment of ischemic stroke
  6067. Mesenchymal Stem cell therapy for inflammatory skin diseases: clinical potential and mode of action
  6068. A review of the emerging potential therapy for neurological disorders: human embryonic Stem cell therapy
  6069. Recent advances in retinal Stem cell therapy
  6070. Alzheimer’s disease, dementia, and Stem cell therapy
  6071. A pilot study of mesenchymal Stem cell therapy for acute liver allograft rejection
  6072. Human neural Stem cell therapy for chronic ischemic stroke: charting progress from laboratory to patients
  6073. Stem cell therapy for chronic pain management: review of uses, advances, and adverse effects
  6074. Current perspective of Stem cell therapy in neurodegenerative and metabolic diseases
  6075. Mesenchymal Stem cell therapy in Parkinson’s disease animal models
  6076. Benefit of cardiopoietic mesenchymal Stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative therapy
  6077. SyStematic review with meta-analysis: the efficacy and safety of Stem cell therapy for Crohn’s disease
  6078. A molecular and clinical review of Stem cell therapy in critical limb ischemia
  6079. A nano-in-micro syStem for enhanced Stem cell therapy of ischemic diseases
  6080. Intrinsic mesenchymal Stem cell dysfunction in diabetes mellitus: implications for autologous cell therapy
  6081. Exosomes generated from iPSC-derivatives: new direction for Stem cell therapy in human heart diseases
  6082. Stem cell therapy for nerve injury
  6083. Stem cell therapy for nerve injury.
  6084. Exosomes as potential alternatives to Stem cell therapy for intervertebral disc degeneration: in-vitro study on exosomes in interaction of nucleus pulposus cells
  6085. Stem cell-derived exosomes, autophagy, extracellular matrix turnover, and miRNAs in cardiac regeneration during Stem cell therapy
  6086. Stem cell therapy for reconstruction of alveolar cleft and trauma defects in adults: a randomized controlled, clinical trial
  6087. Improved Stem cell therapy of spinal cord injury using GDNF-overexpressed bone marrow Stem cells in a rat model
  6088. Cortical bone Stem cell therapy preserves cardiac structure and function after myocardial infarction
  6089. … improves BMSC cell therapy: anticoagulant treatment by heparin improves the safety and therapeutic effect of bone marrow-derived mesenchymal Stem cell
  6090. Mesenchymal Stem cell therapy on tendon/ligament healing
  6091. Mesenchymal Stem cell therapy protects lungs from radiation-induced endothelial cell loss by restoring superoxide dismutase 1 expression
  6092. A comprehensive review of Stemcell therapy
  6093. Stem cell therapy: healing or hype? why Stem cell delivery doesn’t work
  6094. Contemplating Stem cell therapy for epilepsy-induced neuropsychiatric symptoms
  6095. Adipose Extracellular Matrix/Stromal Vascular Fraction Gel: A Novel Adipose Tissue–Derived Injectable for Stem cell therapy
  6096. Stem cell therapy for enhancement of bone consolidation in distraction osteogenesis: A contemporary review of experimental studies
  6097. Is Stem cell therapy ready for prime time in treatment of inflammatory bowel diseases?
  6098. G-CSF and Stem cell therapy for the treatment of refractory thin lining in assisted reproductive technology
  6099. Phase I/II randomized controlled trial of autologous bone marrow-derived mesenchymal Stem cell therapy for chronic stroke
  6100. The influence of timing and frequency of adipose-derived mesenchymal Stem cell therapy on immunomodulation outcomes after vascularized composite …
  6101. Resituating overseas Stem cell therapy
  6102. Safety analysis of autologous Stem cell therapy in a variety of degenerative diseases and injuries using the stromal vascular fraction
  6103. Adult Stem cell therapy for cardiac repair in patients after acute myocardial infarction leading to ischemic heart failure: an overview of evidence from the recent clinical …
  6104. Pre‐clinical validation of a selective anti‐cancer Stem cell therapy for Numb‐deficient human breast cancers
  6105. Effect of autologous adipose-derived mesenchymal Stem cell therapy in the treatment of a post-traumatic chondral defect of the knee
  6106. Hydrogel based 3D carriers in the application of Stem cell therapy by direct injection
  6107. Priming of the cells: hypoxic preconditioning for Stem cell therapy
  6108. Stem cell therapy for inflammatory bowel disease
  6109. Stemcell therapy for erectile dysfunction
  6110. Combining gene and Stem cell therapy for peripheral nerve tissue engineering
  6111. A review of Stem cell therapy for spinal cord injury: large animal models and the frontier in humans
  6112. Progress in Stem cell‐based therapy for liver disease
  6113. Mechanisms in endocrinology: towards the clinical translation of Stem cell therapy for type 1 diabetes
  6114. cell therapy in Parkinson’s disease: host brain repair machinery gets a boost from Stem cell grafts
  6115. Towards the standardization of Stem cell therapy studies for ischemic heart diseases: bridging the gap between animal models and the clinical setting
  6116. The effect of autologous adipose derived mesenchymal Stem cell therapy in the treatment of a large osteochondral defect of the knee following unsuccessful …
  6117. Multimodal assessment of mesenchymal Stem cell therapy for diabetic vascular complications
  6118. Induction of spermatogenesis after Stem cell therapy of azoospermic guinea pigs
  6119. Transamniotic Stem cell therapy (TRASCET) in a leporine model of gastroschisis
  6120. Stem cell therapy for the treatment of Peyronie’s disease
  6121. Rapid deterioration of preexisting renal insufficiency after autologous mesenchymal Stem cell therapy
  6122. Efficacy and safety of autologous hematopoietic Stem cell therapy for refractory Crohn’s disease: A syStematic review and meta-analysis
  6123. Allogenic adipose-derived Stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: syStems biology study
  6124. Stem cell therapy in wound healing
  6125. Stem cell therapy for the syStemic right ventricle
  6126. Hematopoietic Stem cell gene therapy: progress and lessons learned
  6127. Stem cell therapies in preclinical models of stroke. Is the aged brain microenvironment refractory to cell therapy?
  6128. Stem cell therapy clinical research: a regulatory conundrum for academia
  6129. Donor mesenchymal Stem cells home to maternal wounds after transamniotic Stem cell therapy (TRASCET) in a rodent model
  6130. cellular layer-by-layer coculture platform using biodegradable, nanoarchitectured membranes for Stem cell therapy
  6131. Stem cell therapy: A Rising Tide: How Stem cells Are Disrupting Medicine and Transforming Livespdf
  6132. Biogovernance beyond the state: The shaping of Stem cell therapy by patient organizations in India
  6133. Bone marrow Stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1‐antitrypsin
  6134. Adipose Stem cell therapy mitigates chronic pancreatitis via differentiation into acinar-like cells in mice
  6135. Sources of hematopoietic Stem and progenitor cells and methods to optimize yields for clinical cell therapy
  6136. Bone marrow very small embryonic-like Stem cells: new generation of autologous cell therapy soon ready for prime time?
  6137. Exendin-4-assisted adipose derived mesenchymal Stem cell therapy protects renal function against co-existing acute kidney ischemia-reperfusion injury and …
  6138. Stem cell therapy for Fanconi anemia
  6139. Stem cell therapy for avascular necrosis of femoral head in sickle cell disease: report of 11 cases and review of literature
  6140. Mesenchymal Stem cell therapy for laryngotracheal stenosis: a syStematic review of preclinical studies
  6141. Stem cell transplantation therapy for multifaceted therapeutic benefits after stroke
  6142. Should we practice Stem cell therapy for type 1 diabetes mellitus as precision medicine?
  6143. Stem cell therapy: An emerging modality in glomerular diseases
  6144. Stem cell therapy in fecal incontinence: a narrative review
  6145. Next-generation Stem cell therapy: genetically modified mesenchymal Stem cells for cardiac repair
  6146. Autologous bone marrow derived Stem cell therapy in patients with type 2 diabetes mellitus-defining adequate administration methods
  6147. Adipose Stem cell therapy for chronic pancreatitis
  6148. Mesenchymal Stem cell-based therapy as a new horizon for kidney injuries
  6149. Stem cell therapy: A promising therapeutic approach for multiple sclerosis
  6150. Fetal Stem cell and gene therapy
  6151. Stem cell manipulation, gene therapy and the risk of cancer Stem cell emergence
  6152. Autologous pluripotent Stem cell–derived β-like cells for diabetes cellular therapy
  6153. Characteristics, applications and prospects of mesenchymal Stem cells in cell therapy
  6154. Hematopoietic Stemcell gene therapy for cerebral adrenoleukodystrophy
  6155. Tumor-homing Stem cell therapy for brain cancer
  6156. Mesenchymal Stem cell therapy for advanced liver cirrhosis: a case report
  6157. Enhancing plasticity of the central nervous syStem: drugs, Stem cell therapy, and neuro-implants
  6158. Melatonin as a promising agent of regulating Stem cell biology and its application in disease therapy
  6159. Mesenchymal Stem cell (MSC) as a potential cell therapy for immune related disease
  6160. Adipose tissue-derived Stem cell therapy for erectile dysfunction in rats: a syStematic review and meta-analysis
  6161. Attitudes to Stem cell therapy among ischemic stroke survivors in the Lund Stroke Recovery Study
  6162. Autologous adipose Stem cell therapy for autonomic nervous syStem dysfunction in two young patients
  6163. Nanoporous immunoprotective device for Stemcell-derived β-cell replacement therapy
  6164. Differences in Stem cell Processing Lead to Distinct Secretomes Secretion—Implications for Differential Results of Previous Clinical Trials of Stem cell therapy for …
  6165. Phase I clinical trial of autologous Stem cell–sheet transplantation therapy for treating cardiomyopathy
  6166. Focus on mesenchymal Stem cell-derived exosomes: opportunities and challenges in cell-free therapy
  6167. Recent progress in nanotechnology for Stem cell differentiation, labeling, tracking and therapy
  6168. Two complementary strategies to improve cell engraftment in mesenchymal Stem cell-based therapy: Increasing transplanted cell resistance and increasing tissue …
  6169. Hematopoietic Stem cell gene therapy for storage disease: current and new indications
  6170. Angiopoietin-1 modified human umbilical cord mesenchymal Stem cell therapy for endotoxin-induced acute lung injury in rats
  6171. SyStematic review of patient factors affecting adipose Stem cell viability and function: implications for regenerative therapy
  6172. Repair of neonatal brain injury: Bringing Stem cell‐based therapy into clinical practice
  6173. Emerging regenerative approaches for periodontal regeneration: the future perspective of cytokine therapy and Stem cell therapy
  6174. Limbal stromal Stem cell therapy for acute and chronic superficial corneal pathologies: early clinical outcomes of the Funderburgh technique
  6175. Hematopoietic Stem cell transplantation and cellular therapy
  6176. Review on Stem cell therapy and their role in cancer treatment
  6177. Does Stem cell therapy induce myocardial neoangiogenesis? Histological evaluation in an ischemia/reperfusion animal model
  6178. Single-cell molecular analysis defines therapy response and immunophenotype of Stem cell subpopulations in CML
  6179. Stem cell therapy in pediatric neurological disabilities
  6180. Complications following Stem cell therapy in inflammatory bowel disease
  6181. CRISPR/Cas9 gene-edited hematopoietic Stem cell therapy for sickle cell disease
  6182. Catching moving targets: cancer Stem cell hierarchies, therapy-resistance & considerations for clinical intervention
  6183. An update clinical application of amniotic fluid-derived Stem cells (AFSCs) in cancer cell therapy and tissue engineering
  6184. Historical perspective on the current renaissance for hematopoietic Stem cell gene therapy
  6185. Pursuing meaningful end-points for Stem cell therapy assessment in ischemic cardiac disease
  6186. Mesenchymal Stem cell therapy for the treatment of heart failure caused by ischemic or non-ischemic cardiomyopathy: immunosuppression and its implications
  6187. Cure for thalassemia major–from allogeneic hematopoietic Stem cell transplantation to gene therapy
  6188. Novel murine xenograft model for the evaluation of Stem cell therapy for profound dysphagia
  6189. Can the outcomes of mesenchymal Stem cell‐based therapy for myocardial infarction be improved? Providing weapons and armour to cells
  6190. Human embryonic Stem cell therapy for aplastic anemia
  6191. Neural Stem cell plasticity: advantages in therapy for the injured central nervous syStem
  6192. Infrapatellar fat pad Stem cells: from developmental biology to cell therapy
  6193. Evidence supporting intralesional Stem cell therapy to improve equine flexor tendon healing
  6194. Multi-functional nanotracers for image-guided Stem cell gene therapy
  6195. Overview of retinal differentiation potential of mesenchymal Stem cells: A promising approach for retinal cell therapy
  6196. Neural Stem cell–based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients
  6197. Mesenchymal Stem cell therapy to promote limb transplant functional recovery
  6198. Regenerative Stem cell therapy optimization via tissue engineering in heart failure with reduced ejection fraction
  6199. The potential of microRNAs for Stem cell-based therapy for degenerative skeletal diseases
  6200. Efficient and fast differentiation of human neural Stem cells from human embryonic Stem cells for cell therapy
  6201. Mesenchymal Stem cell therapy of hepatocellular carcinoma in rats: Detection of cell homing and tumor mass by magnetic resonance imaging using iron oxide …
  6202. Stem cell therapy and its potential role in pituitary disorders
  6203. Generation of human induced pluripotent Stem cell-derived bona fide neural Stem cells for ex vivo gene therapy of metachromatic leukodystrophy
  6204. … promotes survival of aged human mesenchymal Stem cells via FAIM: a pharmacological strategy to improve Stem cell-based therapy for rat myocardial …
  6205. Hematopoietic Stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy
  6206. … characterization in an HIV-infected individual following allogeneic Stem cell transplant and analytic cessation of antiretroviral therapy: A case study
  6207. A homologous Stem cell therapy for obesity and its related metabolic disorders
  6208. The effects of music therapy in patients with high‐dose chemotherapy and Stem cell support: a randomized pilot study
  6209. Induced pluripotent Stem cell-based therapy for age-related macular degeneration
  6210. Thrombotic microangiopathy after allogeneic Stem cell transplantation: a comparison of eculizumab therapy and conventional therapy
  6211. Controlling adult Stem cell behavior using nanodiamond-reinforced hydrogel: implication in bone regeneration therapy
  6212. Emerging nanotechnology for Stem cell therapy
  6213. The RANK/RANKL/OPG syStem in tumorigenesis and metastasis of cancer Stem cell: potential targets for anticancer therapy
  6214. Tracheal replacement therapy with a Stem cell-seeded graft: lessons from compassionate use application of a GMP-compliant tissue-engineered medicine
  6215. Stem cell-derived exosomes: a novel vector for tissue repair and diabetic therapy
  6216. … , prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic Stem cell
  6217. Stem cell therapy for brain injury in neonates
  6218. Perspectives of Stem cell–Based therapy for Age-Related Retinal Degenerative Diseases
  6219. Process parameters for the high-scale production of alginate-encapsulated Stem cells for storage and distribution throughout the cell therapy supply chain
  6220. … variability in LQT3 human induced pluripotent Stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: an in silico …
  6221. Unproven Stem cell therapy for macular degeneration
  6222. Stem cell, biomaterials and growth factors therapy for hepatocellular carcinoma
  6223. Retinoic acid postconsolidation therapy for high‐risk neuroblastoma patients treated with autologous haematopoietic Stem cell transplantation
  6224. … of biotinylated IGF‑1 with biotinylated self‑assembling peptides combined with bone marrow Stem cell transplantation promotes cell therapy for myocardial infarction
  6225. Nivolumab salvage therapy before or after allogeneic Stem cell transplantation in Hodgkin lymphoma
  6226. Inhibition of p38MAPK potentiates mesenchymal Stem cell therapy against myocardial infarction injury in rats
  6227. Endocrine therapy of estrogen receptor-positive breast cancer cells: early differential effects on Stem cell markers
  6228. Ruxolitinib as salvage therapy in steroid-refractory acute graft-versus-host disease in pediatric hematopoietic Stem cell transplant patients
  6229. Combination of low-energy shock-wave therapy and bone marrow mesenchymal Stem cell transplantation to improve the erectile function of diabetic rats
  6230. cell therapy using embryonic Stem cell source in clinical trial studies: advantages and limitations
  6231. Introduction to gene and Stemcell therapy
  6232. Bone marrow as a hematopoietic Stem cell source for gene therapy in sickle cell disease: evidence from rhesus and SCD patients
  6233. Clinical studies of bone marrow-derived Stem cell therapy in stroke patients
  6234. Outcomes of maintenance therapy with bortezomib after autologous Stem cell transplantation for patients with multiple myeloma
  6235. Concise review: dental pulp Stem cells: a novel cell therapy for retinal and central nervous syStem repair
  6236. cellular therapy for multiple pathogen infections after hematopoietic Stem cell transplant
  6237. … -dose therapy and autologous Stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma cell Disorder sub-committee of …
  6238. Music therapy for symptom management after autologous Stem cell transplantation: results from a randomized study
  6239. Non-coding RNAs are promising targets for Stem cell-based cancer therapy
  6240. Treatment by Stem cell therapy of erectile dysfunction of diabetic origin: State of the art
  6241. … , prophylaxis and therapy for hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic Stem cell
  6242. Correlation of micro vessel density and c-Myc expression in breast tumor of mice following mesenchymal Stem cell therapy
  6243. Preclinical studies for a phase 1 clinical trial of autologous hematopoietic Stem cell gene therapy for sickle cell disease
  6244. Targeting transferrin receptor delivery of temozolomide for a potential glioma Stem cell-mediated therapy
  6245. Outcome after intensive reinduction therapy and allogeneic Stem cell transplant in paediatric relapsed acute myeloid leukaemia
  6246. Imaging of hepatic toxicity of syStemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic Stem cell transplantation, molecular targeted therapies, and …
  6247. Immunosuppressive therapy versus alternative donor hematopoietic Stem cell transplantation for children with severe aplastic anemia who lack an HLA …
  6248. Long-term results of high-dose therapy and autologous Stem cell transplantation for mantle cell lymphoma: effectiveness of maintenance rituximab
  6249. Stem cell therapy for neurodegenerative disorders
  6250. Delineation of the timing of second-line therapy post–autologous Stem cell transplant in patients with AL amyloidosis
  6251. The Met tyrosine kinase receptor as a therapeutic target and a potential cancer Stem cell factor responsible for therapy resistance
  6252. CRISPR-Mediated Knockout of Cybb in NSG Mice Establishes a Model of Chronic Granulomatous Disease for Human Stemcell Gene therapy Transplants
  6253. Update on a phase II study of ixazomib with lenalidomide as maintenance therapy following autologous Stem cell transplant in patients with multiple myeloma
  6254. Liver fibrosis and Stem cell therapy
  6255. Favorable impact of allogeneic Stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status
  6256. Stem cell therapy: The Phoenix in Clinical Medicine?
  6257. Reduced-intensity and non-myeloablative allogeneic Stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the …
  6258. General Overview of the 14th International Symposium on Stem cell therapy and Cardiovascular Innovations: Working Progress of a Global Initiative in 2017
  6259. Efficient ex vivo engineering and expansion of highly purified human hematopoietic Stem and progenitor cell populations for gene therapy
  6260. Good outcome of severe lupus patients with high-dose immunosuppressive therapy and autologous peripheral blood Stem cell transplantation: a 10-year follow …
  6261. Motor skill delays in pre-school children with leukemia one year after treatment: Hematopoietic Stem cell transplantation therapy as an important risk factor
  6262. … severity and on salivary levels of CXCL8/interleukin 8, nitrite, and myeloperoxidase in patients undergoing hematopoietic Stem cell transplantation: a randomized …
  6263. Gene-cell therapy of HIV and hematological malignances based on hematopoietic Stem cell transplantation and site-specific genome editing
  6264. Impact of pretransplant induction therapy on autologous Stem cell transplantation for patients with newly diagnosed POEMS syndrome
  6265. Reducing second gram-negative antibiotic therapy on pediatric oncology and hematopoietic Stem cell transplantation services
  6266. T cell depletion as an alternative approach for patients 55 years or older undergoing allogeneic Stem cell transplantation as curative therapy for hematologic …
  6267. Mesenchymal Stem cell in venous leg ulcer: an intoxicating therapy
  6268. Reply: Mechanical Isolation of Stromal Vascular Fraction: A New Advance in Stem cell therapy?
  6269. Enhancement of bone-marrow-derived mesenchymal Stem cell angiogenic capacity by NPWT for a combinatorial therapy to promote wound healing with large …
  6270. Autonomous magnetic labelling of functional mesenchymal Stem cells for improved traceability and spatial control in cell therapy applications
  6271. Mesenchymal Stem cell therapy for retro-corneal membrane–a clinical challenge in full-thickness transplantation of biosynthetic corneal equivalents
  6272. … : a comparative analysis of patients treated with autologous nonmyeloablative hematopoietic Stemcell transplantation and conventional medical therapy
  6273. Embryonic Stem cell therapy applications for autoimmune, cardiovascular, and neurological diseases: a review
  6274. Lenalidomide in combination or alone as maintenance therapy following autologous Stem cell transplant in patients with multiple myeloma: a review of options for and …
  6275. Progress of the application of Stem cell therapy for end-stage liver disease
  6276. Stem cell therapy to restore pancreatic function in dogs and cats
  6277. Comparison of haploidentical hematopoietic Stem cell transplantation and immunosuppressive therapy for the treatment of acquired severe aplastic anemia in …
  6278. Brief report: external beam radiation therapy for the treatment of human pluripotent Stem cell-derived teratomas
  6279. An update on Stem cell therapy for neurological disorders: cell death pathways as therapeutic targets
  6280. Stem cell therapy in Traumatic Brain Injury
  6281. Stem cell therapy in diabetes
  6282. Bortezomib, lenalidomide and dexamethasone (VRD-GEM) as induction therapy prior autologous Stem cell transplantation (ASCT) in multiple myeloma (MM) …
  6283. Stem cell therapy in the treatment of rheumatic diseases and application in the treatment of syStemic lupus erythematosus
  6284. (Mesenchymal) Stem cell-based therapy in cisplatin-induced acute kidney injury animal model: risk of immunogenicity and tumorigenicity
  6285. Clinical applications of Stem cells from human exfoliated deciduous teeth in Stem cell therapy
  6286. Mesenchymal Stem cells as a source of dopaminergic neurons: a potential cell based therapy for Parkinson’s disease
  6287. India cracks down on clinics offering Stem cell therapy and blood cord banking
  6288. Lenalidomide maintenance therapy post-autologous Stem cell transplant: a healthcare cost-impact analysis in Europe
  6289. Biomaterial-assisted cell therapy in osteoarthritis: From mesenchymal Stem cells to cell encapsulation
  6290. (Mesenchymal) Stem cell-based therapy in cisplatin-induced acute kidney injury animal model: risk of immunogenicity and tumorigenicity
  6291. Causes of early death in multiple myeloma patients treated with high-dose therapy followed by autologous Stem cell transplantation: a study based on the nationwide …
  6292. Stem cell therapy in heart failure
  6293. The frustration and futility of intracoronary Stem cell therapy
  6294. Transplantation of airway epithelial Stem/progenitor cells: a future for cell-based therapy
  6295. Stem cell therapy with skeletal myoblasts accelerates neointima formation in a mouse model of vein graft disease
  6296. Preclinical safety evaluation of allogeneic induced pluripotent Stem cell-based therapy in a swine model of myocardial infarction
  6297. Stem cell therapy for Autoimmune Disease
  6298. Injection therapy: intra-articular platelet-rich plasma and Stem cell therapy
  6299. Towards Stem cell therapy of polycystic ovary syndrome (PCOS): Human mesenchymal Stem cells engrafment in letrozole-induced PCOS murine model
  6300. Adoptive T-cell therapy with 3rd party CMV-pp65-specific CTLs for CMV viremia and disease arising after allogeneic hematopoietic Stem cell transplant
  6301. … approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic Stem cell transplantation recipients with oral ribavirin therapy: a pilot study
  6302. Combination therapy of exendin-4 and allogenic adipose-derived mesenchymal Stem cell preserved renal function in a chronic kidney disease and sepsis …
  6303. Single cell-based vector tracing in patients with ADA-SCID treated with Stem cell gene therapy
  6304. Novel therapy for pancreatic fistula using adipose-derived Stem cell sheets treated with mannose
  6305. Gene-modified Mesenchymal Stem cell–based therapy in Renal Ischemia-Reperfusion Injury
  6306. Effect of Stem cell therapy on gentamicin induced testicular dysfunction in rats
  6307. Enhanced chondrogenesis of bone marrow-derived Stem cells by using a combinatory cell therapy strategy with BMP-2/TGF-β1, hypoxia, and COL1A1/HtrA1 …
  6308. IL-11 promotes the treatment efficacy of hematopoietic Stem cell transplant therapy in aplastic anemia model mice through a NF-κB/microRNA-204 …
  6309. Conditioning regimens for autologous haematopoietic Stem cell transplantation-can natural killer cell therapy help?
  6310. Stem cell regulation by death ligands and their use in cell therapy
  6311. Stem cell therapy for Ischemic Heart Disease
  6312. Optimization of a neural Stemcell-mediated carboxylesterase/irinotecan gene therapy for metastatic neuroblastoma
  6313. Fetal therapy model of myelomeningocele with three-dimensional skin using amniotic fluid cell-derived induced pluripotent Stem cells
  6314. Imaging cardiac Stem cell therapy
  6315. Usage of human mesenchymal Stem cells in cell-based therapy: advantages and disadvantages
  6316. Stem cell therapy in autism spectrum disorders
  6317. Allogeneic mesenchymal Stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation …
  6318. Biohybrid membrane syStems for testing molecules and Stem cell therapy in neuronal tissue engineering
  6319. Promises and challenges in hematopoietic Stem cell gene therapy
  6320. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous Stem cell rescue
  6321. Preliminary results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous Stem cell transplant in patients with multiple …
  6322. Adult Stem cell therapy for salivary glands, with a special emphasis on mesenchymal Stem cells
  6323. Stem cell therapy in Duchenne Muscular Dystrophy
  6324. Stem cell therapy and tissue engineering in urogenital diseases
  6325. Stem cell therapy for Amyotrophic Lateral Sclerosis
  6326. Cardiac Stem cell-based regenerative therapy for the ischemic injured heart—a short update 2017
  6327. Stem cell therapy
  6328. Current Research of the Renin-Angiotensin SyStem Effect on Stem cell therapy
  6329. Intrathecal autologous bone marrow derived mesenchymal Stem cell therapy for amyotrophic lateral sclerosis
  6330. Advanced approaches in Stem cell therapy for stroke and traumatic brain injury
  6331. Advances in umbilical cord blood therapy: Hematopoietic Stem cell transplantation and beyond
  6332. Stemcell therapy
  6333. Gene and cell therapy for β-thalassemia and sickle cell disease with induced pluripotent Stem cells (iPSCs): the next frontier
  6334. Stem cell-transplantation therapy for adrenoleukodystrophy: current perspectives
  6335. Stem cell therapy in Muscle Degeneration
  6336. Opening marrow niches in patients undergoing autologous hematopoietic Stem cell gene therapy
  6337. Multiple myeloma: Maintenance therapy after autologous hematopoietic Stem cell transplantation, depending on minimal residual disease
  6338. Use of brentuximab vedotin as salvage therapy pre‐allogeneic Stem cell transplantation in relapsed/refractory CD30 positive lympho‐proliferative disorders: a single …
  6339. Targeted drugs as maintenance therapy after autologous Stem cell transplantation in patients with mantle cell lymphoma
  6340. Stem cell transplantation for myeloproliferative diseases in the era of molecular therapy
  6341. Engineering A11 minibody-conjugated, polypeptide-based gold nanoshells for prostate Stem cell antigen (PSCA)–targeted photothermal therapy
  6342. Salvage therapy for acute chemorefractory leukemia by allogeneic Stem cell transplantation: the Korean experience
  6343. Development of cost efficient platforms for the industrial manufacture of pluripotent Stem cell-derived products for cell therapy: cell expansion is the starting point
  6344. Computed tomographic assessment of coronary arteries in patients undergoing Stem cell therapy following an acute myocardial infarction
  6345. Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous Stem cell transplantation
  6346. The optimization of cell therapy by combinational application with apicidin-treated mesenchymal Stem cells after myocardial infarction
  6347. Endogenous repair mechanisms enhanced in Parkinson’s disease following Stem cell therapy
  6348. High-dose therapy and autologous Stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma
  6349. CAR-T cell therapy in combination with allogeneic Stem cell transplantation
  6350. Stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females receiving hormonal replacement therapy
  6351. Stem cell therapy on the Internet: information quality and content analysis of English language web pages returned by Google
  6352. Adipose-Derived Mesenchymal Stem cell therapy for Liver Cirrhosis in Mice
  6353. Human mesenchymal stromal/Stem cell as a source of cell therapy and a pharmacological target for disease treatment.
  6354. A dual therapy of off-pump temporary left ventricular extracorporeal device and amniotic Stem cell for cardiogenic shock
  6355. Acute respiratory failure in a patient with idiopathic pulmonary fibrosis following nebulized and intravenous Stem cell therapy
  6356. Complete cartilage regeneration Stem cell therapy for osteochondral lesions of the talus: early outcomes in a pilot study
  6357. Intrinsic variability present in Wharton’s jelly mesenchymal Stem cells and T cell responses may impact cell therapy
  6358. Mesenchymal Stem/stromal cell therapy for inflammatory bowel disease: an updated review with maintenance of remission
  6359. Mesenchymal Stem cell therapy for ex vivo repair of ischemic injury in pig donor lungs
  6360. Current strategy of fetal therapy I: Principles of in-utero treatment, pharmacologic intervention, Stem cell transplantation and gene therapy
  6361. … adolescents with leukemia after hematopoietic Stem cell transplantation: prolonged steroid therapy for GvHD and endocrinopathy after hematopoietic Stem cell
  6362. … (d; dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (HDT) and autologous Stem cell
  6363. Induced Pluripotent Stem cell-Derived Autologous cell therapy for Age-Related Macular Degeneration
  6364. Histological study on the promising role of mesenchymal Stem cell therapy in paraquat induced lung injury in adult male albino rats
  6365. Evaluation of lymphoma patients receiving high-dose therapy and autologous Stem cell transplantation: experience of a single center
  6366. Genetic modulation therapy through Stem cell transplantation for human immunodeficiency virus 1 infection
  6367. Effects of human umbilical cord mesenchymal Stem cell therapy on the immune function and prognosis in patients with decompensated liver cirrhosis due to hepatitis …
  6368. Nestin and CD146 expression in metaplastic breast cancer: Stemcell therapy in need? Lessons reported from a male patient
  6369. Stem cell-based therapy in transplantation and immune-mediated diseases
  6370. Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic Stem cell transplant …
  6371. Stem cell therapy in Stroke
  6372. therapy targeting Stem cell in patients with decompensated cirrhosis of liver in a tertiary treatment care center of Bangladesh
  6373. Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous Stem cell transplantation
  6374. Application of Bone Marrow Stem cell Based therapy in Bone Loss Diseases
  6375. From Stem cell therapy to Cancer Treatment
  6376. Stem cell therapy in Osteoarthritis
  6377. Concept of Targeted Cancer Stem cell therapy and New Versions
  6378. Stem cell therapy: from translational hurdles to new frontiers
  6379. A randomized study comparing Stem cell transplantation versus conventional therapy for low-and intermediate-risk myelodysplastic Syndromes patients
  6380. Stem cell therapy in Glaucoma
  6381. Stem cell therapy As A Regenerative Approach In Veterinary Medicine
  6382. Stem cell therapy in Diabetes Mellitus
  6383. DESIGNING PROTEIN-ENGINEERED BIOMATERIALS FOR Stem cell therapy
  6384. Stem cell therapy Applications: The Challenge of Regenerative Medicine
  6385. New Advances in Stem cell therapy for Diabetes Mellitus
  6386. Haploidentical hematopoietic Stem cell transplantation with myeloablative conditioning regimen could serve as an optional salvage therapy for younger patients with …
  6387. Stem cell therapy in glaucoma
  6388. Evasion of targeted cancer therapy through Stemcell-like reprogramming
  6389. Cardiac Stem cell therapy: Current status
  6390. Inflammation and Stem cell therapy for stroke
  6391. A novel highly conserved hematopoietic Stem/progenitor cell population for Stem cell transplantation and gene therapy
  6392. Stem cell therapy for Type-1 Diabetes Mellitus
  6393. Stem cell therapy In Spinal Cord Injury
  6394. Osteoarthritis and Mesenchymal Stem cell therapy: An Overview
  6395. Rationale for Stem cell therapy for type 2 diabetes mellitus
  6396. Single dose preemptive plerixafor for Stem cell mobilization for ASCT after lenalidomide based therapy in multiple myeloma: impact in resource limited setting
  6397. Evaluation of low‐dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for Stem cell transplantation
  6398. Stem cell therapy for Autism
  6399. Stem cell therapy for Spinal Cord Injury
  6400. Stem cell therapy for Autism
  6401. Stem cell therapy: an Adjunct in the Treatment of MDR Tuberculosis
  6402. Bone marrow Stem cell therapy for stroke
  6403. Gene and Stem cell therapy for type 1 diabetes mellitus
  6404. Update of Stem cell therapy for orthopedic diseases of animals
  6405. therapy targeting Stem cell in patients with decompensated cirrhosis of liver in a tertiary treatment care center of Bangladesh
  6406. High-dose chemotherapy and Stemcell rescue for salvage therapy for relapsed malignant mixed ovarian germ cell tumor: A case report
  6407. Impact of post-autologous Stem cell transplant (ASCT) maintenance therapy on outcomes in patients (Pts) with newly diagnosed multiple myeloma (NDMM) using the …
  6408. Progress of Stem cell therapy in Spinal Cord Injury
  6409. Bone Marrow Hematopoietic Stem cell therapy in Stroke
  6410. When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic Stem cell transplant recipients?
  6411. Stem cell therapy for Retinal Disease Treatment: An Update
  6412. Stem cell therapy in Neurological and Neurodegenerative Disease
  6413. Safety of Neural Stem cell therapy for Traumatic Brain Injury
  6414. Therapeutic and economic implications of regulating Stem cell therapy and blood components
  6415. … (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous Stem cell
  6416. Stem cell therapy for chronic bladder ischaemia
  6417. Stem cell therapy for glaucoma—there is still a long way to go
  6418. Stem cell therapy as an Effective Treatment Method for Traumatic Burn Injuries
  6419. Future Medicine such as Gene or Stem cell therapy are Better than Nonbiological or Some Biological (Antibiotic) Medicine
  6420. Anterior cruciate ligament injury and Stem cell therapy
  6421. Stem cell therapy for Neurovascular and Traumatic Brain Diseases
  6422. Development of Membrane-Based Coculture Platforms for Effective Stem cell therapy
  6423. Research progress and challenge of the Stem cell therapy for intervertebral disc regeneration
  6424. Future Medicine such as Gene or Stem cell therapy Are Better Than Non biological or Some Biological (Antibiotic) Medicine
  6425. Embryonic Toxic Lesions and Stem cell therapy
  6426. Novel Stem cell-targeted therapy for multiple myeloma based on dual inhibition of EZH1/2
  6427. Feasibility of renal tissue Stem cell therapy for acute renal failure
  6428. Mesenchymal Stem cell therapy for Chronic Wound Healing in Dogs
  6429. Clinical Findings and Outcome after Stroke. Including a Translational Stem cell therapy Perspective.
  6430. Into the hearts of babes: Stem cell therapy for pediatric heart failure
  6431. TYPE 2 DIABETES MELLITUS AND Stem cell therapy: A REVIEW
  6432. Stem cell therapy in patients with ischemic stroke: A syStematic review and meta-analysis of randomized controlled trials
  6433. Human Umbilical Cord Mesenchymal Stem cell therapy for Patients
  6434. … strategies after allogeneic hematopoietic Stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy
  6435. Nitazoxanide is effective therapy for norovirus gastroenteritis after hematopoietic Stem cell transplantation
  6436. Mesenchymal Stem cell therapy for Liver Cirrhosis Treatment: Mechanisms and Bioeffects
  6437. GENE AND Stem cell therapy IN β-THALASSEMIA
  6438. Stem cell therapy for intervertebral disc regeneration
  6439. Acute Respiratory Failure In A Patient With Ipf Following Nebulized And Intravenous Stem cell therapy
  6440. Stem cell transplantation in patients with syStemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy
  6441. Mesenchymal Stem cell therapy for Airway Restoration Following Surgery
  6442. Potential Ciliary Neurotrophic Factor Application in Dental Stem cell therapy
  6443. POTENTIAL OF Stem cell therapy DURING DENGUE INFECTION IN MICE
  6444. Preclinical development of a neural Stem cell therapy for stroke and traumatic brain injury
  6445. Immunomodulatory Effects of Stem cell therapy on Racehorses with Musculoskeletal Disorders
  6446. Soldier with brain injury can have experimental Stem cell therapy, says judge
  6447. Stem cell therapy for Articular Cartilage Repair
  6448. A Compressed Collagen Gel Vehicle for Stem cell therapy of Wounded Corneas
  6449. Stem cell therapy in End Stage Liver Disease and Liver Failure
  6450. Induced Pluripotent Stem cell therapy and Safety Concerns in Age-Related Chronic Neurodegenerative Diseases
  6451. Stem cell AND ITS therapy
  6452. Manufacturing solutions for mesenchymal stromal/Stem cell therapy expansion
  6453. Regenerating Life: Exploring the Potential for Stem cell therapy in Traumatic Brain Injury
  6454. The effect of human mesenchymal Stem cell therapy on in vitro model of alopecia areata
  6455. Shear susceptibility of human mesenchymal Stem cells increases with generation number: Implications for Stem cell therapy scale-up and manufacturing
  6456. Cervical papanicolaou smears in hematopoietic Stem cell transplant recipients: high prevalence of therapy-related atypia during the acute phase
  6457. Autologous mesenchymal Stem cell therapy in behcet disease
  6458. Stem cell therapy: Optimization, Regeneration, Reprogramming, Expansion, Tissue Engineering
  6459. Modulation of structural and functional networks in the ischemic mouse brain by Stem cell therapy
  6460. CD34+ Stem cell therapy Does Not Increase the Risk of Arrhythmias in Patients With Chronic Heart Failure
  6461. EFFECTS OF ADIPOSE TISSUE MESENCHYMAL Stem cell therapy ON DIABETIC RATS
  6462. Mechanisms of action of mesenchymal Stem cell therapy in lung emphysema
  6463. Does Stem cell therapy improve beta cell function in type 2 diabetic mellitus patients: A syStematic review and single arm meta-analysis
  6464. The Impact of Sex on the Response to Mesenchymal Stem cell therapy in Patients With Non-Ischemic Dilated Cardiomyopathy
  6465. Development of a cost efficient platform for the industrial manufacturing of pluripotent Stem cell derived products for cell therapy: cell expansion is the starting …
  6466. ROS, pH and temperature responsive hydrogels for Stem cell therapy
  6467. Mixed phenotype acute leukemia with t (9; 22): success with nonacute myeloid leukemia‐type intensive induction therapy and Stem cell transplantation
  6468. Stem cell therapy Effect on the Inflammatory Response in a Porcine Model of Acute Lung Injury
  6469. Dose adaptation of the drugs used for hematopoietic Stemcell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines …
  6470. Imaging in Stem cell Transplant and cell-based therapy
  6471. … UPDATED COMPREHENSIVE META-ANALYSIS OF RANDOMIZED TRIALS EVALUATING THE EFFICACY OF Stem cell therapy FOR REFRACTORY ANGINA
  6472. P6319Novel swine models of single syStemic ventricle for Stem cell therapy in univentricular heart application
  6473. Adipose Stem cell therapy for Early Retinal Complications of Diabetes in the Ins2Akita Mouse
  6474. Phenotype of Super-Responders to Stem cell therapy for Non-Ischemic Dilated Cardiomyopathy
  6475. GW28-e0652 Meta-analysis of Bone Marrow Stem cell therapy on Patients with Chronic Ischemic Heart Disease and Congestive Heart Failure
  6476. … of liver regenerative therapy for cirrhosis by intrahepatic arterial infusion of freshly isolated autologous adipose tissue-derived stromal/Stem (regenerative) cell
  6477. Stromal vascular fraction and adipose derived Stem cells from chronic disease and obese patients can affect Stem cell therapy
  6478. Clinical trials of Stem cell therapy in dogs and cats with refractory diseases
  6479. Olfactory Stem cell therapy in Canine Age-related Disorders Treatment: A Controlled Study
  6480. 14 Stem cell therapy in Duchenne Muscular Dystrophy
  6481. Clinical applications of a Stem cell-based therapy for oral bone reconstruction
  6482. Stem cell Biology, Research & therapy
  6483. ID: 1041 Effectiveness of human adipose-derived Stem cell therapy pretreated with hepatocyte growth factor in liver fibrosis mouse model
  6484. Bilateral Osteonecrosis Associated with Corticosteroid Treatment: Stem cell therapy Versus Core Decompression in the Same Patient
  6485. Stem cell therapy for end stage COPD: a cautionary tale of direct-to-consumer advertising
  6486. Human Mesenchymal Stem cell therapy Reverses Sugen/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
  6487. Mesenchymal Stem cell therapy on Tendon/Ligament Healing. J Cytokine Biol 2: 112
  6488. P 53: Stem cell therapy for Treatment of Autoimmune Diseases (with Emphasis on Multiple Sclerosis)
  6489. Use of Stem cell in Fetal therapy: Current Status and Future Perspectives
  6490. Effect of mesenchymal Stem cell therapy on the proteinuria of dogs with chronic kidney disease.
  6491. THE ROLE OF GENDER ON MESENCHYMAL Stem cell therapy IN NON-ISCHEMIC DILATED CARDIOMYOPATHY: A SUB-ANALYSIS OF THE POSEIDON …
  6492. P 111: Use of Stem cell therapy for Treatment of Temporal Lobe Epilepsy (TLE)
  6493. To evaluate the effect of autologous adipose derived mesenchymal Stem cell therapy in the treatment of osteoarthritis–A case series analysis
  6494. Do Males and Females with Non-Ischemic Dilated Cardiomyopathy Respond Similarly to Stem cell therapy? an Analysis From the POSEIDON-DCM Trial
  6495. Optimal delivery route of mesoangioblasts for Stem cell therapy in rat model for simulated vaginal birth injury
  6496. 193 Does Stem cell therapy Hold Promise In The Management Of Traumatic Brain Injuries? A Literature Review of Animal Studies
  6497. Human umbilical cord-mesenchymal Stem cell therapy protects against experimental ischemic stroke and neurotrauma
  6498. Final analysis of the phase I/II study of CC-486 (oral azacitidine) maintenance therapy after allogeneic Stem cell transplantation (Allo-SCT) in patients with …
  6499. Granulocyte colony-stimulating factor and autologous CD133-positive Stemcell therapy in liver cirrhosis (REALISTIC)
  6500. Novel strategies for generation and hypothermic storage of human pluripotent Stem cell-derived cardiomyocytes for cell therapy applications
  6501. A syStemically-delivered Stem cell therapy for dry age related macular degeneration
  6502. Evaluation of the effectiveness of Stem cell therapy with use of adult multipotent neural crest-derived Stem cells for modeled adrenal-induced glaucoma treatment
  6503. Biological performance of novel phosphate-based glass microspheres for mesenchymal Stem cell therapy in osteoporotic patients
  6504. Stem cell Pool: What Are the Best Patterns for cellular therapy?
  6505. Exosomes isolated from human inducible pluripotent Stem cell-derived cardiomyocytes enhance angiogenesis in-vitro; a new potential therapy for the post-ischemic …
  6506. … to: Evaluation of patients with multiple sclerosis using reverse nutech functional score and expanded disability status scale after human embryonic Stem cell therapy
  6507. Post-Autologous Stem cell Transplantation therapy for Multiple Myeloma Patients: Impact on Clinical Outcomes
  6508. Recover of voluntary muscular contractile capacity in spinal cord injury patients who received combined autologous Stem cell therapy: In spinal cord and skeletal …
  6509. T‐cell‐rich HLA‐haploidentical hematopoietic Stem cell transplantation for relapsed/refractory pediatric Philadelphia chromosome‐positive acute lymphoblastic …
  6510. Impact of FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous Stem cell transplant on total healthcare …
  6511. Generation of HIV-1 resistant, functional blood cells from human pluripotent Stem cells for the Stem cell-based therapy
  6512. Stem cell-derived exosome transplantation as a new cell-free therapy for liver regeneration
  6513. P11: Can delivery of mesenchymal Stem cell aggregates enhance retention of cells at the site of injury in cell therapy of equine tendon?
  6514. Cutting Edge Advances in Stem cell Biology and therapy
  6515. Towards an experimental Stem cell-based therapy for Age-related Macular Degeneration
  6516. Maintenance rituximab after high-dose therapy and autologous Stem cell transplantation in mantle cell lymphoma
  6517. PDTM-18. INVESTIGATING INTRA-CAVITY NEURAL Stem cell therapy FOR POST-SURGICAL DISEASE IN A NOVEL SURGICAL RESECTION/RECURRENCE …
  6518. Progress of Stem/progenitor cell-based therapy for retinal degeneration
  6519. Treatment of Myocardial Infarction by Stem cell Based therapy
  6520. IGF-1 C domain-modified hydrogel facilitates Stem cell therapy in renal ischemia in diabetic mice
  6521. Stem cell Biology, Research & therapy
  6522. … of biotinylated IGF-1 with biotinylated self-assembling peptides combined with bone marrow Stem cell transplantation promotes cell therapy for myocardial infarction
  6523. Stem cell Strategies for the Modeling and therapy of Alzheimer’s Disease
  6524. Comparisons of efficacy and safety of CBV, BEAM and BEAC high-dose therapy followed by autologous hematopoietic Stem cell transplantation in Hodgkin’s …
  6525. … myeloid leukemia (SM-AML): a poor-risk multi-mutated disease that follows a distinct diagnostic algorithm and requires high-dose Stem cell-targeting therapy
  6526. Development of Stem cell-based therapy for cornea-from tissue Stem cell to iPS cell
  6527. Stem-40. THE ROLE OF SYMMETRIC cell DIVISION IN POST therapy GLIOMA Stem cell EXPANSION
  6528. Development of a Stem cell gene therapy for Sanfilippo syndrome type B
  6529. … Phase II Study of Clarithromycin or Placebo Combined with VCD Induction therapy Prior to High-Dose Melphalan with Stem cell Support in Patients with …
  6530. Benefits afforded by combined temozolomide, radiation and Stem cell strategy for glioma therapy
  6531. Lung Stem cell-based therapy: a possible way to repair the injuried lung
  6532. Combining multiple therapeutic strategies for Friedreich’s ataxia (FRDA): antioxidant metallic nanoclusters as coadjuvants for gene and Stem cell therapy
  6533. Clinical Safety and Applications of Stem cell Gene therapy
  6534. Clinical study on foscarnet prophylaxis and pre-emptive therapy for cytomegalovirus infection in hematopoietic Stem cell transplantation
  6535. … Azacitidine and High Dose Lenalidomide therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem cell Transplantation for Actue …
  6536. Melphalan dose in myeloma patients over 65 years of age undergoing high-dose therapy and autologous Stem cell transplantation
  6537. Predictive model for Stem cell transplantation with suicidal gene construct for the treatment of leukemia: Analytical model for gene therapy of leukemia
  6538. Design of a quality control and safety program Stem cell-based therapy
  6539. Hematopoietic Stem cell gene therapy corrects neuronopathic phenotype in
  6540. Mesenchymal stromal/Stem cells: a new era in the cell-based targeted gene therapy of cancer
  6541. IND-Enabling GLP study to support a clinical trial of dual adoptive cell therapy combining Stem cells and T cells engineered with an NY-ESO-1 TCR
  6542. … -World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet therapy without Stem cell Transplant: An Enhanced …
  6543. Acute Kidney Injury during Vancomycin therapy Associated with Combination Use of Piperacillin-Tazobactam after Allogeneic Stem cell Transplantation
  6544. Optimized gene therapy normalizes wound healing and Stem cell marker expression in cultured diabetic limbal epithelial cells.
  6545. Stem cells as potential candidates for psoriasis cell-replacement therapy
  6546. Directly induced Neural Stem cells transplantation and prospects for Stem cell-based therapy
  6547. Foam-cell Signified Blood Vessel Endhotel Repair and Histopatology of Abdominal Aorta through Stem cell Allogenous therapy to Rats (Rattus norvegicus) …
  6548. … STUDIES OF NEURAL Stem cell MEDIATED CARBOXYLESTERASE/IRINOTECAN ENZYME/PRODRUG GENE therapy FOR RECURRENT GLIOMA LEADING …
  6549. … radiation based conditioning for relapsed/refractory Hodgkin lymphoma patients undergoing high dose therapy and autologous Stem cell transplantation (HDT-ASCT)
  6550. A Single autologous Stem cell transplant (ASCT) followed by two years of post-transplant therapy is safe in older recently diagnosed multiple myeloma (MM) …
  6551. Reduction of Gingival Black Triangles with Dental Pulp or Gingival Stem cell Injection therapy: Clinical and Outcomes Research Gaps
  6552. The pathway regulation and targeted therapy of tumor Stem cells regulatory and targeting therapy of tumor Stem cell related signal pathway
  6553. Engineering Stem cell fate for drug development and therapy
  6554. Gene Modified Stem/Progenitor‐cell therapy for Ischemic Stroke
  6555. Lenalidomide maintenance therapy after autologous peripheral blood Stem cell transplant (PBSCT) in multiple myeloma patients: factors that impact treatment
  6556. Hematopoietic Stem cell transplantation in the era of molecular targeted therapy.
  6557. Infectious complications associated with infliximab therapy for allogeneic Stem cell transplant patients with corticosteroid refractory acute graft versus host disease
  6558. LACE high dose therapy with autologous Stem cell support
  6559. Effective BiRd therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem cell Transplantation
  6560. A Mathematical Model of Cancer Stem cell Kinetics and Response to Radiation therapy
  6561. A quest for the best retinal pigment epithelium (Stem) cell replacement therapy
  6562. Establishing the optimal viral load threshold for initiation of therapy for cytomegalovirus infection in hematopoietic Stem cell transplant recipients: a prospective …
  6563. Interleukin-6 blockade, a novel cancer Stem cell targeted therapy, attenuates lung cancer tissue construction
  6564. Supportive (Maintenance) therapy in Hematopoietic Stem cell Transplantation: Main Principles and New Perspectives
  6565. Inherent immunogenicity or lack thereof of pluripotent Stem cells: implications for cell replacement therapy
  6566. … myeloma patients undergoing intensive preparative regimen with autologous Stem cell transplantation (ASCT) followed by maintenance therapy using novel agents
  6567. Cancer Stem cell-selective photodynamic therapy
  6568. Stem cell-Based therapy in Transplantation and Immune-Mediated Diseases
  6569. … OF QUALITATIVE AND QUANTITATIVE INDICATORS OF SUBSTITUTIONARY TRANSFUSION therapy IN DIFFERENT TYPES OF HEMATOPOIETIC Stem cell
  6570. PP27. ESTABLISHMENT OF A HAEMATOPOIETIC Stemcell BASED therapy FOR BRAIN TUMOURS IN PRE-CLINICAL MOUSE MODELS
  6571. The role of high-dose therapy and autologous Stem cell transplantation in the treatment of patients with multiple myeloma
  6572. … by CHASER as induction therapy for high-dose chemotherapy (HDT), LEED, and autologous Stemcell transplantation (ASCT) in poor-risk diffuse large B-cell
  6573. Prospects for Stem cell-based mucosal regeneration therapy in inflammatory bowel disease.
  6574. Research progress of Stem cell-derived RPE cell transplantation therapy for retinal degenerative diseases
  6575. … of scientific reports and lectures at the XI Raisa Gorbacheva meeting hematopoietic Stem cell transplantation. Gene and cellular therapy (September 14-16 …
  6576. Neuroanatomy of music therapy and hematopoietic Stemcell transplantation
  6577. Human Gingiva: A Promising Source of Mesenchymal Stem cells for cell therapy and Regenerative Medicine
  6578. EXTH-20. ENHANCEMENT OF GAP JUNCTIONAL ACTIVITY BY iPS cell-DERIVED NEURAL Stem cells IN Stem cell-BASED SUICIDE GENE therapy
  6579. PRELIMINARY RESULTS OF THE PHASE I CLINICAL STUDY EVALUATING NEURAL Stem cell BASED therapy FOR PARKINSON’S DISEASE (S4. 004)
  6580. Development of iPS (induced pluripotent Stem cells) using natural product from extract of fish oocyte to provide Stem cell for regenerative therapy
  6581. High-Dose therapy and Haemopoietic Stem cell Transplantation in Waldenström’s Macroglobulinaemia
  6582. Mesenchymal Stem cell based-suicide gene therapy for the treatment of brain tumors
  6583. Stem cell Replacement therapy for the Mammalian Inner Ear: A SyStematic Literature
  6584. … to Any First Line therapy for Multiple Myeloma Should Proceed to Autologous Stem cell Transplantation Instead of Receiving Second Line therapy to …
  6585. Mesenchymal Stem cell-based therapy for autoimmune disease: immunomodulatory potential and clinical applications
  6586. Stem-11. A MAPK-DRIVEN miR-124-SOX9 AXIS IS CRITICAL FOR Stem cell MAINTENANCE, PROGRESSION, AND therapy-RESISTANCE IN …
  6587. Stem cell-engineered invariant natural killer T cells for cancer therapy
  6588. … /congelation of hematopoietic Stem cell grafts in a pediatric context: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy
  6589. Lentiviral Hematopoietic Stem cell Gene therapy for MNGIE
  6590. Analysis of cytokines from different disease modify therapy treated multiple sclerosis patients by mesenchymal Stem cell stimulation
  6591. Multiple Myeloma and Renal Impairment: Analysis of Induction therapy Strategies and Outcome after Autologous Stem cell Transplantation
  6592. Long-Term Clinical and Molecular Remissions in Patients with Follicular Lymphoma (FL) Following High-Dose therapy (HDT) and Autologous Stem cell
  6593. 2325: Steroid therapy limits Stem cell activation required to enact mucosal healing in inflammatory bowel disease
  6594. Development of Mesenchymal Stem cell Laden Patch-Type therapy using 3D cell-Printing Technology for Liver Cirrhosis Treatment
  6595. … Establishment of Tumorigenicity Assay Promise the Safety in the Cardiomyogenesis therapy Using Human Induced Pluripotent Stem cell-Derived Cardiomyocytes for …
  6596. … treated with autologous nonmyeloablative hematopoietic Stemcell transplantation (AHST) compared with conventional medical therapy (CT). research design …
  6597. Maintenance therapy with Azacitadine and Valproic Acid after Allogeneic Stem cell Transplant in Patients with High-Risk Acute Myelogenous Leukemia
  6598. Outcomes of Salvage Second Autologous Stem cell Transplantation for Relapsed/Refractory Multiple Myeloma in the Era of Modern therapy
  6599. Post Autologous Stem cell Transplant Light Chain Response Is a Prognostic Marker in Multiple Myeloma Patients in PR/VGPR after Induction therapy
  6600. Factors Determining Utilization of Stem cell Transplant (SCT) for Initial therapy of Multiple Myeloma (MM) By Patient Race: Exploring Intra-Racial Healthcare …
  6601. The efficacy of Salvage Autologous Stem cell Transplant for Patients With Multiple Myeloma Who Received Maintenance therapy Post an Initial Transplant
  6602. … II study of intensive consolidation and Stem cell mobilization therapy with ofatumumab, etoposide, and high-dose ara-C (OVA), followed by autologous Stem cell
  6603. … of the angiogenic subset of human adipose-derived Stem cells by evaluation of capability to induce M2-dominant macrophage polarization in cell therapy
  6604. Understanding cell signaling in cancer Stem cells for targeted therapy–can phosphoproteomics help to reveal the secrets?
  6605. Result of Bortezomib Induction therapy Prior to Stem cell Transplantation in Newly Diagnosed Multiple Myeloma Cases in Mongolia
  6606. therapy Related Myeloid Neoplasia in Hodgkin Lymphoma after Autologous Stem cell Transplantation (ASCT)–A Case Report
  6607. Double Autologous Stem cell Transplantation Followed by Maintenance therapy Conquers the Adverse Cytogenetic Abnormalities in Newly Diagnosed Multiple …
  6608. In situ immune expression signatures before and after ipilimumab therapy for relapsed acute myeloid leukemia after allogeneic Stem cell transplantation
  6609. A novel process using human sera for the production of secretome and potentially clinical grade mesenchymal Stem cell for regenerative therapy/Nazmul Haque
  6610. Improving Oral Assessments and Implementing Preventative Low Level Laser therapy in Hematopoietic Stem cell Transplant Patients to Prevent Oral Mucositis
  6611. … of Duration of Induction therapy on Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Undergoing Upfront Autologous Stem cell
  6612. 18f-FDG PET-CT Assessment of Responses to Salvage therapy and Autologous Stem cell Transplant (ASCT) in Relapsed/Refractory Classical Hodgkin …
  6613. The Effect of Sorafenib therapy on the Outcome of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem cell Transplantation
  6614. TMOD-03. GENES PRESERVING Stem cell STATE IN GROUP 3 MB BTICS CONTRIBUTE TO therapy EVASION AND RELAPSE
  6615. Hypoxia Promotes Stem cell Phenotypes, Resistance to therapy and Poor Prognosis through Epigenetic Regulation of DICER
  6616. Update on safety and efficacy of lentiviral hematopoietic Stem cell gene therapy (HSC-GT) for metachromatic leukodystrophy (MLD)
  6617. Non eligibility criteria for hematopoietic Stem cell donors: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM-TC)
  6618. 2203: Engraftment and gene expression of an HIV resistant immune syStem in a Phase I trial of an HIV Stem cell gene therapy strategy
  6619. MEDU-30. GENES PRESERVING Stem cell STATE IN GROUP 3 MB BTICS CONTRIBUTE TO therapy EVASION AND RELAPSE
  6620. Brentuximab Vedotin Consolidation therapy after Autologous Stemcell Transplantation in Patients with High-Risk Hodgkin’s Lymphoma: The Real World Experience …
  6621. Improved Survival Outcomes By Iron Chelating therapy with Deferasirox after Allogeneic Hematopoietic Stem cell Transplantation in Patients with Acute …
  6622. Clinical investigation of sequential therapy with micafungin and reduced-dose voriconazole in prevention of fungal in patients after allogeneic hematopoietic Stem cell
  6623. … in-Hospital Morbidity and Mortality in SyStemic Light Chain (AL) Amyloidosis after High Dose therapy and Autologous Stem cell Transplant (HDT/ASCT)
  6624. … of Cytomegalovirus (CMV) Viral Load on Probability of Spontaneous Clearance and Efficacy of Pre-Emptive therapy Among CMV Seropositive Allogeneic Stem cell
  6625. Comprehensive assessment of cancer Stem cell like cells in prediction of pathologic complete response to preoperative dual anti–HER2 therapy for HER2–positive …
  6626. Corrigendum to “Combination of low-energy shock-wave therapy and bone marrow mesenchymal Stem cell transplantation to improve the erectile function of diabetic …
  6627. Intensification therapy with autologous Stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma patients: A …
  6628. … choroidal thickness and peripapillary retinal thickness after high‐dose melphalan therapy followed by autologous peripheral blood Stem cell transplantation in a …
  6629. The Impact of Thalidomide, Zoledronate and High-dose therapy with Autologous Stem cell Support on Patient Reported Outcomes in Multiple Myeloma: Results of …
  6630. … dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous Stem cell
  6631. … and Vorinostat Followed By CD19 CAR-T therapy in a Patient with MLL-Rearranged ALL after Early Relapse Post Allogeneic Hematopoietic Stem cell
  6632. … B-regulatory cells from donor adipose tissue derived mesenchymal Stem cells and recipient peripheral blood mononuclear cells for potential cell therapy
  6633. Assay development and cell characterization challenges of human induced pluripotent Stem cells for cell therapy applications
  6634. Bioprocessing of human Pluripotent Stem cells for cardiac cell therapy and pre-clinical research
  6635. Damaging effects of cigarette smoke on organs and Stem/progenitor cells and the restorative potential of cell therapy
  6636. cell therapy of combat related spinal cord injury with use of adult neural crest-derived multipotent Stem cells
  6637. Human-cell microparticles for celltherapy and cargo delivery to Stem cells
  6638. Age of Donor of Human Mesenchymal Stem cells Drastically Affects Structural and Functional Recovery After cell therapy Following Ischemic Stroke
  6639. 5T4-targeted therapy ablates cancer Stem cells and prevents recurrence of head and neck squamous cell carcinoma
  6640. Is there a place for human fetal-derived Stem cells for cell replacement therapy in Huntington’s disease?
  6641. Therapeutic value of immune cell therapy based on T memory Stem cells and central memory T cells for hematological malignancies
  6642. … Resveratrol Treatment for the Reduction in the Induced Pluripotent Stem (iPS) cell Tumorigenicity to Confirm the Safety of iPS cell-Based Cardiomyogenesis therapy
  6643. Induced pluripotent Stem cells (iPSC) from small volume peripheral blood samples for in vitro modeling and cell therapy of pediatric liver diseases
  6644. Microencapsulated Umbilical Cord Wharton Jelly-Derived Human Mesenchymal Stem cells for the cell therapy of Type 1 Diabetes Mellitus (T1d): Applications …
  6645. The use of mesenchymal Stem cells (MSCs) for amyotrophic lateral sclerosis (ALS) therapy–a perspective on cell biological mechanisms
  6646. An analysis of the transcriptional response of myelodysplastic syndrome Stem cells to therapy at single-cell resolution
  6647. Ex Vivo Expanded Murine Mesenchymal Stem cells as Targets for the Generation of a cell Replacement therapy for Type 1 Diabetes
  6648. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem cells for Gene therapy of Beta-Thalassemia and Sickle cell Disease
  6649. A potential therapy using engineered neural Stem cells prevented malignant melanoma from cell proliferation, epithelial-mesenchymal transition and metastasis in …
  6650. A Modified Approach to Induce Differentiation of Muscle-Derived Stem cells into Schwann cell-Like cells: Implications for Remyelination therapy
  6651. … -23. PHASE I STUDY OF ADOPTIVE cellULAR therapy (X-ALT) PLUS TOTAL TUMOR RNA-DENDRITIC cell VACCINE (TTRNA-DC)+ HEMATOPOIETIC Stem
  6652. Abstract LB-149: ITGA1 marks pre-malignant pancreatic lesions and drives Stem-like cell survival and TGFβ/collagen-induced therapy resistance and metastasis in …
  6653. Stem/progenitor cell neurogenic behaviour0009: Detection and quantification of bacteria in degenerating intervertebral discs0120: SMaRT human Stem cells to modify …
  6654. Neural Stem cell therapy—Brief review
  6655. Stem cell therapy in heart diseases–cell types, mechanisms and improvement strategies
  6656. Stem cell therapy: a new therapeutic option for cardiovascular diseases
  6657. Preclinical studies of Stem cell therapy for heart disease
  6658. Osteoarthritis and Stem cell therapy in humans: a syStematic review
  6659. Mesenchymal Stem cell therapy for bone regeneration
  6660. Stem cell therapy for multiple sclerosis
  6661. Stem cell therapy for diabetic foot ulcers: a review of preclinical and clinical research
  6662. A biodegradable hybrid inorganic nanoscaffold for advanced Stem cell therapy
  6663. Current approaches for the treatment of premature ovarian failure with Stem cell therapy
  6664. Neural Stem cell therapy for subacute and chronic ischemic stroke
  6665. Mesenchymal Stem cell therapy for ischemic tissues
  6666. Novel approach to Stem cell therapy in Parkinson’s disease
  6667. Intra-articular mesenchymal Stem cell therapy for the human joint: a syStematic review
  6668. Stem cell therapy in Asherman syndrome and thin endometrium: Stem cell-based therapy
  6669. Induced pluripotent Stem cells: the most versatile source for Stem cell therapy
  6670. Stem cell therapy: a promising therapeutic method for intracerebral hemorrhage
  6671. The current status of Stem cell therapy in ischemic heart disease
  6672. Mesenchymal Stem cell therapy in stroke: a syStematic review of literature in pre-clinical and clinical research
  6673. Hematopoietic Stem cell therapy for autoimmune diseases–clinical experience and mechanisms
  6674. Long-term efficacy and safety of Stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease
  6675. Advances in Stem cell therapy for amyotrophic lateral sclerosis
  6676. The application of nanomaterials in Stem cell therapy for some neurological diseases
  6677. Stem cell therapy in autism: recent insights
  6678. Optimal electrical stimulation boosts Stem cell therapy in nerve regeneration
  6679. … and Stem cell therapy: AMPK as an applicable pharmacological target for rejuvenation of aged Stem cells and achieving higher efficacy in Stem cell therapy
  6680. Limited evidence for adipose-derived Stem cell therapy on the treatment of osteoarthritis
  6681. Neural Stem cell therapy aiming at better functional recovery after spinal cord injury
  6682. Mesenchymal Stem cell therapy in cats: Current knowledge and future potential
  6683. Advances in Stem cell therapy for erectile dysfunction
  6684. Stem cell therapy in chronic obstructive pulmonary disease. How far is it to the clinic?
  6685. Safety and efficacy of adult Stem cell therapy for acute myocardial infarction and ischemic heart failure (Safecell Heart): a syStematic review and meta-analysis
  6686. Mesenchymal Stem cell therapy of pulmonary fibrosis: improvement with target combination
  6687. Stemcell therapy and platelet-rich plasma in regenerative medicines: A review on pros and cons of the technologies
  6688. Stem cell therapy for treating osteonecrosis of the femoral head: from clinical applications to related basic research
  6689. A review on Stem cell therapy for multiple sclerosis: special focus on human embryonic Stem cells
  6690. First off-the-shelf mesenchymal Stem cell therapy nears European approval
  6691. Autologous Stem cell therapy in critical limb ischemia: a meta-analysis of randomized controlled trials
  6692. The promise of mesenchymal Stem cell therapy for acute respiratory distress syndrome
  6693. Mesenchymal Stem cell therapy in Ischemic stroke: a meta‐analysis of preclinical studies
  6694. Stem cell therapy on skin: mechanisms, recent advances and drug reviewing issues
  6695. Tissue engineering in osteoarthritis: current status and prospect of mesenchymal Stem cell therapy
  6696. Stem cell therapy for articular cartilage repair: review of the entity of cell populations used and the result of the clinical application of each entity
  6697. Stem cell therapy for patients with diabetes: a syStematic review and meta-analysis of metabolomics-based risks and benefits
  6698. Stem cell therapy and type 1 diabetes mellitus: treatment strategies and future perspectives
  6699. Pluripotent Stem cell-derived cardiomyocytes as a platform for cell therapy applications: progress and hurdles for clinical translation
  6700. The current state of Stem cell therapy for ocular disease
  6701. Stem cell therapy in necrotizing enterocolitis: Current state and future directions
  6702. Outcome of allogeneic adult Stem cell therapy in dogs suffering from osteoarthritis and other joint defects
  6703. Promotion of cell-based therapy: special focus on the cooperation of mesenchymal Stem cell therapy and gene therapy for clinical trial studies
  6704. A syStematic review and meta-analysis of clinical trials of mesenchymal Stem cell therapy for cartilage repair
  6705. Mesenchymal Stem cell-mediated immunomodulation in cell therapy of neurodegenerative diseases
  6706. Efficacy of Stem cell therapy in ambulatory and nonambulatory children with Duchenne muscular dystrophy–Phase I–II
  6707. Stem cell therapy for hypoplastic left heart syndrome: mechanism, clinical application, and future directions
  6708. Stem cell therapy: Repurposing cell-based regenerative medicine beyond cell replacement
  6709. The role of Stem cell therapy in regeneration of dentine-pulp complex: a syStematic review
  6710. Nanomedicine in cancer Stem cell therapy: from fringe to forefront
  6711. Feasibility, safety, and tolerance of mesenchymal Stem cell therapy for obstructive chronic lung allograft dysfunction
  6712. Mesenchymal Stem cell therapy for acute and chronic pancreatitis
  6713. Stem cell therapy in refractory perineal Crohn’s disease: long‐term follow‐up
  6714. Potentials of combining nanomaterials and Stem cell therapy in myocardial repair
  6715. Mesenchymal Stem cell therapy for aging frailty
  6716. Granulocyte colony-stimulating factor and autologous CD133-positive Stemcell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled …
  6717. Improvement in left ventricular function with intracoronary mesenchymal Stem cell therapy in a patient with anterior wall ST-segment elevation myocardial …
  6718. Human leukocyte antigen class I and II knockout human induced pluripotent Stem cell–derived cells: universal donor for cell therapy
  6719. Current status of Stem cell therapy, scaffolds for the treatment of diabetes mellitus
  6720. Donor mesenchymal Stem cell linetics after transamniotic Stem cell therapy (TRASCET) for experimental spina bifida
  6721. Combinatorial screening of nanoclay-reinforced hydrogels: a glimpse of the “holy grail” in orthopedic Stem cell therapy?
  6722. Maturation of pluripotent Stem cell-derived cardiomyocytes: a critical step for drug development and cell therapy
  6723. Interaction between hypothermia and delayed mesenchymal Stem cell therapy in neonatal hypoxic-ischemic brain injury
  6724. Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia
  6725. The ratio of ADSCs to HSC-progenitors in adipose tissue derived SVF may provide the key to predict the outcome of Stemcell therapy
  6726. Efficient promotion of autophagy and angiogenesis using mesenchymal Stem cell therapy enhanced by the low-energy shock waves in the treatment of …
  6727. Inducible pluripotent Stem cell-derived mesenchymal Stem cell therapy effectively protected kidney from acute ischemia-reperfusion injury
  6728. Role of autologous bone marrow-derived Stem cell therapy for follicular recruitment in premature ovarian insufficiency: review of literature and a case report of …
  6729. Articular cartilage aging-potential regenerative capacities of cell manipulation and Stem cell therapy
  6730. Stem cell therapy for faecal incontinence: current state and future perspectives
  6731. Stem cell therapy in patients with chronic nonischemic heart failure
  6732. Compressed collagen enhances Stem cell therapy for corneal scarring
  6733. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger’s disease)
  6734. Autologous and allogeneic cardiac Stem cell therapy for cardiovascular diseases
  6735. Towards standardized Stem cell therapy in type 2 diabetes mellitus: a syStematic review
  6736. Specific cancer Stem celltherapy by albumin nanoparticles functionalized with CD44-mediated targeting
  6737. Stem cell therapy for COPD: where are we?
  6738. Haemopoietic Stem cell therapy in cirrhosis: the end of the story?
  6739. Subchondral Stem cell therapy versus contralateral total knee arthroplasty for osteoarthritis following secondary osteonecrosis of the knee
  6740. Ethical and safety issues of Stem cell-based therapy
  6741. Mesenchymal Stem cell therapy for paraquat poisoning: a syStematic review and meta-analysis of preclinical studies
  6742. Immune inflammatory modulation as a potential therapeutic strategy of Stem cell therapy for ALS and neurodegenerative diseases
  6743. Stem cell therapy for multiple sclerosis
  6744. Stem cell therapy targeting the right ventricle in pulmonary arterial hypertension: is it a potential avenue of therapy?
  6745. Regulation of Stem cell therapy travel
  6746. Transamniotic Stem cell therapy: a novel strategy for the prenatal management of congenital anomalies
  6747. Stem cell therapy of gliomas
  6748. Gender-independent efficacy of mesenchymal Stem cell therapy in sex hormone-deficient bone loss via immunosuppression and resident Stem cell recovery
  6749. Mesenchymal Stem cell therapy in intracerebral haemorrhagic stroke
  6750. Mesenchymal Stem cell therapy for ischemic heart disease: Advances and challenges
  6751. Allogeneic adipose‐derived mesenchymal Stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety
  6752. Stem cell therapy for osteonecrosis of the femoral head: current trends and comprehensive review
  6753. Composite hydrogel modified by IGF-1C domain improves Stem cell therapy for limb ischemia
  6754. Cochrane Corner: Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
  6755. Clinical performance of Stem cell therapy in patients with acute-on-chronic liver failure: a syStematic review and meta-analysis
  6756. Mesenchymal Stem cell-based therapy for cardiovascular disease: progress and challenges
  6757. Current approaches for the treatment of male infertility with Stem cell therapy
  6758. Evaluation of the curative effect of umbilical cord mesenchymal Stem cell therapy for knee arthritis in dogs using imaging technology
  6759. Advances in Stem cell therapy for cartilage regeneration in osteoarthritis
  6760. A review of Stem cell therapy for acquired brain injuries and neurodegenerative central nervous syStem diseases
  6761. Stem cell therapy for tendon regeneration: current status and future directions
  6762. Postnatal periodontal ligament as a novel adult Stem cell source for regenerative corneal cell therapy
  6763. Mesenchymal Stem cell therapy prevents abortion in CBA/J× DBA/2 mating
  6764. Bladder regeneration through Stem cell therapy
  6765. Stemcell therapy Advances in China
  6766. Potential of Stem cell-based therapy for ischemic stroke
  6767. Is Stem cell therapy the future of orthopedics?
  6768. Stemcell therapy in ST‐segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double‐blind randomized trial
  6769. Stem cell therapy for lung diseases: From fundamental aspects to clinical applications
  6770. Stem cell therapy in early post-traumatic talus osteonecrosis
  6771. Fetal bone marrow homing of donor mesenchymal Stem cells after transamniotic Stem cell therapy (TRASCET)
  6772. Stem cell therapy for retinal ganglion cell degeneration
  6773. Stem cell therapy using bone marrow-derived mononuclear cells in treatment of lower limb lymphedema: a randomized controlled clinical trial
  6774. A collagen based cryogel bioscaffold coated with nanostructured polydopamine as a platform for mesenchymal Stem cell therapy
  6775. Intra-cavity Stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection
  6776. High-grade purification of third-generation HIV-based lentiviral vectors by anion exchange chromatography for experimental gene and Stem cell therapy applications
  6777. Pluripotent Stem cell-based therapy for Parkinson’s disease: Current status and future prospects
  6778. Will nanotechnology bring new hope for Stem cell therapy?
  6779. An oxygen plasma treated poly (dimethylsiloxane) bioscaffold coated with polydopamine for Stem cell therapy
  6780. Stem cell therapy in cerebrovascular disease
  6781. Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic Stem cell transplantation treated by CAR T-cell therapy: a case report
  6782. Stem cell fate in cancer growth, progression and therapy resistance
  6783. Hematopoietic Stem cell transplantation in the era of engineered cell therapy
  6784. Amputation-site soft-tissue restoration using adipose Stem cell therapy
  6785. Stem cell therapy for perianal Crohn’s disease
  6786. Mesenchymal Stem cell/red blood cell-inspired nanoparticle therapy in mice with carbon tetrachloride-induced acute liver failure
  6787. Human mesenchymal Stem cell therapy reverses Su5416/hypoxia-induced pulmonary arterial hypertension in mice
  6788. Autologous Stem cell therapy for inherited and acquired retinal disease
  6789. The challenges of Stem cell therapy in myocardial infarction and heart failure and the potential strategies to improve the outcomes
  6790. Cancer Stem cell metabolism: target for cancer therapy
  6791. Recent updates on treatment of ocular microbial infections by Stem cell therapy: a review
  6792. Advancement in Stem cell therapy for ischemic myocardial cell: A syStematic review
  6793. Clinical experience with regenerative therapy in heart failure: advancing care with cardiopoietic Stem cell interventions
  6794. Human mesenchymal Stem cell therapy in the management of luminal and perianal fistulizing Crohn’s disease–review of pathomechanism and existing clinical data
  6795. Stem cell functionality is microenvironmentally defined during tumour expansion and therapy response in colon cancer
  6796. Treating childhood traumatic brain injury with autologous Stem cell therapy
  6797. Stem cell therapy in osteonecrosis of the femoral head
  6798. A pooled analysis of mesenchymal Stem cell-based therapy for liver disease
  6799. Concise review: optimized strategies for Stem cell-based therapy in myocardial repair: clinical translatability and potential limitation
  6800. Mesenchymal Stem cell therapy in osteoarthritis and regenerative medicine
  6801. Six years’ experience of tolerance induction in renal transplantation using Stem cell therapy
  6802. Progress in mesenchymal Stem cell–based therapy for acute liver failure
  6803. Mesenchymal Stem cell migration during bone formation and bone diseases therapy
  6804. Stem cell therapy for acute myocardial infarction: on the horizon or still a dream?
  6805. NK cell therapy after hematopoietic Stem cell transplantation: can we improve anti-tumor effect?
  6806. A review of clinical trials: mesenchymal Stem cell transplant therapy in type 1 and type 2 diabetes mellitus
  6807. Stem cell therapy in erectile dysfunction: science fiction or realistic treatment option?
  6808. Current status and potential challenges of mesenchymal Stem cell-based therapy for malignant gliomas
  6809. Mesenchymal Stem cell-based therapy for radiation-induced lung injury
  6810. Stem cell therapy in bilateral osteonecrosis: computer-assisted surgery versus conventional fluoroscopic technique on the contralateral side
  6811. Current perspectives regarding Stem cell-based therapy for liver cirrhosis
  6812. Efficiency of Stem cell based therapy in the treatment of diabetic foot ulcer: a meta-analysis
  6813. Combining Stem cell therapy for advanced heart failure and ventricular assist devices: a review
  6814. cell-free therapy based on adipose tissue Stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway
  6815. Cancer-testis antigens: Unique cancer Stem cell biomarkers and targets for cancer therapy
  6816. Lipocalin 2 enhances mesenchymal Stem cell-based cell therapy in acute kidney injury rat model
  6817. Mesenchymal Stem cell therapy in hematopoietic Stem cell transplantation
  6818. Current perspectives regarding Stem cell-based therapy for Alzheimer’s disease
  6819. Sports Injuries: Diagnosis, Prevention, Stem cell therapy, and Medical Sport Strategy
  6820. … differentiation of mesenchymal Stem cells to vascular cells regulated by the HMGB1/RAGE axis: its application in cell therapy for transplant arteriosclerosis
  6821. Early relapse for multiple myeloma patients undergoing single autologous Stem cell therapy: a single-center experience
  6822. The effect of age on Stem cell function and utility for therapy
  6823. Modulation of autophagy as new approach in mesenchymal Stem cell-based therapy
  6824. Local mesenchymal Stem cell therapy in experimentally induced colitis in the rat
  6825. Advantages of graphene biosensors for human Stem cell therapy potency assays
  6826. Intrathecal autologous bone marrow-derived hematopoietic Stem cell therapy in neurological diseases
  6827. The use of Stem cell therapy to reverse opioid tolerance
  6828. Stem cell properties of peripheral blood endothelial progenitors are stimulated by soluble CD146 via miR-21: potential use in autologous cell therapy
  6829. Safety and efficacy of hematopoietic and mesanchymal Stem cell therapy for treatment of T1DM: a syStematic review and meta-analysis protocol
  6830. An acute immune response underlies the benefit of cardiac adult Stem cell therapy
  6831. Stem cell culture in microgravity and its application in cell-based therapy
  6832. Molecular and cellular mechanisms involved in mesenchymal Stem cell-based therapy of inflammatory bowel diseases
  6833. Stem cell therapy in severe pediatric motility disorders
  6834. Current perspectives regarding Stem cell-based therapy for ischemic stroke
  6835. Donor-derived second generation of CD19 CAR-T cell therapy for relapsed B-cell acute lymphoblastic leukemia after allogenic Stem cell transplantation
  6836. Biomaterials for Stem cell therapy for cardiac disease
  6837. A new approach for loading anticancer drugs into mesenchymal Stem cell-derived exosome mimetics for cancer therapy
  6838. Psychological Issues for Patients Undergoing Stem cell therapy and Regenerative Medicine
  6839. Music therapy supported the health‐related quality of life for children undergoing haematopoietic Stem cell transplants
  6840. Intranasal Stem cell treatment as a novel therapy for subarachnoid hemorrhage
  6841. Brain‐targeted Stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms
  6842. Sorafenib as maintenance therapy post allogeneic Stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo …
  6843. Critical role of tumor necrosis factor signaling in mesenchymal Stem cell-based therapy for autoimmune and inflammatory diseases
  6844. Modulation of post-stroke plasticity and regeneration by Stem cell therapy and exogenic factors
  6845. Stem cell-based RPE therapy for retinal diseases: engineering 3D tissues amenable for regenerative medicine
  6846. Stem cell therapy for stroke: lessons learned from recent successful randomized trials of interventional therapy for stroke
  6847. HDACis (class I), cancer Stem cell, and phytochemicals: Cancer therapy and prevention implications
  6848. Long-term survival of older patients with MDS treated with HMA therapy without subsequent Stem cell transplantation
  6849. Stemcell therapy restores heart function after MI in macaques
  6850. Twenty years of limbal epithelial therapy: an update on managing limbal Stem cell deficiency
  6851. Cerebrospinal fluid-Stem cell interactions may pave the path for cell-based therapy in neurological diseases
  6852. Surface functionalization of polymeric nanoparticles with umbilical cord-derived mesenchymal Stem cell membrane for tumor-targeted therapy
  6853. Intravenous C16 and angiopoietin-1 improve the efficacy of placenta-derived mesenchymal Stem cell therapy for EAE
  6854. cell therapy for ischemic stroke. Stem cell types and results of pre-clinical trials
  6855. Mesenchymal Stem cell expressing TRAIL as targeted therapy against sensitised tumour
  6856. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic Stem cell
  6857. Upfront autologous Stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the …
  6858. Hydrogel-Based Strategies for Stem cell therapy
  6859. … approaches in regenerative medicine for the treatment of diabetes: introducing CRISPR/CAS9 technology and the case for non-embryonic Stem cell therapy
  6860. Stem cell therapy for cirrhosis of liver in Bangladesh: Specific design compatible for developing country
  6861. Pharmacological approaches promoting Stem cell-based therapy following ischemic stroke insults
  6862. Understanding the therapeutic potential of bone marrow Stem cell therapy in ischemic stroke
  6863. Stem cell‐and gene‐based therapies as potential candidates in Alzheimer’s therapy
  6864. FDA approval summary: lenalidomide as maintenance therapy after autologous Stem cell transplant in newly diagnosed multiple myeloma
  6865. Improvement of common variable immunodeficiency using embryonic Stem cell therapy in a patient with lyme disease: A clinical case report
  6866. Human mesenchymal Stem cell-derived extracellular vesicles/estrogen combined therapy safely ameliorates experimentally induced intrauterine adhesions in …
  6867. Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by Stem cell gene therapy
  6868. Unique Aspects of the Design of Phase I/II Clinical Trials of Stem cell therapy
  6869. NAMPT is a potent oncogene in colon cancer progression that modulates cancer Stem cell properties and resistance to therapy through Sirt1 and PARP
  6870. Stem cells treatment to combat Cancer and genetic disease: from Stem cell therapy to gene-editing correction
  6871. siRNA delivery with Stem cell membrane-coated magnetic nanoparticles for imaging-guided photothermal therapy and gene therapy
  6872. Stemcell cardiospheres for myocardial regeneration: advancing cell therapy in myocardial infarction and heart failure
  6873. Impact of the initial fitness level on the effects of a structured exercise therapy during pediatric Stem cell transplantation
  6874. A Light‐Triggered Mesenchymal Stem cell Delivery SyStem for Photoacoustic Imaging and Chemo‐Photothermal therapy of Triple Negative Breast Cancer
  6875. Objective demonstration of improvement of neurogenic bowel dysfunction in a case of spinal cord injury following Stem cell therapy
  6876. Apparent diffusion coefficient is a useful biomarker for monitoring adipose-derived mesenchymal Stem cell therapy of renal ischemic-reperfusion injury
  6877. The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent Stem cell-derived therapy of myocardial infarction
  6878. Personalizing therapy for atrial fibrillation: the role of Stem cell and in silico disease models
  6879. Impact of induction therapy on the outcome of immunoglobulin light chain amyloidosis after autologous hematopoietic Stem cell transplantation
  6880. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic Stem cell transplantation …
  6881. A comprehensive meta‐analysis of Stem cell therapy for chronic angina
  6882. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic Stem cell transplantation in myelodysplastic syndromes and …
  6883. Stem cell therapy role in neurodegenerative disorders
  6884. Enhancement strategies for cardiac regenerative cell therapy: focus on adult Stem cells
  6885. Limbal stromal Stem cell therapy for acute and chronic superficial corneal pathologies: one-year outcomes
  6886. Graphene oxide cellular patches for mesenchymal Stem cell-based cancer therapy
  6887. Regulating human Stem cell research and therapy in low-and middle-income countries: Malaysian perspectives
  6888. Stem cell biology: a new hope in regenerations and replenishments therapy
  6889. Nanotechnology-assisted adipose-derived Stem cell (ADSC) therapy for erectile dysfunction of cavernous nerve injury: In vivo cell tracking, optimized injection …
  6890. … (D; Dara‐Vrd) vs. Vrd in patients (PTS) with newly diagnosed (nd) multiple myeloma (Mm) eligible for High‐Dose therapy (HDT) and autologous Stem cell
  6891. Stem cell therapy for Alzheimer’s Disease
  6892. The promise of Stem cell markers in the diagnosis and therapy of epithelial dysplasia and oral squamous cell carcinoma
  6893. … ebmt autoimmune diseases working party and the autologous Stem cell transplantation in refractory cd—low intensity therapy evaluation study investigators
  6894. Preclinical efficacy and safety evaluation of hematopoietic Stem cell gene therapy in a mouse model of MNGIE
  6895. Mesenchymal Stem cell-derived exosomes: applications in cell-free therapy
  6896. Impact of oral side effects from conditioning therapy before hematopoietic Stem cell transplantation: protocol for a multicenter study
  6897. Nicotine augments the beneficial effects of mesenchymal Stem cell-based therapy in rat model of multiple sclerosis
  6898. Serum Stem cell growth factor beta for the prediction of therapy response in hepatocellular carcinoma
  6899. External beam radiation therapy enhances mesenchymal Stem cell–mediated sodium–iodide symporter gene delivery
  6900. Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous Stem cell transplantation
  6901. Age of donor of human mesenchymal Stem cells affects structural and functional recovery after cell therapy following ischaemic stroke
  6902. Successful nivolumab therapy in an allogeneic Stem cell transplant child with post‐transplant lymphoproliferative disorder
  6903. One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy
  6904. A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic Stem cell transplantation in patients with FLT3-ITD+ AML.
  6905. Sirtuin3 protects aged human mesenchymal Stem cells against oxidative stress and enhances efficacy of cell therapy for ischaemic heart diseases
  6906. Regenerative medicine/cardiac cell therapy: Pluripotent Stem cells
  6907. Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic Stem cell
  6908. Trends in Stem cell therapy
  6909. Stem cell therapy for Parkinson’s disease: a review
  6910. PET/CT for lymphoma post-therapy response assessment in other lymphomas, response assessment for autologous Stem cell transplant, and lymphoma follow-up
  6911. Stem cell therapy: recent success and continuing progress in treating diabetes
  6912. Hematopoietic Stem cell gene therapy for IFNγR1 deficiency protects mice from mycobacterial infections
  6913. Concomitant use of mesenchymal Stem cells and neural Stem cells for treatment of spinal cord injury: A combo cell therapy approach
  6914. Creation of dystrophin expressing chimeric cells of myoblast origin as a novel Stem cell based therapy for Duchenne muscular dystrophy
  6915. A Study to evaluate the effectiveness of structured teaching program regarding collection of cord blood for Stem cell therapy in terms of knowledge among staff nurses …
  6916. The effect of combined pulsed wave low‐level laser therapy and mesenchymal Stem cell‐conditioned medium on the healing of an infected wound with methicillin …
  6917. Handling, processing and disposal of Stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for …
  6918. Stem cell therapy for ischemic stroke: from bench to bedside
  6919. cell therapy of a knee osteoarthritis rat model using precartilaginous Stem cells
  6920. Optimal delivery strategy for Stem cell therapy in patients with ischemic heart disease
  6921. Stem cell therapy in anal fistula: a mini review
  6922. Immunogenicity and safety of yellow fever vaccine in allogeneic hematopoietic Stem cell transplant recipients after withdrawal of immunosuppressive therapy
  6923. Delivering hematopoietic Stem cell gene therapy treatments for neurological lysosomal diseases
  6924. Diabetic patients on Rutherford’s stage 5 is the best indication of Stem cell therapy in peripheral artery disease: A retrospective study on 367 patients
  6925. Problems in Stem cell therapy for cardiac repair and tissue engineering approaches based on graphene and its derivatives
  6926. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous Stem cell transplantation for non-Hodgkin lymphoma: no differences in …
  6927. … and prospective factor analysis of high-dose therapy combined with autologous peripheral blood Stem cell transplantation in patients with peripheral T-cell
  6928. Tonsil-derived mesenchymal Stem cell-embedded in situ crosslinkable gelatin hydrogel therapy recovers postmenopausal osteoporosis through bone …
  6929. Stem cell therapy for liver cirrhosis unREALISTIC?
  6930. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic Stem cell support in fit patients with mantle cell lymphoma: 20 years …
  6931. High‐dose therapy and autologous Stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL …
  6932. Autologous Stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure who reach complete response after rescue …
  6933. Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous Stem cell transplantation
  6934. General Approaches to the Stem cell therapy in Diabetes Mellitus as Innovative Researches
  6935. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the Stem cell graft in newly diagnosed patients …
  6936. Stem cell therapy in Veterinary Medicine
  6937. The efficacy of salvage autologous Stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant
  6938. … phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous Stem cell
  6939. Bcl-2 overexpression improves survival and efficacy of neural Stem cell-mediated enzyme prodrug therapy
  6940. Knowledge and attitude toward Stem cell therapy in health and disease.
  6941. A Review on Stem cell therapy in Cerebral Palsy with a Focus on Motor Function Improvement
  6942. Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous Stem cell transplantation: the Memorial Sloan …
  6943. The Regulation of Mesenchymal Stem cell therapy through magnetic resonance imaging agents-based cellular condition and oxygen environment
  6944. Mesenchymal Stem cell-based therapy improves lower limb movement after spinal cord ischemia in rats
  6945. Predictors of mononuclear cell yield in patients undergoing autologous mononuclear Stem cell therapy in non-haemopoietic degenerative disorders
  6946. The role of FLT3 inhibitors as maintenance therapy following hematopoietic Stem cell transplant
  6947. Flame-Spheroidized Phosphate-based glass particles with improved characteristics for applications in mesenchymal Stem cell culture therapy and tissue engineering
  6948. Updated results of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous Stem cell transplant (AuSCT) in patients (Pts) with …
  6949. Combination therapy of autologous adipose mesenchymal Stem cell‐enriched, high‐density lipoaspirate and topical timolol for healing chronic wounds
  6950. Novel challenges of Stem cell therapy in neurodegenerative disorders
  6951. Effect of Stem cell therapy on Patients’ Quality of Life in Heart Failure with Reduced Ejection Fraction
  6952. A perspective on Stem cell therapy for ear disorders
  6953. Influence of Stem cell therapy on thyroid function and reactive oxygen species production in diabetic rats
  6954. The current status and future of cardiac Stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy
  6955. Human urine-derived Stem cells: potential for cell-based therapy of cartilage defects
  6956. Editing the genome ex vivo Stem cell therapy
  6957. Low‐dose azacitidine maintenance therapy after allogeneic Stem cell transplantation for high‐risk pediatric acute myeloid leukemia
  6958. Regenerative Medicine and Stem cell therapy for the Eye
  6959. Regulatable lentiviral hematopoietic Stem cell gene therapy in a mouse model of Parkinson’s disease
  6960. Maintenance therapy with the oral proteasome inhibitor (PI) ixazomib significantly prolongs progression-free survival (PFS) following autologous Stem cell
  6961. Methodological exploration of bone marrow Stem cell therapy in acute myocardial infarction-how to achieve greater benefit on cardiac outcomes: A syStematic review …
  6962. Umbilical cord mesenchymal Stem cell and neural Stem cell therapy for cerebral palsy: study protocol for a randomized, parallel-controlled trial
  6963. Gynura divaricata attenuates tumor growth and tumor relapse after cisplatin therapy in HCC xenograft model through suppression of cancer Stem cell growth and Wnt …
  6964. Stem cells and beta cell replacement therapy: a prospective health technology assessment study
  6965. Preliminary Report on the Effect of Mesenchymal Stem cell therapy in Patients with Chronic Lung Allograft Dysfunction
  6966. … disease after allogeneic Stem cell transplantation have altered metabolic profiles due to the disease and immunosuppressive therapy: potential implication for …
  6967. Abstract QS11: Stem cell therapy enriched fat graft reconstruction of craniofacial deficits
  6968. Allogeneic hematopoietic Stem cell transplantation in therapy-related myeloid neoplasms (t-MN) of the adult: monocentric observational study and review of …
  6969. Time-dependent recovery of human synovial membrane mesenchymal Stem cell function after high-dose steroid therapy: case report and laboratory study
  6970. Acute myeloid leukaemia relapsing after allogeneic haemopoietic Stem cell transplantation: prognostic factors and impact of initial therapy of relapse
  6971. Administration of Cripto in GRP 78 overexpressed human MSC s enhances Stem cell viability and angiogenesis during human MSC transplantation therapy
  6972. Stem cell therapy for male infertility: A review
  6973. Analysis of fractional order mathematical model of hematopoietic Stem cell gene-based therapy
  6974. Ecto-mesenchymal Stem cells: a new player for immune regulation and cell therapy
  6975. Feasibility of busulfan melphalan and Stem cell rescue after 131I-MIBG and topotecan therapy for refractory or relapsed metastatic neuroblastoma: the French …
  6976. Stem cell-based gene therapy in neurological disorders
  6977. Safety analysis of intra-patient dose-study of crenolanib maintenance therapy in patients with FLT3 mutant AML following allogeneic hematopoietic Stem cell
  6978. … post-transplant endothelial injury in a genetically predisposed infant with metachromatic leukodystrophy undergoing hematopoietic Stem cell gene therapy
  6979. Intervertebral Disc Degeneration and Low Back Pain: Molecular Mechanisms and Stem cell therapy
  6980. Mesenchymal Stem cell therapy for osteoarthritis: how apoptotic cells modulate inflammation
  6981. Current advances in combining Stem cell and gene therapy for neurodegenerative diseases
  6982. P691 Cx601, a novel Stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
  6983. Prospective randomization of post-remission therapy comparing autologous peripheral blood Stem cell transplantation versus high-dose cytarabine consolidation for …
  6984. CD19-CAR therapy using naive/memory or central memory T cells integrated into the autologous Stem cell transplant regimen for patients with B-NHL
  6985. Stem cell therapy for erectile dysfunction: Preliminary results from a single-center pilot study in Greece
  6986. Regenerative medicine in the retina: from Stem cells to cell replacement therapy
  6987. Stemcell therapy for non-nAMD: We’re Getting Closer
  6988. Noncoding RNAs and Stem cell function and therapy
  6989. Stemcell therapy in Fistulizing Perianal Crohn’s Disease
  6990. Estrogen Iontophoresis Versus Stem cell therapy in the Treatment of Chronic Wound in the Lower Limb
  6991. Combining electrical stimulation with Stem cell therapy improves endogenous mechanisms of stroke recovery
  6992. A single autologous Stem cell transplant (ASCT) followed by two years of post-transplant therapy in recently diagnosed elderly multiple myeloma (MM) …
  6993. Stem cell transplantation unit: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)
  6994. … receptor T cells therapy strategy that dual targeting CD19 and CD123 to treat relapsed acute lymphoblastic leukemia after allogeneic hematopoietic Stem cell
  6995. … of alternative antiviral therapy and poor outcomes of acyclovir‐resistant herpes simplex virus infections in recipients of allogeneic Stem cell transplant–a retrospective …
  6996. Biocrossing Heterotopia: Revisiting Contemporary Stem cell Research and therapy in India
  6997. … of high-dose iodine-131-metaiodobenzylguanidine therapy for high-risk neuroblastoma preceding myeloablative chemotherapy and hematopoietic Stem cell
  6998. Negative pressure wound therapy promotes muscle‐derived Stem cell osteogenic differentiation through MAPK pathway
  6999. No evidence of disease activity after five years of autologous hematopoietic Stem cell therapy for multiple sclerosis: detailed report of five patients
  7000. Neurodegeneration with brain iron accumulation for Stemcell therapy: Anesthetic management
  7001. Combined treatment with extracorporeal shock‑wave therapy and bone marrow mesenchymal Stem cell transplantation improves bone repair in a rabbit …
  7002. Early consolidation with high-dose therapy and autologous Stem cell transplantation is a feasible and effective treatment option in HIV-associated non …
  7003. … , dexamethasone (KCRD) vs an immunomodulatory agent containing triplet (CTD/CRD) induction therapy prior to autologous Stem cell transplant: results of …
  7004. Stem cell therapy: Promises versus Challenges
  7005. Stem cell therapy for the damaged heart
  7006. … -controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with Stem cell support in patients …
  7007. Stem cell therapy IN DIABETES
  7008. MP81-20 NON-INVASIVE, DUAL-LABELING TECHNOLOGY FOR cell TRACKING IN Stem cell therapy FOR ERECTILE DYSFUNCTION
  7009. A Review on Stem cell therapy a Beginning of New Revolution.
  7010. Mesenchymal Stem/Stromal cell-Based therapy for Heart Failure―What Is the Best Source?―
  7011. Interim Clinical Assessment of a Neural Stem cell Based therapy for Parkinson’s Disease (S26. 002)
  7012. Stem cell therapy in liver disease
  7013. Stem cell therapy for Management of Chronic Pancreatitis
  7014. The effects of autologous mesenchymal Stem cell therapy on elbow osteoarthritis in dogs: A pilot study
  7015. … (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous Stem cell
  7016. Transforming the treatment landscape with Stem cell therapy
  7017. Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous Stem cell transplantation
  7018. Second autologous hematopoietic Stem cell transplant as salvage therapy for relapsed multiple myeloma: a global treatment option for eligible patients
  7019. CD19-CAR-T therapy followed by allogeneic hematopoietic Stem cell transplantation in refractory/relapsed and High risk B-cell acute lymphoblastic leukemia
  7020. Early changes in tumor perfusion from T1-weighted dynamic contrast-enhanced MRI following neural Stem cell-mediated therapy of recurrent high-grade …
  7021. Neural Stem cell therapy: A case of identity
  7022. Division of Stem cell therapy
  7023. Stem cell therapy for thalassemia: present and future
  7024. Imaging in Stem cell Transplant and cell-Based therapy
  7025. Human mesenchymal Stem cell therapy of polycystic ovary syndrome (PCOS) enhances adiponectin expression in the fat and protect against brown fat whitening
  7026. Banked cord blood is a potential source of cells for deriving induced pluripotent Stem cell lines suitable for cellular therapy
  7027. Stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM-TC) in …
  7028. Adipose Derived Mesenchymal Stem cell therapy Is Comparable or Superior to Bone-Marrow Derived on Hypoxia-Induced Lung Injury in Primary Rat Alveolar …
  7029. Stem cell therapy and regenerative medicine in RPE degenerative disease: advances and challenges
  7030. Mixed cell therapy of bone marrow-derived mesenchymal Stem cells and articular cartilage chondrocytes ameliorates osteoarthritis development
  7031. Stem cell therapy in Reproductive Medicine
  7032. Hematopoietic Stem cell gene therapy for the cure of blood diseases: primary immunodeficiencies
  7033. The current application of Stem cell based therapy in pulmonary hypertension
  7034. Advances in Stem cell therapy for amyotrophic lateral sclerosis
  7035. … Medicine: Stem cell and Gene therapy Organized Jointly by the European Society of Gene & cell therapy (ESGCT), International Society for Stem cell
  7036. T1 Mapping in Stem cell therapy
  7037. Stem cell therapy and Regenerative Medicine in the Cornea
  7038. What can we do to optimize Stem and progenitor cell therapy for heart failure?
  7039. Intrathecal Autologous Stem cell therapy in Neurological Diseases
  7040. Stem cell therapy: in treatment of neurodegenerative diseases
  7041. The role of BMP-2, low-level laser therapy and low x-ray doses in dental follicle Stem cell migration
  7042. Consider using biological agents or Stem cell therapy when managing perianal Crohn’s disease
  7043. Stem cell therapy in Neonates—the Time Has (Almost) Come
  7044. High transplant-related mortality associated with haematopoietic Stem cell transplantation for paediatric therapy-related acute myeloid leukaemia (t-AML). A study on …
  7045. Identification of novel targets for lung cancer therapy using an induced pluripotent Stem cell model
  7046. Engineering mesenchymal Stem cells to improve their exosome efficacy and yield for cell-free therapy
  7047. Stem cell therapy: hype or hope?
  7048. Data Science Research to Support Stem cell therapy for Muscular Dystrophy
  7049. Abstract A071: PSMA-specific CARTyrin T-Stem cell memory therapy eliminates solid tumor in subcutaneous prostate cancer model
  7050. P137: Stem cell therapy in Alzheimer’s Disease
  7051. Stem cell therapy and the Central nervous syStem diseases: findings, obstacles, and future
  7052. High-dose therapy and hematopoietic Stem cell transplantation in Waldenström macroglobulinemia
  7053. REVIEW ON Stem cell therapy AS A INITIATIVE TOWARDS DIABETES MELLITUS
  7054. Mesenchymal Stem cell therapy for the Treatment of Osteoarthritis
  7055. Stem cell therapy for traumatic spinal cord injury
  7056. Stem cell therapy enhancement with gold nanoparticles functionalized with nerve growth factor in an animal model of laser damaged retina
  7057. Magnesium-based supports for Stem cell therapy of vascular disease
  7058. … DYSFUNCTION REVEALS PATHWAYS ASSOCIATED WITH THERAPEUTIC EFFECTIVENESS OF Stem cell therapy FOR ISCHEMIC CARDIOMYOPATHIES
  7059. Stem cell therapy for Cirrhosis of Liver in Bangladesh: Specific Design Compatible for Developing Country
  7060. The role of ixazomib as an augmented conditioning therapy in salvage autologous Stem cell transplant (ASCT) and as a post-ASCT consolidation and …
  7061. Aging and Stem cell therapy: ampk as an applicable pharmacological target for rejuvenation of aged Stem cells and achieving higher efficacy in Stem cell therapy
  7062. A Stem cell therapy of amyotrophic lateral sclerosis: From bench to bedside
  7063. … prevention of chemotherapy-induced nausea and vomiting in patients undergoing cyclophosphamide-based conditioning regimens prior to hematopoietic Stem cell
  7064. Mesenchymal Stem cell therapy for diabetic foot ulcer
  7065. Adoptive therapy with EBV-Specific T cells for Treatment of CNS EBV Post-Transplant Lymphoproliferative Disease Arising after Hematopoietic Stem cell
  7066. … D–red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti‐D and panreactive autoantibodies arising after hematopoietic Stem cell
  7067. Induced pluripotent Stem cells: cell therapy and disease modeling
  7068. Autologous Adipose Tissue-Derived Mesenchymal Stem cell therapy Improves Skin Photo-Ageing
  7069. THE ROLE OF cell DEATH IN MESENCHYMAL Stem cell therapy FOR OSTEOARTHRITIS
  7070. Treatment with bortezomib-based therapy, followed by autologous Stem cell transplantation, improves outcomes in light chain amyloidosis: a retrospective study
  7071. Meta-analysis to evaluate high-dose therapy followed by Stem cell transplant in patients with multiple myeloma
  7072. Low-Dose Laser Activated Stem cell therapy
  7073. Stem cell therapy in Anterior Cruciate Ligament (ACL) Injury
  7074. Magnesium-based supports for Stem cell therapy of vascular disease
  7075. Thymocyte self-renewal and oncogenic risk in immunodeficient mouse models: relevance for human gene therapy clinical trials targeting haematopoietic Stem cell
  7076. Progress and opportunities of gene and Stem cell therapy on hereditary ocular fundus diseases
  7077. cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of the Francophone Society for Stem cell Transplantation and cell therapy
  7078. Targeted Delivery of Insulin-Like Growth Factor-1 Improves Stem cell therapy in A Rat Myocardial Infarction Model
  7079. A phase 1 clinical trial of personalized adoptive cellular therapy targeting myelodysplastic syndrome (MDS) Stem cell neoantigens (PACTN)
  7080. Mesenchymal Stem cell therapy in Proteoglycan Induced Arthritis
  7081. Utility of cell therapy to control relapsed acute myeloid leukemia following allogeneic Stem cell transplantation: Does cell source matter
  7082. Hysteroscopy and Stem cell therapy to Approach Refractory Asherman’s Syndrome
  7083. Re-educating immunity in respiratory allergies: the potential for hematopoietic Stem cell-mediated gene therapy
  7084. Stem cell therapy For Stroke. Modulation of structural and functional adjustments after Stem cell implantation in a mouse model of cortical stroke
  7085. Stem cell therapy for the treatment of severe tissue damage after radiation exposure
  7086. Meta-analysis to Evaluate High-Dose therapy Followed by Stem cell Transplant in Patients With Multiple Myeloma—Reply
  7087. … from the CALGB study of lenalidomide maintenance therapy in newly diagnosed multiple myeloma post-autologous Stem cell transplantation adjusted for …
  7088. cell-free therapy with the secretome of adipose tissue-derived Stem cells in rats’ frozen-thawed ovarian grafts
  7089. Arrhythmogenic consequences of Stem cell therapy for cardiac regeneration
  7090. … Follow Up of Chronic Spinal Cord Injury Patients Receiving Autologous Bone Marrow-Derived Mesenchymal Stem cell therapy Combined with Physical therapy
  7091. Hyperbaric Oxygen therapy (HBOT) of an Adolescent Stem cell Transplantation (SCT) Recipient with Hemorrhagic Cystitis, and BK Virus: A Rare Case Study in the …
  7092. Stem cell therapy, COST AND TOP 10 HOSPITALS IN INDIA-A RAY OF HOPE FOR COMMONS AND MIDDLE CLASS PEOPLE
  7093. Role of Notch signaling pathway in bone marrow mesenchymal Stem cell therapy for phosgene inhalationinduced lung injury in rats
  7094. Stem cell-mediated Biobridge: Crossing the Great Divide Between Bench and Clinic in Translating cell therapy for Stroke
  7095. Stem cell therapy for treatment of ischemic optic neuropathy
  7096. How optimizing efficiency for autologous Stem cell collection can set the stage for novel cell therapy growth in multiple departments
  7097. Effectiveness assessment of kidney Stem cell therapy, derived from cat metanephro, in the treatment of chronic kidney disease in felines.
  7098. Double-Blind, Placebo-Controlled, Randomized Trial of Stem cell therapy Combined With Bypass Surgery-The MiHeart Trial
  7099. Could mesenchymal Stem cell therapy help in the treatment of muscle damage caused by Bothrops alternatus venom?
  7100. The Impact of Mesenchymal Stem cell therapy on Cognitive Performance in People Living with Multiple Sclerosis
  7101. James B Richardson: persuaded NICE to recommend Stem cell therapy for cartilage repair
  7102. Secretome from bone marrow mesenchymal Stem cells: A promising, cell-free therapy for allergic rhinitis
  7103. … quality of life with 5mg versus 25mg lenalidomide maintenance after first-line high-dose therapy and autologous blood Stem cell transplantation for multiple …
  7104. Human Mesenchymal Stem cell therapy Reverses SU5416/Hypoxia-Induced Pulmonary Arterial Hypertension in Mice
  7105. A syStematic review of conventional therapy and role of Stem cell transplantation for primary plasma cell leukemia
  7106. cell therapy Using Genetically Modified Mesenchymal Stem cell in a Murine Model of Sepsis
  7107. Whole-body vibration training as a supportive therapy during allogeneic haematopoietic Stem cell transplantation—a randomised controlled trial
  7108. Stem-02. DEVELOPING BRAIN METASTATIC TUMOR MODELS FOR TARGETED Stem cell therapy
  7109. KCNN4 Ion Channel Gene-Transfer Enhances the Effectiveness of Stemcell therapy for Cardiac Injury
  7110. … of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous Stem cell therapy for orthopaedic conditions
  7111. Noncoding RNA Regulatory Networks, Epigenetics, and Programming Stem cell Renewal and Differentiation: Implications for Stem cell therapy
  7112. cost-effectiveness analysis of lenalidomide for maintenance therapy after autologous Stem cell transplant (ASCT) in newly diagnosed multiple myeloma …
  7113. Mechanisms of Mesenchymal Stem cell therapy for Enteric Neuropathy Associated with Colitis
  7114. Human Placental Stem cell therapy in Stroke: Endothelial/Smooth Muscle Mechanisms Underlying Protection
  7115. TMOD-31. NOVEL HETEROGENEOUS GLIOBLASTOMA MODELS TO OPTIMIZE HUMAN TUMORICIDAL NEURAL Stem cell therapy
  7116. The mesenchymal Stem cell therapy for canadians with multiple sclerosis (MESCAMS) clinical trial: cell manufacturing of autologous bone marrow-derived mscs in …
  7117. … the quality of Stem cell-derived hepatocytes for cell therapy: Role of pluripotency state in determining lineage commitment of human induced pluripotent Stem cells
  7118. An Evaluation of Procedural Sedation Techniques in Duchenne Muscular Dystrophy Patients Undergoing Stem cell therapy
  7119. Expression profile of Stem cell pathway genes in patients with advanced breast cancer after neoadjuvant therapy
  7120. 2P-211: Hierarchically multipatterned topographical cues for Stem cell therapy approaches
  7121. Stem/cell/syStematics/and/potentials/for/modeling/and/therapy
  7122. Stem cell therapy Suppresses Infiltration of Platelets into Healing Corneal Wounds
  7123. therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic Stem cell transplantation, from a persistent R882H-DNMT3A mutated …
  7124. … based Chinese herbal medicine extraction inhibits cancer Stem cell growth and sensitizes of drug-resistant human non-small cell lung cancer cells for targeted therapy
  7125. Functional Activation of Autologous Human Diabetic Stem cells for cell therapy
  7126. PGD to select HLA matched embryo for Stem cell therapy in epidermolysis bullosa dystrophica
  7127. Preclinical development of a hematopoietic Stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia A
  7128. Comparison of TVT-secur mini-sling & Stem cell therapy in the treatment of stress urinary incontinence in women
  7129. Differential risk of viral infections in children undergoing complex anticancer therapy or hematopoietic Stem cell transplantation
  7130. An evolution of Stem cell research and therapy in Viet Nam
  7131. … study to assess the effectiveness of self-instructional module (Sim) on knowledge regarding cord blood banking & Stem cell therapy among antenatal women in …
  7132. Successful steroid therapy for lipoid pneumonia developing after allogeneic hematopoietic Stem cell transplant: a case report
  7133. Phase 1 safety outcomes of mesenchymal stromal Stem cell therapy in pateints with low and intermediate-1 ipss risk myelodysplastic syndrome
  7134. P165: Therapeutic Potentials of Stemcell-Based therapy for Parkinson’s Disease; Current Status of Human Endometrium-Derived Mesenchymal Stem cells
  7135. … inhibition induces metabolic reprogramming in T-cells leading to induction of Stem cell memory CD8 cells that enhance potency of adoptive cell therapy and anti-OX40 …
  7136. … /refractory patients with FLT3-ITD mutated AML are poor when treated with non-targeted therapy with a potential role for Stem cell transplantation: results from …
  7137. A rotating cerium anode X-ray syStem allows visualization of intramural coronary vessels after cardiac Stem cell therapy for myocardial infarction
  7138. Prospective evaluation of minimal residual disease in multiple myeloma following autologous Stem cell transplantation (ASCT) and consolidation therapy.
  7139. Using Functional Assessment of Cancer therapy-Bone Marrow Transplant (FACT-BMT) Tool to Explore Quality of Life in Patients Undergoing Autologous Stem cell
  7140. Consolidative whole-brain radiation therapy versus autologous Stem cell transplant for primary central nervous syStem lymphoma: a large dose of perspective and …
  7141. Using Stem cell-Derived Microvesicles in Regenerative Medicine: A New Paradigm for cell-Based-cell-Free therapy
  7142. … multiforme treated with Stem cell sparing intensity-modulated radiation therapy and nonStem cell sparing three-dimensional conformal radiation therapy: a …
  7143. A Novel therapy Protocol Improves Outcomes of Hematopoietic Stem cell Transplantation in Juvenile Myelomonocytic Leukemia Patients Using …
  7144. Stem cells derived from amniotic fluid: a potential pluripotent-like cell source for cellular therapy?
  7145. Effect of the preventative allopurinol therapy within the framework of the peripheral blood Stem cell donation
  7146. Stem cell Transplantation in Scleroderma therapy
  7147. Superiority of allogenic Stem cell transplantation after anti-pd1 therapy over anti-pd1 monotherapy alone in relapse/refractory Hodgkin lymphoma: real world evidence …
  7148. Validation of a library of cGMP-compliant human pluripotent Stem cell lines for use in liver therapy
  7149. … EFFICIENCY OF RITUXIMAB therapy IN CHILDREN WITH RENAL THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH HEMATOPOIETIC Stem cell
  7150. therapy for limbal Stem cell deficiency: cell fate after limbal Stem cell transplants
  7151. XII R. Gorbacheva Memorial Symposium Hematopoietic Stem cell Transplantation. Gene and cellular therapy: an Overview
  7152. A Universal Approach to Correct Various HBB Gene Mutations in Human Stem cells for Gene therapy of Beta-Thalassemia and Sickle cell Disease
  7153. FVIII induced expression in adipose-derived Mesenchymal Stem cells for Haemophilia A cell therapy
  7154. Hydrogels for Stem cell Encapsulation: Toward cellular therapy for Diabetes
  7155. Public Opinion About Stem cell Research And Human Cloning-The Bioethics Of Stem cell Research And therapy
  7156. … myeloma using molecular and clinical prognostic factors in 657 patients treated with bortezomib-based induction, high-dose therapy and autologous Stem cell
  7157. Abstract IA13: Imaging Stem cell signals in cancer heterogeneity and therapy resistance
  7158. Adipose-derived Stem cell-Based Immunomodulatory therapy in a Translational Porcine Limb Transplant Model
  7159. … relapsed/refractory large cell lymphoma who were also refractory to salvage chemotherapy: outcome with salvage radiation therapy followed by autologous Stem cell
  7160. Photobiomodulation therapy and vitamin C on longevity of cell sheets of human dental pulp Stem cells
  7161. Multiple Myeloma: Front Line therapy and Autologous Stem cell Transplantation
  7162. Lenalidomide maintenance therapy after autologous peripheral blood Stem cell transplant (PBSCT) in multiple myeloma patients: Factors that impact treatment
  7163. Mesenchymal Stem cell-based therapy for infectious disease.
  7164. Dual Effects of Mesenchymal Stem/Stromal cell in Tumor Animal Models: A SyStematic Review For Risk Management therapy of Stem cell in Cancer Patients
  7165. The New Age of Stem cell Gene therapy for Regenerative Medicine
  7166. The Efficacy of Mesenchymal Stem cell Injection Versus Physical therapy Intervention on Womac Scores in Patients with Knee Osteoarthritis: A Meta-Analysis
  7167. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose therapy and Autologous Hematopoietic Stem cell Transplantation
  7168. Molecular basis of adipose-derived Stem cell (ASCs) therapy for management of radiation-induced fibrosis (RIF)
  7169. Advances in biomarkers and Stem cell-targeted therapy for hepatocellular carcinoma
  7170. A Global View on Regulatory Issues in Stem cell Transplantation and cellular therapy
  7171. P100 Stem cell Factor Leads to Lung Cancer Escapes from Anti-Angiogenic therapy by Increasing the ALDH1+ Lung Cancer cell Number
  7172. Use of iPS cell-Derived Neural Stem cell as a cellular Vehicle for Glioma and Breast Cancer therapy
  7173. Stem cell-derived exosomes as a biomaterial source for immune modulating therapy
  7174. … and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic Stem cell
  7175. Development of core technology for promotion of radiation therapy efficacy by targeting cancer Stem cell
  7176. therapy-related Myelodysplastic Syndrome after Autologous Stem cell Transplantation Using Plerixafor for Mobilized Stem cells in a Patient with Multiple Myeloma
  7177. Development of a Stem cell-based therapy for the recovery of skeletal muscle mass following immobilization
  7178. A new insight on the Stem cell growth factor beta as astrong predictor of therapy response in hepatocellular carcinoma
  7179. A preliminary study to assess the impact of Stem cell sparing radiation therapy on the outcomes of the treatment of glioblastoma multiformae
  7180. Salvage Autologous Stem cell Transplantation in Multiple Myeloma: Investigating the Impact of Pre-Transplant therapy
  7181. Development of New Neural Stem cell-Based Tumor-Targeted Gene therapy Approaches
  7182. Genes preserving Stem cell state in group 3 medulloblastoma brain tumor initiating cells contribute to therapy evasion and relapse
  7183. [Retracted] Combined treatment with extracorporeal shock‑wave therapy and bone marrow mesenchymal Stem cell transplantation improves bone repair in a rabbit …
  7184. The Effect of Maintenance therapy Following Salvage Autologous Stem cell Transplant in Multiple Myeloma Patients
  7185. Trends in utilization and in-hospital outcomes of high dose therapy and autologous Stem cell transplantation among patients with AL amyloidosis in the United States.
  7186. Evaluation of Antiemetic therapy for Breakthrough Nausea and Vomiting in Patients with Hematopoietic Stem cell Transplantation
  7187. Efficacy of Maintenance therapy after Autologous Hematopoietic Stem cell Transplantation in High-Risk Aggressive Lymphoma: A Single-Center Prospective …
  7188. Autologous Stem cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous therapy and Histological Subtype
  7189. OPTIMIZATION OF A COMBINED ADIPOSE Stem cell-GDF6 therapy FOR INTERVERTEBRAL DISC REGENERATION
  7190. therapy of relapse and progression of classical Hodgkin lymphoma after allogeneic hematopoetic Stem cell transplantation
  7191. Second allogeneic hematopoietic Stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)
  7192. … Induction therapy+ Autologous Stem cell Trasplantation, Comparing Velcade-Dexametasone to Alkylating Polichemotherapy As Induction therapy
  7193. Immune modulation by a cellular network of mesenchymal Stem cells and breast cancer cell subsets: Implication for cancer therapy
  7194. The outcome of patients with non-chemosensitive relapsed and refractory DLBCL salvaged with radiation therapy followed by autologous Stem cell transplant.
  7195. Role of Hypomethylating therapy in Patients with Myelodysplastic Syndrome Before Allogeneic Hematopoietic Stem cell Transplantation
  7196. Abstract CT137: Biomarkers of response to leukemia Stem cell targeted therapy with low dose daunorubicin in relapsed/refractory acute leukemia
  7197. First-Line therapy with Donor Derived HCMV-Specific T cells Reduce Persistent HCMV Infection after Allogenic Stem cell Transplantation
  7198. Abstract B014: Simulating prostate cancer Stem cell dynamics to predict patient-specific sensitivity or resistance to intermittent androgen-deprivation therapy
  7199. Anti-PD1 (muDX 400) therapy given after radiation has greatest impact on (CD8+ Tim3-CD73+) Stem cell like cells: Implications for improved clinical trial design …
  7200. The Development of Angiogenesis cell therapy Using Syngeneic Adipose-Derived Stem cells for Lower Limb Ischemia in Mice
  7201. A cellular therapy with Haploidentical Peripheral Hematopoietic Stem cell Transplantation MAY be a Therapeutic Option in Patients with Relapsed …
  7202. Establishment of insulin-producing cells from human embryonic Stem cells underhypoxic condition for cell based therapy
  7203. therapy-Related Myeloid Neoplasms Following Autologous Stem cell Transplantation: The Prevalence of Chip Mutations at Time of Transplantation—a …
  7204. Stem cell-derived extracellular vesicles as a cell-free therapy for tissue repair/regeneration: a syStematic review and meta-analysis of preclinical studies
  7205. Stem cell-Specific Internalizing Immunotoxin as a therapy for Myelodysplastic Syndromes
  7206. Successful treatment with brentuximab vedotin maintenance therapy after autologous Stem cell transplantation in high-risk Hodgkin lymphoma
  7207. 1601. Effect of Preemptive Rituximab therapy on Epstein–Barr Reactivation in Allogenic Hematopoietic Stem cell Pediatric Transplants
  7208. Mesenchymal Stem cells: applications in immuno-cell therapy
  7209. Plastic Adaptation: A Neuronal Imperative Capable of Confounding the Goals of Stem cell Replacement therapy for either Huntington’s or Parkinson’s Disease
  7210. Enabling efficient ex vivo expansion of long-term human hematopoietic Stem and progenitor cells for cell therapy
  7211. Comparison of two automated cell counters for enumeration and viability of mesenchymal Stem cells for clinical cellular therapy trials
  7212. Varied therapeutic effects of Human Amniotic Mesenchymal Stem cell Transplantation with Different Transplantation Methods for Spinal Cord Injury therapy in Rats
  7213. Impact of Combined Adipose-Derived Mesenchymal Stem cell (ADMSC) and Low-Energy of Extracorporeal Shock Wave therapy on Protecting Brain Death-Induced …
  7214. … 2 Trial Using the Begev Regimen (Bendamustine, Gemcitabine And Vinorelbine) As Salvage therapy Prior to Autologous Stem cell Transplant for Relapsed …
  7215. Lenti-D Hematopoietic Stem cell Gene therapy to Arrest Progression of Cerebral Adrenoleukodystrophy: Interim Results of an International Phase 2/3 Trial
  7216. Treatment efficacy of ponatinib as salvage therapy in relapse chronic myeloid leukemia with T315I mutation after allogeneic Stem cell transplantation: report of 12 …
  7217. Epigenetic therapy Targets Th1/Th17 Polarization to Reversing Immune Evasion and Treating Leukemia Relapse Post Allogeneic Stem cell Transplantation in Non …
  7218. 54 Genes preserving Stem cell state in Group 3 MB BTICs contribute to therapy evasion and relapse
  7219. Hematopoietic Stem cell transplantation with alpha/beta T lymphocyte and CD19 cell depletion in adolescents and young adults with paroxysmal nocturnal …
  7220. … -Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction therapy Prior to Autologous Stem cell Transplantation in Japanese …
  7221. therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed By Autologous Stem cell Transplantation for AL …
  7222. Abstract A28: Donor lymphocyte infusion after allogeneic Stem cell transplantation is a feasible therapy option with acceptable toxicity rates in patients with refractory …
  7223. … -CD (25) monoclonal antibody as a salvage therapy for steroid-refractory acute graft-versus-host disease in 80 patients receiving allogeneic hematopoietic Stem cell
  7224. Stem cell, low-energy shock wave and phosphodiesterase type 5 inhibitor therapy to promote erectile function recovery in a rat pelvic neurovascular trauma model
  7225. … Study to Evaluate Ruxolitinib Compared to Best Available therapy in Patients with Corticosteroid-Refractory Acute Graft vs Host Disease after Allogeneic Stem cell
  7226. … clinical data collection: impact on clinicians’ time and administrative costs151. Isolation and characterization of an adult Stem cell population within human epidural …
  7227. Polyinosinic-Polycytidylic Acid Primes Cardiac Progenitors From Human Induced Pluripotent Stem cells for Enhanced cell therapy and Cardiomyocyte Maturation
  7228. Photoreceptor cell Replacement therapy from Stem cells
  7229. Interferon-gamma/Hypoxia Primed Mesenchymal Stem cells for an Improved Immunosuppressive cell therapy
  7230. Generation and selection of photoreceptor precursors from human-induced pluripotent Stem cells for cell therapy
  7231. Abstract SY39-01: Stem cells in squamous cell carcinomas: Their biology, heterogeneity, and resistance to therapy
  7232. Myogenic differentiation of human induced pluripotent Stem cells: a tool for cell therapy and disease modelling of myotonic dystrophy type 1= Diferenciación …
  7233. IMMU-20. HEMATOPOIETIC Stem cells POTENTIATE EFFICACY OF ADOPTIVE cell therapy AGAINST BRAIN Stem GLIOMA
  7234. Functional Polymeric Hydrogels in Stem/Progenitor cell therapy and Therapeutic Angiogenesis
  7235. Preclinical efficacy of dendritic cells derived from bone marrow hematopoietic Stem cells for the treatment of syngeneic prostate cancer immune cell therapy.
  7236. Metastatic cell responses to anticancer therapy: The possible role of cancer Stem cells
  7237. … and Mitotic Activity in Peripheral Lymphocytes to Predict Life Expectancy of Patients with Metastatic Non-Small cell Lung Cancer after Conventional therapy
  7238. Single-agent plerixafor mobilization to collect autologous Stem cells for use in gene therapy for severe sickle cell disease
  7239. cell population (RMBs) in treatment-resistant, advanced metastatic colorectal cancer: Evaluation of a biological-syStems approach to cancer therapy (US FDA …
  7240. … -110 (G> A) mRNA restores β-globin levels in a novel cell model and acts as mono-and combination therapy for β-thalassemia in primary hematopoietic Stem
  7241. … [IVSI-110 (G> A)] mRNA restores-globin levels in a novel cell model and acts as mono-and combination therapy for-thalassemia in primary hematopoietic Stem
  7242. Exploiting Molecular Subtype cell Plasticity As Novel Strategy for Targeting Glioma Stem cells Through Alternating therapy
  7243. Challenges and controversies in human mesenchymal Stem cell therapy
  7244. Stem cell therapy for neurological disorders
  7245. Mesenchymal Stem cell therapy for the treatment of inflammatory diseases: challenges, opportunities, and future perspectives
  7246. Concise review: Stem cell therapy for stroke patients: are we there yet?
  7247. Stem cell therapy: A novel approach for myocardial infarction
  7248. The clinical trials of mesenchymal Stem cell therapy in skin diseases: an update and concise review
  7249. Nanoparticle technology and Stem cell therapy team up against neurodegenerative disorders
  7250. Stem cell therapy for neurological disorders: a focus on aging
  7251. Stem cell therapy for erectile dysfunction
  7252. Neural Stem cell therapy for stroke: A multimechanistic approach to restoring neurological function
  7253. Stem cell therapy for heart failure: an unfulfilled promise?
  7254. Adipose-derived mesenchymal Stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial
  7255. Mesenchymal Stem cell therapy for the treatment of traumatic brain injury: progress and prospects
  7256. Myths, reality and future of mesenchymal Stem cell therapy
  7257. Stem cell therapy in Alzheimer’s disease: possible benefits and limiting drawbacks
  7258. Thrombogenic risk induced by intravascular mesenchymal Stem cell therapy: current status and future perspectives
  7259. Biomaterials used in Stem cell therapy for spinal cord injury
  7260. Intravascular mesenchymal stromal/Stem cell therapy product diversification: time for new clinical guidelines
  7261. Dual Stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction
  7262. Mitochondrial dysfunction in stroke: implications of Stem cell therapy
  7263. Efficacy of mesenchymal Stem cell therapy in systolic heart failure: a syStematic review and meta-analysis
  7264. Transamniotic Stem cell therapy (TRASCET) in a rabbit model of spina bifida
  7265. Safety and efficacy of Stem cell therapy for treatment of neural damage in patients with multiple sclerosis
  7266. Development of hematopoietic Stem cell-engineered invariant natural killer T cell therapy for cancer
  7267. Stem cell therapy in discogenic back pain
  7268. Stem cell therapy for chronic skin wounds in the era of personalized medicine: from bench to bedside
  7269. New advances in Stem cell therapy for osteonecrosis of the femoral head
  7270. Bone marrow mesenchymal Stem cell therapy and related bone marrow-derived orthobiologic therapeutics
  7271. Combined adipose tissue-derived mesenchymal Stem cell therapy and rehabilitation in experimental stroke
  7272. Mesenchymal Stem cell therapy for doxorubicin-induced cardiomyopathy: potential mechanisms, governing factors, and implications of the heart Stem cell
  7273. Advances, challenges, and perspectives in translational Stem cell therapy for amyotrophic lateral sclerosis
  7274. Mechanisms of endometrial fibrosis and the potential application of Stem cell therapy
  7275. 3D Bioprinting of cardiac tissue and cardiac Stem cell therapy
  7276. Rationale and design of the European multicentre study on Stem cell therapy in IschEmic Non‐treatable Cardiac diseasE (SCIENCE)
  7277. Ankylosing spondylitis and mesenchymal stromal/Stem cell therapy: a new therapeutic approach
  7278. Mesenchymal Stem cell therapy for spinal cord contusion: a comparative study on small and large animal models
  7279. Stem cell therapy for hepatocellular carcinoma: future perspectives
  7280. Stemcell therapy for hearing loss: are we there yet?
  7281. Advances of hyaluronic acid in Stem cell therapy and tissue engineering, including current clinical trials
  7282. Bone Marrow–Derived and Adipose‐Derived Mesenchymal Stem cell therapy in Primary Knee Osteoarthritis: A Narrative Review
  7283. Transplantation of human-induced pluripotent Stem cell-derived cardiomyocytes is superior to somatic Stem cell therapy for restoring cardiac function and …
  7284. Stem cell therapy in pain medicine
  7285. Adoptive T cell therapy strategies for viral infections in patients receiving haematopoietic Stem cell transplantation
  7286. Is Stem cell therapy an answer to heart failure: a literature search
  7287. Advancing mesenchymal Stem cell therapy with CRISPR/Cas9 for clinical trial studies
  7288. The clinical efficacy of Stem cell therapy for complex perianal fistulas: a meta-analysis
  7289. Nomenclature inconsistency and selective outcome reporting hinder understanding of Stem cell therapy for the knee
  7290. The potential of Stem cell therapy to repair white matter injury in preterm infants: lessons learned from experimental models
  7291. Mesenchymal Stem cell therapy targeting mitochondrial dysfunction in acute kidney injury
  7292. The role of electrospun fiber scaffolds in Stem cell therapy for skin tissue regeneration
  7293. Application of injectable hydrogels for cardiac Stem cell therapy and tissue engineering
  7294. Mesenchymal Stem cell therapy assisted by nanotechnology: a possible combinational treatment for brain tumor and central nerve regeneration
  7295. Human umbilical cord-derived mesenchymal Stem cell therapy ameliorates nonalcoholic fatty liver disease in obese type 2 diabetic mice
  7296. Osteochondritis dissecans (OCD) in horses–Molecular background of its pathogenesis and perspectives for progenitor Stem cell therapy
  7297. … antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic Stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia …
  7298. Office-based mesenchymal Stem cell therapy for the treatment of musculoskeletal disease: a syStematic review of recent human studies
  7299. Immunological considerations for retinal Stem cell therapy
  7300. Neurodegeneration and neuro-regeneration—Alzheimer’s disease and Stem cell therapy
  7301. Two‐step Stem cell therapy improves bone regeneration compared to concentrated bone marrow therapy
  7302. Should platelet-rich plasma or Stem cell therapy be used to treat osteoarthritis?
  7303. Recent biomedical applications on Stem cell therapy: a brief overview
  7304. Allogeneic mesenchymal Stem cell therapy: A regenerative medicine approach to geroscience
  7305. Mesenchymal Stemcell therapy for perianal fistulas in Crohn’s disease: a syStematic review and meta-analysis
  7306. Cortical bone-derived Stem cell therapy reduces apoptosis after myocardial infarction
  7307. Human induced pluripotent Stem cell-derived mesenchymal Stem cell therapy effectively reduced brain infarct volume and preserved neurological function in …
  7308. Effect of autologous bone marrow Stem cell therapy in patients with liver cirrhosis: a meta-analysis
  7309. The role of autologous Stem cell transplantation in the treatment of diffuse large B-cell lymphoma in the era of CAR-T cell therapy
  7310. Autologous Stem cell therapy for hypoplastic left heart syndrome: safety and feasibility of intraoperative intramyocardial injections
  7311. Potentials of “Stem celltherapy” in pancreatic cancer: An update
  7312. Stem cell therapy for musculoskeletal diseases
  7313. Bone marrow-derived mesenchymal Stem cell (BM-MSC): a tool of cell therapy in hydatid experimentally infected rats
  7314. Targeting hyaluronan interactions for glioblastoma Stem cell therapy
  7315. In utero amniotic fluid Stem cell therapy protects against myelomeningocele via spinal cord coverage and hepatocyte growth factor secretion
  7316. Tumoricidal Stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma
  7317. Hydrogen sulfide enhances the effectiveness of mesenchymal Stem cell therapy in rats with heart failure: In vitro preconditioning versus in vivo co-delivery
  7318. Autologous haematopoietic Stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working …
  7319. Bone mesenchymal Stem cell therapy for ovariectomized osteoporotic rats: a syStematic review and meta-analysis
  7320. Mesenchymal Stem cell and bone marrow mononuclear cell therapy for cardiomyopathy: from bench to bedside
  7321. Subconjunctival bone marrow‐derived mesenchymal Stem cell therapy as a novel treatment alternative for equine immune‐mediated keratitis: A case series
  7322. Stand alone or join forces? Stem cell therapy for stroke
  7323. Efficacy and safety of Stem cell therapy in patients with dilated cardiomyopathy: a syStematic appraisal and meta-analysis
  7324. Hyaluronan-based grafting strategies for liver Stem cell therapy and tracking methods
  7325. Stand alone or join forces? Stem cell therapy for stroke
  7326. Tissue engineering and Stem cell therapy in pediatric urology
  7327. Back to square one: The future of Stem cell therapy and regenerative medicine after the recent events
  7328. Development of functional dendrisomes based on a single molecule of polyesterbenzylether dendrimer and their application in cancer Stem cell therapy
  7329. High-dose melphalan and Stem cell transplantation in syStemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review
  7330. Adipose-derived Stem cell therapy inhibits the deterioration of cerebral infarction by altering macrophage kinetics
  7331. Stem cell therapy for Parkinson’s disease using non-human primate models
  7332. Stemcell therapy for ovariectomy-induced osteoporosis in rats: a comparison of three treatment modalities
  7333. Non-invasive cell tracking with brighter and red-transferred luciferase for potential application in Stem cell therapy
  7334. Reparative dentin formation using Stem cell therapy versus calcium hydroxide in direct pulp capping: an animal study
  7335. Stem cell therapy for autoimmune disease
  7336. Characterization of the chondrogenic and osteogenic potential of male and female human muscle‐derived Stem cells: Implication for Stem cell therapy
  7337. Adipose-derived Stem cell therapy ameliorates ionizing irradiation fibrosis via hepatocyte growth factor-mediated transforming growth factor-β downregulation and …
  7338. Stemcell therapy for esophageal anastomotic leakage by autografting stromal cells in fibrin scaffold
  7339. Intra-articular umbilical cord derived mesenchymal Stem cell therapy for chronic elbow osteoarthritis in dogs: a double-blinded, placebo-controlled clinical trial
  7340. Neural Stem cell transplantation therapy for brain ischemic stroke: Review and perspectives
  7341. Novel application method for mesenchymal Stem cell therapy utilizing its attractant-responsive accumulation property
  7342. cell therapy for spinal cord injury using induced pluripotent Stem cells
  7343. Mesenchymal Stem cell therapy inhibited inflammatory and profibrotic pathways induced by partial bladder outlet obstruction and prevented high-pressure urine …
  7344. Mesenchymal Stem cell-based therapy of osteoarthritis: current knowledge and future perspectives
  7345. Efficacy and safety of Stem cell therapy in advanced heart failure patients: a syStematic review with a meta-analysis of recent trials between 2017 and 2019
  7346. Intra-arterial Stem cell therapy modulates neuronal calcineurin and confers neuroprotection after ischemic stroke
  7347. Stem cell therapy in diabetic men with erectile dysfunction: a step closer to safe and effective regenerative technology
  7348. Mesenchymal Stem cells: cell therapy and regeneration potential
  7349. Wnt signaling: the double-edged sword diminishing the potential of Stem cell therapy in congenital heart disease
  7350. ARTIFICIAL cell evolves into nanomedicine, biotherapeutics, blood substitutes, drug delivery, enzyme/gene therapy, cancer therapy, cell/Stem cell therapy
  7351. Mesenchymal Stem cell therapy Facilitates Donor Lung Preservation by Reducing Oxidative Damage during Ischemia
  7352. Cardiac regeneration by statin-polymer nanoparticle-loaded adipose-derived Stem cell therapy in myocardial infarction
  7353. Animal‐and human‐based evidence for the protective effects of Stem cell therapy against cardiovascular disorders
  7354. Stem cell therapy-An Overview
  7355. Intravenous Stem cell therapy for high-grade aneurysmal subarachnoid hemorrhage: case report and literature review
  7356. Lercanidipine boosts the efficacy of mesenchymal Stem cell therapy in 3-NP-induced Huntington’s disease model rats via modulation of the calcium/calcineurin …
  7357. Mesenchymal Stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives
  7358. Effect of autologous adipose-derived mesenchymal Stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
  7359. Human umbilical cord mesenchymal Stemcell therapy to increase the density of osteoporotic mandibular bone
  7360. A Mini Review: Stem cell therapy for osteonecrosis of the femoral head and pharmacological aspects
  7361. Patient experience of chimeric antigen receptor (CAR)-T cell therapy vs. Stem cell transplant: longitudinal patient reported adverse events, cognition and …
  7362. Mesenchymal Stem cell therapy overcomes steroid resistance in severe gastrointestinal acute graft-versus-host disease
  7363. Collagen fibrillar structures in vocal fold scarring and repair using Stem cell therapy: a detailed histological, immunohistochemical and atomic force microscopy study
  7364. Advances in Stem cell therapy for male stress urinary incontinence
  7365. Exploring the most promising Stem cell therapy in liver failure: a syStematic review
  7366. Coexpression profile of leukemic Stem cell markers for combinatorial targeted therapy in AML
  7367. Stem cells from the apical papilla: a promising source for Stem cell-based therapy
  7368. Stem cell therapy in critical limb ischemia: Current scenario and future trends
  7369. Recent advances in the design of injectable hydrogels for Stem cell-based therapy
  7370. Stem cell therapy for diabetes mellitus: Recent progress and hurdles
  7371. Stem cell therapy to promote limb function recovery in peripheral nerve damage in a rat model”–Experimental research
  7372. Stem cell‐based therapy for Parkinson’s disease with a focus on human endometrium‐derived mesenchymal Stem cells
  7373. Mesenchymal Stem cell-derived extracellular vesicle therapy for stroke: challenges and progress
  7374. Effects of exercise training and Stem cell therapy on the left ventricle of infarcted rats
  7375. cell therapy for Parkinson’s disease with induced pluripotent Stem cells
  7376. Efficacy of Stem cell therapy for pulmonary arterial hypertension: a syStematic review and meta-analysis of preclinical studies
  7377. Cytokine interplay among the diseased retina, inflammatory cells and mesenchymal Stem cells-a clue to Stem cell-based therapy
  7378. Mesenchymal Stem cell therapy in submandibular salivary gland Allotransplantation: experimental study
  7379. Mesenchymal Stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases
  7380. Phage-based artificial niche: the recent progress and future opportunities in Stem cell therapy
  7381. Scleral ischemia in acute ocular chemical injury: long-term impact on rehabilitation with limbal Stem cell therapy
  7382. Influence of lineage-negative Stem cell therapy on articulatory functions in ALS patients
  7383. Cancer Stem cell (a) symmetry & plasticity: tumorigenesis and therapy relevance
  7384. Human keratinocyte Stem cells: From cell biology to cell therapy
  7385. The mesenchymal Stem cell secretome as an acellular regenerative therapy for liver disease
  7386. Teeth‐derived Stem cells: a source for cell therapy
  7387. Adipose tissue-derived Stem cell therapy for cavernous nerve injury-induced erectile dysfunction in the rat model: a syStematic review and meta-analysis using …
  7388. Allogeneic Stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy for the treatment of non-Hodgkin lymphoma
  7389. “Microgravity” as a unique and useful Stem cell culture environment for cell-based therapy
  7390. Intrabone hematopoietic Stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent ß-thalassemia
  7391. Regeneration of trabecular meshwork in primary open angle glaucoma by Stem cell therapy: A new treatment approach
  7392. Stem cell plasticity and dormancy in the development of cancer therapy resistance
  7393. Stem cell-based therapy for inflammatory bowel disease
  7394. Japan responds: Stemcell therapy justified
  7395. Mesenchymal Stem cell exosomes: a two-edged sword in cancer therapy
  7396. Recent updates on mesenchymal Stem cell based therapy for acute renal failure
  7397. Effect of nonmyeloablative hematopoietic Stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting …
  7398. Combination of Stem cell and gene therapy ameliorates symptoms in Huntington’s disease mice
  7399. Miraculous’ Stem cell therapy has sickened people in five states
  7400. Utilization of hematopoietic Stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted therapy
  7401. Mesenchymal Stem cell exosomes as a cell-free therapy for nerve injury–induced pain in rats
  7402. In vivo hematopoietic Stem cell gene therapy ameliorates murine thalassemia intermedia
  7403. Fetal Stem cell transplantation and gene therapy
  7404. Dental pulp Stem cell-derived conditioned medium: an attractive alternative for regenerative therapy
  7405. Delivery of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting Stem cell marker CD133
  7406. Computational strategies for niche-dependent cell conversion to assist Stem cell therapy
  7407. Autologous Stemcell-based gene therapy for inherited disorders: state of the art and perspectives
  7408. Targeting cancer Stem cell redox metabolism to enhance therapy responses
  7409. A review on different methods to increase the efficiency of mesenchymal Stem cell‐based wound therapy
  7410. Stem cell therapy for Alzheimer’s disease: research status and developmental trend
  7411. … Commentary: Considering Clinical Application of Bone Marrow Aspirate Concentrate for Restoration of Cartilage Defects in the Knee? Is It a Kind of Stem cell therapy
  7412. … , multi-lineage differentiation and aging of zebrafish heart and liver tissue-derived mesenchymal Stem cells as a novel approach in Stem cell-based therapy
  7413. Mesenchymal Stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles
  7414. Single cell gene expression analysis reveals human Stem cell-derived graft composition in a cell therapy model of Parkinson’s disease
  7415. Xenofree generation of limbal Stem cells for ocular surface advanced cell therapy
  7416. Hematopoietic Stem cell transplantation and cellular therapy in sickle cell disease: where are we now?
  7417. Validation of current good manufacturing practice compliant human pluripotent Stem cell-derived hepatocytes for cell-based therapy
  7418. Engineered mesenchymal Stem cell/nanomedicine spheroid as an active drug delivery platform for combinational glioblastoma therapy
  7419. Mesenchymal Stem cell therapy improves spatial memory and hippocampal structure in aging rats
  7420. Cancer Stem cell‐platelet hybrid membrane‐coated magnetic nanoparticles for enhanced photothermal therapy of head and neck squamous cell carcinoma
  7421. Innovative curative treatment of beta thalassemia: cost-efficacy analysis of gene therapy versus allogenic hematopoietic Stemcell transplantation
  7422. Allogeneic Stem cell transplantation as part of front line therapy for Mantle cell lymphoma
  7423. Haploidentical Stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a …
  7424. Verification of mesenchymal Stem cell injection therapy for interstitial cystitis in a rat model
  7425. New era of heart failure therapy in pediatrics: cardiac Stem cell therapy on the start line
  7426. Scientific Basis for Stem cell therapy
  7427. Mesenchymal Stem cells for spinal cord injury: current options, limitations, and future of cell therapy
  7428. Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic Stem cell transplantation
  7429. Stem cell derived exosomes: microRNA therapy for age-related musculoskeletal disorders
  7430. Therapeutic abortion and ectopic pregnancy: alternative sources for fetal Stem cell research and therapy in Iran as an Islamic country
  7431. Is the adipose-derived mesenchymal Stem cell therapy effective for treatment of knee osteoarthritis?
  7432. Role of the microenvironment in regulating normal and cancer Stem cell activity: implications for breast cancer progression and therapy response
  7433. Prodrug suicide gene therapy for cancer targeted intracellular by mesenchymal Stem cell exosomes
  7434. The landscape of hematopoietic Stem cell transplant and gene therapy for X-linked adrenoleukodystrophy
  7435. Local Stem cell therapy for Crohn’s Perianal Fistulae
  7436. Psychophysical effects of an exercise therapy during pediatric Stem cell transplantation: a randomized controlled trial
  7437. Novel Stem cell and gene therapy in diabetic retinopathy, age related macular degeneration, and retinitis pigmentosa
  7438. Activity of p53 in human amniotic fluid Stem cells increases their potentiality as a candidate for Stem cell therapy
  7439. Mesenchymal Stem cell therapy of male infertility
  7440. Advances of Stem cell therapy to treat heart failure
  7441. Brief review: Can modulating DNA methylation state help the clinical application of oligodendrocyte precursor cells as a source of Stem cell therapy?
  7442. Adoptive T cell therapy following haploidentical hematopoietic Stem cell transplantation
  7443. Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for Stem cell transplantation: a structured review
  7444. Long-term follow-up of patients with Buerger’s disease after autologous Stem cell therapy
  7445. Role of physical therapy before and after hematopoietic Stem cell transplantation: white paper report
  7446. … -based strategy with autologous Stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for cell therapy and …
  7447. 4. Bone Stem cell therapy in the clinical perspective: a focus on nonrandomized and randomized trials
  7448. Assessing Stem cell DNA integrity for cardiac cell therapy
  7449. Autoimmune enteropathy: an updated review with special focus on Stem cell transplant therapy
  7450. Cancer therapy-induced cardiomyopathy: can human induced pluripotent Stem cell modelling help prevent it?
  7451. Characteristics of intestinal microecology during mesenchymal Stem cell-based therapy for mouse acute liver injury
  7452. Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic Stemcell transplantation for acute myeloid …
  7453. Reprogramming of cancer Stem cells into non-tumorigenic cells using Stem cell exosomes for cancer therapy
  7454. Pre-clinical safety and efficacy of lentiviral vector-mediated ex vivo Stem cell gene therapy for the treatment of mucopolysaccharidosis IIIA
  7455. The effect of photobiomodulation therapy on the differentiation, proliferation, and migration of the mesenchymal Stem cell: a review
  7456. Stem cell-derived models of neural crest are essential to understand melanoma progression and therapy resistance
  7457. Concise review: reduction of adverse cardiac scarring facilitates pluripotent Stem cell-based therapy for myocardial infarction
  7458. Human embryonic Stem cell-derived cardiomyocyte therapy in mouse permanent ischemia and ischemia-reperfusion models
  7459. GDNF enhances the anti-inflammatory effect of human adipose-derived mesenchymal Stem cell-based therapy in renal interstitial fibrosis
  7460. Hypoxia induced cancer Stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer
  7461. cell-derived exosome promote endothelial cell angiogenesis in a dose dependent manner: a new perspective on regenerative medicine and cell-free therapy
  7462. Mesenchymal Stem cell therapy modulates synovial macrophages in a murine model of osteoarthritis
  7463. BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic Stem cell transplantation in patients with FLT3 …
  7464. Exploiting tumor-intrinsic signals to induce mesenchymal Stem cell-mediated suicide gene therapy to fight malignant glioma
  7465. Current status of Stem cell therapy for sepsis and acute respiratory distress syndrome
  7466. Quality of life (QOL) in patients undergoing CAR-T therapy versus Stem cell transplant (SCT).
  7467. Genetic communication by extracellular vesicles is an important mechanism underlying Stem cell-based therapy-mediated protection against acute kidney …
  7468. Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic Stem cell transplant?
  7469. Low-dose anti-inflammatory combinatorial therapy reduced cancer Stem cell formation in patient-derived preclinical models for tumour relapse prevention
  7470. Eltrombopag is an effective and safe therapy for refractory thrombocytopenia after haploidentical hematopoietic Stem cell transplantation
  7471. Bone marrow–derived mesenchymal Stem cell–mediated dual-gene therapy for glioblastoma
  7472. Physical therapy pathway and protocol for patients undergoing hematopoietic Stem cell transplantation: recommendations from the eastern Mediterranean …
  7473. An explorative study of qualities in interactive processes with children and their parents in music therapy during and after pediatric hematopoietic Stem cell
  7474. A Hyaluronan hydrogel scaffold for culture of human oral mucosal epithelial cells in limbal Stemcell therapy
  7475. Splenectomy following JAK1/JAK2 inhibitor therapy in patients with myelofibrosis undergoing allogeneic Stem cell transplantation
  7476. Antisense oligonucleotide therapy rescues aggresome formation in a novel spinocerebellar ataxia type 3 human embryonic Stem cell line
  7477. Can Stem cell therapy increase the rate of myocardial recovery in left ventricular assist device-supported advanced heart failure patients?—current data and …
  7478. Autologous bone marrow Stem cell therapy for patients undergoing coronary artery bypass grafting: A meta‑analysis of 14 randomized controlled trials
  7479. Stem cell membrane vesicle–coated nanoparticles for efficient tumor‐targeted therapy of orthotopic breast cancer
  7480. Histone deacetylase inhibitor panobinostat potentiates the anti-cancer effects of mesenchymal Stem cell-based sTRAIL gene therapy against malignant glioma
  7481. Dental pulp Stem cells: an attractive alternative for cell therapy in ischemic stroke
  7482. Comparison of outcomes of frontline immunosuppressive therapy and frontline haploidentical hematopoietic Stem cell transplantation for children with severe …
  7483. … reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre-or post-Stem cell
  7484. Stem cell-derived exosomes protect astrocyte cultures from in vitro ischemia and decrease injury as post-stroke intravenous therapy
  7485. Cancer prevention and therapy of two types of gap junctional intercellular communication–deficient “cancer Stem cell
  7486. Outcome of hematopoietic Stem cell gene therapy for Wiskott-Aldrich syndrome
  7487. Identification and targeting of Stem cell-activated pathways in cancer therapy
  7488. Impact of consolidation therapy post autologous Stem cell transplant in patients with light chain amyloidosis
  7489. SyStemic dental pulp Stem cell secretome therapy in a mouse model of amyotrophic lateral sclerosis
  7490. Mesenchymal Stem/stromal cell therapy for pulmonary arterial hypertension: Comprehensive review of preclinical studies
  7491. Latent Stem cell-stimulating therapy for regeneration of chronic tympanic membrane perforations using IGFBP2-releasing chitosan patch scaffolds
  7492. Reversal of surfactant protein B deficiency in patient specific human induced pluripotent Stem cell derived lung organoids by gene therapy
  7493. Paving the road for mesenchymal Stem cell-derived exosome therapy in bronchopulmonary dysplasia and pulmonary hypertension
  7494. cellular and molecular assessment of rose bengal photodynamic antimicrobial therapy on keratocytes, corneal endothelium and limbal Stem cell niche
  7495. Hematopoietic Stem cell-Targeted Neonatal Gene therapy with a Clinically Applicable Lentiviral Vector Corrects Osteopetrosis in oc/oc Mice
  7496. Adipocyte-derived Stem cell-based gene therapy upon adipogenic differentiation on microcarriers attenuates type 1 diabetes in mice
  7497. Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic Stem cell transplantation, assessed by patient-reported …
  7498. In vivo selection for gene-corrected HSPCs advances gene therapy for a rare Stem cell disease
  7499. … following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem cell Transplantation and cellular therapy (SFGM …
  7500. High tibial osteotomy in combination with arthroscopic abrasion arthroplasty and autologous adipose-derived mesenchymal Stem cell therapy in the treatment …
  7501. Insights into GBA Parkinson’s disease pathology and therapy with induced pluripotent Stem cell model syStems
  7502. Productivity losses in patients with newly diagnosed multiple myeloma following Stem cell transplantation and the impact of maintenance therapy
  7503. … induction therapy, autologous Stem cell transplantation, and rituximab maintenance allow to reach a high 7-year survival rate in patients with mantle cell
  7504. Role of Stem cell therapy for Pain
  7505. Treatment of the bone marrow stromal Stem cell supernatant by nasal administration—a new approach to EAE therapy
  7506. Cardiac Stem cell therapy, Resident Progenitor cells and the role of cellular Signalling; a Review
  7507. Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem cell–Mediated Sodium Iodide Symporter (NIS) Gene 131I therapy
  7508. Interaction between mesenchymal Stem cells and intervertebral disc microenvironment: from cell therapy to tissue engineering
  7509. A novel approach for image-guided 131I therapy of pancreatic ductal adenocarcinoma using mesenchymal Stem cell-mediated NIS gene delivery
  7510. Melphalan dose in myeloma patients≥ 65 years of age undergoing high-dose therapy and autologous Stem cell transplantation: a multicentric observational registry …
  7511. Stem cell-Based therapy for Lung Disease
  7512. Stem cell therapy in the elderly with liver disease
  7513. Autologous Stem cell transplantation in refractory Crohn’s disease–low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised …
  7514. A single dose of CD117 antibody drug conjugate enables autologous gene-modified hematopoietic Stem cell transplant (gene therapy) in nonhuman primates
  7515. … ) in autoimmune disease adult patients in France: analysis of the long-term outcome from the French Society for Bone Marrow Transplantation and cellular therapy
  7516. Autologous Stem cell transplantation is a viable postremission therapy for intermediate-risk acute myeloid leukemia in first complete remission in the absence of a …
  7517. Stem cell therapy for knee osteoarthritis: a narrative review of a rapidly evolving treatment with implications for physical therapy management
  7518. Stem cell-based therapy for ischemic stroke
  7519. … with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic Stem cell
  7520. Stem cell therapy
  7521. … 1–specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical Stem cell transplantation: a feasibility pre …
  7522. Induced pluripotent Stem cells for disease modeling, cell therapy and drug discovery in genetic autonomic disorders: a review
  7523. Stem cell therapy in Motor Neuron Disease
  7524. The impact of multiple myeloma induction therapy on hematopoietic Stem cell mobilization and collection: 25-year experience
  7525. Stem cell therapy for Liver Diseases
  7526. Review on: regenerative medicine, tissue engineering and Stem cell therapy in diabetes mellitus
  7527. Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous Stem cell
  7528. … T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic Stem cell transplantation or after gene therapy
  7529. Mesenchymal Stem cell exosome-mediated prodrug gene therapy for cancer
  7530. Public Engagement for Regulatory Reform: A Case Study of Autologous Stem cell therapy Regulation in Australia
  7531. Induced Pluripotent Stem cell-Based cell therapy of the Retina
  7532. Comparison between autologous and allogeneic Stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous Stem cell
  7533. Evaulation of intra-articular adipose derived mesenchymal Stem cell therapy in the treatment of symptomatic knee osteoarthritis–a randomised controlled trial.
  7534. Ultrasonic debridement with Stem cell therapy of suspensory branch desmitis in an equine patient
  7535. Stem cell and Left Ventricular Assist Device Combination therapy: A Novel Approach Aiming to Achieve Myocardial Recovery in Patients With Advanced Chronic …
  7536. Recent advances in cancer Stem cell targeted therapy
  7537. … hematopoietic Stem cell transplant: How to choose the best donor? Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy
  7538. Diffuse iris melanoma: conservative treatment with proton beam therapy after limbal Stem cell preservation or enucleation?
  7539. Extensive metabolic correction of hurler disease by hematopoietic Stem cell-based gene therapy: Preliminary results from a phase I/II trial
  7540. Stem cell therapy for perianal Crohn’s
  7541. Nerve growth factor gene therapy improves bone marrow sensory innervation and nociceptor-mediated Stem cell release in a mouse model of type 1 diabetes …
  7542. Ex-Vivo Expanded NK cell therapy Combined with Elotuzumab for MRD after Autologous Stem cell Transplantation: A Phase I/II Clinical Trial in Progress
  7543. Negative pressure wound therapy with potential autologous Stem cell therapy: the challenge and future of complex defect healing
  7544. GP248 Mesenchymal Stem cell therapy in microvillus inclusion disease
  7545. Autologous Stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy
  7546. Mesenchymal Stem cell therapy for neonatal intraventricular hemorrhage: a long way to go?
  7547. Personal cell therapy for interstitial cystitis with autologous stromal vascular fraction Stem cells
  7548. Stem cell therapy
  7549. Bone marrow harvesting from paediatric patients undergoing haematopoietic Stem cell gene therapy
  7550. cell-based therapy Using Induced Plutipotent Stem cell
  7551. Comparative analysis of mesenchymal Stem cells from bone marrow, adipose tissue, and dental pulp as sources of cell therapy for zone of stasis burns
  7552. The evolving role of maintenance therapy following autologous Stem cell transplantation in multiple myeloma
  7553. Stem cell therapy
  7554. Role of cancer Stem cell, apoptotic factor, dna repair, and telomerase toward radiation therapy response in stage IIIB cervical cancer
  7555. Effect of sirolimus exposure on the need for preemptive antiviral therapy for cytomeglovirus infection after allogeneic hematopoietic Stem cell transplantation
  7556. Stem cell therapy: A Great Leap Forward in Alzheimer’s Treatment
  7557. A comparison of BMP2 delivery by coacervate and gene therapy for promoting human muscle-derived Stem cell-mediated articular cartilage repair
  7558. Inflammasome Mediated reduction of myeloperoxidase in ischemic stroke by intra-arterial mesenchymal Stem cell therapy
  7559. … chimeric antigen receptor T-cell therapy for recurrent chronic myeloid leukemia in lymphoid blast crisis after allogeneic hematopoietic Stem cell transplantation: a two …
  7560. Safety and Feasibility of Chimeric Antigen Receptor T cell therapy after Allogeneic Stem cell therapy in Relapsed/Refractory B cell Lymphomas
  7561. Stem cell therapy for Multiple Sclerosis: An Exciting Challenge or a Treatment Hope
  7562. Mesenchymal Stem cell Based therapy for Parkinsonʼs Disease
  7563. Revisiting CLEC 12A as leukaemic Stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy
  7564. Personalized cell therapy for pulpitis using autologous dental pulp Stem cells and leukocyte platelet-rich fibrin: a case report
  7565. therapy with single‐dose rituximab for Epstein‐Barr virus infection to prevent post‐transplant lymphoproliferative disease after pediatric hematopoietic Stem cell
  7566. Stem cell therapy: An overview
  7567. Treatment for Canine Corneal Ulcer using Adipose Tissue-derived Mesenchymal Stem cell therapy-Case Report
  7568. Peripheral Stem cell apheresis is feasible post 131Iodine-metaiodobenzylguanidine-therapy in high-risk neuroblastoma, but results in delayed platelet reconstitution
  7569. A fatal case of Exophiala dermatitidis disseminated infection in an allogenic hematopoietic Stem cell transplant recipient during micafungin therapy
  7570. Rapid regulation of human mesenchymal Stem cell proliferation using inducible caspase-9 suicide gene for safe cell-based therapy
  7571. Human limbus-derived mesenchymal/stromal Stem cell therapy for superficial corneal pathologies: Two-year outcomes
  7572. Case Report: Effect of autologous adipose-derived mesenchymal Stem cell therapy in the treatment of acromioclavicular joint osteoarthritis
  7573. Stem cell therapy in Nepal: Challenges and Opportunities
  7574. Effects of Mesenchymal Stem cell therapy in BPD
  7575. Indication of autologous Stem cell transplantation in chronic inflammatory demyelinating polyneuropathy: guidelines from the Francophone Society of Bone Marrow …
  7576. Stem cell factor lifted as a promising clinical target for cancer therapy
  7577. Adipose-derived mesenchymal Stem cell therapy in the treatment of knee osteoarthritis—reply
  7578. Cost‐effectiveness of antifungal prophylaxis, preemptive therapy, or empiric treatment following allogeneic hematopoietic Stem cell transplant
  7579. Brincidofovir as a salvage therapy in controlling adenoviremia in pediatric recipients of hematopoietic Stem cell transplant
  7580. cell therapy using extraocular mesenchymal Stem cells
  7581. Challenges and Opportunities for the Future of Stem cell therapy for Lung Diseases
  7582. Combination cell therapy: A New Approach for Stem cell therapy
  7583. Current status of Stem cell therapy
  7584. Possible Mechanisms and Prospects of Stem cell therapy for Keloids
  7585. Call for Papers: Special Issue on Stem cell therapy for Traumatic Brain Injury: Submission Deadline: October 1, 2019
  7586. Stem cell therapy and hair loss: Present evidence and future perspectives
  7587. Maintenance therapy with the oral proteasome inhibitor (PI) ixazomib significantly prolongs progression-free survival (PFS) following autologous Stem cell
  7588. Accelerated bone regeneration via three-dimensional cell-printed constructs containing human nasal turbinate-derived Stem cells as a clinically applicable therapy
  7589. Vasculogenic Stem and progenitor cells in human: future cell therapy product or liquid biopsy for vascular disease
  7590. Cancer Stem cell resistance to targeted therapy
  7591. Hematopoietic Stem cell Transplant and cellular therapy
  7592. Novel mesenchymal Stem cell delivery syStem as targeted therapy against neuroblastoma using the TH-MYCN mouse model
  7593. … of critically Ill pediatric cancer and hematopoietic Stem cell transplant patients requiring continuous renal replacement therapy: a retrospective nationwide …
  7594. Stemcell therapy in Human Osteoarthritis: A Debate
  7595. Stem cell therapy for Enteric Neuropathies
  7596. Mesenchymal Stem versus stromal cells: International Society for cell & Gene therapy (ISCT®) Mesenchymal Stromal cell committee position statement on …
  7597. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous Stem cell transplantation in a case of syStemic light-chain amyloidosis with …
  7598. Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic Stem cell
  7599. Stem cell–Derived Islets: Next Steps for Histologic and Functional Assessment During Development as a cellular therapy for the Treatment of Diabetes
  7600. Differential effects of neural Stem cell therapy in adult and middle-aged Parkinsonian mice
  7601. Stem cell Based therapy for Lung Disease Preclinical evidence for the role of Stem/stromal cells Clinical application of Stem/stromal cells in lung fibrosis
  7602. Therapeutic application of Stem cell and gene therapy in Parkinson’s disease
  7603. Stem cell therapy for renal failure: present considerations
  7604. Ethics of Stem cell therapy for heart failure
  7605. Stem cell therapy for ischemic stroke injury: A current status
  7606. Auditory Dysfunction in Aging: Prospects for Stem cell therapy
  7607. Stem cell therapy in T2DM: Progress and Challenges
  7608. Current Status of Stem cell therapy for Thromboangiitis Obliterans (Buerger’s Disease)
  7609. AL amyloidosis: the effects of maintenance therapy on autologous Stem cell transplantation outcomes
  7610. … in autologous and allogenic hematopoietic Stem cell transplant: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy
  7611. Dental pulp Stem cells: Novel cell-based and cell-free therapy for peripheral nerve repair
  7612. A Phase II, multicenter study of high dose chemotherapy with autologous Stem cell transplant followed by maintenance therapy with romidepsin for T-cell
  7613. Circulatory support and Stem cell therapy in the management of advanced heart failure: a concise review of available evidence
  7614. Efficacy and safety of a weekly cyclophosphamide-bortezomib-dexamethasone regimen as induction therapy prior to autologous Stem cell transplantation in Japanese …
  7615. … as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous Stem cell transplantation: A report …
  7616. Fight for Regulation and its Enforcement on Stem cell therapy in China
  7617. Music therapy: an intervention effecting quality of life and health in children going through hematopoietic Stem cell transplantation
  7618. Combination treatment of autologous bone marrow Stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial
  7619. A Prospective, Multicenter Study of Involved-Field Radiation therapy With Autologous Stem cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive …
  7620. Is Stem cell therapy an Answer to Heart Failure: A Literature Search
  7621. Optoacoustic guidance for Stem cell therapy
  7622. Immuno-suppressive hydrogels for Stem cell therapy after traumatic brain injury
  7623. Stem cell Joint therapy: Promising, but Not Ready for Prime Time
  7624. Hypomethylating agent maintenance therapy after allogeneic Stem cell transplant improves transplant outcome in high risk acute myelogenous leukemia
  7625. Stem cell therapy in stroke: Mechanism and progress in clinical research
  7626. STATE OF THE ART OF Stem cell therapy FOR ISCHAEMIC CARDIOMYOPATHY PART
  7627. Stem cell therapy in regenerative medicine of reproductive diseases
  7628. Commentary: Stem cell therapy for single-ventricle congenital heart disease: Exciting, but a long way to go
  7629. Mechanisms and Clinical Applications of Stem cell therapy
  7630. Efficacy of Mesenchymal Stem cell therapy for Steroid-Refractory Acute Graft-versus-Host Disease: A SyStematic Review and Meta-Analysis
  7631. Mesenchymal Stem cell-Based therapy of Osteoarthritis: Current Clinical Developments and Future Therapeutic Strategies
  7632. State of the art of Stem cell therapy for ischaemic cardiomyopathy. Part 2.
  7633. Effects of recombinant thrombomodulin therapy and soluble human leukocyte antigen-G levels during hematopoietic Stem cell transplantation
  7634. towards Stem cell therapy of polycystic ovary syndrome (PCOS): therapeutic effect of human mesenchymal Stem cells transplantation in pcos mouse model by …
  7635. Mesenchymal Stem cell therapy logistics: A paradigm between quantity and/or quality of the “reparative” cell product
  7636. Differentiation of human adipose-derived Stem cells into neuron/motoneuron-like cells for cell replacement therapy of spinal cord injury
  7637. Safety and efficacy of allogeneic Stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma
  7638. Principles and advances in Stem cell therapy in neuropsychiatric disorders
  7639. Stem cell therapy for Parkinson’s Disease: Past, Present and Future
  7640. … for treatment of cytomegalovirus reactivations in allogeneic haematopoietic Stem cell transplant recipients who are intolerant/unsuitable for Ganciclovir therapy
  7641. Enhancement of functionality and therapeutic efficacy of cell-based therapy using mesenchymal Stem cells for cardiovascular disease
  7642. Current Stem cell therapy for Osteoarthritis
  7643. Stem cell therapy Acquiring a Medical Patent
  7644. Adult Stem cell therapy: Social Risks
  7645. BEAM-modified conditioning therapy with cisplatin+ dexamethasone instead of carmustine prior to autologous hematopoietic Stem cell transplantation (HSCT) …
  7646. E-077 Stem cell therapy for spinal cord injury
  7647. Outcome of autologous Stem cell transplantation following PD-(L) 1 based salvage therapy for multiply relapsed patients with classic Hodgkin lymphoma
  7648. Role of Stem cells in Cardiac cell therapy and Tissue Engineering
  7649. Tuberculosis: A Complication after Hematopoietic Stem cell therapy (HSCT) and Bone Marrow Transplant.
  7650. therapy versus melphalan and prednisolone doublet combination therapy in Japanese patients with newly diagnosed multiple myeloma ineligible for autologous Stem
  7651. Adipose Stem cell therapy for Amputation Site Soft Tissue Restoration: A Prospective, Randomized Controlled Clinical Trial
  7652. Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic Stem cell transplant recipients
  7653. P5746 Human induced pluripotent Stem cell-derived mesenchymal Stem cell therapy effectively reduced brain infarct volume and preserved neurological function in …
  7654. Autologous Stem cell therapy in Acute Motor Sensory Axonal Neuropathy
  7655. Stem cell therapy to Avoid Major Leg Amputation
  7656. A Medical/Legal Perspective on Stem cell therapy: A Scientific Breakthrough or Snake Oil?
  7657. Durable control of hepatitis C through interferon‐free antiviral combination therapy immediately prior to allogeneic haematopoietic Stem cell transplantation
  7658. A meta-analysis of randomized controlled trials conducted using Stem cell therapy for patients with ischemic stroke
  7659. Osteochondroreticular Stem cell therapy for osteoarthritis: the right cells for the job
  7660. Cortical-bone Stem cell therapy Alters the Inflammatory Response After Myocardial Infarction
  7661. The human amniotic fluid mesenchymal Stem cells therapy on, SKOV3, ovarian cancer cell line
  7662. Bloodstream Infections in Children Undergoing Allogeneic, Autologous Hematopoietic Stem cell Transplantation or Chimeric Antigen Receptor T cell therapy
  7663. Stem cell therapy for patient with osteoarthritis detected by Radiology imaging Case report and literature review
  7664. Mesenchymal Stem cell therapy for Liver Cirrhosis-Basic Study and Clinical Application
  7665. … -Thymocyte Globulin in Unrelated Donor Stem cell Transplant Recipients: Longer Follow-up of a Multicentre cell therapy Transplant Canada Randomized …
  7666. Stem cell transplantation in aplastic anemia: Impact on choices for first line therapy
  7667. Stem cell therapy To Improve Burn Wound Healing
  7668. Mesenchymal Stem cell therapy in Graft Versus Host Disease
  7669. Induction therapy and Stemcell mobilization in myeloma, look at the past to plan the future
  7670. Islet Transplantation in Type 1 Diabetes: Stem cell Research and therapy
  7671. Induction therapy with Novel Agents and Autologous Stem cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma
  7672. Human Induced Pluripotent Stem cell-and mRNA-based Gene therapy Strategies for Treatment of Arginase Deficiency
  7673. ALLOGENIC Stem cell therapy FOR IMMUNE MEDIATED HEMOLYTIC ANEMIA
  7674. … CHIMERIC ANTIGEN RECEPTOR (CAR)-T cell therapy VS. AUTOLOGOUS AND ALLOGENEIC Stem cell TRANSPLANT FOR HEMATOLOGIC …
  7675. Enzyme Replacement therapy and Hematopoietic Stem cell Transplantation Results in Patients with Hurler Syndrome: Clinical Cases
  7676. Muscle Stem cell Biology and Implications in Gene therapy
  7677. Mesenchymal Stem cell therapy and Chronic Non-Tuberculous Mycobacterium Infection
  7678. SAT-102 AUTOLOGOUS Stem cell therapy USING LENTIVIRAL VECTOR FOR TREATMENT OF FABRY DISEASE
  7679. A Rat Model of Radiation Vasculitis for the Study of Mesenchymal Stem cell-Based therapy
  7680. Feasibility of brentuximab vedotin as consolidation therapy after autologous Stemcell transplantation in children and adolescents (< 18 years) with early relapse …
  7681. The Effects of Mesenchymal Stem cell therapy on Knee Pain and Function During Knee Osteoarthritis
  7682. Potential and therapeutic efficacy of cell-based therapy using mesenchymal Stem cells for acute/chronic kidney disease
  7683. Coreceptor-Based Hematopoietic Stem cell Gene therapy for HIV Disease
  7684. 152. Stem cell therapy for pressure injury: a pilot study with autologous bone marrow derived Stem cell (BM-MNC)
  7685. Autologous Hematopoietic Stem cell Infusion for Myelosuppression after Bcma-CART therapy in Relapsed Myeloma Patients
  7686. THER-15. DEVELOPING TUMOR-HOMING CYTOTOXIC HUMAN INDUCED NEURAL Stem cell therapy FOR BRAIN METASTASES
  7687. Treatment for Canine Corneal Ulcer using Adipose Tissue-derived Mesenchymal Stem cell therapy-Case Report
  7688. Administration of Third-Party Virus-Specific T-cells (VST) at the Time of Initial therapy for Infection after Haemopoietic Stem cell Transplant Is Safe and …
  7689. A New Step in Understanding of Fanconi Patients Peripheral Stem cell Harvesting, a Bridge to Gene therapy
  7690. Inferior Survival with Use of Autologous Stem cell Transplant As Second-Line therapy in Multiple Myeloma
  7691. … embryonic Stem (hES) cells and human induced pluripotent Stem (hiPS) cells as well as biomaterials used in clinical trials of Stem cell therapy. Human pluripotent Stem
  7692. Maintenance therapy after second autologous Stem cell transplant in multiple myeloma improves overall survival
  7693. Assessing Myo‐mechanicals Characteristic of Rectus Abdominis Muscle after Stem cell therapy
  7694. Efficacy and safety of autologous Stem cell transplantation after induction therapy with lenalidomide, bortezomib, and dexamethasone
  7695. PBI3 A REVIEW ON PEARLS & PITFALLS OF AUTOLOGOUS BONE MARROW DERIVED MESENCHYMAL STROMAL/Stem cell therapy IN END STAGE LUNG …
  7696. Abstract TP140: Intra-Arterial Mesenchymal Stem cell therapy Modulates Expression of NLRP1 Inflammasome in Animal Model of Ischemic Stroke
  7697. Human Placental Stem cell therapy in Stroke: Endothelial/Smooth Muscle Mechanisms Underlying Protection?
  7698. Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood Stem cell
  7699. Allogeneic Stem cell Transplantation in therapy-Related Myelodysplasia after Autologous Transplantation for Lymphoma: A Retrospective Study of the …
  7700. Towards cell therapy of polycystic ovary syndrome (PCOS): Human mesenchymal Stem cells secretome inhibits androgen production by pcos theca cells
  7701. Development of Stem cell-Based therapy for Limbal Stem cell Deficiency—From Tissue Stem cell to iPS cell
  7702. Anti tumor activity of cord blood Stem cell derived CD16 positive NK cells as an immune cell therapy for acute lymphoblastic leukemia (ALL)
  7703. Updated safety and efficacy outcomes from an ongoing phase 2/3 trial of lenti-D autologous hematopoietic Stem cell gene therapy for the treatment of cerebral …
  7704. Successful Treatment of Severe Aspergillosis with Isavuconazole therapy after Allogeneic Stem cell Transplantation
  7705. Combination of Extracorporeal Life Support and Mesenchymal Stem cell therapy for Treatment of ARDS in Combat Casualties and Evacuation of Service Members …
  7706. Results of an Open Label, Dose Escalating, Phase 1 Clinical Trial Evaluating the Safety of a Human Neural Stem cell Based therapy in Parkinson’s Disease (P1. 8 …
  7707. Healthcare professionals’, students’, patients’ and donors’ perceptions of Stem cell research and therapy: a syStematic review protocol
  7708. Antioxidant preconditioning enhances adipose tissue-derived Stem cell therapy by increasing intrahepatic engraftment for liver fibrosis
  7709. Correction to: Hypoxic Preconditioning Enhances Dental Pulp Stem cell therapy for Infection-Caused Bone Destruction by Wu Y, Huang F, Zhou X, Yu S, Tang Q, Li S
  7710. … -Specific CD8+ T cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral therapy in Allogeneic Hematopoietic Stem cell Transplant …
  7711. Hematopoietic Stem cell gene therapy for inherited monogenic diseases and its implications for future gene therapy trials in Turkey
  7712. Characteristics and Outcomes of therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem cell Transplantation
  7713. Mapping Stem cell Dependencies in Cancer Heterogeneity and therapy Resistance
  7714. Stem cell GENE therapy FOR INHERITED MONOGENIC DISEASES AND ITS IMPLICATIONS FOR FUTURE GENE therapy TRIALS IN TURKEY
  7715. Allogeneic Stem cell transplantation (AlloSCT) for patients (pts) with acute leukemia following venetoclax-based therapy.
  7716. art therapy and quality of life among children undergoing Stem cell transplantation: a pilot study
  7717. … and comparative analysis secreted from exfoliated deciduous teeth, dental pulp, and bone marrow derived mesenchymal Stem cells for functional cell-based therapy
  7718. Myelosuppression After Radiation therapy in Patients With and Without Autologous Peripheral Blood Stem cell Transplantation: A Retrospective Observational Study
  7719. … Markers of Dental Pulp Stem cell Isolated from Impacted Third Molar Based on International Society for cellular therapy Proposed Mesenchymal Stem cell
  7720. Design and Development of Small Molecules from Somatic, Stem cell Reprogramming, and therapy
  7721. Maintenance therapy with Decitabine after Allogeneic Hematopoietic Stem cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia
  7722. MEDU-25. genes preserving Stem cell state in group 3 MB BTICs contribute to therapy evasion and relapse
  7723. Sequential matrix-RICE therapy followed by autologous Stem cell transplant in patients with diffuse large B-cell lymphoma and secondary central nervous …
  7724. Azacitidine as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndrome after allogeneic hematopoietic Stem cell transplantation
  7725. Stemcell based therapy for dry AMD
  7726. cell-based interferon gene therapy using proliferation-controllable, interferon-releasing mesenchymal Stem cells
  7727. Patterns of Relapse After Salvage Autologous Stem cell Transplant for Hodgkin’s Lymphoma: Should Sites of Relapse Relative to Initially Involved Sites Be Used to …
  7728. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after Stem cell
  7729. Stem cell Factor Antibody: Effective Manipulation of Antihormonal therapy in Resistant Human Breast Cancer In Vitro.
  7730. Retraction of “Glioma Gene therapy Using Induced Pluripotent Stem cell Derived Neural Stem cells
  7731. The Effects of Pre-transplant Music therapy on Distress, Quality of Life, Pain, Anxiety, Mood, and Pain Medication for Patients Undergoing Hematopoietic Stem cell
  7732. cell therapy of liver disease: From hepatocytes to Stem cells
  7733. Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline Stem cell transplant in …
  7734. Mesenchymal Stem cell–Based therapy for Chronic Kidney Disease
  7735. All‑trans retinoic acid therapy induces asymmetric division of glioma Stem cells from the U87MG cell line
  7736. New Methods for Lentiviral-Based Hematopoietic Stem cell Gene therapy
  7737. The Role of Radiation therapy in Hematopoietic Stem cell Transplantation
  7738. Automation in Hemopoietic Stem cell Gene therapy: Results of a Head-to-Head Comparison of a Manual Vs an Automated Procedure
  7739. Intraarticular xenogeneic mesenchymal Stem cell-based therapy increases CD4+ CD25+ cells in the synovial fluid but does not contribute to pathological change
  7740. Fully Closed, Large-Scale, and Clinical Grade cell Sorting of Hematopoietic Stem cell (HSC)-Enriched CD90+ cells for Transplantation and Gene therapy
  7741. Stem-01. CHARACTERIZATION OF ORTHOTOPIC GLIOBLASTOMA MODEL FOR THE GENE-AND cell therapy
  7742. Polymer Composite Strategies in Cancer therapy, Augment Stem cell Osteogenesis, Diagnostics in the Central Nervous SyStem, and Drug Delivery
  7743. Lentiviral haemopoietic Stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1 …
  7744. … ) is associated with less complications in Individuals with Type 1 Diabetes treated with hematopoetic Stemcell transplantation and conventional therapy
  7745. Optimal therapy for Relapsed AL Amyloidosis Post Autologous Stem cell Transplant
  7746. Use of Maintenance therapy Post Autologous Stem cell Transplantation Outside of Clinical Trial Setting for Multiple Myeloma: Single Institution Experience
  7747. Hematopoietic Stem cell transplantation gene therapy for hemophilia a using non-genotoxic ANTI-CD117 immunotoxin conditioning
  7748. Mesenchymal Stem/Stromal cell therapy for Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit
  7749. Interferon‐regulated suprabasin is essential for stress‐induced Stem‐like cell conversion and therapy resistance of human malignancies
  7750. Outcomes of chronic myeloid leukemia with T315I mutation in the absence of targeted therapy or hematopoietic Stem cell transplantation
  7751. … HLA Matching with Outcome of Unrelated Donor Hematopoietic Stem cell Transplantation: A Study from the cellular therapy and Immunobiology Working …
  7752. Molecular and cellular mechanisms underlying the Stem cell Educator therapy for the clinical treatment of diabetes
  7753. Multiple Myeloma in a Patient with ANKRD26-Related Thrombocytopenia Successfully Treated with Combination therapy and Autologous Stem cell
  7754. Long-Term Clinical and Molecular Remissions in Patients with Mantle cell Lymphoma (MCL) Following High-Dose therapy (HDT) and Autologous Stem cell
  7755. … Oligodendroglial Differentiation as Potential Therapeutic Mechanisms of Mesenchymal Stem cell-Derived Neural Progenitors (MSC-NPs) cellular therapy in MS (P2 …
  7756. Depth of Response and Outcomes by Initial therapy Prior to Autologous Hematopoietic Stem cell Transplantation for Multiple Myeloma
  7757. Is Stem cell injection therapy an effective treatment option for osteoarthritic knee pain?
  7758. … Diffuse Large B cell Lymphoma Who Are Ineligible for Autologous Stem cell Transplantation and Receive Commercially-Available Salvage therapy
  7759. Focus on Stem cell-based therapy for retinal degenerative diseases
  7760. Outcomes of therapy Related Acute Lymphoblastic Leukemia in Adults after Allogeneic Stem cell Transplantation-Twenty-Year Experience from a Tertiary …
  7761. Evaluation of human induced pluripotent Stem cell (IPSC)-derived mesenchymal stromal/Stem cells (MSC) for use in cell-based therapy
  7762. Renal transplantationplus hematopoietic Stem cell transplantation as Induction therapy: a single-center 10-year experience
  7763. Outpatient PT Management of Patient with Bilateral Knee Pain S/P Stem cell Cartilage Replacement therapy of Both Knees
  7764. Production of insulin producing cells from cord blood mesenchymal Stem cells and their potential in cell therapy
  7765. Mesenchymal Stem cell-based therapy for Treatment of Bone Metastases in Breast Cancer
  7766. Stratification therapy for cytomegalovirus infection after allogeneic hematopoietic Stem cell transplantation
  7767. Antimicrobial therapy in cancer patients and hematopoietic Stem cell transplantation receptors
  7768. Total Skin Electron Beam therapy in Patients with Advanced Cutaneous T cell Lymphoma Undergoing Allogeneic Stem cell Transplantation: A Single Centre …
  7769. … of Outcomes in Adult Patients with therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem cell Transplantation-Twenty Year …
  7770. … TERM FOLLOW-UP OF MAINTENANCE therapy WITH INTEREFRON ALPHA AFTER AUTOLOGOUS HEMATOPOIETIC Stem cell TRANSPLANT IN MULTIPLE …
  7771. PS1220 EX-VIVO HEMATOPOIETIC Stem cell GENE therapy (GT) FOR MUCOPOLYSACCHARIDOSIS TYPE I HURLER (MPSIH): PRELIMINARY RESULTS …
  7772. Outcomes Following Allogeneic Stem cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD …
  7773. Mesenchymal Stem cell‐Based Delivery of Gene‐Silencing Products: Toward a Biological therapy
  7774. SUN-339 External Beam Radiation therapy Improves TGFB1-Induced Mesenchymal Stem cell-Mediated NIS Gene 131I therapy
  7775. Genes Preserving Stem cell State in Medulloblastoma Contribute to therapy Evasion and Relapse
  7776. PS1389 IMPACT OF DIFFERENT MAINTENANCE therapy OPTIONS AFTER AUTOLOGOUS HEMATOPOIETIC Stem cell TRANSPLANTATION IN MULTIPLE …
  7777. … HEMATOPOIETIC Stem cell TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH SUBOPTIMAL RESPONSE TO PRIMARY INDUCTION therapy
  7778. Low scale production of advanced therapy medicinal products for limbal Stem cell deficiency.
  7779. Abstract DP-003: TOWARD A HEMATOPOIETIC Stem cell-BASED PROPHYLACTIC IMMUNO-GENE therapy APPROACH FOR OVARIAN CANCER
  7780. ROLE OF MESENCHYMAL Stem cell EXTRAcellULAR VESICLES IN CARTILAGE BIOLOGY AND therapy
  7781. Antimicrobial therapy in cancer patients and hematopoietic Stem cell transplantation receptors Parte iv. Terapia antimicrobiana en pacientes con cáncer y receptores …
  7782. Maintenance therapy after hematopoietic Stem cell transplantation for abdominal myeloid sarcoma: a case report and literature review
  7783. Subcutaneous Bortezomib, Thalidomide and Dexamethasone As Induction therapy Prior to Autologous Peripheral Blood Stem cell Transplantation in Young …
  7784. Stem cell transplantation in patients with multiple myeloma. Impact of disease characteristics, disease status at transplant, and prior number of lines of therapy. Results …
  7785. … failure after allogeneic hematopoietic Stem cell transplantation: Recommendations of the Francophone Society of Bone Marrow transplantation and cellular therapy
  7786. The efficacy of empirical antibiotic therapy of febrile neutropenia in patients after allogeneic hematopoietic Stem cell transplantation
  7787. Research advances in glioma Stem cell surface marker CD133 and related targeted therapy
  7788. Reprogramming human gastrointestinal Stem cells into insulin-secreting cells: developing a cell therapy for diabetes
  7789. A Single Autologous Stem cell Transplant (ASCT) Followed By Two Years of Post-Transplant therapy in Older Recently Diagnosed Multiple Myeloma (MM) Patients …
  7790. Overcoming therapy resistance in Stem cell-rich triple negative breast cancer through p38 MAP kinase inhibition
  7791. Autologous Stem cell transplantation may be curative for patients with follicular lymphoma with early therapy failure without the need for immunotherapy
  7792. PS1536 EMPIRICAL ANTIBIOTIC therapy FOR NEUTROPENIC FEVER AFTER ALLOGENEIC Stem cell TRANSPLANTATION INFLUENCES GRAFT-VERSUS …
  7793. Salvage therapy of haploidentical hematopoietic Stem cell transplantation for one hepatosplenic αβ T-cell lymphoma: a case report
  7794. … -RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE therapy POST AUTOLOGOUS Stem cell TRANSPLANT (ASCT) IN …
  7795. Ibrutinib therapy for a blastoid variant mantle cell lymphoma patient with early extranodal relapse after autologous Stem cell transplantation
  7796. … Line of therapy in Patients with Lenalidomide-Pretreated Multiple Myeloma: Subanalysis of the Phase 3 Optimismm Trial By Patient Age and Prior Stem cell
  7797. High-CLDN4 ESCC cells harbor Stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma
  7798. … Effects of Pre-Transplant Music therapy on Distress, Quality of Life, Pain, Anxiety, Mood, and Pain Medication Use for Patients Undergoing Hematopoietic Stem cell
  7799. Can Peri-Transplant Radiation therapy Improve Outcomes of Autologous Stem cell Transplant in Hodgkin Lymphoma?
  7800. Hyperbaric Oxygen therapy for Refractory Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem cell Transplantation
  7801. Stem cell transplantation for healthcare professionals: Recommendations of the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM …
  7802. Lentiviral hematopoietic Stem and progenitor cell gene therapy for Wiskott-Aldrich Syndrome (WAS): up to 8 years of follow up in 17 subjects treated since 2010
  7803. Thrombopoietin receptor agonist romiplostim in refractory thrombocytopenia as a bridging therapy to the second allogeneic Stem cell transplantation
  7804. … DEXAMETHASONE IN THE CHINESE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BUT INELIGIBLE FOR Stem cell TRANSPLANT therapy
  7805. PS1535 AUTOLOGOUS Stem cell TRANSPLANT FOLLOWED BY POST-TRANSPLANT IMMUNOtherapy WITH NIVOLUMAB AND UNSELECTED …
  7806. Health-related quality of life (HRQOL) outcomes of oral ixazomib maintenance therapy post autologous Stem cell transplant (ASCT) in newly diagnosed multiple …
  7807. Analysis of children who received anticancer agent therapy, underwent Stem cell transplantation, and were treated with metronidazole injection at our institute …
  7808. Effects of different doses of cytarabine consolidation therapy followed by haploidentical hematopoietic Stem cell transplantation on low-risk and intermediate-risk acute …
  7809. therapy AND ALTERNATIVE TREATMENTS FOR PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA (MM) INELIGIBLE FOR Stem cell
  7810. Brentuximab Vedotin As Consolidation therapy Post Hematopoietic Stem cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma …
  7811. Treatment with mesenchymal Stem cells for xerostomia: a new paradigm in cell therapy
  7812. Intelligent photosensitive mesenchymal Stem cells and cell-derived microvesicles for photothermal therapy of prostate cancer
  7813. … the EpiX™ Technology–A Unique Solution that Unleashes the Potential of Tissue-Resident Epithelial Stem and Progenitor cells for Regenerative cell therapy
  7814. cell Biology and Translational Medicine, Volume 5: Stem cells: Translational Science to therapy
  7815. Protective effect of photobiomodulation therapy and bone marrow stromal Stem cells conditioned media on pheochromocytoma cell line 12 against oxidative …
  7816. Towards cell free therapy of premature ovarian insufficiency: human bone marrow mesenchymal Stem cells secretome enhances angiogenesis in human …
  7817. RPE tissue engineering based on human pluripotent Stem cells for cell therapy
  7818. Production of hepatocytes from human pluripotent Stem cells for cell-based therapy
  7819. Mesenchymal Stem/Stromal cell therapy during Pediatric Cardiac Surgery on Neurogenesis in the Porcine Subventricular Zone (P5. 6-055)
  7820. PANCREATIC β cell REGENERATION FROM HUMAN EMBRYONIC Stem cells AS A POSSIBLE therapy FOR TYPE 1 DIABETES
  7821. … transplantation in non-human primates of human muscle-derived Stem cells (MuStem cells), a promising candidate for cell therapy of muscular dystrophies
  7822. Induced pluripotent Stem cells: cell therapy in regenerative medicine and modeling of human disease
  7823. Human CD271+ Adipose-Derived Stem cells Possess Angiogenic Capacity Through Mediating M2-Dominant Macrophage Polarization in cell therapy
  7824. Comparison of CD44 expression in pancreatic cancer, pancreatic Stem and normal pancreatic cells: Development of CLENs for tumor targeting and therapy using cell
  7825. Inhibition of cancer Stem-like cells in esophageal squamous cell carcinoma with SOCS-1 gene therapy
  7826. … )/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer Stem
  7827. cell DISEASE TREATED UNDER A REVISED PROTOCOL WITH LENTIGLOBIN GENE therapy USING PLERIXAFOR-MOBILISED HAEMATOPOIETIC Stem
  7828. Genetically distinct glioma Stem-like cell xenografts established from paired glioblastoma samples harvested before and after molecularly targeted therapy
  7829. Correction: By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer Stem cells to hormonal therapy
  7830. Mesenchymal Stem cells: the cell replacement therapy for liver cirrhosis
  7831. Stem cells for the cell and Molecular therapy of Type 1 Diabetes Mellitus (T1D) between Lights and Shadows
  7832. Pluripotent Stem cell-based cell therapy—promise and challenges
  7833. Mesenchymal Stem cell therapy for COVID-19: present or future
  7834. Stem cell therapy for COVID‐19: Possibilities and challenges
  7835. Recent progress of Stem cell therapy in cancer treatment: molecular mechanisms and potential applications
  7836. An acute immune response underlies the benefit of cardiac Stem cell therapy
  7837. Mechanisms of cancer Stem cell therapy
  7838. The emerging antioxidant paradigm of mesenchymal Stem cell therapy
  7839. Stem cell therapy for Alzheimer’s disease
  7840. The potential of mesenchymal Stem cell therapy for chronic lung disease
  7841. Current progress in Stem cell therapy for type 1 diabetes mellitus
  7842. Progress in Stem cell therapy for spinal cord injury
  7843. Stem cell therapy for preventing neonatal diseases in the 21st century: current understanding and challenges
  7844. Mesenchymal Stem cell therapy for liver disease: full of chances and challenges
  7845. Combating COVID-19 with mesenchymal Stem cell therapy
  7846. Mesenchymal Stem cell therapy for acute respiratory distress syndrome: from basic to clinics
  7847. Stem cell therapy: old challenges and new solutions
  7848. Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis
  7849. Stem cell therapy in heart failure: Where do we stand today?
  7850. Mesenchymal Stem cell‐conditioned media: A novel alternative of Stem cell therapy for quality wound healing
  7851. Sequential paracrine mechanisms are necessary for the therapeutic benefits of Stem cell therapy
  7852. Human umbilical cord-derived mesenchymal Stem cell therapy in patients with COVID-19: a phase 1 clinical trial
  7853. Stem cell therapy for Parkinson’s disease: safety and modeling
  7854. Clinical trials of Stem cell therapy for cerebral ischemic stroke
  7855. Stem cell therapy for muscular dystrophies
  7856. Optimizing Stem cell therapy after ischemic brain injury
  7857. Stroke treatment: Is exosome therapy superior to Stem cell therapy?
  7858. The clinical efficacy and safety of Stem cell therapy for diabetes mellitus: a syStematic review and meta-analysis
  7859. Prospect of Stem cell therapy and regenerative medicine in osteoporosis
  7860. Recent advances in Stem cell therapy for limbal Stem cell deficiency: a narrative review
  7861. Stem cell-based disease modeling and cell therapy
  7862. Current and future directions of Stem cell therapy for bladder dysfunction
  7863. Feasibility of mesenchymal Stem cell therapy for COVID-19: a mini review
  7864. From the lab to patients: a syStematic review and meta-analysis of mesenchymal Stem cell therapy for stroke
  7865. Mesenchymal Stem cell therapy in severe COVID-19: A retrospective study of short-term treatment efficacy and side effects
  7866. Stem cell therapy as a treatment for osteogenesis imperfecta
  7867. Current status and future prospects of Stem cell therapy in Alzheimer’s disease
  7868. Stem cell therapy for COVID-19 and other respiratory diseases: Global trends of clinical trials
  7869. Current status of mesenchymal Stem cell therapy for immune/inflammatory lung disorders: Gleaning insights for possible use in COVID-19
  7870. A review on the Stem cell therapy and an introduction to exosomes as a new tool in reproductive medicine
  7871. Efficacy of Stem cell therapy for tendon disorders: a syStematic review
  7872. Recent trends in Stem cell therapy for premature ovarian insufficiency and its therapeutic potential: a review
  7873. Cardiopoietic Stem cell therapy in ischaemic heart failure: long‐term clinical outcomes
  7874. Can mesenchymal Stem cell therapy be the interim management of COVID-19?
  7875. Neural Stem cell therapy for neurovascular injury in Alzheimer’s disease
  7876. Stem cell therapy for Alzheimer’s disease
  7877. Stem cell therapy for diabetes: beta cells versus pancreatic progenitors
  7878. Stem cell therapy of myocardial infarction: a promising opportunity in bioengineering
  7879. An update on Stem cell therapy for Asherman syndrome
  7880. Efficacy of mesenchymal Stem cell therapy for sepsis: a meta-analysis of preclinical studies
  7881. Mesenchymal Stem cell therapy alleviates the neuroinflammation associated with acquired brain injury
  7882. Mesenchymal Stem cell therapy and Alzheimer’s disease: current status and future perspectives
  7883. Mesenchymal Stem cell therapy in acute kidney injury (AKI): review and perspectives
  7884. Inflammatory bowel disease: Therapeutic limitations and prospective of the Stem cell therapy
  7885. Efficacy of Stem cell therapy for burn wounds: a syStematic review and meta-analysis of preclinical studies
  7886. Cytoprotective effects of antioxidant supplementation on mesenchymal Stem cell therapy
  7887. Human mesenchymal Stem cell therapy for cartilage repair: review on isolation, expansion, and constructs
  7888. Ethical and practical considerations for integrating cellular (“Stem cell”) therapy into clinical practice
  7889. Cardiopoietic Stem cell therapy restores infarction-altered cardiac proteome
  7890. Replacing what’s lost: a new era of Stem cell therapy for Parkinson’s disease
  7891. Mesenchymal Stem cell therapy for sports injuries-From research to clinical practice
  7892. First-in-human high-cumulative-dose Stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline
  7893. Multifaceted application of nanoparticle-based labeling strategies for Stem cell therapy
  7894. Mesenchymal Stem cell therapy for liver fibrosis/cirrhosis
  7895. Prospect of Different Types of Magnetic Nanoparticles in Stem cell therapy
  7896. A safety consideration of mesenchymal Stem cell therapy on COVID-19
  7897. A syStematic review of human trials using Stem cell therapy for erectile dysfunction
  7898. Challenges in bone tissue regeneration: Stem cell therapy, biofunctionality and antimicrobial properties of novel materials and its evolution
  7899. Overview of Stem cell therapy for acute respiratory distress syndrome with focus on COVID 19
  7900. Stem cell therapy for osteonecrosis of femoral head: Opportunities and challenges
  7901. Clinical efficacy and safety of Stem cell therapy for knee osteoarthritis: a meta-analysis
  7902. Prenatal Stem cell therapy for inherited diseases: Past, present, and future treatment strategies
  7903. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury
  7904. Ventricular remodeling in ischemic heart failure stratifies responders to Stem cell therapy
  7905. Developing implantable scaffolds to enhance neural Stem cell therapy for post-operative glioblastoma
  7906. Biomechanical modulation therapy—a Stem cell therapy without Stem cells for the treatment of severe ocular burns
  7907. Targeting strategies for renal cancer Stem cell therapy
  7908. Regenerative potential of Wharton’s jelly‐derived mesenchymal Stem cells: A new horizon of Stem cell therapy
  7909. Stem cell therapy for neurodegenerative diseases: how do Stem cells bypass the blood-brain barrier and home to the brain?
  7910. Fetal surgery and Stem cell therapy for meningomyelocele
  7911. Therapeutic effect and safety of Stem cell therapy for chronic liver disease: a syStematic review and meta-analysis of randomized controlled trials
  7912. A nitric oxide-releasing hydrogel for enhancing the therapeutic effects of mesenchymal Stem cell therapy for hindlimb ischemia
  7913. Adipose-derived Stem cell therapy shows promising results for secondary lymphedema
  7914. Correlation between the efficacy of Stem cell therapy for osteonecrosis of the femoral head and cell viability
  7915. Limbal epithelial and mesenchymal Stem cell therapy for corneal regeneration
  7916. The application of Stem cell therapy and brown adipose tissue transplantation in metabolic disorders
  7917. Engineering of SPECT/photoacoustic imaging/antioxidative stress triple-function nanoprobe for advanced mesenchymal Stem cell therapy of cerebral ischemia
  7918. … of current position on cell therapy in transfusion science and medicine: from fictional promises to factual and perspectives from red cell substitution to Stem cell therapy
  7919. Advancing a Stem cell therapy for age-related macular degeneration
  7920. Chimeric antigen receptor T‐cell therapy as a bridge to haematopoietic Stem cell transplantation for refractory/relapsed B‐cell acute lymphoblastic leukemia
  7921. The effect of Stem cell therapy and comprehensive physical therapy in motor and non-motor symptoms in patients with multiple sclerosis: A comparative study
  7922. Potential of Stem cell therapy in intracerebral hemorrhage
  7923. Bioprocess Development for Human Mesenchymal Stem cell therapy Products
  7924. Mesenchymal Stem cell therapy for diabetic kidney disease: a review of the studies using syngeneic, autologous, allogeneic, and xenogeneic cells
  7925. Mesenchymal Stem cell therapy for osteoradionecrosis of the mandible: a syStematic review of preclinical and human studies
  7926. Prussian blue nanocubes as a multimodal contrast agent for image-guided Stem cell therapy of the spinal cord
  7927. Matrix-delivered autologous mesenchymal Stem cell therapy for refractory rectovaginal Crohn’s fistulas
  7928. Neural Stem cell therapy of foetal onset hydrocephalus using the HTx rat as experimental model
  7929. Mesenchymal Stem cell therapy using human umbilical cord in a rat model of autoimmune-induced premature ovarian failure
  7930. Stem cell therapy offers a possible safe and promising alternative approach for treating vitiligo: a review
  7931. Efficacy and Safety of Stem cell therapy for T1DM: An Updated SyStematic Review and Meta-Analysis
  7932. Advancing Stem cell therapy for repair of damaged lung microvasculature in amyotrophic lateral sclerosis
  7933. Autologous bone marrow-derived Stem cell therapy for Asherman’s syndrome and endometrial atrophy: a 5-year follow-up study
  7934. Autologous adipose Stem cell therapy for knee osteoarthritis: where are we now?
  7935. Mesenchymal Stem cell therapy improves erectile dysfunction in experimental spinal cord injury
  7936. Online direct-to-consumer advertising of Stem cell therapy for musculoskeletal injury and disease: misinformation and violation of ethical and legal advertising …
  7937. Enhancing the efficacy of Stem cell therapy with glycosaminoglycans
  7938. A review on Stem cell therapy for neuropathic pain
  7939. Is Stem cell therapy the new savior for cerebral palsy patients? A Review
  7940. Stem cell therapy in heart disease: limitations and future possibilities
  7941. Mesenchymal Stem cell therapy in chondral defects of knee: current concept review
  7942. Intraperitoneal injection of graphene oxide nanoparticle accelerates Stem cell therapy effects on acute kidney injury
  7943. Application of mesenchymal Stem cell therapy and inner ear regeneration for hearing loss: a review
  7944. A review of application of Stem cell therapy in the management of congenital heart disease
  7945. … -activated protein-based injectable adhesive hydrogel incorporated with decellularized adipose extracellular matrix for tissue-specific regenerative Stem cell therapy
  7946. A multicenter experience using adipose-derived mesenchymal Stem cell therapy for cats with chronic, non-responsive gingivostomatitis
  7947. Effects of mesenchymal Stem cell therapy on alopecia areata in cellular and hair follicle organ culture models
  7948. Sorafenib and Mesenchymal Stem cell therapy: A Promising Approach for Treatment of HCC
  7949. Blood-based biomarkers and Stem cell therapy in human stroke: a syStematic review
  7950. Patients’ expectations and experiences of Stem cell therapy for the treatment of knee osteoarthritis
  7951. Research Trends in the Efficacy of Stem cell therapy for Hepatic Diseases Based on MicroRNA Profiling
  7952. Stem cell therapy in brain ischemia: the role of mitochondrial transfer
  7953. Stem cell therapy improves heart function by triggering an acute immune response
  7954. Evaluation of autologous adipose-derived mesenchymal Stem cell therapy in focal chondral defects of the knee: a pilot case series
  7955. Healing the broken heart; the immunomodulatory effects of Stem cell therapy
  7956. Mechanisms underlying the protective effects of mesenchymal Stem cell-based therapy
  7957. Long-term follow-up of CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory acute lymphoblastic leukemia after allogeneic hematopoietic Stem cell
  7958. Current status of Regulatory perspectives on Stem cell therapy in India
  7959. Efficacy and safety of Stem cell therapy for the early-stage osteonecrosis of femoral head: a syStematic review and meta-analysis of randomized controlled …
  7960. Stem cell–based therapy for coronavirus disease 2019
  7961. Consolidative allogeneic hematopoietic Stem cell transplantation after chimeric antigen receptor T-cell therapy for relapsed/refractory B-cell acute …
  7962. Umbilical cord blood Stem cell therapy in premature brain injury: opportunities and challenges
  7963. Stemcell therapy as a Potential Strategy for Radiation-Induced Brain Injury
  7964. Hematogenous donor cell routing pathway after transamniotic Stem cell therapy
  7965. Human Umbilical Cord–Derived Mesenchymal Stem cell therapy Effectively Protected the Brain Architecture and Neurological Function in Rat After Acute Traumatic …
  7966. Combining growth factor and Stem cell therapy for stroke rehabilitation, a review
  7967. Treatment with shCCL20-CCR6 nanodendriplexes and human mesenchymal Stem cell therapy improves pathology in mice with repeated traumatic brain injury
  7968. A narrative review of research advances in mesenchymal Stem cell therapy for asthma
  7969. Value of mesenchymal Stem cell therapy for patients with septic shock: an early health economic evaluation
  7970. Mesenchymal Stem cell therapy can transcend perianal crohn’s disease: How colorectal surgeons can help in the coronavirus disease 2019 crisis
  7971. Stem cell therapy for neurogenic bladder after spinal cord injury: clinically possible?
  7972. Targeting cancer Stem cell pathways for cancer therapy
  7973. An overview of Stem cell therapy for paediatric heart failure
  7974. Nanomedicine in Cancer Stem cell therapy
  7975. Transamniotic mesenchymal Stem cell therapy for neural tube defects preserves neural function through lesion-specific engraftment and regeneration
  7976. Safety and efficacy of Stem cell therapy in patients with ischemic stroke
  7977. Stem celltherapy‘advertisements in China: Infodemic, regulations and recommendations
  7978. Intra-amniotic delivery of CRMP4 siRNA improves mesenchymal Stem cell therapy in a rat spina bifida model
  7979. Safety and efficacy of human adipose-derived stromal/Stem cell therapy in an immunocompetent murine pressure ulcer model
  7980. Initial mechanistic screening of transamniotic Stem cell therapy in the rodent model of spina bifida: host bone marrow and paracrine activity
  7981. Heat shock protein 27 as a neuroprotective biomarker and a suitable target for Stem cell therapy and pharmacotherapy in ischemic stroke
  7982. Improving human kidney function in renovascular disease with mesenchymal Stem cell therapy
  7983. Stem cell programs in cancer initiation, progression, and therapy resistance
  7984. Autologous bone-marrow mononuclear Stem cell therapy in patients with stroke: a meta-analysis of comparative studies
  7985. In vitro study of SDF-1α-loaded injectable and thermally responsive hydrogels for adipose Stem cell therapy by SDF-1/CXCR4 axis
  7986. Evaluation of mesenchymal Stem cell therapy for sepsis: a randomized controlled porcine study
  7987. Altered T-lymphocyte biology following high-dose melphalan and autologous Stem cell transplantation with implications for adoptive T-cell therapy
  7988. A biomarker for predicting responsiveness to Stem cell therapy based on mechanism-of-action: evidence from cerebral injury
  7989. Transcriptomic analysis of human mesenchymal Stem cell therapy in incontinent rat injured urethra
  7990. Historical aspects of gene therapy and Stem cell therapy in the treatment of hearing and balance disorder
  7991. Stem cell therapy and FUS [1‐359]‐transgenic mice: A recent study highlighting a promising ALS model and a promising therapy
  7992. Hydrogel‐Based Multifunctional Dressing Combining Magnetothermally Responsive Drug Delivery and Stem cell therapy for Enhanced Wound Healing
  7993. Congenital diaphragmatic hernia as a potential target for transamniotic Stem cell therapy
  7994. Effects of nicotine on the translation of Stem cell therapy
  7995. Mesenchymal Stem cell therapy for heart failure: A meta-analysis
  7996. A comparison between placental and amniotic mesenchymal Stem cells in transamniotic Stem cell therapy for experimental gastroschisis
  7997. Mircrining the injured heart with Stem cell-derived exosomes: an emerging strategy of cell-free therapy
  7998. Cytokine storm in COVID-19: An overview, mechanism, treatment strategies, and Stem cell therapy perspective
  7999. Donor mesenchymal Stem cell kinetics after transamniotic Stem cell therapy (TRASCET) in a rodent model of gastroschisis
  8000. … membrane vesicles of human umbilical cord mesenchymal Stem cells ameliorate acetaminophen-induced damage in HepG2 cells: a novel Stem cell therapy
  8001. Immunogenicity in Stem cell therapy for cardiac regeneration
  8002. Possible roles of epigenetics in Stem cell therapy for Parkinson’s disease
  8003. Application of nanotechnology in Stemcell-based therapy of neurodegenerative diseases
  8004. Liver damage in schistosomiasis is reduced by adipose tissue-derived Stem cell therapy after praziquantel treatment
  8005. Influence of bone marrow-derived mesenchymal Stem cell therapy on oxidative stress intensity in minimally conscious state patients
  8006. Stem cell therapy for neurogenic bladder dysfunction in rodent models: a syStematic review
  8007. … receptor T-cell therapy followed by radiotherapy for a recurrence of blastic plasmacytoid dendritic cell neoplasm after allogeneic hematopoietic Stem cell
  8008. Stem cell therapy for thromboangiitis obliterans (Buerger’s disease)
  8009. Peripheral Blood Stem cell therapy Does Not Improve Outcomes of Femoral Head Osteonecrosis With Cap‐Shaped Separated Cartilage Defect
  8010. Stem cell based therapy option in COVID-19: is it really promising?
  8011. Stem cell transplantation: a promising therapy for spinal cord injury
  8012. Status, challenges, and future prospects of Stem cell therapy in pelvic floor disorders
  8013. The efficacy of mesenchymal Stem cell therapy in experimental sepsis induced by carbapenem-resistant K. pneumoniae in neutropenic mice model
  8014. Advances in Stem cell therapy for the treatment of Peyronie’s disease
  8015. … (PET) for Assessment of Post Myocardial Infarction Angiogenesis as a Predictor for Left Ventricular Remodeling in Mice after Cardiac Stem cell therapy
  8016. Stem cell therapy: a potential for the perils of pancreatitis
  8017. Stemcell therapy for bronchopulmonary dysplasia
  8018. Challenges for mesenchymal Stem cell-based therapy for COVID-19
  8019. Some aspects of Stem cell therapy
  8020. Advances in Stem cell-based therapy for hair loss
  8021. RPE and Stem cell therapy
  8022. Multifunctional nanoparticles in Stem cell therapy for cellular treating of kidney and liver diseases
  8023. Stem cell therapy as a Treatment Method for Rheumatoid Arthritis
  8024. Mesenchymal Stem cell therapy combined with arthroscopic abrasion arthroplasty regenerates cartilage in patients with severe knee osteoarthritis: A case series
  8025. Polymeric biomaterial scaffolds for tumoricidal Stem cell glioblastoma therapy
  8026. Effect of autologous adipose-derived mesenchymal Stem cell therapy in the treatment of an osteochondral lesion of the ankle
  8027. Genetically modified mesenchymal Stem cells: The next generation of Stem cell-based therapy for TBI
  8028. What is the role of Stem cell therapy in the treatment of anal incontinence?
  8029. Mapping global research trends in Stem cell therapy for inflammatory bowel disease: a bibliometric analysis from 1991 to 2019
  8030. Role of liposomes-based Stem cell for multimodal cancer therapy
  8031. Arrhythmogenic risks of Stem cell replacement therapy for cardiovascular diseases
  8032. Mesenchymal Stem cell-derived extracellular vesicles: a novel cell-free therapy
  8033. The achievements and challenges of mesenchymal Stem cell-based therapy in inflammatory bowel disease and its associated colorectal cancer
  8034. Plasticity of cancer Stem cell: origin and role in disease progression and therapy resistance
  8035. Effect of SyStemic adipose-derived Stem cell therapy on functional nerve regeneration in a rodent model
  8036. Stem cell therapy and Hydrogen Sulfide: Conventional or Nonconventional Mechanisms of Action?
  8037. Adiponectin stimulates exosome release to enhance mesenchymal Stemcell-driven therapy of heart failure in mice
  8038. SOX2 for Stem cell therapy and Medical Use: Pros or Cons?
  8039. Stem cell therapy for Acute Myocardial Infarctions: A SyStematic Review
  8040. Stroke gets in your eyes: stroke-induced retinal ischemia and the potential of Stem cell therapy
  8041. Autologous haematopoietic Stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated …
  8042. Epithelial–mesenchymal transition programs and cancer Stem cell phenotypes: mediators of breast cancer therapy resistance
  8043. Stem cell research and therapy in India: General awareness for the public and Stem cell therapy providers
  8044. Clinical Efficacy and Safety of Stem cell-Based therapy in Treating Asherman Syndrome: A SyStem Review and Meta-Analysis
  8045. Preconditioning strategies to enhance neural Stem cell-based therapy for ischemic stroke
  8046. Hypoxia-mediated cancer Stem cell resistance and targeted therapy
  8047. Effectiveness of Stem cell therapy in the treatment of ovarian disorders and female infertility: a syStematic review
  8048. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous Stem cell transplantation and receive active therapy. A retrospective analysis of …
  8049. Pluripotent-Stemcell-derived hepatic cells: hepatocytes and organoids for liver therapy and regeneration
  8050. Promising impacts of mesenchymal Stem cell therapy in treatment of SARS-CoV-2 (COVID-19)
  8051. Mesenchymal Stem cell-derived exosome: A promising alternative in the therapy of Alzheimer’s disease
  8052. Stem cell therapy for Chronic and Advanced Heart Failure
  8053. … in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (Stem) cell (MSC) therapy—Achieving global consensus and …
  8054. Adoptive natural killer cell therapy: a human pluripotent Stem cell perspective
  8055. Introduction for Stem cell–Based therapy for Neurodegenerative Diseases
  8056. Stem cell therapy and Cats: What Do We Know at This Time
  8057. Curative options for sickle cell disease: haploidentical Stem cell transplantation or gene therapy?
  8058. Inflammatory mediators in glioma microenvironment play a dual role in gliomagenesis and mesenchymal Stem cell homing: implication for cellular therapy
  8059. … Working Party of the European Society for blood and marrow transplantation (EBMT) and the Spanish hematopoietic Stem cell transplantation and cell therapy
  8060. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic Stem cell transplant relapse
  8061. Nanoparticles for Stem cell therapy bioengineering in glioma
  8062. SyStematic review of platelet-rich plasma use in androgenetic alopecia compared with Minoxidil®, Finasteride®, and adult Stem cell-based therapy
  8063. SyStematic Review of Stemcell-Based therapy of Burn Wounds: Lessons Learned from Animal and Clinical Studies
  8064. … haematopoietic Stemcell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy
  8065. Stem cell therapy for pediatric traumatic brain injury
  8066. Pathogenesis of inflammatory bowel disease and mesenchymal Stem cell therapy: therapeutic application and existing problems
  8067. Mesenchymal Stem cell-derived extracellular vesicles: a novel cell-free therapy for sepsis
  8068. Current Status of Stem cell therapy for Sepsis and Acute Respiratory Distress Syndrome
  8069. A Comparative Study of Novel Stem cell therapy-Based Treatments for Diabetic Foot Ulcers
  8070. Importance of Stem cell migration and angiogenesis study for regenerative cell-based therapy: a review
  8071. Hematopoietic Stem cell gene therapy: The optimal use of lentivirus and gene editing approaches
  8072. cellular therapy of corneal epithelial defect by adipose mesenchymal Stem cell-derived epithelial progenitors
  8073. Autologous fractionated adipose tissue as a natural biomaterial and novel one-step Stem cell therapy for repairing articular cartilage defects
  8074. Impact of ultrasound therapy on Stem cell differentiation-a syStematic review
  8075. Establishment of a Rapid Lesion-Controllable Retinal Degeneration Monkey Model for Preclinical Stem cell therapy
  8076. Human artificial chromosomes for pluripotent Stem cell-based tissue replacement therapy
  8077. … of an ongoing phase I trial of FT500, a first-in-class, off-the-shelf, induced pluripotent Stem cell (iPSC) derived natural killer (NK) cell therapy in advanced solid …
  8078. The effect of Stem cell transplantation therapy for post viral chronic liver cell failure on associated type II diabetes mellitus: a pilot study
  8079. A nano-based thermotherapy for cancer Stem cell-targeted therapy
  8080. Melatonin preconditioning is an effective strategy for mesenchymal Stem cell‐based therapy for kidney disease
  8081. Research and development strategy for future embryonic Stem cell-based therapy in Japan
  8082. Safety and efficacy of a mesenchymal Stem cell intramammary therapy in dairy cows with experimentally induced Staphylococcus aureus clinical mastitis
  8083. Acute graft-versus-host disease after humanized anti-CD19-CAR T therapy in relapsed B-ALL patients after allogeneic hematopoietic Stem cell transplant
  8084. Trends and targets of various types of Stem cell derived transfusable RBC substitution therapy: Obstacles that need to be converted to opportunity
  8085. Stem cell‐Derived Liver cells: From Model SyStem to therapy
  8086. … artery transplantation of bone marrow-derived NCS-01 cells for ischemic stroke: Behavioral and histological readouts and mechanistic insights into Stem cell therapy
  8087. Stromal cell-derived factor-1 (SDF-1) expression in very preterm human lungs: Potential relevance for Stem cell therapy for bronchopulmonary dysplasia
  8088. Suppression of inflammation and fibrosis using soluble epoxide hydrolase inhibitors enhances cardiac Stem cell-based therapy
  8089. Haematopoietic Stem cell gene therapy with IL‐1Ra rescues cognitive loss in mucopolysaccharidosis IIIA
  8090. Intravitreal Stem cell paracrine properties as a potential neuroprotective therapy for retinal photoreceptor neurodegenerative diseases
  8091. A combined approach to intracerebral hemorrhage: intravenous mesenchymal Stem cell therapy with minimally invasive hematoma evacuation
  8092. Comparison of Different Culture Conditions for Mesenchymal Stem cells from Human Umbilical Cord Wharton’s Jelly for Stem cell therapy
  8093. Ubiquitination in cancer Stem cell: roles and targeted cancer therapy
  8094. Stem cell-based delivery of gold/chlorin e6 nanocomplexes for combined photothermal and photodynamic therapy
  8095. Challenges and translational considerations of mesenchymal Stem/stromal cell therapy for Parkinson’s disease
  8096. Sequential scalp assessment in hair regeneration therapy using an adipose-derived Stem cell–conditioned medium
  8097. The roles of nanoparticles in Stem cell-based therapy for cardiovascular disease
  8098. Lentiviral hematopoietic Stem cell gene therapy corrects murine Pompe disease
  8099. Amniotic fluid and breast milk: a rationale for breast milk Stem cell therapy in neonatal diseases
  8100. Physical training prior to myocardial infarction potentializes Stem cell therapy, SDF-1/CXCR4 axis activation and inhibits the vasoconstrictor response in hypertensive …
  8101. … the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and Stem cell
  8102. Sequential response-driven bortezomib-based therapy followed by autologous Stem cell transplant in AL amyloidosis
  8103. Stem cell therapy, ophthalmic applications, and the current controversies with direct-to-consumer marketing
  8104. De novo modeling and structural characterization of IL9-IL9 receptor complex: A potential drug target for hematopoietic Stem cell therapy
  8105. Curative in vivo hematopoietic Stem cell gene therapy of murine thalassemia using large regulatory elements
  8106. Mesenchymal Stem cell-Based therapy for Allergic Rhinitis
  8107. Improving mesenchymal Stem/stromal cell potency and survival: Proceedings from the International Society of cell therapy (ISCT) MSC preconference held in May …
  8108. … epithelial-to-mesenchymal transition and cancer Stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary syStemic therapy
  8109. Hematopoietic Stem cell Gene therapy for Brain Metastases Using Myeloid cell–Specific Gene Promoters
  8110. The Future of Brain Repair: A Realist’s Guide to Stem cell therapy
  8111. Cxcr6-based mesenchymal Stem cell gene therapy potentiates skin regeneration in murine diabetic wounds
  8112. Nelarabine as salvage therapy and bridge to allogeneic Stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia …
  8113. Stem cell therapy for stress urinary incontinence
  8114. CXCR4 antagonists as Stem cell mobilizers and therapy sensitizers for acute myeloid leukemia and glioblastoma?
  8115. The anti-scarring effect of corneal stromal Stem cell therapy is mediated by transforming growth factor β3
  8116. Still’dwelling in the possibility’-critical update on Stem cell therapy for acute on chronic liver failure
  8117. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic Stem cell transplantation
  8118. AL amyloidosis: the effect of maintenance therapy on autologous Stem cell transplantation outcomes
  8119. Clinical-grade human pluripotent Stem cells for cell therapy: characterization strategy
  8120. Future challenges and perspectives for Stem cell therapy of neurodegenerative diseases
  8121. A current update in COVID-19 associated acute respiratory distress syndrome: Focus on mesenchymal Stem cell therapy
  8122. Autoimmune cytopenias following allogeneic hematopoietic Stem cell transplant in pediatric patients: Response to therapy and late effects
  8123. Novel Players and a Target of Stem cell therapy for the Heart
  8124. CD38-directed CAR-T cell therapy: A novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic Stem cell transplantation
  8125. CORR synthesis: what is the evidence for the clinical use of Stem cell-based therapy in the treatment of osteoarthritis of the knee?
  8126. Autologous hematopoietic Stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
  8127. Stem cell therapy in Wound Care
  8128. Stem cell derived exosomes-based therapy for acute lung injury and acute respiratory distress syndrome: a novel therapeutic strategy
  8129. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post–autologous Stem cell transplantation
  8130. Comparison between the Effect of Hyaluronic Acid and Mesenchymal Stem cell therapy on Cornea of Adult Albino Rats after Exposure to Alkali Burn (Light and …
  8131. Prospect of Stem cell therapy to avoid cytokine storm in severe covid-19
  8132. Postnatal fate of donor mesenchymal Stem cells after transamniotic Stem cell therapy in a healthy model
  8133. cellular therapy in Follicular Lymphoma: Autologous Stem cell Transplantation, Allogeneic Stem cell Transplantation, and Chimeric Antigen Receptor T-cell therapy
  8134. Stem cell-based therapy for Neurodegenerative Diseases
  8135. Stem cell membrane–camouflaged bioinspired nanoparticles for targeted photodynamic therapy of lung cancer
  8136. Stem cell transplantation therapy: a potential method for treating cytokine storm syndromes induced by COVID-19
  8137. Editorial Commentary: Are We Ready to Apply Stem cell therapy in Rotator Cuff Tear Surgery?
  8138. Cardiac Stem cell therapy among Clinics of Uncertain Regulatory Status (COURS): under-regulated, under-observed, incompletely understood
  8139. Stem cell membrane-coated Au-Ag-PDA nanoparticle-guided photothermal acne therapy
  8140. Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic Stem cell transplant recipient
  8141. … induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous Stem cell
  8142. Identification of AAV serotypes for lung gene therapy in human embryonic Stem cell-derived lung organoids
  8143. Stem cell therapy in Orthopedics
  8144. … life of first-line haploidentical hematopoietic Stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe …
  8145. Stem cell therapy for Parkinson’s disease
  8146. … antibody tocilizumab as salvage therapy in severe chronic graft-versus-host disease after allogeneic hematopoietic Stem cell transplantation: a retrospective …
  8147. Prophylactic in vivo hematopoietic Stem cell gene therapy with an immune checkpoint inhibitor reverses tumor growth in syngeneic mouse tumor models
  8148. Mesenchymal Stem cell-based Smad7 gene therapy for experimental liver cirrhosis
  8149. Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic Stem cell transplantation for refractory hemophagocytic lymphohistiocytosis
  8150. … effectiveness of treatment strategy of tandem high‐dose chemotherapy and autologous Stem cell transplantation in combination with 131I‐MIBG therapy for high‐risk …
  8151. Epigenetic Research in Stem cell Bioengineering—Anti-Cancer therapy, Regenerative and Reconstructive Medicine in Human Clinical Trials
  8152. Polydopamine nanoparticles camouflaged by Stem cell membranes for synergistic chemo-photothermal therapy of malignant bone tumors
  8153. Transplantation site affects the outcomes of adipose-derived Stem cell-based therapy for retinal degeneration
  8154. Human CD34+ hematopoietic Stem cells culture in humanized culture medium for cell therapy
  8155. Promise of autologous CD34+ Stem/progenitor cell therapy for treatment of cardiovascular disease
  8156. therapy with donor-derived Human Cytomegalovirus (HCMV)–specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic Stem
  8157. Role of natural cellulose and hydrogel matrices in Stem cell therapy of diabetic foot ulcer
  8158. … landmark treatment methods—allogeneic hematopoietic Stem cell transplantation and chimeric antigen receptor T cell therapy together to cure high-risk B cell
  8159. On Our Doorstep, A Precious Cargo From MSCs: The Role of Extracellular Vesicles in Stem cell therapy
  8160. Bone marrow stromal cells induce an ALDH+ Stem cell-like phenotype and enhance therapy resistance in AML through a TGF-β-p38-ALDH2 pathway
  8161. A combinational therapy of articular cartilage defects: rapid and effective regeneration by using Low-Intensity focused ultrasound after adipose tissue-derived Stem cell
  8162. The role of the Stem cell epigenome in normal aging and rejuvenative therapy
  8163. … donors in hematopoietic Stem cell transplantation. A real world experience from the Argentine Group For Bone Marrow Transplantation And cell therapy (GATMO-TC …
  8164. Personalized therapy and Stem cell transplantation for pro-inflammatory modulation of cancer Stem cells microenvironment in glioblastoma
  8165. Potential survival benefit for patients receiving allogeneic hematopoietic Stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin …
  8166. Author Correction: Intravenous C16 and angiopoietin-1 improve the efficacy of placenta-derived mesenchymal Stem cell therapy for EAE
  8167. Maintenance therapy with decitabine after allogeneic hematopoietic Stem cell transplantation to prevent relapse of high-risk acute myeloid leukemia
  8168. Photobiomodulation and Stem cell therapy for Temporomandibular Joint Disc Disorders
  8169. Upfront autologous hematopoietic Stemcell transplantation improves overall survival in comparison with bortezomib-based intensification therapy in newly …
  8170. LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem cell Population during Temozolomide therapy in Glioblastoma
  8171. CDK5 Inhibition Abrogates TNBC Stemcell Property and Enhances Anti‐PD‐1 therapy
  8172. Tolerability and efficacy of treatment with azacytidine as prophylactic or preemptive therapy for myeloid neoplasms after allogeneic Stem cell transplantation
  8173. RETRACTED ARTICLE: High-dose therapy and autologous Stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
  8174. Photobiomodulation therapy improves human dental pulp Stem cell viability and migration in vitro associated to upregulation of histone acetylation
  8175. Stem cell transplantation therapy for retinal degenerative diseases
  8176. Mesenchymal Stem cell therapy improves pulmonary function and exercise tolerance in patients with chronic obstructive pulmonary disease (copd) and high baseline …
  8177. Autologous Mesenchimal Stem cell therapy in Patients with Unexplainable Low Ovarian Response
  8178. Preclinical development of autologous hematopoietic Stem cell-based gene therapy for immune deficiencies: a journey from mouse cage to bed side
  8179. 89Zr-Labeled Multifunctional Liposomes Conjugate Chitosan for PET-Trackable Triple-Negative Breast Cancer Stem cell Targeted therapy
  8180. Successful chimeric antigen receptor T cells therapy in extramedullary relapses of acute lymphoblastic leukemia after allogeneic hematopoietic Stem cell
  8181. In vitro generation of red blood cells from Stem cell and targeted therapy
  8182. Clinical profiles and outcomes of patients with neurological diseases treated with Stem cell therapy: a single-center experience in the Philippines
  8183. Comparison of frontline treatment with intensive immunosuppression therapy and HLA-haploidentical hematopoietic Stem cell transplantation for young patients with …
  8184. Convalescent plasma and mesenchymal Stem cell therapy
  8185. … Outcomes Following Donor-Derived Anti-CD19 CAR-T cell therapy for B-cell Acute Lymphoblastic Leukemia Patients Relapsed after Allogenic Stem cell
  8186. Mechanistic underpinnings of Stem cell therapy for neurological disorders
  8187. Hepatic focal nodular hyperplasia after pediatric hematopoietic Stem cell transplantation: The impact of hormonal replacement therapy and iron overload
  8188. Functional and histological evaluation of bone marrow Stem cell-derived exosomes therapy on the submandibular salivary gland of diabetic Albino rats …
  8189. Establishment of a novel fetal growth restriction model and development of a Stemcell therapy using umbilical cord-derived mesenchymal stromal cells
  8190. … and pathways in macrophages responsible for the Th1/Th17 inflammatory condition of Periodontal infection that can be candidates in Stem cell therapy of the disease.
  8191. Allogeneic donor-derived anti-CD19 CAR T cell is a promising therapy for relapsed/refractory B-ALL after allogeneic hematopoietic Stemcell transplantation
  8192. Stem cell therapy for Acute Respiratory Distress Syndrome: There Are Certain Things That Should Be Done and Should Not Be Done
  8193. Encapsulation of Mesenchymal Stem cells: Dissecting the Underlying Mechanism of Mesenchymal Stem cell Transplantation therapy
  8194. … refractory classical hodgkin lymphoma who relapsed after salvage autologous Stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup …
  8195. Nephroprotective effect of mesenchymal Stem cell-based therapy of kidney disease induced by toxicants
  8196. Evaluating the clinical effectiveness of autologous haematopoietic Stem cell transplantation versus disease-modifying therapy in multiple sclerosis using a matching …
  8197. Clinical applicability of adult human mesenchymal Stem cell therapy in the treatment of knee osteoarthritis
  8198. Allogeneic Stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste
  8199. Influence of Organismal Aging in Mesenchymal Stem cell therapy
  8200. Cancer Stem cell as Target of CAR-T cell therapy
  8201. A neural crest Stem cell-like state drives nongenetic resistance to targeted therapy in melanoma
  8202. Modeling and Analyzing Stemcell therapy toward Cancer: Evolutionary Game Theory Perspective
  8203. Development of Effective Stem cell therapy by cell Surface Modification
  8204. … is necessary to ameliorate central nervous syStem involvement of murine model of mucopolysaccharidosis type II by hematopoietic Stem cell targeted gene therapy
  8205. … Megatherapy with Autologous Stem cell Transplantation in Children with Relapsing or therapy-Resistant Extracranial Germ-cell Tumors—A Retrospective Analysis
  8206. Treating primary immunodeficiencies with defects in NK cells: from Stem cell therapy to gene editing
  8207. therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood Stem cell
  8208. Effects of hormone replacement therapy on bone mass after allogeneic hematopoietic Stem cell transplantation
  8209. Lentiviral hematopoietic Stem cell gene therapy rescues clinical phenotypes in a murine model of Pompe disease
  8210. Mesenchymal Stem cell therapy maximizes lung preservation by preventing ischemic organ injury
  8211. Analyzing the Effectiveness of Adipose Tissue Stem cell and Microvesicle therapy in Premature Skin Aging Caused by Chronic Exposure to Ultraviolet Radiation
  8212. Improvement in viability and mineralization of osteoporotic bone marrow mesenchymal Stem cell through combined application of photobiomodulation therapy and …
  8213. Decision-analytic modeling as a tool for selecting optimal therapy incorporating hematopoietic Stem cell transplantation in patients with hematological malignancy
  8214. Outcome and risk factors for therapy-related myeloid neoplasms treated with allogeneic Stem cell transplantation in Japan
  8215. Infection prophylaxis patterns following pediatric autologous hematopoietic Stem cell transplantation: A survey of Pediatric Transplant and cell therapy Consortium …
  8216. Impact of preemptive therapy for cytomegalovirus on hospitalizations and cost after hematopoietic Stem cell transplantation
  8217. Lung adenocarcinoma resistance to therapy with EGFR‑tyrosine kinase inhibitors is related to increased expression of cancer Stem cell markers SOX2, OCT4 …
  8218. Pluripotent Stem cell Modeling of Anticancer therapy–Induced Cardiotoxicity
  8219. Mouse models in hematopoietic Stem cell gene therapy and genome editing
  8220. Exploring the potential of mesenchymal Stem cell-based therapy in mouse models of vascular cognitive impairment
  8221. Mesenchymal Stem cell therapy—Is the Vessel Half Full or Half Empty?
  8222. … experience and quality of life of children and adolescents undergoing hematopoietic Stem cell transplantation compared to chimeric antigen receptor T-cell therapy
  8223. Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous Stemcell transplantation
  8224. Immortalized Stem cell-derived hepatocyte-like cells: An alternative model for studying dengue pathogenesis and therapy
  8225. Intra-articular xenogeneic mesenchymal Stem cell-based therapy increases CD4+ CD25+ cells in synovial fluid
  8226. Update of a phase II study of lenalidomide-elotuzumab as maintenance therapy post-autologous Stem cell transplant (AuSCT) in patients (pts) with multiple …
  8227. Anti-inflammatory exosomes mediate the beneficial effect of mesenchymal Stem cell therapy on lung preservation
  8228. … of autologous hematopoietic Stem cell transplantation with gene addition therapy for transfusion-dependent β-thalassemia, sickle cell disease, and cerebral …
  8229. Immune dysregulation in HFpEF: a target for mesenchymal Stem/stromal cell therapy
  8230. Lines of therapy before Autologous Stem cell Transplant (ASCT) and CAR-T Infusion Affect Outcomes in Aggressive Non-Hodgkin’s Lymphoma (NHL)
  8231. Effect of autologous adipose-derived mesenchymal Stem cell therapy in combination with autologous platelet-rich plasma in the treatment of elbow tendinopathy
  8232. … and quality of life experienced by children undergoing Hematopoietic Stem cell Transplantation or Chimeric Antigen Receptor T-cell therapy: an argument for …
  8233. CD34 cells in somatic, regenerative and cancer Stem cells: developmental biology, cell therapy, and omics big data perspective
  8234. Phospholipase Cγ signaling in bone marrow Stem cell and relevant natural compounds therapy
  8235. (NNN03) Preliminary Cognitive Outcomes Following Mesenchymal Stem cell therapy in Multiple Sclerosis.
  8236. Personalized Stem cell-based therapy for degenerative retinal diseases
  8237. Lines of therapy in patients with relapsed or refractory large B-cell lymphoma and Stem cell transplant-intended treatment
  8238. A novel Stem cell therapy for hepatitis B virus-related acute-on-chronic liver failure
  8239. Xenogeneic and Stem cell-based therapy for cardiovascular diseases: genetic engineering of porcine cells and their applications in heart regeneration
  8240. Umbilical Cord Derived Mesenchymal Stem cell therapy for Osteoarthritis: A Consolidated Review
  8241. cell therapy with mesenchymal Stem cells induces an innate immune memory response that attenuates experimental colitis in the long term
  8242. Stem cell therapy in improving the motor function of patients with cerebral palsy: SyStematic review with meta-analysis.
  8243. Towards Biology-Driven Strategies for Stem cell therapy Applications
  8244. EXTH-52. GLIOBLASTOMA-TARGETING AUTOLOGOUS INDUCED NEURAL Stem cell therapy: EVALUATING SAFETY, TOXICITY, PERSISTENCE, AND …
  8245. Cerebrospinal fluid (CSF) exchange therapy with artificial CSF enriched with mesenchymal Stem cell secretions ameliorates cognitive deficits and brain pathology in …
  8246. The effect of autologous adipose derived mesenchymal Stem cell therapy on juvenile osteochondritis dissecans of the patella: a case study
  8247. … as post-autologous Stem cell transplant maintenance therapyin patients with multiple myeloma (MM) using minimal residual disease todirect therapy duration …
  8248. Willingness of volunteers from Canadian Blood Service’s Stem cell Registry to donate blood, marrow, and other tissues for regenerative therapy
  8249. Postremission therapy with repeated courses of high‐dose cytarabine, idarubicin, and limited autologous Stem cell support achieves a very good long‐term outcome …
  8250. Hematological Findings in COVID-19 and Insights to Stem cell therapy: From Bench to Practice
  8251. Calcium sensing receptor involving in therapy of embryonic Stem cell transplantation alleviates acute myocardial infarction by inhibiting apoptosis and …
  8252. The genetically-engineered Stem cell therapy of huntington disease: spt4 knockout hd patient ipsc-npcs transplantation rescue abnormal neuronal dysfunction in the …
  8253. Corneal Stem cells as a source of regenerative cell-based therapy
  8254. Stem cell therapy for Vascular Diseases: State of the Evidence and Clinical Applications
  8255. INSPIRE Neuro-Spinal Scaffold™: An Implantable Alternative to Stemcell therapy for Endogenous Repair in Spinal Cord Injury
  8256. Effective hematopoietic Stem cell-based gene therapy in a murine model of hereditary pulmonary alveolar proteinosis
  8257. Stem cell therapy for Brain Injury
  8258. Sticky bone-specific artificial extracellular matrix for Stem cell-mediated rapid craniofacial bone therapy
  8259. … acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic Stem cell transplantation can improve …
  8260. … Phase I Study of Allogeneic Mesenchymal Stem cell therapy in Patients with Heart Failure Secondary to Anthracycline-induced Cardiomyopathy: The Cctrn Stem cell
  8261. Optimising process quality and cost for closed, automated and commercial scale manufacture of allogeneic Stem cell therapy products
  8262. A long-term response to allogeneic hemopoietic Stem cell transplantation from haploidentical donor and post-transplant therapy in an adolescent with primary …
  8263. POTENTIAL OF Stem cell therapy IN TREATMENT OF PARKINSON’S DISEASE
  8264. Introduction and Basic Concepts in Stem cell Research and therapy: The Facts and the Hype
  8265. Effectiveness of the Structures Teaching Programme on Stem cell therapy
  8266. Faculty ofPostgraduate Childhood Studies, Faculty ofMedicine-Ain Shams University, Cairo, Egypt Stem cell therapy Group Vienna Medical University of …
  8267. New-onset post-transplant diabetes and therapy in long-term survivors after allogeneic hematopoietic Stem cell transplantation
  8268. Human Umbilical Cord-Derived Mesenchymal Stem cell therapy in COVID-19 Patients: A Phase 1 Clinical Trial
  8269. SIRT3 Transfection of Aged Human Bone Marrow-Derived Mesenchymal Stem cells Improves cell therapy-Mediated Myocardial Repair
  8270. Stem cell therapy in knee osteoarthritis
  8271. Mesenchymal Stem cell-Mediated therapy of Peripheral Artery Disease Is Stimulated by a Lamin A-Progerin Binding Inhibitor
  8272. Autologous Stem cell therapy for Cerebral Palsy
  8273. … of cytomegalovirus DNAemia blips in allogeneic hematopoietic Stem cell transplant recipients: Implications for optimization of preemptive antiviral therapy
  8274. … Myeloablative Conditioning before Allogeneic Hematopoietic Stem cell Transplantation: A Multicenter Analysis from the Kanto Study Group for cell therapy
  8275. Elotuzumab-based maintenance therapy following autologous Stem cell transplant in multiple myeloma deepens post-transplant responses
  8276. Hyperbaric oxygen therapy of an adolescent Stem cell transplantation recipient with hemorrhagic cystitis and BK virus
  8277. Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic Stem cell-derived cardiomyocytes
  8278. Stem cell therapy in Treating Type 1 Diabetes Mellitus–Potential and Ethical Issues.
  8279. Feasibility of Stem cell therapy for renal ischemia/reperfusion injury: a syStematic review based on animal experiments
  8280. Implications of Stem cell therapy in Cancer Treatment
  8281. Is Stem cell therapy the New Savior for Cerebral Palsy Patients? A Review
  8282. Therapeutic effect of autologous bone marrow Stem cell mobilization combined with anti-infective therapy on moyamoya disease
  8283. Transcriptional Analysis Reveals Alteration of Lung Macrophages Following Mesenchymal Stem cell therapy in Neonatal Mice With Hyperoxia-Induced Injury
  8284. Concerns About Mesenchymal Stem cell therapy
  8285. CHAPTER Stem cell therapy for Psychiatric Disorders
  8286. Stem cell therapy for dilated cardiomyopathy: syStematic review of the existing data and ongoing trials
  8287. Best available therapy versus autologous hematopoietic Stem cell transplantation for multiple sclerosis
  8288. Important considerations for cell therapy manufacturing of mesenchymal Stem cell
  8289. Case report: Effect of autologous adipose-derived mesenchymal Stem cell therapy in combination with autologous platelet-rich plasma in the treatment of …
  8290. Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent Stem cells‐derived hepatic Stem cells
  8291. DOP85 The role of fibroblasts in the pathogenesis of Crohn’s disease-associated fistulas and in mesenchymal Stem cell therapy
  8292. Imaging of Stem cell therapy in Acute Respiratory Distress Syndrome in sheep and its relationship with histopathology
  8293. Antitumor effect of cell therapy with mesenchymal Stem cells on murine melanoma B16-F10
  8294. Present and future challenge for the use of Stem cell in hematopoietic transplantation and cell therapy
  8295. Human placental-derived Stem cell therapy ameliorates experimental necrotizing enterocolitis and supports restoration of the intestinal Stem cell niche
  8296. Combining cell therapy with Autologous Schwann cell and Bone Marrow-derived Mesenchymal Stem cell in Patients with Subacute Complete Spinal Cord …
  8297. Stem cell therapy for Your Brain
  8298. Stem cell therapy for non-obstructive azoospermia
  8299. Autologous hematopoietic Stem cell transplantation for syStemic sclerosis: Position statement of the Stem cell therapy working party of the German Society of …
  8300. 213. Study comparing NTG-101, a growth factor-based therapy with mesenchymal Stem cell (MSC) based treatment of degenerative disc disease (DDD) in pre-clinical …
  8301. Stem cell therapy: cell‐Based therapy for Canavan Disease Using Human iPSC‐Derived NPCs and OPCs (Adv. Sci. 23/2020)
  8302. Outcomes of therapy‐related acute lymphoblastic leukemia in adults after allogeneic Stem cell transplantation
  8303. Stem cell therapy as an Alternative for Osteoarthritis of the Knee
  8304. Mesenchymal Stem cells could be considered as a candidate for further studies in cell-based therapy of Alzheimer’s disease via targeting the signaling pathways
  8305. Maintenance therapy following salvage autologous Stem cell transplant in patients with multiple myeloma
  8306. In horses with osteoarthritis, is mesenchymal Stem cell therapy more effective at managing lameness than intra-articular corticosteroids?
  8307. An In Vitro study to investigate the effects of Stem cell therapy for treating Osteoarthritis
  8308. Healing a Broken Heart: Can Stem cell and Gene therapy Regenerate and Repair the Myocardium?
  8309. Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem cell Transplantation With Biomodulatory therapy
  8310. Mesenchymal Stem cell therapy for Traumatic Brain Injury
  8311. Postnatal Fate of Donor Mesenchymal Stem cells after Transamniotic Stem cell therapy
  8312. Mesenchymal Stem cell therapy for Severe Sepsis and Septic Sock.
  8313. Should Mesenchymal Stem cell therapy be used in the treatment of COVID-19?
  8314. Stem cell therapy IN COMMUNICATION DISORDERS
  8315. Comparison of breakthrough Gram‐positive cocci infection during vancomycin vs teicoplanin therapy in patients receiving haematopoietic Stem cell transplantation
  8316. Novel Application Method for Mesenchymal Stem cell therapy Utilizing Its Attractant-Responsive Accumulation Property
  8317. Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic Stem cell transplantation: a prospective …
  8318. Stem cell therapy as a potential therapy for Duchenne muscular dystrophy.
  8319. In Reply to the Letter to the Editor Regarding” Bibliometric and Visualized Analysis of Stem cell therapy for Spinal Cord Injury Based on Web of Science and …
  8320. AUTOLOGOUS Stem cell therapy FOR SINGLE RIGHT VENTRICULAR DYSFUNCTION AFTER FONTAN OPERATION: PHASE I SAFETY AND FEASIBILITY …
  8321. Stem cell therapy in Diabetes-Techniques and its therapeutic potential
  8322. Retraction Note to: high-dose therapy and autologous Stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey
  8323. Stem cell therapy: Differences between expanded cells, adipose tissue preparations, bone marrow aspirates
  8324. Platelet-rich plasma therapy enhances the beneficial effect of bone marrow Stem cell transplant on endometrial regeneration
  8325. Stem cell therapy: A Breakthrough in Diabetes Mellitus
  8326. The impact of Stem cell therapy in chronic ischaemic heart disease and congestive heart failure: an updated cochrane syStematic review and meta-analysis of …
  8327. Relapse Management and Role for Consolidative Hematopoietic Stem cell Transplantation Following CAR T-cell therapy
  8328. Stem cell therapy modulates inflammasome signaling in stroke: Possible involvement of Mitochondria?(1588)
  8329. Stem cell therapy for Ischemic Heart Disease: Clinical Use
  8330. Owner of a Broken Heart: Stem cell therapy, Inflammation, and Wound Healing in the Infarcted Heart
  8331. Stem cell therapy for osteogenesis imperfecta: a syStematic review and meta-analysis of preclinical studies using mouse models
  8332. An acute immune response underlies the benefit of cardiac Stem cell therapy
  8333. Successful salvage treosulfan-based megachemotherapy with allogeneic Stem cell transplantation in nonsyndromic, therapy-resistant disseminated juvenile …
  8334. MiRNA Mediated Stem cell therapy for Cardiac Arrhythmia
  8335. Unique anabolic action of Stem cell gene therapy overexpressing PDGFB-DSS6 fusion protein in OVX osteoporosis mouse model
  8336. Recent Advances in Stem cell therapy for Limbal Stem cell Deficiency: A Narrative Review
  8337. Mesenchymal Stem cell‐conditioned media: A novel alternative of Stem cell therapy for quality wound healing
  8338. Concept formation of non-expansion technology in Stem cell therapy and its application prospect
  8339. Enhancing the therapeutic potential of mesenchymal Stem cell-based therapy via CRISPR/Cas9-based genome editing
  8340. Stemcell therapy for musculoskeletal conditions
  8341. Regression of renal amyloid deposits by VAD therapy plus autologous Stem cell transplantation in a patient with primary AL amyloidosis
  8342. Nicotine does not affect Stem cell properties requisite for suicide gene therapy against glioma
  8343. A Review of Mesenchymal Stem cell therapy for Severe SARS-CoV-2 Infection
  8344. TURNITIN Stem cell therapy: ITS LEGALITY IN THE PERSPECTIVES OF INDONESIAN LAW AND PROGRESSIVE ISLAMIC JURISPRUDENCE
  8345. Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and Stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas
  8346. … t (9; 11) translocation presenting as blueberry muffin baby: successful treatment by ALL-BFM induction therapy, allogeneic Stem cell transplantation from an …
  8347. Successful Anti-TNF-Alpha therapy for Crohn’s Disease After Allogeneic Stem cell Transplantation: A Case Report
  8348. Pluripotent Stem cell–Derived Islet Replacement therapy for Diabetes
  8349. Wound Healing: Hydrogel‐Based Multifunctional Dressing Combining Magnetothermally Responsive Drug Delivery and Stem cell therapy for Enhanced Wound …
  8350. Athersys Stem cell therapy Targets Top Cause of COVID-19 Deaths: Chairman and CEO Gil Van Bokkelen, PhD, Discusses BARDA’s “Highly Relevant” Designation …
  8351. Stem cell based therapy option in COVID-19: is it really promising?
  8352. Mesenchymal Stem cell therapy for hip osteoarthritis: a syStematic review
  8353. Safety and Ethical Issues in Mesenchymal Stem cell therapy
  8354. Stem cell therapy for Muscular Dystrophy 2020
  8355. Stem cell therapy for Burn Victims–As a Fast Growing Modality of Treatment
  8356. PICU Admission Rates in Pediatric Cancer and Hematopoietic Stem cell Transplant Patients Receiving High-flow Nasal Cannula Oxygen therapy on the General …
  8357. Allogeneic Stem cell therapy for cardiac repair and host immune response
  8358. Pilot study of Stem cell therapy in Heart Failure Patients
  8359. Analysis of the suicide gene based-safeguard syStem for induced pluripotent Stem cell-based therapy of Parkinson’s disease
  8360. Stem cell therapy to cure syStemic lupus erythematosus; a revolutionary therapy or a temporarily hype?
  8361. Pseudo-Allogeneic CAR-T therapy after Allogeneic Stem cell Transplantation in Relapsed/Refractory B-cell NHL
  8362. Getting to the Root of It All: The Anatomical Record Explores Advances in Gene and Stem cell therapy in the Treatment of Hearing, Balance and Other Head and …
  8363. The Effect of Mesenchymal Secretome Stem cell therapy toward Caspase-3 Expression in Pregnant Mice with Pristan-Induced Lupus Model
  8364. … (HDC) with Autologous Stemcell Transplant (ASCT) with Consolidative Radiation therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-cell
  8365. SAFEty and efficacy of autologous bone marrow–derived mononuclear Stem cell therapy in patients with severe chronic ischemic Heart Failure–rationale and …
  8366. Intranasal Stem cell Secretome therapy to prevent COVID-19 complications
  8367. First-line therapy, autologous Stemcell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma
  8368. … TREATMENT STRATEGY AGAINST ISCHEMIC BRAIN DAMAGE BASED ON COMBINED APPLICATION OF Stem cell therapy AND PLANT POLYPHENOLS
  8369. Combination between Stem cell therapy and Cocoa Consumption for Treatment of Parkinson’s Disease in Indonesia
  8370. Successful treatment of steroid-refractory gastrointestinal acute graft-versus-host disease with adjuvant vedolizumab therapy in a pediatric allogeneic Stem cell
  8371. 310 Does Improvement in Endothelial Function affect Erectile Function following Stem cell therapy in Men with Cardiomyopathy?
  8372. Functional Neurorehabilitation and Stem cell therapy in Canine Degenerative Myelopathy
  8373. Targeted therapy for medullary and extramedullary relapse of FLT3-ITD acute myeloid leukemia following allogeneic hematopoietic Stem cell transplantation
  8374. Hematopoietic Stem cell gene therapy for the treatment of β-hemoglobinopathies
  8375. Angiogenesis following peripheral blood Stem cell therapy: evidence from perfusion MRI of patients with ischemic stroke
  8376. False Promises: The Danger of Unproven Stem cell therapy Clinics
  8377. Attitudes of Batswana towards Stem cell technology as an alternative therapy in Botswana
  8378. Autologous Mesenchymal Stem cell therapy in Patients with Unexplainable Low Ovarian Response: First Case in Mexico
  8379. Updates on Stem cell therapy in Transfusion Medicine, New Approaches to RBC Substitution therapy, the Use of IFC for the Assessment of Extracellular-Derived …
  8380. Innovation in induced mesenchymal Stem cell uses in therapy
  8381. … globulin for patients with early-onset hemophagocytic lymphohistiocytosis refractory to steroid and etoposide therapy following allogeneic hematopoietic Stem cell
  8382. Stability study of autologous mesoangioblasts intermediate and drug product for myogenic Stem cell therapy for m. 3243A> G mutation carriers
  8383. Study on Optimized Stem cell therapy Methods for Promoting Bone Consolidation in Distraction Osteogenesis
  8384. Mesenchymal Stem cell therapy in Cartilage Injuries of Knee–Review
  8385. A Study to Assess the Awareness Regarding Umbilical Cord Stem cell therapy among Health Team Members in Tertiary Care Hospital, Karad
  8386. Stem cell therapy as an Alternative to Reconstruction of Complete ACL Tears and Associated Physical therapy Considerations–A Case Report
  8387. ALLOGENIC MESENCHYMAL Stem cell therapy FOR IMMUNE MEDIATED CYTOPENIAS–A 22 CASE SERIES
  8388. cell biobank as a necessary infrastructure for the development and implementation of mesenchymal Stem cell-based therapy in the treatment of anthracycline-induced …
  8389. … Low-Dose Ruxolitinib Led to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients with cGvHD after Allogeneic Hematopoietic Stem cell
  8390. Bidirectional enhancement of cell proliferation between iron oxide nanoparticle-labeled mesenchymal Stem cells and choroid plexus in a cell-based therapy
  8391. Dual Stem cell therapy Improves the Cardiac Function After Experimental Myocardial Infarction
  8392. EXTH-02. TUMOR-HOMING INDUCED NEURAL Stem cell therapy INHIBITS THE PROGRESSION OF BREAST CANCER BRAIN METASTASIS AND …
  8393. … life after allogeneic hematopoietic Stem cell transplant: Guidelines and patient booklet from the Francophone Society of Bone marrow Transplant and cellular therapy
  8394. Stem cell therapy combined with CRISPR to engineer anti-inflammatory chondrocytes to improve neuroinflammation in rheumatoid arthritis
  8395. Immunosuppressive therapy and Immunomodulation in Stem cell Transplantation
  8396. Mesenchymal stromal/Stem cell therapy for acute graft versus host disease: the next step
  8397. 56. TUMOR-HOMING Stem cell therapy INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS
  8398. Clathrin-mediated Endocytosis Plays a Key Role in Stem cell therapy for Ischemic Heart Disease
  8399. Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic Stem cell transplant recipients
  8400. … Wound Healing in Rat (Wistar) by Using the Combination of Peripheral Blood Mononuclear cells (PBMCs) and Bone Marroe BM-Derived Mesenchymal Stem cell
  8401. 032 Stem cell therapy for the Treatment of Erectile Dysfunction and Peyronie’s Disease: A Survey of Stem cell Clinics Across the USA
  8402. A Single Dose of CD117 Antibody Drug Conjugate Enables Hematopoietic Stem cell Based Gene therapy in Nonhuman Primates
  8403. Music therapy for children going through haematopoietic Stem cell transplantation
  8404. Induced pluripotent Stem cells: Reprogramming platforms and applications in cell replacement therapy
  8405. Salvage therapy versus upfront autologous Stem cell transplantation in multiple myeloma patients with progressive disease after first-line induction therapy
  8406. Downregulation of Inflammation and a Cascade of Proangiogenic Signals Mediate the Beneficial Effects of Gene-Modified Stem cell therapy in Hindlimb Ischemia
  8407. Updates on safety and efficacy of maintenance therapy after autologous Stem cell transplantation in newly diagnosed multiple myeloma: A syStematic review.
  8408. Ex-vivo autologous Stem cell gene therapy clinical trial for mucopolysaccharidosis type IIIA: trial in progress-NCT04201405
  8409. … for validation and improvement of a highly efficient culture (HEC) assay for detection of undifferentiated human pluripotent Stem cells intermingled in cell therapy
  8410. Patient Specific Models of Nutrient Availability in Degenerated Intervertebral Discs: Which Patients are Candidates for Stem cell therapy?
  8411. Evaluating Tumor-Homing Neural Stem cell therapy Using Bio-Inspired 3D Models of Brain Cancer
  8412. 199 Enhanced immune responses in human breast and colon cancer following checkpoint therapy in a CD34+ Stem cell humanized NCG (HuCD34NCG) mouse …
  8413. Hematopoietic Stem cell Gene therapy for the Treatment of Beta-hemoglobinopathies
  8414. P095: Safety and efficacy of intravenous allogeneic umbilical cord blood-derived mesenchymal Stem cell therapy in patients with recessive dystrophic epidermolysis …
  8415. Effects of Stem cell therapy on 6-Minute Walk Test Distance and Left Ventricular Ejection Fraction in Patients with Nonischemic Cardiomyopathy
  8416. Efficacy of Amniotic Membrane-Mesenchymal Stem cell therapy for Burn wounds: Metaanalysis study
  8417. COVID-19 SARS-CoV-2 zoonotic risk from domestic and exotic animals and possible mitigation by mesenchymal Stem cell therapy
  8418. Evaluation of CD34+ hematopoietic Stem cell-associated extracellular vesicles as a potential personalized therapy for osteoarthritis
  8419. Stem cell transplantation therapy in glaucoma
  8420. … of the European Society for Blood and Marrow Transplantation and the Joint Accreditation Committee of the International Society for cellular therapy (4540)
  8421. Role of Adoptive T-cell therapy in Post Hematopoietic Stem cells Transplant Viral Infections-: A SyStemic Review
  8422. Early Intervention Stem cell Based therapy (EISCBT) for Corneal Burns and Trauma
  8423. Predictors of Outcomes in Adult Patients with therapy Related Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem cell Transplant-Twenty Year …
  8424. Cortical Bone Stem cell therapy Alters Macrophage Phenotype and Reduces Cardiac cell Death After Myocardial Infarction
  8425. Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic Stem cell transplantation
  8426. 23 Increasing capacity for autologous Stem cell transplants by outpatient conditioning therapy: a quality improvement study
  8427. Introduction to Hematopoietic Stem cell Transplantation and cellular therapy
  8428. Novel therapies for heart failure treatment: Stem cell and protein therapy
  8429. Brain-Derived Neurotrophic Factor and Stem cell-Based Technologies in Huntington’s Disease therapy
  8430. Relevance of antibodies in hematopoietic Stem cell transplantation: Antibodies anti-HLA, anti-platelets, anti-granulocytes, anti-erythrocytes and anti-MICA. Guidelines …
  8431. Combination of Lodenafil and Human Mesenchymal Stem cell therapy Reduces Cardiac Remodeling and Vascular Dysfunction in Su5416/hypoxia-induced …
  8432. The Risk Factors of Ventriculo-peritoneal Shunt Tube Blockage in Infantile Hydrocephalus and the Effect of Mesenchymal Stem cell therapy Prior to Surgery
  8433. Stem cell cure for kidney injury: therapy to solve most complex issues in renal syStem
  8434. Handbook of Stem cell Transplantation and cellular therapy Management
  8435. Allogeneic Hematopoietic Stem cell Transplant Versus Gene therapy in Sickle cell Disease: Updated Results from a SyStematic Review
  8436. Effectiveness and Clinical Perspectives of Adipose Derived Stem cell Based therapy in Vascularized Composite Allotransplantation
  8437. 2P-260: Novel Stem cell therapy using blue light based photobiomodulation for improving angiogenesis in mouse hindlimb ischemia
  8438. Second Autologous Stem cell Transplant As Salvage therapy in Multiple Myeloma-the Oregon Health and Science University Experience
  8439. … Cytomegalovirus Infection and Graft-Versus-Host Disease in an Allogeneic Hematopoietic Stem cell Transplant Recipient: Review of Antiviral therapy and Use of …
  8440. Angiogenic Effect of Amniotic Mesenchymal Stem cell Spheroid-Derived Secretome as a cell-Free therapy in Cardiac Repair
  8441. Efficacy and tolerability of high-versus low-dose lenalidomide maintenance therapy of multiple myeloma after autologous blood Stem cell transplantation
  8442. OR29-03 The Effects of Hormone therapy on Premature Ovarian Failure Following Allogenic Hematopoietic Stem cell Transplantation: A Single-Center …
  8443. cell therapy for Parkinson’s disease with induced pluripotent Stem cells
  8444. Lenti-D Hematopoietic Stem cell Gene therapy Stabilizes Neurologic Function in Boys with Cerebral Adrenoleukodystrophy
  8445. A Single Dose of Short Half-Life CD117 Antibody Drug Conjugate Enables Hematopoietic Stem cell Based Gene therapy in Nonhuman Primates
  8446. Real-World Use of Maintenance therapy and Associated Outcomes Following Autologous Stem cell Transplant in US Patients with Newly Diagnosed …
  8447. Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous Stemcell transplant and its effect on health-related quality of life
  8448. 156 Discovery of TSC-100: A natural HA-1-specific TCR to treat leukemia following hematopoietic Stem cell transplant therapy
  8449. Combined Human Umbilical Cord-Derived Stem cell and Hyperbaric Oxygen therapy Effectively Preserved the Neurological Function and Brain Architecture in …
  8450. … . The Real-World Use of Isavuconazole as Primary or salvage therapy of Invasive Fungal infections in High-Risk Patients with Hematologic Malignancy or Stem cell
  8451. Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem cell Transplant By Venetoclax Combination therapy
  8452. Consolidative Radiation therapy Following Autologous Stem cell Transplant in Relapsed or Refractory Hodgkin Lymphoma
  8453. A doxycycline-inducible C17.2 neural Stem cell-based combination of differentiation and suicide gene therapy for an in vitro tumorigenic C6 glioma model
  8454. … mold agents in preventing early invasive fungal disease after allogeneic Stem cell transplantation: assessment of antifungal therapy in haematological disease …
  8455. Differentiation and Maturation Effect of All-trans Retinoic Acid on Cultured Fetal RPE and Stem cell-Derived RPE cells for cell-Based therapy
  8456. Mesenchymal Stem cell-derived exosomes and regenerative medicine: outlook for future cell-free therapy in clinical practice
  8457. Autologous Stem cell-Derived β cells for Diabetes cell Replacement therapy
  8458. Ex vivo Stem cell gene therapy of the skin: Ready for clinical use?
  8459. cellULAR therapy AND Stem cell USAGE DURING HAIR LOSS: FUTURE PERSPECTIVES
  8460. … of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem cell Transplantation (alloSCT) with Venetoclax-Based therapy
  8461. Hematopoietic Stem cell transplantation ocular complications: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM …
  8462. … of Hypomethylating Agents in Combination with Donor Lymphocyte Infusions As Initial Salvage therapy Post Allogeneic Stem cell Transplant in Relapsed …
  8463. Retraction Note: Targeted suicide gene therapy for glioma using human embryonic Stem cell-derived neural Stem cells genetically modified by baculoviral vectors
  8464. Hyperbaric Oxygen therapy for Late-Onset Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem cell Transplantation and Effective Factors Prediction
  8465. C-Stem, a new technology fro scale up of cell therapy production
  8466. Clonal Hematopoiesis Drives therapy-Related Myeloid Neoplasms Following Autologous Stem cell Transplantation and Propagates during Disease …
  8467. … Myelofibrosis Undergoing a Two-Step Approach to Hematopoietic Stem cell Transplantation (HSCT): Effects of Donor Source and Pre-HSCT Splenic therapy
  8468. Applications of Stem cell-derived extracellular vesicles in bone regenerative therapy
  8469. Plasticity of cancer Stem cell: origin and role in disease progression and therapy resistance
  8470. Relapsed/refractory ETP-all successfully treated with novel combination therapy venetoclax with nelarabine prior to allogeneic Stem cell transplant
  8471. Vyxeos in high-risk MDS as induction therapy prior to Stem cell transplantation
  8472. Desensitization therapy for Patients with DSA Receiving Haploidentical (Haplo) Stem cell Transplantation
  8473. Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma Stem cell-bearing glioma model by downregulating the Akt/NFkB/MDR1 pathway
  8474. Low-Dose Decitabine Plus Venetoclax Maintenance therapy Can Decrease the Relapse after Allogeneic Stem cell Transplantation for MRD Positive High …
  8475. … acute carbon monoxide poisoning from oak burning gas cured by therapy combined with transplantation of human umbilical cord blood Stem cell, injection of nicholine …
  8476. Hematopoietic Stem cell Transplantation versus Immunosuppressive therapy in Patients with Acquired Severe Aplastic Anemia: A Cost-Effectiveness Analysis
  8477. cell Transplant (HSCT) Patients with Graft Versus Host Disease (GvHD) On High Dose≥ 0.5 mg/kg/day (HD) and Low Dose< 0.5 mg/kg/day (LD) Steroid therapy
  8478. Clinical observation of cidofovir in salvage therapy for cytomegalovirus infection in patients with haploid hematopoietic Stem cell transplantation
  8479. … Grade Human Induced Pluripotent Stem cell-derived Cardiac Tissues for a Rat Myocardial Infarction Model: A Pre-clinical Study for a cell Transplantation therapy
  8480. Nutritional status and nutritional therapy in pediatric and adolescent patients submitted to autologous hematopoietic Stem cell transplantation
  8481. Research advances on umbilical cord blood derived mesenchymal Stem cell in therapy of sensorineural hearing loss
  8482. Disparities in utilization of autologous Stem cell transplantation as consolidative therapy for multiple myeloma: A single-institution retrospective review.
  8483. Alzheimer Disease (AD) cell therapy Using Human Neural Stem cells: Validity of the Approach
  8484. … Post Autologous Stem cell Transplant (ASCT) in Patients with Multiple Myeloma (MM) Based on Dosage of Melphalan (mel) As Part of Conditioning therapy: Single …
  8485. … Anti-CD117 Antibody Drug Conjugate (ADC) Designed for Patient Conditioning Prior to Stem cell Transplant and HSC-Based Gene therapy Has a Broad …
  8486. … Burden of Cytomegalovirus infection in CMV-Seropositive Hematopoietic Stem cell Transplant Recipients Managed with Pre-Emptive therapy: A Single Center …
  8487. Stem cell Transplantation Outcomes: A Study from the cellular therapy and Immunobiology Working Party (CTIWP) of the EBMT A Study from the cellular therapy
  8488. … analysis of antithrombin III replacement therapy for the treatment of hepatic sinusoidal obstruction syndrome in children following hematopoietic Stem cell
  8489. Tumor mhicroenvironment effects on hematopoietic Stem cell induced tumor growth following radiation therapy
  8490. Measles, Mumps & Rubella Titers Post Autologous Stem cell Transplant in Multiple Myeloma Patients Induced with Modern therapy
  8491. Building New Arteriogenic therapy for Ischemic Cardiomyopathyusing Notch-induced Mesenchymal Stem cell Patch
  8492. Can Peri-Transplant Radiation therapy Improve Outcomes of Autologous Stem cell Transplant in Hodgkin Lymphoma?
  8493. … Patients with Severe Aplastic Anemia Treated with Combined Immunosuppressive therapy, Eltrombopag and Eculizumab and Their Clinical Course to Stem cell
  8494. Mesenchymal Stem cell-Derived Extracellular Vesicle therapy Delivered in a Hydrogel Preserves Hemodynamic Function Following Myocardial Infarction
  8495. 205. Rectal Stool Surveillance Cultures to Guide Empiric Antibiotic therapy in Patients with Hematologic Malignancies with or without Hematopoietic Stem cell
  8496. Re: Verification of Mesenchymal Stem cell Injection therapy for Interstitial Cystitis in a Rat Model
  8497. Transplantation site affects the outcome of adipose-derived Stem cell-based therapy for retinal degeneration
  8498. … TREATMENT WITH COMBINATION OF MESENCHYMAL Stem cell DERIVED EXOSOMES AND FOCUSED LOW-INTENSIVE SHOCK WAVE therapy
  8499. Nanoparticle enhanced combination therapy for Stem-like progenitors defined by single-cell transcriptomics in chemotherapy-resistant osteosarcoma
  8500. … paraspinal muscles in a rat modelPresentation J61. Abstract 157: A self-assembling peptide biomaterial to enhance human neural Stem cell-based regeneration of …
  8501. Allogeneic Hematopoietic Stem cell Transplantation Overcomes the Poor Prognosis in MLL-Rearranged Solid Tumor therapy Related-Acute Myeloid Leukemia
  8502. INVESTIGATING THE POTENTIAL OF COMBINED therapy USING MESENCHYMAL Stem cell EXOSOMES WITH HYALURONIC ACID FOR FUNCTIONAL …
  8503. Mesenchymal Stem cell Spheroids as an Active Nanomedicine Delivery Platform for Cancer therapy
  8504. Tyrosine kinase inhibitor maintenance therapy following allogenic hematopoietic Stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic …
  8505. Abstract PO-112: miR-149-3p inhibits the glioma Stem cell phenotype and re-sensitizes therapy-resistant GBM cells
  8506. Clinical observation of haploid hematopoietic Stem cell transplantation and intensive immunosuppressive therapy for the treatment of severe aplastic anemia in …
  8507. Biomimetic nanovesicles made from iPS cell-derived mesenchymal Stem cells for targeted therapy of triple-negative breast cancer
  8508. Effect of IA10 regimen induction therapy on newly diagnosed adult acute myeloid leukemia patients without allogeneic hematopoietic Stem cell transplantation and the …
  8509. therapy and Maintenance therapy with Immunomodulatory Drugs (Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem cell Transplantation in the …
  8510. … HUCPVC) and Bone Marrow-Derived Mesencymal Stem cells (BMSC) using the chemstress® fingerprinting assay, reveals hidden differences between cell therapy
  8511. Peripheral nerve-derived adult pluripotent Stem (NEDAPS) cells for induction to osteoblast as a cell therapy in segmental bone defect fractures
  8512. Genetic Modification of Mesenchymal Stem cells for Neurological Disease therapy: What Effects Does it Have on Phenotype/cell Behavior, Determining Their …
  8513. 773 Adoptive cell therapy Response in Melanoma is Mediated by Stem-like CD8 T cells
  8514. Mesenchymal Stem cells cultured on innovate composites and their derivatives as a novel cell therapy approaches in the treatment of osteoarthritis In Vivo
  8515. The secretome of Mesenchymal Stem cells as a cell-free based therapy for Spinal Cord Injury
  8516. Wound healing and cell dynamics including mesenchymal and dental pulp Stem cells induced by photobiomodulation therapy: an example of socket-preserving …
  8517. Mgta-456, a cell therapy Utilizing Expansion of CD34+ Hematopoietic Stem cells (HSC), Improves HLA Matching for Adult Recipients, Promotes Faster …
  8518. EFFECTS OF EXOSOMES FROM MESENCHYMAL Stem cells ON NUCLEUS PULPOSUS-DERIVED cells: A POTENTIAL cell-FREE therapy
  8519. Optimization of Nanoparticle Gene therapy for Stem cells using cell Penetrating Peptides
  8520. RONC-13. RADIATION INDUCED BRAIN Stem GLIOMA AFTER RADIATION therapy FOR MIXED GERM cell TUMOR
  8521. Inhibition of PAK6-Mediated Survival and cell Cycle Controls Selectively Targets therapy-Resistant CML Stem/Progenitor cells
  8522. Stem cell therapy for spinal cord injury
  8523. Progress in mesenchymal Stem cell therapy for ischemic stroke
  8524. The development of mesenchymal Stem cell therapy in the present, and the perspective of cell-free therapy in the future
  8525. Application of Stem cell therapy for infertility
  8526. Stem cell therapy in the heart: Biomaterials as a key route
  8527. Nanotechnology shaping Stem cell therapy: Recent advances, application, challenges, and future outlook
  8528. The quest of cell surface markers for Stem cell therapy
  8529. Emerging understanding of apoptosis in mediating mesenchymal Stem cell therapy
  8530. Engrafted Stem cell therapy for Alzheimer’s disease: A promising treatment strategy with clinical outcome
  8531. Mesenchymal Stem cell therapy for ischemic stroke: a look into treatment mechanism and therapeutic potential
  8532. Fostering mesenchymal Stem cell therapy to halt cytokine storm in COVID-19
  8533. Autologous Stem cell therapy in knee osteoarthritis: a syStematic review of randomised controlled trials
  8534. Nanoconjugates-based Stem cell therapy for the management of COVID-19
  8535. Mesenchymal Stem cell therapy for severe COVID-19
  8536. Stem cell therapy for burns: story so far
  8537. Stem cell therapy potency in personalizing severe COVID-19 treatment
  8538. … in mesenchymal Stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent Stem cell‐derived mesenchymal Stem cells
  8539. Mesenchymal Stem cell therapy for severe COVID-19 ARDS
  8540. The syStematic effect of mesenchymal Stem cell therapy in critical COVID-19 patients: a prospective double controlled trial
  8541. An update on the potential of mesenchymal Stem cell therapy for cutaneous diseases
  8542. Mesenchymal Stem cell therapy for Alzheimer’s disease
  8543. Mechanisms of Stem cell therapy in Spinal Cord Injuries
  8544. Characteristics and developments in mesenchymal Stem cell therapy for COVID-19: An update
  8545. Stem cell therapy for heart failure: Medical breakthrough, or dead end?
  8546. Surfing the clinical trials of mesenchymal Stem cell therapy in ischemic cardiomyopathy
  8547. A Nanoformulation‐Mediated Multifunctional Stem cell therapy with Improved Beta‐Amyloid Clearance and Neural Regeneration for Alzheimer’s Disease
  8548. Regenerative Stem cell therapy for neurodegenerative diseases: An overview
  8549. An update for mesenchymal Stem cell therapy in lupus nephritis
  8550. Current progress of rehabilitative strategies in Stem cell therapy for spinal cord injury: a review
  8551. Looking backward to move forward: a meta-analysis of Stem cell therapy in amyotrophic lateral sclerosis
  8552. Neuronal Replacement in Stem cell therapy for Stroke: Filling the Gap
  8553. An update on Alzheimer’s disease: Immunotherapeutic agents, Stem cell therapy and gene editing
  8554. Advantages and challenges of Stem cell therapy for osteoarthritis
  8555. Application of Stem cell therapy in myelofibrosis
  8556. Application of Stem cell therapy for ACL graft regeneration
  8557. Pluripotent Stem cell therapy for retinal diseases
  8558. The Current Dilemma and Breakthrough of Stem cell therapy in Ischemic Heart Disease
  8559. Stem cell therapy in coronavirus disease 2019: current evidence and future potential
  8560. Targeting mesenchymal Stem cell therapy for severe pneumonia patients
  8561. Application of mesenchymal Stem cell therapy for aging frailty: From mechanisms to therapeutics
  8562. Mesenchymal Stem cell therapy for liver disease: current status and future perspectives
  8563. Stem cell therapy for microvascular injury associated with ischemic nephropathy
  8564. Stem cell therapy: A paradigm shift in breast cancer treatment
  8565. Convergence of 3D printed biomimetic wound dressings and adult Stem cell therapy
  8566. Stem cell therapy for chronic obstructive pulmonary disease
  8567. Hematopoietic Stem cell therapy for Wiskott–Aldrich syndrome: improved outcome and quality of life
  8568. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy: a syStematic review of preclinical studies
  8569. Control of microbial opsin expression in Stem cell derived cones for improved outcomes in cell therapy
  8570. The Feasibility and Applicability of Stem cell therapy for the Cure of Type 1 Diabetes
  8571. Progress in clinical trials of Stem cell therapy for cerebral palsy
  8572. Insights into Stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis
  8573. Mesenchymal Stem cell therapy for osteogenesis imperfecta
  8574. Stem cell therapy in ocular pathologies in the past 20 years
  8575. Umbilical cord mesenchymal Stem cell therapy for regenerative treatment of rheumatoid arthritis: opportunities and challenges
  8576. Neuroregeneration and functional recovery after stroke: Advancing neural Stem cell therapy toward clinical application
  8577. Personalized‐induced neural Stem cell therapy: Generation, transplant, and safety in a large animal model
  8578. Angiogenic CD34 Stem cell therapy in Coronary Microvascular Repair—A SyStematic Review
  8579. Stemcell therapy for erectile dysfunction: a review of clinical outcomes
  8580. Mesenchymal Stem cell therapy for patients with ischemic heart failure-past, present, and future
  8581. Stem cell therapy for copd: Hope and exploitation
  8582. Application prospects of mesenchymal Stem cell therapy for bronchopulmonary dysplasia and the challenges encountered
  8583. COVID-19 and hematopoietic Stem cell transplantation and immune effector cell therapy: a US cancer center experience
  8584. Safety and feasibility of mesenchymal Stem cell therapy in patients with aqueous deficient dry eye disease
  8585. Preclinical efficacy of Stem cell therapy for skin flap: a syStematic review and meta-analysis
  8586. Allogeneic Stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy
  8587. Stem cell therapy for retinal degeneration: the evidence to date
  8588. On the road from phenotypic plasticity to Stem cell therapy
  8589. Effectiveness and mechanisms of adipose-derived Stem cell therapy in animal models of Parkinson’s disease: a syStematic review and meta-analysis
  8590. Human mesenchymal Stem cell therapy and other novel treatment approaches for premature ovarian insufficiency
  8591. Stem cell therapy for modulating neuroinflammation in neuropathic pain
  8592. Safety and efficacy of Stem cell therapy: an overview protocol on published meta-analyses and evidence mapping
  8593. Nanotechnology in cardiac Stem cell therapy: cell modulation, imaging and gene delivery
  8594. Molecular Mechanisms of Multi-Organ Failure in COVID-19 and Potential of Stem cell therapy
  8595. Comparative analysis on the anti-inflammatory/immune effect of mesenchymal Stem cell therapy for the treatment of pulmonary arterial hypertension
  8596. Hybrid SMART spheroids to enhance Stem cell therapy for CNS injuries
  8597. Lung multipotent Stem cells of mesenchymal nature: cellular basis, clinical relevance, and implications for Stem cell therapy
  8598. Combined hydrogel and mesenchymal Stem cell therapy for moderate-severity disc degeneration in goats
  8599. Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A syStematic review
  8600. Developing bioinspired three-dimensional models of brain cancer to evaluate tumor-homing neural Stem cell therapy
  8601. Human pluripotent Stem cell-derived cardiac cells: application in disease modeling, cell therapy, and drug discovery
  8602. Impact of SARS-CoV-2 in hematopoietic Stem cell transplantation and chimeric antigen receptor T cell therapy recipients
  8603. Mesenchymal Stem cell therapy in pulmonary fibrosis: a meta-analysis of preclinical studies
  8604. Human Stem cell models of polyglutamine diseases: sources for disease models and cell therapy
  8605. Understanding neural Stem cell regulation in vivo and applying the insights to cell therapy for strokes
  8606. Human mesenchymal Stem cell therapy promotes retinal ganglion cell survival and target reconnection after optic nerve crush in adult rats
  8607. In vivo study for clinical application of dental Stem cell therapy incorporated with dental titanium implants
  8608. Stem cell therapy in Dengue Virus-Infected BALB/C Mice Improves Hepatic Injury
  8609. Intravenous allogeneic umbilical cord blood–derived mesenchymal Stem cell therapy in recessive dystrophic epidermolysis bullosa patients
  8610. Human-induced neural and mesenchymal Stem cell therapy combined with a curcumin nanoconjugate as a spinal cord injury treatment
  8611. Constructing a cell microenvironment with biomaterial scaffolds for Stem cell therapy
  8612. Mesenchymal Stem cell therapy of acute thermal burns: a syStematic review of the effect on inflammation and wound healing
  8613. … an excellent option for children and young adult relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after CAR-T-cell therapy
  8614. Intranasal mesenchymal Stem cell therapy to boost myelination after encephalopathy of prematurity
  8615. Cancer Stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects
  8616. Mesenchymal Stem cell therapy for intractable neonatal disorders
  8617. A single-blinded randomized controlled trial of mesenchymal Stem cell therapy for the treatment of osteoarthritis of the knee with active control
  8618. Advances in Stem cell therapy for Brain Diseases via the Intranasal Route
  8619. Stem cell therapy and tissue engineering strategies using cell aggregates and decellularized scaffolds for the rescue of liver failure
  8620. Current concepts of Stem cell therapy for chronic spinal cord injury
  8621. Wnt signaling activation: Targets and therapeutic opportunities for Stem cell therapy and regenerative medicine
  8622. Mesenchymal Stem cell therapy in Canine Osteoarthritis Research:“Experientia Docet”(Experience Will Teach Us)
  8623. Progress and prospect of Stem cell therapy for diabetic erectile dysfunction
  8624. Autophagy controls mesenchymal Stem cell therapy in psychological stress colitis mice
  8625. Neural Stem cell therapy for brain disease
  8626. Stem cell therapy in patients with epilepsy: A syStematic review
  8627. Enhancing the surface properties of a bioengineered anterior cruciate ligament matrix for use with point-of-care Stem cell therapy
  8628. Stem cell therapy as a treatment for autoimmune disease—updates in lupus, scleroderma, and multiple sclerosis
  8629. Stem cell therapy for Crohn’s disease: syStematic review and meta-analysis of preclinical and clinical studies
  8630. Human umbilical cord-derived mesenchymal Stem cell therapy ameliorates lupus through increasing CD4+ T cell senescence via MiR-199a-5p/Sirt1/p53 axis
  8631. Review of operative considerations in spinal cord Stem cell therapy
  8632. The promise (s) of mesenchymal Stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model syStems
  8633. Highly interconnected inverse opal extracellular matrix scaffolds enhance Stem cell therapy in limb ischemia
  8634. Gain of CXCR7 function with mesenchymal Stem cell therapy ameliorates experimental arthritis via enhancing tissue regeneration and immunomodulation
  8635. Preclinical Stem cell therapy in fetuses with myelomeningocele: A syStematic review and meta‐analysis
  8636. Mesenchymal Stem cell therapy in hypertrophic and keloid scars
  8637. Functional assessment of cryopreserved clinical grade hESC-RPE cells as a qualified cell source for Stem cell therapy of retinal degenerative diseases
  8638. … CAR T-cell therapy and transplantation: comparisons of safety and long-term efficacy of allogeneic hematopoietic Stem cell transplantation after CAR T-cell or …
  8639. Efficacy of mesenchymal Stem cell therapy on glucose levels in type 2 diabetes mellitus: A syStematic review and meta‐analysis
  8640. Perspective on Stem cell therapy in Organ Fibrosis: Animal Models and Human Studies
  8641. Stem cell therapy in liver regeneration: Focus on mesenchymal Stem cells and induced pluripotent Stem cells
  8642. Therapeutic Aspects of Mesenchymal Stem cell-Based cell therapy with a Focus on Human Amniotic Epithelial cells in Multiple Sclerosis: A Mechanistic …
  8643. Novel Balance Mechanism Participates in Stem cell therapy to Alleviate Neuropathology and Cognitive Impairment in Animal Models with Alzheimer’s Disease
  8644. Can nanotechnology overcome challenges facing Stem cell therapy? A review
  8645. Combining cell therapy with human autologous Schwann cell and bone marrow-derived mesenchymal Stem cell in patients with subacute complete spinal …
  8646. Brain morphological and connectivity changes on MRI after Stem cell therapy in a rat stroke model
  8647. Autologous Stem cell therapy for Chronic Lower Extremity Wounds: A Meta-Analysis of Randomized Controlled Trials
  8648. … DNAemia and risk of mortality in allogeneic hematopoietic Stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and cell therapy
  8649. Mesenchymal Stem cell therapy ameliorates metabolic dysfunction and restores fertility in a PCOS mouse model through interleukin-10
  8650. Recent advances in Stem cell therapy for neurodegenerative disease: Three dimensional tracing and its emerging use
  8651. Fractional numerical simulation of mathematical model of HIV-1 infection with Stem cell therapy.
  8652. Neuroblastoma and Stem cell therapy: An updated review
  8653. Research Progress of Mesenchymal Stem cell therapy for Severe COVID-19
  8654. Cardiomyocyte death and genome-edited Stem cell therapy for ischemic heart disease
  8655. Stem cell therapy and diabetic erectile dysfunction: A critical review
  8656. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic Stem cell
  8657. Molecular investigation of adequate sources of mesenchymal Stem cells for cell therapy of COVID-19-associated organ failure
  8658. An Overview of the Safety, Efficiency, and Signal Pathways of Stem cell therapy for SyStemic Lupus Erythematosus
  8659. Hyaluronic acid supplement as a chondrogenic adjuvant in promoting the therapeutic efficacy of Stem cell therapy in cartilage healing
  8660. Human Stem cell-derived oligodendrocytes: From humanized animal models to cell therapy in myelin diseases
  8661. Treatment of COVID-19 by stage: any space left for mesenchymal Stem cell therapy?
  8662. Current evidence on mesenchymal Stem cell therapy for traumatic spinal cord injury: SyStematic review and meta-analysis
  8663. Neuromodulation-based Stem cell therapy in brain repair: recent advances and future perspectives
  8664. Stem cells and Cancer Stem cells: The Jekyll and Hyde Scenario and Their Implications in Stem cell therapy
  8665. Current status of hepatocyte-like cell therapy from Stem cells
  8666. Where Do We Stand in Stem cell therapy for the Management of Diabetes Mellitus?—A Scientometric Research Trend Analysis from 1990 to 2020
  8667. Multipronged Attack of Stem cell therapy in Treating the Neurological and Neuropsychiatric Symptoms of Epilepsy
  8668. Quantitative Analysis of Factors Regulating Angiogenesis for Stem cell therapy
  8669. Comparison of Fat harvested from flank and falciform regions for Stem cell therapy in dogs
  8670. Age-related changes in the inflammatory status of human mesenchymal Stem cells: implications for cell therapy
  8671. Endovascular Stem cell therapy post stroke rescues neurons from endoplasmic reticulum stress-induced apoptosis by modulating brain-derived neurotrophic factor …
  8672. Narrative review of Stem cell therapy for ischemic brain injury
  8673. Stem cell therapy and Exercise for Treatment of Intervertebral Disc Degeneration
  8674. Mesenchymal Stem cell therapy improved outcome of early post-traumatic shoulder osteonecrosis: A prospective randomized clinical study of fifty patients with over …
  8675. A New Predictive Technology for Perinatal Stem cell Isolation Suited for cell therapy Approaches
  8676. … Extramedullary Multiple Myeloma With Anti-BCMA CAR-T cell therapy Followed by Haploidentical Hematopoietic Stem cell Transplantation: A Case Report …
  8677. Additional benefit of induced pluripotent Stem cell-derived mesenchymal Stem cell therapy on sepsis syndrome-associated acute kidney injury in rat treated …
  8678. Intra-arterial Stem cell therapy diminishes inflammasome activation after ischemic stroke: a possible role of acid sensing ion channel 1a
  8679. Clinical Trial of Allogeneic Mesenchymal Stem cell therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to …
  8680. Allogeneic mesenchymal Stem cell sheet therapy: A new frontier in drug delivery syStems
  8681. Stem cell-based therapy for COVID-19 and ARDS: a syStematic review
  8682. Stem cell therapy for Post-Traumatic Stress Disorder: A Novel Therapeutic Approach
  8683. Stem cell therapy as a recent advanced approach in male infertility
  8684. Clinical mesenchymal Stem cell therapy in ischemic cardiomyopathy
  8685. Dual Stem cell therapy Improves the Myocardial Recovery Post-Infarction through Reciprocal Modulation of cell Functions
  8686. Stem cell therapy in the Management of Fracture Non-Union–Evaluating cellular Mechanisms and Clinical Progress
  8687. Stem cell therapy: A promising treatment for COVID-19
  8688. Integrative analysis of microRNAs and mRNAs in LPS-induced macrophage inflammation based on adipose tissue Stem cell therapy
  8689. Stem cell therapy prior to full-mouth tooth extraction lacks substantial clinical efficacy in cats affected by chronic gingivostomatitis
  8690. Adipose-derived Stem cells secretome and its potential application in “Stem cell-free therapy
  8691. Human placental-derived Stem cell therapy ameliorates experimental necrotizing enterocolitis
  8692. Induced pluripotent Stem cell technology for spinal cord injury: a promising alternative therapy
  8693. Clinical application of Stem cell therapy in neurogenic bladder: a syStematic review and meta-analysis
  8694. Fetal hematogenous routing of a donor hematopoietic Stem cell line in a healthy syngeneic model of transamniotic Stem cell therapy
  8695. Comparative evaluation of pulpal repair after direct pulp capping using Stem cell therapy and biodentine: an animal study
  8696. Mesenchymal Stem cell-based therapy for retinal degenerative diseases: experimental models and clinical trials
  8697. Stem cell therapy: A Promising Approach in Treatment of COVID-19
  8698. The potential of platelet-rich plasma injections and Stem cell therapy for penile rejuvenation
  8699. Mesenchymal Stem cell‐derived small extracellular vesicles as cell‐free therapy: Perspectives in periodontal regeneration
  8700. Current advances of Stem cell-based therapy for kidney diseases
  8701. Human allogeneic bone marrow-derived mesenchymal Stem cell therapy for cerebellar ataxia: A case report
  8702. Intrapericardial Delivery of APA-Microcapsules as Promising Stem cell therapy Carriers in an Experimental Acute Myocardial Infarction Model
  8703. Stem cell therapy in dermatology
  8704. Stem cell therapy in the Treatment of Patients With Autism Spectrum Disorder: a SyStematic Review and Meta-analysis
  8705. Stem cell therapy for acute myocardial infarction-focusing on the comparison between Muse cells and mesenchymal Stem cells
  8706. Programmed cell death in Stem cell-based therapy: Mechanisms and clinical applications
  8707. Stem cell-based therapy for experimental ischemic stroke: A preclinical syStematic review
  8708. Bone marrow mesenchymal Stem cell therapy regulates gut microbiota to improve post-stroke neurological function recovery in rats
  8709. Mesenchymal Stem cell spheroids: potential cell materials for cell therapy
  8710. Mesenchymal Stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study
  8711. Chimeric antigen receptor T-cell therapy after allogeneic Stem cell transplant for relapsed/refractory large B-cell lymphoma
  8712. Exercise Training in Boosting Post-Mi Mesenchymal Stem cell therapy
  8713. The future of regenerative medicine: cell therapy using pluripotent Stem cells and acellular therapies based on extracellular vesicles
  8714. Transamniotic Stem cell therapy for experimental congenital diaphragmatic hernia: structural, transcriptional, and cell kinetics analyses in the nitrofen model
  8715. Mesenchymal Stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises
  8716. A syStematic review and meta-analysis on the efficacy of Stem cell therapy on bone brittleness in mouse models of osteogenesis imperfecta
  8717. The critical role of mesenchymal stromal/Stem cell therapy in COVID‐19 patients: An updated review
  8718. Stem cell‐derived mitochondria transplantation: A promising therapy for mitochondrial encephalomyopathy
  8719. The promise of Stem cell-derived islet replacement therapy
  8720. Cross-Culture Online Knowledge Validation and the Exclusive Practice of Stem cell therapy
  8721. An Alternative cell therapy for Cancers: Induced Pluripotent Stem cell (iPSC)-Derived Natural Killer cells
  8722. Stem cell therapy for fracture non-union: The current evidence from human studies
  8723. Development of pH-Responsive Polymer Coating as an Alternative to Enzyme-Based Stem cell Dissociation for cell therapy
  8724. Results and prospects of using activator of hematopoietic Stem cell differentiation in complex therapy for patients with COVID-19
  8725. Stem cell-based therapy for COVID-19 and ARDS: a syStematic review
  8726. Mesenchymal Stem cell-based therapy for COVID-19: possibility and potential
  8727. … results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent Stem cell (iPSC) line expressing high …
  8728. cell therapy in patients with COVID-19 using Wharton’s jelly mesenchymal Stem cells: a phase 1 clinical trial
  8729. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic Stem cell transplantation
  8730. Enhancing Stem cell therapy for Cartilage Repair in Osteoarthritis—A Hydrogel Focused Approach
  8731. Correction to: Treating primary immunodeficiencies with defects in NK cells: from Stem cell therapy to gene editing
  8732. Clinical Efficacy and Safety of Human Mesenchymal Stem cell therapy for Degenerative Disc Disease: A SyStematic Review and Meta-Analysis of …
  8733. Probable Factors Associated with Response to Mesenchymal Stem cell therapy in Stroke Patients: A Post Hoc Analysis of the STARTING-2 Trial
  8734. Mesenchymal Stem cell-based therapy for stroke: current understanding and challenges
  8735. Efficacy of mesenchymal Stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis
  8736. Mesenchymal Stem cell-based therapy for diabetes mellitus: enhancement strategies and future perspectives
  8737. Hematopoietic Stem cell‐and induced pluripotent Stem cell‐derived CAR‐NK cells as reliable cell‐based therapy solutions
  8738. Enhancement of transamniotic Stem cell therapy for spina bifida by genetic engineering of donor mesenchymal Stem cells with an Fgf2 transgene
  8739. Mesenchymal Stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial
  8740. Stem cell therapy for dilated cardiomyopathy
  8741. Consolidative Hematopoietic Stem cell Transplantation After CD19 CAR-T cell therapy for Acute Lymphoblastic Leukemia: A SyStematic Review and Meta …
  8742. Stem cell-based therapy as a promising approach in Alzheimer’s disease: current perspectives on novel treatment
  8743. Autologous bone marrow derived mesenchymal Stem cell therapy for osteonecrosis of femoral head: A syStematic overview of overlapping meta-analyses
  8744. Role of prostaglandin E2 in allogeneic mesenchymal Stem cell therapy for cardiac repair
  8745. Translational Stem cell therapy: vascularized skin grafts in skin repair and regeneration
  8746. Clinical benefits of single vs repeated courses of mesenchymal Stem cell therapy in epilepsy patients
  8747. Efficacy and safety of neural Stem cell therapy for spinal cord injury: A syStematic literature review
  8748. Label-Free Quantitative Proteome Profiling of Cerebrospinal Fluid from a Rat Stroke Model with Stem cell therapy
  8749. Stem cell-derived exosomes as a cell free therapy against spinal cord injury
  8750. Making More Womb: Clinical Perspectives Supporting the Development and Utilization of Mesenchymal Stem cell therapy for Endometrial Regeneration and …
  8751. Stem cell sheet therapy: another option for acute kidney injury?
  8752. Mesenchymal Stem cell-based therapy and exosomes in COVID-19: current trends and prospects
  8753. Prospect of Stem cell therapy and Nanotechnology
  8754. Stem cell therapy and Its Significance in Pain Management
  8755. Stem cell therapy in stroke
  8756. Cross-Sectional Survey of Clinical Trials of Stem cell therapy for Heart Disease Registered at ClinicalTrials. gov
  8757. Mesenchymal Stem cell and microRNA therapy of musculoskeletal diseases
  8758. Experiences of Pain in Hospitalized Children During Hematopoietic Stem cell Transplantation therapy
  8759. Current status and challenges of Stem cell-based therapy for the treating of glioblastoma multiforme
  8760. The comparative effects of mesenchymal Stem cell transplantation therapy for spinal cord injury in humans and animal models: A syStematic review and meta-analysis
  8761. Mesenchymal Stem cell-derived exosome microRNA as therapy for cardiac ischemic injury
  8762. Stem cell therapy for the management of lateral elbow tendinopathy: A syStematic literature review
  8763. From Hematopoietic Stem cell Transplantation to Chimeric Antigen Receptor therapy: Advances, Limitations and Future Perspectives
  8764. Evaluation of the Efficacy of Stem cell therapy in Ovariectomized Osteoporotic Rats Based on Micro-CT and Dual-Energy X-Ray Absorptiometry: A …
  8765. Efficacy and safety of allogenic canine adipose tissue-derived mesenchymal Stem cell therapy for insulin-dependent diabetes mellitus in four dogs: A pilot study
  8766. ROS-scavenging hybrid hydrogel for genetically engineered Stem cell delivery and limb ischemia therapy
  8767. Surgical options for perianal fistula in patients with Crohn’s disease: A comparison of seton placement, fistulotomy, and Stem cell therapy
  8768. Exploring the Current Trends of Artificial Intelligence in Stem cell therapy: A SyStematic Review
  8769. Update on clinical ex vivo hematopoietic Stem cell gene therapy for inherited monogenic diseases
  8770. Molecular Basis of the Effect of Atorvastatin Pre-treatment on Stem cell therapy in Chronic Ischemic Diseases–Critical Limb Ischemia
  8771. Stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and cell therapy
  8772. Establishment of a novel mesenchymal Stem cell-based regimen for chronic myeloid leukemia differentiation therapy
  8773. A comparative study of mesenchymal Stem cell transplantation and NTG-101 molecular therapy to treat degenerative disc disease
  8774. … of human-induced pluripotent Stem cell-derived mesenchymal stromal cells to enhance the therapeutic efficacy of cell-based therapy for treatment of …
  8775. A syStematic review of quality of life in sickle cell disease and thalassemia after Stem cell transplant or gene therapy
  8776. … and Glyco (proteo) mic tools in the profiling of cardiac progenitors and pluripotent Stem cell derived cardiomyocytes: Accelerating translation into therapy
  8777. Cone Reconstruction for Ebstein Anomaly: Ventricular Remodeling and Preliminary Impact of Stem cell therapy
  8778. Therapeutic potential of mesenchymal Stem cell-derived extracellular vesicles as novel cell-free therapy for treatment of autoimmune disorders
  8779. Human amniotic fluid Stem cell-derived exosomes as a novel cell-free therapy for cutaneous regeneration
  8780. The safety and efficacy of mesenchymal Stem cell therapy in diabetic lower extremity vascular disease: a meta-analysis and syStematic review
  8781. Allogeneic expanded adipose‐derived mesenchymal Stem cell therapy for perianal fistulas in Crohn’s disease: A case series
  8782. Stem cell therapy and Its Significance in HIV Infection
  8783. Comparative analysis of mouse bone marrow and adipose tissue mesenchymal Stem cells for critical limb ischemia cell therapy
  8784. Efficacy of Stem cell application in diabetes mellitus: promising future therapy for diabetes and its complications
  8785. Current Status of Stem cell therapy and Nanofibrous Scaffolds in Cardiovascular Tissue Engineering
  8786. Insights into Stem cell therapy for premature ovarian insufficiency
  8787. Stem cell therapy targets the neointimal smooth muscle cells in experimentally induced atherosclerosis: involvement of intracellular adhesion molecule (ICAM …
  8788. Ex vivo mesenchymal Stem cell therapy to regenerate machine perfused organs
  8789. Long-term effects of muscle-derived Stem cell therapy on the regeneration of the urethra of female rats
  8790. Process development and safety evaluation of ABCB5+ limbal Stem cells as advanced-therapy medicinal product to treat limbal Stem cell deficiency
  8791. Stem cell therapy in Single-Ventricle Physiology: Recent Progress and Future Directions
  8792. Mesenchymal Stem cell-derived extracellular vesicles carrying miRNA as a potential multi target therapy to COVID-19: an in silico analysis
  8793. Mesenchymal Stem cell-based therapy for burn wound healing
  8794. Enzyme replacement therapy and hematopoietic Stem cell transplant: a new paradigm of treatment in Wolman disease
  8795. Mesenchymal Stem cell therapy for COVID-19
  8796. Case Report: Stem cell therapy in amyotrophic lateral sclerosis
  8797. Stem cell therapy in Children With Sensorineural Hearing Loss: A Narrative Review
  8798. Regional hyperthermia enhances mesenchymal Stem cell recruitment to tumor stroma: implications for mesenchymal Stem cell-based tumor therapy
  8799. Case Report: Capillary Leak Syndrome With Kidney Transplant Failure Following Autologous Mesenchymal Stem cell therapy
  8800. Addressing the importance of Stem cell-based therapy: a perspective in the treatment of COVID-19
  8801. A Review on the Role of Artificial Intelligence in Stem cell therapy: An Initiative for Modern Medicines
  8802. Application Effect Analysis of Nursing Intervention in Stem cell therapy for Stroke Patients
  8803. Towards Tissue-Specific Stem cell therapy for the Intervertebral Disc: PPARδ Agonist Increases the Yield of Human Nucleus Pulposus Progenitor cells in Expansion
  8804. … International Regenerative Medicine & Surgery Societies: recommendations in the use of platelet-rich plasma (PRP), autologous Stem cell-based therapy (ASC-BT) in …
  8805. Nicotinamide N-Methyltransferase in Acquisition of Stem cell Properties and therapy Resistance in Cancer
  8806. Identification of key genes in type 2 diabetes‐induced erectile dysfunction rats with Stem cell therapy through high‐throughput sequencing and bioinformatic analysis
  8807. Stem cell-based therapy for ameliorating intrauterine adhesion and endometrium injury
  8808. Long-term follow-up of hematopoietic Stemcell gene therapy for cerebral adrenoleukodystrophy
  8809. Glioblastoma therapy: Rationale for a Mesenchymal Stem cell-based Vehicle to Carry Recombinant Viruses
  8810. Roles of mesenchymal Stem cell-derived exosomes in cancer development and targeted therapy
  8811. Autologous Stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma
  8812. Pluripotent Stem cell-based gene therapy approach: human de novo synthesized chromosomes
  8813. Immune reprogramming precision photodynamic therapy of peritoneal metastasis by scalable Stemcell-derived extracellular vesicles
  8814. MRD-Negative Remission Induced in EP300-ZNF384 Positive B-ALL Patients by Tandem CD19/CD22 CAR T-cell therapy Bridging to Allogeneic Stem cell
  8815. Mesenchymal Stem cell therapy for Oral Inflammatory Diseases: Research Progress and Future Perspectives
  8816. Gene therapy of dominant CRX-Leber congenital amaurosis using patient Stem cell-derived retinal organoids
  8817. Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer Stem cell properties
  8818. Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic Stem cell transplantation for myelofibrosis: a study of the CMWP …
  8819. MATRix–RICE therapy and autologous haematopoietic Stemcell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement …
  8820. Case Report: Successful Chimeric Antigen Receptor T cell therapy in Haploidentical-Allogeneic Stem cell Transplant Patients With Post-Transplant …
  8821. … Peripheral Blood Hematopoietic Stem cell Transplant Combined With Adoptive T-cell therapy for the Treatment of High-Grade B-cell Lymphoma in Ten …
  8822. Efficacy and safety of autologous adipose tissue-derived Stem cell therapy for children with refractory Crohn’s complex fistula: a Phase IV clinical study
  8823. Method Categorization of Stem cell therapy for Degenerative Osteoarthritis of the Knee: A Review
  8824. Nanofat cell-Mediated Anti-Aging therapy: Evidence-Based Analysis of Efficacy and an Update of Stem cell Facelift
  8825. … Crest Stem cells to Combat Ischemic Stroke. Comment on Othman, FA; Tan, SC Preconditioning Strategies to Enhance Neural Stem cell-Based therapy for …
  8826. Regeneration of Trabecular Meshwork in Primary Open Angle Glaucoma by Stem cell therapy
  8827. Research progress of Stem cell therapy for ischemic stroke
  8828. Dysregulation of mitophagy and mitochondrial homeostasis in cancer Stem cells: Novel mechanism for anti‐cancer Stem cell‐targeted cancer therapy
  8829. Mesenchymal Stem cell therapy efficacy in COVID-19 patients: A syStematic review and meta-analysis
  8830. Goals and challenges of Stem cell-based therapy for corneal blindness due to limbal deficiency
  8831. Diagnosis and Treatment Guidelines for Mesenchymal Stem cell therapy for Coronavirus Disease 2019 (Beijing, 2021)
  8832. Mesenchymal Stem cell-derived extracellular vesicle-based therapy for Alzheimer’s disease: progress and opportunity
  8833. Will Mesenchymal Stem cell therapy Be Effective In COVID-19?
  8834. Concentrated autologous bone marrow aspirate is not “Stem celltherapy in the repair of nonunions and bone defects
  8835. Mesenchymal Stem cell-derived extracellular vesicles in therapy against fibrotic diseases
  8836. Continuous renal replacement therapy: a review of use and application in pediatric hematopoietic Stem cell transplant recipients
  8837. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic Stem cell transplantation
  8838. Stem cell therapy for Anal Fistula Treatment-Video Vignette.
  8839. Identification of Key microRNAs in Diabetes Mellitus Erectile Dysfunction Rats with Stem cell therapy by Bioinformatic Analysis of Deep Sequencing Data
  8840. … antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous Stem cell transplantation (ASCT) as …
  8841. Stem cell therapy against COVID-19
  8842. Autologous haematopoietic Stem cell transplantation as a first-line disease-modifying therapy in patients with ‘aggressive’multiple sclerosis
  8843. MESENCHYMAL Stem cell therapy FOR ACUTE KIDNEY DISEASE IN A CAT–CASE REPORT
  8844. SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic Stem cell transplantation
  8845. Hematopoietic Dyscrasias and Stem cell Transplantation/CAR-T cell therapy
  8846. Stem cells for Huntington’s Disease (SC4HD): An International Consortium to Facilitate Stem cell-Based therapy for Huntington’s Disease
  8847. Stem cell-Based therapy for Asherman Syndrome: Promises and Challenges
  8848. … graft‐versus‐host disease in allogeneic peripheral blood Stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy
  8849. Single-cell RNA Sequencing of Human Pluripotent Stem cell-Derived Macrophages for Quality Control of The cell therapy Product
  8850. Predicting genotoxicity of viral vectors for Stem cell gene therapy using gene expression-based machine learning
  8851. Cancer Stem cell for Tumor therapy
  8852. New Prospects for Stem cell therapy in Alzheimer’s Disease
  8853. Stem cell therapy in ischemic stroke: A syStematic review and meta-analysis of randomized controlled trials
  8854. Combating COVID-19 with mesenchymal Stem/stromal cell therapy: Promise and challenges
  8855. Intrathecal autologous bone marrow Stem cell therapy in children with autism: A randomized controlled trial
  8856. Neuroprotective therapy for retinal neurodegenerative diseases by Stem cell secretome
  8857. Stem cell-based islet replacement therapy in diabetes: A road trip that reached the clinic
  8858. Efficacy and Safety of Stem cell Combination therapy for Osteonecrosis of the Femoral Head: A SyStematic Review and Meta-Analysis
  8859. … -based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic Stem cell
  8860. … in a Rat Hemisection Spinal Cord Injury Model With Combined Neural Stem cell, Endothelial Progenitor cell, and Biomimetic Hydrogel Matrix therapy
  8861. Deep tumor‐penetrated nanosyStem eliminates cancer Stem cell for highly efficient liver cancer therapy
  8862. … Multiforme (GBM) with super hyperfractionated radiation therapy: Implication of temporal dose fractionation optimization including cancer Stem cell dynamics
  8863. Stem cell therapy and Regenerative Medicine in Autoimmune Diseases
  8864. Randomized controlled study for the anti‐aging effect of human adipocyte‐derived mesenchymal Stem cell media combined with niacinamide after laser therapy
  8865. Critical roles of TLRs on the polarization of mesenchymal Stem cells for cell therapy of viral infections: a notice for COVID-19 treatment
  8866. Mesenchymal Stem cell-Based Heart cell therapy: The Effect of Route of cell Delivery in the Clinical Perspective
  8867. Clinical Application of Stem cell therapy for Liver Cirrhosis: Progress, Pitfalls, and Prospects.
  8868. A syStematic review of Stem cell therapy treatment for women suffering from stress urinary incontinence
  8869. Azacitidine maintenance therapy post-allogeneic Stem cell transplantation in poor-risk acute myeloid leukemia
  8870. Establishment of a cell processing laboratory to support hematopoietic Stem cell transplantation and chimeric antigen receptor (CAR)-T cell therapy
  8871. The role of mesenchymal Stem cell therapy in traumatic brain injury: a review from basic research to clinical challenges.
  8872. Mesenchymal Stem cells: The Potential Therapeutic cell therapy to Reduce Brain Stroke Side Effects
  8873. cell therapy and Methods of Stem cell Delivery for Regeneration of Heart Tissue Following Myocardial Infarction
  8874. Stem cell-Derived Nanovesicles: A Novel cell-Free therapy for Wound Healing
  8875. Potential for Stem cell-Based therapy in the Road of Treatment for Neurological Disorders Secondary to COVID-19
  8876. Predictors of outcomes of therapy-related acute myeloid leukemia after allogeneic hematopoietic Stem cell transplantation
  8877. Exploring the potential of Stem cell-based therapy for aesthetic and plastic surgery
  8878. Human Stem cell-based retina on chip as new translational model for validation of AAV retinal gene therapy vectors
  8879. Success Stories and Challenges Ahead in Hematopoietic Stem cell Gene therapy: Hemoglobinopathies as Disease Models
  8880. Is Stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy
  8881. Physical therapy exerts sub-additive and suppressive effects on intracerebral neural Stem cell implantation in a rat model of stroke
  8882. Adult Stem cell transplantation combined with conventional therapy for the treatment of end-stage liver disease: a syStematic review and meta-analysis
  8883. Stem cell-based therapy for hirschsprung disease, do we have the guts to treat?
  8884. Mesenchymal Stem cell therapy in a Preterm Infant with Bronchopulmonary Dysplasia
  8885. Stem cell as Vehicles of Antibody in Treatment of Lymphoma: A Novel and Potential Targeted therapy
  8886. The Antiviral Drug Efavirenz in Breast Cancer Stem cell therapy
  8887. Diabetic Retinopathy and Stem cell therapy
  8888. Quality Management and Accreditation in Hematopoietic Stem cell Transplantation and cellular therapy: The JACIE Guide
  8889. Advancements in transplantation therapy for diabetes: Pancreas, islet and Stem cell
  8890. Stemcell therapy Following High-Dose Chemotherapy in Advanced Retinoblastoma: A SyStematic Review
  8891. … as an effective salvage therapy and bridge to allogeneic hematopoietic Stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia
  8892. Investigating the barrier activity of novel, human enhancer-blocking chromatin insulators for hematopoietic Stem cell gene therapy
  8893. HEMATOLOGICAL FINDINGS IN COVID-19 AND INSIGHTS TO Stem cell therapy
  8894. Improving outcomes for children requiring extracorporeal membrane oxygenation therapy following hematopoietic Stem cell transplantation
  8895. Stem cell therapy for Stroke
  8896. Autologous Stemcell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience
  8897. O6 Analysis of angiogenic gene profiling after E-selectin+ Stem cell therapy in murine ischemic limb
  8898. Mesenchymal Stem cell-Based therapy for Advanced Colorectal Cancer: Potential Mechanisms of therapy and Associated Risks
  8899. Stem cell therapy for degenerative disc disease: A review
  8900. Hematopoietic Stem cell Gene therapy for Cystinosis: From Bench-to-Bedside
  8901. Efficacy and safety of mesenchymal Stem/stromal cell therapy for inflammatory bowel diseases: an up-to-date syStematic review
  8902. Stem cell therapy as a Treatment for Autoimmune Disease—Updates in Lupus, Scleroderma, and Multiple Sclerosis
  8903. Immunosuppressive therapy after autologous hematopoietic Stem cell transplantation in syStemic sclerosis patients—high efficacy of Rituximab
  8904. Stem cell therapy for the Treatment of Myocardial Infarction: How Far Are We Now?
  8905. … and prognostic impact of clonal hematopoiesis in multiple myeloma patients receiving post-autologous Stem cell transplantation lenalidomide maintenance therapy
  8906. Lines of therapy before autologous Stem cell transplant and CAR-T affect outcomes in aggressive Non-Hodgkin’s lymphoma
  8907. The Potential Safe Antifibrotic Effect of Stem cell Conditioned Medium and Nilotinib Combined therapy by Selective Elimination of Rat Activated HSCs
  8908. Hematopoietic Stem cell gene therapy targeting TGFβ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model
  8909. 196-LB: Stem cell–derived islet replacement therapy (VC-02) demonstrates production of C-peptide in patients with type 1 diabetes (T1D) and hypoglycemia …
  8910. Introduction to Stem cell therapy and Its Application in Vascular Diseases
  8911. Post-Resuscitation Neuroinflammation in a Porcine Model of Cardiac Arrest: Effect of SyStemic Allogeneic Mesenchymal Stem cell therapy
  8912. Mesenchymal Stem cell therapy For COVID-19; Is A New Challenge Review
  8913. Perspectives on Stem cell-Based Regenerative Medicine with a Particular Emphasis on Mesenchymal Stem cell therapy
  8914. Stem cell-based therapy Strategy for Hepatic Fibrosis by Targeting Intrahepatic cells
  8915. Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic Stem cell transplantation …
  8916. Relationship between left ventricular global longitudinal strain, infarct size and left ventricular function in patients with acute myocardial infarction in a Stem cell therapy
  8917. Iron toxicity and chelation therapy in hematopoietic Stem cell transplant
  8918. Stem cell therapy Delivery in Liver Disease
  8919. … analysis of allogeneic versus autologous Stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy
  8920. Stem cell therapy Enhances Motor Activity of Triceps Surae Muscle in Mice with Hereditary Peripheral Neuropathy
  8921. Temporomandibular Joint Osteoarthritis: Regenerative Treatment by a Stem cell Containing Advanced therapy Medicinal Product (ATMP)—An In Vivo Animal Trial
  8922. Stem cell therapy for COVID-19
  8923. Sepsis and Septic Shock; Current Treatment Dilemma and Role of Stem cell therapy in Pediatrics
  8924. Stem cell therapy to Improve Acute Myocardial Infarction Remodeling
  8925. Stem cell therapy in Alzheimer’s disease
  8926. Stem cell and Gene-Based therapy for Erectile Dysfunction: Current Status and Future Needs
  8927. … gene imaging “visualized” the integration of two growing technologies: CRISPR/Cas9-based genome editing and induced pluripotent Stem cell therapy
  8928. Stem cell therapy in Children With Sensorineural Hearing Loss: A Narrative Review
  8929. Stemcell therapy for the Treatment of Knee Osteoarthritis
  8930. Stem cell therapy for Diabetic Foot Ulcers
  8931. Neural Crest-Like Stem cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and therapy Resistance
  8932. cell therapy in transplantation: A comprehensive review of the current applications of cell therapy in transplant patients with the focus on Tregs, CAR Tregs, and …
  8933. Mesenchymal Stem cell-Derived Extracellular Vesicle: A Promising Alternative therapy for Osteoporosis
  8934. therapy and a Combination of Eltrombopag Plus Immunosuppression therapy and Human Leukocyte Antigen-Haploidentical Hematopoietic Stem cell
  8935. Editorial Commentary: Stem cell therapy for the Knee: Heterogeneity in cell Sources, Delivery Methods, and Concomitant Surgery Needs to Be Considered
  8936. Molecular Imaging of Stem cell therapy in Ischemic Cardiomyopathy
  8937. Autologous hematopoietic Stem cell transplantation following alemtuzumab therapy in aggressive multiple sclerosis: A report of three cases
  8938. Safety and efficacy of consolidation therapy with ipilimumab plus nivolumab after autologous Stem cell transplantation
  8939. Induced pluripotent Stem cell-based disease modeling and prospective immune therapy for coronavirus disease 2019
  8940. Mesenchymal Stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints
  8941. Stem cell therapy for Ophthalmic Vascular Disease
  8942. Mesenchymal Stem cell-Derived Exosomes for COVID-19 therapy, Preclinical and Clinical Evidence
  8943. The Clinical Outcomes of Stem cell therapy for Decompensated Liver Disease: A SyStematic Review and Meta-Analysis
  8944. Off-label use of letermovir as preemptive anti-cytomegalovirus therapy in a pediatric allogeneic peripheral blood Stem cell transplant
  8945. Sphingosine kinase 1 could enhance Stem cell therapy efficiency for neurodegenerative diseases through induction of HIF-1
  8946. Challenges in Stem cell-derived islet replacement therapy can be overcome
  8947. Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem cell Line to Mass Produce Off-the-Shelf CAR T-cell therapy
  8948. Targeting Programmed cell Death to Improve Stem cell therapy: Implications for Treating Diabetes and Diabetes-Related Diseases
  8949. Allogeneic umbilical cord mesenchymal Stem cell therapy for autism
  8950. … for validation and improvement of a highly efficient culture assay for detection of undifferentiated human pluripotent Stem cells intermingled in cell therapy
  8951. … in older patients with primary CNS lymphoma treated with R-MPV/cytarabine without whole brain radiotherapy or autologous Stem cell transplantation therapy
  8952. cell therapy of Stroke: Do the Intra-Arterially Transplanted Mesenchymal Stem cells Cross the Blood–Brain Barrier?
  8953. Hematopoietic Stem-and progenitor-cell gene therapy for Hurler syndrome
  8954. Targeted cell therapy for partial-thickness cartilage defects using membrane modified mesenchymal Stem cells by transglutaminase 2
  8955. Stem cell Transplantation: Expert Review from the Biobehavioral Research Special Interest Group of the American Society for Transplantation and cellular therapy
  8956. An Overview of Mesenchymal Stem cell-based therapy Mediated by Noncoding RNAs in the Treatment of Neurodegenerative Diseases
  8957. The Ethical Challenges of Stem cell therapy in Vascular Disorders
  8958. Pluripotent Stem cells for cell therapy
  8959. Stem cell therapy in the treatment of organic and dysfunctional endometrial pathology.
  8960. Immune Protection of Stem cell-Derived Islet cell therapy for Treating Diabetes
  8961. The role of induction therapy before autologous Stem cell transplantation in low disease burden AL amyloidosis patients
  8962. Functional maturation of immature β cells: A roadblock for Stem cell therapy for type 1 diabetes
  8963. The preconditioning of lithium promotes mesenchymal Stem cell-based therapy for the degenerated intervertebral disc via upregulating cellular ROS
  8964. Stemcell therapy with bone marrow (hematopoietic) Stem cells for intestinal diseases
  8965. Stem cell therapy for Lymphedema
  8966. Alzheimer’s Disease: Neural Stem cell therapy using 3x-Tg Mice
  8967. Author Correction: The promise (s) of mesenchymal Stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model syStems
  8968. Intra-arterial Stem cell therapy Diminishes Inflammasome Activation After Ischemic Stroke: a Possible Role of Acid Sensing Ion Channel 1a
  8969. Review on Stem cell therapy: An Approach to Combat Cancer Proliferation
  8970. Recent Research and Development in Stem cell therapy for Cancer Treatment: Promising Future and Challenges
  8971. Cytokine and Chemokine Responses in Invasive Aspergillosis Following Hematopoietic Stem cell Transplantation: Past Evidence for Future therapy of Aspergillosis
  8972. Stem cell therapy for periodontal disease: new progress of microenvironment cognition
  8973. Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma Stem cell-bearing glioma model by downregulating the Akt/NF-κB/MDR1 pathway
  8974. Immune cell therapy against disseminated melanoma by utilizing induced pluripotent Stem cell-derived myeloid cell lines producing interferon-beta or interleukin-15 …
  8975. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous Stem cell transplantation for multiple myeloma
  8976. T-control: T-cell therapy in the context of allogeneic Stem cell transplantation
  8977. Outcomes with autologous Stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma
  8978. Bone marrow mesenchymal Stem cell co-adjuvant therapy with albendazole for managing Toxocara vitulorum-rat model
  8979. Brentuximab vedotin consolidation therapy after autologous Stemcell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study
  8980. Hematopoietic Stemcell transplantation versus immunosuppressive therapy in patients with adult acquired severe aplastic anemia: a cost-effectiveness …
  8981. RAPID cell PHENOTYPING USING ARRAY-BASED SENSORS: APPLICATIONS IN CANCER Stem cell therapy AND HIGH-CONTENT SCREENING
  8982. Biomaterials and Scaffolds in Stem cell therapy
  8983. … trial of high-dose [131I] meta-iodobenzylguanidine therapy for high-risk neuroblastoma preceding single myeloablative chemotherapy and haematopoietic Stem cell
  8984. In vitro follicular activation and Stem cell therapy as a novel treatment strategies in Dismished ovarian reserve and primary ovarian insufficiency
  8985. Multicenter Trial of Stem cell therapy for Osteoarthritis (MILES)
  8986. Therapeutic effect of mesenchymal Stem cell therapy in the LVEF, LVEDV, and LVESV after myocardial infarction.
  8987. Using Big Data Analytics on Health Industry Development: The Empirical Intellectual Property Analysis from Stem cell therapy
  8988. Stem cell therapy for the Treatment of Chronic Ischemic Heart Disease
  8989. Correction to: Intra-arterial Stem cell therapy Diminishes Inflammasome Activation After Ischemic Stroke: a Possible Role of Acid Sensing Ion Channel 1a
  8990. Non-genotoxic conditioning facilitates hematopoietic Stem cell gene therapy for hemophilia A using bioengineered factor VIII
  8991. Stem cell-free therapy for glaucoma to preserve vision
  8992. Possibility of in utero Stem cell therapy for multiple fetal genetic diseases
  8993. Role of mesenchymal and other Stem cell therapy in intestinal diseases
  8994. Positive aspects, negative aspects and challenges associated with Stem cell therapy for COVID-19: A Mini-Review.
  8995. A Novel CMV-Specific TCR-T cell therapy Is Effective and Safe for Refractory CMV Infection after Allogeneic Hematopoietic Stem cell Transplantation
  8996. Impact of time to relapse and response to salvage therapy on post autologous Stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.
  8997. … of Allogeneic Hematopoietic Stem cell Transplantation after Chimeric Antigen Receptor T-cell therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
  8998. The effect of music therapy on the physical and mental parameters of cancer patients during hematopoietic Stem cell transplantation
  8999. Autologous Stemcell transplantation in syStemic sclerosis-associated interstitial lung disease: early action in selected patients rather than escalation therapy for all
  9000. Autologous Mesenchymal Stem cell therapy for Idiopathic Pulmonary Fibrosis and Comprehensive Assessment of Circulating Immune Populations cells
  9001. Commentary: Evidence based human Stem cell therapy for myocardial healing:’Miles to go’
  9002. Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous Stem cell transplantation
  9003. Microphysiological stroke model for syStematic evaluation of neurorestorative potential of Stem cell therapy
  9004. Biomaterials: The Holy Grail for Stem cell therapy in the Infarcted heart
  9005. Epigenetic‐based therapy in allogenic hematopoietic Stem cell transplantation: Novel opportunities for personalized treatment
  9006. Molecular Mechanisms of Mesenchymal Stem cell-Based therapy in Acute Kidney Injury
  9007. Effect of umbilical cord blood Stem cell transplantation on restenosis after endovascular interventional therapy for diabetic hindlimb vascular disease
  9008. Stem cell therapy for skin regeneration using mesenchymal Stem cells derived from the progeroid Werner syndrome-specific iPS cells
  9009. Stem cell therapy and Diabetes
  9010. Is autologous Stem cell transplantation a safe and effective alternative to whole brain radiation as consolidation therapy in patients with primary central nervous syStem
  9011. Characterization of Stem cells from human ovarian follicular fluid; a potential source of autologous Stem cell for cell-based therapy
  9012. … Crest Stem cells to Combat Ischemic Stroke. Comment on Othman, FA; Tan, SC Preconditioning Strategies to Enhance Neural Stem cell-Based therapy for …
  9013. In Vitro Models for Stem cell therapy: Methods and Protocols
  9014. Stem cell therapy in patients with nonischemic heart failure
  9015. A REVIEW ON Stem cell therapy IN TREATMENT OF DIFFERENT DISEASE
  9016. Mesenchymal Stem cell-Based therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future Perspectives
  9017. A Mutation-Agnostic Hematopoietic Stem cell Gene therapy for Metachromatic Leukodystrophy
  9018. 094 Platelet-Rich Plasma and Stem cell therapy for Erectile Dysfunction: Characterization of Market Forces in a Major Metropolitan Area
  9019. … Lymphoma (r/r B-NHL) Patients with TP53 Gene Disruption Treated with CD19/22 Cocktail CAR T-cell therapy Alone or Incorporated with Autologous Stem cell
  9020. Adipose-derived Mesenchymal Stem cell therapy for Reverse Bleomycin-induced Experimental Pulmonary Fibrosis
  9021. Impact of pre-transplant induction therapy on outcomes of patients who undergo autologous Stem cell transplantation for mantle cell lymphoma in first …
  9022. Mesenchymal Stem cell-Based therapy for Rheumatoid Arthritis
  9023. Mesenchymal Stem cell-Derived Exosomes as an Emerging Paradigm for Regenerative therapy and Nano-Medicine: A Comprehensive Review
  9024. Cytokine adsorption therapy in lymphoma-associated hemophagocytic lymphohistiocytosis and allogeneic Stem cell transplantation
  9025. Stem cell therapy for the Treatment of Hip Osteonecrosis
  9026. Case Report: Combination therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem cell Transplantation Resulted in …
  9027. Stem cell therapy For The Treatment Of Crohn’s Disease; Current Obstacles And Future Hopes.(Mini-Review).
  9028. … -Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem cell
  9029. Potential of Stem cell therapy to Combat Mastitis in Dairy Animals
  9030. Angiogenesis in aging hearts—Cardiac Stem cell therapy
  9031. Prior anti-PD-1 therapy as a risk factor for life-threatening peri-engraftment respiratory distress syndrome in patients undergoing autologous Stem cell transplantation
  9032. Combining extracorporeal life support and cell therapy in critical illness: mesenchymal Stem cell therapy and extracorporeal membrane oxygenation in the …
  9033. Effect of combination therapy with neural Stem cell transplantation and teramethylpyrazine in rats following acute spinal cord injury
  9034. HISTOMORPHOMETRIC ASSESSMENT OF AUTOGENOUS Stem cell therapy IN HORIZONTAL ALVEOLAR RIDGE AUGMENTATION (EXPERIMENTAL …
  9035. Stem cell transplantation therapy for diabetic foot ulcer: a narrative review
  9036. Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous Stem cell transplantation: Czech Registry Data
  9037. Specific Blood cells Derived from Pluripotent Stem cells: An Emerging Field with Great Potential in Clinical cell therapy
  9038. Efficacy of Allogeneic Hematopoietic Stem cell Transplantation in Relapse/Refractory B-ALL Patients After Chimeric Antigen Receptor T cell therapy: A …
  9039. Emerging value of Stem cell therapy in rheumatic diseases
  9040. Application of Stem cell therapy during the treatment of HIV/AIDS and Duchenne Muscular Dystrophy.
  9041. Development of a” Pro-Matrix” Advanced cell Scaffold Biomaterial to Support Mesenchymal Stem cell therapy
  9042. Cardiac Stem cell therapy, Quo Vadis
  9043. Developing Induced Neural Stem cell therapy to Treat Triple-Negative Breast Cancer and Brain Metastases
  9044. Access to the Apical Cochlear Modiolus for Possible Stem cell-Based and Gene therapy of the Auditory Nerve
  9045. Mesenchymal Stem cells: an overview of their potential in cell-based therapy for diabetic nephropathy
  9046. Animal models in research examining Stem cell therapy for human lung disease: a support in the quest to develop therapies
  9047. Rational Route of Delivery Mesenchymal Stem cell therapy for Acute Myocardial Infarction (AMI) and Chronic Ischemic Cardiomyopathy (ICM): a SyStematic …
  9048. Mesenchymal Stem cell‐derived exosomes for organ development and cell‐free therapy
  9049. Evaluation of Stem cell-derived cellular therapy products
  9050. cell Transplantation for Refractory/Relapsed T-cell Acute Lymphoblastic Leukemia/Lymphoma after Donor-Derived CD7-Chimeric Antigen Receptor T-cell therapy
  9051. Mesenchymal Stem/Stromal cell therapy in Blood–Brain Barrier Preservation Following Ischemia: Molecular Mechanisms and Prospects
  9052. Ruxolitinib combined with corticosteroids as first-line therapy for acute graft-versus-host disease in haploidentical peripheral blood Stem cell transplantation recipients
  9053. Stem cell therapy in children with acute liver failure: The dream could come true
  9054. Stem cell–secreted factor therapy regenerates the ovarian niche and rescues follicles
  9055. Autism and Stem cell therapy
  9056. therapy preconditioning modifies nitric oxide pathway and oxidative stress in human-induced pluripotent Stem cell-derived ventricular cardiomyocytes treated with …
  9057. Promise of Mesenchymal Stem cell Lysates in IBD therapy: Are the Parts Greater than the Whole?
  9058. Stem cell therapy: A Whole World of New Era
  9059. Early high dose corticosteroid therapy in hematopoietic Stem cell transplantation patients with acute respiratory distress syndrome: a propensity score matched study
  9060. A Review of Neural Stem cell Transplant therapy for Traumatic Spinal Cord Injury
  9061. Corrigendum: Stem cell therapy in Dengue Virus-Infected BALB/C Mice Improves Hepatic Injury
  9062. Hematopoietic Stem cell Transplantation Cures therapy-refractory Aspergillosis in Chronic Granulomatous Disease
  9063. … Peripheral Blood Stem cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide therapy
  9064. Stem cell therapy IN BREAST CANCER
  9065. The Future of Stem cell therapy Regulation Under the FDA’s Comprehensive Regenerative Medicine Policy Framework Through a Public Health Lens
  9066. FLT3-ITDos and FLT3-ITDon’ts: navigating maintenance therapy in FLT3-ITD-positive acute myeloid leukemia following Stem cell transplantation
  9067. Stem cell therapy for erectile dysfunction: An update
  9068. The Utilization of Mesenchymal Stem cell therapy in the treatment of human diseases
  9069. Allogenic adipose mesenchymal Stem cell therapy in ischemic stroke with hypertension and hyperglycemia. Experimental animal models
  9070. cell Cultured Procedure in Normal Human Lymphocytes for Stem cell therapy
  9071. Survey On Knowledge, Awareness and Attitude Regarding Dental Stem cell therapy among Dental Students
  9072. Salvage autologous hematopoietic Stem cell transplantation for multiple myeloma performed with Stem cells procured after previous high dose therapy–a multicenter …
  9073. A Case of Two Adult Brothers with Wiskott-Aldrich Syndrome, One Treated with Gene therapy and One with HLA-Identical Hematopoietic Stem cell
  9074. Invited Discussion on:“Nanofat cell-Mediated Anti-Aging therapy: Evidence-Based Analysis of Efficacy and an Update of Stem cell Facelift” by Bishara Atiyeh, Fadi …
  9075. Allogeneic hematopoietic Stem cell transplantation overcomes the poor prognosis in MLL-rearranged solid tumor therapy related-acute myeloid leukemia
  9076. Effectiveness of hyperbaric oxygen therapy for virus-associated hemorrhagic cystitis after allogeneic hematopoietic Stem cell transplantation
  9077. Efficacy and mechanism of action of intravenous allogenic umbilical cord blood-derived mesenchymal Stem cell therapy in patients with recessive dystrophic …
  9078. … Hematopoietic Stem cell Transplant for Acute Myeloid Leukemia: a Retrospective Study From Francophone Society of Bone Marrow Transplantation and cell therapy
  9079. In Vivo Hematopoietic Stem cell Gene therapy Might Become a Reality
  9080. … of Antioxidant Poly (Propylene Sulfide)-Microspheres for Pretreatment of Inflammatory Cytokine-Induced Chondrocytes to Facilitate Adipose-Drived Stem cell therapy
  9081. Comparative Effectiveness of Arthroscopy and Non-arthroscopy Using Mesenchymal Stem cell therapy (MSCs) and Conditioned Medium for Osteoarthritis (OA)
  9082. Case Report: Combination therapy With PD-1 Blockade for Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem cell Transplantation Resulted in …
  9083. Comparative analysis of delivery methods for Stem cell therapy in liver diseases.
  9084. Disparities in Utilization of Autologous Stem cell Transplantation as Consolidative therapy for Multiple Myeloma: A Single Institution Retrospective Review
  9085. Recognition of Hematopoietic Stem cell Transplantation and cellular therapy Expertise to Promote Care Accessibility: A Formally Credentialed Area of Focused …
  9086. Stem cell therapy: A Potential Therapeutic Modality against COVID-19
  9087. Engineering of human induced pluripotent Stem cells via human artificial chromosome vectors for cell therapy and disease modeling
  9088. In Vitro Models for Stem cell therapy
  9089. Human Pluripotent Stem cell-Derived Hepatocyte-Like cells and Organoids for Liver Disease and therapy
  9090. Efficacy and Safety of mesenchymal Stem cell therapy in patients with acute myocardial infarction: a syStematic review and meta-analysis of randomized controlled …
  9091. O11-Regulatory Challenges in Stem cell therapy
  9092. Evaluation of Safety and Efficacy of cell therapy Based on Osteoblast Derived from Umbilical Cord Mesenchymal Stem cell for Osteonecrosis of the Femoral …
  9093. PIWI proteins and piRNAs in cervical cancer: a propitious dart in cancer Stem cell-targeted therapy
  9094. Mesenchymal Stem cell therapy for Acetaminophen-Related Liver Injury: A SyStematic Review and Meta-Analysis of Experimental Studies in Vivo.
  9095. Allogeneic hematopoietic Stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy
  9096. Application of marine collagen for Stemcell‑based therapy and tissue regeneration
  9097. Research status and future of Stem cell therapy for spinal cord injury
  9098. Nebulization therapy with umbilical cord mesenchymal Stem cell-derived exosomes for COVID-19 pneumonia
  9099. Stem cell therapy: Health Care Providers’ Knowledge and Attitude
  9100. CD133+ Stem cell therapy Effects on Myocardial Regeneration Through Increased Vascular Endothelial Growth Factor Correlate with Cardiac Magnetic Resonance …
  9101. Mesenchymal Stem cell therapy for Knee Osteoarthritis: 5 years Follow-Up of Three Patients
  9102. Engineered Stem cells combine Stem cell and gene therapy approaches to move intestine therapy from bench to bed
  9103. Stem cells to the Rescue: Development and Application of cell-Based therapy for Microvascular Repair
  9104. Intra-Articular Application of Mesenchymal Stem cell therapy for Osteoarthritis—The Next Step: Optimization of Therapeutic Capacity and Applicability
  9105. P36-The Major Ethical Questions in Stem cell therapy
  9106. Homology-directed gene-editing approaches for hematopoietic Stem and progenitor cell gene therapy
  9107. Effect of Nicotine Exposure to Induced Pluripotent Stem cell Derived Endothelial cell therapy in a Murine Model of Peripheral Artery Disease
  9108. cell therapy of COVID-19 patients using mesenchymal Stem cell; benefits and challenges
  9109. O29-Stem cell therapy in Atherosclerosis
  9110. P-MUC1C-ALLO1: A Fully Allogeneic Stem cell Memory T cell (TSCM) CAR-T therapy with Broad Potential in Solid Tumor
  9111. The enzymatic disaggregation by trypsin does not alter cell quality and genomic stability of adipose-derived Stem cells cultivated for human cell therapy
  9112. Stem cells and cell therapy: Sober view
  9113. Stem cell therapy as a potential therapy for Duchenne muscular dystrophy.
  9114. Ethical issues of using umbilical cord blood Stem cell therapy of John Stuart Mill perspective
  9115. Outcomes with COVID-19 in patients with hematopoietic Stem cell transplant and cellular therapy: A syStemic review and meta-analysis.
  9116. Canine dental pulp and umbilical cord-derived mesenchymal Stem cells as alternative sources for cell therapy in dogs
  9117. Stem cell therapy: A Promising Treatment of Parkinson’s Diseases
  9118. Correction to: Quality Management and Accreditation in Hematopoietic Stem cell Transplantation and cellular therapy
  9119. Stem cell therapy for the Treatment of Musculoskeletal Diseases: Safe and Effective or Costly and Temporary?
  9120. … following allogeneic hematopoietic Stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy
  9121. Should mesenchymal Stem cell therapy be used in adults with COVID-19?
  9122. … after Allogeneic Stem cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second cellular therapy
  9123. … : opportunities and challenges in cell-free therapy focus on mesenchymal Stem cell-derived exosomes: opportunities and challenges in cell-free therapy
  9124. Effects of Aerobic and Resistance Exercise therapy with and without Weight Bearing on the Outcomes of Stem cell therapy for Knee Osteoarthritis: A Randomized …
  9125. Research and Application of Stem cell-Based therapy in Idiopathic Pulmonary Fibrosis: A Review
  9126. CD7-deleted hematopoietic Stem cells can restore immunity after CAR T cell therapy
  9127. Mesenchymal Stem cell-Based therapy for Retinal Degenerative Diseases: Experimental Models and Clinical Trials. cells 2021, 10, 588
  9128. Protocol for human placental mesenchymal Stem cell therapy in a murine model of intra-abdominal infection of hypervirulent Klebsiella
  9129. … of Bone Marrow Mesenchymal Stem cell-Mediated Synthetic Radiosensitive Promoter-Combined Sodium Iodide Symporter for Radiogenetic Ovarian Cancer therapy
  9130. A Brief review on Safety of intra-articular celltherapy with culture-expanded Stem cells
  9131. Autologous peripheral blood Stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study
  9132. Gene and Stem cell therapy in β-thalassemia
  9133. Neural Stem cell-mediated brain tumor therapy
  9134. Outcomes of high dose therapy and autologous haematopoietic Stem cell transplantation for non‐hodgkin lymphoma: A retrospective analysis in a resource‐limited …
  9135. The Effect of Autologous Adipose Derived Mesenchymal Stem cell therapy in Chronic Patellar Tendinitis: A Case Study
  9136. In Utero Fetal therapy: Stem cells, cell Transplantation, Gene therapy, and CRISPR-Cas9
  9137. Effectiveness of structure teaching programme on knowledge regarding umbilical cord Stem cell therapy among staff nurses in Apollo hospital at Gandhinagar, Gujarat
  9138. Brentuximab vedotin as consolidation therapy after autologous Stem cell transplantation in children and adolescents (< 18 y) with early relapse hodgkin lymphoma
  9139. Setting up Stem cell therapy for human retina: from organotypic cultures to cell fusion understanding
  9140. Translating a Stem cell-based therapy for epidermolysis bullosa into the clinic
  9141. Discovery of TSC-101: A First-in-Class Natural HA-2-Specific TCR to Treat Leukemia Following Hematopoietic Stem cell Transplant therapy
  9142. Combination of Mesenchymal Stem cell-Delivered Oncolytic Virus with Prodrug Activation Increases Efficacy and Safety of Colorectal Cancer therapy
  9143. DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous Stem cell transplantation
  9144. P-185: Impact of the changing landscape of induction therapy prior to autologous Stem cell transplantation in 540 myeloma patients: a retrospective real-world study
  9145. Hematopoietic Stem cell Transplantation Is a Curative therapy for Transferrin Receptor 1 (TFRC) Deficiency
  9146. … Hematopoietic Stem cell Transplant for Acute Myeloid Leukemia: a Retrospective Study From Francophone Society of Bone Marrow Transplantation and cell therapy
  9147. The Safety and Efficacy of Stem cell therapy as an Emerging therapy for ALS: A SyStematic Review of Controlled Clinical Trials
  9148. OFR-9 An RCT of autologous Stemcell transplantation in treatment refractory Crohn’s disease (low-intensity therapy evaluation): ASTIClite
  9149. Preliminary study of early diagnosis by contrast-enhanced ultrasound combined with mesenchymal Stem cell therapy in improving prognosis of biliary ischemia after …
  9150. Chidamide Maintenance therapy after Induction or Salvage Treatment in Patients with Peripheral T-cell Lymphoma Ineligible for Autologous Stem cell
  9151. Stem cell nebulization therapy for COVID-19 infection: radiological and clinical outcomes
  9152. Allogeneic Hematopoietic Stem cell Transplantation in therapy Related Acute Leukemia
  9153. Journal: Quality Management and Accreditation in Hematopoietic Stem cell Transplantation and cellular therapy, 2021, p. 165-176
  9154. Successful Salvage therapy by Second Haploidentical Allogeneic Hematopoietic Stem cell Transplantation in a Severe Aplastic Anemia Patient Presenting …
  9155. The Comparative Effects of Mesenchymal Stem cell Transplantation therapy for Spinal Cord Injury in Humans and Animal Models: A SyStematic Review and Meta …
  9156. Prolonged Lenalidomide therapy Does Not Impact Autologous Peripheral Blood Stem cell Mobilization and Collection in Multiple Myeloma Patients: A Single …
  9157. In Utero Stem cell Transplantation, Enzyme Replacement, and Gene therapy
  9158. Review on Therapeutic Efficacy of Mesenchymal Stem cell (MSC) therapy for Treating Different Disease
  9159. Sequential therapy of Inotuzumab Ozogamicin and Blinatumomab as a Bridge-to Hematopoietic Stem cell Transplantation in a Pediatric Patient With Primary …
  9160. Easix before Conditioning therapy Predicts Sepsis after Allogeneic Stem cell Transplantation
  9161. Mesenchymal Stem cell therapy: Hope for Patients With SyStemic Lupus Erythematosus
  9162. Mesenchymal Stem/stromal cell-based therapy: Mechanism, syStemic safety and biodistribution for precision clinical applications
  9163. Autologous Hematopoietic Stem cell Transplantation for AL Amyloidosis Refractory to Induction therapy
  9164. Characterizing Safety in Patients with Hematologic Malignancies Receiving Allogeneic Stem cell Transplant (Allo-SCT) Following Pembrolizumab therapy
  9165. Prospects of Mesenchymal Stem cell Secretome in Veterinary Regenerative therapy
  9166. cell therapy for factor V deficiency: An approach based on human decidua mesenchymal Stem cells
  9167. … and Refractory Peripheral T-cell Lymphoma (PTCL) with Intention for Curative therapy Incorporating High Dose Chemotherapy and Hematopoietic Stem cell
  9168. … Single cell Transcriptomics in Paired Pediatric T-ALL Samples Collected at Diagnosis and Following End of Induction therapy Reveals an MRD-Associated Stem cell
  9169. Stem cell Based therapy-in COVID-19
  9170. … and Young Adults Outcomes Differ from Those of Children? a Study on Behalf of the Francophone Society of Stem cell Transplantation and cellular therapy (SFGM …
  9171. A Novel RPS19-Edited Hematopoietic Stem cell Model of Diamond-Blackfan Anemia for Development of Lentiviral Vector Gene therapy
  9172. Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem cell Mobilization and Protects BM Niches from Anti-Leukemia therapy
  9173. Mesenchymal Stem/stromal cell-based therapy for the treatment of rheumatoid arthritis: An update on preclinical studies
  9174. The Role of Stem cell Transplant in the therapy of Acute Myeloid Leukemia (AML)
  9175. Restored Hematopoietic Stem cell Transcriptional Program in Fanconi Anemia Patients Following Gene therapy
  9176. Stem cell therapy for Neurodegenerative Diseases: Strategies for Regeneration against Degeneration
  9177. Stem cell therapy for Neurodegenerative Diseases: Strategies for Regeneration against Degeneration
  9178. Efficacy and safety of mesenchymal Stem/stromal cell therapy for inflammatory bowel diseases: an up-to-date syStematic review. Biomolecules. 2021; 11 (1): 82
  9179. Isolation and Characterization of Swine MIAMI cells: A Valuable Animal Model for Adult Stem cell therapy
  9180. Letermovir Prophylaxis Versus Pre-Emptive therapy for Cytomegalovirus after Hematopoietic Stemcell Transplantation
  9181. MP36-19 PLATELET-RICH PLASMA AND Stem cell therapy FOR ERECTILE DYSFUNCTION: CHARACTERIZATION OF MARKET FORCES IN MAJOR …
  9182. Sustained Response to Selinexor-Based therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem cell Transplantation
  9183. The use of gene-modified bone marrow mesenchymal Stem cells for cochlear cell therapy
  9184. Stem cell transplantation is a promising therapy for traumatic brain injury (TBI), but low efficiency of survival and differentiation of transplanted Stem cells limits its …
  9185. Safety of Anti-NKG2A Blocking Antibody Monalizumab As Maintenance therapy after Allogeneic Hematopoietic Stem cell Transplantation: A Phase I Study
  9186. MicroRNA-7 agomir is a potential bioactive material for breast cancer therapy by inhibiting breast cancer Stem cell tumorigenicity
  9187. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem cell Characteristics and therapy Resistance in Ovarian …
  9188. High-dose Chemotherapy Combined with Autologous Hematopoietic Stem cell Transplantation as Frontline therapy for Intermediate/High-risk Diffuse Large B cell
  9189. … of Patellofemoral Bone Marrow Oedema and Subchondral Cysts on MRI Post a Single Autologous Fat-Derived Expanded Mesenchymal Stem cell therapy
  9190. Regenerative therapy for Sensorineural Hearing Loss: Recent Progress and Future Directions. J Stem cell Res Dev Ther 7: 082
  9191. Newer Horizon of Mesenchymal Stem cell–Based therapy in the Management of SARS-CoV-2–Associated Mucormycosis: A Safe Hope for Future Medicine
  9192. … Alpha-Thalassemia to Study Abnormal Iron Metabolism and Erythropoiesis, Hematopoietic Stem cell Behavior and Development of a Gene therapy Approach for Its …
  9193. … Study of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Starting Second-or Third-Line therapy and Not Receiving Autologous Stem cell
  9194. Advances in Adoptive cell therapy Using Induced Pluripotent Stem cell-Derived T cells
  9195. Inhibition of DNA-Pkcs As Novel therapy for the Prevention of Acute Gvhd Following Hematopoietic Stem cell Transplantation
  9196. Shaping the Microglia in Retinal Degenerative Diseases Using Stem cell therapy: Practice and Prospects
  9197. Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lmphoblastic leukemia after allogeneic hematopoietic Stem cell transplantation
  9198. I. Progress Towards a Stem cell Based therapy for Diabetes
  9199. Effects of a structured exercise therapy on cancer-related fatigue during and after paediatric Stem cell transplantation: a randomized controlled trial
  9200. Cancer Stem cell biomarkers: critical roles, challenges, clinical applications and perspectives in cancer therapy
  9201. Outcomes with COVID-19 in hematopoietic Stem cell transplant and cellular therapy patients.
  9202. cell therapy research for Diabetes: Pancreatic β cell differentiation from pluripotent Stem cells
  9203. Hypoxia in Bone and Oxygen Releasing Biomaterials in Fracture Treatments Using Mesenchymal Stem cell therapy: A Review
  9204. Complete Resolution of Extensive Labral tear and Para-labral Cysts on MRI Following 3D Collagen-Based Stem cell therapy in Dysplastic Hip: Case Report
  9205. Enhancing Matured Stem-Cardiac cell Generation and Transplantation: A Novel Strategy for Heart Failure therapy
  9206. Allogeneic Stem cell transplantation remains an effective therapeutic approach for patients with therapy-related acute myeloid leukemia
  9207. HL-007: Brentuximab Vedotin Consolidation therapy after Autologous Stemcell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center …
  9208. A Phase II Single Arm Study of Nivolumab As Maintenance therapy after Autologous Stem cell Transplantation in Patients with Hodgkin Lymphoma at Risk of …
  9209. Derivation of Multipotent Neural Progenitors from Human Embryonic Stem cells for cell therapy and Biomedical Applications
  9210. Brentuximab Vedotin As Consolidation therapy Following Autologous Stem cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin …
  9211. … Candidacy in Pediatric Patients Treated With Hematopoietic Stem cell Transplant and Chimeric Antigen Receptor T-cell therapy: An International Survey
  9212. Outcomes of Tyrosine Kinase Inhibitors Maintenance therapy with or without Allogeneic Hematopoietic Stem cell Transplantation in Philadelphia Positive Acute …
  9213. … Consolidation with High-Dose therapy-Autologous Stemcell Transplantation (HDT-ASCT) in the Frontline Treatment of Patients with Enteropathy-Associated T-cell
  9214. Humanized Anti-CD19 CAR-T cell therapy and Sequential Allogeneic Hematopoietic Stem cell Transplantation Achieved Long-Term Survival in Refractory …
  9215. Lysosomal Acid Lipase a (LIPA) Modulates Leukemia Stem cell (LSC) Response to Venetoclax/TKI Combination therapy in Blast Phase Chronic Myeloid Leukemia
  9216. … Pomalidomide with Dexamethasone As Maintenance therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem cell Transplant in Multiple …
  9217. Review on Therapeutic Efficacy of Mesenchymal Stem cell (MSC) therapy for Treating Different
  9218. Sex Differences in Mesenchymal Stem cell therapy With Gelatin-Based Microribbon Hydrogels in a Murine Long Bone Critical-Size Defect Model
  9219. Efficacy and Safety of Hematopoietic Stem cell Transplantation Vs. Immunosuppressive therapy in Patients with Hepatitis-Associated Aplastic Anemia: A Single …
  9220. Stem cell epigenetics in medical therapy
  9221. Stem cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental cell therapy to Patients With Rare Serious …
  9222. Stem cell Institute’s Use of Food and Drug Administration-Expanded Access Guidelines to Provide Experimental cell therapy to Patients With Rare Serious …
  9223. Single-cell Proteomic Profiling Identifies Nanoparticle Enhanced therapy for Triple Negative Breast Cancer Stem cells
  9224. Auto Hematopoietic Stem cell Transplantation Combined with Another Target Humanized CAR-T cells for Refractory/Relapsed B-cell Non-Hodgkin Lymphoma after …
  9225. Prospective Follow-up of Panel Reactive Antibodies From Diagnosis Until Completion of therapy Including Allogeneic Stem cell Transplantation Among Patients With …
  9226. … II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance therapy for TP53 Mutated AML or MDS Following Allogeneic Stem cell
  9227. Mechanism of Action of Bone Marrow Mesenchymal Stem cell in Combination with miR-36b therapy in cellular Repair of Septic Lung Injury
  9228. Fanconi Anemia: Hematopoietic Stem cell Transplant or Gene therapy?
  9229. Evaluation of an In-Patient Exercise, Relaxation, and Music therapy Program for Allogeneic Hematopoietic Stem cell Transplant Patients
  9230. Conditioned medium derived from bovine umbilical mesenchymal Stem cells as an alternative source of cell-free therapy
  9231. Stem cell Transplantation therapy as a Treatment for Autism Spectrum Disorder
  9232. CAR-T therapy: the role of the hematopoietic Stem cell processing laboratory
  9233. Evaluation of an In-patient Exercise, Relaxation, and Music therapy Program for Allogeneic Hematopoietic Stem cell Transplant Patients
  9234. Stem cell and Alopecia therapy
  9235. … MRI (DW-MRI) Has Strong Predictive Relevance for Survival in Newly Diagnosed Multiple Myeloma Patients on Maintenance therapy after Autologous Stem cell
  9236. MESENCHYMAL Stem cell-BASED therapy FOR CHRONIC KIDNEY FAILURE RELATING LUPUS ERYTHEMATOSUS-A CASE REPORT
  9237. Transcriptional Regulation of the Colorectal Cancer Stem cell Markers, Nanog and Oct4, Induced by a Thermodynamic-Based therapy Approach
  9238. Bladder cancer Stem cell markers and related signaling pathways: antibody targeted therapy
  9239. Efficacy of Amniotic Membrane Stem cell Conditioned Medium (AMSC-CM) and Vitamin C following CO2 Fractional Laser for Photoaging therapy
  9240. CART therapy followed by allo-HSCT for patients with B-cell acute lymphoblastic leukemia relapsing after the first hematopoietic Stem cell transplantation
  9241. Foetal Stem cell conversion as a new mechanism of therapy resistance in intestinal cancer
  9242. Antimicrobial photodynamic therapy as treatment of infected oral ulcers in patients undergoing hematopoietic Stem cell transplantation: Report of two cases.
  9243. … Sclerosis before and after using High-dose Immunosuppressive therapy with Autologous Hematopoietic Stem cell Transplantation: Preliminary Results.
  9244. Mesenchymal Stem cell Control of Metastatic Prostate Cancer cell Evolution and therapy Resistance in the Bone Microenvironment
  9245. Hematopoietic Stem cell transplantation and gene therapy are the sole treatments for sickle cell disease and other hemoglobinopathies
  9246. Human Umbilical Cord Mesenchymal Stem cell (HUCMSC)-derived Exosomes as a cell-Free therapy for Soluble Fms-like Tyrosine Kinase-1 (Sflt-1)-induced …
  9247. Mesenchymal Stem cells in glioblastoma therapy and progression: How one cell does it all
  9248. cell and gene therapy for anemia: hematopoietic Stem cells and gene editing
  9249. Targeting glioma Stem cell metabolism to enhance therapy responses and minimize resistance
  9250. … Trehalose Protects the Bone Marrow-Derived Mesenchymal Stem cells Under Oxidative Stress and Enhances the Stem cell-Based therapy for Cerebral Ischemic …
  9251. … who subsequently received high dose chemotherapy (HDCT) with peripheral Stem cell transplant (PBSCT) following failure of initial therapy for metastatic disease …
  9252. ALSTaR cells-Novel Stemcell-based therapy for Amyotrophic Lateral Sclerosis: A Research Protocol
  9253. Engineering cell adhesive properties on the hydrogel surface for Stem cell spheroid-based therapy
  9254. Peripheral blood Stem and progenitor cell collection in pediatric candidates for ex vivo gene therapy: a 10-year series
  9255. Measurable residual disease including AML leukemia Stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry
  9256. Autologous Stem cell transplantation (ASCT) versus whole brain radiation (WBRT) as a consolidation therapy in primary CNS lymphoma (PCNSL): A nationwide …
  9257. Extracorporeal shock wave therapy combined with engineered mesenchymal Stem cells expressing stromal cell-derived factor-1 can improve erectile …
  9258. Performance features of hospital nurses in multidisciplinary rehabilitation team for the patients undergoing cytostatic therapy and hematopoietic Stem cell
  9259. Bioinformatics-Guided Design of Endogenously Regulated Lentiviral Vectors for Hematopoietic Stem cell Gene therapy
  9260. Biological bone tissue engineering with adipose Stem cell combined gene therapy: A future prospect in treating o…
  9261. Optimization of Preservation Solution and Temperature of Human Induced Pluripotent Stem cell-Derived Cardiomyocyte Patch for Regenerative therapy
  9262. In prenatal Stem cell transplantation and in utero gene therapy, a wide spectrum of genetic diseases can be diagnosed and treated before birth
  9263. therapy for Patients With High Level of Anti-Human Leukocyte Antigen Donor-Specific Antibodies (Anti-HLA DSAs) Prior to Haploidentical Hematopoietic Stem cell
  9264. Mesenchymal Stem cells in the treatment of spinal cord injury: cell therapy and combination of new drugs and biomaterials
  9265. Safety and efficacy of mesenchymal Stem cell (MSC) therapy in symptom management of multiple sclerosis as compared to the currently approved …
  9266. Efficacy analysis of allogeneic hematopoietic Stem cell transplantation on therapy-related leukemia
  9267. therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous Stem cell
  9268. Technological Advances of 3D Scaffold-Based Stem cell/Exosome therapy in Tissues and Organs
  9269. Transplantation of human pluripotent Stem cell-derived cardiomyocytes for cardiac regenerative therapy
  9270. Prospective Follow-up of Panel Reactive Antibodies From Diagnosis Until Completion of therapy Including Allogeneic Stem cell Transplantation Among Patients With …
  9271. Preclinical Development of Autologous Hematopoietic Stem cell Based Gene therapy for Immune Deficiencies: A Journey from Mouse Cage to Bed Side
  9272. Potential cancer targeted therapy: role of microRNAs in breast cancer metastasis via epithelial-mesenchymal transition and cancer Stem cell regulation
  9273. Long-term Outcomes of Brain-targeted Stem cell Gene therapy for Mucopolysaccharidosis Type II in a Pre-Clinical MPSII Mouse Model.
  9274. Potential targeted therapy: The role of MicroRNAs in breast cancer metastasis via epithelial-mesenchymal transition and cancer Stem cell regulation
  9275. Mesenchymal Stem/stromal cell-based delivery: a rapidly evolving strategy for cancer therapy
  9276. Emerging Antioxidant Paradigm of Mesenchymal Stem cell-Derived Exosome therapy
  9277. Adiponectin Stimulates Exosome Release to Enhance Mesenchymal Stemcell-Driven therapy of Heart Failure in Mice
  9278. Induced pluripotent Stem cells derived from the developing striatum as a potential donor source for cell replacement therapy for Huntington disease
  9279. Supplement to: Parotid Gland Stem cell Sparing Radiation therapy for Patients With Head and Neck Cancer: A Double-Blind Randomized Controlled Trial
  9280. Mesenchymal Stem cell-Derived Exosome therapy of Microbial Diseases: From Bench to Bed
  9281. … herpesvirus 6 re-activation after allogeneic Stem cell transplantation. Nakayama H, Yamazaki R, Kato J, et al. Transplantation and cellular therapy. 2021; 27: 174. e1 …
  9282. The contributions of music therapy to the prevention and mitigation of the effects of toxic stress and trauma in pediatric patients undergoing Hematopoietic Stem cell
  9283. Profiling of gene and exosomal microRNA as therapy targets and biomarkers of cisplatin resistance in triple negative breast cancer Stem cell-like subpopulation
  9284. The enzymatic disaggregation by trypsin does not alter cell quality and genomic stability of adipose-derived Stem cells cultivated for human cell therapy
  9285. Mesenchymal Stem cells Derived Extracellular Vesicles as a New cell Free Biological Regenerative therapy
  9286. Therapeutic Overcoming of Cancer Stem cell-Featured Chemo-Resistant Ovarian Cancer via Photodynamic therapy and Cascadic Chemotherapy Combined …
  9287. Cytotoxic Engineered Induced Neural Stem cells as an Intravenous therapy for Primary Non–Small cell Lung Cancer and Triple-Negative Breast Cancer
  9288. Stem cell transplantation under venetoclax bridging myeloablative preconditioning regimen for an acute myeloid leukemia patient with primary induction therapy
  9289. … of Immunosuppressive therapy for Severe Aplastic Anemia Progressing From Non-SAA: Improved Outcome After Allogeneic Hematopoietic Stem cell
  9290. Different Aspects of Head and Neck Squamous cell Carcinoma: Cancer Stem cells, their Niche and Targeted therapy
  9291. Corona virus, origin and disease characteristics till cell therapy by mesenchymal Stem cells and exosomes: a gate for an effective therapeutic strategies
  9292. … to allogeneic hematopoietic Stem cell transplantation followed by daratumumab and lenalidomide maintenance therapy for primary plasma cell leukemia: report of …
  9293. … Followed by Sequential Autologous Hematopoietic Stem cell Transplantation and Lenalidomide-Based Maintenance therapy in Plasmablastic Lymphoma
  9294. … Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stemcell
  9295. Epigenetic therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem cell
  9296. Mesenchymal Stem cells Lysate as a cell-Free therapy: A Review
  9297. … of flavonoid compounds in walnut green skin on increasing cell therapy efficiency by differentiating adipose-derived mesenchymal Stem cells into insulin …
  9298. Human Stem Leydig cells: A possible source for cell therapy in hypogonadism?
  9299. Gene therapy with hematopoietic Stem and progenitor cell for monogenic disorders: a syStematic review and meta-analysis
  9300. Engineering Human Stem cells for cell-Based therapy
  9301. Immunosuppressed Miniswine as a Model for Testing cell therapy Success: Experience With Implants of Human Salivary Stem/Progenitor cell Constructs
  9302. Stem cells Following Azacytidine to Successfully Treat Severe Invasive Pulmonary Aspergillosis After therapy-Related Myelodysplastic Syndrome and CD8+ T-cell
  9303. Klotho and mesenchymal Stem cells: a review on cell and gene therapy for chronic kidney disease and acute kidney disease
  9304. From Stem cells to functional lymphocytes: cell differentiation and gene therapy implementation for RAG-SCID
  9305. Programmed cell Death Ligand 1-Transfected Mouse Bone Marrow Mesenchymal Stem cells as Targeted therapy for Rheumatoid Arthritis
  9306. Lentiviral Hematopoietic Stem and Progenitor cell Gene therapy for Metachromatic Leukodystrophy (MLD): Clinical Outcomes from 38 Patients
  9307. Combined transcriptional, translational and cell surface targeted gene therapy of HER2-positive breast cancer Stem cells in three-dimentional cell culture
  9308. Priming of mesenchymal Stem cells with a hydrosoluble form of curcumin allows keeping their mesenchymal properties for cell‐based therapy development
  9309. … underlying highly-active or antiretroviral therapy-induced lipodystrophy: atazanavir, a protease inhibitor, compromises adipogenic conversion of adipose-derived Stem
  9310. cell‐Based therapy: Partial Coated Stem cells with Bioinspired Silica as New Generation of cellular Hybrid Materials (Adv. Funct. Mater. 29/2021)
  9311. Effects of PARP Inhibitor therapy on p53-Deficient Hematopoietic Stem and Progenitor cell Fitness
  9312. Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor cell Gene therapy for Wiskott-Aldrich Syndrome
  9313. Advances in cell cryopreservation take a cue from nature: To minimize damage to frozen and thawed Stem cells used for therapy and research, new cryopreservation …
  9314. Stem cell therapy: From idea to clinical practice
  9315. Is hypoimmunogenic Stem cell therapy safe in times of pandemics?
  9316. A Review of Recent Advances in Nanomaterial-based Stem cell therapy and the Corresponding Risks
  9317. Innovations in Stem cell therapy for diabetic wound healing
  9318. The synthetic artificial Stem cell (SASC): Shifting the paradigm of cell therapy in regenerative engineering
  9319. Stem cell therapy Targets: Repêchage!
  9320. Cardiac Stem cell therapy: Does a newborn infant’s heart have infinite potential for Stem cell therapy?
  9321. Clinical translation of Stem cell therapy in traumatic brain injury: the potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1
  9322. Dental Pulp Stem cell therapy in Ischemic Stroke: A Meta-Analysis of Preclinical Studies
  9323. Exploring the role of Stem cell therapy in treating neurodegenerative diseases: Challenges and current perspectives
  9324. Preclinical studies and clinical trials on mesenchymal Stem cell therapy for knee osteoarthritis: A syStematic review on models and cell doses
  9325. Combination of Stem cell therapy and acupuncture to treat ischemic stroke: a prospective review
  9326. Stemcell therapy for Bronchopulmonary Dysplasia (BPD) in Newborns
  9327. Shining the light on clinical application of mesenchymal Stem cell therapy in autoimmune diseases
  9328. Mesenchymal Stem cell therapy in Diabetic Cardiomyopathy
  9329. Stem cell therapy applied for digestive anastomosis: Current state and future perspectives
  9330. SUPT4H1-edited Stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease
  9331. Adult Stem cell therapy for premature ovarian failure: from bench to bedside
  9332. Evolution of Mesenchymal Stem cell therapy as an Advanced Therapeutic Medicinal Product (ATMP)—An Indian Perspective
  9333. Stem cell therapy for Neuroprotection in the Growth-Restricted Newborn
  9334. … ‐CoV‐2 vaccination in hematopoietic Stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem cell Transplantation and cell therapy
  9335. Current status of clinical trials assessing mesenchymal Stem cell therapy for graft versus host disease: a syStematic review
  9336. Targeted mesenchymal Stem cell therapy equipped with a cell-tissue nanomatchmaker attenuates osteoarthritis progression
  9337. Neurofunctional and neuroimaging readouts for designing a preclinical Stemcell therapy trial in experimental stroke
  9338. Stem cell therapy for vocal fold regeneration after scarring: a review of experimental approaches
  9339. Electroactive Scaffolds to Improve Neural Stem cell therapy for Spinal Cord Injury
  9340. Application of some graphene derivatives to increase the efficiency of Stem cell therapy
  9341. An Outstanding Role of Adipose Tissue in Canine Stem cell therapy
  9342. … mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal Stem cell therapy following ischemic stroke
  9343. Biomaterial-assisted biotherapy: A brief review of biomaterials used in drug delivery, vaccine development, gene therapy, and Stem cell therapy
  9344. Stem cell therapy for pulmonary arterial hypertension: An update
  9345. Real-world evidence of mesenchymal Stem cell therapy in knee osteoarthritis: a large prospective two-year case series
  9346. Safety study of allogeneic mesenchymal Stem cell therapy in animal model
  9347. Intrauterine Growth Restriction (IUGR) as a potential target for transamniotic Stem cell therapy
  9348. Neural Stem cell therapy in conjunction with curcumin loaded in niosomal nanoparticles enhanced recovery from traumatic brain injury
  9349. Efficacy of Stem cell therapy in Large Animal Models of Ischemic Cardiomyopathies: A SyStematic Review and Meta-Analysis
  9350. Mesenchymal stromal (Stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury
  9351. Injectable Self-Crosslinkable Thiolated Hyaluronic Acid for Stem cell therapy of Atopic Dermatitis
  9352. Efficacy and Safety of Stem cell therapy in Children With Autism Spectrum Disorders: A SyStematic Review and Meta-Analysis
  9353. Advances in Stem cell therapy in Alzheimer’s disease: a comprehensive clinical trial review
  9354. Stem cell therapy for Alzheimer’s disease: An overview of experimental models and reality
  9355. Neurophysiological outcomes following mesenchymal Stem cell therapy in multiple sclerosis
  9356. Mesenchymal Stem cell-based COVID-19 therapy: Bioengineering perspectives
  9357. Normal ex vivo mesenchymal Stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic …
  9358. Genetically Engineered Mesenchymal Stem cell therapy Against Murine Experimental Autoimmune Encephalomyelitis
  9359. Stem cell therapy for COVID-19 pneumonia
  9360. Mesenchymal stromal/Stem cell therapy for radiation-induced salivary gland hypofunction in animal models: a protocol for a syStematic review and meta …
  9361. Applications of Stem cell therapy and Adipose-Derived Stem cells for Skin Repair
  9362. Human corneal stromal Stem cells express anti-fibrotic microRNA-29a and 381-5p–a robust cell selection tool for Stem cell therapy of corneal scarring
  9363. Polyphenols as potential enhancers of Stem cell therapy against neurodegeneration
  9364. Save the day with a Stem cell Rescue’: Use of autologous hematopoietic Stem cell boost for hematopoietic recovery after CAR T cell therapy
  9365. Stem cell therapy–When We Can Use Such Terminology?
  9366. Current Status of Stem cell therapy in Heart Failure
  9367. Mesenchymal Stem cell therapy for Focal Epilepsy: A SyStematic Review of Preclinical Models and Clinical Studies
  9368. Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous Stemcell transplantation for high‐risk newly diagnosed …
  9369. Novel vision restoration techniques: 3D bioprinting, gene and Stem cell therapy, optogenetics, and the bionic eye
  9370. Recent Investigations on Neurotransmitters’ Role in Acute White Matter Injury of Perinatal Glia and Pharmacotherapies—Glia Dynamics in Stem cell therapy
  9371. Is there a role for Stem cell therapy in erectile dysfunction secondary to cavernous nerve injury? Network meta-analysis from animal studies and human trials
  9372. Mesenchymal Stem cell therapy and cognition in MS: Preliminary findings from a phase II clinical trial
  9373. Mesenchymal Stem cell therapy attenuates complement C3 deposition and improves the delicate equilibrium between angiogenic and anti-angiogenic factors in …
  9374. Autologous CD34+ Stem cell therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction
  9375. Melatonin treatment improves human umbilical cord mesenchymal Stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling …
  9376. Mesenchymal Stem cell therapy Awareness, Knowledge, and Use for the Treatment of Fistulizing Crohn’s Disease: An International Survey Among …
  9377. Immunological barriers to haematopoietic Stem cell gene therapy
  9378. Autologous versus allogeneic mesenchymal Stem cell therapy: The pros and cons
  9379. An Investigation of Google Searches for Knee Osteoarthritis and Stem cell therapy: What are Patients Searching Online?
  9380. Effects of Stem cell therapy on Diabetic Mellitus Erectile Dysfunction: A SyStematic Review and Meta-analysis
  9381. Regenerative Rehabilitation and Stem cell therapy Targeting Chronic Spinal Cord Injury: A Review of Preclinical Studies
  9382. Wharton’s jelly‐derived stromal cells and their cell therapy applications in allogeneic haematopoietic Stem cell transplantation
  9383. Mesenchymal Stem cell therapy for alleviating ocular surface inflammation in allergic conjunctivitis
  9384. Low-dose mesenchymal Stem cell therapy for discogenic pain: safety and efficacy results from a 1-year feasibility study
  9385. Stem cell therapy for Parkinson’s disease
  9386. Inducible caspase-9 suicide gene under control of endogenous oct4 to safeguard mouse and human pluripotent Stem cell therapy
  9387. The Current Role of Stem cell therapy and iPS cells
  9388. Metabolic Rewiring by Human Placenta-Derived Mesenchymal Stem cell therapy Promotes Rejuvenation in Aged Female Rats
  9389. Strategies of pluripotent Stem cell-based therapy for retinal degeneration: update and challenges
  9390. Current Status and Perspectives of Human Mesenchymal Stem cell therapy 2020
  9391. Multimodality imaging in the assessment of bone marrow-derived mesenchymal Stem cell therapy for doxorubicin-induced cardiomyopathy
  9392. Mesenchymal Stem cell therapy in the Treatment of Neurodegenerative Cerebellar Ataxias: a SyStematic Review and Meta-analysis
  9393. Neuronal circuitry reconstruction after Stem cell therapy in damaged brain
  9394. Development of an induced pluripotent Stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products
  9395. Stem cell therapy for Spinal Cord Injury: A Review of Recent Clinical Trials
  9396. The Potential Therapeutic Effect of Orexin-Treated versus Orexin-Untreated Adipose Tissue-Derived Mesenchymal Stem cell therapy on Insulin Resistance …
  9397. Mesenchymal Stem cell-Derived Nanovesicles as a Credible Agent for therapy of Pulmonary Hypertension
  9398. Allogeneic double‐negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic Stem cell transplantation: A first‐in‐human …
  9399. Mesenchymal Stem cell therapy for Chronic Wound Healing
  9400. Mesenchymal Stem cell therapy for Osteoarthritis: Practice and Possible Promises
  9401. Stem cell and Exosome therapy in Pulmonary Hypertension
  9402. Mesenchymal Stem cell (MSCs) therapy for Ischemic Heart Disease: A Promising Frontier
  9403. Stem cell therapy: From Idea to Clinical Practice.
  9404. Cost utility of lifelong immunoglobulin replacement therapy vs hematopoietic Stem cell transplant to treat agammaglobulinemia
  9405. Autologous NK cells as consolidation therapy following Stem cell transplantation in multiple myeloma
  9406. Combination therapy of Stem cell-derived Exosomes and Biomaterials in the Wound Healing
  9407. Stem cell Transplantation therapy and Neurological Disorders: Current Status and Future Perspectives
  9408. Stem cell therapy for Learning Disability
  9409. Mesenchymal Stem cell therapy for Inflammatory Bowel Disease
  9410. Clinical Application of Stem cell therapy in Reconstructing Maxillary Cleft Alveolar Bone Defects: A SyStematic Review of Randomized Clinical Trials
  9411. Evolution of Mesenchymal Stem cell therapy as an Advanced Therapeutic Medicinal Product (ATMP)—An Indian Perspective. Bioengineering 2022, 9, 111
  9412. CAR19/22 T cell cocktail therapy for B-ALL relapsed after allogeneic hematopoietic Stem cell transplantation
  9413. Autologous Stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma
  9414. Stem cell Educator therapy in type 1 diabetes: From the bench to clinical trials
  9415. Mesenchymal Stem cell-derived exosome: A tumor regulator and carrier for targeted tumor therapy
  9416. Longitudinal Patient Reported Outcomes with CAR-T cell therapy vs Autologous and Allogeneic Stem cell Transplant
  9417. Cardiac cell therapy with Pluripotent Stem cell-Derived Cardiomyocytes: What Has Been Done and What Remains to Do?
  9418. Clinical features, pathophysiology, and therapy of poor graft function post–allogeneic Stem cell transplantation
  9419. Meniscus repair: up-to-date advances in Stem cell-based therapy
  9420. Stem cell therapy and Regenerative Medicine for ARDS: Can Stem cell therapy and Regenerative Medicine Contribute to the Protection or Recovery of the Injured …
  9421. Therapeutic potential of mesenchymal Stem cell-derived exosomes as a cell-free therapy approach for the treatment of skin, bone, and cartilage defects
  9422. A 3D Mathematical Model of Coupled Stem cell-Nutrient Dynamics in Myocardial Regeneration therapy
  9423. Mesenchymal Stem cell (MSC)-derived exosomes as novel vehicles for delivery of miRNAs in cancer therapy
  9424. Potential of Stem cell-Based therapy to Restore Function in Aging SyStems: Are We There Yet?
  9425. Online seminars as an information source for direct-to-consumer Stem cell therapy
  9426. Nanoparticles functionalized with Stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy
  9427. Tracking cell Viability for Adipose-Derived Mesenchymal Stem cell-Based therapy by Quantitative Fluorescence Imaging in the Second Near-Infrared Window
  9428. Recent advances of 3D hydrogel culture syStems for mesenchymal Stem cell-based therapy and cell behavior regulation
  9429. Current State of Stem cell therapy for Heart Diseases
  9430. Multinuclear MRI reveals early efficacy of Stem cell therapy in stroke
  9431. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy
  9432. Breast Cancer Stem cell Membrane Biomarkers: therapy Targeting and Clinical Implications
  9433. Stem cell therapy: Significance and Applications of Stem cell Products in Tissue Engineering and Regenerative Medicine
  9434. Engineered mesenchymal Stem cell-derived exosomes with high CXCR4 levels for targeted siRNA gene therapy against cancer
  9435. Stem cell-derived extracellular vesicle therapy for acute brain insults and neurodegenerative diseases
  9436. Inflammation, Stem cell therapy, and Cardiac Repair
  9437. Induction therapy prior to autologous Stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update
  9438. Stem cell therapy for Myocardial Infarction: A Mini-Review
  9439. Lentiviral haematopoietic Stemcell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase …
  9440. Mesenchymal Stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives
  9441. Genetically-modified Stem cell in regenerative medicine and cancer therapy; a new era
  9442. Niche-directed therapy in acute myeloid leukemia: optimization of Stem cell competition for niche occupancy
  9443. Author Correction: SUPT4H1-edited Stem cell therapy rescues neuronal dysfunction in a mouse model for Huntington’s disease
  9444. Impact of induction therapy with VRD versus VCD on outcomes in patients with multiple myeloma in partial response or better undergoing upfront autologous Stem cell
  9445. Parotid gland Stem cell sparing radiation therapy for patients with head and neck cancer: A double-blind randomized controlled trial
  9446. Iron Oxide Nanoparticles in Mesenchymal Stem cell Detection and therapy
  9447. Preconditioning and Engineering Strategies for Improving the Efficacy of Mesenchymal Stem cell-Derived Exosomes in cell-Free therapy
  9448. Embryonic and fetal toxic lesions and Stem cell therapy
  9449. Moral obligations in conducting Stem cell-based therapy trials for autism spectrum disorder
  9450. … antigen receptor T‐cell therapy combined with autologous Stem cell transplantation improved progression‐free survival of relapsed or refractory diffuse large B‐cell
  9451. Allogeneic Stem cell therapy in Heart Failure
  9452. Anti-Xa based dosing of enoxaparin in hematopoietic Stem cell transplant and adoptive cell therapy patients: A single center experience
  9453. Rituximab as adjunctive therapy to BEAM conditioning for autologous Stem cell transplantation in Hodgkin lymphoma
  9454. Mesenchymal Stem cell–Based therapy as a New Approach for the Treatment of SyStemic Sclerosis
  9455. Neural Stem cell-Derived Exosomal Netrin1 Contributes to Neuron Differentiation of Mesenchymal Stem cells in therapy of Spinal Bifida Aperta
  9456. Targeting Oxidative Stress in Cancer: Opportunity for Natural and Synthetic Compounds, and Cancer Stem cell therapy
  9457. Off-the-Shelf Third-Party Virus-Specific T cell therapy to Treat JC Polyomavirus Infection in Hematopoietic Stem cell Transplantation Recipients
  9458. The combined therapy of mesenchymal Stem cell transplantation and resveratrol for diabetes: Future applications and challenges
  9459. Impact of maintenance therapy post autologous Stem cell transplantation for multiple myeloma in early and delayed transplant
  9460. therapy Stem cell Engineering Committee review comparing outcomes, accessibility and cost of ex vivo Stem cell gene therapy versus allogeneic hematopoietic Stem
  9461. Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous Stem cell transplantation
  9462. Heterogeneity of mesenchymal Stem cells: characterization and application in cell therapy
  9463. Stem cell therapy to Approach Refractory Asherman’s Syndrome
  9464. Role of flow cytometry in evaluation of the cellular therapy products used in haematopoietic Stem cell transplantation
  9465. Preemptive Interferon-α therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem cell
  9466. A review on the progress of Stem cell therapy as a treatment for Diabetes mellitus
  9467. An organoid model of colorectal circulating tumor cells with Stem cell features, hybrid EMT state and distinctive therapy response profile
  9468. Role of Stem cell therapy in neurosciences
  9469. Suicide gene therapy by canine mesenchymal Stem cell transduced with thymidine kinase in a u-87 glioblastoma murine model: Secretory profile and …
  9470. Haematopoietic Stem cell gene therapy in inborn errors of metabolism
  9471. Current status, challenges and reflections on Stem cell therapy for liver diseases
  9472. Registered Trials on Stem cell therapy in Liver Diseases: a Cross-sectional Study on ClinicalTrials. gov
  9473. … and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic Stem cell transplantation for relapsed Philadelphia chromosome-like B-cell
  9474. Mesenchymal Stem cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and therapy
  9475. Salvage high-dose melphalan with autologous Stem cell transplantation as bridge to consolidation therapy for chemoresistant aggressive B-cell lymphoma
  9476. Advances, Opportunities, and Challenges in Stem cell-Based therapy
  9477. Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical Stem cell transplantation and factors affecting efficacy
  9478. A Compendium of Recent Research on Stem cell-Based therapy for Covid-19
  9479. Stem cell therapy in the Treatment of Elbow Joint Osteoarthritis in Dogs
  9480. Carbonic anhydrase IX-targeted chemodynamic & photodynamic cancer Stem cell therapy
  9481. Preventive Effects of a Human Hematopoietic Mesenchymal Stem cell (hHMSC) therapy in Ovalbumin-Induced Food Allergy
  9482. Autophagy Regulation on Cancer Stem cell Maintenance, Metastasis, and therapy Resistance
  9483. Recognising inequalities in haematopoietic Stemcell transplantation and cellular therapy training
  9484. A New Target of Dental Pulp-Derived Stem cell-Based therapy on Recipient Bone Marrow Niche in SyStemic Lupus Erythematosus
  9485. … Modulation of Inflammasome Signaling Confers Neuroprotection in Rodent Model of Ischemic Stroke Following Endovascular Mesenchymal Stem cell therapy (S33 …
  9486. Rapid Stem cell Extraction and Culture Device for Regenerative therapy Using Biodegradable Nonwoven Fabrics with Strongly Oriented Fibers
  9487. Ocular disorders and Stem cell therapy: A review
  9488. Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous Stem cell transplantation
  9489. Use of stromal vascular fraction Stem cell therapy for functional and cosmetic outcomes in a young female patient with deep dermal flame burns on the face
  9490. Safety Assessment of Autologous Stem cell Combination therapy in Patients With Decompensated Liver Cirrhosis: A Pilot Study
  9491. Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem cell Gene therapy the Solution for This Devastating Disorder?
  9492. Commentary: Defining the role of Stem cell therapy in neonatal cardiac regeneration
  9493. Patient-Derived Stem cell therapy for Diabetic Kidney Disease
  9494. Isolation and Purification of Self-Renewable Human Neural Stem cells from iPSCs for cell therapy in Experimental Model of Ischemic Stroke
  9495. … fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous Stem cell transplant between 2000 …
  9496. Hematopoietic Stem cell transplantation and cellular therapy
  9497. Stem cell therapy in Advanced Heart Failure
  9498. Canine adipose tissue-derived mesenchymal Stem cell therapy in a dog with renal Fanconi syndrome
  9499. Stem cell therapy in Non-ischemic, Non-treatable Dilated Cardiomyopathies II: A Pilot Study
  9500. Preclinical Research of Mesenchymal Stem cell-Based therapy for Ocular Diseases
  9501. … of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic Stem cell
  9502. A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent Stem cells
  9503. Stem cell-based therapy for myopic maculopathy: a new concept
  9504. Real-World Use of Isavuconazole as Primary therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem cell Transplant
  9505. Applications and Challenges of Neural Stem cell therapy
  9506. Current Concepts of Neural Stem/Progenitor cell therapy for Chronic Spinal Cord Injury
  9507. Gene-Directed Enzyme/Prodrug therapy of Rat Brain Tumor Mediated by Human Mesenchymal Stem cell Suicide Gene Extracellular Vesicles In Vitro and In Vivo
  9508. Donor hematopoietic Stem cell/lymphocyte as maintenance treatment after CAR T-cell therapy in B-cell acute lymphoblastic leukemia relapsed after Stem cell
  9509. cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin therapy
  9510. A new step in understanding Stem cell mobilization in patients with Fanconi anemia: A bridge to gene therapy
  9511. Mesenchymal Stem cell derived exosomes-based immunological signature in a rat model of corneal allograft rejection therapy
  9512. Allogeneic hematopoietic Stem cell transplantation in patients with therapy‐related hematologic malignancies developing after multiple myeloma
  9513. First-line high-dose therapy and autologous blood Stem cell transplantation in patients with primary central nervous syStem non-Hodgkin lymphomas—a …
  9514. Hematopoietic Stem cell Gene therapy Ameliorates CNS Involvement in Murine Model of GM1-gangliosidosis
  9515. Blinatumomab as a Bridge therapy for Hematopoietic Stem cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
  9516. Chemotherapy or Allogeneic Stem cell Transplantation as Salvage therapy for Patients with Refractory Acute Myeloid Leukemia: A Multicenter Analysis
  9517. Mesenchymal Stem cell-Extracellular Vesicle therapy in Patients with Stroke
  9518. Mesenchymal Stem cell therapy in COVID-19 pneumonia: a prospective, randomized clinical research
  9519. Stem cell and Gene therapy for Inherited Retinal Diseases
  9520. Mesenchymal Stem cell therapy for Patients with Post COVID ARDS on ECMO Referred for Lung Transplantation-Single Center Experience from India
  9521. Quality Improvement in Hematopoietic Stem cell Transplant and cellular therapy: Using the Model for Improvement to impact Outcomes
  9522. Disease modifying therapy management of multiple sclerosis after Stem cell therapies: A retrospective case series
  9523. Nanotechnology in Stem cell Regenerative therapy and Its Applications
  9524. Alzheimer’s disease: from pathogenesis to mesenchymal Stem cell therapy—bridging the missing link
  9525. The Secret World of Stem cell therapy: What YOU Need to Know about the Health, Beauty, and Anti-Aging Breakthrough
  9526. Heal thyself: The promise of autologous hematopoietic Stem cell gene therapy in neurometabolic disorders
  9527. Stem cell therapy in Ischemic Non-treatable Cardiac Disease
  9528. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic Stem cell transplant recipients
  9529. … Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem cell Transplant Followed by Melphalan therapy
  9530. Mesenchymal Stem cell-derived extracellular vesicles for cell-free therapy of ocular diseases
  9531. Volumetric modulated arc therapy total body irradiation in pediatric and adolescent/young adult patients undergoing Stem cell transplantation: Early outcomes and …
  9532. Gut Microbiota Modulation for Therapeutic Management of Various Diseases: A New Perspective Using Stem cell therapy.
  9533. Mesenchymal Stem cell as a Successful therapy for COVID-19 Patient: SyStematic Review
  9534. … of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic Stem cell transplantatio: a multi …
  9535. Research advances on Stem cell therapy for diabetic foot wounds
  9536. Parotid Gland Stem cell Sparing Radiation therapy for Patients With Head and Neck Cancer: A Double-Blind Randomized Controlled Trial
  9537. The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous Stem cell transplantation
  9538. The Use of Mesenchymal Stem cell therapy in the Management of Spinal Cord Injuries
  9539. Effect of Stem cell Infusion therapy on Sexual Function in Men and Women with Type 2 Diabetes and Metabolic Syndrome: Results from the ACESO & CERES …
  9540. WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem cell Transplantation and cellular therapy
  9541. Reply to” Prophylactic Allogeneic Hematopoietic Stem cell therapy for CSF1R-Related Leukoencephalopathy”
  9542. The EHA Research Roadmap: Hematopoietic Stem cell Gene therapy
  9543. Augmenting Mesenchymal Stem cell-Based therapy of the Infarcted Myocardium with Statins
  9544. … )-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic Stem cell
  9545. Correction to Endovascular Stem cell therapy Post Stroke Rescues Neurons from Endoplasmic Reticulum Stress-Induced Apoptosis by Modulating Brain-Derived …
  9546. … , ViaCyte Dose First Patient with cell therapy for Type 1 Diabetes: VCTX210 uses gene editing to engineer ViaCyte’s CyT49 pluripotent human Stem cell line, to avoid …
  9547. Training the Graft: Enriched Environment and Exercise Enhance Stem cell therapy for Stroke, Parkinson’s Disease, and Huntington’s Disease
  9548. Mesenchymal Stem cell therapy: challenges and future prospects
  9549. Transformative Stem cell-Based therapy in Neurological Diseases and Beyond
  9550. … with Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem cell
  9551. … Reconstitution following High-Dose Chemotherapy and Autologous Stem cell Transplantation with or without Pembrolizumab Maintenance therapy in Patients with …
  9552. The Promise of CAR T-cell therapy for the treatment of cancer Stem cells: A Short Review.
  9553. Short and Medium-term results of the autologous adult mucosa Stem cell therapy compared with mini-sling surgery in the treatment of women’s stress urinary …
  9554. Impact of radiation therapy after high dose chemotherapy and autologous hematopoietic Stem cell transplantation in patients with relapsed/refractory lymphomas: A …
  9555. Stem cell therapy for Treatment of Lower Back Pain Due to Degenerative Disk Disease: A SyStematic Review
  9556. Stem cell therapy in Rats with Experimental Intrauterine Adhesions Induced by Trichloroacetic Acid
  9557. … t-lymphocyte globulin and cyclosporine is effective in prevention of graft versus host disease after allogeneic peripheral blood Stem cell transplantation for hematologic …
  9558. Stem cell Educator therapy in Diabetes
  9559. Activation of the AKT/GSK-3β/β-catenin pathway via photobiomodulation therapy promotes neural Stem cell proliferation in neonatal rat models of hypoxic …
  9560. Efficacy and Safety of Iron Chelation therapy After Allogeneic Hematopoietic Stem cell Transplantation in Pediatric Thalassemia Patients: A Retrospective …
  9561. An innovative hematopoietic Stem cell gene therapy approach benefits CLN1 disease in the mouse model
  9562. Antibiotic therapy and Gastrointestinal Graft-Versus-Host Disease in the Allogeneic Stem cell Transplantation Population
  9563. Mesenchymal Stem cell therapy for COVID-19-induced ARDS patients. A successful phase1, randomized, control-placebo group, clinical trial
  9564. Radiation therapy for Young Children Treated with High-Dose Chemotherapy and Autologous Stem cell Transplantation for Primary Brain Tumors
  9565. Donor hematopoietic Stem cell/lymphocyte as maintenance treatment after CAR T-cell therapy in B-cell acute lymphoblastic leukemia relapsed after Stem cell
  9566. Dose-dependent Improvement In Stroke Outcomes Following Intra-arterial Mesenchymal Stem cell therapy In A Canine Endovascular Stroke Model
  9567. Breast Cancer Stem cell Membrane Biomarkers: therapy Targeting and Clinical Implications. cells 2022, 11, 934
  9568. Outcome of therapy‐related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic Stem cell transplantation: A propensity …
  9569. Remarkable pain control and functional improvement in clubfeet-related ankle osteoarthritis post autologous expanded mesenchymal Stem cell therapy
  9570. … caused by multidrug-resistant Pseudomonas aeruginosa after allogeneic hematopoietic Stem cell transplantation with colistin and amikacin inhalation therapy
  9571. Expanded Mesenchymal Stem cell therapy for Symptomatic Knee Osteoarthritis
  9572. Stem cell-Based therapy for Diabetic Foot Ulcers.
  9573. Mesenchymal Stem cells: As a multi-target cell therapy for clearing β-amyloid deposition in Alzheimer’s disease
  9574. Application of Stem cell and Exosome-Based therapy in COVID
  9575. Cytokine storm and Stem cell activation in unveiling potential targets for diagnosis and therapy
  9576. Integrin Receptor-Binding Nanofibrous Peptide Hydrogel for Combined Mesenchymal Stem cell therapy and Nitric Oxide Delivery in Renal Ischemia/Reperfusion …
  9577. Immune restoration therapy for multidrug-resistant CMV disease in an allogenic Stem cell transplant recipient
  9578. Preclinical Studies of Neural Stem/Progenitor cell therapy for Ischemic Stroke: A SyStematic Review.
  9579. An Infodemic of Misinformation on Stem cell therapy Among the Population of Saudi Arabia: A Cross-Sectional Study
  9580. … a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem cell
  9581. Safety and efficacy of allogeneic hematopoietic Stem cell transplantation in R/R B-NHL patients with disease progression after CAR-T therapy
  9582. Mesenchymal Stem cell-based therapy and female infertility: limitations and advances.
  9583. Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem cell therapy
  9584. Allogeneic Mesenchymal Human Stem cell Infusion therapy for Endothelial Dysfunction in Diabetic Subjects (ACESO)
  9585. A Pilot Study of the Therapeutic Potential of Stem cell Educator therapy in Type 1 Diabetes
  9586. Sequential CAR T-cell therapy After Autologous Stem cell Transplantation for the Treatment of Relapsed/Refractory Intravascular Large B-cell Lymphoma With …
  9587. Erratum to: Stem cell-derived extracellular vesicle therapy for acute brain insults and neurodegenerative diseases
  9588. S106: LONG-TERM FOLLOW-UP OF BETA-THALASSEMIA PATIENTS TREATED WITH HEMATOPOIETIC Stem cell GENE therapy
  9589. cell therapy Based on Gingiva-Derived Mesenchymal Stem cells Seeded in a Xenogeneic Collagen Matrix for Root Coverage of RT1 Gingival Lesions: An In Vivo …
  9590. Will novel targeted drugs or immunocyte therapy replace hematopoietic Stem cell transplantation
  9591. E-Selectin-Overexpressing Mesenchymal Stem cell therapy Confers Improved Reperfusion, Repair, and Regeneration in a Murine Critical Limb Ischemia …
  9592. The key factors influencing patients in selecting autologous hematopoietic Stemcell transplantation as the main therapy for multiple myeloma: A population …
  9593. Generation of thymic cells from pluripotent Stem cells for basic research and cell therapy
  9594. Reversal of Type 1 Diabetes in Children by Stem cell Educator therapy
  9595. … case report of haploidentical hematopoietic Stem cell trans-plantation for diffuse large B-cell lymphoma developing in the course of immunosuppressive therapy
  9596. Attenuation of the Stem cell properties and the oxidative phosphorylation by ampelopsin in therapy-resistant MDA-MB-231 breast cancer cells.
  9597. Lenalidomide, Bortezomib, and Dexamethasone as Induction therapy Before Autologous Stem cell Transplant for Multiple Myeloma
  9598. Effectiveness of combined therapy with midostaurin and standard chemotherapy and high-dose chemotherapy with allogeneic Stem cell transplantation in high-risk …
  9599. Stem cell-Based therapy in Retinal Degeneration
  9600. Acute radiation syndrome: On the issues of triage, Stem cell sources and immunosuppressive therapy
  9601. Expression of RAD6, DDB2 and Cancer Stem cell / CSC Protein (CD44 +/CD24 -) on therapy Response to the Administration of Chemotherapy in Ovarian Cancer …
  9602. Music therapy Effects after Autologous Stem cell Transplantation (ASCT)
  9603. Adoptive therapy with CMV-specific T cells for CMV infection after haploidentical Stem cell transplantation and factors affecting efficacy.
  9604. Low-Level Laser therapy: A Literature Review of the Prevention and Reduction of Oral Mucositis in Patients Undergoing Stem cell Transplantation
  9605. Safety and efficacy of high‐dose cytarabine MEAM therapy and other treatments for auto‐peripheral blood Stem cell transplantation: A retrospective comparative study
  9606. Hematopoietic Stem cell-derived fibrocytes as targets and tools for cancer therapy: mechanisms and therapeutic implications
  9607. hiPSC-neural Stem/progenitor cell transplantation therapy for spinal cord injury.
  9608. Improving the Safety of Mesenchymal Stem cell-Based Ex Vivo therapy Using Herpes Simplex Virus Thymidine Kinase.
  9609. … and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem cell Transplantation and cellular therapy
  9610. Mesenchymal Stem cell-Derived Extracellular Vesicles in Liver Immunity and therapy
  9611. Mesenchymal Stem cell-Based therapy for Lysosomal Storage Diseases and Other Neurodegenerative Disorders
  9612. … T-lymphoid progenitors as a tool to accelerate immune reconstitution after partially HLA compatible hematopoietic Stem cell transplantation or after gene therapy
  9613. Limbal Mesenchymal Stem cell Secretome as Potential Adjuvant therapy for Ocular Alkali Injury
  9614. Physiologic isolation and expansion of human mesenchymal Stem/stromal cells for manufacturing of cell‐based therapy products
  9615. Preferential Expansion of Human CD34+CD133+CD90+ Hematopoietic Stem cells Enhances Gene-Modified cell Frequency for Gene therapy
  9616. Stem cell-Derived Exosome therapy of Microbial Diseases: From Bench to Bed
  9617. … ) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning therapy for Autologous Stem cell Transplantation in Patients …
  9618. Mesenchymal Stemcell Derived Exosome therapy as a Potential Future Approach for Treatment of Male Infertility Caused by Chlamydia Infection
  9619. The CCR5 gene-edited CD34+ CD90+ Hematopoietic Stem cell population serves as an optimal graft source for HIV gene therapy
  9620. Comparison of Hematopoietic Stem cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive therapy
  9621. Targeting HIF-1α/NOTCH1 pathway eliminates CD44+ cancer Stem-like cell phenotypes, malignancy, and resistance to therapy in head and neck squamous cell
  9622. Enzymatic self-assembly nanofibers anchoring mesenchymal Stem cells induce cell spheroids and amplify paracrine function for myocardial infarction therapy
  9623. Intratumoural haematopoietic Stem and progenitor cell differentiation into M2 macrophages facilitates the regrowth of solid tumours after radiation therapy
  9624. … Potential of Microvesicles in cell therapy and Regenerative Medicine of Ocular Diseases With an Especial Focus on Mesenchymal Stem cells-Derived Microvesicles …
  9625. Long-term safety and efficacy of lentiviral hematopoietic Stem/progenitor cell gene therapy for Wiskott–Aldrich syndrome
  9626. … Tissue-Mesenchymal Stem cells Caused to Change the Methylation Status of hTERT Gene Promoter CpG Islands of Molt-4 Leukemia cells as cell-based therapy
  9627. Utilising S/MAR DNA vectors for the genetic modification of human induced pluripotent Stem cells for cell and gene therapy
  9628. Melanocyte Stem cells in skin diseases and their potential in cell-based therapy.
  9629. Mesenchymal Stem/stromal cells as adjuvant therapy in COVID-19-associated acute lung injury and cytokine storm: Importance of cell identification.
  9630. … syStem suicide gene therapy using Stem cells of human exfoliated deciduous teeth (SHED) expressing “Modified” HSV-TK against brain metastasis of non small cell
Shopping Cart
Scroll to Top